PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ELLENBERGER, TE; BRANDL, CJ; STRUHL, K; HARRISON, SC				ELLENBERGER, TE; BRANDL, CJ; STRUHL, K; HARRISON, SC			THE GCN4 BASIC REGION LEUCINE ZIPPER BINDS DNA AS A DIMER OF UNINTERRUPTED ALPHA-HELICES - CRYSTAL-STRUCTURE OF THE PROTEIN-DNA COMPLEX	CELL			English	Article							TRANSCRIPTIONAL ACTIVATOR PROTEIN; LAMBDA-REPRESSOR; 2.8-A RESOLUTION; COILED COIL; FOS; JUN; RECOGNITION; DOMAIN; YEAST; SITE	The yeast transcriptional activator GCN4 is 1 of over 30 identified eukaryotic proteins containing the basic region leucine zipper (bZIP) DNA-binding motif. We have determined the crystal structure of the GCN4 bZIP element complexed with DNA at 2.9 angstrom resolution. The bZIP dimer is a pair of continuous alpha helices that form a parallel coiled coil over their carboxy-terminal 30 residues and gradually diverge toward their amino termini to pass through the major groove of the DNA-binding site. The coiled-coil dimerization interface is oriented almost perpendicular to the DNA axis, giving the complex the appearance of the letter T. There are no kinks or sharp bends in either bZIP monomer. Numerous contacts to DNA bases and phosphate oxygens are made by basic region residues that are conserved in the bZIP protein family. The details of the bZIP dimer interaction with DNA can explain recognition of the AP-1 site by the GCN4 protein.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute	ELLENBERGER, TE (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1990, X PLORV 2 1 MANUAL; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; COHEN DR, 1990, ONCOGENE, V5, P929; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAPTEIN R, 1991, CURR OPIN STRUC BIOL, V2, P109; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; OAKLEY MG, 1990, SCIENCE, V248, P847, DOI 10.1126/science.2111578; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; WEISS MA, 1984, P NATL ACAD SCI-BIOL, V81, P6019, DOI 10.1073/pnas.81.19.6019; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	54	864	898	1	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1223	1237		10.1016/S0092-8674(05)80070-4	http://dx.doi.org/10.1016/S0092-8674(05)80070-4			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473154				2022-12-28	WOS:A1992KE60400016
J	GOULD, TH; CROSBY, DL; HARMER, M; LLOYD, SM; LUNN, JN; REES, GAD; ROBERTS, DE; WEBSTER, JA				GOULD, TH; CROSBY, DL; HARMER, M; LLOYD, SM; LUNN, JN; REES, GAD; ROBERTS, DE; WEBSTER, JA			POLICY FOR CONTROLLING PAIN AFTER SURGERY - EFFECT OF SEQUENTIAL-CHANGES IN MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article							POSTOPERATIVE PAIN; SERVICE; ANALGESIA	Objective-To observe the effects of introducing an acute pain service to the general surgical wards of a large teaching hospital. Design-A study in seven stages: (1) an audit of current hospital practice succeeded by the sequential introduction to the general surgical wards of (2) pain assessment charts; (3) an algorithm to allow more frequent use of intramuscular analgesia; (4) increased use of local anaesthetic techniques of wound infiltration and nerve blocks; (5) an information sheet for patients about postoperative pain; (6) the introduction of patient controlled analgesia; (7) a repeat audit of hospital practice. Data were collected on each patient 24 hours after operation. Setting-University Hospital of Wales, which has both district general and tertiary referral functions. Patients-2035 patients over nine months from all surgical specialties (excluding cardiac) at the hospital. General surgical operations were studied in detail and separated into major, intermediate, and minor for data collection. Main outcome measures-A change in the median visual analogue pain scores 24 hours after surgery for pain during relaxation, pain on movement, and pain on deep inspiration at each stage of the study. Results-There was a reduction in median visual analogue scores during the study. The median (95% confidence interval) scores for pain during relaxation decreased from 45 (34 to 53) in stage 1 to 16 (10 to 20) in stage 7 for major surgical procedures. Pain on movement decreased from 78 (66 to 80) to 46 (38 to 48), and pain on deep inspiration decreased from 64 (48 to 78) to 36 (31 to 38). The reductions in median scores for intermediate and minor operative procedures showed similar patterns. Conclusions-The introduction of an acute pain service to the general surgical wards led to considerable improvement in the level of postoperative pain as assessed by visual analogue scores. Simple techniques of regular pain assessment and the more frequent use of intramuscular analgesia as a result of using an algorithm were particularly effective.	UNIV HOSP WALES,DEPT ANAESTHET,CARDIFF,WALES; UNIV WALES COLL MED,DEPT ANAESTHET,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University								BAHAR M, 1985, ANASTHESIA, V40, P5529; BANOS JE, 1989, METHOD FIND EXP CLIN, V11, P123; FELL D, 1982, BMJ, V283, P92; Lee A, 1990, ANAESTHESIA, V46, P1028; LEHMANN KA, 1985, PATIENT CONTROLLED A, P134; LIU WHD, 1991, BRIT J ANAESTH, V67, P768, DOI 10.1093/bja/67.6.768; MACINTYRE PE, 1990, MED J AUSTRALIA, V153, P417, DOI 10.5694/j.1326-5377.1990.tb125503.x; MAGNANI B, 1990, PATIENT CONTROLLED A, P85; MATHER LE, 1975, BRIT J ANAESTH, V47, P1269, DOI 10.1093/bja/47.12.1269; MELZACK R, 1975, PAIN, V1, P275; OWEN H, 1989, ANAESTHESIA, V44, P11, DOI 10.1111/j.1365-2044.1989.tb11088.x; READY LB, 1988, ANESTHESIOLOGY, V68, P100, DOI 10.1097/00000542-198801000-00016; REVILL SI, 1976, ANAESTHESIA, V31, P1191, DOI 10.1111/j.1365-2044.1976.tb11971.x; Siegel S., 1988, NONPARAMETRIC STAT B, P213, DOI DOI 10.1177/014662168901300212; Siegel S., 1988, NONPARAMETRIC STAT B; Smith G., 1984, QUALITY CARE ANAESTH, P164; WHEATLEY RG, 1991, BRIT J ANAESTH, V67, P353, DOI 10.1093/bja/67.3.353; WHITE WD, 1979, BRIT MED J, V2, P166, DOI 10.1136/bmj.2.6183.166; ZAR JH, 1984, BIOSTAT ANAL, P219; 1990, WORKING PARTY PAIN S; 1991, CURRENT PROBLEMS, V31, P3	21	161	163	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1992	305	6863					1187	1193		10.1136/bmj.305.6863.1187	http://dx.doi.org/10.1136/bmj.305.6863.1187			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467721	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JY77700020
J	METCALFE, D				METCALFE, D			LONDON AFTER TOMLINSON .2. CARE IN THE CAPITAL - WHAT NEEDS TO BE DONE	BMJ-BRITISH MEDICAL JOURNAL			English	Article								One of the aims of the Tomlinson report is to shift more care from the secondary to the primary sector in London. But the primary sector is already underresourced and overloaded. The capital has a heterogeneous population which often makes inappropriate demands on general practitioners. Many premises are inadequate and there are insufficient support staff. David Metcalfe emphasises that London is special and that the shift will not become a reality unless these problems are tackled. He suggests the establishment of different models of practice centres which could treat some of the patients who now go to accident and emergency departments. Some would be the night emergency service base, some would have primary care beds, and each would have a different mix of specialist support.	UNIV MANCHESTER, DEPT GEN PRACTICE, MANCHESTER M14 5NP, ENGLAND	University of Manchester								[Anonymous], 1980, INEQUALITIES HLTH RE; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; LEAVEY R, 1985, BRIT MED J, V291, P709, DOI 10.1136/bmj.291.6497.709; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; Tomlinson B., 1992, REPORT INQUIRY LONDO; 1980, RCGP16 ROYAL COLL GE; 1992, LONDONS HLTH CARE 20; 1981, PRIMARY CARE INNER L	8	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 7	1992	305	6862					1141	1144		10.1136/bmj.305.6862.1141	http://dx.doi.org/10.1136/bmj.305.6862.1141			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463953	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JX84100027
J	SWAI, AB; KITANGE, HM; MASUKI, G; KILIMA, PM; ALBERTI, KGMM; MCLARTY, DG				SWAI, AB; KITANGE, HM; MASUKI, G; KILIMA, PM; ALBERTI, KGMM; MCLARTY, DG			IS DIABETES-MELLITUS RELATED TO UNDERNUTRITION IN RURAL TANZANIA	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; PROTEIN-CALORIE MALNUTRITION; INSULIN-SECRETION; PREVALENCE; COMMUNITY; CHILDREN; FETAL	Objective-To investigate the relation between undernutrition and diabetes. Design-Survey of glucose tolerance in rural Tanzania. Setting-Eight villages in three widely separated regions of Tanzania. Subjects-8581 people aged 15 and above: 3705 men and 4876 women. Main outcome measures-Oral glucose tolerance, body mass index, height, and low haemoglobin and cholesterol concentrations. Results-In the eight villages 42.7-56.9% of all men and 30.0-45.2% of all women had a body mass index below 20 kg/m2; the lowest quintile was 18.2 kg/m2 in men and 18.6 kg/m2 in women. The prevalence of diabetes did not change significantly from the lowest to the highest fifths of body mass index in men (lowest 1.6% (95% confidence interval 0.8% to 2.9%) v highest 1.3% (0.7% to 2.5%)) or women (1.1% (0.6% to 2.1%) v 0.5% (0.2% to 1.2%)). In men and in women prevalence of impaired glucose tolerance was greater in the lowest fifths of height (8.2% (6.3% to 10.6%), and 11.1% (9.2% to 13.3%)) respectively and body mass index (9.6% (7.5% to 12.1%), and 8.4% (6.7% to 10.5%)) than in the highest fifths (impaired glucose tolerance 4.7% (3.4% to 6.5%); and 5.1% (3.9% to 6.7%); body mass index 5.1% (3.7% to 7.0%), and 7.7% (6.2% to 9.6%). Conclusion-Rates of diabetes were not significantly associated with low body mass index or height, but overall rates were much lower than those in well nourished Western populations. Increased impaired glucose tolerance in the most malnourished people may reflect the larger glucose load per kilogram weight. The role of undernutrition in the aetiology of diabetes must be questioned.	UNIV NEWCASTLE UPON TYNE,CTR HUMAN DIABET & METAB RES,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV DAR ES SALAAM,MUHIMBILI MED CTR,DEPT MED,DAR ES SALAAM,TANZANIA; MINIST HLTH,DAR ES SALAAM,TANZANIA	Newcastle University - UK; University of Dar es Salaam								ABOUBAKARE A, 1986, LANCET, V1, P1135; ALBERTI K G M M, 1988, Diabetes Research and Clinical Practice, V5, pS449; ALLAIN CC, 1974, CLIN CHEM, V20, P470; BAJAJ JS, 1984, DIABETES MELLITUS; BECKER DJ, 1971, DIABETES, V20, P542, DOI 10.2337/diab.20.8.542; BENNETT PH, 1992, INT TXB DIABETES MEL, P147; COOK GC, 1967, NATURE, V215, P1295, DOI 10.1038/2151295a0; DAVIES JNP, 1948, LANCET, V1, P317; Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; FLEMING A. F., 1984, PRINCIPLES MED AFRIC, P705; GOPALAN C., 1952, Indian Journal of Medical Sciences, V6, P277; GUPTA OP, 1976, EXCERPTA MED INT C S, V390, P23; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HEARD CRC, 1967, DIABETES, V16, P96, DOI 10.2337/diab.16.2.96; Himsworth H. P., 1949, P ROY SOC MED, V62, P323; KEEN H, 1984, BRIT MED BULL, V40, P359, DOI 10.1093/oxfordjournals.bmb.a072005; KHARDORI R, 1985, DIABETES CARE, V8, P302, DOI 10.2337/diacare.8.3.302a; KIMATI VP, 1985, E AFR MED J, V62, P105; LESTER FT, 1984, IDF B, V29, P14; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MCLARTY DG, 1990, DIABETIC MED, V7, P670, DOI 10.1111/j.1464-5491.1990.tb01470.x; MCLARTY DG, 1989, LANCET, V1, P871; McMillan D E, 1979, Diabetes Care, V2, P202, DOI 10.2337/diacare.2.2.202; MRISHO F, 1986, MALNUTRITION TANZANI, P7; NORUSIS MJ, 1986, SPSS PC SPSS IBM PC; NWOKOLO C, 1980, LANCET, V1, P457; OLURIN EO, 1969, BMJ-BRIT MED J, V4, P534, DOI 10.1136/bmj.4.5682.534; PITCHUMONI CS, 1988, PANCREAS, V3, P220, DOI 10.1097/00006676-198804000-00018; RAO RH, 1988, ENDOCR REV, V9, P67, DOI 10.1210/edrv-9-1-67; RAO RH, 1984, DIABETES CARE, V7, P595, DOI 10.2337/diacare.7.6.595; SHAPER AG, 1960, LANCET, V1, P1223; SMITH SR, 1975, METABOLISM, V24, P1073, DOI 10.1016/0026-0495(75)90101-8; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; SWAI ABM, 1991, DIABETES, V40, P516, DOI 10.2337/diabetes.40.4.516; SWAI ABM, IN PRESS DIABETES CA; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; TANNER JM, 1956, ARCH DIS CHILD, V31, P372, DOI 10.1136/adc.31.159.372; TANNER M, 1987, ACTA TROP, V44, P137; WALKER M, 1988, J EPIDEMIOL COMMUN H, V42, P299, DOI 10.1136/jech.42.3.299; WEST KM, 1971, DIABETES, V20, P99, DOI 10.2337/diab.20.2.99; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P231; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P74; WHINCUP PH, 1988, BMJ, V197, P980; 1987, PRELIMINARY REPORT H; 1989, ARCH INTERN MED, V149, P2650; [No title captured]	47	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1057	1062		10.1136/bmj.305.6861.1057	http://dx.doi.org/10.1136/bmj.305.6861.1057			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467685	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JW70100018
J	FRANK, E; WINKLEBY, MA; FORTMANN, SP; ROCKHILL, B; FARQUHAR, JW				FRANK, E; WINKLEBY, MA; FORTMANN, SP; ROCKHILL, B; FARQUHAR, JW			IMPROVED CHOLESTEROL-RELATED KNOWLEDGE AND BEHAVIOR AND PLASMA-CHOLESTEROL LEVELS IN ADULTS DURING THE 1980S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STANFORD 5-CITY PROJECT; COMMUNITY-HEALTH EDUCATION; 2 NATIONAL SURVEYS; HEART-DISEASE; RISK-FACTORS; SOCIAL-CLASS; PERSPECTIVE; PHYSICIAN	Objectives.-To determine whether cholesterol-related knowledge and behavior and plasma cholesterol levels were stable until the inception of large-scale national interventions in the middle to late 1980s, whether they subsequently improved, and whether these levels varied by subgroups. Design, Setting, and Participants.-Data were collected from 4173 adults aged 25 through 74 years in the two control cities (San Luis Obispo and Modesto, Calif) of the Stanford Five-City Project. Five separate, community-based surveys were conducted in 1979-1980, 1981-1982, 1983-1984, 1985-1986, and 1989-1990. Results.-Cholesterol-related knowledge and behavior and plasma cholesterol levels improved (P=.0001) in both cities after the early 1980s. Those who were more educated, female, older, or nonsmokers had significantly higher knowledge and behavior scores, and those who were younger, more educated, or normotensive had significantly lower plasma cholesterol levels. Conclusion.-Improvements in this population's cholesterol-related knowledge and behavior and plasma cholesterol levels began in 1985-1986, suggesting that the extensive cholesterol interventions that began in the middle 1980s in the United States created positive cholesterol-related changes at the community level.	STANFORD UNIV, SCH MED, STANFORD CTR RES DIS PREVENT, 1000 WELCH RD, PALO ALTO, CA 94304 USA; STANFORD UNIV, SCH MED, DEPT MED, PALO ALTO, CA 94304 USA	Stanford University; Stanford University				Frank, Erica/0000-0001-7159-5417	NHLBI NIH HHS [5T32-HL-07034, 1R01-HL-21906] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007034, R01HL021906] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; BURKE GL, 1991, NEW ENGL J MED, V324, P941, DOI 10.1056/NEJM199104043241402; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; FARQUHAR JW, 1985, AM J EPIDEMIOL, V122, P323, DOI 10.1093/oxfordjournals.aje.a114104; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FORTMANN SP, 1990, AM J EPIDEMIOL, V132, P629, DOI 10.1093/oxfordjournals.aje.a115705; LENFANT C, 1986, CIRCULATION, V73, P855, DOI 10.1161/01.CIR.73.5.855; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030; MCKIBBEN Bill, 1989, END NATURE; NIKNIAN M, 1991, AM J PUBLIC HEALTH, V81, P203, DOI 10.2105/AJPH.81.2.205; Olien C. N., 1983, MASS COMMUNICATION R, V4, P455; RIFKIN J, 1992, BEEF RISE FALL CATTL; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3527, DOI 10.1001/jama.258.24.3527; SCHUCKER B, 1991, ARCH INTERN MED, V151, P666, DOI 10.1001/archinte.151.4.666; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3521, DOI 10.1001/jama.258.24.3521; TAYLOR CB, 1991, AM J EPIDEMIOL, V134, P235, DOI 10.1093/oxfordjournals.aje.a116077; WILLIAMS F, 1977, J COMMUN, V27, P95, DOI 10.1111/j.1460-2466.1977.tb01803.x; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; WINKLEBY MA, IN PRESS HISP J BEHA; 1974, US DHEW NIH75628 PUB, P1	23	44	44	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1566	1572		10.1001/jama.268.12.1566	http://dx.doi.org/10.1001/jama.268.12.1566			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1518111				2022-12-28	WOS:A1992JN25600027
J	PATHMAN, DE; KONRAD, TR; RICKETTS, TC				PATHMAN, DE; KONRAD, TR; RICKETTS, TC			THE COMPARATIVE RETENTION OF NATIONAL-HEALTH-SERVICE-CORPS AND OTHER RURAL PHYSICIANS - RESULTS OF A 9-YEAR FOLLOW-UP-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY CARE PROGRAMS; SURVIVAL	Objective.-To contrast the retention of physicians serving National Health Service Corps (NHSC) Scholarship Program obligations in rural settings to that of non-NHSC physicians working in the same or similar practices, and to identify promising retention-enhancing strategies. Design.-Cohort study. Participants.-Four hundred twelve primary care physicians initially identified during an earlier study as working in a national stratified random sample of 178 externally subsidized rural clinics in 1981. Thirty-six percent were serving obligations to the NHSC, nearly all through the NHSC's Scholarship Program. The NHSC and non-NHSC inception cohorts (those first coming to their 1981 [or "index"] practices from May 1979 through December 1981) were created from within the entire group for use in most analyses. Intervention.-In 1990, physicians were resurveyed to learn of their backgrounds, experiences in their index practices, and their subsequent career moves. Results.-By 1984 and in each year thereafter, fewer NHSC than non-NHSC physicians of the entire respondent cohort remained (1) in their index practices, (2) in their index communities, and (3) in practice in any rural county (P<.001). In the inception cohort, fewer NHSC than non-NHSC physicians were retained within all three settings by the third year after their initial dates of employment (P less-than-or-equal-to .01). After 8 years of employment, group retention rates for NHSC and non-NHSC inception cohort physicians were 12% vs 39% in the index practice and 29% vs 52% in nonmetropolitan practice. Physicians in both NHSC and non-NHSC groups who left their index practices generally left rural practice altogether. Conclusions.-When compared to non-NHSC physicians working in comparable rural settings, the retention of rural NHSC physicians is seen to be poor and only partially explained by fixed physician, practice, or community variables. Long-term retention of NHSC providers is now receiving much needed attention at the federal level.	UNIV N CAROLINA,DEPT FAMILY MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	PATHMAN, DE (corresponding author), UNIV N CAROLINA,CECIL G SHEPS CTR HLTH SERV RES,N CAROLINA RURAL HLTH RES PROGRAM,CHAPEL HILL,NC 27599, USA.		Konrad, Thomas R./AAT-9276-2020	Konrad, Thomas R/0000-0002-5269-0440; Pathman, Donald/0000-0002-6708-3707	AHRQ HHS [1-RO1-HS06544-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		APPLEBOME P, 1990, NY TIMES        0212, pB11; Applebome Peter, 1990, N Y Times Web, pA21; BARBANEL J, 1990, NY TIMES        0624, P17; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; COX DR, 1972, J R STAT SOC B, V34, P187; FINE M, 1990, NY TIMES        0728, P20; GAPEN P, 1988, MED HLTH PERSPE 0704; Haglund K, 1979, New Physician, V28, P20; KEHRER BH, 1982, 240790056 HLTH SERV; LEWIS CE, 1976, RIGHT HLTH PROBLEM A, P127; MCCORMICK K, 1989, MED HLTH PERSPE 0911; MCLAUGHLIN CP, 1985, AM J PUBLIC HEALTH, V75, P749, DOI 10.2105/AJPH.75.7.749; MICHELSEN E, 1979, PUBLIC HEALTH REP, V94, P11; MULLAN F, 1980, PUBLIC HEALTH REP, V95, P9; MULLAN F, 1984, REFORMING MED LESSON, P176; RICKETTS TC, 1983, AM J PUBLIC HEALTH, V73, P406, DOI 10.2105/AJPH.73.4.406; RICKETTS TC, 1984, AM J PUBLIC HEALTH, V74, P816, DOI 10.2105/AJPH.74.8.816; ROSENBLATT RA, 1980, MILBANK FUND Q, V58, P283, DOI 10.2307/3349715; ROSENBLATT RA, 1978, J FAM PRACTICE, V7, P755; Samuels M E, 1978, Ann N Y Acad Sci, V310, P163, DOI 10.1111/j.1749-6632.1978.tb22069.x; SHEPS CG, 1983, AM J PUBLIC HEALTH, V73, P38, DOI 10.2105/AJPH.73.1.38; Silver P, 1980, J Miss State Med Assoc, V21, P29; STONE VE, 1991, J HEALTH CARE POOR U, V2, P1; WEAVER DL, 1990, ACAD MED, V65, pS43, DOI 10.1097/00001888-199012000-00034; 1990, UNPUB NATIONAL HLTH; 1987, UNPUB PHYSICIANS COM; 1978, HRD77135 COMPTR GEN; 1988, NHSC SCHOLARSHIP PRO; 1990, OTAH434 OFF TECHN AS; 1989, PROPOSED STRATEGIES; 1977, RETENTION NATIONAL H; 1991, UNPUB HRSAS LONG RAN; 1982, 240800046 US DEP HLT	33	76	76	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1552	1558						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1518110				2022-12-28	WOS:A1992JN25600025
J	VINCENT, GM; TIMOTHY, KW; LEPPERT, M; KEATING, M				VINCENT, GM; TIMOTHY, KW; LEPPERT, M; KEATING, M			THE SPECTRUM OF SYMPTOMS AND QT INTERVALS IN CARRIERS OF THE GENE FOR THE LONG-QT SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-RATE; LINKAGE	Background. The familial long-QT syndrome is characterized by a prolonged QT interval on the electro-cardiogram, ventricular arrhythmias, and sudden death. It is not certain, however, that the length of the QT interval is a sensitive or a specific diagnostic criterion. Recently, we identified genetic markers on chromosome 11 that distinguished between carriers and noncarriers of the gene for the long-QT syndrome in three families. In this study, we compared the clinical features of carriers and noncarriers and assessed the diagnostic accuracy of the QT interval. Methods. We obtained medical histories and electro-cardiograms from 199 family members. OT intervals corrected for heart rate (QT(c)) were determined independently by two blinded investigators. Carriers of the long-QT gene (83 subjects) and noncarriers (1 16 subjects) were distinguished by genetic-linkage analysis. Results. Fifty-two of the carriers of the long-QT gene (63 percent) had a history of syncope, whereas four 5 percent had a history of aborted sudden death. The QT(c) intervals of the gene carriers ranged from 0.41 to 0.59 second (mean, 0.49). By contrast, the QT(c) intervals of the noncarriers ranged from 0.38 to 0.47 second (mean, 0.42). On average, carriers of the gene for the long-QT syndrome had longer QT(c) intervals than noncarriers, but there was substantial overlap (in 126 of the 199 subjects, or 63 percent). The use of a QT(c) interval above 0.44 second as a diagnostic criterion resulted in 22 misclassifications among the 199 family members (11 percent). QT(c) intervals of 0.47 second or longer in males and 0.48 second or longer in females were completely predictive but resulted in false negative diagnoses in 40 percent of the males and 20 percent of the females. Conclusions. In families affected by the long-QT syndrome, measurement of the QT(c) interval may not permit an accurate diagnosis. DNA markers make it possible to make a genetic diagnosis in some families, but not all gene carriers have symptoms.	UNIV UTAH,HLTH SCI CTR,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,DEPT MED,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	VINCENT, GM (corresponding author), UNIV UTAH,LATTER DAY ST HOSP,HLTH SCI CTR,DEPT MED,SALT LAKE CITY,UT 84143, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00064] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; Hashiba K, 1987, Heart Vessels Suppl, V2, P47; HASHIBA K, 1978, JPN CIRC J, V42, P1133, DOI 10.1253/jcj.42.1133; KEATING M, 1991, AM J HUM GENET, V49, P1335; KEATING M, 1992, CIRCULATION, V85, P1973, DOI 10.1161/01.CIR.85.6.1973; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; LIPMAN BS, 1973, CLIN SCALAR ELECTROC, P670; MOSS AJ, 1986, JAMA-J AM MED ASSOC, V256, P2985; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; MOSS AJ, 1987, JAMA-J AM MED ASSOC, V257, P487; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; SCHWARTZ PJ, 1985, AM HEART J, V109, P399, DOI 10.1016/0002-8703(85)90626-X; VINCENT G M, 1974, Progress in Cardiovascular Diseases, V16, P523; VINCENT GM, 1991, AM J CARDIOL, V68, P498, DOI 10.1016/0002-9149(91)90785-J; VINCENT GM, 1986, AM HEART J, V112, P61, DOI 10.1016/0002-8703(86)90678-2; VINCENT GM, 1989, CLIN ASPECTS VENTRIC, P411; VINCENT GM, 1989, CIRCULATION S2, V80, P654; WARD O C, 1964, J Ir Med Assoc, V54, P103; WEINSTEIN MV, 1980, CLIN DECISION ANAL, P79; WEINTRAUB RG, 1990, J AM COLL CARDIOL, V16, P674, DOI 10.1016/0735-1097(90)90359-W; Zar JH., 1999, BIOSTAT ANAL	23	487	498	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					846	852		10.1056/NEJM199209173271204	http://dx.doi.org/10.1056/NEJM199209173271204			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1508244	Bronze			2022-12-28	WOS:A1992JN12000004
J	ROTHE, M; PEHL, M; TAUBERT, H; JACKLE, H				ROTHE, M; PEHL, M; TAUBERT, H; JACKLE, H			LOSS OF GENE-FUNCTION THROUGH RAPID MITOTIC-CYCLES IN THE DROSOPHILA EMBRYO	NATURE			English	Article							PATTERN; KNIRPS; SEGMENTATION; SUPERFAMILY	THE early developmental period in Drosophila is characterized by rapid mitotic divisions, when the body pattern becomes organized by a cascade of segmentation gene activity1,2. During this process localized expression of the gap gene knirps (kni) is required to establish abdomen segmentation3,4. The knirps-related gene (knrl) encodes a kni-homologous nuclear hormone receptor-like protein5,6 and shares the spatial patterns of kni expression. The two genes differ with respect to the size of their transcription units; kni contains 1 kilobase and knrl 19 kilobases of intron sequences. The consequence of this difference in intron size is that knrl cannot substitute for kni segmentation function, although it gains this ability when expressed from an intronless transgene. Here we show that the length of mitotic cycles provides a physiological barrier to transcript size, and is therefore a significant factor in controlling developmental gene activity during short 'phenocritical' periods. The required coordination of cycle length and gene size provides severe constraints towards the evolution of rapid development.	MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,W-3400 GOTTINGEN,GERMANY	Max Planck Society								AKAM M, 1987, DEVELOPMENT, V101, P1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; EDGAR B, 1990, CELL, V52, P469; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOE VE, 1983, J CELL SCI, V61, P31; FOE VE, 1989, DEVELOPMENT, V107, P1; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HOCH M, 1992, SCIENCE, V256, P94, DOI 10.1126/science.1348871; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; LEHMANN R, 1988, DEVELOPMENT, V104, P17; LEHMANN R, 1985, THESIS U TUBINGEN; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1989, DEVELOPMENT, V107, P133; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; STRECKER TR, 1986, DEV BIOL, V113, P64, DOI 10.1016/0012-1606(86)90108-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041	20	120	121	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					156	159		10.1038/359156a0	http://dx.doi.org/10.1038/359156a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522901				2022-12-28	WOS:A1992JM49400056
J	STEWART, CL; KASPAR, P; BRUNET, LJ; BHATT, H; GADI, I; KONTGEN, F; ABBONDANZO, SJ				STEWART, CL; KASPAR, P; BRUNET, LJ; BHATT, H; GADI, I; KONTGEN, F; ABBONDANZO, SJ			BLASTOCYST IMPLANTATION DEPENDS ON MATERNAL EXPRESSION OF LEUKEMIA INHIBITORY FACTOR	NATURE			English	Article							COLONY-STIMULATING FACTOR; EMBRYONIC STEM-CELLS; PREIMPLANTATION DEVELOPMENT; PROTO-ONCOGENE; FACTOR LIF; MURINE; GENES; CSF-1; INTERLEUKIN-6; CYTOKINES	A CRITICAL point during mammalian pregnancy is the implantation of the blastocyst when the embryo attaches to the wall of the uterus. The autonomously developing preimplantation embryo then becomes dependent on the maternal environment for its continued development. Little is known about the regulation of implantation, except that a complex interaction between peptide and steroid hormones synchronizes the preparation of the uterus for implantation with the development of the embryo. Whether the implantation event is under maternal or embryonic control is also unclear (reviewed in refs 1, 2). We have previously shown that a cytokine, leukaemia inhibitory factor (LIF), is expressed in the uterine endometrial glands specifically on the fourth day of pregnancy3. This burst of expression is under maternal control and always precedes implantation of the blastocyst. Here we report that transient expression of LIF in mice is essential for implantation. Females lacking a functional LIF gene are fertile, but their blastocysts fail to implant and do not develop. The blastocysts, however, are viable and, when transferred to wild-type pseudopregnant recipients, they can implant and develop to term.	INST MOLEC GENET, PRAGUE 6, CZECHOSLOVAKIA; ROCHE BIOMED LABS INC, RARITAN, NJ USA; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES, BASEL NEW TECHNOL, CH-4002 BASEL, SWITZERLAND	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Roche Holding	STEWART, CL (corresponding author), ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT CELL & DEV BIOL, 340 KINGSLAND ST, NUTLEY, NJ 07110 USA.		Kaspar, Petr/J-1705-2014; Kaspar, Petr/G-5864-2014					BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BHATT H, 1991, P NATL ACAD SCI USA, V88, P11408, DOI 10.1073/pnas.88.24.11408; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CONQUET F, 1990, MOL CELL BIOL, V10, P3801, DOI 10.1128/MCB.10.7.3801; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, NEW BIOL, V4, P61; HILTON DJ, 1991, J CELL PHYSIOL, V148, P430, DOI 10.1002/jcp.1041480315; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; Hodgen G.D., 1988, P1995; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KOENTGEN F, 1992, THESIS U FREIBOURG G; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MURRAY R, 1990, MOL CELL BIOL, V10, P4953, DOI 10.1128/MCB.10.9.4953; PAMPFER S, 1991, BIOESSAYS, V13, P535, DOI 10.1002/bies.950131007; POLALRD JW, 1987, NATURE, V390, P484; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; Sambrook J, 1989, MOL CLONING LABORATO; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL J, 1990, J BIOL CHEM, V265, P8833; STEWART CL, 1987, EMBO J, V6, P383, DOI 10.1002/j.1460-2075.1987.tb04766.x; TARTAKOVSKY B, 1991, DEV BIOL, V146, P345, DOI 10.1016/0012-1606(91)90236-V; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Weitlauf H.M., 1988, P231; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; ZJILSTRA M, 1990, NATURE, V344, P742	31	1673	1767	2	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					76	79		10.1038/359076a0	http://dx.doi.org/10.1038/359076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522892				2022-12-28	WOS:A1992JL66200058
J	SHARPE, M; HAWTON, K; SEAGROATT, V; PASVOL, G				SHARPE, M; HAWTON, K; SEAGROATT, V; PASVOL, G			FOLLOW-UP OF PATIENTS PRESENTING WITH FATIGUE TO AN INFECTIOUS-DISEASES CLINIC	BRITISH MEDICAL JOURNAL			English	Article							POSTVIRAL FATIGUE; HOSPITAL ANXIETY; DEPRESSION SCALE	Objectives-To determine the symptomatic and functional status during follow up of patients referred to hospital with unexplained fatigue and to identify patient variables associated with persistent functional impairment. Design-Follow up by postal questionnaire six weeks to four years (median 1 year) after initial clinical assessment of patients referred to hospital during 1984-8. Setting-Infectious diseases outpatient clinic in a teaching hospital. Patients-200 consecutive patients with fatigue of uncertain cause for at least six weeks; 177 fulfilled the inclusion criteria. Main outcome measures-Findings at initial assessment; current symptoms, beliefs about the cause of illness, coping behaviours emotional disorder, social variables including membership of self help organisations, and degrees of recovery and functional impairment from questionnaire responses. Results-144 (81%) patients returned completed questionnaires. Initial assessment did not indicate the cause of fatigue, other than preceding infection. The proportion of patients with functional impairment was significantly smaller with longer follow up (33% (11/33) at two to four years, 73% (29/40) at six weeks to six months; chi-2 for trend = 12.5, df=1; p<0.05). Functional impairment was significantly associated with belief in a viral cause of the illness (odds ratio=3-9; 95% confidence interval 1.5 to 9.9), limiting exercise (3.2; 1.5 to 6.6), avoiding alcohol (4.5; 1.8 to 11.3), changing or leaving employment (3.1; 1.4 to 6.9), belonging to a self help organisation (7.8; 2.5 to 23.9), and current emotional disorder (4.4; 2.0 to 9.3). Conclusions-Short term prognosis for recovery of function was poor but improved with time. Most patients had made a functional recovery by two years after initial clinic attendance. Impaired functioning was more likely with certain patient characteristics. Prospective studies are required to clarify whether these associations are the consequences of a more disabling illness or indicate factors contributing to impaired function.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OXFORD,ENGLAND	University of Oxford; University of Oxford	SHARPE, M (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.		Pasvol, Geoffrey/B-7113-2009	sharpe, michael/0000-0002-6474-9980				BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; BUTLER S, 1991, J NEUROL NEUROSUR PS, V54, P153, DOI 10.1136/jnnp.54.2.153; DOWSETT EG, 1991, POSTGRAD MED J, V66, P526; HICKIE I, 1990, BRIT J PSYCHIAT, V156, P534, DOI 10.1192/bjp.156.4.534; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; LANDAY A, 1991, LANCET, V338, P701; LANE TJ, 1990, AM J MED SCI, V299, P313, DOI 10.1097/00000441-199005000-00005; LEWIS G, 1990, BRIT J PSYCHIAT, V157, P860, DOI 10.1192/bjp.157.6.860; MANU P, 1989, J AFFECT DISORDERS, V17, P165, DOI 10.1016/0165-0327(89)90039-6; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; Millon C, 1989, PSYCHOL HEALTH, V3, P131; Nelson E, 1987, Fam Pract Res J, V6, P175; NIXON DF, 1987, J CLIN PATHOL, V40, P673, DOI 10.1136/jcp.40.6.673; SHARPE M, 1991, BRIT MED BULL, V47, P989, DOI 10.1093/oxfordjournals.bmb.a072525; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; VALDINI A, 1989, FAM PRACT, V6, P286, DOI 10.1093/fampra/6.4.286; VALDINI AF, 1988, J FAM PRACTICE, V26, P33; VINCENT A, 1985, J NEUROL NEUROSUR PS, V48, P1246, DOI 10.1136/jnnp.48.12.1246; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WESSELY S, 1989, J ROY COLL GEN PRACT, V39, P26; YOUSEF GE, 1988, LANCET, V1, P146; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	24	148	149	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					147	152		10.1136/bmj.305.6846.147	http://dx.doi.org/10.1136/bmj.305.6846.147			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515828	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JF06300020
J	SMITH, PD; QUINN, TC; STROBER, W; JANOFF, EN; MASUR, H				SMITH, PD; QUINN, TC; STROBER, W; JANOFF, EN; MASUR, H			GASTROINTESTINAL INFECTIONS IN AIDS	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME; MYCOBACTERIUM-AVIUM COMPLEX; CYTOMEGALO-VIRUS INFECTION; ANTI-BACTERIAL ACTIVITY; HOMOSEXUAL MEN; HERPES-SIMPLEX; IMMUNOCOMPROMISED PATIENTS; HUMAN CRYPTOSPORIDIOSIS; SALMONELLA-TYPHIMURIUM	As the largest lymphoid organ in the body, the gastrointestinal tract is a potential reservoir for human immunodeficiency virus (HIV), the causative agent of the acquired immunodeficiency syndrome (AIDS), and it is an important site for HIV-induced immunodeficiency. The resulting defects in cellular and humoral defense mechanisms predispose the gastrointestinal tract to a spectrum of viral, fungal, bacterial, and protozoan pathogens that cause relentless morbidity and, in some cases, death. With a thorough diagnostic evaluation, physicians can identify one or more of these pathogens in a majority of patients with AIDS who have gastrointestinal symptoms. The identification of enteric pathogens in patients with AIDS is important because an increasing array of therapeutic regimens is becoming available to treat many of these infections.			SMITH, PD (corresponding author), NIH, BLDG 30, ROOM 322, BETHESDA, MD 20892 USA.		Quinn, Thomas/A-2494-2010					ALLASONJONES E, 1986, NEW ENGL J MED, V315, P353, DOI 10.1056/NEJM198608073150603; ALLEN JB, 1990, J CLIN INVEST, V85, P192, DOI 10.1172/JCI114412; AMMANN AJ, 1984, JAMA-J AM MED ASSOC, V251, P1447, DOI 10.1001/jama.251.11.1447; ARCHIBALD DW, 1987, J INFECT DIS, V156, P240, DOI 10.1093/infdis/156.1.240; ARCHIBALD DW, 1986, BLOOD, V67, P831; ARCHIBALD DW, 1987, J INFECT DIS, V155, P793, DOI 10.1093/infdis/155.4.793; BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933; BASKIN DH, 1987, AM J GASTROENTEROL, V82, P338; BELEC L, 1989, J INFECT DIS, V159, P324, DOI 10.1093/infdis/159.2.324; BLASER MJ, 1989, AM J MED, V86, P105, DOI 10.1016/0002-9343(89)90239-8; BUDHRAJA M, 1987, AM J GASTROENTEROL, V82, P427; CALI A, 1990, J PROTOZOOL, V37, P145, DOI 10.1111/j.1550-7408.1990.tb05885.x; CAMPBELL PN, 1983, J CLIN MICROBIOL, V18, P165, DOI 10.1128/JCM.18.1.165-169.1983; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; CHACHOUA A, 1987, ANN INTERN MED, V107, P133, DOI 10.7326/0003-4819-107-2-133; CHIU J, 1990, ANN INTERN MED, V113, P358, DOI 10.7326/0003-4819-113-5-358; COLEBUNDERS R, 1987, AM J GASTROENTEROL, V82, P859; COOK DJ, 1988, ANN INTERN MED, V108, P708, DOI 10.7326/0003-4819-108-5-708; COOPER DA, 1985, LANCET, V1, P537; CRAWFORD JT, 1986, AM REV RESPIR DIS, V134, P659; CROWLE AJ, 1986, J CLIN MICROBIOL, V24, P812, DOI 10.1128/JCM.24.5.812-821.1986; CROWLE AJ, 1989, INFECT IMMUN, V57, P1445, DOI 10.1128/IAI.57.5.1445-1451.1989; CULPEPPERMORGAN JA, 1987, AM J GASTROENTEROL, V82, P1264; CUNNINGHAM AL, 1988, J INFECT DIS, V158, P386, DOI 10.1093/infdis/158.2.386; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; DAMSKER B, 1985, J INFECT DIS, V151, P179, DOI 10.1093/infdis/151.1.179; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; DESPORTES I, 1985, J PROTOZOOL, V32, P250; DEWIT S, 1989, LANCET, V1, P746; DINARI G, 1987, J INFECT DIS, V155, P1065, DOI 10.1093/infdis/155.5.1065; DRIKS MR, 1990, 30TH P INT C ANT AG, pA1272; DRYDEN MS, 1988, J INFECTION, V17, P107, DOI 10.1016/S0163-4453(88)91515-0; DWORKIN B, 1985, AM J GASTROENTEROL, V80, P774; DWORKIN B, 1986, AM J MED, V80, P965, DOI 10.1016/0002-9343(86)90646-7; EISNER M S, 1990, Gastroenterology, V98, pA446; ELLAKANY S, 1987, AM J CLIN PATHOL, V87, P356, DOI 10.1093/ajcp/87.3.356; ERICE A, 1989, NEW ENGL J MED, V320, P289, DOI 10.1056/NEJM198902023200505; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; FRANCIS ND, 1989, J CLIN PATHOL, V42, P1055, DOI 10.1136/jcp.42.10.1055; GANDER RM, 1987, DIAGN MICR INFEC DIS, V8, P193, DOI 10.1016/0732-8893(87)90172-6; GANGADHARAM PRJ, 1989, MICROB PATHOGENESIS, V7, P263, DOI 10.1016/0882-4010(89)90045-4; GARCIAPENARRUBIA P, 1989, J EXP MED, V169, P99, DOI 10.1084/jem.169.1.99; GILLIN JS, 1985, ANN INTERN MED, V102, P619, DOI 10.7326/0003-4819-102-5-619; GILLIN JS, 1983, GASTROENTEROLOGY, V85, P1187; GLASER JB, 1985, ANN INTERN MED, V102, P189, DOI 10.7326/0003-4819-102-2-189; GOODELL SE, 1983, NEW ENGL J MED, V308, P868, DOI 10.1056/NEJM198304143081503; GRAY JR, 1989, AM J GASTROENTEROL, V84, P1521; HARRIMAN GR, 1989, ARCH INTERN MED, V149, P2039, DOI 10.1001/archinte.149.9.2039; HEISE C, 1991, GASTROENTEROLOGY, V100, P1521, DOI 10.1016/0016-5085(91)90648-5; HILL DR, 1987, INFECT IMMUN, V55, P3155, DOI 10.1128/IAI.55.12.3155-3161.1987; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; HOY J, 1990, J INFECT DIS, V161, P801, DOI 10.1093/infdis/161.4.801; JACKSON S, 1990, ADVANCES IN MUCOSAL IMMUNOLOGY, P665; JACOBS JL, 1985, ANN INTERN MED, V102, P186, DOI 10.7326/0003-4819-102-2-186; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; Janoff E. N., 1990, Giardiasis., P215; JANOFF E N, 1989, Gastroenterology, V96, pA236; JANOFF EN, 1988, J INFECT DIS, V158, P983, DOI 10.1093/infdis/158.5.983; JANOFF EN, 1988, GASTROENTEROL CLIN N, V17, P451; JANOFF EN, 1987, J CLIN MICROBIOL, V25, P967, DOI 10.1128/JCM.25.6.967-975.1987; JANOFF EN, 1990, ANN INTERN MED, V112, P75, DOI 10.7326/0003-4819-112-1-75; JANOFF EN, 1991, J IMMUNOL, V147, P2130; JANOFF EN, 1988, J INFECT DIS, V157, P798, DOI 10.1093/infdis/157.4.798; JANOFF EN, 1991, GASTROENTEROLOGY, V100, P976, DOI 10.1016/0016-5085(91)90272-M; JARRY A, 1990, HISTOPATHOLOGY, V16, P133; JOHANSON JF, 1990, ANN INTERN MED, V112, P942, DOI 10.7326/0003-4819-112-12-942; JOKIPII L, 1986, NEW ENGL J MED, V315, P1643, DOI 10.1056/NEJM198612253152604; KALJOT KT, 1989, GASTROENTEROLOGY, V97, P1031, DOI 10.1016/0016-5085(89)91516-3; KAVIN H, 1986, ANN INTERN MED, V104, P53, DOI 10.7326/0003-4819-104-1-53; KAWANISHI H, 1983, J EXP MED, V157, P433, DOI 10.1084/jem.157.2.433; KIEHN TE, 1985, J CLIN MICROBIOL, V21, P168, DOI 10.1128/JCM.21.2.168-173.1985; KIYONO H, 1985, J EXP MED, V161, P731, DOI 10.1084/jem.161.4.731; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; KLIMPEL GR, 1986, J IMMUNOL, V136, P1081; KNAPP AB, 1983, GASTROENTEROLOGY, V85, P1399; KOTLER DP, 1984, ANN INTERN MED, V101, P421, DOI 10.7326/0003-4819-101-4-421; KOTLER DP, 1990, ANN INTERN MED, V113, P444; KOTLER DP, 1989, AM J GASTROENTEROL, V84, P313; KOTLER DP, 1987, DIGEST DIS SCI, V32, P129, DOI 10.1007/BF01297100; KUNIMOTO DY, 1988, J IMMUNOL, V141, P713; LAKEBAKAAR G, 1988, ANN INTERN MED, V109, P502, DOI 10.7326/0003-4819-109-6-502; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; LOUIE E, 1987, CLIN IMMUNOL IMMUNOP, V44, P329, DOI 10.1016/0090-1229(87)90077-8; LUFT BJ, 1984, JAMA-J AM MED ASSOC, V252, P913, DOI 10.1001/jama.252.7.913; MA P, 1983, J INFECT DIS, V147, P824, DOI 10.1093/infdis/147.5.824; Ma P, 1984, AIDS RES, V1, P327; MAI UE, 1992, IN PRESS J EXP MED; MAI UEH, 1991, J CLIN INVEST, V87, P894, DOI 10.1172/JCI115095; MALEBRANCHE R, 1983, LANCET, V2, P873; MANDELL W, 1986, JAMA-J AM MED ASSOC, V255, P3116, DOI 10.1001/jama.1986.03370220078021; MARGULIS SJ, 1986, ANN INTERN MED, V105, P207, DOI 10.7326/0003-4819-105-2-207; MASUR H, 1990, PRINCIPLES PRACTICE, P1102; MAY RG, 1983, 32ND ANN M AM SOC TR; MCKINSEY DS, 1989, ANN INTERN MED, V111, P655, DOI 10.7326/0003-4819-111-8-655; MEISEL JL, 1976, GASTROENTEROLOGY, V70, P1156; MEISELMAN MS, 1985, GASTROENTEROLOGY, V88, P171, DOI 10.1016/S0016-5085(85)80150-5; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MILLER RA, 1988, REV INFECT DIS, V10, P930; MODIGLIANI R, 1985, GUT, V26, P179, DOI 10.1136/gut.26.2.179; MORGAN DR, 1984, INFECT IMMUN, V46, P25, DOI 10.1128/IAI.46.1.25-33.1984; MOSKOVITZ BL, 1988, J ANTIMICROB CHEMOTH, V22, P189, DOI 10.1093/jac/22.Supplement_B.189; MURRAY HW, 1984, NEW ENGL J MED, V310, P883, DOI 10.1056/NEJM198404053101404; NELSON JA, 1988, LANCET, V1, P259; NG E, 1984, J CLIN MICROBIOL, V20, P384, DOI 10.1128/JCM.20.3.384-386.1984; OLIVER NM, 1989, ANTIMICROB AGENTS CH, V33, P635, DOI 10.1128/AAC.33.5.635; ORENSTEIN JM, 1990, HUM PATHOL, V21, P475; ORENSTEIN JM, 1990, LANCET, V336, P1127, DOI 10.1016/0140-6736(90)92600-M; PEARCE RB, 1987, NEW ENGL J MED, V316, P690, DOI 10.1056/NEJM198703123161111; PERLMAN DM, 1988, ANN INTERN MED, V108, P540, DOI 10.7326/0003-4819-108-4-540; PITLIK SD, 1983, ARCH INTERN MED, V143, P2269, DOI 10.1001/archinte.143.12.2269; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; QUINN TC, 1984, ANN INTERN MED, V101, P187, DOI 10.7326/0003-4819-101-2-187; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; QUINN TC, 1983, NEW ENGL J MED, V309, P576, DOI 10.1056/NEJM198309083091002; QUINNAN GV, 1984, JAMA-J AM MED ASSOC, V252, P72, DOI 10.1001/jama.252.1.72; RABENECK L, 1990, JAMA-J AM MED ASSOC, V263, P2318, DOI 10.1001/jama.263.17.2318; RAGNI MV, 1987, J LAB CLIN MED, V109, P545; RENE E, 1988, DIGEST DIS SCI, V33, P741, DOI 10.1007/BF01540440; RESTREPO C, 1987, AM J CLIN PATHOL, V87, P536, DOI 10.1093/ajcp/87.4.536; RIJPSTRA AC, 1988, J INFECT DIS, V157, P827, DOI 10.1093/infdis/157.4.827; RODGERS VD, 1986, GASTROENTEROLOGY, V90, P552, DOI 10.1016/0016-5085(86)91108-X; ROOK AH, 1983, J CLIN INVEST, V72, P398, DOI 10.1172/JCI110981; ROTH RI, 1983, NEW ENGL J MED, V309, P1324; ROTH RI, 1985, DIGEST DIS SCI, V30, P497, DOI 10.1007/BF01318186; SACKS SL, 1989, ANN INTERN MED, V111, P893, DOI 10.7326/0003-4819-111-11-893; SALTZBERG DM, 1986, AM J GASTROENTEROL, V81, P209; SAXON A, 1987, J PARASITOL, V73, P413, DOI 10.2307/3282099; SCHNEIDERMAN DJ, 1987, ANN INTERN MED, V106, P546, DOI 10.7326/0003-4819-106-4-546; SCHNITTMAN S, 1988, J CLIN IMMUNOL, V8, P234, DOI 10.1007/BF00916551; SENAY H, 1990, J INFECT DIS, V162, P987, DOI 10.1093/infdis/162.4.987; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SHADDUCK JA, 1989, REV INFECT DIS, V11, P203; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; SIMON GL, 1984, GASTROENTEROLOGY, V86, P174; SMITH PD, 1983, CELL IMMUNOL, V82, P308, DOI 10.1016/0008-8749(83)90164-8; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; SMITH PD, 1988, GASTROENTEROL CLIN N, V17, P587; SMITH PD, 1985, ANN INTERN MED, V102, P207, DOI 10.7326/0003-4819-102-2-207; SMITH PD, 1984, J CLIN INVEST, V74, P2121, DOI 10.1172/JCI111637; SMITH PD, 1991, IN PRESS LARGE INTES; SNELLER MC, 1986, J INFECT DIS, V154, P737, DOI 10.1093/infdis/154.5.737; SOAVE R, 1986, REV INFECT DIS, V8, P1012; SOAVE R, 1984, ANN INTERN MED, V100, P504, DOI 10.7326/0003-4819-100-4-504; SOAVE R, 1988, J INFECT DIS, V157, P225, DOI 10.1093/infdis/157.2.225; SPERBER SJ, 1987, REV INFECT DIS, V9, P925; STROBER W, 1988, IMMUNOLOGICAL DISEAS, P79; TAGLIABUE A, 1988, J IMMUNOL, V141, P2607; TAGLIABUE A, 1983, NATURE, V306, P184, DOI 10.1038/306184a0; TAGLIABUE A, 1985, J IMMUNOL, V135, P4178; TAVITIAN A, 1986, ANN INTERN MED, V104, P54, DOI 10.7326/0003-4819-104-1-54; TERADA S, 1987, ANN INTERN MED, V107, P61, DOI 10.7326/0003-4819-107-1-61; TOBA H, 1989, INFECT IMMUN, V57, P239, DOI 10.1128/IAI.57.1.239-244.1989; ULLRICH R, 1989, ANN INTERN MED, V111, P15, DOI 10.7326/0003-4819-111-1-15; UNGAR BLP, 1986, J INFECT DIS, V153, P570, DOI 10.1093/infdis/153.3.570; UNGAR BLP, 1990, INFECT IMMUN, V58, P961, DOI 10.1128/IAI.58.4.961-969.1990; VANDEPERRE P, 1988, J PEDIATR-US, V113, P1039, DOI 10.1016/S0022-3476(88)80578-X; VANDISSEL JT, 1985, J IMMUNOL, V134, P3404; VANGOOL T, 1990, LANCET, V336, P697, DOI 10.1016/0140-6736(90)92198-Q; WARNOCK DW, 1989, J ANTIMICROB CHEMOTH, V24, P275, DOI 10.1093/jac/24.3.275; WASHTON H, 1989, DIAGN MICR INFEC DIS, V12, pS229; WHEAT LJ, 1989, AM J MED, V87, P396, DOI 10.1016/S0002-9343(89)80820-4; WHELAN WL, 1990, J INFECT DIS, V162, P513, DOI 10.1093/infdis/162.2.513; WILCOX CM, 1990, ANN INTERN MED, V113, P589, DOI 10.7326/0003-4819-113-8-589; WILCOX CM, 1990, GASTROENTEROLOGY, V99, P263, DOI 10.1016/0016-5085(90)91257-7; WINTER SM, 1985, J INFECT DIS, V151, P523, DOI 10.1093/infdis/151.3.523	167	194	200	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1992	116	1					63	77		10.7326/0003-4819-116-1-63	http://dx.doi.org/10.7326/0003-4819-116-1-63			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX157	1463471				2022-12-28	WOS:A1992GX15700011
J	ARTHUR, LO; BESS, JW; SOWDER, RC; BENVENISTE, RE; MANN, DL; CHERMANN, JC; HENDERSON, LE				ARTHUR, LO; BESS, JW; SOWDER, RC; BENVENISTE, RE; MANN, DL; CHERMANN, JC; HENDERSON, LE			CELLULAR PROTEINS BOUND TO IMMUNODEFICIENCY VIRUSES - IMPLICATIONS FOR PATHOGENESIS AND VACCINES	SCIENCE			English	Article							T4 MOLECULE; CELLS; ANTIGENS; MHC; BETA-2-MICROGLOBULIN; RECEPTOR; COMPLEX; HIV; HISTOCOMPATIBILITY; ASSOCIATION	Cellular proteins associated with immunodeficiency viruses were identified by determination of the amino acid sequence of the proteins and peptides present in sucrose density gradient-purified human immunodeficiency virus (HIV)-1, HIV-2, and simian immunodeficiency virus (SIV). Beta2 microglobulin (beta2m) and the alpha and beta chains of human lymphocyte antigen (HLA) DR were present in virus preparations at one-fifth the concentration of Gag on a molar basis. Antisera to HLA DR, beta2m, as well as HLA class I precipitated intact viral particles, suggesting that these cellular proteins were physically associated with the surface of the virus. Antisera to class I, beta2m, and HLA DR also inhibited infection of cultured cells by both HIV-1 and SIV. The specific, selective association of these cellular proteins in a physiologically relevant manner has major implications for our understanding of the infection process and the pathogenesis of immunodeficiency viruses and should be considered in the design of vaccines.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; INSERM,UNITE RECH RETROVIRUS & MALAD ASSOCIEES,F-13273 MARSEILLE 9,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Institut National de la Sante et de la Recherche Medicale (Inserm)	ARTHUR, LO (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,AIDS VACCINE PROGRAM,FREDERICK,MD 21702, USA.		Bess, Jr., Julian/B-5343-2012		OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; BENVENISTE RE, UNPUB; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BERNABEU C, 1984, NATURE, V308, P642, DOI 10.1038/308642a0; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BESS JW, UNPUB; CHERMANN JC, UNPUB; CORBEAU P, 1990, J VIROL, V64, P1459, DOI 10.1128/JVI.64.4.1459-1464.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FERNANDEZLARSSON R, 1992, P NATL ACAD SCI USA, V89, P2223, DOI 10.1073/pnas.89.6.2223; GELDERBLOM H, 1987, Z NATURFORSCH C, V42, P1328; GELDERBLOM HR, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P50; HENDERSON LE, 1988, SCIENCE, V241, P199, DOI 10.1126/science.3388031; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HENDERSON LE, 1990, J MED PRIMATOL, V19, P411; HENDERSON LE, 1987, J VIROL, V61, P629, DOI 10.1128/JVI.61.2.629-632.1987; HOXIE JA, 1987, HUM IMMUNOL, V18, P39, DOI 10.1016/0198-8859(87)90111-X; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; KANNAGI M, 1987, J VIROL, V61, P1421, DOI 10.1128/JVI.61.5.1421-1426.1987; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KUBOTA K, 1984, J IMMUNOL, V133, P3203; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; MANN DL, 1988, J IMMUNOL, V141, P1131; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; SCHMIDT W, 1981, IMMUNOGENETICS, V13, P483, DOI 10.1007/BF00343716; SCHOLS D, 1992, VIROLOGY, V189, P374, DOI 10.1016/0042-6822(92)90719-6; SHEPPARD HW, 1992, J ACQ IMMUN DEF SYND, V5, P143; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; WRIGHTHAM M, 1991, CLIN EXP IMMUNOL, V85, P75, DOI 10.1111/j.1365-2249.1991.tb05685.x	32	494	511	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1935	1938		10.1126/science.1470916	http://dx.doi.org/10.1126/science.1470916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470916				2022-12-28	WOS:A1992KD08800031
J	FREIJE, D; HELMS, C; WATSON, MS; DONISKELLER, H				FREIJE, D; HELMS, C; WATSON, MS; DONISKELLER, H			IDENTIFICATION OF A 2ND PSEUDOAUTOSOMAL REGION NEAR THE XQ AND YQ TELOMERES	SCIENCE			English	Article							HUMAN SEX-CHROMOSOMES; SHORT ARM; HUMAN SPERMATOCYTES; PAIRING REGION; DNA; SEQUENCES; HOMOLOGY; AMPLIFICATION; POLYMORPHISM; EVOLUTION	The telomeres of Xq and Yq have been observed to associate during meiosis, and in rare cases a short synaptonemal complex is present. Molecular cloning of loci from Xqter and Yqter has revealed that their sequence homology extends over 400 kilobases, which suggests the possibility of genetic exchange. This hypothesis was tested by the development of two highly informative microsatellite markers from yeast artificial chromosome clones that carried Xqter sequences and the following of their inheritance in a set of reference pedigrees from the Centre d'Etude du Polymorphisme Humain in Paris, France. From a total of 195 informative male meioses, four recombination events between these loci were observed. In three cases, paternal X alleles were inherited by male offspring, and in one case a female offspring inherited her father's Y allele. These data support the existence of genetic exchange at Xq-Yq, which defines a second pseudoautosomal region between the sex chromosomes.	WASHINGTON UNIV,SCH MED,DEPT SURG,DIV HUMAN MOLEC GENET,660 S EUCLID ST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NHGRI NIH HHS [HG00100, HG00201] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AFFARA NA, 1986, NUCLEIC ACIDS RES, V14, P5353, DOI 10.1093/nar/14.13.5353; ANDERSSON M, 1986, SCIENCE, V233, P786, DOI 10.1126/science.3738510; ARVEILER B, 1989, GENOMICS, V4, P460, DOI 10.1016/0888-7543(89)90269-3; BENGTSSON BO, 1987, ANN HUM GENET, V51, P57, DOI 10.1111/j.1469-1809.1987.tb00865.x; BICKMORE WA, 1987, NUCLEIC ACIDS RES, V15, P6261, DOI 10.1093/nar/15.15.6261; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; BURGOYNE PS, 1982, HUM GENET, V61, P85, DOI 10.1007/BF00274192; CHANDLEY AC, 1984, CYTOGENET CELL GENET, V38, P241, DOI 10.1159/000132070; COOKE HJ, 1984, NATURE, V311, P259, DOI 10.1038/311259a0; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; EDWARDS A, 1991, AM J HUM GENET, V49, P746; FREIJE D, 1992, AM J HUM GENET, V51, P66; GREEN P, UNPUB CRI MAP VERSIO; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; Koller PC, 1934, J GENET, V29, P159, DOI 10.1007/BF02982193; KRISHNAN BR, 1991, NUCLEIC ACIDS RES, V19, P1153, DOI 10.1093/nar/19.5.1153; LUTY JA, 1990, AM J HUM GENET, V46, P776; PAGE D C, 1987, Genomics, V1, P243, DOI 10.1016/0888-7543(87)90051-6; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PAGE DC, 1984, NATURE, V311, P119, DOI 10.1038/311119a0; PEDICINI A, 1991, GENOMICS, V11, P482, DOI 10.1016/0888-7543(91)90167-D; ROUYER F, 1986, NATURE, V319, P291, DOI 10.1038/319291a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SIMMLER MC, 1985, NATURE, V317, P692, DOI 10.1038/317692a0; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SOLARI AJ, 1980, CHROMOSOMA, V81, P315, DOI 10.1007/BF00368145; SPEED RM, 1988, HUM GENET, V78, P260, DOI 10.1007/BF00291673; SPEED RM, 1990, HUM GENET, V84, P547; WILKIE AOM, 1991, CELL, V64, P595, DOI 10.1016/0092-8674(91)90243-R	31	152	156	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1784	1787		10.1126/science.1465614	http://dx.doi.org/10.1126/science.1465614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465614				2022-12-28	WOS:A1992KB96400036
J	ARONSON, JK; HARDMAN, M; REYNOLDS, DJM				ARONSON, JK; HARDMAN, M; REYNOLDS, DJM			ABC OF MONITORING DRUG-THERAPY - THEOPYLLINE	BRITISH MEDICAL JOURNAL			English	Article									ICI PLC,DIV MED RES,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND		ARONSON, JK (corresponding author), RADCLIFFE INFIRM,OXFORD OX2 6HE,ENGLAND.							MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; SMOLENSKY, 1987, J ASTHMA, V24, P90	2	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1355	1358		10.1136/bmj.305.6865.1355	http://dx.doi.org/10.1136/bmj.305.6865.1355			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483087	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992KA77300034
J	JACOBSON, B				JACOBSON, B			LONDON AFTER TOMLINSON .5. PUBLIC-HEALTH IN INNER LONDON	BRITISH MEDICAL JOURNAL			English	Article								One of Sir Bernard Tomlinson's aims in his inquiry into London's health services was to advise the secretary of state for health on the future balance of primary and secondary health care "taking account of the health needs of Londoners."1 Sir Bernard, however, also made it clear that "we have not seen it as part of our remit to carry out a comprehensive needs assessment for the whole of London," but concluded that the extremes of health need found in London were "unparalleled in the rest of England. Dr Jacobson highlights some of the major determinants of health inequality in inner London and assesses the extent to which the proposed solutions are likely to meet these needs.			JACOBSON, B (corresponding author), CITY & HACKNEY HLTH AUTHOR,DEPT PUBL HLTH,LONDON N1 5LZ,ENGLAND.							BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; BALARAJAN R, 1986, BRIT MED J, V292, P911, DOI 10.1136/bmj.292.6524.911; BEARDOW R, 1989, BMJ, V299, P782; BENZEVAL M, 1992, HLTH STATUS LONDONER; Blaxter M., 1990, HLTH LIFESTYLES; JACOBSON B, 1991, NATIONS HLTH STRATEG; JONES AGH, 1991, COMMUNICABLE DISEASE, V1, P93; MARMOT MG, 1984, STUDIES MED POPULATI, V4; ROBSON J, 1989, BMJ-BRIT MED J, V298, P433, DOI 10.1136/bmj.298.6671.433; RUDAT K, 1992, TOMORROWS YOUNG ADUL; SCHEUER MA, 1991, 4 KINGS FUND OCC PAP; Tomlinson B., 1992, REPORT INQUIRY LONDO; VICTOR CR, 1992, BRIT MED J, V305, P387, DOI 10.1136/bmj.305.6850.387; VICTOR CR, 1989, BRIT MED J, V299, P725, DOI 10.1136/bmj.299.6701.725; Whitehead M., 1992, INEQUALITIES HLTH BL; 1992, 1992 CIT HACKN HLTH; 1992, LRC HOUSING UPDATE; 1991, 1990 CITY HACKN HLTH; [No title captured]; 1989, WHAT IS ENOUGH NEW E; 1992, LONDONS HLTH CARE 20	21	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1344	1347		10.1136/bmj.305.6865.1344	http://dx.doi.org/10.1136/bmj.305.6865.1344			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483084	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KA77300031
J	LILFORD, RJ; KELLY, M; BAINES, A; CAMERON, S; CAVE, M; GUTHRIE, K; THORNTON, J				LILFORD, RJ; KELLY, M; BAINES, A; CAMERON, S; CAVE, M; GUTHRIE, K; THORNTON, J			EFFECT OF USING PROTOCOLS ON MEDICAL-CARE - RANDOMIZED TRIAL OF 3 METHODS OF TAKING AN ANTENATAL HISTORY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AUDIT	Objective-To compare the effectiveness of three methods of taking an antenatal history on the quality of obstetric care. Design-Randomised controlled trial. Setting-Antenatal clinic of St james's University Hospital, Leeds. Subjects-2424 women attending the hospital for the first (booking) visit. Interventions-Histories were taken by midwives using an unstructured paper questionnaire, a structured paper questionnaire (incorporating a checklist), or an interactive computerised questionnaire (incorporating 101 clinical reminders). Main outcome measures-The number of clinical responses to factors arising from the antenatal booking history according to method of taking the history. Actions were categorised as medical and surgical, obstetric, personal, current symptoms and treatment, related to maternal age, and related to two common actions (cervical smear testing and dental hygiene) and were weighted for clinical importance by 10 obstetricians. Results-Overall the unstructured questionnaire generated 1063 actions, the structured questionnaire 1146, and the computerised questionnaire 1122. The clinical importance of these actions was lowest for the unstructured questionnaire (overall total value score 1987 v 2182 and 2110 for the structured and computerised questionnaires respectively). The structured questionnaire was better than the computerised questionnaire in the medical and surgical (total value score 191 v 184), obstetric (275 v 241), and personal (430 v 360) categories but inferior in the current symptoms category (179 v 191). Conclusion-Structured questionnaires (computerised or paper) provide more and better information, and their use improves clinical response to risk factors. Computerised systems offer no further advantage in antenatal clinics.	UNIV LEEDS, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; MATERN HOSP, Kingston Upon Hull HU9 5LX, ENGLAND	University of Leeds	LILFORD, RJ (corresponding author), INST EPIDEMIOL & HLTH SERV RES, LEEDS LS2 9LN, ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				BINGHAM P, 1984, EUR J OBSTET GYN R B, V18, P43, DOI 10.1016/0028-2243(84)90032-7; BROWNBRIDGE G, 1988, MED CARE, V26, P474, DOI 10.1097/00005650-198805000-00004; CHNG PK, 1980, BMJ-BRIT MED J, V281, P1184, DOI 10.1136/bmj.281.6249.1184; Dreyfus H. L., 1986, MIND MACHINE POWER H; GONZALEZ FA, 1989, BRIT J OBSTET GYNAEC, V96, P1323, DOI 10.1111/j.1471-0528.1989.tb03231.x; GUTHRIE KA, 1989, BRIT J OBSTET GYNAEC, V96, P552, DOI 10.1111/j.1471-0528.1989.tb03254.x; Lilford R J, 1985, Am J Perinatol, V2, P143, DOI 10.1055/s-2007-999933; LILFORD RJ, 1990, BAILLIERE CLIN OB GY, V4, P723, DOI 10.1016/S0950-3552(05)80341-4; LILFORD RJ, 1983, METHOD INFORM MED, V22, P189; LILFORD RJ, 1981, BMJ-BRIT MED J, V283, P533, DOI 10.1136/bmj.283.6290.533; LILFORD RJ, 1984, ACTA OBSTETRICA GYNA, V36, P119; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; QUAAK MJ, 1987, BMJ-BRIT MED J, V295, P184, DOI 10.1136/bmj.295.6591.184; Staines C, 1983, Midwives Chron, V96, P6; Weed LL, 1969, MED RECORDS MED ED P	15	40	42	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1992	305	6863					1181	1184		10.1136/bmj.305.6863.1181	http://dx.doi.org/10.1136/bmj.305.6863.1181			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467719	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JY77700018
J	CHAPMAN, AB; RUBINSTEIN, D; HUGHES, R; STEARS, JC; EARNEST, MP; JOHNSON, AM; GABOW, PA; KAEHNY, WD				CHAPMAN, AB; RUBINSTEIN, D; HUGHES, R; STEARS, JC; EARNEST, MP; JOHNSON, AM; GABOW, PA; KAEHNY, WD			INTRACRANIAL ANEURYSMS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPUTED-TOMOGRAPHY; RISK-FACTORS; DIAGNOSIS	Background and Methods. Intracranial aneurysms are a feature of autosomal dominant polycystic kidney disease, but their prevalence is uncertain. We studied 92 subjects with autosomal dominant polycystic kidney disease who had no symptoms or signs of any neurologic disorder. To determine the prevalence of intracranial aneurysms, we performed high-resolution computed tomography (CT) in 60 subjects, four-vessel cerebral angiography in 21, and both procedures in 11. Results. Four of the 88 subjects in whom the radiologic studies were successfully completed had intracranial aneurysms (4 percent; 95 percent confidence interval, 0.1 to 9 percent), as compared with the prevalence of 1 percent reported for an angiographic study of the general population. Three of the four subjects had multiple aneurysms. Seven subjects for whom the results of CT studies were suspicious underwent cerebral angiography: two had aneurysms, and five had normal vascular structures that accounted for the suspicious results of tomography. Four subjects who had normal CT imaging studies also had normal angiographic examinations. Eight of the 32 subjects who underwent angiography (25 percent) had transient complications, as compared with 22 of 220 control subjects (10 percent) who did not have polycystic kidney disease (P<0.05). We could not identify any risk factor in these subjects that was related to the occurrence of aneurysm. Conclusions. Asymptomatic intracranial aneurysms appear to be more frequent in people with polycystic kidney disease than in the general population, although our 95 percent confidence interval includes the possibility of no difference. Because cerebral angiography is associated with increased morbidity in people with polycystic kidney disease, we recommend high-resolution CT as a screening test.	UNIV HOSP DENVER, DENVER, CO USA; DEPT VET AFFAIRS MED CTR, DENVER, CO USA; DENVER GEN HOSP, DENVER, CO 80204 USA; UNIV COLORADO, SCH MED, DEPT MED, DENVER, CO 80202 USA; UNIV COLORADO, SCH MED, DEPT RADIOL, DENVER, CO 80202 USA; UNIV COLORADO, SCH MED, DEPT NEUROL, DENVER, CO 80202 USA	University of Colorado System; University of Colorado Hospital; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Johnson, Anne/0000-0003-1330-7100	NCRR NIH HHS [MO-RR00051] Funding Source: Medline; NIDDK NIH HHS [DK34039] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACOSTARUA GJ, 1978, ARCH NEUROL-CHICAGO, V35, P675, DOI 10.1001/archneur.1978.00500340051010; ASKUPMARK E, 1950, ACTA MED SCAND, V138, P15; ATKINSON JLD, 1989, J NEUROSURG, V70, P551, DOI 10.3171/jns.1989.70.4.0551; BIGELOW NH, 1953, AM J MED SCI, V225, P485, DOI 10.1097/00000441-195305000-00004; Braasch WF, 1933, SURG GYNECOL OBSTET, V57, P467; BROWN R A P, 1951, Glasgow Med J, V32, P333; DALGAARD O Z, 1957, Acta Med Scand Suppl, V328, P1; DELAMONTE SM, 1985, AM J MED, V78, P957, DOI 10.1016/0002-9343(85)90218-9; DITLEFSEN EML, 1960, ACTA MED SCAND, V168, P51; Dunger R, 1904, BEITR PATHOL ANAT AL, V35, P445; EADIE MJ, 1964, J NEUROL SCI, V1, P501, DOI 10.1016/0022-510X(64)90170-4; EARNEST MP, 1987, STROKE, V18, P292; GABOW PA, 1984, ANN INTERN MED, V101, P238, DOI 10.7326/0003-4819-101-2-238; GABOW PA, 1990, HEPATOLOGY, V11, P1033, DOI 10.1002/hep.1840110619; HASSLER OVE, 1959, ACTA PATHOL ET MICROBIOL SCAND, V46, P305; HOSSACK KF, 1988, NEW ENGL J MED, V319, P907, DOI 10.1056/NEJM198810063191404; ISHIBASHI A, 1981, JPN J NEPHROL, V23, P1003; JAIN KK, 1974, ACTA NEUROCHIR, V30, P129, DOI 10.1007/BF01405761; KOBAYASHI H, 1984, SURG NEUROL, V21, P258, DOI 10.1016/0090-3019(84)90198-8; LEVEY AS, 1983, NEW ENGL J MED, V308, P986, DOI 10.1056/NEJM198304283081702; MATSUMURA M, 1986, ACTA NEUROCHIR, V79, P94, DOI 10.1007/BF01407451; NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006; PHILLIPS LH, 1980, NEUROLOGY, V30, P1034, DOI 10.1212/WNL.30.10.1034; SALTZMAN GF, 1959, ACTA RADIOL, V51, P415, DOI 10.3109/00016925909171114; SCHMID UD, 1987, NEURORADIOLOGY, V29, P152, DOI 10.1007/BF00327540; TABONE J, 1949, CR HEBD ACAD SCI, V229, P471; TORRES VE, 1990, J AM SOC NEPHROL, V1, P84; WAKABAYASHI T, 1983, J NEUROSURG, V58, P488, DOI 10.3171/jns.1983.58.4.0488	28	240	248	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					916	920		10.1056/NEJM199209243271303	http://dx.doi.org/10.1056/NEJM199209243271303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP014	1513348				2022-12-28	WOS:A1992JP01400003
J	TAKEMOTO, S; TERASAKI, PI; CECKA, JM; CHO, YW; GJERTSON, DW				TAKEMOTO, S; TERASAKI, PI; CECKA, JM; CHO, YW; GJERTSON, DW			SURVIVAL OF NATIONALLY SHARED, HLA-MATCHED KIDNEY-TRANSPLANTS FROM CADAVERIC DONORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENAL-TRANSPLANTATION; BENEFITS	Background. The importance of HLA histocompatibility typing to the outcome of transplantation of cadaveric kidneys has been controversial. Four years ago, a prospective trial began in all U.S. transplantation centers to determine whether the results of transplantation would improve with the nationwide shipment of kidneys from cadaveric donors to waiting patients undergoing dialysis when there was a match at the HLA-A, B, and DR loci. Methods. A total of 1386 cadaveric kidneys were shipped from 108 organ centers to 198 transplantation centers and distributed among HLA-matched recipients, 1004 of whom were receiving a first transplant and 382 of whom were receiving a subsequent transplant. Graft survival in these recipients was compared with that in 22,188 recipients of first transplants and 3950 recipients of subsequent transplants whose HLA antigens differed from those of the donor. Results. The rate of graft survival at one year in recipients of HLA-matched first transplants was 88 percent, as compared with 79 percent in the recipients of mismatched grafts (P<0.001). The estimated half-life of the kidney after the first year was 17.3 years for matched grafts, as compared with 7.8 years for mismatched grafts (P = 0.003). Among paired kidneys from 470 donors, one-year graft survival was 87 percent in the recipients of matched first grafts, as compared with 80 percent in the recipients of the contralateral kidneys, who did not have HLA matches with the donors. In donors and recipients matched for the more highly defined split Class I and Class II HLA antigens, the rate of graft survival after one year was as high as 90 percent. Conclusions. The collaborative renal-transplantation program for HLA matching of donors and recipients yielded an increased rate of one-year graft survival and an estimated half-life for matched grafts twice that for mismatched grafts. An increased role for HLA matching in kidney allocation is therefore indicated.			TAKEMOTO, S (corresponding author), UNIV CALIF LOS ANGELES,DEPT SURG,TISSUE TYPING LAB,950 VET AVE,LOS ANGELES,CA 90024, USA.							Cho Y W, 1988, Clin Transpl, P277; CICCIARELLI J, 1987, TRANSPLANTATION, V43, P636, DOI 10.1097/00007890-198705000-00006; COX DR, 1972, J R STAT SOC B, V34, P187; Dixon W. J., 1990, BMDP STATISTICAL SOF; GILKS WR, 1987, TRANSPLANTATION, V43, P669, DOI 10.1097/00007890-198705000-00013; GJERTSON DW, 1991, NEW ENGL J MED, V324, P1032, DOI 10.1056/NEJM199104113241505; Lau M, 1991, Clin Transpl, P385; MICKEY MR, 1989, TRANSPLANTATION, V47, P401; OPELZ G, 1991, LANCET, V338, P461, DOI 10.1016/0140-6736(91)90540-6; OPELZ G, 1988, LANCET, V2, P61; OPELZ G, 1988, NEW ENGL J MED, V318, P1289, DOI 10.1056/NEJM198805193182001; Persijn G G, 1988, Clin Transpl, P237; SANFILIPPO F, 1984, NEW ENGL J MED, V311, P358, DOI 10.1056/NEJM198408093110603; STARZL TE, 1987, JAMA-J AM MED ASSOC, V57, P3073; TAKIFF H, 1988, TRANSPLANTATION, V45, P410, DOI 10.1097/00007890-198802000-00033; TERASAKI PI, 1991, KIDNEY INT, V39, P557, DOI 10.1038/ki.1991.64; TERASAKI PI, 1990, CLIN TRANSPLANTS 199, P585	17	184	187	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					834	839		10.1056/NEJM199209173271202	http://dx.doi.org/10.1056/NEJM199209173271202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1508242	Bronze			2022-12-28	WOS:A1992JN12000002
J	FAUSER, JJ				FAUSER, JJ			ACCREDITATION OF ALLIED HEALTH-EDUCATION - ASSESSING FOR EDUCATIONAL-EFFECTIVENESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FAUSER, JJ (corresponding author), AMER MED ASSOC,DIV ALLIED HLTH EDUC & ACCREDITAT,515 N STATE ST,CHICAGO,IL 60610, USA.							Fauser J J, 1990, J Allied Health, V19, P1; GUPTA GC, 1992, ALLIED HLTH ED DIREC, P304; SHUGARS DA, 1991, HLTH AM PRACTITIONER, P2; Stull G A, 1989, J Allied Health, V18, P425; 1986, ED QUALIT ACCREDITAT, P4; 1991, REPORT TASK FORCE OU, P4; 1991, OUTCOMES ASSESSMENT; 1991, MANUAL CAHEA POLICIE; 1991, REPORT TASK FORCE I, P6	9	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1123	1126						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK681	1501335				2022-12-28	WOS:A1992JK68100010
J	DELSAL, G; RUARO, ME; PHILIPSON, L; SCHNEIDER, C				DELSAL, G; RUARO, ME; PHILIPSON, L; SCHNEIDER, C			THE GROWTH ARREST-SPECIFIC GENE, GAS1, IS INVOLVED IN GROWTH SUPPRESSION	CELL			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN TRANSFERRIN RECEPTOR; LARGE TUMOR-ANTIGEN; MESSENGER-RNA; CELL-CYCLE; 3T3 CELLS; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS	This report describes the structure of the mRNA, the protein product, and the growth-regulating activity of one of the growth arrest-specific genes, gas1. From the predicted amino acid sequence, in vitro translation of gas1 mRNA, and immunofluorescence of cells in culture, it appears that the gas1 protein is an integral plasma membrane protein whose expression is linked to growth arrest. When gas1 is overexpressed from a constitutive promoter in quiescent cells, the serum-induced transition from the G0 to the S phase of the cell cycle is inhibited without affecting the normal early serum response. Ectopic expression of the gas1 gene by microinjection in normal and transformed NIH 3T3 cell lines with the notable exception of SV40-transformed 3T3 cells leads to inhibition of DNA synthesis. Thus, gas1 appears to be one component of a negative circuit that governs growth suppression. Its effect is, however, abolished in SV40-transformed cells.	EUROPEAN MOLEC BIOL LAB, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)	DELSAL, G (corresponding author), INT CTR GENET ENGN & BIOTECHNOL, CONSORTIUM INTERUNIV BIOTECHNOL LABS, AREA SCI PK, 99 PADRICIANO, I-34012 TRIESTE, ITALY.			DEL SAL, GIANNINO/0000-0003-2185-6003				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIGNAMI M, 1988, ONCOGENE, V2, P509; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRANCOLINI C, 1991, P NATL ACAD SCI USA, V88, P6936, DOI 10.1073/pnas.88.16.6936; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASSO MC, 1989, NUCLEIC ACIDS RES, V17, P3129, DOI 10.1093/nar/17.8.3129; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; Harris H., 1970, CELL FUSION; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAU JTY, 1983, J BIOL CHEM, V258, P5255; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEDL T, 1984, J CELL BIOL, V99, P155, DOI 10.1083/jcb.99.1.155; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Schneider C, 1991, CURR OPIN CELL BIOL, V3, P276, DOI 10.1016/0955-0674(91)90152-O; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x	72	248	257	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1992	70	4					595	607		10.1016/0092-8674(92)90429-G	http://dx.doi.org/10.1016/0092-8674(92)90429-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505026				2022-12-28	WOS:A1992JJ88600009
J	PFAFFLE, RW; DIMATTIA, GE; PARKS, JS; BROWN, MR; WIT, JM; JANSEN, M; VANDERNAT, H; VANDENBRANDE, JL; ROSENFELD, MG; INGRAHAM, HA				PFAFFLE, RW; DIMATTIA, GE; PARKS, JS; BROWN, MR; WIT, JM; JANSEN, M; VANDERNAT, H; VANDENBRANDE, JL; ROSENFELD, MG; INGRAHAM, HA			MUTATION OF THE POU-SPECIFIC DOMAIN OF PIT-1 AND HYPOPITUITARISM WITHOUT PITUITARY HYPOPLASIA	SCIENCE			English	Article							THYROID STIMULATING HORMONE; TRANSCRIPTION FACTOR; GROWTH-HORMONE; GENE-EXPRESSION; DNA-BINDING; PROLACTIN; PROTEIN	A point mutation in the POU-specific portion of the human gene that encodes the tissue-specific POU-domain transcription factor, Pit-1, results in hypopituitarism, with deficiencies of growth hormone, prolactin, and thyroid-stimulating hormone. In two unrelated Dutch families, a mutation in Pit-1 that altered an alanine in the first putative alpha-helix of the POU-specific domain to proline was observed. This mutation generated a protein capable of binding to DNA response elements but unable to effectively activate its known target genes, growth hormone and prolactin. The phenotype of the affected individuals suggests that the mutant Pit-1 protein is competent to initiate other programs of gene activation required for normal proliferation of somatotrope, lactotrope, and thyrotrope cell types. Thus, a mutation in the POU-specific domain of Pit- 1 has a selective effect on a subset of Pit-1 target genes.	EMORY UNIV,SCH MED,DEPT PEDIAT,DIV PEDIAT ENDOCRINOL,2040 RIDGEWOOD DR,ATLANTA,GA 30322; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV UTRECHT,DEPT PEDIAT,UTRECHT,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,VIROL LAB,BILTHOVEN,NETHERLANDS	Emory University; Howard Hughes Medical Institute; University of California System; University of California San Diego; Utrecht University; Netherlands National Institute for Public Health & the Environment			Parks, John/F-8570-2011		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018477] Funding Source: NIH RePORTER; NICHD NIH HHS [HD2697, HD24960] Funding Source: Medline; NIDDK NIH HHS [NIDDK 18477] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASA SL, 1991, ENDOCRINE SOC ANN M; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; DIMATTIA GE, UNPUB; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; LEW AM, 1991, NUCLEIC ACIDS RES, V19, P6329, DOI 10.1093/nar/19.22.6329; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ROGOL AD, 1976, J PEDIATR-US, V88, P953, DOI 10.1016/S0022-3476(76)81048-7; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; STEINFELDER HJ, 1992, J CLIN INVEST, V89, P409, DOI 10.1172/JCI115600; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; TATSUMI K, 1992, NAT GENET, V1, P56, DOI 10.1038/ng0492-56; VANBUULOFFERS SC, 1984, THESIS U UTRECHT; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; WINTER JSD, 1974, J CLIN ENDOCR METAB, V39, P356, DOI 10.1210/jcem-39-2-356; WIT JM, 1989, HORM RES, V32, P170, DOI 10.1159/000181284; YOSHIMOTO M, 1990, ACTA PAEDIATR SCAND, V79, P1247	23	378	387	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1118	1121		10.1126/science.257.5073.1118	http://dx.doi.org/10.1126/science.257.5073.1118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509263				2022-12-28	WOS:A1992JJ88400033
J	SHAANAN, B; GRONENBORN, AM; COHEN, GH; GILLILAND, GL; VEERAPANDIAN, B; DAVIES, DR; CLORE, GM				SHAANAN, B; GRONENBORN, AM; COHEN, GH; GILLILAND, GL; VEERAPANDIAN, B; DAVIES, DR; CLORE, GM			COMBINING EXPERIMENTAL INFORMATION FROM CRYSTAL AND SOLUTION STUDIES - JOINT X-RAY AND NMR REFINEMENT	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; INTERPROTON DISTANCE RESTRAINTS; AMYLASE INHIBITOR TENDAMISTAT; MOLECULAR-DYNAMICS; SINGLE-CRYSTALS; R-FACTOR; PROTEINS; INTERLEUKIN-1-BETA; DIFFRACTION; RESOLUTION	Joint refinement of macromolecules against crystallographic and nuclear magnetic resonance (NMR) observations is presented as a way of combining experimental information from the two methods. The model of interleukin-1-beta derived by the joint x-ray and NMR refinement is shown to be consistent with the experimental observations of both methods and to have crystallographic R value and geometrical parameters that are of the same quality as or better than those of models obtained by conventional crystallographic studies. The few NMR observations that are violated by the model serve as an indicator for genuine differences between the crystal and solution structures. The joint x-ray-NMR refinement can resolve structural ambiguities encountered in studies of multidomain proteins, in which low- to medium-resolution diffraction data can be complemented by higher resolution NMR data obtained for the individual domains.	NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892; NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892; NATL INST STAND & TECHNOL,ROCKVILLE,MD 20850; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,SHADY GROVE,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institute of Standards & Technology (NIST) - USA			Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018; Shaanan, Boaz/F-1202-2012	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Shaanan, Boaz/0000-0001-8925-4362; Gronenborn, Angela M/0000-0001-9072-3525				BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BHAT TN, 1984, J APPL CRYSTALLOGR, V17, P244, DOI 10.1107/S0021889884011456; BILLETER M, 1989, J MOL BIOL, V206, P677, DOI 10.1016/0022-2836(89)90575-5; BRAUN W, 1989, J MOL BIOL, V206, P669, DOI 10.1016/0022-2836(89)90574-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P1049, DOI 10.1126/science.235.4792.1049; BRUNGER AT, 1987, PROTEIN ENG, V1, P399, DOI 10.1093/protein/1.5.399; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR VERSION 21; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1991, J MOL BIOL, V221, P47, DOI 10.1016/0022-2836(91)90802-D; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2316; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HOCH JC, 1991, COMPUTATIONAL ASPECT, P57; HOLAK TA, 1989, J MOL BIOL, V210, P649, DOI 10.1016/0022-2836(89)90138-1; JACK A, 1978, ACTA CRYSTALLOGR A, V34, P931, DOI 10.1107/S0567739478001904; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; WLODAWER A, 1982, ACTA CRYSTALLOGR A, V38, P239, DOI 10.1107/S0567739482000527; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719	25	60	62	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					961	964		10.1126/science.1502561	http://dx.doi.org/10.1126/science.1502561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1502561				2022-12-28	WOS:A1992JH82700034
J	COLLINGS, S				COLLINGS, S			THROMBOCYTOPENIA ASSOCIATED WITH LITHIUM-CARBONATE	BRITISH MEDICAL JOURNAL			English	Letter							CHEMOTHERAPY		MAUDSLEY JOINT HOSP,LONDON,ENGLAND	South London & Maudsley NHS Trust	COLLINGS, S (corresponding author), BETHLEM JOINT HOSP,LONDON,ENGLAND.			Collings, Sunny/0000-0002-5486-1194				GALLICCHIO VS, 1987, MED SCI RES-BIOCHEM, V15, P691; HUSSAIN MZ, 1973, CAN MED ASSOC J, V108, P724; JOFFE RT, 1984, NEW ENGL J MED, V311, P674; LYMAN GH, 1980, NEW ENGL J MED, V302, P257, DOI 10.1056/NEJM198001313020503; PRAKASH R, 1981, AM J PSYCHIAT, V138, P849; RICHMAN CM, 1984, AM J HEMATOL, V16, P313, DOI 10.1002/ajh.2830160402	6	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					159	159		10.1136/bmj.305.6846.159	http://dx.doi.org/10.1136/bmj.305.6846.159			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515834	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JF06300025
J	MENNIM, P; COYLE, CF; TAYLOR, JD				MENNIM, P; COYLE, CF; TAYLOR, JD			LESSON OF THE WEEK - VENOUS AIR-EMBOLISM ASSOCIATED WITH REMOVAL OF CENTRAL VENOUS CATHETER	BRITISH MEDICAL JOURNAL			English	Article									LEIGHTON HOSP,CREWE CW1 4QJ,ENGLAND									DYER C, 1991, BRIT MED J, V303, P1218, DOI 10.1136/bmj.303.6812.1218; FLANAGAN JP, 1969, NEW ENGL J MED, V281, P488, DOI 10.1056/NEJM196908282810907; HOSAL VL, 1971, ARCH SURG-CHICAGO, V102, P253; Mendieta J M, 1988, J Ky Med Assoc, V86, P169; SEIDELIN PH, 1987, BRIT J HOSP MED, V38, P438; Thielen J B, 1991, J Intraven Nurs, V14, P114; TURNAGE WS, 1991, ANESTH ANALG, V72, P559	7	35	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					171	172		10.1136/bmj.305.6846.171	http://dx.doi.org/10.1136/bmj.305.6846.171			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515837	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JF06300031
J	KAPLAN, NM				KAPLAN, NM			THE APPROPRIATE GOALS OF ANTIHYPERTENSIVE THERAPY - NEITHER TOO MUCH NOR TOO LITTLE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						ANTIHYPERTENSIVE AGENTS; QUALITY OF LIFE; HYPERTENSION; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG	BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; HYPERTENSION; PREVENTION; REDUCTION; DISEASE; TRIAL	Although the treatment of hypertension has increased markedly during the last decade, many patients have been left undertreated, including many of the disadvantaged, the elderly, and those at relatively high overall risk for cardiovascular disease. A rapidly growing number of patients, however, are being exposed to overtreatment with resultant interference with their quality of life and potential hazards to their health. These include patients who are diagnosed and treated without adequate documentation of the presence of persistent hypertension, patients who are not appropriately managed with nondrug therapies, and patients who are given inappropriate and overly aggressive drug therapies. Better recognition of the frequency and potential hazards of overtreatment is needed so that more appropriate goals of antihypertensive therapy can be established and maintained.			KAPLAN, NM (corresponding author), UNIV TEXAS, SW MED CTR, C88-102, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.							[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; [Anonymous], 1982, Lancet, V1, P185; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BOSTICK RM, 1991, ARCH INTERN MED, V151, P478; BRETT AS, 1984, AM J MED, V76, P557, DOI 10.1016/0002-9343(84)90272-9; BRUNNER HR, 1990, J HYPERTENS, V8, P3, DOI 10.1097/00004872-199001000-00002; CARLSEN JE, 1990, BRIT MED J, V300, P975, DOI 10.1136/bmj.300.6730.975; CUMMINGS DM, 1991, ARCH INTERN MED, V151, P250, DOI 10.1001/archinte.151.2.250; EVANS CE, 1989, J HYPERTENS, V7, P133; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; FREIS ED, 1990, AM J CARDIOL, V66, P368, DOI 10.1016/0002-9149(90)90852-R; GINZBERG E, 1991, JAMA-J AM MED ASSOC, V265, P2559, DOI 10.1001/jama.265.19.2559; GUTTMACHER S, 1981, HASTINGS CENT REP, V11, P12, DOI 10.2307/3561589; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; HANSSON L, 1990, AM J HYPERTENS, V3, P726, DOI 10.1093/ajh/3.9.726; HERXHEIMER A, 1991, LANCET, V337, P346, DOI 10.1016/0140-6736(91)90958-R; HOLZGREVE H, 1989, BRIT MED J, V299, P881, DOI 10.1136/bmj.299.6704.881; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; KAPLAN NM, 1990, J HYPERTENS, V8, pS175; Kaplan S. L., 1990, CLIN PEDIAT ENDOCRIN, P1; KHOURY AF, 1991, JAMA-J AM MED ASSOC, V266, P394, DOI 10.1001/jama.266.3.394; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MEJIA AD, 1990, ANN INTERN MED, V112, P270, DOI 10.7326/0003-4819-112-4-270; MOGENSEN CE, 1990, SEMIN NEPHROL, V10, P260; PARKER M, 1990, HYPERTENSION, V16, P398, DOI 10.1161/01.HYP.16.4.398; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SCHOTTE DE, 1990, ARCH INTERN MED, V150, P1701, DOI 10.1001/archinte.150.8.1701; STEWART IMG, 1979, LANCET, V1, P861; STRANDGAARD S, 1987, LANCET, V2, P658; STRASSER T, 1991, J HYPERTENS, V9, P283; WAEBER B, 1987, LANCET, V2, P732; WEILAND SK, 1991, J HYPERTENS, V9, P131, DOI 10.1097/00004872-199102000-00005; 1990, MMWR MORBID WKLY REP, V39, P704; 1989, J HYPERTENS, V7, P689	37	23	23	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1992	116	8					686	690		10.7326/0003-4819-116-8-686	http://dx.doi.org/10.7326/0003-4819-116-8-686			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HN844	1463478				2022-12-28	WOS:A1992HN84400013
J	REISER, SJ				REISER, SJ			CONSUMER COMPETENCE AND THE REFORM OF AMERICAN HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This report examines the role of the expert in the American health care system, both as provider and administrative policymaker. It shows that the guiding assumption of American health care policy, ie, that the medical system can and should be managed by experts on behalf of consumers and patients, does not hold up to scrutiny. It also demonstrates that the important theme in American history of placing authority and responsibility for action in the hands of the individual has not been sufficiently influential in American health care. Drawing on this theme and creating consumer competence and responsibility in health care choices as the keys to health care reform in the United States are advocated.	UNIV TEXAS, HLTH SCI CTR, INST HLTH POLICY, HOUSTON, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston	REISER, SJ (corresponding author), UNIV TEXAS, HLTH SCI CTR, PROGRAM HUMANITIES & TECHNOL HLTH CARE, POB 20708, HOUSTON, TX 77225 USA.							[Anonymous], 1990, CLIN PRACTICE GUIDEL; BEAUCHAMP TL, 1989, MED ETHICS, P173; Bursztajn H, 1990, MED CHOICES MED CHAN; BUTLER SM, 1991, JAMA-J AM MED ASSOC, V265, P2541, DOI 10.1001/jama.265.19.2541; DENTZER S, 1991, DARTMOUTH ALUMNI MAY, P16; ECKHOLM E, 1991, NY TIMES        0428, P15; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P105, DOI 10.1001/jama.265.1.105; FOX DM, 1989, J HEALTH POLIT POLIC, V14, P239, DOI 10.1215/03616878-14-2-239; HISASHIGE A, 1990, OCT INT S HLTH EC HL; LEVIT KR, 1990, HEALTH AFFAIR, V9, P171, DOI 10.1377/hlthaff.9.2.171; MARMOR TR, 1990, AM PROSPECT      FAL, P20; PAUKER SG, 1981, J CHRON DIS, V34, P77, DOI 10.1016/0021-9681(81)90053-9; PEAR R, 1991, NY TIMES        0802, P6; REISER SJ, 1991, LIABILITY MAZE IMPAC, P227; RICH S, 1991, WASHINGTON POST 0606, pA4; STOECKLE JD, 1987, ENCOUNTERS PATIENTS, P1; THOMPSON MS, 1983, MED DECIS MAKING, V3, P285, DOI 10.1177/0272989X8300300304; UCHITELLE L, 1991, NY TIMES        0501, pA14; VANMCCRARY S, 1989, JAMA-J AM MED ASSOC, V262, P2411, DOI 10.1001/jama.1989.03430170073031; 1990, HLTH CARE FINANCING, V11, P4	20	24	24	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1992	267	11					1511	1515		10.1001/jama.267.11.1511	http://dx.doi.org/10.1001/jama.267.11.1511			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH488	1482428				2022-12-28	WOS:A1992HH48800033
J	ASFAW, B; BEYENE, Y; SUWA, G; WALTER, RC; WHITE, TD; WOLDEGABRIEL, G; YEMANE, T				ASFAW, B; BEYENE, Y; SUWA, G; WALTER, RC; WHITE, TD; WOLDEGABRIEL, G; YEMANE, T			THE EARLIEST ACHEULEAN FROM KONSO-GARDULA	NATURE			English	Article							PALEOANTHROPOLOGICAL RESEARCH; KENYA; ETHIOPIA; OLORGESAILIE; PLEISTOCENE; CALIBRATION; TURKANA	KONSO-GARDULA is a palaeoanthropological area discovered by the 1991 Palaeoanthropological Inventory of Ethiopia1-5 in the southern Main Ethiopian Rift. The Konso-Gardula sediments span the period about 1.3-1.9 million years ago. They contain rich Acheulean archaeological occurrences. Vertebrate fossils include early Homo.	UNIV TOKYO,DEPT ANTHROPOL,BUNKYO KU,TOKYO 113,JAPAN; CTR GEOCHRONOL,INST HUMAN ORIGINS,BERKELEY,CA 94709; UNIV CALIF BERKELEY,DEPT ANTHROPOL,HUMAN EVOLUT STUDIES LAB,BERKELEY,CA 94720; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; IOWA STATE UNIV SCI & TECHNOL,DEPT EARTH SCI,AMES,IA 50011	University of Tokyo; University of California System; University of California Berkeley; United States Department of Energy (DOE); Los Alamos National Laboratory; Iowa State University	ASFAW, B (corresponding author), MINIST CULTURE,PALAEOANTHROPOL LAB,POB 5717,ADDIS ABABA,ETHIOPIA.		Walter, Robert/AAD-7642-2020; Klein, Richard G/B-5910-2009	Walter, Robert/0000-0001-8761-5355; 				ASFAW B, 1990, NATL GEOGR RES, V6, P418; ASFAW B, 1991, J HUM EVOL, V21, P137, DOI 10.1016/0047-2484(91)90004-F; BRAIN CK, 1981, ANN GEOL SOC S AFR, V84, P1; BROWN T, 1990, AM J PHYS ANTHROPOL, V81, P545, DOI 10.1002/ajpa.1330810410; BYE BA, 1987, NATURE, V329, P237, DOI 10.1038/329237a0; Chavaillon J., 1975, B SOC PREHISTORIQUE, V72, P134; Clark J.D., 1970, PREHISTORY AFRICA; CLARK JD, 1979, NATURE, V282, P33, DOI 10.1038/282033a0; DEINO A, 1990, J GEOPHYS RES-SOLID, V95, P8453, DOI 10.1029/JB095iB06p08453; DEINO A, 1990, J GEOL, V98, P567, DOI 10.1086/629425; DZAPARIDZE V, 1989, JB ROM GERM ZENTRALM, V36, P67; FEIBEL CS, 1989, AM J PHYS ANTHROPOL, V78, P595, DOI 10.1002/ajpa.1330780412; FORMICOLA V, 1991, AM J PHYS ANTHROPOL, V86, P85, DOI 10.1002/ajpa.1330860108; FRBA ES, 1988, EVOLUTION HIST ROBUS, P405; HILL A, 1987, J HUM EVOL, V16, P583, DOI 10.1016/0047-2484(87)90014-5; HILL A, 1992, NATURE, V355, P719, DOI 10.1038/355719a0; Isaac G. L., 1978, KOOBI FORA RES PROJE, V1, P64; Leakey M.D., 1971, OLDUVAI GORGE; MCDOUGALL I, 1985, GEOL SOC AM BULL, V96, P159, DOI 10.1130/0016-7606(1985)96<159:KAADOT>2.0.CO;2; Prentice M.L., 1988, P383; SAMSON SD, 1987, CHEM GEOL, V66, P27, DOI 10.1016/0168-9622(87)90025-X; SUWA G, 1991, Palaeontologia Africana, V28, P23; TOBIAS PV, 1991, OLDUVAI GORGE PROJEC, V4; Walter R.C., 1992, QUATERN INT, V14, P37, DOI DOI 10.1016/1040-6182(92)90008-P; WALTER RC, 1991, NATURE, V354, P145, DOI 10.1038/354145a0; White T.D., 1988, P449; WOLDEGABRIEL G, 1991, J AFR EARTH SCI, V13, P437, DOI 10.1016/0899-5362(91)90107-A; WOLDEGABRIEL G, IN PRESS J FIELD ARC, V19; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; Wood B., 1991, HOMINID CRANIAL REMA, V4	30	215	218	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					732	735		10.1038/360732a0	http://dx.doi.org/10.1038/360732a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465142				2022-12-28	WOS:A1992KE47200031
J	DEVARY, Y; GOTTLIEB, RA; SMEAL, T; KARIN, M				DEVARY, Y; GOTTLIEB, RA; SMEAL, T; KARIN, M			THE MAMMALIAN ULTRAVIOLET RESPONSE IS TRIGGERED BY ACTIVATION OF SRC TYROSINE KINASES	CELL			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-KINASE; C-JUN; IONIZING-RADIATION; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; UV RESPONSE; DNA DAMAGE	Exposure of mammalian cells to DNA-damaging agents induces the ultraviolet (UV) response, involving transcription factor AP-1, composed of Jun and Fos proteins. We investigated the mechanism by which UV irradiation induces the c-jun gene. The earliest detectable step was activation of Src tyrosine kinases, followed by activation of Ha-Ras and Raf-1. The response to UV was blocked by tyrosine kinase inhibitors and dominant negative mutants of v-src, Ha-ras, and raf-1. This signaling cascade leads to increased phosphorylation of c-Jun on two serine residues that potentiate its activity. These results strongly suggest that the UV response is initiated at or near the plasma membrane rather than the nucleus. The response may be elicited by oxidative stress, because it is inhibited by elevation of intracellular glutathione. Using tyrosine kinase inhibitors, we demonstrate that the UV response has a protective function.	UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	DEVARY, Y (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.			Gottlieb, Roberta/0000-0002-1432-006X				AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; [Anonymous], 1985, DNA REPAIR; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUSCHER M, 1988, ONCOGENE, V3, P301; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EISEMAN E, 1992, NATURE, V355, P78; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FRILING RS, 1991, P NATL ACAD SCI USA, V87, P6258; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9225; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KARIN M, 1989, GENES SIGNAL TRANSDU, P415; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MUSTELIN T, 1990, ONCOGENE, V5, P809; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Romerdahl C A, 1989, Cancer Commun, V1, P209; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SHIMM DS, 1992, RADIAT RES, V129, P149, DOI 10.2307/3578151; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4	71	865	886	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1081	1091		10.1016/S0092-8674(05)80058-3	http://dx.doi.org/10.1016/S0092-8674(05)80058-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473146				2022-12-28	WOS:A1992KE60400004
J	PARMET, WE				PARMET, WE			THE IMPACT OF HEALTH-INSURANCE REFORM ON THE LAW GOVERNING THE PHYSICIAN-PATIENT RELATIONSHIP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANADA				PARMET, WE (corresponding author), NORTHEASTERN UNIV,SCH LAW,400 HUNTINGTON AVE,BOSTON,MA 02115, USA.							ANNAS GJ, 1975, DUKE LAW J, P1335; Annas GJ, 1990, AM HLTH LAW; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2509, DOI 10.1001/jama.267.18.2509; BONFIELD AE, 1989, STATE FEDERAL ADM LA; BOYD TH, 1989, DEPAUL LAW REV, V39, P139; BRAVEMAN PA, 1991, JAMA-J AM MED ASSOC, V266, P3300, DOI 10.1001/jama.266.23.3300; CLINTON B, 1992, NEW ENGL J MED, V227, P804; DANIELS N, 1991, JAMA-J AM MED ASSOC, V265, P2332; DANZON PM, 1985, MED MALPRACTICE THEO; FOX DM, 1989, J HEALTH POLIT POLIC, V14, P239, DOI 10.1215/03616878-14-2-239; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; FURROW BR, 1991, HLTH LAW CASES MATER; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; INGLEHART JK, 1992, NEW ENGL J MED, V326, P962; KATZ SJ, 1991, JAMA-J AM MED ASSOC, V266, P1108, DOI 10.1001/jama.266.8.1108; LUNDBERG GD, 1992, JAMA-J AM MED ASSOC, V267, P2521; PARMET WE, 1989, J HEALTH POLIT POLIC, V14, P741, DOI 10.1215/03616878-14-4-741; SANDERS J, 1990, HOUSTON LAW REV, V27, P207; STONE D, 1992, AM PROSPECT, V9, P51; SULLIVAN LW, 1992, NEW ENGL J MED, V327, P801, DOI 10.1056/NEJM199209103271111; 1992, WHITE HOUSE FACT SHE; 1990, PATIENTS DOCTORS LAW	22	7	7	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3468	3472						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460739				2022-12-28	WOS:A1992KC83900037
J	ANDREWS, P				ANDREWS, P			EVOLUTION AND ENVIRONMENT IN THE HOMINOIDEA	NATURE			English	Review							DNA HYBRIDIZATION EVIDENCE; MIOCENE CHINJI FORMATION; MIDDLE MIOCENE; PHYLOGENETIC-RELATIONSHIPS; MITOCHONDRIAL-DNA; MABOKO ISLAND; AFRICAN APES; GREAT APES; KENYA; SIVAPITHECUS	Between 10 and 20 million years ago, a variety of hominoid primates lived in Africa, Europe and Asia. The question of which of these, if any, lie closest to the ancestries of humans and modern apes remains a lively source of debate. Recent fossil discoveries, though, shed light on the environments in which the various groups of hominoid emerged and, it is hoped, on their evolution. But the lack of a hominid fossil record before about 5 million years ago-and any fossil record for the African apes-is still a frustrating barrier.			ANDREWS, P (corresponding author), NAT HIST MUSEUM, DEPT PALAEONTOL, LONDON SW7 5BD, ENGLAND.							AIELLO LC, 1981, ASPECTS HUMAN EVOLUT, P63; ALPAGUT B, 1990, J HUM EVOL, V19, P397, DOI 10.1016/0047-2484(90)90052-D; ANDREWS P, 1982, NATURE, V297, P541, DOI 10.1038/297541a0; ANDREWS P, 1975, CONTRIB PRIMATOL, V5, P62; ANDREWS P, 1991, PHILOS T R SOC B, V334, P199, DOI 10.1098/rstb.1991.0109; ANDREWS P, 1987, J HUM EVOL, V16, P101, DOI 10.1016/0047-2484(87)90062-5; ANDREWS P, 1979, BIOL J LINN SOC, V11, P177, DOI 10.1111/j.1095-8312.1979.tb00034.x; ANDREWS P, 1990, NATURE, V345, P664; ANDREWS P, 1990, J HUM EVOL, V19, P569, DOI 10.1016/0047-2484(90)90065-J; Andrews P., 1985, P14; ANDREWS P, 1992, NATURE, V356, P106, DOI 10.1038/356106a0; ANDREWS P, 1981, ASPECTS HUMAN EVOLUT, P25; Andrews P.J., 1978, Bulletin of the British Museum (Natural History) Geology, V30, P85; Andrews P.J., 1987, Bulletin of the British Museum (Natural History) Geology, V41, P383; ANDREWS PJ, 1989, J HUM EVOL, V18, P173, DOI 10.1016/0047-2484(89)90071-7; BEGUN DR, 1992, SCIENCE, V257, P1929, DOI 10.1126/science.1411507; BEGUN DR, 1992, AM J PHYS ANTHROPOL, V87, P311, DOI 10.1002/ajpa.1330870307; BENEFIT BR, 1989, J HUM EVOL, V18, P493, DOI 10.1016/0047-2484(89)90078-X; BIANCHI NO, 1985, J MOL EVOL, V22, P323, DOI 10.1007/BF02115688; BISHOP WW, 1969, AM J SCI, V267, P669, DOI 10.2475/ajs.267.6.669; BOSCHETTO HB, 1992, J HUM EVOL, V22, P47, DOI 10.1016/0047-2484(92)90029-9; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; CLARK WE, 1951, FOSSIL MAMMALS AFRIC, V3, P1; Collinson M.E., 1985, INT ASS ANGIOSPERM P, P4; CONROY GC, 1992, NATURE, V356, P144, DOI 10.1038/356144a0; DEAN D, 1992, NATURE, V359, P676, DOI 10.1038/359676a0; DEBONIS L, 1990, NATURE, V345, P712, DOI 10.1038/345712a0; DELSON E, 1985, NATURE, V318, P107, DOI 10.1038/318107a0; Delson E., 1975, P405; DJLAN P, 1989, P NATL ACAD SCI USA, V86, P8447; Dutrillaux B, 1980, J Reprod Fertil Suppl, VSuppl 28, P105; EVANS EMN, 1981, J HUM EVOL, V10, P99, DOI 10.1016/S0047-2484(81)80027-9; FEIBEL CS, 1991, J HUM EVOL, V21, P221, DOI 10.1016/0047-2484(91)90063-2; GEBO DL, 1988, J HUM EVOL, V17, P393, DOI 10.1016/0047-2484(88)90028-0; GOODMAN M, 1983, NATURE, V303, P546, DOI 10.1038/303546a0; HARRISON T, 1987, J HUM EVOL, V16, P41, DOI 10.1016/0047-2484(87)90060-1; HARRISON T, 1989, J HUM EVOL, V18, P537, DOI 10.1016/0047-2484(89)90017-1; HARRISON T, 1986, J HUM EVOL, V15, P541, DOI 10.1016/S0047-2484(86)80073-2; HARRISON T, IN PRESS PRIMATES; Harrison T., 1982, THESIS U LONDON; Hasegawa M., 1991, P303; HASEGAWA M, 1988, STATISTICAL THEORY D, V2, P1; HILL A, 1992, J HUM EVOL, V22, P439, DOI 10.1016/0047-2484(92)90079-O; HIXSON JE, 1986, MOL BIOL EVOL, V3, P1; HOLMES EC, 1989, J HUM EVOL, V18, P775, DOI 10.1016/0047-2484(89)90089-4; HOLMQUIST R, 1988, MOL BIOL EVOL, V5, P201; ISHIDA H, 1984, AF STUDY MONOG, V1, P73; KAPPELMAN J, 1991, J HUM EVOL, V21, P61, DOI 10.1016/0047-2484(91)90036-U; KAPPELMAN J, 1991, J HUM EVOL, V20, P95, DOI 10.1016/0047-2484(91)90053-X; Kay R.F., 1983, P577; KAY RF, 1977, NATURE, V268, P628, DOI 10.1038/268628a0; KAY RF, 1981, AM J PHYS ANTHROPOL, V55, P141, DOI 10.1002/ajpa.1330550202; Kelley J., 1986, COMP PRIMATE BIOL, P361; KING T, 1992, THESIS U LONDON; KOOP BF, 1986, NATURE, V319, P234, DOI 10.1038/319234a0; KRAJEWSKI C, 1990, SYST ZOOL, V39, P383, DOI 10.2307/2992358; KRETZOI M, 1974, FLORA FAUNA STRATIGR, P365; LARSON SG, 1988, AM J PHYS ANTHROPOL, V76, P449, DOI 10.1002/ajpa.1330760405; LEAKEY RE, 1986, NATURE, V324, P143, DOI 10.1038/324143a0; LEAKEY REF, 1985, NATURE, V318, P173, DOI 10.1038/318173a0; MADDEN C T, 1980, Primates, V21, P241, DOI 10.1007/BF02374037; MARKS J, 1982, CYTOGENET CELL GENET, V34, P261, DOI 10.1159/000131814; MARTIN L, 1985, NATURE, V314, P260, DOI 10.1038/314260a0; Martin L., 1984, Courier Forschungsinstitut Senckenberg, V69, P25; Martin L., 1986, P161; MARTIN L, 1991, AM J PHYS ANTHROPOL, V12, P126; MIYAMOTO MM, 1987, SCIENCE, V238, P369, DOI 10.1126/science.3116671; Napier J. R., 1959, Fossil Mammals of Africa, V16, P1; PICKFORD M, 1987, J HUM EVOL, V16, P305, DOI 10.1016/0047-2484(87)90006-6; PICKFORD M, 1981, J HUM EVOL, V10, P11, DOI 10.1016/S0047-2484(81)80023-1; Pickford M., 1983, P421; PICKFORD M, 1985, J HUM EVOL, V14, P113, DOI 10.1016/S0047-2484(85)80002-6; PILBEAM D, 1990, NATURE, V348, P237, DOI 10.1038/348237a0; Pilbeam D. R., 1969, Bulletin of the Peabody Museum of Natural History, V31, P1; RETALLACK GJ, 1988, AM J PHYS ANTHROPOL, V75, P260; ROSE MD, 1989, J HUM EVOL, V18, P131, DOI 10.1016/0047-2484(89)90067-5; ROSE MD, 1992, J HUM EVOL, V22, P255, DOI 10.1016/0047-2484(92)90058-H; RUFF CB, 1989, J HUM EVOL, V18, P515, DOI 10.1016/0047-2484(89)90016-X; RUVOLO M, 1986, MOL BIOL EVOL, V3, P285; RUVOLO M, 1991, P NATL ACAD SCI USA, V88, P1570, DOI 10.1073/pnas.88.4.1570; SAITOU N, 1991, AM J PHYS ANTHROPOL, V84, P75, DOI 10.1002/ajpa.1330840107; SARICH VM, 1967, SCIENCE, V158, P1200, DOI 10.1126/science.158.3805.1200; SCHWARTZ JH, 1984, NATURE, V308, P501, DOI 10.1038/308501a0; SCHWARTZ JH, 1990, J HUM EVOL, V19, P591, DOI 10.1016/0047-2484(90)90001-R; SHEA BT, 1988, BIOL ORANGUTAN, P233; SIBLEY CG, 1990, J MOL EVOL, V30, P202, DOI 10.1007/BF02099992; SIBLEY CG, 1987, J MOL EVOL, V26, P99, DOI 10.1007/BF02111285; SLIGHTOM JL, 1985, MOL BIOL EVOL, V2, P370; SMOUSE PE, 1987, EVOLUTION, V41, P1162, DOI 10.1111/j.1558-5646.1987.tb02458.x; STERN JT, 1983, AM J PHYS ANTHROPOL, V60, P279, DOI 10.1002/ajpa.1330600302; Szalay F.S., 1979, EVOLUTIONARY HIST PR; TEAFORD MF, 1984, AM J PHYS ANTHROPOL, V64, P191, DOI 10.1002/ajpa.1330640213; TEMPLETON AR, 1987, MOL BIOL EVOL, V4, P315; TEMPLETON AR, 1983, EVOLUTION, V37, P221, DOI 10.1111/j.1558-5646.1983.tb05533.x; WALKER A, 1989, SCI AM, V260, P76, DOI 10.1038/scientificamerican0189-76; WALKER A, 1983, NATURE, V305, P525, DOI 10.1038/305525a0; Walker A.C., 1983, P325; WALKER AC, IN PRESS J HUM EVOL; WARD CV, 1991, J HUM EVOL, V21, P215, DOI 10.1016/0047-2484(91)90062-Z; WARD S, 1987, AM J PHYS ANTHROPOL, V72, P21, DOI 10.1002/ajpa.1330720104; Ward S.C., 1983, P211; WHITE TD, 1986, ANTHROPOS BRNO, V23, P79; WHYBROW PJ, 1987, B BR MUS NAT HIS G, V41, P371; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; WYNN T, 1989, MAN, V24, P383, DOI 10.2307/2802697; YUNIS JJ, 1982, SCIENCE, V215, P1525, DOI 10.1126/science.7063861; [No title captured]	107	183	185	0	34	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 17	1992	360	6405					641	646		10.1038/360641a0	http://dx.doi.org/10.1038/360641a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465127				2022-12-28	WOS:A1992KD08200044
J	ALLBRITTON, NL; MEYER, T; STRYER, L				ALLBRITTON, NL; MEYER, T; STRYER, L			RANGE OF MESSENGER ACTION OF CALCIUM-ION AND INOSITOL 1,4,5-TRISPHOSPHATE	SCIENCE			English	Article							DIFFUSION; OSCILLATIONS; INDICATORS; KINETICS; RECEPTOR; BINDING; MUSCLE; CELLS; CA-2+; PHOSPHATES	The range of messenger action of a point source of Ca2+ or inositol 1,4,5-trisphosphate (IP3) was determined from measurements of their diffusion coefficients in a cytosolic extract from Xenopus laevis oocytes. The diffusion coefficient (D) of [H-3]IP3 injected into an extract was 283 mum2/s. D for Ca2+ increased from 13 to 65 mum2/s when the free calcium concentration was raised from about 90 nM to 1 muM. The slow diffusion of Ca2+ in the physiologic concentration range results from its binding to slowly mobile or immobile buffers. The calculated effective ranges of free Ca2+ before it is buffered, buffered Ca2+, and IP3 determined from their diffusion coefficients and lifetimes were 0.1 mum, 5 mum, and 24 mum, respectively. Thus, for a transient point source of messenger in cells smaller than 20 mum, IP3 is a global messenger, whereas Ca2+ acts in restricted domains.	DUKE UNIV,DEPT CELL BIOL,DURHAM,NC 27710	Duke University	ALLBRITTON, NL (corresponding author), STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305, USA.			Meyer, Tobias/0000-0003-4339-3804	NIAID NIH HHS [5F32AI0814203] Funding Source: Medline; NIMH NIH HHS [MH45324] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045324] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHMED Z, 1988, CELL CALCIUM, V9, P57, DOI 10.1016/0143-4160(88)90025-5; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BLATTER LA, 1990, BIOPHYS J, V58, P1491, DOI 10.1016/S0006-3495(90)82494-2; BORSE N, 1992, SCIENCE, V256, P1021; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BURGESS GM, 1985, BIOCHEM J, V232, P237, DOI 10.1042/bj2320237; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; Cohen P, 1988, CALMODULIN; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CRANK J, 1975, MATH DIFFUSION, P12; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DONAHUE BS, 1987, CELL CALCIUM, V8, P437, DOI 10.1016/0143-4160(87)90027-3; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HODGKIN AL, 1957, J PHYSIOL-LONDON, V138, P253, DOI 10.1113/jphysiol.1957.sp005850; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KUSHMERICK MJ, 1969, SCIENCE, V166, P1297, DOI 10.1126/science.166.3910.1297; KUSHMERICK MJ, 1980, BIOPHYSICAL CHEM 2, P570; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MINTA A, 1989, J BIOL CHEM, V264, P8171; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASI E, 1985, BIOPHYS J, V47, P735, DOI 10.1016/S0006-3495(85)83972-2; NEHR E, 1992, J PHYSL, V450, P273; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PARYS JB, 1992, J BIOL CHEM, V267, P18776; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SALA F, 1990, BIOPHYS J, V57, P313, DOI 10.1016/S0006-3495(90)82533-9; SHAYMAN JA, 1988, BIOCHEM BIOPH RES CO, V151, P114, DOI 10.1016/0006-291X(88)90566-9; SULPICE JC, 1990, METHODS INOSITIDE RE, P45; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TIMMERMAN MP, 1986, FEBS LETT, V209, P1, DOI 10.1016/0014-5793(86)81073-0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WANG JH, 1952, J AM CHEM SOC, V74, P1611, DOI 10.1021/ja01126a524; WANG JH, 1953, J AM CHEM SOC, V75, P1769, DOI 10.1021/ja01103a539; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	48	881	892	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1812	1815		10.1126/science.1465619	http://dx.doi.org/10.1126/science.1465619			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465619				2022-12-28	WOS:A1992KB96400044
J	TAGGART, AKP; FISHER, TS; PUGH, BF				TAGGART, AKP; FISHER, TS; PUGH, BF			THE TATA-BINDING PROTEIN AND ASSOCIATED FACTORS ARE COMPONENTS OF POL-III TRANSCRIPTION FACTOR TFIIIB	CELL			English	Article							RNA POLYMERASE-III; HUMAN U6 GENE; DNA-BINDING; INVITRO TRANSCRIPTION; ACCURATE TRANSCRIPTION; PROMOTER; COMPLEXES; UPSTREAM; INITIATION; ACTIVATION	RNA polymerases I, II, and III require the TATA-binding protein (TBP) to initiate promoter-specific transcription. We have separated HeLa TBP into four phosphocellulose fractions that elicit polymerase specificity in supplying TBP activity to TBP-depleted pol II and pol III transcription reactions. Polymerase specificity might arise in part through distinct TBP-associated factors (TAFs), which have recently been identified in pol I and II transcription. However, the requirement for pol III TAFs has not been established. Here we show that classical pol III transcription involves a minimum of two novel TAFs: TAF-172 and TAF-L. Not only does TAF-172 activate pol III transcription, but it also inhibits the binding of TBP to the TATA box, thereby repressing pol II transcription. The TBP-TAF-172-TAF-L complex can replace TFIIIB both in transcription reactions reconstituted with TFIIIC and in template commitment assays. Thus SL1, TFIID, and TFIIIB might be functionally similar TBP-TAF complexes that direct pol I, II, and III transcription, respectively.			TAGGART, AKP (corresponding author), PENN STATE UNIV,DEPT MOLEC & CELL BIOL,CTR GENE REGULAT,UNIV PK,PA 16802, USA.				NIGMS NIH HHS [GM47855-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BOULANGER PA, 1987, J BIOL CHEM, V262, P15098; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREDOW S, 1990, GENE, V86, P217, DOI 10.1016/0378-1119(90)90282-V; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CARLES C, 1991, J BIOL CHEM, V266, P24092; COLBERT T, 1992, IN PRESS GENES DEV; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CORTES P, 1992, J MOL CELL BIOL, V12, P413; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; INOSTROZA JA, 1992, CELL, V70, P477; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITCHELL MT, 1992, J BIOL CHEM, V267, P1995; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REEDER RH, 1990, TRENDS GENET, V6, P390, DOI 10.1016/0168-9525(90)90298-K; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9163; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; Weinmann Roberto, 1992, Gene Expression, V2, P81; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; Wolffe AP, 1991, CURR OPIN CELL BIOL, V3, P461, DOI 10.1016/0955-0674(91)90074-9; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	66	142	146	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1015	1028		10.1016/0092-8674(92)90396-T	http://dx.doi.org/10.1016/0092-8674(92)90396-T			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458533				2022-12-28	WOS:A1992KB99000013
J	MOFFATT, CJ; FRANKS, PJ; OLDROYD, M; BOSANQUET, N; BROWN, P; GREENHALGH, RM; MCCOLLUM, CN				MOFFATT, CJ; FRANKS, PJ; OLDROYD, M; BOSANQUET, N; BROWN, P; GREENHALGH, RM; MCCOLLUM, CN			COMMUNITY CLINICS FOR LEG ULCERS AND IMPACT ON HEALING	BRITISH MEDICAL JOURNAL			English	Article							CHRONIC VENOUS ULCERS; COMPRESSION; TRIAL	Objective-To evaluate the effectiveness of community clinics for leg ulcers. Design-All patients with leg ulceration were invited to community clinics that offered treatment developed in a hospital research clinic. Patients without serious arterial disease (Doppler ankle/brachial index > 0.8) were treated with a high compression bandage of four layers. Setting-Six community clinics held in health centres in Riverside District Health Authority supported by the Charing Cross vascular surgical service. Patients-All patients referred to the community services with leg ulceration, irrespective of cause and duration of ulceration. Main outcome measures-Time to complete healing by the life table method. Results-550 ulcerated legs were seen in 475 patients of mean (SD) age 73.8 (11.9) years. There were 477 venous ulcers of median size 4.2 cm2 (range 0.1-117 cm2), 128 being larger than 10 cm2. These ulcers had been present for a median of three months (range one week to 63 years) with 150 present for over one year. Four layer bandaging in the community clinics achieved complete healing in 318 (69%) venous ulcers by 12 weeks and 375 (83%) by 24 weeks. There were 56 patients with an ankle/brachial arterial pressure index < 0.8, indicating arterial disease. The 50 patients with pressure index <0.8>0.5 were treated with reduced compression, and 24 (56%) healed by 12 weeks and 31 (75%) by 24 weeks. The figures for overall healing for all leg ulcers were 351/550 (67%) at 12 weeks and 417/550 (81%) at 24 weeks, compared with only 11/51 (22%) at 12 weeks before the community clinics were set up. Conclusions-Community clinics for venous ulcers offer an effective means of achieving healing in most patients with leg ulcers.	UNIV LONDON,ROYAL HOLLOWAY & BEDFORD NEW COLL,DEPT SOCIAL POLICY,SURREY TW20 0EX,ENGLAND; W LONDON HOSP,RIVERSIDE DIST HLTH AUTHOR,FAMILY & COMMUNITY SERV UNIT,LONDON W6 7DQ,ENGLAND; UNIV HOSP S MANCHESTER,DEPT SURG,MANCHESTER M20 8LR,LANCS,ENGLAND	University of London; Royal Holloway University London; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	MOFFATT, CJ (corresponding author), CHARING CROSS HOSP,DEPT SURG,LONDON W6 8RF,ENGLAND.		Franks, Peter J/G-3592-2013	Franks, Peter J/0000-0002-9782-0181; Moffatt, Christine/0000-0002-2436-0129				BACKHOUSE CM, 1987, BRIT J SURG, V74, P626, DOI 10.1002/bjs.1800740732; BALE S, 1989, CARE, V7, P90; BLAIR SD, 1988, BRIT MED J, V297, P1159, DOI 10.1136/bmj.297.6657.1159; BLAIR SD, 1988, PHLEBOLOGY, V3, P129; CALLAM MJ, 1987, BRIT MED J, V295, P1382, DOI 10.1136/bmj.295.6610.1382; CALLAM MJ, 1985, BRIT MED J, V290, P1855, DOI 10.1136/bmj.290.6485.1855; COLGAN MP, 1990, BRIT MED J, V300, P972, DOI 10.1136/bmj.300.6730.972; CORNWALL JV, 1986, BRIT J SURG, V73, P693, DOI 10.1002/bjs.1800730905; POSKITT KR, 1987, BRIT MED J, V294, P674, DOI 10.1136/bmj.294.6573.674; WRIGHT D, 1987, Journal of Cardiovascular Surgery, V28, P97; YAO ST, 1969, BRIT J SURG, V56, P676, DOI 10.1002/bjs.1800560910	11	191	193	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1389	1392		10.1136/bmj.305.6866.1389	http://dx.doi.org/10.1136/bmj.305.6866.1389			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486301	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992KB85600019
J	VOSS, LD; MULLIGAN, J; BETTS, PR; WILKIN, TJ				VOSS, LD; MULLIGAN, J; BETTS, PR; WILKIN, TJ			POOR GROWTH IN SCHOOL ENTRANTS AS AN INDEX OF ORGANIC-DISEASE - THE WESSEX GROWTH STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHORT STATURE; HEIGHT; RELIABILITY; CHILDREN; NEED	Objective-To establish whether poor height or height velocity, assessed during the year of school entry, might identify children with previously undiagnosed organic disease. Design-Observation of a total population and their case controls. Setting-Community base. Subjects-All 14346 children in two health districts entering school during two consecutive years were screened for height by school nurses, and those whose height lay below the 3rd centile according to Tanner and Whitehouse standards (n=180) were identified. After excluding 32 with known organic disease, five from ethnic minorities, and three who refused to take part, the remaining 140 short normal children were matched with 140 age and sex matched controls of average height (10th-90th centile) and their height velocities over 12 months measured. Main outcome measures-Height, height velocity, previously diagnosed organic disease, and organic disease diagnosed as a result of blood tests and specialist examination. Results-Twenty five of the 180 short children (14%) were already known to have chronic organic disease which could explain their poor growth. Blood tests and specialist examination revealed a further seven with organic disease, which was acquired rather than congenital in three, and a second cause of short stature in one with known organic disease. These eight conditions had been missed at the school entry medical examination. The shorter the child, the more likely an underlying organic disorder, with seven of the 12 children whose heights were more than 3 standard deviations below the mean having some organic disease. Height velocity measured over 12 months, however, did not distinguish short normal children from those with disease or from their matched controls. Conclusions-Height, but not height velocity, is a useful index for identifying unrecognised organic disease at school entry. The shorter the stature the greater the prevalence of organic disease. The frequency of newly diagnosed remediable disease in this study (1 in 3-4000) is similar to that of neonatal hypothyroidism, which is routinely screened for. Routine investigation of all very short school entrants is recommended.			VOSS, LD (corresponding author), SOUTHAMPTON GEN HOSP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AYNSLEYGREEN A, 1983, ARCH DIS CHILD, V58, P535; BROOK CGD, 1991, ARCH DIS CHILD, V66, P85, DOI 10.1136/adc.66.1.85; BROOK CGD, 1989, CLIN PAEDIATRIC ENDO, P118; CHINN S, 1989, ARCH DIS CHILD, V64, P1545, DOI 10.1136/adc.64.11.1545; CROSS AW, 1985, J PEDIATR-US, V107, P653, DOI 10.1016/S0022-3476(85)80388-7; DONALD RA, 1984, ENDOCRINE DISORDERS; HINDMARSH PC, 1988, ACTA PAEDIATR SCAND, P73; KENNEDY FD, 1988, ARCH DIS CHILD, V63, P1261, DOI 10.1136/adc.63.10.1261; LACEY KA, 1974, LANCET, V1, P42; PARKIN JM, 1989, CLIN PAEDIATRIC ENDO, P96; SMITH GC, 1990, ARCH DIS CHILD, V65, P225, DOI 10.1136/adc.65.2.225; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; TANNER JM, 1986, HUMAN GROWTH COMPREH, V3, P95; VIMPANI GV, 1981, ARCH DIS CHILD, V56, P922, DOI 10.1136/adc.56.12.922; VOSS L, 1989, ACTA PAEDIATR SCAND, P65; VOSS LD, 1991, ARCH DIS CHILD, V66, P833, DOI 10.1136/adc.66.7.833; VOSS LD, 1987, LANCET, V2, P447; VOSS LD, 1990, ARCH DIS CHILD, V65, P1340, DOI 10.1136/adc.65.12.1340; ZERFAS AJ, 1986, HUMAN GROWTH, P490	19	73	75	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1992	305	6866					1400	1402		10.1136/bmj.305.6866.1400	http://dx.doi.org/10.1136/bmj.305.6866.1400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486305	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992KB85600023
J	HOWEY, J				HOWEY, J			AIDS CARE CURRICULUM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1227	1227		10.1001/jama.268.10.1227	http://dx.doi.org/10.1001/jama.268.10.1227			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507360				2022-12-28	WOS:A1992JL60800001
J	SIMONS, M; EDELMAN, ER; DEKEYSER, JL; LANGER, R; ROSENBERG, RD				SIMONS, M; EDELMAN, ER; DEKEYSER, JL; LANGER, R; ROSENBERG, RD			ANTISENSE C-MYB OLIGONUCLEOTIDES INHIBIT INTIMAL ARTERIAL SMOOTH-MUSCLE CELL ACCUMULATION INVIVO	NATURE			English	Article							FIBROBLAST GROWTH-FACTOR; VASCULAR INJURY; PROLIFERATION; HEPARIN; ANGIOPLASTY; EXPRESSION; ANTIBODY	SYNTHETIC antisense oligonucleotides have been used to dissect gene function in vitro. Technical difficulties prevented the use of this approach for investigating the effect of gene products in vivo. Here we report the use of local delivery of antisense c-myb oligonucleotide to suppress intimal accumulation of rat carotid arterial smooth muscle cells. Our results suggest that antisense oligonucleotides can be used to define the in vivo biological role of specific macromolecules in the blood vessel wall and could potentially serve as a new class of therapeutic agents for cardiovascular disorders.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DIV HLTH SCI TECHNOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734				AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1983, LAB INVEST, V49, P327; DEUEL TF, 1984, J CLIN INVEST, V74, P669, DOI 10.1172/JCI111482; DILLEY RJ, 1987, ATHEROSCLEROSIS, V63, P99, DOI 10.1016/0021-9150(87)90109-2; EDELMAN ER, 1990, P NATL ACAD SCI USA, V87, P3773, DOI 10.1073/pnas.87.10.3773; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HANSSON GK, 1988, CIRC RES, V63, P712, DOI 10.1161/01.RES.63.4.712; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; JONASSON L, 1988, P NATL ACAD SCI USA, V85, P2303, DOI 10.1073/pnas.85.7.2303; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V17, P433, DOI 10.1016/S0735-1097(10)80111-1; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; PUKAC LA, 1991, AM J PATHOL, V139, P1501; REILLY CF, 1989, J BIOL CHEM, V264, P6990; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0	24	680	821	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					67	70		10.1038/359067a0	http://dx.doi.org/10.1038/359067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522889				2022-12-28	WOS:A1992JL66200055
J	MEADOR, WE; MEANS, AR; QUIOCHO, FA				MEADOR, WE; MEANS, AR; QUIOCHO, FA			TARGET ENZYME RECOGNITION BY CALMODULIN - 2.4-ANGSTROM STRUCTURE OF A CALMODULIN-PEPTIDE COMPLEX	SCIENCE			English	Article							LIGHT-CHAIN KINASE; BINDING DOMAIN; CENTRAL HELIX; TROPONIN-C; MYOSIN; ACTIVATION; SEQUENCE; SITE	The crystal structure of calcium-bound calmodulin (Ca2+-CaM) bound to a peptide analog of the CaM-binding region of chicken smooth muscle myosin light chain kinase has been determined and refined to a resolution of 2.4 angstroms (angstrom). The structure is compact and has the shape of an ellipsoid (axial ratio approximately 2:1). The bound CaM forms a tunnel diagonal to its long axis that engulfs the helical peptide, with the hydrophobic regions of CaM melded into a single area that closely covers the hydrophobic side of the peptide. There is a remarkably high pseudo-twofold symmetry between the closely associated domains. The central helix of the native CaM is unwound and expanded into a bend between residues 73 and 77. About 185 contacts (<4 angstrom) are formed between CaM and the peptide, with van der Waals contacts comprising approximately 80% of this total.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Duke University								BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BRUNGER AT, 1990, XPLOR VERSION 2 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHATTOPADHYAYA R, IN PRESS J MOL BIOL; COX JA, 1985, J BIOL CHEM, V260, P2527; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; IKURA M, 1991, BIOCHEMISTRY-US, V30, P5498, DOI 10.1021/bi00236a024; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LEACHMAN SA, 1992, J BIOL CHEM, V267, P4930; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; LUKAS TS, 1988, COLD SPRING HARB SYM, V63, P185; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, P501; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; ROTH SM, 1992, BIOCHEMISTRY-US, V31, P1443, DOI 10.1021/bi00120a022; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; Seeholzer S.H., 1987, CALCIUM BINDING PROT, P360; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; TOROK K, 1992, BIOCHEMISTRY-US, V31, P3452, DOI 10.1021/bi00128a020; VANBERKUM MF, 1990, J BIOL CHEM, V265, P3950; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; VORHERR T, 1992, EUR J BIOCHEM, V204, P931, DOI 10.1111/j.1432-1033.1992.tb16714.x; VORHERR T, 1990, BIOCHEMISTRY, V29	38	979	986	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1251	1255		10.1126/science.1519061	http://dx.doi.org/10.1126/science.1519061			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519061				2022-12-28	WOS:A1992JL05000025
J	CHRISTEN, WG; MANSON, JE; SEDDON, JM; GLYNN, RJ; BURING, JE; ROSNER, B; HENNEKENS, CH				CHRISTEN, WG; MANSON, JE; SEDDON, JM; GLYNN, RJ; BURING, JE; ROSNER, B; HENNEKENS, CH			A PROSPECTIVE-STUDY OF CIGARETTE-SMOKING AND RISK OF CATARACT IN MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTERIOR SUBCAPSULAR CATARACTS; LENS OPACITIES; NUCLEAR; PREVALENCE; ALCOHOL; PLASMA; EYES	Objective.-To examine the association between cigarette smoking and the incidence of cataract. Design, Setting, and Participants.-The design was a prospective cohort study using data from the Physicians' Health Study, a randomized trial of aspirin and beta carotene among 22 071 US male physicians aged 40 to 84 years that began in 1982. This analysis includes the 17 824 physicians who did not report cataract at baseline and did provide complete risk factor information. Based on information reported at baseline, 10% were current smokers, 39% were past smokers, and 51% were never smokers. Main Outcome Measure.-An incident cataract was defined as a self-report confirmed by medical record review to have been first diagnosed after randomization, age-related in origin, and responsible for a decrease in best corrected visual acuity to 20/30 or worse. Main Results.-During 60 months of follow-up, 557 incident cataracts among 371 participants were confirmed. Compared with never smokers, current smokers of 20 or more cigarettes per day had a statistically significant increase in the risk of cataract (relative fisk [RR], 2.16; 95% confidence interval [CI], 1.46 to 3.20; P<.001). Similar results were obtained after simultaneously controlling for other potential cataract risk factors in a logistic regression model (RR, 2.05; 95% CI, 1.38 to 3.05; P<.001). Among the 557 eyes with cataract, nuclear sclerotic changes were present in 442 while posterior subcapsular changes were present in 204. After controlling for other potential cataract risk factors, current smokers of 20 or more cigarettes per day had statistically significant increases in nuclear sclerosis (RR, 2.24; 95% CI, 1.47 to 3.41; P<.001) and posterior subcapsular (RR, 3.17; 95% CI, 1.81 to 5.53; P<.001) cataract. Past smokers had an elevated risk of posterior subcapsular (RR, 1.44; 95% CI, 0.97 to 2.13; P=.07) but not nuclear sclerosis cataract. For current smokers of fewer than 20 cigarettes per day, no increased risks were observed of total, nuclear sclerosis, or posterior subcapsular cataract. Conclusions.-These data provide support for the hypothesis that cigarette smoking increases the risk of developing both nuclear sclerosis and posterior subcapsular cataract.	HARVARD UNIV,SCH MED,DEPT MED,CHANNING LAB,PHYSICIANS HLTH STUDY,900 COMMONWEALTH AVE E,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,DEPT OPHTHALMOL,EPIDEMIOL UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary					NEI NIH HHS [EY03355] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1991, AM J EPIDEMIOL, V133, P541; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; BUNCE GE, 1990, ANNU REV NUTR, V10, P233, DOI 10.1146/annurev.nu.10.070190.001313; CHOW CK, 1986, J AM COLL NUTR, V5, P305; CLAYTON RM, 1982, T OPHTHAL SOC UK, V102, P331; EDERER F, 1973, ARCH OPHTHALMOL-CHIC, V89, P1; FLAYE DE, 1989, EYE, V3, P379, DOI 10.1038/eye.1989.56; HANKINSON SE, 1992, JAMA-J AM MED ASSOC, V268, P994, DOI 10.1001/jama.268.8.994; HARDING JJ, 1988, BRIT J OPHTHALMOL, V72, P809, DOI 10.1136/bjo.72.11.809; HILLER R, 1986, AM J EPIDEMIOL, V124, P916, DOI 10.1093/oxfordjournals.aje.a114481; JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022; KLEIN BEK, 1985, OPHTHALMOLOGY, V92, P1191; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; PERKINS ES, 1984, BRIT J OPHTHALMOL, V68, P293, DOI 10.1136/bjo.68.5.293; ROSNER B, 1982, BIOMETRICS, V38, P105, DOI 10.2307/2530293; SPERDUTO RD, 1984, OPHTHALMOLOGY, V91, P815; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; WEST S, 1989, ARCH OPHTHALMOL-CHIC, V107, P1166, DOI 10.1001/archopht.1989.01070020232031; 1983, DHHS NIH822469 PUBL, P7; 1980, WORLD BLINDNESS ITS	24	168	168	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					989	993						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501324				2022-12-28	WOS:A1992JK12900022
J	EISENBERG, L				EISENBERG, L			TREATING DEPRESSION AND ANXIETY IN PRIMARY CARE - CLOSING THE GAP BETWEEN KNOWLEDGE AND PRACTICE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MENTAL-HEALTH TREATMENT; PSYCHIATRIC-DISORDERS; SOMATIZATION; RECOGNITION; MANAGEMENT; OUTCOMES; SERVICES				EISENBERG, L (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.							BARRETT J, 1991, J FAM PRACTICE, V33, P19; BARRETT JE, 1988, ARCH GEN PSYCHIAT, V45, P1100; BECK AT, 1979, COGNITIVE THERAPY DE; BRIDGES K, 1991, PSYCHOL MED, V21, P473, DOI 10.1017/S0033291700020584; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; CORYELL W, 1991, CLIN MANAGEMENT ANXI; EISENBERG L, 1980, AM J MED, V69, P277, DOI 10.1016/0002-9343(80)90389-7; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P1053; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; GOLDBERG D, 1991, PSYCHIATRIC B, V15, P593; Goldberg DP., 1992, COMMON MENTAL DISORD; GOOD MJD, 1987, J FAM PRACTICE, V25, P53; Kirmayer L. J., 1988, BIOMEDICINE EXAMINED, P57; Kleinman A. M., 1988, ILNESS NARRATIVES SU; Klerman G.L., 1984, INTERPERSONAL THERAP; KLERMAN GL, 1987, MED CARE, V25, P1078, DOI 10.1097/00005650-198711000-00006; LIPOWSKI ZJ, 1988, AM J PSYCHIAT, V145, P1358; Mishler EG, 1984, DISCOURSE MED DIALEC; MUMFORD E, 1984, AM J PSYCHIAT, V141, P1145; ORLEANS CT, 1985, AM J PSYCHIAT, V142, P52; ORMEL J, 1991, ARCH GEN PSYCHIAT, V48, P700; ORMEL J, 1990, PSYCHOL MED, V20, P909, DOI 10.1017/S0033291700036606; PAYKEL ES, 1988, J AFFECT DISORDERS, V14, P83, DOI 10.1016/0165-0327(88)90075-4; POTTER WZ, 1991, NEW ENGL J MED, V325, P633; REGIER DA, 1982, ARCH GEN PSYCHIAT, V39, P219; REGIER DA, 1978, ARCH GEN PSYCHIAT, V35, P685; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; SCHULBERG HC, 1988, GEN HOSP PSYCHIAT, V10, P79, DOI 10.1016/0163-8343(88)90092-8; SCHULBERG HC, 1987, GEN HOSP PSYCHIAT, V9, P1, DOI 10.1016/0163-8343(87)90094-6; SCHULBERG HC, 1990, DHHS PHS903460 DEP H, P71; SHAPIRO S, 1984, ARCH GEN PSYCHIAT, V41, P971; SHAPIRO S, 1987, MED CARE, V25, P327, DOI 10.1097/00005650-198704000-00006; SMITH GR, 1986, NEW ENGL J MED, V314, P1407, DOI 10.1056/NEJM198605293142203; VONKORFF M, 1990, PSYCHOL DISORDERS GE, P159; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914	36	270	270	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1992	326	16					1080	1083		10.1056/NEJM199204163261610	http://dx.doi.org/10.1056/NEJM199204163261610			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HN738	1463479				2022-12-28	WOS:A1992HN73800010
J	WRIGHT, J; FORD, H				WRIGHT, J; FORD, H			LETTER FROM AFRICA - ANOTHER AFRICAN DISASTER	BRITISH MEDICAL JOURNAL			English	Article											WRIGHT, J (corresponding author), GOOD SHEPHERD HOSP,SITEKI,SWAZILAND.		Wright, John/H-1624-2012	Wright, John/0000-0001-9572-7293					0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1479	1480		10.1136/bmj.305.6867.1479	http://dx.doi.org/10.1136/bmj.305.6867.1479			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493396	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992KC91800027
J	DONALDSON, LJ				DONALDSON, LJ			LONDON AFTER TOMLINSON - MAINTAINING EXCELLENCE - THE PRESERVATION AND DEVELOPMENT OF SPECIALIZED SERVICES .4.	BRITISH MEDICAL JOURNAL			English	Article								The advent of the Tomlinson inquiry draws attention to the need to strike a balance between market led and planned approaches to health care delivery. This is important not just for hospital rationalisation but also for the preservation and development of services which are provided in a smaller number of hospitals. Specialised services are often in the forefront of raising standards of care and introducing new developments and innovations. They are the only option for a small number of patients with serious illnesses. In the internal market for health care provision created by the 1990 NHS reforms more sophisticated and flexible mechanisms must be found to provide stability for specialised services while at the same time enabling the benefits of purchaser choice and provider competition to be realised.			DONALDSON, LJ (corresponding author), NO REG HLTH AUTHOR,NEWCASTLE TYNE NE6 4PY,ENGLAND.							[Anonymous], 1979, CMND7615; CROWLEY P, 1989, EFFECTIVE CARE PREGN, P125; KHANNA R, 1992, REPORT PERINATAL LAT; LIGGINS GC, 1972, PEDIATRICS, V50, P515; ROBERTS H, 1990, OUTCOME PERFORMANCE; 1991, RES HLTH RES DEV STR; 1962, CMND1604; 1992, HC291 HOUS COMM HLTH; 1992, ASSESSING EFFECTS HL; 1969, FUNCTIONS DISTRICT G; 1989, CMND555; 1992, REPORT INQUIRY LONDO	12	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1280	1284		10.1136/bmj.305.6864.1280	http://dx.doi.org/10.1136/bmj.305.6864.1280			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477576	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JZ52100032
J	ARONSON, JK; HARDMAN, M				ARONSON, JK; HARDMAN, M			ABC OF MONITORING DRUG-THERAPY - DIGOXIN	BRITISH MEDICAL JOURNAL			English	Article									ICI PLC,DIV MED RES,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND		ARONSON, JK (corresponding author), RADCLIFFE INFIRM,PHARMACOL,OXFORD OX2 6HE,ENGLAND.							ARONSON JK, THESIS; LLOYD, 1978, AM J CARDIOL, V42, P129; REDFORS A, 1972, BRIT HEART J, V34, P383; SMITH TW, 1970, J CLIN INVEST, V49, P2377, DOI 10.1172/JCI106457	4	17	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1149	1152		10.1136/bmj.305.6862.1149	http://dx.doi.org/10.1136/bmj.305.6862.1149			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463955	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JX84100029
J	LI, JX; ADEREM, A				LI, JX; ADEREM, A			MACMARCKS, A NOVEL MEMBER OF THE MARCKS FAMILY OF PROTEIN-KINASE-C SUBSTRATES	CELL			English	Article							PROMINENT CELLULAR SUBSTRATE; PHOSPHORYLATION SITE DOMAIN; BACTERIAL LIPOPOLYSACCHARIDES; MOLECULAR-CLONING; TRANSFORMING PROTEIN; MEMBRANE ATTACHMENT; CALMODULIN-BINDING; ENHANCED RELEASE; PLASMA-MEMBRANE; PHORBOL ESTERS	MARCKS is a specific protein kinase C (PKC) substrate that binds both calmodulin and actin and is phosphorylated during phagocyte activation, neurosecretion, and growth factor-dependent mitogenesis. We report here on MacMARCKS, a MARCKS homolog, whose synthesis is dramatically increased in macrophages when these cells are exposed to bacterial lipopolysaccharide. We have purified rabbit MacMARCKS and cloned its cDNA from rabbit and mouse. The effector domains of MacMARCKS and MARCKS are nearly identical, and both proteins bind calmodulin in a phosphorylation-regulated manner. MacMARCKS and MARCKS also share a second, highly conserved region also found in the internalization domain of the mannose-6-phosphate receptor. Our data suggest the existence of a family of PKC substrates that are targeted to different subcellular locations and that function to integrate PKC and calcium/calmodulin-dependent signals in the control of the plastic actin cytoskeleton.			LI, JX (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.				NIAID NIH HHS [AI-32972, AI-25032] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI025032, R01AI032972, R01AI025032] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ADEREM AA, 1988, J EXP MED, V167, P623, DOI 10.1084/jem.167.2.623; ADEREM AA, 1984, J CELL BIOL, V99, P1235, DOI 10.1083/jcb.99.4.1235; ADEREM AA, 1986, P NATL ACAD SCI USA, V83, P5817, DOI 10.1073/pnas.83.16.5817; ADEREM AA, 1988, BACT HOST CELL INTER, P141; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BIRKELAND ML, 1987, J EXP MED, V166, P506, DOI 10.1084/jem.166.2.506; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; COHN ZA, 1988, CURR OPIN IMMUNOL, V1; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GORDONWEEKS PR, 1989, TRENDS NEUROSCI, V12, P363, DOI 10.1016/0166-2236(89)90073-8; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; LABATE ME, 1989, NEURON, V3, P299, DOI 10.1016/0896-6273(89)90254-7; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MOORE RD, 1964, BRIT J EXP PATHOL, V45, P488; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SHINJI H, 1991, EXP CELL RES, V193, P127, DOI 10.1016/0014-4827(91)90546-7; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249	51	119	122	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					791	801		10.1016/0092-8674(92)90312-Z	http://dx.doi.org/10.1016/0092-8674(92)90312-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516135				2022-12-28	WOS:A1992JL66300010
J	VANDERSLUIJS, P; HULL, M; WEBSTER, P; MALE, P; GOUD, B; MELLMAN, I				VANDERSLUIJS, P; HULL, M; WEBSTER, P; MALE, P; GOUD, B; MELLMAN, I			THE SMALL GTP-BINDING PROTEIN RAB4 CONTROLS AN EARLY SORTING EVENT ON THE ENDOCYTIC PATHWAY	CELL			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; SEMLIKI FOREST VIRUS; TRANSFERRIN RECEPTOR; MDCK CELLS; K562 CELLS; VESICULAR TRANSPORT; PLASMA-MEMBRANE; EARLY ENDOSOMES; DOMAIN; SECRETION	rab4 is a ras-like GTP-binding protein that associates with early endosomes in a cell cycle-dependent fashion. To determine its role during endocytosis, we generated stable cell lines that overexpressed mutant or wild-type rab4. By measuring endocytosis, transport to lysosomes, and recycling, we found that overexpression of wild-type rab4 had differential effects on the endocytic pathway. Although initial rates of internalization and degradation were not inhibited, the transfectants exhibited a 3-fold decrease in fluid phase endocytosis as well as an alteration in transferrin receptor (Tfn-R) recycling. Wild-type rab4 caused a re-distribution of Tfn-R's from endosomes to the plasma membrane. It also blocked iron discharge by preventing the delivery of Tfn to acidic early endosomes, instead causing Tfn accumulation in a population of nonacidic vesicles and tubules. rab4 thus appears to control the function or formation of endosomes involved in recycling.	INST PASTEUR,F-75724 PARIS,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	VANDERSLUIJS, P (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510, USA.		Goud, Bruno/GWC-4807-2022; Mellman, Ira/ABG-5896-2020	Webster, Paul/0000-0002-1980-6931				BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ENFERT C, 1991, J CELL BIOL, V114, P663; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KLAUSNER RD, 1984, J CELL BIOL, V98, P1098, DOI 10.1083/jcb.98.3.1098; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MARSH M, 1986, P NATL ACAD SCI USA, V83, P2899, DOI 10.1073/pnas.83.9.2899; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; STEIN BS, 1984, J BIOL CHEM, V259, P4762; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VANDERSLUIJS P, 1992, IN PRESS EMBO J; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WEISSMAN AM, 1986, J CELL BIOL, V102, P951, DOI 10.1083/jcb.102.3.951; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	56	531	536	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					729	740		10.1016/0092-8674(92)90307-X	http://dx.doi.org/10.1016/0092-8674(92)90307-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516131				2022-12-28	WOS:A1992JL66300005
J	SCHLICK, T; OLSON, WK				SCHLICK, T; OLSON, WK			TREFOIL KNOTTING REVEALED BY MOLECULAR-DYNAMICS SIMULATIONS OF SUPERCOILED DNA	SCIENCE			English	Article							CONFORMATIONAL CHANGE; CIRCULAR DNAS; B-DNA; TOPOISOMERASES; RECOMBINATION; GYRASE; COMPLEX; PBR322; MUTANT; SCHEME	Computer simulations of the supercoiling of DNA, largely limited to stochastic search techniques, can offer important information to complement analytical models and experimental data. Through association of an energy function, minimum-energy supercoiled conformations, fluctuations about these states, and interconversions among forms may be sought. In theory, the observation of such large-scale conformational changes is possible, but modeling and numerical considerations limit the picture obtained in practice. A new computational approach is reported that combines an idealized elastic energy model, a compact B-spline representation of circular duplex DNA, and deterministic minimization and molecular dynamics algorithms. A trefoil knotting result, made possible by a large time-step dynamics scheme, is described. The simulated strand passage supports and details a supercoiled-directed knotting mechanism. This process may be associated with collective bending and twisting motions involved in supercoiling propagation and interwound branching. The results also demonstrate the potential effectiveness of the Langevin/implicit-Euler dynamics scheme for studying biomolecular folding and reactions over biologically interesting time scales.	NYU, COURANT INST MATH SCI, NEW YORK, NY 10012 USA; RUTGERS STATE UNIV, WRIGHT RIEMAN LABS, DEPT CHEM, NEW BRUNSWICK, NJ 08903 USA	New York University; Rutgers State University New Brunswick	SCHLICK, T (corresponding author), NYU, DEPT CHEM, 251 MERCER ST, NEW YORK, NY 10012 USA.			Schlick, Tamar/0000-0002-2392-2062	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034809] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34809] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN M, 1990, EMBO J, V9, P4551, DOI 10.1002/j.1460-2075.1990.tb07907.x; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; Bartels RH, 1987, INTRO SPLINES USE CO; BAUER WR, 1980, SCI AM, V243, P118; BENHAM CJ, 1989, PHYS REV A, V39, P2852; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; COZZARELLI NR, 1980, SCIENCE, V207, P953, DOI 10.1126/science.6243420; Dahlquist G., 1974, NUMERICAL METHODS; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; Frank-Kamenetskii M. D., 1981, Soviet Physics - Uspekhi, V24, P679, DOI 10.1070/PU1981v024n08ABEH004835; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HAO MH, 1989, BIOPOLYMERS, V28, P873, DOI 10.1002/bip.360280407; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KLENIN KV, 1991, J MOL BIOL, V217, P413, DOI 10.1016/0022-2836(91)90745-R; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; LANDAU LD, 1975, THEORY ELASTICITY, pCH2; LEBRET M, 1979, BIOPOLYMERS, V18, P1709, DOI 10.1002/bip.1979.360180710; LEBRET M, 1984, BIOPOLYMERS, V23, P1835, DOI 10.1002/bip.360231004; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIVOLANT F, 1989, NATURE, V339, P724, DOI 10.1038/339724a0; Love A.E.H., 1944, TREATISE MATH THEORY; MANDELKERN M, 1981, J MOL BIOL, V152, P153, DOI 10.1016/0022-2836(81)90099-1; McCammon JA., 1987, DYNAMICS PROTEINS NU; MUZARD G, 1990, EMBO J, V9, P1289, DOI 10.1002/j.1460-2075.1990.tb08238.x; NYBERG A, IN PRESS CHEM PHYS L; NYBERG AM, 1991, J CHEM PHYS, V95, P4986, DOI 10.1063/1.461715; OLSON WK, 1991, METHODS ENZYMOLOGY M, V203, P403; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; PESKIN CS, 1989, COMMUN PUR APPL MATH, V42, P1001, DOI 10.1002/cpa.3160420706; RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621; RAU DC, 1987, J MOL BIOL, V193, P555, DOI 10.1016/0022-2836(87)90266-X; SCHLICK T, 1989, COMMUN PUR APPL MATH, V42, P1141, DOI 10.1002/cpa.3160420807; SCHLICK T, 1992, J MOL BIOL, V223, P1089, DOI 10.1016/0022-2836(92)90263-J; SCHLICK T, 1992, ACM T MATH SOFTWARE, V18, P46, DOI 10.1145/128745.150973; SCHLICK T, 1987, J COMPUT CHEM, V8, P1025, DOI 10.1002/jcc.540080711; SCHLICK T, 1991, J CHEM PHYS, V94, P2118, DOI 10.1063/1.459935; SHISHIDO K, 1989, NUCLEIC ACIDS RES, V17, P9749, DOI 10.1093/nar/17.23.9749; SPENGLER SJ, 1985, CELL, V42, P325, DOI 10.1016/S0092-8674(85)80128-8; SUMNERS DW, 1990, MATH INTELL, V12, P71, DOI 10.1007/BF03024022; TAN RKZ, 1991, THEORETICAL BIOCH MO, V1, P125; TELEMAN O, 1986, J COMPUT CHEM, V7, P58, DOI 10.1002/jcc.540070108; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; TIMSIT Y, 1991, NATURE, V354, P167, DOI 10.1038/354167a0; TIMSIT Y, 1991, J MOL BIOL, V221, P919, DOI 10.1016/0022-2836(91)80184-V; TUCKERMAN ME, 1991, J CHEM PHYS, V94, P1465, DOI 10.1063/1.460004; VANGUNSTEREN WF, 1980, MOL PHYS, V40, P1015, DOI 10.1080/00268978000102101; VINOGRAD J, 1966, J GEN PHYSIOL, V49, P103, DOI 10.1085/jgp.49.6.103; WANG JC, 1982, SCI AM, V247, P94, DOI 10.1038/scientificamerican0782-94; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1986, CYCLIC POLYM, P225; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; WHITE JH, 1969, AM J MATH, V91, P693, DOI 10.2307/2373348; WHITE JH, 1989, MATH METHODS DNA SEQ, pCH9; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	58	89	90	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1992	257	5073					1110	1115		10.1126/science.257.5073.1110	http://dx.doi.org/10.1126/science.257.5073.1110			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509261				2022-12-28	WOS:A1992JJ88400031
J	GIMENO, CJ; FINK, GR				GIMENO, CJ; FINK, GR			THE LOGIC OF CELL-DIVISION IN THE LIFE-CYCLE OF YEAST	SCIENCE			English	Editorial Material									MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	GIMENO, CJ (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040266, R01GM035010, R37GM035010] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40266, GM35010] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		FREIFELDER D, 1960, J BACTERIOL, V80, P567, DOI 10.1128/JB.80.4.567-568.1960; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HANSEN EC, 1886, C R TRAV LAB CARLS P, V2, P92; HAWTHORNE DC, 1955, GENETICS, V40, P511; HERSKOWITZ I, 1992, NATURE, V357, P190, DOI 10.1038/357190a0; HICKS JB, 1977, GENETICS, V85, P395; LODDER J, 1970, YEASTS TAXONOMIC STU, P51; MORTIMER RK, 1986, GENETICS, V113, P35; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; SCHERR GH, 1953, BACTERIOL REV, V17, P51, DOI 10.1128/MMBR.17.1.51-92.1953; THOMAS JH, 1987, GENETICS, V115, P229	11	53	54	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					626	626		10.1126/science.1496375	http://dx.doi.org/10.1126/science.1496375			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496375				2022-12-28	WOS:A1992JF85200024
J	SEHGAL, A; GALBRAITH, A; CHESNEY, M; SCHOENFELD, P; CHARLES, G; LO, B				SEHGAL, A; GALBRAITH, A; CHESNEY, M; SCHOENFELD, P; CHARLES, G; LO, B			HOW STRICTLY DO DIALYSIS PATIENTS WANT THEIR ADVANCE DIRECTIVES FOLLOWED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHOOSING DEATH; RESUSCITATION; WITHDRAWAL; CARE	Objective. - The Cruzan case and the Patient Self-Determination Act will encourage patients to specify in advance which life-sustaining treatments they would want if they become mentally incompetent. However, strictly following such advance directives may not always be in a patient's best interests. We sought to determine whether patients diff er in how strictly they want advance directives followed. Design. - Interview study. Setting. - Seven outpatient chronic dialysis centers. Participants. - One hundred fifty mentally competent dialysis patients. Intervention. - Using a structured questionnaire, we asked the subjects whether they would want dialysis continued or stopped if they developed advanced Alzheimer's disease. We then asked how much leeway their physician and surrogate should have to override that advance directive if overriding were in their best interests, Subjects granting leeway were also asked what factors should be considered in making decisions for them. Results. - Subjects varied greatly in how much leeway they would give surrogates to override their advance directives: "no leeway" (39%), "a little leeway" (19%), "a lot of leeway" (11%), and "complete leeway" (31%). Subjects also varied in how much they wanted various factors considered in making decisions, such as pain or suffering, quality of life, possibility of a new treatment, indignity caused by continued treatment, financial impact of treatment on family members, and religious beliefs. Conclusions. - Strictly following all advance directives may not truly reflect patients' preferences. To improve advance directives, we recommend that physicians explicitly ask patients how strictly they want their advance directives followed and what factors they want considered in making decisions.	DEPT VET AFFAIRS,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV NEPHROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV NEPHROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	SEHGAL, A (corresponding author), UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,BOX 0903,SAN FRANCISCO,CA 94143, USA.							ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BOPP J, 1990, HASTINGS CENT REP, V20, P42, DOI 10.2307/3562976; BUCHANAN AE, 1991, ANN INTERN MED, V114, P895; Dresser R S, 1989, Law Med Health Care, V17, P234; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FULLER, 1941, COL L REV, V41, P799; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LO B, 1991, JAMA-J AM MED ASSOC, V265, P1874, DOI 10.1001/jama.265.14.1874; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; PORT FK, 1989, AM J NEPHROL, V9, P145, DOI 10.1159/000167954; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; Rhoden N, 1989, Law Med Health Care, V17, P264; ROBERTS JC, 1988, ACTA MED SCAND, V223, P181; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SILVERSTEIN MD, 1991, MAYO CLIN PROC, V66, P906, DOI 10.1016/S0025-6196(12)61577-8; STEINBROOK R, 1984, NEW ENGL J MED, V310, P1598, DOI 10.1056/NEJM198406143102411; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; 1989, USRDS1989 NAT I HLTH	23	239	239	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	1992	267	1					59	63		10.1001/jama.267.1.59	http://dx.doi.org/10.1001/jama.267.1.59			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW848	1489360				2022-12-28	WOS:A1992GW84800024
J	BOSENBERG, MW; PANDIELLA, A; MASSAGUE, J				BOSENBERG, MW; PANDIELLA, A; MASSAGUE, J			THE CYTOPLASMIC CARBOXY-TERMINAL AMINO-ACID SPECIFIES CLEAVAGE OF MEMBRANE TGF-ALPHA INTO SOLUBLE GROWTH-FACTOR	CELL			English	Article							STIMULATING FACTOR CSF-1; CELL-SURFACE; KIT LIGAND; MOLECULAR-CLONING; FACTOR RECEPTORS; PLASMA-MEMBRANE; SI-LOCUS; PRECURSOR; TRANSMEMBRANE; PROTEIN	Membrane-anchored transforming growth factor a (proTGFalpha) belongs to a group of transmembrane proteins whose extracellular domains are selectively cleaved and released into the medium. We demonstrate that the carboxy-terminal valine in the cytoplasmic tail of proTGFalpha is required for cleavage of the growth factor ectodomain in response to various activators. This cleavage process occurs outside Golgi or lysosomal locations, affects cell surface proTGFalpha, and requires little or no membrane traffic. We propose that cleavage and release of proTGFalpha ectodomain involve a specialized proteolytic system and depend on the recognition of a simple and specific determinant located in the proTGFalpha cytoplasmic tail.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	BOSENBERG, MW (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.		Pandiella, Atanasio/O-5180-2014	Pandiella, Atanasio/0000-0002-4704-8971; Massague, Joan/0000-0001-9324-8408				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERNSTEIN SE, 1960, MOUSE NEWS LETT, V23, P33; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KISHIMOTO TE, 1989, SCIENCE, V245, P1338; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; PAABO S, 1986, EMBO J, V5, P1921, DOI 10.1002/j.1460-2075.1986.tb04445.x; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; Sambrook J, 1989, MOL CLONING LABORATO; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STEIN J, 1991, ONCOGENE, V6, P601; TEIXIDO J, 1987, NATURE, V326, P883, DOI 10.1038/326883a0; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	50	130	133	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1157	1165		10.1016/S0092-8674(05)80064-9	http://dx.doi.org/10.1016/S0092-8674(05)80064-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473151				2022-12-28	WOS:A1992KE60400010
J	MAZUR, P; COLE, KW; HALL, JW; SCHREUDERS, PD; MAHOWALD, AP				MAZUR, P; COLE, KW; HALL, JW; SCHREUDERS, PD; MAHOWALD, AP			CRYOBIOLOGICAL PRESERVATION OF DROSOPHILA EMBRYOS	SCIENCE			English	Article							MOUSE EMBRYOS; MELANOGASTER EMBRYOS; SURVIVAL; PERMEABILIZATION; FROZEN; EGGS	The inability to cryobiologically preserve the fruit fly Drosophila melanogaster has required that fly stocks be maintained by frequent transfer of adults. This method is costly in terms of time and can lead to loss of stocks. Traditional slow freezing methods do not succeed because the embryos are highly sensitive to chilling. With the procedures described here, 68 percent of precisely staged 15-hour Oregon R (wild-type) embryos hatch after vitrification at -205-degrees-C, and 40 percent of the resulting larvae develop into normal adult flies. These embryos are among the most complex organisms successfully preserved by cryobiology.	UNIV TENNESSEE,OAK RIDGE GRAD SCH BIOMED SCI,OAK RIDGE NATL LAB,OAK RIDGE,TN 37831; OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Chicago	MAZUR, P (corresponding author), UNIV TENNESSEE,OAK RIDGE GRAD SCH BIOMED SCI,DIV BIOL,OAK RIDGE,TN 37831, USA.				NICHD NIH HHS [HD17607] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017607] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON KV, 1981, DEV BIOL, V82, P127, DOI 10.1016/0012-1606(81)90434-6; Ashburner M., 1978, GENETICS BIOL DROS A, P1; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; EDGLEY M, 1988, CAENORHABDITIS GENET; Hadley N.F., 1986, SCI AM, V254, P104; LIMBOURG B, 1973, DEV BIOL, V35, P382, DOI 10.1016/0012-1606(73)90034-1; LYNCH DV, 1989, CRYOBIOLOGY, V26, P445, DOI 10.1016/0011-2240(89)90069-2; MAZUR P, 1992, CRYOBIOLOGY, V29, P210, DOI 10.1016/0011-2240(92)90021-S; MAZUR P, 1992, CRYOBIOLOGY, V29, P39, DOI 10.1016/0011-2240(92)90005-M; MAZUR P, 1990, CELL BIOPHYS, V17, P53, DOI 10.1007/BF02989804; MAZUR P, IN PRESS CRYOBIOLOGY; MYERS S P, 1990, Cryobiology, V27, P651; MYERS SP, 1988, CRYOBIOLOGY, V25, P544, DOI 10.1016/0011-2240(88)90401-4; MYERS SP, 1989, CRYOBIOLOGY, V26, P472, DOI 10.1016/0011-2240(89)90071-0; RALL WF, 1987, CRYOBIOLOGY, V24, P387, DOI 10.1016/0011-2240(87)90042-3; RAMINANI LN, 1975, J INSECT MORPHOL EMB, V4, P517; SCHNEIDER U, 1983, BIOL REPROD, V29, P121, DOI 10.1095/biolreprod29.1.121; SCHREUDERS PD, IN PRESS CRYOBIOLOGY; STEPONKUS PL, 1990, NATURE, V345, P170, DOI 10.1038/345170a0; STEPONKUS PL, IN PRES CRYOBIOLOGY; STRONGGUNDERSON JM, 1989, ENVIRON ENTOMOL, V18, P756, DOI 10.1093/ee/18.5.756; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WHITTINGHAM DG, 1972, SCIENCE, V178, P411, DOI 10.1126/science.178.4059.411; Wieschaus E., 1986, P199; ZALOKAR M, 1977, EMBO WORKSHOP GIF SU	25	153	166	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1932	1935		10.1126/science.1470915	http://dx.doi.org/10.1126/science.1470915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470915				2022-12-28	WOS:A1992KD08800030
J	ARONSON, JK; REYNOLDS, DJM				ARONSON, JK; REYNOLDS, DJM			ABC OF MONITORING DRUG-THERAPY - LITHIUM	BRITISH MEDICAL JOURNAL			English	Article											ARONSON, JK (corresponding author), RADCLIFFE INFIRM,OXFORD OX2 6HE,ENGLAND.							AMDISEN, 1975, DANISH MED B, V22, P227; BRODIE, 1988, MED INT, V59, P2435; STOKES PE, 1976, ARCH GEN PSYCHIAT, V33, P1080	3	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1273	1276		10.1136/bmj.305.6864.1273	http://dx.doi.org/10.1136/bmj.305.6864.1273			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477574	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JZ52100030
J	DONEGAN, WL				DONEGAN, WL			CURRENT CONCEPTS - EVALUATION OF A PALPABLE BREAST MASS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FINE-NEEDLE ASPIRATION; FROZEN SECTION DIAGNOSIS; PHYSICAL-EXAMINATION; CYTOLOGIC DIAGNOSIS; COST-EFFECTIVENESS; BIOPSY; CANCER; MAMMOGRAPHY; MANAGEMENT; TUMORS		MED COLL WISCONSIN, DEPT SURG, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin								ABELE JS, 1983, ARCH SURG-CHICAGO, V118, P859; ADYE B, 1988, ARCH SURG-CHICAGO, V123, P37; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BELL DA, 1983, CANCER, V51, P1182, DOI 10.1002/1097-0142(19830401)51:7<1182::AID-CNCR2820510703>3.0.CO;2-A; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BOYD NF, 1981, AM J SURG, V142, P331, DOI 10.1016/0002-9610(81)90341-X; BUTLER JA, 1990, ARCH SURG-CHICAGO, V125, P893; CAHILL CJ, 1981, BRIT J SURG, V68, P882, DOI 10.1002/bjs.1800681215; CARSWELL H, 1992, DIAGNOSTIC IMAGI MAR, P51; CIATTO S, 1987, ACTA CYTOL, V31, P301; DERSHAW DD, 1990, AM J ROENTGENOL, V155, P35, DOI 10.2214/ajr.155.1.2112861; DOBERNECK RC, 1980, ANN SURG, V192, P152, DOI 10.1097/00000658-198008000-00003; DONEGAN WL, 1988, CANCER BREAST, P125; EGELI RA, 1979, CANCER-AM CANCER SOC, V43, P878, DOI 10.1002/1097-0142(197903)43:3<878::AID-CNCR2820430315>3.0.CO;2-K; Frable W J, 1982, Va Med, V109, P452; GRANT CS, 1986, MAYO CLIN PROC, V61, P377, DOI 10.1016/S0025-6196(12)61956-9; HALL FM, 1986, NEW ENGL J MED, V314, P53, DOI 10.1056/NEJM198601023140111; HAMED H, 1989, ARCH SURG-CHICAGO, V124, P253; HAMMOND S, 1987, ACTA CYTOL, V31, P276; HAYASHI N, 1985, BRIT J RADIOL, V58, P611, DOI 10.1259/0007-1285-58-691-611; HUGHES LE, 1989, WORLD J SURG, V13, P711, DOI 10.1007/BF01658419; KAGALI VA, 1983, SURG GYNECOL OBSTET, V156, P168; KAHKY MP, 1988, AM J SURG, V156, P450, DOI 10.1016/S0002-9610(88)80525-7; KLINE TS, 1991, DIAGN CYTOPATHOL, V7, P98, DOI 10.1002/dc.2840070126; LANNIN DR, 1986, ANN SURG, V203, P474, DOI 10.1097/00000658-198605000-00005; LAYFIELD LJ, 1989, PATHOL ANNU, V24, P23; LEIS H P JR, 1991, Contemporary Surgery, V39, P13; LESNICK GJ, 1977, JAMA-J AM MED ASSOC, V237, P967, DOI 10.1001/jama.237.10.967; LIGON RE, 1980, AM J SURG, V140, P779, DOI 10.1016/0002-9610(80)90116-6; MARTIN JE, 1979, AM J ROENTGENOL, V132, P737, DOI 10.2214/ajr.132.5.737; MCCLOW MV, 1973, ANN SURG, V177, P616; MCSWEENEY MB, 1985, RADIOL CLIN N AM, V23, P157; NICASTRI GR, 1991, SURG GYNECOL OBSTET, V172, P457; POWELL DE, 1988, PATHOL ANNU, V23, P159; ROSEMOND GP, 1969, SURG GYNECOL OBSTETR, V128, P351; ROSEN PP, 1978, ANN SURG, V187, P17, DOI 10.1097/00000658-197801000-00004; ROSNER D, 1985, J SURG ONCOL, V28, P308, DOI 10.1002/jso.2930280415; SAUNDERS G, 1991, SURG GYNECOL OBSTET, V172, P437; SHABOT MM, 1982, ANN SURG, V196, P122, DOI 10.1097/00000658-198208000-00002; SHEIKH FA, 1987, AM J SURG, V154, P470, DOI 10.1016/0002-9610(87)90254-6; SICKLES EA, 1983, AM J SURG, V145, P395, DOI 10.1016/0002-9610(83)90210-6; SICKLES EA, 1990, RECENT RES CANCER, V119, P127; SMITH C, 1988, SURGERY, V103, P178; STERNS EE, 1991, SURGERY, V110, P617; TINNEMANS JGM, 1988, WORLD J SURG, V12, P382, DOI 10.1007/BF01655680; VANDAM PA, 1988, RADIOLOGY, V166, P435, DOI 10.1148/radiology.166.2.3275983; WANEBO HJ, 1984, ANN SURG, V199, P569, DOI 10.1097/00000658-198405000-00012; WATSON DPH, 1987, SURG GYNECOL OBSTET, V165, P435; WINCHESTER DP, 1983, CANCER, V51, P2535, DOI 10.1002/1097-0142(19830615)51:12+<2535::AID-CNCR2820511326>3.0.CO;2-C; WOLBERG WH, 1989, ARCH SURG-CHICAGO, V124, P814; 1979, NEW ENGL J MED, V301, P340; 1990, BREAST CANCER STUDY	52	105	105	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					937	942						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP014	1513351				2022-12-28	WOS:A1992JP01400007
J	RAPHAEL, JC; CHASTANG, C; CHEVRET, S; GAJDOS, P				RAPHAEL, JC; CHASTANG, C; CHEVRET, S; GAJDOS, P			INTRAVENOUS IMMUNE GLOBULIN VERSUS PLASMA-EXCHANGE IN GUILLAIN-BARRE-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									HOP ST LOUIS,F-75010 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	RAPHAEL, JC (corresponding author), HOP RAY POINCARE,F-92380 GARCHES,FRANCE.			chevret, sylvie/0000-0001-6449-4730				CHASTANG C, 1988, STAT MED, V7, P1243, DOI 10.1002/sim.4780071205; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; RODARY C, 1989, STAT MED, V8, P593, DOI 10.1002/sim.4780080508; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; 1987, ANN NEUROL, V22, P753; IN PRESS ANN NEUROL; 1985, NEUROLOGY, V35, P1096; 1986, JAMA-J AM MED ASSOC, V256, P1333	8	16	16	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					816	816						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501669				2022-12-28	WOS:A1992JL66100029
J	SETTLEMAN, J; ALBRIGHT, CF; FOSTER, LC; WEINBERG, RA				SETTLEMAN, J; ALBRIGHT, CF; FOSTER, LC; WEINBERG, RA			ASSOCIATION BETWEEN GTPASE ACTIVATORS FOR RHO AND RAS FAMILIES	NATURE			English	Article							ESCHERICHIA-COLI; TYROSINE KINASES; BINDING PROTEINS; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; RAS-P21; PRODUCT; GENE; SITE	THE ras-related low-molecular-mass GTPases participate in signal transduction involving a variety of cellular functions, including cell-cycle progression, cellular differentiation, cytoskeletal organization, protein transport and secretion1-2. The cycling of these proteins between GTP-bound and GDP-bound states is partially controlled by GTPase activating proteins (GAPs) which stimulate the intrinsic GTP-hydrolysing activity of specific GTPases1-6. The ras GTPase-activating protein (Ras-GAP) forms a complex with a second protein, p190 (M(r) 190,000), in growth-factor stimulated and tyrosine-kinase transformed cells7,8. At its carboxy-terminal end, p190 contains a region that is conserved in the breakpoint cluster region, n-chimaerin, and Rho-GAP9. Each of these three proteins exhibits GAP activity for at least one member of the rho family of small GTPases10. We have tested recombinant p190 protein for GAP activity on GTPases of the ras, rho and rab families, and show here that p190 can function as a GAP specifically for members of the rho family. Consequently, the formation of a complex between Ras-GAP and p190 in growth-factor stimulated cells may allow the coupling of signalling pathways that involve ras and rho GTPases.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	SETTLEMAN, J (corresponding author), MIT,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Evans T, 1991, CURR OPIN CELL BIOL, V3, P185, DOI 10.1016/0955-0674(91)90137-N; FRECH M, 1990, J BIOL CHEM, V265, P6353; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1990, J BIOL CHEM, V265, P5990; LEROSEY I, 1991, J BIOL CHEM, V266, P4315; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	30	298	303	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					153	154		10.1038/359153a0	http://dx.doi.org/10.1038/359153a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522900				2022-12-28	WOS:A1992JM49400054
J	TURPIE, AGG; GENT, M; COTE, R; LEVINE, MN; GINSBERG, JS; POWERS, PJ; LECLERC, J; GEERTS, W; JAY, R; NEEMEH, J; KLIMEK, M; HIRSH, J				TURPIE, AGG; GENT, M; COTE, R; LEVINE, MN; GINSBERG, JS; POWERS, PJ; LECLERC, J; GEERTS, W; JAY, R; NEEMEH, J; KLIMEK, M; HIRSH, J			A LOW-MOLECULAR-WEIGHT HEPARINOID COMPARED WITH UNFRACTIONATED HEPARIN IN THE PREVENTION OF DEEP-VEIN THROMBOSIS IN PATIENTS WITH ACUTE ISCHEMIC STROKE - A RANDOMIZED, DOUBLE-BLIND-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						CEREBROVASCULAR DISORDERS; HEPARINOID; ENOXAPARIN; HEPARIN; THROMBOEMBOLISM	LOW-DOSE HEPARIN; VENOUS THROMBOSIS; CONTROLLED TRIAL; HIP-SURGERY; ORG-10172; PROPHYLAXIS; LEG	Objective: To compare the relative safety and efficacy of a low-molecular-weight heparinoid (ORG 10172) with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Design: Double-blind randomized trial. Setting: Seven Canadian university-affiliated hospitals. Participants: Eighty-seven patients with acute ischemic stroke resulting in lower-limb paresis. Intervention: Patients received either low-molecular-weight heparinoid, 750 anti-factor Xa units twice daily, or unfractionated heparin, 5000 units subcutaneously twice daily. Treatment was continued for 14 days or until hospital discharge if sooner. Measurements: Deep vein thrombosis was diagnosed using I-125-labeled fibrinogen leg scanning and impedance plethysmography. Venography was indicated if either test was positive. Overt hemorrhage, major or minor, was assessed clinically. Results: Venous thrombosis occurred in four patients (9%) given low-molecular-weight heparinoid and in 13 patients (31%) given heparin (relative risk reduction, 71%; 95% CI, 16% to 93%. The corresponding rates for proximal vein thrombosis were 4% and 12%, respectively (relative risk reduction, 63%; P > 0.2). The incidence of hemorrhage was 2% in both groups. Conclusion: Low-molecular-weight heparinoid, given in a fixed dose of 750 anti-factor Xa units subcutaneously twice daily, is more effective than subcutaneous low-dose heparin for the prevention of deep vein thrombosis in patients with acute ischemic stroke.	MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA; HAMILTON CIVIC HOSP, RES CTR, HAMILTON L8V 1C3, ONTARIO, CANADA; MCGILL UNIV, MONTREAL H3A 2T5, QUEBEC, CANADA; UNIV MONTREAL, MONTREAL H3C 3J7, QUEBEC, CANADA	McMaster University; McMaster University; McGill University; Universite de Montreal			ginsberg, jeffrey s/ABC-1065-2020					BERGQVIST D, 1988, BRIT J SURG, V75, P888, DOI 10.1002/bjs.1800750920; BERGQVIST D, 1991, SURGERY, V109, P617; BROWN M, 1973, JAMA-J AM MED ASSOC, V224, P1493, DOI 10.1001/jama.224.11.1493; CARTER CJ, 1982, BLOOD, V59, P1239; CZECHANOWSKI B, 1981, DEUT MED WOCHENSCHR, V106, P1254, DOI 10.1055/s-2008-1070492; Fleiss JL, 1981, STATISTICAL METHODS, P19; HULL R, 1979, THROMB RES, V15, P227, DOI 10.1016/0049-3848(79)90068-9; KAKKAR V, 1972, ARCH SURG-CHICAGO, V104, P152; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P315; LEYVRAZ PF, 1991, BRIT MED J, V303, P543, DOI 10.1136/bmj.303.6802.543; MCCARTHY ST, 1977, LANCET, V2, P800; MCCARTHY ST, 1986, AGE AGEING, V15, P84, DOI 10.1093/ageing/15.2.84; MEULEMAN DG, 1982, THROMB RES, V27, P353, DOI 10.1016/0049-3848(82)90082-2; PRINS MH, 1989, HAEMOSTASIS, V19, P245; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SANDSET PM, 1990, SEMIN THROMB HEMOST, V16, P25; TEIEN AN, 1976, THROMB RES, V8, P413, DOI 10.1016/0049-3848(76)90034-7; TURPIE AG, 1990, VENOUS THROMBOEMBOLI, P303; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; TURPIE AGG, 1987, LANCET, V1, P523; WARLOW C, 1972, LANCET, V1, P1305	21	108	109	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					353	357		10.7326/0003-4819-117-5-353	http://dx.doi.org/10.7326/0003-4819-117-5-353			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503326				2022-12-28	WOS:A1992JK67800001
J	KANG, SM; BEVERLY, B; TRAN, AC; BRORSON, K; SCHWARTZ, RH; LENARDO, MJ				KANG, SM; BEVERLY, B; TRAN, AC; BRORSON, K; SCHWARTZ, RH; LENARDO, MJ			TRANSACTIVATION BY AP-1 IS A MOLECULAR TARGET OF T-CELL CLONAL ANERGY	SCIENCE			English	Article							LYMPHOCYTE-SPECIFIC FACTORS; HUMAN IL-2 GENE; INTERLEUKIN-2 GENE; CYCLOSPORINE-A; COSTIMULATORY SIGNAL; ANTIGEN RECEPTOR; SELF-TOLERANCE; ACTIVATION; EXPRESSION; ENHANCER	Anergy is a mechanism of T lymphocyte tolerance induced by antigen receptor stimulation in the absence of co-stimulation. Anergic T cells were shown to have a defect in antigen-induced transcription of the interleukin-2 gene. Analysis of the promoter indicated that the transcription factor AP-1 and its corresponding cis element were specifically down-regulated. Exposure of anergic T cells to interleukin-2 restored both antigen responsiveness and activity of the AP-1 element.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BEVERLY B, IN PRESS MOL MECHANI; BILLINGHAM RE, 1956, PHILOS T R SOC B, V239, P357, DOI 10.1098/rstb.1956.0006; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BONNEVILLE M, 1990, NATURE, V344, P163, DOI 10.1038/344163a0; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRORSON KA, 1991, J IMMUNOL, V147, P3601; BRUNVAND MW, 1988, J BIOL CHEM, V263, P18904; BURKLY LC, 1990, SCIENCE, V248, P1364, DOI 10.1126/science.1694042; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DESILVA DR, 1991, J IMMUNOL, V147, P3261; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSER DW, 1962, IMMUNOLOGY, V5, P378; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; ESSERY G, 1988, IMMUNOLOGY, V64, P413; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FORSDYKE DR, 1968, LANCET, V1, P281; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FUGITA T, 1986, CELL, V46, P401; GOODNOW CC, 1990, SCIENCE, V248, P1373, DOI 10.1126/science.2356469; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, IN PRESS INT REV CYT; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HECHT TT, 1983, J IMMUNOL, V131, P1049; HUBBARD SC, 1986, P NATL ACAD SCI USA, V83, P1852, DOI 10.1073/pnas.83.6.1852; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; Kang S.-G., UNPUB; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KANG SM, 1992, MOL CELL BIOL, V12, P3149, DOI 10.1128/MCB.12.7.3149; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LENARDO M, UNPUB; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN PJ, 1986, J IMMUNOL, V136, P3282; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MUELLER DL, 1989, J IMMUNOL, V142, P2617; NOSSAL GJV, 1980, P NATL ACAD SCI USA, V77, P16026; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; QUILL H, 1987, J IMMUNOL, V138, P3704; RADLER-POHL A, 1990, New Biologist, V2, P566; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; REISER H, 1992, P NATL ACAD SCI USA, V89, P271, DOI 10.1073/pnas.89.1.271; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHIBUYA H, 1989, NUCLEIC ACIDS RES, V17, P9173, DOI 10.1093/nar/17.22.9173; SHIBUYA H, 1989, INT IMMUNOL, V1, P143; SITKOVSKY MV, 1982, J IMMUNOL, V129, P1372; TOMONARI K, 1985, CELL IMMUNOL, V96, P147, DOI 10.1016/0008-8749(85)90347-8; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WILLIAMS TM, 1988, J IMMUNOL, V141, P662	79	336	357	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1134	1138		10.1126/science.257.5073.1134	http://dx.doi.org/10.1126/science.257.5073.1134			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509265				2022-12-28	WOS:A1992JJ88400038
J	HENSHAW, RC; TEMPLETON, AA; NAJI, SA; RUSSELL, IT				HENSHAW, RC; TEMPLETON, AA; NAJI, SA; RUSSELL, IT			MEDICAL ABORTION	BRITISH MEDICAL JOURNAL			English	Letter									UNIV ABERDEEN,HLTH SERV RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen	HENSHAW, RC (corresponding author), ABERDEEN MATERN HOSP,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZD,SCOTLAND.		Russell, Ian T/H-1181-2012					CASTADOT RG, 1986, FERTIL STERIL, V45, P5; HEARD M, 1992, BRIT MED J, V304, P195, DOI 10.1136/bmj.304.6821.195; MUNDAY D, 1989, BRIT MED J, V298, P1231, DOI 10.1136/bmj.298.6682.1231; 1990, BRIT J OBSTET GYNAEC, V97, P480; 1989, ABORTION STATISTICS	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					914	914		10.1136/bmj.304.6831.914-a	http://dx.doi.org/10.1136/bmj.304.6831.914-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HM835	1472255	Green Published			2022-12-28	WOS:A1992HM83500060
J	STOTT, NCH				STOTT, NCH			DAY CASE SURGERY GENERATES NO INCREASED WORKLOAD FOR COMMUNITY BASED STAFF - TRUE OR FALSE	BRITISH MEDICAL JOURNAL			English	Article											STOTT, NCH (corresponding author), UNIV WALES COLL CARDIFF,COLL MED,LLANEDEYRN HLTH CTR,CARDIFF CF3 7PN,WALES.							ADLER MW, 1978, J EPIDEMIOL COMMUN H, V32, P136, DOI 10.1136/jech.32.2.136; [Anonymous], 1990, SHORT CUT BETTER SER; BURN JMB, 1983, BRIT MED J, V286, P492, DOI 10.1136/bmj.286.6363.492; GARRAWAY WM, 1978, PRACTITIONER, V221, P22; MORGAN M, 1990, J EPIDEMIOL COMMUN H, V44, P90, DOI 10.1136/jech.44.2.90; RUCKLEY CV, 1980, NURSING TIMES    FEB, P255; RUCKLEY V, 1990, BRIT MED J, V301, P1213, DOI 10.1136/bmj.301.6762.1213; RUSSELL IT, 1977, LANCET, V1, P844; 1985, GUIDELINES DAY CASE; 1991, NHS3 OCC PAP	10	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1992	304	6830					825	826		10.1136/bmj.304.6830.825	http://dx.doi.org/10.1136/bmj.304.6830.825			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL827	1489421	Green Published, Bronze			2022-12-28	WOS:A1992HL82700026
J	VANKAER, L; ASHTONRICKARDT, PG; PLOEGH, HL; TONEGAWA, S				VANKAER, L; ASHTONRICKARDT, PG; PLOEGH, HL; TONEGAWA, S			TAP1 MUTANT MICE ARE DEFICIENT IN ANTIGEN PRESENTATION, SURFACE CLASS-I MOLECULES, AND CD4-8+ T-CELLS	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; H-2-DEFICIENT LYMPHOMA VARIANTS; LYMPHOCYTES-T; ENDOPLASMIC-RETICULUM; LYMPHOBLASTOID-CELLS; SELF-PEPTIDES; MHC MOLECULES; H-2 ANTIGENS; EXPRESSION; PROTEINS	The transporter associated with the antigen processing 1 (TAP1) gene encodes a subunit for a transporter, presumed to be involved in the delivery of peptides across the endoplasmic reticulum membrane to class I molecules. We have generated mice with a disrupted TAP1 gene using embryonic stem cell technology. TAP1-deficient mice are defective in the stable assembly and intracellular transport of class I molecules and consequently show severely reduced levels of surface class I molecules. These properties are strikingly similar to those described for the TAP2 mutant cell line RMA-S. Cells from the TAP1-deficient mice are unable to present cytosolic antigens to class I-restricted cytotoxic T cells. As predicted from the near absence of class I surface expression, TAP1-deficient mice lack CD4-8+ T cells.	MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	VANKAER, L (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309				AOSAI F, 1991, EUR J IMMUNOL, V21, P2767, DOI 10.1002/eji.1830211118; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BODMER JG, 1992, IMMUNOGENETICS, V36, P135, DOI 10.1007/BF00661090; BOEHMER HV, 1978, P NATL ACAD SCI USA, V75, P2439, DOI 10.1073/pnas.75.5.2439; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUCHMEIER MJ, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DERES K, 1992, EUR J IMMUNOL, V22, P1603, DOI 10.1002/eji.1830220638; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; ELLIOTT T, 1991, IMMUNOL TODAY, V12, P386; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, IMMUNOGENETICS, V32, P440; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NEEFJES JJ, 1992, EUR J IMMUNOL, V22, P1609, DOI 10.1002/eji.1830220639; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P4200, DOI 10.1073/pnas.88.10.4200; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1989, COLD SH Q B, V54, P299; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; van Bleek G M, 1992, Trends Cell Biol, V2, P202, DOI 10.1016/0962-8924(92)90247-K; WALDEN PR, 1990, P NATL ACAD SCI USA, V87, P9015, DOI 10.1073/pnas.87.22.9015; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YEWDELL JW, 1988, SCIENCE, V239, P637, DOI 10.1126/science.3257585; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL RM, 1978, NATURE, V271, P251, DOI 10.1038/271251a0	58	617	625	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1205	1214						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473153				2022-12-28	WOS:A1992KE60400014
J	HUGO, P; KAPPLER, JW; GODFREY, DI; MARRACK, PC				HUGO, P; KAPPLER, JW; GODFREY, DI; MARRACK, PC			A CELL-LINE THAT CAN INDUCE THYMOCYTE POSITIVE SELECTION	NATURE			English	Article							ANTIGEN-PRESENTING ABILITY; THYMIC EPITHELIAL-CELLS; T-CELLS; SELF-RECOGNITION; STROMAL CELL; DIFFERENTIATION; EXPRESSION; APPEARANCE; KINETICS; GROWTH	THE thymus positively selects thymocytes that bear T-cell receptors which recognize antigen presented by self major histocompatibility complex (MHC) proteins1,2. positive selection is usually driven by MHC products on radiation-resistant cortical epithelial cells3-5. It is unknown whether positive selection is mediated by all thymic epithelial cells or by some specialized subsets4. Here we introduce an H-2(b)-expressing thymic epithelial cell line into the thymuses of lethally irradiated H-2k animals reconstituted with H-2b/k F1 BM or fetal liver cells. I-A(b)-restricted T cells are found in these animals, demonstrating that selection occurs on the introduced epithelial cells.	DNAX RES INST MOLEC & CELLULAR BIOL INC,MOLEC & CELLULAR BIOL RES INST,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	HUGO, P (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,HOWARD HUGHES MED INST,1400 JACKSON ST,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Godfrey, Dale/0000-0002-3009-5472; Marrack, Philippa/0000-0003-1883-3687				BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; Benoist C, 1989, Semin Immunol, V1, P117; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BERRIH S, 1985, J IMMUNOL, V135, P1165; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BILL J, 1989, NATURE, V341, P649, DOI 10.1038/341649a0; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; FISCHER M, 1991, J IMMUNOL, V146, P3452; GOLDSCHNEIDER I, 1986, J EXP MED, V163, P1, DOI 10.1084/jem.163.1.1; LO D, 1986, J IMMUNOL, V137, P1772; LONGO DL, 1983, J IMMUNOL, V130, P2525; MCDEVITT HO, 1972, J EXP MED, V135, P1259, DOI 10.1084/jem.135.6.1259; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NISHIMURA T, 1990, J IMMUNOL, V145, P4012; PARDOLL D, 1992, CURR OPIN IMMUNOL, V4, P162, DOI 10.1016/0952-7915(92)90006-Z; POTWOROWSKI EF, 1986, IN VITRO CELL DEV B, V22, P557; RANSOM J, 1991, CELL IMMUNOL, V134, P180, DOI 10.1016/0008-8749(91)90341-8; Shortman K, 1990, Semin Immunol, V2, P3; SPANGRUDE GJ, 1990, J IMMUNOL, V145, P3661; VUKMANOVIC S, 1992, NATURE, V359, P729, DOI 10.1038/359729a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZLOTNIK A, 1983, J IMMUNOL, V131, P2814	25	102	102	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					679	682		10.1038/360679a0	http://dx.doi.org/10.1038/360679a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465132				2022-12-28	WOS:A1992KD08200058
J	MOLLON, JD; BOWMAKER, JK				MOLLON, JD; BOWMAKER, JK			THE SPATIAL ARRANGEMENT OF CONES IN THE PRIMATE FOVEA	NATURE			English	Article							COLOR-VISION; MACACA-FASCICULARIS; SENSITIVE CONES; WORLD PRIMATE; PIGMENTS	THE retinae of Old World primates contain three classes of light-sensitive cone, which exhibit peak absorption in different spectral regions1-4. But how are the different types of cone arranged in the hexagonal mosaic of the fovea? This question has often been answered with artists' impressions5-7, but never with direct measurements. Staining for antibodies specific to the short-wave photopigment has revealed a sparse, semiregular array of cones8; but nothing is known about the arrangement of the more numerous long- and middle-wave cones. Are they randomly distributed, with chance aggregations of one type, as Hartridge postulated in these columns nearly 50 years ago9,10? Or do they exhibit a regular alternation, recalling the systematic mosaics seen in some non-mammalian species6,11? Or, conversely, is there positive clumping of particular cone types, as might be expected if local patches of cones were descended from a single precursor cell? We have made direct microspectrophotometric measurements of patches of foveal retina from Old World monkeys, and report here that the distribution of long- and middle-wave cones is locally random. These two cone types are present in almost equal numbers, and not in the ratio of 2:1 that has been postulated for the human fovea.	UNIV LONDON, INST OPHTHALMOL, BATH ST, LONDON EC1V 9EL, ENGLAND	University of London; University College London	MOLLON, JD (corresponding author), UNIV CAMBRIDGE, DEPT EXPTL PSYCHOL, CAMBRIDGE CB2 3EB, ENGLAND.		Mollon, John/C-3520-2009; Mollon, John/U-2631-2019	Mollon, John/0000-0001-8533-033X; Mollon, John/0000-0001-8533-033X				AHNELT PK, 1987, J COMP NEUROL, V255, P18, DOI 10.1002/cne.902550103; [Anonymous], 1991, COMPUTATIONAL MODELS, DOI [10.7551/mitpress/2002.003.0010, DOI 10.7551/MITPRESS/2002.003.0010]; BAYLOR DA, 1987, J PHYSIOL-LONDON, V390, P145, DOI 10.1113/jphysiol.1987.sp016691; BOWMAKER JK, 1987, VISION RES, V27, P2101, DOI 10.1016/0042-6989(87)90124-6; BOWMAKER JK, 1991, J EXP BIOL, V156, P1; BOWMAKER JK, 1980, J PHYSIOL-LONDON, V298, P131, DOI 10.1113/jphysiol.1980.sp013071; CICERONE CM, 1989, VISION RES, V29, P115, DOI 10.1016/0042-6989(89)90178-8; CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411; DEMONASTERIO FM, 1981, SCIENCE, V213, P1278, DOI 10.1126/science.7268439; DOBELLE WH, 1969, SCIENCE, V166, P1508, DOI 10.1126/science.166.3912.1508; HAROSI FI, 1987, J GEN PHYSIOL, V89, P717, DOI 10.1085/jgp.89.5.717; HARTRIDGE H, 1947, PHILOS T ROY SOC B, V232, P519, DOI 10.1098/rstb.1947.0004; HARTRIDGE H, 1946, NATURE, V157, P482, DOI 10.1038/157482b0; Hartridge H, 1944, NATURE, V153, P45, DOI 10.1038/153045a0; Knowles A., 1977, PHOTOBIOLOGY VISION; LIEBMAN PA, 1964, J OPT SOC AM, V54, P1451, DOI 10.1364/JOSA.54.001451; Lythgoe J.N., 1979, ECOLOGY VISION; MARC RE, 1977, SCIENCE, V196, P454, DOI 10.1126/science.403607; MOLLON JD, 1989, J EXP BIOL, V146, P21; MOLLON JD, 1984, PROC R SOC SER B-BIO, V222, P373, DOI 10.1098/rspb.1984.0071; POKORNY J, 1991, PIGMENTS PERCEPTION; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; WALRAVEN PL, 1974, VISION RES, V14, P1339, DOI 10.1016/0042-6989(74)90007-8; WILLIAMS DR, 1991, PIGMENTS PERCEPTION	24	114	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1992	360	6405					677	679		10.1038/360677a0	http://dx.doi.org/10.1038/360677a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465131				2022-12-28	WOS:A1992KD08200057
J	CROSSLEY, D; MYRES, MP; WILKINSON, G				CROSSLEY, D; MYRES, MP; WILKINSON, G			ASSESSMENT OF PSYCHOLOGICAL CARE IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-ILLNESS; HEALTH QUESTIONNAIRE; PRACTITIONERS	Objective-To pilot a method of assessing psychological care by general practitioners. Design-Prospective examination of psychological care given in general practice by using general health questionnaire with predetermined quantifiable and case specific indices of outcome established at th original consultation. Setting-Rural general practice in Clwyd, North Wales. Subjects-447 consecutive adult general practice attenders. Main outcome measures-Three month follow up consultation rates, one year retrospective consultation rates, continuity of care, changes in general health questionnaire scores at follw up, general satisfaction, and acceptability of outcome measures. Results-The principal and trainee identified 72 patients with psychological problems, 46 of whom had new conditions. 133 patients scored over 6 on the 28 item general health questionnaire, 33 of whom were identified as new cases by the general practitioners. 62 patients were seen at follow up, including 23 patients identified by the questionnaire but not by the doctor. The doctors used diagnostic terms to describe the presenting condition in 38 cases. At three month follow up the general health questionnaire scores had fallen by more than 5 points in 22/39 patients identified and managed by doctors and 11/23 identified by the questionnaire. The agreed index of good outcome was almost or completely achieved by 20 of the 39 patients managed by doctors. Conclusion-Quantifiable methods of evaluating the quality of the structure, process, and outcome of psychological care can be achieved in general practice.	THE SURGERY,OVERTON ON DEE,CLWYD,WALES; UNIV LONDON LONDON HOSP,COLL MED,ACAD DEPT PSYCHIAT,LONDON E1 2AD,ENGLAND	University of London; University College London								BOARDMAN AP, 1987, BRIT J PSYCHIAT, V151, P373, DOI 10.1192/bjp.151.3.373; Burton R H, 1982, J R Coll Gen Pract, V32, P558; GOLDBERG D, 1987, J ROY COLL GEN PRACT, V37, P15; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; Howie J G, 1972, J R Coll Gen Pract, V22, P310; KRAUPLTAYLOR F, 1980, PSYCHOL MED, V10, P419; MARKS JN, 1979, PSYCHOL MED, V9, P337, DOI 10.1017/S0033291700030853; METCALFE DHH, 1990, MEASURING OUTCOMES M, P95; SHEPHERD M, 1988, PSYCHOL MED, V18, P263, DOI 10.1017/S0033291700007807; WILKINSON G, 1988, BMJ-BRIT MED J, V297, P1144, DOI 10.1136/bmj.297.6657.1144; WILKINSON G, 1989, PSYCHOL MED, V19, P225, DOI 10.1017/S0033291700011193; WRIGHT AF, 1987, J ROY COLL GEN PRACT, V37, P164; WRIGHT AF, 1988, J ROY COLL GEN PRACT, V38, P542; WRIGHT AF, 1990, BRIT J GEN PRACT, V40, P459	14	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1333	1336		10.1136/bmj.305.6865.1333	http://dx.doi.org/10.1136/bmj.305.6865.1333			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KA773	1483082	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KA77300028
J	FROHLICH, ED; APSTEIN, C; CHOBANIAN, AV; DEVEREUX, RB; DUSTAN, HP; DZAU, V; FAUADTARAZI, F; HORAN, MJ; MARCUS, M; MASSIE, B; PFEFFER, MA; RE, RN; ROCCELLA, EJ; SAVAGE, D; SHUB, C				FROHLICH, ED; APSTEIN, C; CHOBANIAN, AV; DEVEREUX, RB; DUSTAN, HP; DZAU, V; FAUADTARAZI, F; HORAN, MJ; MARCUS, M; MASSIE, B; PFEFFER, MA; RE, RN; ROCCELLA, EJ; SAVAGE, D; SHUB, C			MEDICAL PROGRESS - THE HEART IN HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEFT-VENTRICULAR HYPERTROPHY; NORMAL CORONARY-ARTERIES; CARDIAC-HYPERTROPHY; BLOOD-PRESSURE; MYOCARDIAL HYPERTROPHY; SYSTEMIC HYPERTENSION; SUDDEN-DEATH; COMPUTED-TOMOGRAPHY; ANGINA-PECTORIS; GROWTH-FACTOR		BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA; NEW YORK HOSP, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, NEW YORK, NY 10021 USA; VET AFFAIRS MED CTR, BIRMINGHAM, AL USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; CLEVELAND CLIN EDUC FDN, CLEVELAND, OH 44106 USA; NHLBI, BETHESDA, MD 20892 USA; VET AFFAIRS MED CTR, SAN FRANCISCO, CA USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	Boston University; NewYork-Presbyterian Hospital; Cornell University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Brigham & Women's Hospital; Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); US Department of Veterans Affairs; Veterans Health Administration (VHA); Mayo Clinic	FROHLICH, ED (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN, 1516 JEFFERSON HWY, NEW ORLEANS, LA 70121 USA.							ABRAHAMS C, 1987, LAB INVEST, V56, P676; ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALPERT NR, 1984, GROWTH HEART HLTH DI, P363; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1970, JAMA, V213, P1143; ANVERSA P, 1986, J AM COLL CARDIOL, V7, P1140, DOI 10.1016/S0735-1097(86)80236-4; APSTEIN CS, 1987, J MOL CELL CARDIOL, V19, P119, DOI 10.1016/S0022-2828(87)80551-5; BACHE RJ, 1988, PROG CARDIOVASC DIS, V30, P403, DOI 10.1016/0033-0620(88)90005-9; BADEER HS, 1964, AM J CARDIOL, V14, P133, DOI 10.1016/0002-9149(64)90123-7; BARRETT TB, 1987, P NATL ACAD SCI USA, V84, P1099, DOI 10.1073/pnas.84.4.1099; BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; BLAKE J, 1988, AM J CARDIOL, V62, P246, DOI 10.1016/0002-9149(88)90220-2; BLAKE J, 1990, AM J MED, V88, P477, DOI 10.1016/0002-9343(90)90426-E; BREISCH EA, 1984, LAB INVEST, V51, P333; BRESLIN DJ, 1966, CIRCULATION, V33, P87, DOI 10.1161/01.CIR.33.1.87; BRUSH JE, 1988, NEW ENGL J MED, V319, P1302, DOI 10.1056/NEJM198811173192002; CASALE PN, 1987, CIRCULATION, V75, P565, DOI 10.1161/01.CIR.75.3.565; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; COOPER RS, 1990, AM J CARDIOL, V65, P441, DOI 10.1016/0002-9149(90)90807-D; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; CURTIS MJ, 1989, J MOL CELL CARDIOL, V21, P21, DOI 10.1016/0022-2828(89)91490-9; DELLSPERGER KC, 1988, CIRC RES, V63, P87, DOI 10.1161/01.RES.63.1.87; DEPUEY EG, 1988, AM J CARDIOL, V62, P234, DOI 10.1016/0002-9149(88)90218-4; DEVEREUX RB, 1984, J AM COLL CARDIOL, V3, P82, DOI 10.1016/S0735-1097(84)80433-7; DEVEREUX RB, 1986, AM J CARDIOL, V57, P1388, DOI 10.1016/0002-9149(86)90224-9; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1983, AM J CARDIOL, V51, P171, DOI 10.1016/S0002-9149(83)80031-9; DEVEREUX RB, 1982, HYPERTENSION, V4, P524, DOI 10.1161/01.HYP.4.4.524; DEVEREUX RB, 1983, CIRCULATION, V68, P470, DOI 10.1161/01.CIR.68.3.470; DEVEREUX RB, 1987, J CLIN HYPERTENS, V3, P66; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DRAYER JIM, 1983, ARCH INTERN MED, V143, P90, DOI 10.1001/archinte.143.1.90; DRESLINSKI GR, 1981, AM J CARDIOL, V47, P1087, DOI 10.1016/0002-9149(81)90217-4; DUNN FG, 1983, J AM COLL CARDIOL, V1, P1348, DOI 10.1016/S0735-1097(83)80150-8; DUNN FG, 1987, AM J CARDIOL, V60, pI19; DUNN FG, 1977, AM J CARDIOL, V39, P789, DOI 10.1016/S0002-9149(77)80028-3; DZAU VJ, 1987, CIRCULATION, V75, P134; DZAU VJ, 1988, AM J CARDIOL, V62, pG30; ETLINGER JD, 1980, PLASTICITY MUSCLE, P541; FEIRING AJ, 1985, CIRCULATION, V72, P1355, DOI 10.1161/01.CIR.72.6.1355; FOUAD FM, 1984, J AM COLL CARDIOL, V3, P1500, DOI 10.1016/S0735-1097(84)80289-2; FOUADTARAZI FM, 1987, HYPERTENSION, V9, P65; Frohlich E D, 1986, Cardiol Clin, V4, P137; FROHLICH ED, 1971, CIRCULATION, V44, P446, DOI 10.1161/01.CIR.44.3.446; FROHLICH ED, 1991, HYPERTENSION, V18, P2; FROHLICH ED, 1988, J HYPERTENS, V6, pS2, DOI 10.1097/00004872-198812040-00002; FROHLICH ED, 1983, FED PROC, V42, P2709; GANAU A, 1990, CIRCULATION, V81, P25, DOI 10.1161/01.CIR.81.1.25; GARDNER DG, 1988, CARDIOVASC DRUG THER, V2, P479, DOI 10.1007/BF00051186; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRANGER CB, 1985, J AM COLL CARDIOL, V5, P862, DOI 10.1016/S0735-1097(85)80424-1; GROSSMAN W, 1980, AM J MED, V69, P576, DOI 10.1016/0002-9343(80)90471-4; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639, DOI 10.1016/S0735-1097(86)80476-4; HAMMOND IW, 1984, J NATL MED ASSOC, V76, P247; HAMRELL BB, 1985, VENTRICLE BASIC CLIN, P185; HANLEY MR, 1987, NATURE, V328, P668, DOI 10.1038/328668a0; HANSEN DE, 1990, CIRCULATION, V81, P1094, DOI 10.1161/01.CIR.81.3.1094; HARRIS CN, 1973, CHEST, V63, P353, DOI 10.1378/chest.63.3.353; HARRISON DG, 1985, CIRCULATION, V71, P1135, DOI 10.1161/01.CIR.71.6.1135; HARTFORD M, 1985, HYPERTENSION, V7, P97, DOI 10.1161/01.HYP.7.1.97; HEBERT PR, 1988, AM J EPIDEMIOL, V127, P581, DOI 10.1093/oxfordjournals.aje.a114833; HENQUELL L, 1977, CIRC RES, V41, P400, DOI 10.1161/01.RES.41.3.400; HOLT JP, 1968, AM J PHYSIOL, V215, P704, DOI 10.1152/ajplegacy.1968.215.3.704; HOUGHTON JL, 1990, J AM COLL CARDIOL, V15, P43, DOI 10.1016/0735-1097(90)90173-M; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; INOU T, 1983, FED PROC, V42, P1002; INOU T, 1987, AM J PHYSIOL, V253, pH1148, DOI 10.1152/ajpheart.1987.253.5.H1148; INOUYE I, 1984, AM J CARDIOL, V53, P120, DOI 10.1016/0002-9149(84)90695-7; ISOYAMA S, 1987, CIRC RES, V61, P337, DOI 10.1161/01.RES.61.3.337; ISOYAMA S, 1989, J CLIN INVEST, V84, P288, DOI 10.1172/JCI114153; IZUMO S, 1987, Journal of Molecular and Cellular Cardiology, V19, pS30, DOI 10.1016/S0022-2828(87)80713-7; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JALIL JE, 1989, CIRC RES, V64, P1041, DOI 10.1161/01.RES.64.6.1041; Jin M, 1988, Am J Med, V84, P28, DOI 10.1016/0002-9343(88)90202-1; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1972, NEW ENGL J MED, V287, P782; KANNEL WB, 1975, CIRCULATION, V51, P606, DOI 10.1161/01.CIR.51.4.606; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KANNEL WB, 1986, AM HEART J, V111, P391, DOI 10.1016/0002-8703(86)90156-0; KANNEL WB, 1987, AM J CARDIOL, V60, pI85; KATAN M, 1988, NATURE, V332, P203, DOI 10.1038/332203a0; KATZ J, 1988, RADIOLOGY, V169, P495, DOI 10.1148/radiology.169.2.2971985; KELLER AM, 1986, J AM COLL CARDIOL, V8, P113, DOI 10.1016/S0735-1097(86)80100-0; KHAIRALLAH PA, 1972, HYPERTENSION 1972, V212, P20; KJELSBERG MO, 1985, AM J CARDIOL, V55, P1; Klepzig M, 1987, J Cardiovasc Pharmacol, V10 Suppl 6, pS97, DOI 10.1097/00005344-198706106-00013; KOBRIN I, 1986, ARCH INTERN MED, V146, P272, DOI 10.1001/archinte.146.2.272; KOBRIN I, 1984, J AM GERIATR SOC, V32, P896, DOI 10.1111/j.1532-5415.1984.tb00890.x; KOMURO I, 1988, CIRC RES, V62, P1075, DOI 10.1161/01.RES.62.6.1075; KOMURO I, 1988, CIRCULATION S2, V78, P394; KOMURO I, 1988, CIRCULATION S2, V78, P562; KOYANAGI S, 1982, CIRCULATION, V65, P1192, DOI 10.1161/01.CIR.65.6.1192; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1987, AM J CARDIOL, V59, P836, DOI 10.1016/0002-9149(87)91102-7; LEVY D, 1987, AM J CARDIOL, V60, P560, DOI 10.1016/0002-9149(87)90305-5; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LORELL BH, 1987, J AM COLL CARDIOL, V9, P1189, DOI 10.1016/S0735-1097(87)80326-1; LUND DD, 1978, AM J ANAT, V152, P141, DOI 10.1002/aja.1001520202; LUTAS EM, 1985, HYPERTENSION, V7, P979, DOI 10.1161/01.HYP.7.6.979; MAJESKY M, 1987, J MOL CELL CARDIO S4, V19, P3; MARCUS ML, 1979, AM J CARDIOL, V44, P1023, DOI 10.1016/0002-9149(79)90239-X; MARCUS ML, 1982, NEW ENGL J MED, V307, P1362, DOI 10.1056/NEJM198211253072202; MARCUS ML, 1987, CIRCULATION, V75, P19; MARCUS ML, 1983, AM J MED, V75, P62, DOI 10.1016/0002-9343(83)90120-1; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1975, AM J PATHOL, V79, P387; MCLENACHAN JM, 1987, NEW ENGL J MED, V317, P787, DOI 10.1056/NEJM198709243171302; MEERSON FZ, 1983, FAILING HEART ADAPTA, P47; MESSERLI FH, 1983, ANN INTERN MED, V99, P757, DOI 10.7326/0003-4819-99-6-757; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; MIRSKY I, 1983, CIRC RES, V53, P767, DOI 10.1161/01.RES.53.6.767; MUELLER TM, 1978, CIRC RES, V42, P543, DOI 10.1161/01.RES.42.4.543; NAFTILIN AJ, 1988, CIRCULATION S2, V78, P4; OPHERK D, 1984, CIRCULATION, V69, P1, DOI 10.1161/01.CIR.69.1.1; OSTRZEGA E, 1989, AM HEART J, V117, P444, DOI 10.1016/0002-8703(89)90791-6; PAPADEMETRIOU V, 1985, AM J CARDIOL, V56, P546, DOI 10.1016/0002-9149(85)91182-8; PFEFFER JM, 1982, AM J PHYSIOL, V242, pH776, DOI 10.1152/ajpheart.1982.242.5.H776; PFEFFER MA, 1976, CIRC RES, V38, P423, DOI 10.1161/01.RES.38.5.423; PICHARD AD, 1981, AM J CARDIOL, V47, P547, DOI 10.1016/0002-9149(81)90537-3; POLESE A, 1991, CIRCULATION, V83, P845, DOI 10.1161/01.CIR.83.3.845; RAKUSAN K, 1967, CIRC RES, V21, P209, DOI 10.1161/01.RES.21.2.209; REITER SJ, 1986, CIRCULATION, V74, P890, DOI 10.1161/01.CIR.74.4.890; REMBERT JC, 1978, J CLIN INVEST, V62, P379, DOI 10.1172/JCI109139; REN JF, 1985, J AM COLL CARDIOL, V5, P1224, DOI 10.1016/S0735-1097(85)80029-2; RODEMANN HP, 1982, J BIOL CHEM, V257, P8716; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUMBERGER JA, 1987, J AM COLL CARDIOL, V9, P59, DOI 10.1016/S0735-1097(87)80083-9; SAMUELSSON O, 1987, JAMA-J AM MED ASSOC, V258, P1768; SASAYAMA S, 1976, CIRC RES, V38, P172, DOI 10.1161/01.RES.38.3.172; SAVAGE DD, 1990, AM J CARDIOL, V65, P371, DOI 10.1016/0002-9149(90)90304-J; SAVAGE DD, 1987, CIRCULATION, V75, P26; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SCHMIEDER RE, 1989, AM J MED, V87, P22; SEN S, 1983, AM J PHYSIOL, V244, pH97, DOI 10.1152/ajpheart.1983.244.1.H97; SEN S, 1987, HYPERTENSION, V9, P261, DOI 10.1161/01.HYP.9.3.261; SEN S, 1975, CIRCULATION, V52, P98; SEN S, 1983, CARDIAC HYPERTROPHY, V8, P309; SIMMONS BE, 1990, AM HEART J, V119, P513, DOI 10.1016/S0002-8703(05)80272-8; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1989, ANNU REV PHYSIOL, V51, P189, DOI 10.1146/annurev.ph.51.030189.001201; SMITH VE, 1985, J AM COLL CARDIOL, V5, P869, DOI 10.1016/S0735-1097(85)80425-3; SOKOLOW M, 1961, CIRCULATION, V23, P697, DOI 10.1161/01.CIR.23.5.697; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STAMM RB, 1982, AM HEART J, V104, P136, DOI 10.1016/0002-8703(82)90651-2; STARKSEN NF, 1986, P NATL ACAD SCI USA, V83, P8348, DOI 10.1073/pnas.83.21.8348; STRAUER BE, 1979, AM J CARDIOL, V44, P999, DOI 10.1016/0002-9149(79)90235-2; SWYNGHEDAUW B, 1984, AM J CARDIOL, V54, P437, DOI 10.1016/0002-9149(84)90212-1; TARAZI RC, 1969, DIS CHEST, V55, P214, DOI 10.1378/chest.55.3.214; TARAZI RC, 1966, CIRCULATION, V34, P818, DOI 10.1161/01.CIR.34.5.818; THOMAS WA, 1983, LAB INVEST, V48, P245; TOMANEK RJ, 1986, CIRC RES, V58, P38, DOI 10.1161/01.RES.58.1.38; TOPOL EJ, 1985, NEW ENGL J MED, V312, P277, DOI 10.1056/NEJM198501313120504; TRENOUTH RS, 1976, CIRCULATION, V53, P644, DOI 10.1161/01.CIR.53.4.644; TUBAU JF, 1989, AM J CARDIOL, V64, P45, DOI 10.1016/0002-9149(89)90651-6; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VARMUS HE, 1987, SCIENCE, V238, P1337, DOI 10.1126/science.2825348; VERSAILLES JT, 1982, J CARDIOVASC PHARM, V4, P430, DOI 10.1097/00005344-198205000-00013; WALFORD GD, 1988, CIRC RES, V63, P502, DOI 10.1161/01.RES.63.3.502; WASHBURN RA, 1986, AM J CARDIOL, V58, P1248, DOI 10.1016/0002-9149(86)90391-7; WASSERMAN AG, 1984, NEW ENGL J MED, V311, P1276, DOI 10.1056/NEJM198411153112003; WEBER KT, 1988, AM HEART J, V116, P1641, DOI 10.1016/0002-8703(88)90763-6; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; WEBER KT, 1988, CIRC RES, V62, P757, DOI 10.1161/01.RES.62.4.757; WEBER KT, 1990, AM J CARDIOL, V65, pG1; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WILLIAMS LT, 1988, CLIN RES, V36, P5; 1987, TAUBMAN MB, V19, pS6	176	510	518	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					998	1008		10.1056/NEJM199210013271406	http://dx.doi.org/10.1056/NEJM199210013271406			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1518549				2022-12-28	WOS:A1992JQ22500006
J	NOVELLO, AC; SHOSKY, J				NOVELLO, AC; SHOSKY, J			UNDERAGE DRINKING - LAWS, LOOPHOLES, AND ENFORCEMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US DEPT HHS,OFF SURGEON GEN,ROOM 718-E,200 INDEPENDENCE AVE SW,WASHINGTON,DC 20201; US PHS,WASHINGTON,DC	United States Public Health Service								1992, JAMA-J AM MED ASSOC, V268, P961	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1391	1391		10.1001/jama.268.11.1391	http://dx.doi.org/10.1001/jama.268.11.1391			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512898				2022-12-28	WOS:A1992JM84900006
J	WRIGHT, RS; SIMARI, RD; ORSZULAK, TA; EDWARDS, WD; GLEICH, GJ; REEDER, GS				WRIGHT, RS; SIMARI, RD; ORSZULAK, TA; EDWARDS, WD; GLEICH, GJ; REEDER, GS			EOSINOPHILIC ENDOMYOCARDIAL DISEASE PRESENTING AS CYANOSIS, PLATYPNEA, AND ORTHODEOXIA	ANNALS OF INTERNAL MEDICINE			English	Note						CYANOSIS; ORTHODEOXIA; PLATYPNEA; ATRIAL SEPTAL DEFECT; EOSINOPHILIA	HYPEREOSINOPHILIC SYNDROME	A patient with orthodeoxia (upright desaturation), platypnea (upright dyspnea), and progressive cyanosis was found to have eosinophilic endomyocardial disease and increasing right-to-left shunting across a previously "silent" atrial septal defect. Closure of the atrial septal defect, use of a right ventricular assist device, and performance of surgical thrombus decortication resulted in a good outcome.			WRIGHT, RS (corresponding author), MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.				PHS HHS [15231] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		DEMELLO DE, 1990, NEW ENGL J MED, V323, P1542, DOI 10.1056/NEJM199011293232207; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; GERBAUX A, 1956, Bull Mem Soc Med Hop Paris, V72, P456; Loeffler W, 1936, SCHWEIZ MED WOCHENSC, V17, P817; PARRILLO JE, 1979, AM J MED, V67, P572, DOI 10.1016/0002-9343(79)90227-4; SEWARD JB, 1984, MAYO CLIN PROC, V59, P221, DOI 10.1016/S0025-6196(12)61253-1; SMITH JW, 1978, WESTERN J MED, V129, P64	7	14	14	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					482	483		10.7326/0003-4819-117-6-482	http://dx.doi.org/10.7326/0003-4819-117-6-482			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503351				2022-12-28	WOS:A1992JN25700007
J	FERRIS, FL; KASSOFF, A; BUZNEY, SM; MCMEEL, JW; WEITER, JJ; DOYLE, GJ; IMMERMAN, RL; FRIEDMAN, GR; KLEIN, ML; DREYER, R; CHENOWETH, R; HANDELMAN, I; HOHL, R; BIESBROECK, R; SIPPERLEY, J; GARCIA, CA; BLOOME, MA; RUIZ, RS; RIEKHOF, FT; BOHART, WA; GOODART, RA; CLARKE, DH; ORTH, DH; FLOOD, TP; PACKO, KH; MALHOTRA, J; RAHMANI, A; WINTER, EJ; BHATIA, H; MURPHY, RP; FINE, SL; ELMAN, MJ; PROUT, TE; PATZ, A; RICE, TA; NEWSOME, D; AIELLO, LM; RAND, LI; SHAH, ST; COOPPAN, R; CAVALLERANO, J; POOLE, R; SILVER, P; BRIONES, J; WAFAI, MZ; ASMAL, AC; FRANKLIN, RM; AREND, L; BERGSMA, D; TURKISH, L; BEER, P; CARROLL, D; THOMAS, E; BURTON, TC; ABRAMS, GW; KIM, HJ; WILLIAMS, GA; TOPPING, TM; REESER, FH; AABERG, TM; BRINTON, GS; KINGHAM, JK; MEREDITH, TA; MARGHERIO, RR; MURPHY, PL; COX, MS; TRESE, M; WINOKUR, S; AI, E; SORENSON, R; ARSHAM, G; CAVENDER, J; KOPELOW, SM; SHABO, AL; BRIONES, JC; HORNICHTER, RD; BLAIR, NP; GOLDBERG, MF; LINDBERG, CR; ROSS, NL; HAUSER, LE; CUNHAVAZ, J; ERNEST, JT; LIANG, JC; COHEN, SB; VYGANTAS, C; WILLIAMS, G; FLYNN, HW; BLANKENSHIP, GW; KNOBLOCH, WH; RAMSAY, RC; CANTRILL, HL; GOETZ, FC; HOOGWERF, B; BERROCAL, J; PEREZ, R; UMPIERRE, AR; KINYOUN, JL; KALINA, RE; WELLS, CG; GUZAK, SV; PALMER, J; MYERS, FL; BRESNICK, GH; CHANDRA, SR; DAVIS, MD; KLEIN, R; STEVENS, TS; WALLOW, IH; DIXON, R; EHRLICH, E; EWART, R; FRANK, RN; LUCAS, S; WHITEHOUSE, F; WEISS, H; BALLEN, AE; TESKE, M; WARTH, M; BENSON, WE; TASMAN, WS; BROWN, GC; MCNAMARA, JA; LITTLE, HL; JACK, RL; BASSO, L; MILLER, DT; GUNTER, E; BAYSE, DD; HANNON, WH; MYRICK, JE; KNATTERUD, GL; FISHER, MR; PRIOR, MJ; BARTON, F; KUFERA, J; MILLER, TW; HOOPER, JK; CROW, RS; BAKER, RR; PRINEAS, R; DAVIS, MD; HUBBARD, LD; MAGLI, YL; SEGAL, P; MOWERY, RL; CHEW, EY; SEIGEL, DG; CASSEL, G				FERRIS, FL; KASSOFF, A; BUZNEY, SM; MCMEEL, JW; WEITER, JJ; DOYLE, GJ; IMMERMAN, RL; FRIEDMAN, GR; KLEIN, ML; DREYER, R; CHENOWETH, R; HANDELMAN, I; HOHL, R; BIESBROECK, R; SIPPERLEY, J; GARCIA, CA; BLOOME, MA; RUIZ, RS; RIEKHOF, FT; BOHART, WA; GOODART, RA; CLARKE, DH; ORTH, DH; FLOOD, TP; PACKO, KH; MALHOTRA, J; RAHMANI, A; WINTER, EJ; BHATIA, H; MURPHY, RP; FINE, SL; ELMAN, MJ; PROUT, TE; PATZ, A; RICE, TA; NEWSOME, D; AIELLO, LM; RAND, LI; SHAH, ST; COOPPAN, R; CAVALLERANO, J; POOLE, R; SILVER, P; BRIONES, J; WAFAI, MZ; ASMAL, AC; FRANKLIN, RM; AREND, L; BERGSMA, D; TURKISH, L; BEER, P; CARROLL, D; THOMAS, E; BURTON, TC; ABRAMS, GW; KIM, HJ; WILLIAMS, GA; TOPPING, TM; REESER, FH; AABERG, TM; BRINTON, GS; KINGHAM, JK; MEREDITH, TA; MARGHERIO, RR; MURPHY, PL; COX, MS; TRESE, M; WINOKUR, S; AI, E; SORENSON, R; ARSHAM, G; CAVENDER, J; KOPELOW, SM; SHABO, AL; BRIONES, JC; HORNICHTER, RD; BLAIR, NP; GOLDBERG, MF; LINDBERG, CR; ROSS, NL; HAUSER, LE; CUNHAVAZ, J; ERNEST, JT; LIANG, JC; COHEN, SB; VYGANTAS, C; WILLIAMS, G; FLYNN, HW; BLANKENSHIP, GW; KNOBLOCH, WH; RAMSAY, RC; CANTRILL, HL; GOETZ, FC; HOOGWERF, B; BERROCAL, J; PEREZ, R; UMPIERRE, AR; KINYOUN, JL; KALINA, RE; WELLS, CG; GUZAK, SV; PALMER, J; MYERS, FL; BRESNICK, GH; CHANDRA, SR; DAVIS, MD; KLEIN, R; STEVENS, TS; WALLOW, IH; DIXON, R; EHRLICH, E; EWART, R; FRANK, RN; LUCAS, S; WHITEHOUSE, F; WEISS, H; BALLEN, AE; TESKE, M; WARTH, M; BENSON, WE; TASMAN, WS; BROWN, GC; MCNAMARA, JA; LITTLE, HL; JACK, RL; BASSO, L; MILLER, DT; GUNTER, E; BAYSE, DD; HANNON, WH; MYRICK, JE; KNATTERUD, GL; FISHER, MR; PRIOR, MJ; BARTON, F; KUFERA, J; MILLER, TW; HOOPER, JK; CROW, RS; BAKER, RR; PRINEAS, R; DAVIS, MD; HUBBARD, LD; MAGLI, YL; SEGAL, P; MOWERY, RL; CHEW, EY; SEIGEL, DG; CASSEL, G			ASPIRIN EFFECTS ON MORTALITY AND MORBIDITY IN PATIENTS WITH DIABETES-MELLITUS - EARLY TREATMENT DIABETIC-RETINOPATHY STUDY REPORT-14	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VASCULAR-DISEASE; FOLLOW-UP; PLATELETS; AGGREGATION	Objectives.-This report presents information on the effects of aspirin on mortality, the occurrence of cardiovascular events, and the incidence of kidney disease in the patients enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS). Study Design.-This multicenter, randomized clinical trial of aspirin vs placebo was sponsored by the National Eye Institute. Patients.-Patients (N=3711) were enrolled in 22 clinical centers between April 1980 and July 1985. Men and women between the ages of 18 and 70 years with a clinical diagnosis of diabetes mellitus were eligible. Approximately 30% of all patients were considered to have type I diabetes mellitus, 31 % type II, and in 39% type I or II could not be determined definitely. Intervention.-Patients were randomly assigned to aspirin or placebo (two 325-mg tablets once per day). Main Outcome Measures.-Mortality from all causes was specified as the primary outcome measure for assessing the systemic effects of aspirin. Other outcome variables included cause-specific mortality and cardiovascular events. Results.-The estimate of relative risk for total mortality for aspirin-treated patients compared with placebo-treated patients for the entire study period was 0.91 (99% confidence interval, 0.75 to 1.11). Larger differences were noted for the occurrence of fatal and nonfatal myocardial infarction; the estimate of relative risk was 0.83 for the entire follow-up period (99% confidence interval, 0.66 to 1.04). Conclusions.-The effects of aspirin on any of the cardiovascular events considered in the ETDRS were not substantially different from the effects observed in other studies that included mainly nondiabetic persons. Furthermore, there was no evidence of harmful effects of aspirin. Aspirin has been recommended previously for persons at risk for cardiovascular disease. The ETDRS results support application of this recommendation to those persons with diabetes at increased risk of cardiovascular disease.	UNION UNIV, ALBANY, NY 12208 USA; RETINA FDN RETINA ASSOCIATES, EYE RES INST, BOSTON, MA USA; GOOD SAMARITAN HOSP, PORTLAND, OR 97210 USA; UNIV TEXAS, HERMANN EYE CTR, HOUSTON, TX 77025 USA; HOLY CROSS HOSP, SALT LAKE CITY, UT USA; INGALLS MEM HOSP, HARVEY, IL USA; JOHNS HOPKINS UNIV HOSP, WILMER INST, BALTIMORE, MD 21205 USA; JOSLIN DIABET CTR, BEETHAM EYE INST, BOSTON, MA USA; LOUISIANA STATE UNIV, CTR EYE, NEW ORLEANS, LA USA; MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA; MICHIGAN STATE UNIV, ASSOCIATED RETINA CONSULTANTS, E LANSING, MI 48824 USA; PACIFIC PRESBYTERIAN MED CTR, SAN FRANCISCO, CA USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, JULES STEIN EYE INST, LOS ANGELES, CA 90024 USA; UNIV ILLINOIS, CHICAGO, IL 60680 USA; UNIV MIAMI, SCH MED, BASCOM PALMER EYE INST, MIAMI, FL 33152 USA; UNIV MINNESOTA, CTR ECG CODING, MINNEAPOLIS, MN 55455 USA; UNIV PUERTO RICO, RIO PIEDRAS, PR 00931 USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; UNIV WISCONSIN, CTR FUNDUS PHOTOG READING, MADISON, WI 53706 USA; WAYNE STATE UNIV, KRESGE EYE INST, DETROIT, MI 48202 USA; WILLS EYE HOSP & RES INST, PHILADELPHIA, PA 19107 USA; ZWENG MEM RETINAL RES FDN, MENLO PK, CA USA; CTR DIS CONTROL, CENT LAB, ATLANTA, GA 30333 USA; MARYLAND MED RES INST, COORDINATING CTR, BALTIMORE, MD USA; US PHS, CTR DRUG DISTRIBUT, PERRY POINT, MD USA	Union College; University of Texas System; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Joslin Diabetes Center, Inc.; Louisiana State University System; Medical College of Wisconsin; Michigan State University; California Pacific Medical Center; University of California System; University of California Los Angeles; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Bascom Palmer Eye Institute; University of Miami; University of Minnesota System; University of Minnesota Twin Cities; University of Puerto Rico; University of Puerto Rico Rio Piedras; University of Washington; University of Washington Seattle; University of Wisconsin System; University of Wisconsin Madison; Wayne State University; Jefferson University; Centers for Disease Control & Prevention - USA; United States Public Health Service	FERRIS, FL (corresponding author), NEI, BIOMETRY & EPIDEMIOL PROGRAM, ROOM 6A-24, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.			Cavallerano, Jerry/0000-0003-3702-5570				ALMER LO, 1975, DIABETES, V24, P529, DOI 10.2337/diabetes.24.6.529; [Anonymous], 1991, Ophthalmology, V98, P757; [Anonymous], 1991, OPHTHALMOLOGY, V98, P741; [Anonymous], 1988, BRIT MED J, V296, P320; ARMITAGE P, 1971, STATISTICAL METHODS, P116; BELL ET, 1952, AMA ARCH PATHOL, V53, P444; Carroll W W, 1972, Ann Ophthalmol, V4, P1019; COLWELL JA, 1977, METABOLISM, V26, P279, DOI 10.1016/0026-0495(77)90074-9; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER SJ, 1958, J CHRON DIS, V8, P699; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; HALUSHKA PV, 1981, J LAB CLIN MED, V97, P87; HALUSHKA PV, 1977, NEW ENGL J MED, V297, P1306, DOI 10.1056/NEJM197712152972402; HARRIS M, 1979, DIABETES, V28, P1039; HEATH H, 1971, DIABETOLOGIA, V7, P308, DOI 10.1007/BF01219463; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; KESSLER II, 1971, AM J MED, V51, P715, DOI 10.1016/0002-9343(71)90299-3; KWAAN HC, 1972, J LAB CLIN MED, V80, P236; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; MOONEY A J, 1963, Br J Ophthalmol, V47, P513, DOI 10.1136/bjo.47.9.513; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; POWELL EDU, 1964, LANCET, V2, P17; PRIOR MJ, IN PRESS ANN EPIDEMI; RASKIN P, 1978, METABOLISM, V27, P235, DOI 10.1016/0026-0495(78)90169-5; REGNAULT F, 1972, SEM HOP PARIS, V48, P893; Rose G, 1968, CARDIOVASCULAR SURVE; SAGEL J, 1975, ANN INTERN MED, V82, P733, DOI 10.7326/0003-4819-82-6-733; WILLIS AL, 1974, SCIENCE, V183, P325, DOI 10.1126/science.183.4122.325; ZIBOH VA, 1979, EUR J CLIN INVEST, V9, P223, DOI 10.1111/j.1365-2362.1979.tb00927.x; 1985, PB85223006AS; 1991, OPHTHALMOLOGY, V88, P583; 1991, 40TH ANN SCI SESS AM	35	416	425	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1292	1300						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507375				2022-12-28	WOS:A1992JL60800030
J	HALL, WH; GOLDSMITH, LA; ASKIN, FB; CHANG, AE; COHEN, C; DUTCHER, JP; GILGOR, RS; GREEN, S; HARRIS, EL; HAVAS, S; ROBINSON, JK; SWANSON, NA; TEMPERO, MA				HALL, WH; GOLDSMITH, LA; ASKIN, FB; CHANG, AE; COHEN, C; DUTCHER, JP; GILGOR, RS; GREEN, S; HARRIS, EL; HAVAS, S; ROBINSON, JK; SWANSON, NA; TEMPERO, MA			DIAGNOSIS AND TREATMENT OF EARLY MELANOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV ROCHESTER,SCH MED,DEPT DERMATOL,ROCHESTER,NY 14627; JOHNS HOPKINS UNIV HOSP,SURG PATHOL,BALTIMORE,MD 21205; UNIV MICHIGAN,DIV SURG ONCOL,ANN ARBOR,MI 48109; EMORY UNIV,SCH MED,DEPT ANAT PATHOL,ATLANTA,GA 30322; MONTEFIORE MED CTR,ALBERT EINSTEIN CANC CTR,DEPT ONCOL,BRONX,NY 10467; UNIV N CAROLINA,DERMATOL,CHAPEL HILL,NC 27514; DUKE UNIV,DERMATOL,DURHAM,NC 27706; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,SEATTLE,WA 98195; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21218; UNIV MARYLAND,SCH MED,DEPT EPIDEMIOL & PREVENT MED,BALTIMORE,MD 21201; NORTHWESTERN UNIV,SCH MED,DEPT DERMATOL,CHICAGO,IL 60611; OREGON HLTH SCI UNIV,DERMATOL SURG & ONCOL SECT,PORTLAND,OR 97201; UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,ONCOL HEMATOL SECT,OMAHA,NE 68105	University of Rochester; Johns Hopkins University; Johns Hopkins Medicine; University of Michigan System; University of Michigan; Emory University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; Northwestern University; Oregon Health & Science University; University of Nebraska System; University of Nebraska Medical Center	HALL, WH (corresponding author), NIH,OFF MED APPLICAT RES,FED BLDG,ROOM 618,BETHESDA,MD 20892, USA.								0	318	321	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1314	1319		10.1001/jama.1992.03490100112037	http://dx.doi.org/10.1001/jama.1992.03490100112037			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507379				2022-12-28	WOS:A1992JL60800034
J	SPORN, MB; ROBERTS, AB				SPORN, MB; ROBERTS, AB			AUTOCRINE SECRETION - 10 YEARS LATER	ANNALS OF INTERNAL MEDICINE			English	Review						AUTOCRINE MOTILITY FACTOR; CYTOKINES; COLONY-STIMULATING FACTORS; INTERLEUKIN; TUMOR NECROSIS FACTOR; TRANSFORMING GROWTH FACTOR	TRANSFORMING GROWTH-FACTOR; ACUTE PROMYELOCYTIC LEUKEMIA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; FACTOR-BETA-1 GENE-EXPRESSION; TRANS RETINOIC ACID; FACTOR-BETA; CELL-SURFACE; FACTOR-ALPHA; RECEPTOR SUPERFAMILY	The concept of autocrine secretion, its subsequent modifications, its application for understanding pathogenesis of disease, and its potential for developing new approaches to prevention and treatment are reviewed. Peptide growth factors (cytokines) act as local autocrine and paracrine mediators of tissue homeostasis. Many diseases, including cancer, atherosclerosis, rheumatoid arthritis, and other fibrotic diseases characterized by chronic inflammation, are associated with aberrant expression and cellular coordination of the homeostatic action of these regulatory molecules. Modern biotechnology and pharmacology offer unique opportunities for the therapeutic prevention and treatment of these molecular and cellular lesions, using either cytokines or other agents that modify their synthesis and activity.			SPORN, MB (corresponding author), NCI, BLDG 41, ROOM C629, BETHESDA, MD 20892 USA.							ABE J, 1990, J NUTR SCI VITAMINOL, V36, P21, DOI 10.3177/jnsv.36.21; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; AYANLARBATUMAN O, 1991, J CLIN INVEST, V88, P1574, DOI 10.1172/JCI115469; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BISSELL M, 1990, PROGR LIVER DISEASES, V9, P143; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRODER S, 1991, MOL F ONCOLOGY; BROWDER TM, 1989, CANCER CELL-MON REV, V1, P9; Cannon W.B., 1939, WISDOM BODY, DOI [10.1097/00000441-193907000-00031, DOI 10.1097/00000441-193907000-00031]; Cannon WB, 1929, PHYSIOL REV, V9, P399, DOI 10.1152/physrev.1929.9.3.399; CASTAIGNE S, 1990, BLOOD, V76, P1704; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELDMANN M, 1991, IMMUNOL REV, V119, P105, DOI 10.1111/j.1600-065X.1991.tb00580.x; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GOLDE DW, 1990, SEMIN HEMATOL, V27, P1; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; GOTO M, 1986, Journal of Rheumatology, V13, P853; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; Haddow A, 1972, Adv Cancer Res, V16, P181; HARAOUI B, 1985, INT J IMMUNOPHARMACO, V7, P903, DOI 10.1016/0192-0561(85)90054-2; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JOHNS LD, 1991, J IMMUNOL, V147, P1792; KAWADE Y, 1991, Journal of Interferon Research, P177; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KING RJ, 1989, AM J PHYSIOL, V257, pL23, DOI 10.1152/ajplung.1989.257.2.L23; KING TE, 1991, CHEST, V1, pS93; KUJUBU DA, 1989, AM J KIDNEY DIS, V14, P61, DOI 10.1016/S0272-6386(89)80096-4; KURUVILLA AP, 1991, P NATL ACAD SCI USA, V88, P2918, DOI 10.1073/pnas.88.7.2918; LEFER AM, 1990, SCIENCE, V249, P61, DOI 10.1126/science.2164258; LEMIRE JM, 1991, J CLIN INVEST, V87, P1103, DOI 10.1172/JCI115072; LEUTZ A, 1991, PEPTIDE GROWTH FACTO, V2, P655; MANNING AM, 1991, ONCOGENE, V6, P1471; MASSACESI L, 1991, J CLIN INVEST, V88, P1331, DOI 10.1172/JCI115438; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MINNA JD, 1986, COLD SPRING HARB SYM, V51, P843, DOI 10.1101/SQB.1986.051.01.098; MORIMOTO C, 1987, NEW ENGL J MED, V316, P67, DOI 10.1056/NEJM198701083160202; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NIITSU Y, 1988, BLOOD, V71, P263; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; RACKE MK, 1991, J IMMUNOL, V146, P3012; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROBERTS AB, 1992, CANCER SURV, V14, P205; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Schleimer RP, 1989, ANTIINFLAMMATORY STE; SMIDDY WE, 1989, ARCH OPHTHALMOL-CHIC, V107, P577, DOI 10.1001/archopht.1989.01070010591036; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; SPORN MB, 1990, CELL REGUL, V1, P875, DOI 10.1091/mbc.1.12.875; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1986, J CLIN INVEST, V78, P329, DOI 10.1172/JCI112580; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; SPORN MB, 1991, PEPTIDE GROWTH FACTO, V1; STANBRIDGE EJ, 1990, SCIENCE, V247, P12, DOI 10.1126/science.2403692; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WAKEFIELD LM, 1990, TUMOR SUPPRESSOR GEN, P216; Weinberg R. A., 1989, ONCOGENES MOL ORIGIN; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WONG HL, 1991, PEPTIDE GROWTH FACTO, V2, P509; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	90	143	146	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					408	414		10.7326/0003-4819-117-5-408	http://dx.doi.org/10.7326/0003-4819-117-5-408			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503333				2022-12-28	WOS:A1992JK67800011
J	MALINSKI, T; TAHA, Z				MALINSKI, T; TAHA, Z			NITRIC-OXIDE RELEASE FROM A SINGLE CELL MEASURED INSITU BY A PORPHYRINIC-BASED MICROSENSOR	NATURE			English	Article							RELAXING FACTOR; ACETYLCHOLINE; RELAXATION	NITRIC oxide is an important bioregulatory molecule, being responsible, for example, for activity of endothelium-derived relaxing factor (EDRF)1-4. Acute hypertension5, diabetes6, ischaemia7 and atherosclerosis8 are associated with abnormalities of EDRF. Nitric oxide is thought to be a retrograde messenger in the central nervous system9. The technology is not yet available for rapid detection of NO released by a single cell in the presence of oxygen and/or nitrite, so the release, distribution and reactivity of endogenous NO in biological systems cannot be analysed. Here we describe a porphyrinic microsensor that we have developed and applied to monitoring NO release in a microsystem. We selectively measured in situ the NO released from a single cell with a response time of less than 10 ms. The microsensor consists of p-type semiconducting polymeric porphyrin and a cationic exchanger (Nafion) deposited on a thermally sharpened carbon fibre with a tip diameter of approximately 0.5-mu-m. The microsensor, which can be operated in either the amperometric or voltammetric mode, is characterized by a linear response up to 300-mu-M and a detection limit of 10 nM. Nitric oxide at the level of 10(-20) mols can be detected in a single cell.			MALINSKI, T (corresponding author), OAKLAND UNIV,DEPT CHEM,ROCHESTER,MI 48309, USA.							BAILEY F, 1991, ANAL CHEM, V63, P395, DOI 10.1021/ac00004a018; BENNETT JE, 1991, CHEM MATER, V3, P490, DOI 10.1021/cm00015a025; DOWNES MJ, 1976, ANALYST, V101, P742, DOI 10.1039/an9760100742; ENGSTROM RC, 1988, ANAL CHEM, V60, P652, DOI 10.1021/ac00158a010; FREIMAN PC, 1986, CIRC RES, V58, P783, DOI 10.1161/01.RES.58.6.783; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1988, MECHANISM VASODILATI, V4, P101; GERHARDT GA, 1984, BRAIN RES, V290, P390, DOI 10.1016/0006-8993(84)90963-6; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; MALINSKI T, 1991, J ELECTROCHEM SOC, V138, P2008, DOI 10.1149/1.2085915; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PIPER GM, 1988, AM J PHYSIOL, V24, P4825; Rosenthal AM, 1990, CELL CULTURE TECHNIQ, P117; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHIBUKI K, 1990, NEUROSCI RES, V9, P69, DOI 10.1016/0168-0102(90)90048-J; VANBENTHUYSEN KM, 1987, J CLIN INVEST, V79, P265, DOI 10.1172/JCI112793; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781	20	1031	1089	3	97	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					676	678		10.1038/358676a0	http://dx.doi.org/10.1038/358676a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1495562				2022-12-28	WOS:A1992JJ88200056
J	CHALE, SS; SWAI, ABM; MUJINJA, PGM; MCLARTY, DG				CHALE, SS; SWAI, ABM; MUJINJA, PGM; MCLARTY, DG			MUST DIABETES BE A FATAL DISEASE IN AFRICA - STUDY OF COSTS OF TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							TROPICAL AFRICA; TANZANIA; HEALTH	Objective - To estimate the costs of diagnosis and treatment of diabetes in Tanzania. Design - Costs estimated from the reported and recorded experience of patients with newly presenting diabetes in 1989-90 and of diabetic patients first seen in 1981-2. Setting - Muhimbili Medical Centre, Dar es Salaam. Subjects-464 patients (315 men and 149 women). 262 patients diagnosed during 1 September 1989-31 August 1990 (group 1) and 202 during 1 June 1981-31 August 1982 (group 2). Results-The average annual direct cost of diabetes care in 1989-90 was $287 for a patient requiring insulin and $103 for a patient not requiring insulin. Purchase of insulin accounted for 68.2% ($156) of the average annual outpatient costs for patients requiring insulin. For patients not requiring insulin the cost of oral hypoglycaemic drugs and treatment of chronic complications and infections accounted for 42.5% ($29.3) and 48.8% ($33.7) of costs respectively. Cost of outpatient care of diabetic patients for the whole of Tanzania was estimated at $2.7 m, $875 128 (32.2%) of which was for insulin. Doctors' and nurses' costs accounted for 0.2% of total costs of outpatient care. The annual direct inpatient care costs were estimated at $1.25m. Around 0.2% of the Tanzanian population aged 15 years and over used the equivalent of 8% of the total government health expenditure, which was $47 408 382. Conclusion - Diabetes places a severe strain on the limited resources of developing countries. If African patients with diabetes have to pay for their treatment most will be unable to do so and will die.	MUHIMBILI MED CTR,DEPT BEHAV SCI,DAR ES SALAAM,TANZANIA		CHALE, SS (corresponding author), MUHIMBILI MED CTR,DEPT MED,POB 65001,DAR ES SALAAM,TANZANIA.							AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; CORRIGAN CB, 1987, E AFR MED J, V64, P772; Enthoven A., 1984, HLTH DIS, P335; FOX NA, 1988, DIRECT INDIRECT COST; JOHNSON B, 1983, ACTA MED SCAND S, V671, P19; LAING W, 1989, DIABETES MODEL HLTH, P32; MCLARTY DG, 1989, LANCET, V1, P871; MCLARTY DG, 1990, BRIT MED J, V300, P1107, DOI 10.1136/bmj.300.6732.1107; ROLFE M, 1989, J ROY COLL PHYS LOND, V23, P255; SCOTT RS, 1985, DIABETES CARE, V8, P43, DOI 10.2337/diacare.8.1.43; SWAI ABM, 1990, BMJ-BRIT MED J, V300, P1103, DOI 10.1136/bmj.300.6732.1103; TRIOMPHE A, 1988, HEALTH POLICY, V9, P39, DOI 10.1016/0168-8510(88)90116-9; Vaughan P., 1989, Health Policy and Planning, V4, P97, DOI 10.1093/heapol/4.2.97; 1991, WHO FEATURES, P1; 1990, HALI YA UCHUMI WA TA; 1989, UNITED REPUBLIC TANZ	16	49	49	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1215	1218		10.1136/bmj.304.6836.1215	http://dx.doi.org/10.1136/bmj.304.6836.1215			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515790	Green Published, Bronze			2022-12-28	WOS:A1992HT96400020
J	REYNOLDS, DJM; ARONSON, JK				REYNOLDS, DJM; ARONSON, JK			ABC OF MONITORING DRUG-THERAPY - CYCLOSPORINE	BRITISH MEDICAL JOURNAL			English	Article											REYNOLDS, DJM (corresponding author), RADCLIFFE INFIRM,OXFORD OX2 6HE,ENGLAND.							ATKINSON K, 1984, BRIT J HAEMATOL, V56, P223, DOI 10.1111/j.1365-2141.1984.tb03950.x; FREY BM, 1987, TRANSPLANT P, V19, P1713; SJOQVIST F, 1983, 2ND P WORLD C CLIN P, P38; YEE GC, 1986, TRANSPL P, V18, P774	4	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1491	1494		10.1136/bmj.305.6867.1491	http://dx.doi.org/10.1136/bmj.305.6867.1491			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493401	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992KC91800033
J	CORBOY, JR; BUZY, JM; ZINK, MC; CLEMENTS, JE				CORBOY, JR; BUZY, JM; ZINK, MC; CLEMENTS, JE			EXPRESSION DIRECTED FROM HIV LONG TERMINAL REPEATS IN THE CENTRAL-NERVOUS-SYSTEM OF TRANSGENIC MICE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS DEMENTIA COMPLEX; CELL-LINES; GLIAL-CELLS; T-CELL; INFECTION; TYPE-1; BRAIN; GENE; TISSUE	Infection with the human immunodeficiency virus (HIV) is frequently accompanied by the AIDS (acquired immunodeficiency syndrome) dementia complex. The role of specific HIV genetic elements in the pathogenesis of central nervous system (CNS) disease is not clear. Transgenic mice were constructed that contained the long terminal repeats (LTRs) of two CNS-derived strains and a T cell tropic strain of HIV-1. Only mice generated with CNS-derived LTRs directed expression in the CNS, particularly in neurons. Thus, some strains of HIV-1 have a selective advantage for gene expression in the brain, and neurons can supply the cellular factors necessary for their transcription.	JOHNS HOPKINS UNIV,SCH MED,DIV COMPARAT MED NEUROL & MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV COMPARAT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV COMPARAT MED & PATHOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI027297, P30AI028748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007000] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27297, AI28748] Funding Source: Medline; NINDS NIH HHS [NS07000] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANAND R, 1987, LANCET, V2, P234; BUDKA H, 1987, ACTA NEUROPATHOL, V75, P185, DOI 10.1007/BF00687080; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CHENGMAYER C, 1989, P NATL ACAD SCI USA, V86, P8575, DOI 10.1073/pnas.86.21.8575; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFINIS G, 1987, AIDS, V1, P229; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CORBOY JR, UNPUB; EILBOTT DJ, 1989, P NATL ACAD SCI USA, V86, P3337, DOI 10.1073/pnas.86.9.3337; GOZES I, 1989, MOL NEUROBIOL, V3, P201, DOI 10.1007/BF02740606; GRAY F, 1991, ACTA NEUROPATHOL, V82, P229, DOI 10.1007/BF00294450; GYORKEY F, 1987, J INFECT DIS, V155, P870, DOI 10.1093/infdis/155.5.870; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HAROUSE JM, 1989, J VIROL, V63, P2527, DOI 10.1128/JVI.63.6.2527-2533.1989; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HO DD, 1985, NEW ENGL J MED, V313, P1494; HOGAN B, 1986, MANIPULATING MOUSE E; HOLAND CA, 1985, J VIROL, V53, P152; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KUNSCH C, 1989, J VIROL, V63, P5054, DOI 10.1128/JVI.63.12.5054-5061.1989; KURE K, 1990, ACTA NEUROPATHOL, V80, P393, DOI 10.1007/BF00307693; LANGLEY OK, 1984, HDB NEUROCHEMISTRY, pCH4; LENZ J, 1984, NATURE, V308, P467, DOI 10.1038/308467a0; LEONARD J, 1989, AIDS RES HUM RETROV, V5, P421, DOI 10.1089/aid.1989.5.421; LEONARD JM, 1988, SCIENCE, V242, P1665, DOI 10.1126/science.3201255; LEVY JA, 1985, LANCET, V2, P586; LI XL, 1990, J VIROL, V64, P1383, DOI 10.1128/JVI.64.3.1383-1387.1990; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; MANNOJI H, 1986, ACTA NEUROPATHOL, V71, P341, DOI 10.1007/BF00688060; MICHAELS J, 1988, ACTA NEUROPATHOL, V76, P373, DOI 10.1007/BF00686974; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; MYERS G, 1991, HUMAN RETROVIRUSES A; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; OVERBEEK PA, 1986, SCIENCE, V231, P1574, DOI 10.1126/science.3006249; POMERANTZ RJ, 1991, J VIROL, V65, P1041, DOI 10.1128/JVI.65.2.1041-1045.1991; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; POPOVIC M, 1984, LANCET, V2, P1472; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; PUMAROLASUNE T, 1987, ANN NEUROL, V21, P490, DOI 10.1002/ana.410210513; ROSEN CA, 1985, J VIROL, V55, P862, DOI 10.1128/JVI.55.3.862-866.1985; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SKOWRONSKI J, 1991, J VIROL, V65, P754, DOI 10.1128/JVI.65.2.754-762.1991; SMALL JA, 1989, J VIROL, V63, P1891, DOI 10.1128/JVI.63.5.1891-1896.1989; STOLER MH, 1986, JAMA-J AM MED ASSOC, V256, P2360, DOI 10.1001/jama.256.17.2360; VAZEUX R, 1987, AM J PATHOL, V126, P403; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WALKER DG, 1989, J NEUROL NEUROSUR PS, V52, P583, DOI 10.1136/jnnp.52.5.583; WARD JM, 1987, AM J PATHOL, V127, P199; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613; WOLFS TFW, 1991, VIROLOGY, V185, P195, DOI 10.1016/0042-6822(91)90767-6	57	89	90	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1804	1808						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465618				2022-12-28	WOS:A1992KB96400042
J	HANNON, GJ; MARONEY, PA; YU, YT; HANNON, GE; NILSEN, TW				HANNON, GJ; MARONEY, PA; YU, YT; HANNON, GE; NILSEN, TW			INTERACTION OF U6 SNRNA WITH A SEQUENCE REQUIRED FOR FUNCTION OF THE NEMATODE SL RNA IN TRANSSPLICING	SCIENCE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; PRE-MESSENGER-RNA; LEADER RNA; CAENORHABDITIS-ELEGANS; TRANSSPLICING INVITRO; A-PROTEIN; U1 SNRNA; BINDING; SM; SITE	Nematode trans-spliced leader (SL) RNAs are composed of two domains, an exon [the 22-nucleotide spliced leader] and a small nuclear RNA (snRNA)-like sequence. Participation in vitro of the spliced leader RNA in trans-splicing reactions is independent of the exon sequence or size and instead depends on features contained in the snRNA-like domain of the molecule. Chemical modification interference analysis has revealed that two short sequence elements in the snRNA-like domain are necessary for SL RNA activity. These elements are sufficient for such activity because when added to a 72-nucleotide fragment of a nematode U1 snRNA, this hybrid RNA could participate in trans-splicing reactions in vitro. One of the critical sequence elements may function by base-pairing with U6 snRNA, an essential U snRNA for both cis- and trans-splicing.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University			Hannon, Gregory/AAB-3568-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031528] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28799] Funding Source: Medline; NIGMS NIH HHS [GM31528] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACH M, 1990, NUCLEIC ACIDS RES, V18, P449, DOI 10.1093/nar/18.3.449; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; Cao L, UNPUB; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JOSHUA GWP, 1991, MOL BIOCHEM PARASIT, V460, P209; LASALA D, UNPUB; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MARONEY PA, 1990, EMBO J, V9, P3667, DOI 10.1002/j.1460-2075.1990.tb07578.x; MARONEY PA, 1990, P NATL ACAD SCI USA, V87, P709, DOI 10.1073/pnas.87.2.709; MARONEY PA, UNPUB; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; NILSEN TW, 1989, MOL CELL BIOL, V9, P3543, DOI 10.1128/MCB.9.8.3543; PATTON JR, 1989, MOL CELL BIOL, V9, P3360, DOI 10.1128/MCB.9.8.3360; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; QUERY CC, 1989, MOL CELL BIOL, V9, P4872, DOI 10.1128/MCB.9.11.4872; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SHAMBAUGH J, UNPUB; SHARP PA, 1987, CELL, V50, P147, DOI 10.1016/0092-8674(87)90207-8; SUROWY CS, 1989, MOL CELL BIOL, V9, P4179, DOI 10.1128/MCB.9.10.4179; TAKACS AM, 1988, P NATL ACAD SCI USA, V85, P7932, DOI 10.1073/pnas.85.21.7932; THOMAS J, 1990, NUCLEIC ACIDS RES, V18, P2633, DOI 10.1093/nar/18.9.2633; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; VANDOREN K, 1988, NATURE, V335, P556; WATKINS KP, 1991, GENE DEV, V5, P1859, DOI 10.1101/gad.5.10.1859; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZENG WL, 1990, MOL CELL BIOL, V10, P2765, DOI 10.1128/MCB.10.6.2765	32	53	54	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1775	1780		10.1126/science.1465612	http://dx.doi.org/10.1126/science.1465612			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465612				2022-12-28	WOS:A1992KB96400034
J	[Anonymous]				[Anonymous]			CHANGE AT THE KAROLINSKA	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					514	514						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461271				2022-12-28	WOS:A1992KB95900026
J	[Anonymous]				[Anonymous]			NO BIOTECHNOLOGY BANDWAGON	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					528	528						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461273				2022-12-28	WOS:A1992KB95900047
J	KINSHUCK, D				KINSHUCK, D			BILATERAL HYPOPYON AND STREPTOKINASE	BRITISH MEDICAL JOURNAL			English	Letter											KINSHUCK, D (corresponding author), WOLVERHAMPTON EYE INFIRM,WOLVERHAMPTON WV3 3QR,ENGLAND.							BARNES D, 1992, BRIT MED J, V304, P1225, DOI 10.1136/bmj.304.6836.1225-b; DINNING WJ, 1987, SYSTEMIC INFLAMMATOR, P64; NUSSENBLATT RB, 1989, UVEITIS FUNDAMENTAL, P67	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1332	1332		10.1136/bmj.305.6865.1332-c	http://dx.doi.org/10.1136/bmj.305.6865.1332-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483079	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KA77300027
J	NEEDHAM, PR; DALEY, AG; LENNARD, RF				NEEDHAM, PR; DALEY, AG; LENNARD, RF			STEROIDS IN ADVANCED CANCER - SURVEY OF CURRENT PRACTICE	BRITISH MEDICAL JOURNAL			English	Article									ST JOSEPHS HOSP,LONDON E8 4SA,ENGLAND		NEEDHAM, PR (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,DEPT CLIN PHARMACOL & THERAPEUT,LONDON E1 2AD,ENGLAND.							HANKS GW, 1983, POSTGRAD MED J, V59, P702, DOI 10.1136/pgmj.59.697.702; HERXHEIMER A, 1974, DRUG THER B, V16, P63; MOERTEL CG, 1974, CANCER-AM CANCER SOC, V33, P1607, DOI 10.1002/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V; WEISSMAN DE, 1988, J CLIN ONCOL, V6, P543, DOI 10.1200/JCO.1988.6.3.543; WILLOX JC, 1984, BRIT MED J, V288, P27, DOI 10.1136/bmj.288.6410.27	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					999	999		10.1136/bmj.305.6860.999	http://dx.doi.org/10.1136/bmj.305.6860.999			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV776	1458150	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JV77600030
J	KEMPE, A; WISE, PH; BARKAN, SE; SAPPENFIELD, WM; SACHS, B; GORTMAKER, SL; SOBOL, AM; FIRST, LR; PURSLEY, D; RINEHART, H; KOTELCHUCK, M; COLE, FS; GUNTER, N; STOCKBAUER, JW				KEMPE, A; WISE, PH; BARKAN, SE; SAPPENFIELD, WM; SACHS, B; GORTMAKER, SL; SOBOL, AM; FIRST, LR; PURSLEY, D; RINEHART, H; KOTELCHUCK, M; COLE, FS; GUNTER, N; STOCKBAUER, JW			CLINICAL DETERMINANTS OF THE RACIAL DISPARITY IN VERY-LOW-BIRTH-WEIGHT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRETERM DELIVERY; NEONATAL-MORTALITY; PREMATURE RUPTURE; INFANT-MORTALITY; RISK-FACTORS; MEMBRANES; DECLINE	Background. Although the risk of very low birth weight (< 1500 g) is more than twice as high among blacks as among whites in the United States, the clinical conditions associated with this disparity remain poorly explored. Methods and Results. We reviewed the medical records of over 98 percent of all infants weighing 500 to 1499 g who were born in Boston during the period 1980 through 1985 (687 infants), in St. Louis in 1985 and 1986 (397 infants), and in two health districts in Mississippi in 1984 and 1985 (215 infants). The medical records of the infants' mothers were also reviewed. These data were linked to birth-certificate files. During the study periods, there were 49,196 live births in Boston, 16,232 in St. Louis, and 16,332 in the Mississippi districts. The relative risk of very low birth weight among black infants as compared with white infants ranged from 2.3 to 3.2 in the three areas. The higher proportion of black infants with very low birth weights was related to an elevated risk in their mothers of major conditions associated with very low birth weight, primarily chorioamnionitis or premature rupture of the amniotic membrane (associated with 38.0 percent of the excess proportion of black infants with very low birth weights [95 percent confidence interval, 31.3 to 45.4 percent]); idiopathic preterm labor (20.9 percent of the excess [95 percent confidence interval, 16.0 to 26.4 percent]); hypertensive disorders (12.3 percent [95 percent confidence interval, 8.6 to 16.6 percent]); and hemorrhage (9.8 percent [95 percent confidence interval, 5.5 to 13.5 percent]). Conclusions. The higher proportion of black infants with very low birth weights is associated with a greater frequency of all major maternal conditions precipitating delivery among black women. Reductions in the disparity in birth weight between blacks and whites are not likely to result from any single clinical intervention but, rather, from comprehensive preventive strategies.	HARVARD UNIV,SCH MED,HARVARD INST REPROD & CHILD HLTH,RICHARDSON FULLER BLDG,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,JOINT PROGRAM NEONATOL,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT OBSTET & GYNECOL,BOSTON,MA 02215; HARVARD UNIV,SCH PUBL HLTH,DEPT MATERNAL & CHILD HLTH,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH & SOCIAL BEHAV,BOSTON,MA 02115; S CAROLINA DEPT HLTH & ENVIRONM CONTROL,BUR MATERNAL & CHILD HLTH,COLUMBIA,SC 29201; CTR DIS CONTROL,DIV REPROD MED,ATLANTA,GA 30333; ST LOUIS CHILDRENS HOSP,DIV NEWBORN MED,ST LOUIS,MO 63178; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; VANDERBILT UNIV,DEPT OBSTET & GYNECOL,NASHVILLE,TN 37240; MISSOURI DEPT HLTH,JEFFERSON CITY,MO; MISSISSIPPI DEPT HLTH,JACKSON,MS; UNIV N CAROLINA,SCH MED,DEPT MATERNAL & CHILD HLTH,CHAPEL HILL,NC 27514	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Centers for Disease Control & Prevention - USA; St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Vanderbilt University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Pursley, DeWayne/R-8307-2019	Pursley, DeWayne/0000-0003-3466-4828; Cole, F. Sessions/0000-0002-3797-9369	NICHD NIH HHS [HD24124] Funding Source: Medline; PHS HHS [000102] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024124] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMON E, 1987, AM J OBSTET GYNECOL, V156, P1143, DOI 10.1016/0002-9378(87)90128-1; ARIAS F, 1982, OBSTET GYNECOL, V60, P277; BERKOWITZ GS, 1981, AM J EPIDEMIOL, V113, P81, DOI 10.1093/oxfordjournals.aje.a113068; BINKIN NJ, 1985, JAMA-J AM MED ASSOC, V253, P372; BUEHLER JW, 1987, PUBLIC HEALTH REP, V102, P151; COX SM, 1988, OBSTET GYNECOL, V71, P558; DAVID RJ, 1983, PEDIATRICS, V71, P531; JOHNSON JWC, 1981, OBSTET GYNECOL, V57, P547; KLEINMAN JC, 1987, NEW ENGL J MED, V317, P749, DOI 10.1056/NEJM198709173171207; LEVKOFF AH, 1982, OBSTET GYNECOL, V60, P612; LIEBERMAN E, 1987, NEW ENGL J MED, V317, P743, DOI 10.1056/NEJM198709173171206; LOCKWOOD CJ, 1991, NEW ENGL J MED, V325, P669, DOI 10.1056/NEJM199109053251001; MAIN DM, 1985, AM J OBSTET GYNECOL, V151, P892, DOI 10.1016/0002-9378(85)90667-2; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MEIS PJ, 1987, AM J OBSTET GYNECOL, V156, P1165, DOI 10.1016/0002-9378(87)90133-5; ROMERO R, 1988, AM J OBSTET GYNECOL, V159, P661, DOI 10.1016/S0002-9378(88)80030-9; SAVITZ DA, 1991, AM J OBSTET GYNECOL, V164, P467, DOI 10.1016/S0002-9378(11)80001-3; WILLIAMS RL, 1982, NEW ENGL J MED, V306, P207, DOI 10.1056/NEJM198201283060404; WISE PH, 1985, NEW ENGL J MED, V313, P360, DOI 10.1056/NEJM198508083130605; 1989, SAS STAT USERS GUIDE, V1; 1991, MONTHLY VITAL STATIS, V39; 1985, STUDY PREVENTION LOW	22	78	78	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					969	973		10.1056/NEJM199210013271401	http://dx.doi.org/10.1056/NEJM199210013271401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1518548				2022-12-28	WOS:A1992JQ22500001
J	POWE, NR; GRIFFITHS, RI; DELISSOVOY, G; ANDERSON, GF; WATSON, AJ; GREER, JW; HERBERT, RJ; EGGERS, PW; MILAM, RA; WHELTON, PK				POWE, NR; GRIFFITHS, RI; DELISSOVOY, G; ANDERSON, GF; WATSON, AJ; GREER, JW; HERBERT, RJ; EGGERS, PW; MILAM, RA; WHELTON, PK			ACCESS TO RECOMBINANT ERYTHROPOIETIN BY MEDICARE-ENTITLED DIALYSIS PATIENTS IN THE 1ST YEAR AFTER FDA APPROVAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMODIALYSIS-PATIENTS; HEART-DISEASE; MASSACHUSETTS; CAPACITY; THERAPY; QUALITY; WHITES; TRIAL; COST; LIFE	Objective.-Examine access to recombinant human erythropoietin (rHuEPO) by dialysis-dependent end-stage renal disease (ESRD) patients during the first year after FDA approval for use in clinical practice and Medicare coverage. Design.-Longitudinal and cross-sectional claims data analyses. Setting.-All US providers of outpatient dialysis treatment. Patients.-126 201 Medicare-entitled dialysis patients (almost-equal-to 93% of all US dialysis patients). Outcome Measures.-Percentage of patients who received rHuEPO, odds of receiving rHuEPO according to patient characteristics, and cost of rHuEPO to Medicare. Results.-One year after FDA approval, 52% of all dialysis and 60% of in-center hemodialysis patients who regularly had Medicare-paid dialysis services received rHuEPO at a monthly cost to Medicare of $19 million (18% of Medicare ESRD out-patient expenditures and 6% of all ESRD program expenditures). Blacks were less likely than whites to receive rHuEPO (odds ratio, 0.88; 95% confidence interval, 0.86 to 0.91). Home peritoneal and hemodialysis patients were less likely than in-center hemodialysis patients to receive rHuEPO (odds ratios, 0.17 and 0.22, respectively; 95% confidence intervals, 0.16 to 0.17 and 0.20 to 0.24, respectively). Use of rHuEPO varied across geographic regions. The odds of receiving rHuEPO were lower for patients of male vs female sex, of ages 35 through 64 years vs less than 35 years and greater than 65 years, with a longer history of ESRD, with polycystic kidney disease vs other causes of ESRD, and receiving care in nonprofit vs for-profit facilities. First-month hematocrits were slightly higher (1.2 percentage points) for patients starting rHuEPO in the 12th month than in the first month after FDA approval. Conclusions.-With prompt insurance coverage, the majority of Medicare-entitled dialysis patients received rHuEPO following widespread availability. Factors that may not be related to clinical need (race, setting of care, and geography) possibly influenced early patient access. More attention should be paid to monitoring the appropriate use of high-cost biotechnologic therapy.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21218; JOHNS HOPKINS PROGRAM MED TECHNOL & PRACTICE ASSESSMENT,BALTIMORE,MD; WELCH CTR PREVENT CLIN RES & EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS HLTH INST,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DIV NEPHROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT EPIDEMIOL,BALTIMORE,MD 21218; US HLTH CARE FINANCING ADM,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	POWE, NR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV INTERNAL MED,ROOM 8061,1830 E MONUMENT ST,BALTIMORE,MD 21205, USA.							AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Bunn H. F., 1991, HARRISONS PRINCIPLES, P344; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; DOOLITTLE RF, 1991, NEW ENGL J MED, V324, P1360, DOI 10.1056/NEJM199105093241910; EIEENBERG JM, 1986, DOCTORS DECISIONS CO, P5; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GOTCH FA, 1990, AM J KIDNEY DIS, V15, P511, DOI 10.1016/S0272-6386(12)70369-4; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; JAVITT JC, 1991, NEW ENGL J MED, V325, P1418, DOI 10.1056/NEJM199111143252005; LAUPACIS A, 1990, SEMIN NEPHROL, V10, P11; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; Rettig RA, 1991, KIDNEY FAILURE FEDER; ROBERTSON HT, 1990, AM J KIDNEY DIS, V15, P325, DOI 10.1016/S0272-6386(12)80079-5; SISK JE, 1991, JAMA-J AM MED ASSOC, V266, P247, DOI 10.1001/jama.266.2.247; STROGATZ DS, 1990, AM J PUBLIC HEALTH, V80, P290, DOI 10.2105/AJPH.80.3.290; WATSON AJ, 1989, SEMIN NEPHROL, V9, P30; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; [No title captured]; 1990, 03272 HLTH CAR FIN A; 1992, 03319 HLTH CAR FIN A; 1991, AM J KIDNEY DIS S2, V18, P96	26	35	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1434	1440		10.1001/jama.268.11.1434	http://dx.doi.org/10.1001/jama.268.11.1434			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512912				2022-12-28	WOS:A1992JM84900026
J	APPLEBY, MW; GROSS, JA; COOKE, MP; LEVIN, SD; QIAN, X; PERLMUTTER, RM				APPLEBY, MW; GROSS, JA; COOKE, MP; LEVIN, SD; QIAN, X; PERLMUTTER, RM			DEFECTIVE T-CELL RECEPTOR SIGNALING IN MICE LACKING THE THYMIC ISOFORM OF P59(FYN)	CELL			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; CLONAL DELETION; CD4 RECEPTOR; PHOSPHORYLATION; ACTIVATION; P56LCK; STIMULATION; TRANSDUCTION	Considerable evidence supports the hypothesis that the nonreceptor protein tyrosine kinase p59fyn participates in signal transduction from the T cell receptor (TCR). To examine this hypothesis in detail, we have produced mice that lack the thymic isoform of p59fyn but retain expression of the brain isoform of the protein. fynT(null) mice exhibit a remarkably specific lymphoid defect: thymocytes are refractile to stimulation through the TCR with mitogen or antigen, while peripheral T cells, following what appears to be a normal maturation sequence, reacquire significant signaling capabilities. These data confirm that p59fynT plays a pivotal role in TCR signal transduction and demonstrate that additional developmentally regulated signaling components also contribute to TCR-induced lymphocyte activation.	UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT MED,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	APPLEBY, MW (corresponding author), UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195, USA.				NATIONAL CANCER INSTITUTE [T32CA009537, R01CA045682] Funding Source: NIH RePORTER; NCI NIH HHS [CA09537, CA45682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STANLEY JB, 1990, J IMMUNOL, V145, P2189; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUGIE K, 1991, P NATL ACAD SCI USA, V88, P9132, DOI 10.1073/pnas.88.20.9132; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1992, IN PRESS MECHANISMS, V4; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	44	507	520	2	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					751	763		10.1016/0092-8674(92)90309-Z	http://dx.doi.org/10.1016/0092-8674(92)90309-Z			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516132				2022-12-28	WOS:A1992JL66300007
J	WALKER, JB; GU, H; HARRIS, M				WALKER, JB; GU, H; HARRIS, M			CENTRAL VENOUS CATHETERS AND SEPSIS IN PATIENTS WITH QUADRIPLEGIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											WALKER, JB (corresponding author), WALKER INST,PACIFIC PALISADES,CA 90272, USA.							GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; ROST KL, 1989, CLIN PHARM, V2, P195	2	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					735	736						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1495539				2022-12-28	WOS:A1992JL23500029
J	KUNTZ, ID				KUNTZ, ID			STRUCTURE-BASED STRATEGIES FOR DRUG DESIGN AND DISCOVERY	SCIENCE			English	Article							DIHYDROFOLATE-REDUCTASE INHIBITORS; REFINED CRYSTAL-STRUCTURE; SYNTHETIC HIV-1 PROTEASE; RECEPTOR-BINDING SITE; RIBONUCLEASE-H DOMAIN; VIRUS TYPE-1 PROTEASE; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; CRYSTALLOGRAPHIC ANALYSIS; CONFORMATIONAL-ANALYSIS	Most drugs have been discovered in random screens or by exploiting information about macromolecular receptors. One source of this information is in the structures of critical proteins and nucleic acids. The structure-based approach to design couples this information with specialized computer programs to propose novel enzyme inhibitors and other therapeutic agents. Iterated design cycles have produced compounds now in clinical trials. The combination of molecular structure determination and computation is emerging as an important tool for drug development. These ideas will be applied to acquired immunodeficiency syndrome (AIDS) and bacterial drug resistance.			KUNTZ, ID (corresponding author), UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039552, R01GM031497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31497, GM-39552] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE T, 1992, SCIENTIST       0413, P13; ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; APPELT K, 1991, J MED CHEM, V34, P1925, DOI 10.1021/jm00111a001; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BACH AC, 1991, INT J PEPT PROT RES, V38, P314; BEDDELL CR, 1984, BRIT J PHARMACOL, V82, P397, DOI 10.1111/j.1476-5381.1984.tb10775.x; BEDDELL CR, 1976, BRIT J PHARMACOL, V57, P201, DOI 10.1111/j.1476-5381.1976.tb07468.x; BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BODIAN D, UNPUB; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BONE R, 1991, J AM CHEM SOC, V113, P9382, DOI 10.1021/ja00024a061; BURKERT U, 1982, MOL MECHANICS; Clark T., 1985, HDB COMPUTATIONAL CH; COHEN FE, 1991, BIOCHEMISTRY-US, V30, P11221, DOI 10.1021/bi00111a005; COHEN NC, 1990, J MED CHEM, V33, P883, DOI 10.1021/jm00165a001; COHEN SS, 1977, SCIENCE, V197, P431, DOI 10.1126/science.195340; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cramer R D 3rd, 1989, Prog Clin Biol Res, V291, P161; CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005; CRIPPEN GM, 1980, J MED CHEM, V23, P599, DOI 10.1021/jm00180a004; CRIPPEN GM, 1988, DISTANCE GEOMETRY CO; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DEAN PM, 1987, MOL F DRUG RECEPTOR; DEBENEDETTI PG, 1987, J MED CHEM, V30, P459, DOI 10.1021/jm00386a004; DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; DIMASI JA, 1991, CLIN PHARMACOL THER, V50, P471, DOI 10.1038/clpt.1991.172; Dolata D P, 1987, J Comput Aided Mol Des, V1, P73, DOI 10.1007/BF01680558; EDMAN U, 1989, P NATL ACAD SCI USA, V86, P6503, DOI 10.1073/pnas.86.17.6503; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FELDER RA, 1990, CLIN CHEM, V36, P1534; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GEYSEN HM, 1986, SYNTHETIC PEPTIDES A, P131; GHOSE AK, 1990, MOL PHARMACOL, V37, P725; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GOODSELL DS, 1989, J MOL GRAPHICS, V7, P41, DOI 10.1016/0263-7855(89)80055-4; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; GREENLEE WJ, 1987, PHARM RES-DORDR, V4, P364, DOI 10.1023/A:1016422009662; GROOTENHUIS PDJ, 1990, ANTI-CANCER DRUG DES, V5, P237; HANSCH C, 1969, ACCOUNTS CHEM RES, V2, P232, DOI 10.1021/ar50020a002; HANSCH C, 1986, ACCOUNTS CHEM RES, V19, P392, DOI 10.1021/ar00132a003; Hehre W. J., 1986, AB INITIO MOL ORBITA; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; HOL WGJ, 1986, ANGEW CHEM INT EDIT, V25, P767, DOI 10.1002/anie.198607673; HOWARTH TT, 1976, J CHEM SOC CHEM COMM, P266; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; JIANG F, 1991, J MOL BIOL, V219, P79, DOI 10.1016/0022-2836(91)90859-5; JOHNSON M, 1990, CONCEPTS APPLICATION; JONES TR, 1981, EUR J CANCER, V17, P11, DOI 10.1016/0014-2964(81)90206-1; KAPLAN AP, 1991, BIOCHEMISTRY-US, V30, P8165, DOI 10.1021/bi00247a011; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KERWIN SM, 1991, MED CHEM RES, V1, P361; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; KUYPER LF, 1985, J MED CHEM, V28, P303, DOI 10.1021/jm00381a008; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LANGRIDGE R, 1981, SCIENCE, V211, P661, DOI 10.1126/science.7455704; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; LAWRENCE MC, 1992, PROTEINS, V12, P31, DOI 10.1002/prot.340120105; LEACH AR, 1990, J COMPUT CHEM, V11, P1193, DOI 10.1002/jcc.540111012; LEACH AR, 1992, J COMPUT CHEM, V13, P730, DOI 10.1002/jcc.540130608; LEVINSON C, UNPUB; LEWIS RA, 1992, J MOL GRAPHICS, V10, P66, DOI 10.1016/0263-7855(92)80059-M; MARSHALL GR, 1978, COMPUTER ASSISTED DR, P205; MATTHEWS DA, 1977, SCIENCE, V197, P452, DOI 10.1126/science.17920; McCammon JA., 1987, DYNAMICS PROTEINS NU; MCGREGOR M, UNPUB; Meng E., UNPUB; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; MERZ KM, 1989, J AM CHEM SOC, V111, P5649, DOI 10.1021/ja00197a022; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MIRANKER A, 1991, PROTEINS, V11, P29, DOI 10.1002/prot.340110104; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MULLEN DG, 1990, P EUROPEAN PEPTIDE S, P364; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; NAVIA MA, 1992, CURR OPIN STRUC BIOL, V2, P202; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; PATTARONI C, 1990, INT J PEPT PROT RES, V36, P401; PERRY K, UNPUB; PFEILDOYLE J, 1988, J MED CHEM, V31, P1993, DOI 10.1021/jm00118a023; POWERS R, 1991, J MOL BIOL, V221, P1081, DOI 10.1016/0022-2836(91)80113-9; RASHIN AA, 1991, J PHYS CHEM-US, V95, P2942, DOI 10.1021/j100161a002; RING C, UNPUB; RIORDAN ML, 1991, NATURE, V350, P442, DOI 10.1038/350442a0; Ripka W. C., 1987, LECT HETEROCYCL CHEM, V9, pS95; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROSS JI, 1990, MOL MICROBIOL, V4, P1207, DOI 10.1111/j.1365-2958.1990.tb00696.x; RUSINKO A, 1989, J CHEM INF COMP SCI, V29, P251, DOI 10.1021/ci00064a004; RUTENBER E, UNPUB; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SANTI DV, 1980, BURGERS MED CHEM 1, P349; SARUBBI E, 1991, FEBS LETT, V279, P265, DOI 10.1016/0014-5793(91)80164-X; SCHNEBLI HP, 1986, PROTEINASE INHIBITOR, P613; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHOICHET BK, 1991, J MOL BIOL, V221, P327, DOI 10.1016/0022-2836(91)80222-G; SHOICHET BK, 1992, J COMPUT CHEM, V13, P380, DOI 10.1002/jcc.540130311; SHOICHET BK, UNPUB; SMITH TJ, 1986, SCIENCE, V233, P1286, DOI 10.1126/science.3018924; STEVENSON M, 1992, AIDS RES HUM RETROV, V8, P107, DOI 10.1089/aid.1992.8.107; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; SZELKE M, 1982, NATURE, V299, P555, DOI 10.1038/299555a0; VANDRIE JH, 1989, J COMPUT AID MOL DES, V3, P225, DOI 10.1007/BF01533070; VANGUNSTEREN WF, 1990, ANGEW CHEM INT EDIT, V29, P992, DOI 10.1002/anie.199009921; VARNEY MD, 1992, J MED CHEM, V35, P663, DOI 10.1021/jm00082a006; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEARLEY LL, 1991, CRIT REV THER DRUG, V8, P331; WEST IC, 1990, TRENDS BIOCHEM SCI, V15, P42, DOI 10.1016/0968-0004(90)90171-7; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Wilson R. J., 1972, INTRO GRAPH THEORY; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YAMAZAKI T, 1991, BIOCHEMISTRY-US, V30, P6036, DOI 10.1021/bi00238a030; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	123	816	958	5	150	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1992	257	5073					1078	1082		10.1126/science.257.5073.1078	http://dx.doi.org/10.1126/science.257.5073.1078			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509259				2022-12-28	WOS:A1992JJ88400023
J	LIU, YJ; PETER, D; ROGHANI, A; SCHULDINER, S; PRIVE, GG; EISENBERG, D; BRECHA, N; EDWARDS, RH				LIU, YJ; PETER, D; ROGHANI, A; SCHULDINER, S; PRIVE, GG; EISENBERG, D; BRECHA, N; EDWARDS, RH			A CDNA THAT SUPPRESSES MPP+ TOXICITY ENCODES A VESICULAR AMINE TRANSPORTER	CELL			English	Article							ORGAN SYNAPTIC VESICLES; GAMMA-AMINOBUTYRIC ACID; CHROMAFFIN GRANULES; PARKINSONS-DISEASE; ESCHERICHIA-COLI; RAT-BRAIN; RESERPINE BINDING; NEUROTOXIN 1-METHYL-4-PHENYLPYRIDINIUM; DIHYDROTETRABENAZINE BINDING; TETRACYCLINE-RESISTANCE	Classical neurotransmitters are transported into synaptic vesicles so that their release can be regulated by neural activity. In addition, the vesicular transport of biogenic amines modulates susceptibility to N-methyl-4-phenylpyridinium (MPP+), the active metabolite of the neurotoxin N-methyl-1,2,3,6-tetrahydropyridine that produces a model of Parkinson's disease. Taking advantage of selection in MPP+, we have used gene transfer followed by plasmid rescue to identify a cDNA clone that encodes a vesicular amine transporter. The sequence predicts a novel mammalian protein with 12 transmembrane domains and homology to a class of bacterial drug resistance transporters. We have detected messenger RNA transcripts for this transporter only in the adrenal gland. Monoamine cell populations in the brain stem express a distinct but highly related protein.	HEBREW UNIV JERUSALEM,INST LIFE SCI,IL-91904 JERUSALEM,ISRAEL; VET ADM MED CTR BRENTWOOD,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT ANAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST EXTRATERR PHYS,DEPT CELL BIOL & MED,LOS ANGELES,CA 90024	Hebrew University of Jerusalem; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	LIU, YJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT NEUROL,LOS ANGELES,CA 90024, USA.		Schuldiner, Shimon/F-7628-2012; Liu, Yongjian/J-7852-2018	Schuldiner, Shimon/0000-0002-4874-6237; Prive, Gilbert/0000-0002-0712-4319	NATIONAL EYE INSTITUTE [R01EY004067] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY004067] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DC, 1983, MOL PHARMACOL, V24, P48; ANDERSON DC, 1982, BIOCHEMISTRY-US, V21, P3037, DOI 10.1021/bi00256a001; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AXELROD J, 1961, SCIENCE, V133, P383, DOI 10.1126/science.133.3450.383; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARLSON MD, 1989, J BIOL CHEM, V264, P7369; CARLSSON A, 1963, ACTA PHYSL SCAND S, V215, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTENSEN H, 1990, J NEUROCHEM, V54, P1142, DOI 10.1111/j.1471-4159.1990.tb01941.x; COHEN G, 1990, J NEURAL TRANSM-SUPP, V32, P229; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DANIELS AJ, 1988, J BIOL CHEM, V263, P5034; DARCHEN F, 1989, BIOCHEMISTRY-US, V28, P1692, DOI 10.1021/bi00430a040; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; DENTON T, 1987, J NEUROCHEM, V49, P622, DOI 10.1111/j.1471-4159.1987.tb02909.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Frize E.D., 1954, NEW ENGL J MED, V251, P1006; FYKSE EM, 1988, J NEUROCHEM, V50, P1237, DOI 10.1111/j.1471-4159.1988.tb10599.x; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GREENE LA, 1977, BRAIN RES, V129, P247, DOI 10.1016/0006-8993(77)90005-1; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Hokfelt T., 1984, CLASSICAL NEUROTRANS, V2, P277; ISAMBERT MF, 1992, BIOCHEMISTRY-US, V31, P1980, DOI 10.1021/bi00122a012; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; JOHANNESSEN JN, 1985, LIFE SCI, V36, P219, DOI 10.1016/0024-3205(85)90062-1; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KIRSHNER N, 1962, J BIOL CHEM, V237, P2311; KISH PE, 1989, P NATL ACAD SCI USA, V86, P3877, DOI 10.1073/pnas.86.10.3877; KNIGGE KM, 1977, BRAIN RES, V120, P393, DOI 10.1016/0006-8993(77)90394-8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUEGER MJ, 1990, BIOCHEM BIOPH RES CO, V169, P123, DOI 10.1016/0006-291X(90)91442-U; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, SCIENCE, V225, P1480, DOI 10.1126/science.6332378; LIU Y, 1992, IN PRESS P NATL ACAD, V89; MARKEY SP, 1984, NATURE, V311, P464, DOI 10.1038/311464a0; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; NAITO S, 1983, J BIOL CHEM, V258, P696; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P483, DOI 10.1016/0006-291X(90)90698-M; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; RAMSAY RR, 1986, J BIOL CHEM, V261, P7585; RAMSAY RR, 1991, J NEUROCHEM, V56, P1184, DOI 10.1111/j.1471-4159.1991.tb11409.x; REINHARD JF, 1987, P NATL ACAD SCI USA, V84, P8160, DOI 10.1073/pnas.84.22.8160; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; RUDNICK G, 1986, ANNU REV PHYSIOL, V48, P403; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERMAN D, 1986, J NEUROCHEM, V47, P331; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304; SNYDER SH, 1986, MPTP NEUROTOXIN PROD, P191; STERNBACH Y, 1990, J BIOL CHEM, V265, P3961; STERNINI C, 1989, GASTROENTEROLOGY, V97, P348, DOI 10.1016/0016-5085(89)90070-X; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; TANNER CM, 1990, NEUROLOGY, V40, P17; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VINCENT MS, 1991, MOL PHARMACOL, V40, P889; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; [No title captured]; 1989, NEW ENGL J MED, V321, P1364	85	527	543	2	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					539	551		10.1016/0092-8674(92)90425-C	http://dx.doi.org/10.1016/0092-8674(92)90425-C			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505023				2022-12-28	WOS:A1992JJ88600005
J	EISENBERG, RS				EISENBERG, RS			GENES, PATENTS, AND PRODUCT DEVELOPMENT	SCIENCE			English	Article								In the past year,the National Institutes of Health (NIH) has filed patent applications on more than 2750 partial complementary DNA sequences of unknown function. The rationale for the filings-that patent protection may be necessary to ensure that private firms are willing to invest in developing related products-rests on two premises: first, that NIH may obtain patent rights that will offer effective product monopolies to licensee firms, and second, that unless NIH obtains these rights now, firms will be unable to obtain a comparable degree of exclusivity by other means, such as by obtaining patents on their own subsequent innovations. Neither premise is clearly wrong, although both are subject to doubt in view of statements from industry representatives that the NIH patenting strategy will deter rather than promote product development.			EISENBERG, RS (corresponding author), UNIV MICHIGAN,SCH LAW,ANN ARBOR,MI 48109, USA.							Eisenberg Rebecca S, 1990, Emory Law J, V39, P721; EISENBERG RS, 1989, U CHICAGO LAW REV, V56, P1017, DOI 10.2307/1599761; HEALY B, 1992, MAY PUBL M FED COORD; MERGES RP, 1990, COLUMBIA LAW REV, V90, P839, DOI 10.2307/1122920; MOSSINGHOFF GJ, 1992, COMMUNICATION   0528; 1991, POSITION PAPER PATEN; 1992, IBA POSITION PAPER R	7	46	46	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					903	908		10.1126/science.1502556	http://dx.doi.org/10.1126/science.1502556			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JH827	1502556				2022-12-28	WOS:A1992JH82700021
J	LIPSITZ, LA; GOLDBERGER, AL				LIPSITZ, LA; GOLDBERGER, AL			LOSS OF COMPLEXITY AND AGING - POTENTIAL APPLICATIONS OF FRACTALS AND CHAOS THEORY TO SENESCENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-RATE-VARIABILITY; NONLINEAR DYNAMICS; SINUS ARRHYTHMIA; ELDERLY PERSONS; AGE; SYNCOPE; HORMONE; MEN	The concept of "complexity," derived from the field of nonlinear dynamics, can be adapted to measure the output of physiologic processes that generate highly variable fluctuations resembling "chaos." We review data suggesting that physiologic aging is associated with a generalized loss of such complexity in the dynamics of healthy organ system function and hypothesize that such loss of complexity leads to an impaired ability to adapt to physiologic stress. This hypothesis is supported by observations showing an age-related loss of complex variability in multiple physiologic processes including cardiovascular control, pulsatile hormone release, and electroencephalographic potentials. If further research supports this hypothesis, measures of complexity based on chaos theory and the related geometric concept of fractals may provide new ways to monitor senescence and test the efficacy of specific interventions to modify the age-related decline in adaptive capacity.	HARVARD UNIV,SCH MED,DIV AGING,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT MED,DIV GERONTOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	LIPSITZ, LA (corresponding author), HARVARD UNIV,SCH MED,HEBREW REHABIL CTR AGED,RES & TRAINING INST,1200 CTR ST,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008812, P60AG008812] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-42172] Funding Source: Medline; NIA NIH HHS [AGO439O, AGO8812] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOUD S, 1991, CIRC RES, V68, P1751, DOI 10.1161/01.RES.68.6.1751; CALLOWAY NO, 1966, J AM GERIATR SOC, V14, P342, DOI 10.1111/j.1532-5415.1966.tb05595.x; CASERTA F, 1990, PHYS REV LETT, V64, P95, DOI 10.1103/PhysRevLett.64.95; DAVIDSON MB, 1979, METABOLISM, V28, P688, DOI 10.1016/0026-0495(79)90024-6; DEBOER RW, 1984, IEEE T BIO-MED ENG, V31, P384, DOI 10.1109/TBME.1984.325351; FROLKIS VV, 1979, INTERDISCIPLINARY TO, V16, P87; GLENNY RW, 1991, J APPL PHYSIOL, V70, P2351, DOI 10.1152/jappl.1991.70.6.2351; GOLDBERGER A L, 1990, Scientific American, V262, P42; GOLDBERGER AL, 1990, UBIQUITY OF CHAOS, P23; GOLDBERGER AL, 1988, EXPERIENTIA, V44, P983, DOI 10.1007/BF01939894; GOLDBERGER AL, 1987, ANN NY ACAD SCI, V504, P195, DOI 10.1111/j.1749-6632.1987.tb48733.x; GOLDBERGER AL, 1991, NEWS PHYSIOL SCI, V6, P87, DOI 10.1152/physiologyonline.1991.6.2.87; GREENSPAN SL, 1991, AM J PHYSIOL, V260, pE486, DOI 10.1152/ajpendo.1991.260.3.E486; HELLMAN JB, 1976, J APPL PHYSIOL, V41, P734, DOI 10.1152/jappl.1976.41.5.734; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; JARISCH WR, 1987, EXPERIENTIA, V43, P1207, DOI 10.1007/BF01945526; KAPLAN DT, 1991, BIOPHYS J, V59, P945, DOI 10.1016/S0006-3495(91)82309-8; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LIPSITZ LA, 1989, J GERONTOL, V44, pM179, DOI 10.1093/geronj/44.6.M179; LIPSITZ LA, 1990, CIRCULATION, V81, P1803, DOI 10.1161/01.CIR.81.6.1803; MADDENS M, 1987, AM J CARDIOL, V60, P1368, DOI 10.1016/0002-9149(87)90621-7; MADER S, 1984, J AM GERIATR SOC, V32, P548, DOI 10.1111/j.1532-5415.1984.tb02245.x; Mandelbrot B.B., 1982, FRACTAL GEOMETRY NAT, P480; MANDELL AJ, 1990, UBIQUITY OF CHAOS, P35; MOSEKILDE L, 1988, BONE, V9, P247, DOI 10.1016/8756-3282(88)90038-5; MUNSAT TL, 1984, CLIN NEUROLOGY AGING, P416; PAULUS MP, 1990, P NATL ACAD SCI USA, V87, P723, DOI 10.1073/pnas.87.2.723; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; PINCUS SM, 1991, J CLIN MONITOR, V7, P335, DOI 10.1007/BF01619355; RAPP FE, 1990, UBIQUITY CHAOS, P10; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; ROWE JW, 1976, J GERONTOL, V31, P155, DOI 10.1093/geronj/31.2.155; SAMARAS TT, 1974, HUM DEV, V17, P314, DOI 10.1159/000271354; Scheibel A B, 1985, Clin Geriatr Med, V1, P671; SIMPSON DM, 1988, J GERONTOL, V43, pM21, DOI 10.1093/geronj/43.1.M21; SKINNER JE, 1991, CIRC RES, V68, P966, DOI 10.1161/01.RES.68.4.966; SMITH SA, 1982, BRIT MED J, V285, P1599, DOI 10.1136/bmj.285.6355.1599; SMITH TG, 1989, J NEUROSCI METH, V27, P173, DOI 10.1016/0165-0270(89)90100-3; TOBIN JD, 1981, AGING CHALLENGE SCI; URBAN RJ, 1988, J CLIN INVEST, V81, P1020, DOI 10.1172/JCI113412; WEI JY, 1987, CURR PROB CARDIOLOGY, V12, P7; WEST BJ, 1987, AM SCI, V75, P354; 1991, LANCET, V338, P1425	43	815	842	1	46	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1806	1809		10.1001/jama.267.13.1806	http://dx.doi.org/10.1001/jama.267.13.1806			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1482430				2022-12-28	WOS:A1992HK67200031
J	WICHMANN, H; HENGST, L; GALLWITZ, D				WICHMANN, H; HENGST, L; GALLWITZ, D			ENDOCYTOSIS IN YEAST - EVIDENCE FOR THE INVOLVEMENT OF A SMALL GTP-BINDING PROTEIN (YPT7P)	CELL			English	Article							EPITHELIAL-CELL LINE; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; VACUOLAR BIOGENESIS; MOLECULAR-CLONING; PLASMA-MEMBRANE; YPT1/SEC4-RELATED CDNAS; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; MUTATIONAL ANALYSIS	From the budding yeast S. cerevisiae, we have cloned a gene, YPT7, that encodes a GTP-binding protein belonging to the Ypt family of ras-related proteins. The 208 amino acid protein shares identical effector domain and C-terminal sequences with the mammalian Rab7 protein. YPT7 gene disruption did not impair cellular growth at temperatures ranging from 17-degrees-C to 37-degrees-C. ypt7 null mutants are characterized by highly fragmented vacuoles and differential defects of vacuolar protein transport and maturation. The uptake of alpha factor pheromone by wild-type and Ypt7p-deficient cells was found to be indistinguishable, but in mutant cells lacking Ypt7p, degradation of the endocytosed pheromone was severely inhibited. Our findings suggest a role of Ypt7p in protein transport between endosome-like compartments.			WICHMANN, H (corresponding author), MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC GENET, W-3400 GOTTINGEN, GERMANY.			Hengst, Ludger/0000-0002-0605-0223				BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; DULIC V, 1991, METHOD ENZYMOL, V194, P697; ELFERINK LA, 1992, J BIOL CHEM, V267, P5768; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; GUTHRIE C, 1991, METH ENZYMOL, V194; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HASILIK A, 1978, EUR J BIOCHEM, V85, P599, DOI 10.1111/j.1432-1033.1978.tb12275.x; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HAUBRUCK H, 1990, EMBO J, V9, P1957, DOI 10.1002/j.1460-2075.1990.tb08323.x; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRAWETZ SA, 1989, NUCLEIC ACIDS RES, V17, P819, DOI 10.1093/nar/17.2.819; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; MAKAROW M, 1985, EMBO J, V4, P1861, DOI 10.1002/j.1460-2075.1985.tb03861.x; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; MIYAKE S, 1990, EMBO J, V9, P1417, DOI 10.1002/j.1460-2075.1990.tb08257.x; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; PAYNE GS, 1988, J CELL BIOL, V106, P1453, DOI 10.1083/jcb.106.5.1453; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; PRESTON RA, 1987, J CELL BIOL, V105, P1981, DOI 10.1083/jcb.105.5.1981; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; RAYMOND CK, 1992, IN PRESS INT REV CYT; REID GA, 1983, METHOD ENZYMOL, V97, P324; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBINSON JS, 1991, MOL CELL BIOL, V11, P5813, DOI 10.1128/MCB.11.12.5813; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; Stevens B J, 1979, Methods Enzymol, V56, P718; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WAGNER P, 1992, METHOD ENZYMOL, V219, P369; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WOOLFORD CA, 1990, GENETICS, V125, P739; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	79	210	213	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1131	1142		10.1016/S0092-8674(05)80062-5	http://dx.doi.org/10.1016/S0092-8674(05)80062-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473149				2022-12-28	WOS:A1992KE60400008
J	BONE, RC				BONE, RC			TOWARD AN EPIDEMIOLOGY AND NATURAL-HISTORY OF SIRS (SYSTEMIC INFLAMMATORY RESPONSE SYNDROME)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED CLINICAL-TRIAL; SEPTIC SHOCK; SEPSIS	Background.-New definitions for sepsis and the systemic inflammatory response syndrome (SIRS) have been established. Comparatively little is known, however, about the types of patients who will be included within these new definitions. Objectives.-To determine what is and what is not-known about the epidemiology and natural history of severe sepsis and SIRS. Design.-A comparative analysis of patient characteristics in the Methylprednisolone, Veterans Administration Systemic Sepsis, HA-1A, and E5 studies. Results.-At least 15% of patients in these studies had no documented infection; the proportion of all patients with severe SIRS and no documented infection is probably higher. Even among patients with presumed infection, less than half had bacteremia, and only about half had gram-negative infection or shock. The difference in the mean mortality rate of the combined studies at 14 days was 26%, while at 1 month it was 42%. Gram-negative sepsis and gram-positive sepsis seem to have similar mortality rates. Whether shock increases 30-day mortality is unclear. Conclusions.-Patients with severe SIRS should not be assumed to have gram-negative infection; furthermore, data derived from studies of patients with gram-negative infection should be applied cautiously to all patients with SIRS. Studies of patients with sepsis or SIRS should include at least a 1-month follow-up if mortality is an end point. More consistent definitions of these disorders should permit more effective comparisons across studies.	RUSH MED COLL,CHICAGO,IL 60612	Rush University	BONE, RC (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT INTERNAL MED,PULM MED SECT,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.							BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BONE RC, 1991, JAMA-J AM MED ASSOC, V266, P1686, DOI 10.1001/jama.266.12.1686; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BONE RC, 1991, CRIT CARE MED, V19, P973, DOI 10.1097/00003246-199107000-00024; DE M, 1992, DEV BIOL, V151, P297, DOI 10.1016/0012-1606(92)90234-8; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; MCGOWAN JE, 1975, J INFECT DIS, V132, P316, DOI 10.1093/infdis/132.3.316; RUOKONEN E, 1991, CRIT CARE MED, V19, P1146, DOI 10.1097/00003246-199109000-00009; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1987, NEW ENGL J MED, V317, P659; 1992, CHEST, V101, P1644	13	378	422	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3452	3455		10.1001/jama.268.24.3452	http://dx.doi.org/10.1001/jama.268.24.3452			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460735				2022-12-28	WOS:A1992KC83900033
J	MARQUIS, MS; LONG, SH				MARQUIS, MS; LONG, SH			UNINSURED CHILDREN AND NATIONAL-HEALTH REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											MARQUIS, MS (corresponding author), RAND,DEPT SOCIAL POLICY,2100 M ST NW,WASHINGTON,DC 20037, USA.							FRIEDMAN E, 1991, JAMA-J AM MED ASSOC, V265, P2491, DOI 10.1001/jama.265.19.2491; LEIBOWITZ A, 1992, HLTH BENEFITS WORKFO, P77; LILLARD L, 1986, PREVENTIVE MED CARE; Lohr K N, 1986, Med Care, V24, pS1; LONG SH, 1992, HLTH BENEFITS WORKFO, P37; SARDELL A, 1990, J HEALTH POLIT POLIC, V15, P271, DOI 10.1215/03616878-15-2-271; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; 1990, PROVIDING EMPLOYEE H; 1991, HLTH AM CHALLENGE ST	9	13	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3473	3477						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KC839	1460740				2022-12-28	WOS:A1992KC83900038
J	TINSLEY, JM; BLAKE, DJ; ROCHE, A; FAIRBROTHER, U; RISS, J; BYTH, BC; KNIGHT, AE; KENDRICKJONES, J; SUTHERS, GK; LOVE, DR; EDWARDS, YH; DAVIES, KE				TINSLEY, JM; BLAKE, DJ; ROCHE, A; FAIRBROTHER, U; RISS, J; BYTH, BC; KNIGHT, AE; KENDRICKJONES, J; SUTHERS, GK; LOVE, DR; EDWARDS, YH; DAVIES, KE			PRIMARY STRUCTURE OF DYSTROPHIN-RELATED PROTEIN	NATURE			English	Article							BECKER MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; NEUROMUSCULAR-JUNCTIONS; MDX MICE; SEQUENCE; EXPRESSION; MEMBRANE	DYSTROPHIN-RELATED protein (DRP or 'utrophin'1) is localized in normal adult muscle primarily at the neuromuscular junction2-4. In the absence of dystrophin in Duchenne muscular dystrophy (DMD) patients, DRP is also present in the sarcolemma3-7. DRP is expressed in fetal and regenerating muscle and may play a similar role to dystrophin in early development3,7-9, although it remains to be determined whether DRP can functionally replace dystrophin in adult tissue. Previously we described a 3.5-kilobase complementary DNA clone that exhibits 80 per cent homology to the C-terminal domain of dystrophin10. This sequence identifies a 13-kilobase transcript that maps to human chromosome 6 (refs 2, 11). Antibodies raised against the gene product identify a polypeptide with a relative molecular mass of about 400K in all tissues examined7,8,12. To investigate the relationship between DRP and dystrophin in more detail, we have cloned and sequenced the whole DRP cDNA. Homology between DRP and dystrophin extends over their entire length, suggesting that they derive from a common ancestral gene. Comparative analysis of primary sequences highlights regions of functional importance, including those that may mediate the localization of DRP and dystrophin in the muscle cell.	JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; MRC,HUMAN BIOCHEM GENET LAB,GALTON LAB,LONDON NW1 2HE,ENGLAND; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	University of Oxford; University of London; University College London; MRC Laboratory Molecular Biology			Knight, Alex/C-6041-2008	Knight, Alex/0000-0001-7302-1636; Fairbrother, Una/0000-0002-3255-4556; Love, Donald/0000-0003-4669-8769				ARAHATA K, 1991, J NEUROL SCI, V101, P148, DOI 10.1016/0022-510X(91)90039-A; AUGIER N, 1992, J NEUROL SCI, V107, P233, DOI 10.1016/0022-510X(92)90294-U; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGLAND SB, 1992, NATURE, V342, P180; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; KHULMAN PA, 1992, FEBS LETT, V304, P201; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; KOENIG M, 1989, AM J HUM GENET, V45, P498; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEMAIRE C, 1988, NUCLEIC ACIDS RES, V16, P11815, DOI 10.1093/nar/16.24.11815; LEVINE BA, 1990, FEBS LETT, V263, P159, DOI 10.1016/0014-5793(90)80728-2; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PONS F, 1991, FEBS LETT, V282, P161, DOI 10.1016/0014-5793(91)80468-I; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; TAKEMITSU M, 1991, BIOCHEM BIOPH RES CO, V180, P1179, DOI 10.1016/S0006-291X(05)81320-8; TANAKA H, 1991, HISTOCHEMISTRY, V96, P1, DOI 10.1007/BF00266753; THIMAN N, 1991, J CELL BIOL, V115, P1695; VOLT T, 1991, AM J PATHOL, V139, P969; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G	24	361	373	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					591	593		10.1038/360591a0	http://dx.doi.org/10.1038/360591a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461283				2022-12-28	WOS:A1992KB95900087
J	ARONSON, JK; REYNOLDS, DJM				ARONSON, JK; REYNOLDS, DJM			ABC OF MONITORING DRUG-THERAPY - AMINOGLYCOSIDE ANTIBIOTICS	BRITISH MEDICAL JOURNAL			English	Article											ARONSON, JK (corresponding author), RADCLIFFE INFIRM,OXFORD OX2 6HE,ENGLAND.							MOORE RD, 1987, J INFECT DIS, V155, P93, DOI 10.1093/infdis/155.1.93; ORME BM, 1969, CLIN PHARMACOL THER, V10, P543; WENK M, 1984, CLIN PHARMACOKINET, V9, P475, DOI 10.2165/00003088-198409060-00001	3	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1421	1424		10.1136/bmj.305.6866.1421	http://dx.doi.org/10.1136/bmj.305.6866.1421			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486311	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KB85600031
J	KNEKT, P; HELIOVAARA, M; RISSANEN, A; AROMAA, A; AARAN, RK				KNEKT, P; HELIOVAARA, M; RISSANEN, A; AROMAA, A; AARAN, RK			SERUM ANTIOXIDANT VITAMINS AND RISK OF CATARACT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL DISCHARGE DATA; SENILE CATARACT; PREVENTION; VALIDITY; AGE	Objective-To investigate serum concentrations of alpha tocopherol, beta carotene, retinol, and selenium for their prediction of end stage cataract. Design-A case-control study, nested within a cohort study, based on the linkage of records of subjects aged 40-83 from a health survey with those from the national Finnish hospital discharge register. Subjects-47 patients admitted to ophthalmological wards for senile cataract over 15 years and two controls per patient individually matched for sex, age, and municipality. Main outcome measure-Concentration of serum micronutrients, development of cataract according to whether operation was performed. Results-Low serum concentrations of antioxidant vitamins predicted the development of senile cataract, the odds ratio between the lowest third and the two higher thirds of the distribution of serum concentrations of alpha tocopherol and beta carotene being 1-9 (95% confidence interval 0.9 to 4.1) and 1.7 (0.8 to 3.8), respectively. Patients with both alpha tocopherol and beta carotene concentrations in the lowest third had an odds ratio of 2.6 (1.0 to 6.8) of cataract compared with subjects in the top two thirds. The associations were strengthened by adjustment for potential confounding factors such as occupation, smoking, blood pressure, serum cholesterol concentration, body mass index, and diabetes. No association was found between the serum concentrations of selenium, retinol, and retinol binding protein and the risk of cataract. Conclusions-Low serum concentrations of the antioxidant vitamins alpha tocopherol and beta carotene are risk factors for end stage senile cataract. Controlled trials of the role of antioxidant vitamins in cataract prevention are therefore warranted.	UNIV TAMPERE, DEPT BIOMED SCI, TAMPERE, FINLAND	Tampere University	KNEKT, P (corresponding author), SOCIAL INSURANCE INST, POB 78, SF-00381 HELSINKI, FINLAND.							AARAN RK, 1988, J PHARMACEUT BIOMED, V6, P853, DOI 10.1016/0731-7085(88)80101-8; ALFTHAN G, 1982, ANAL CHIM ACTA, V140, P221, DOI 10.1016/S0003-2670(01)95468-6; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; CHENG H, 1989, BRIT MED J, V298, P1470, DOI 10.1136/bmj.298.6686.1470; GERSTER H, 1989, Z ERNAHRUNGSWISS, V28, P56, DOI 10.1007/BF02025566; HELIOVAARA M, 1987, J CHRON DIS, V40, P251, DOI 10.1016/0021-9681(87)90161-5; HELIOVAARA M, 1984, ACTA MED SCAND, V216, P309; JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022; JACQUES PF, 1991, AM J CLIN NUTR, V53, pS352, DOI 10.1093/ajcn/53.1.352S; JACQUES PF, 1988, AM J CLIN NUTR, V48, P152, DOI 10.1093/ajcn/48.1.152; JACQUES PF, 1991, MICRONUTRIENTS HLTH, P359; KENNEDY RH, 1984, INVEST OPHTHALMOL  S, V25, P1; KNEKT P, 1988, AM J EPIDEMIOL, V127, P28, DOI 10.1093/oxfordjournals.aje.a114788; KNEKT P, 1988, SERUM ALPHA TOCOPHER, pML83; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; POIKOLAINEN K, 1983, DRUG ALCOHOL DEPEN, V12, P315, DOI 10.1016/0376-8716(83)90002-9; ROBERTSON JM, 1989, ANN NY ACAD SCI, V570, P372; SHETTY PS, 1979, LANCET, V2, P230; TEIKARI JM, 1987, ACTA OPHTHALMOL, V65, P589; 1985, WHO TECH REP SER, V727	21	126	129	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1992	305	6866					1392	1394		10.1136/bmj.305.6866.1392	http://dx.doi.org/10.1136/bmj.305.6866.1392			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486302	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992KB85600020
J	BLUMENTHAL, S; WESSELY, S				BLUMENTHAL, S; WESSELY, S			NATIONAL SURVEY OF CURRENT ARRANGEMENTS FOR DIVERSION FROM CUSTODY IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To assess the extent and nature of psychiatric assessment schemes based at magistrates' courts in England and Wales for the early diversion of mentally disordered offenders from custody and to determine the response of the NHS to new initiatives conceming alternatives to custody for this group. Design-Postal survey of the probation service, petty sessional divisions, mental health provider units, and district purchasing authorities in England and Wales. Subjects-All chief probation officers (n=55), clerks to the justices (n=284), managers of mental health provider units (n=190), and purchasers of mental health services (n= 190) in each of the district health authorities. Main outcome measures-Number of psychiatric assessment schemes, practical difficulties in their operation, extent of regular liaison with health and social services; current and fitture intentions to purchase or provide services for diversion from custody. Results-Data were obtained from every magistrates' court. Forty eight psychiatric assessment schemes were identified with another 34 under development. Particular problems were lack of adequate transport arrangements, difficulties with hospital admissions, and overdependence on key people. There was litde liaison between health, social services, and members of the criminal justice system. Twenty five of the 106 purchasers who responded had a policy dealing with diversion, and 39 had a scheme under development; 56 purchasers had no current or future plans about diversion. Sixty nine of the 150 providers who responded reported that diversion was included in their current or next business plan. Conclusion-Schemes to divert mentally disordered offenders from the criminal justice system are often hampered by lack of adequate transport arrangements, difficulties in hospital admissions, and overdependence on key people.	UNIV LONDON KINGS COLL HOSP,SCH MED,DEPT PSYCHOL MED,LONDON SE5 9RS,ENGLAND; INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; King's College London			Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929				FENNELL P, 1991, CRIM LAW REV, P333; HIRSCH S, 1992, FACILITIES SERVICES; JAMES DV, 1992, MED SCI LAW, V32, P167, DOI 10.1177/106002809203200212; JAMES DV, 1991, BRIT MED J, V303, P282, DOI 10.1136/bmj.303.6797.282; JONES H, 1992, REVOLVING DOORS; JOSEPH P, 1992, PSYCHIATRIC ASSESSME; 1990, 6690 HOM OFF CIRC; 1991, REPORTS SERVICE ADVI	8	21	21	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1322	1325		10.1136/bmj.305.6865.1322	http://dx.doi.org/10.1136/bmj.305.6865.1322			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483076	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992KA77300020
J	LOWRY, S				LOWRY, S			MEDICAL-EDUCATION .2. STUDENT SELECTION	BRITISH MEDICAL JOURNAL			English	Article							SCHOOL											Allen, 1988, DOCTORS THEIR CAREER; FERRIER BM, 1983, MED EDUC, V17, P72, DOI 10.1111/j.1365-2923.1983.tb01102.x; FIRTHCOZENS J, 1989, BRIT J HOSP MED, V41, P161; LOWRY S, 1988, BRIT MED J, V296, P657, DOI 10.1136/bmj.296.6623.657; MCMANUS IC, 1990, STUD HIGH EDUC, V15, P57, DOI 10.1080/03075079012331377591; MCMANUS IC, 1989, BRIT MED J, V298, P723, DOI 10.1136/bmj.298.6675.723; Mitchell D L, 1975, Br J Med Educ, V9, P133; NEWBLE DI, 1986, MED EDUC, V20, P162, DOI 10.1111/j.1365-2923.1986.tb01163.x; Powis DA, 1992, TEACH LEARN MED, V4, P25; TOOTH D, 1989, MED EDUC, V23, P416, DOI 10.1111/j.1365-2923.1989.tb00896.x; WOODWARD CA, 1982, J MED EDUC, V57, P294; WOODWARD CA, 1989, MEDUCS, V2, P64; 1980, RECOMMENDATIONS BASI; 1987, BMJ, V295, P533; 1988, MED SCH ADMISSIONS R; 1991, UNDERGRADUATE MED ED	16	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1352	1354		10.1136/bmj.305.6865.1352	http://dx.doi.org/10.1136/bmj.305.6865.1352			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483086	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KA77300033
J	STACEY, M				STACEY, M			FOR PUBLIC OR PROFESSION - THE NEW GMC PERFORMANCE PROCEDURES	BRITISH MEDICAL JOURNAL			English	Article								The upheaval in the General Medical Council two decades ago came from doctors not the consumers the council was set up to protect. Since then there have been repeated calls for doctors to improve their self regulation by amending the disciplinary procedures. Private member's bills have failed and the GMC has now proposed performance procedures to deal with doctors who exhibit a "pattern of poor performance." After months of wide consultation in and outside the medical profession the GMC will decide next week whether to endorse the procedures, which unlike the conduct hearings will be inquiries by peers. Professor Margaret Stacey suggests that the procedures lack clarity, smacking of that "trust me" principle whose subtext is "but I'm not telling you what I'm up to."			STACEY, M (corresponding author), UNIV WARWICK,DEPT SOCIOL,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.							KLEIN R, 1973, COMPAINTS DOCTORS ST; SMITH R, 1992, BRIT MED J, V304, P1257, DOI 10.1136/bmj.304.6837.1257; STACEY M, 1992, REGULATING BRIT MED; 1992, PROPOSALS NEW PERFOR; 1975, CMND6016	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1085	1087		10.1136/bmj.305.6861.1085	http://dx.doi.org/10.1136/bmj.305.6861.1085			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467693	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JW70100027
J	BONOW, RO; UDELSON, JE				BONOW, RO; UDELSON, JE			LEFT-VENTRICULAR DIASTOLIC DYSFUNCTION AS A CAUSE OF CONGESTIVE-HEART-FAILURE - MECHANISMS AND MANAGEMENT	ANNALS OF INTERNAL MEDICINE			English	Review						HYPERTENSION; VENTRICULAR FUNCTION, LEFT; HEART FAILURE, CONGESTIVE	PACING-INDUCED ISCHEMIA; SARCOPLASMIC-RETICULUM FUNCTION; HYPERTROPHIC CARDIOMYOPATHY; SYSTOLIC FUNCTION; HYPERTENSIVE PATIENTS; CARDIAC-HYPERTROPHY; ANGINA-PECTORIS; RAT MYOCARDIUM; INTRACELLULAR CALCIUM; CONTRACTION DURATION	Objective: To define the mechanisms underlying left ventricular diastolic dysfunction in patients with congestive heart failure and normal systolic function and to identify the patients at risk for this syndrome. Study Selection: Studies were selected that describe the clinical observations of congestive heart failure with normal systolic function and that provide experimental and clinical insights into the mechanisms responsible for ventricular diastolic dysfunction. Data Synthesis: Recent studies indicate that a large number of patients (up to 40% in some series) presenting with congestive heart failure have preserved left ventricular systolic function. The factors contributing to altered left ventricular diastolic function include fibrosis, hypertrophy, ischemia, and increased afterload. The latter three factors, alone or in combination, predispose to impaired left ventricular relaxation, an active energy-requiring process. Thus, decreased left ventricular diastolic distensibility (increased diastolic pressure at any level of diastolic volume) may arise not only f rom altered passive elastic properties stemming from fibrosis or increased muscle mass but also from derangements in the dynamics of ventricular relaxation. Results: In patients with essential hypertension, all four of the above mechanisms may be operative. Considering the prevalence of hypertension in the general population, hypertension appears to be an important underlying factor in many patients with heart failure on the basis of diastolic mechanisms. In the patient presenting with dyspnea and elevated filling pressures, but with a nondilated, normally contracting ventricle, treatment with standard heart failure medications (such as digitalis, diuretics, and vasodilators) is often ineffective and may be deleterious. Such patients may respond more favorably to beta-blockers and calcium-channel blockers. Conclusions: Diastolic dysfunction should be considered in the patient presenting with heart failure symptoms but with normal systolic function, particularly in hypertensive patients with left ventricular hypertrophy.	TUFTS UNIV, SCH MED, NEW ENGLAND MED CTR HOSP, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University	BONOW, RO (corresponding author), NORTHWESTERN UNIV, SCH MED,DIV CARDIOL,WESLEY PAVILL,SUITE 524, 250 E SUPERIOR ST, CHICAGO, IL 60611 USA.							AGUIRRE FV, 1989, AM J CARDIOL, V63, P1098, DOI 10.1016/0002-9149(89)90085-4; AROESTY JM, 1985, CIRCULATION, V71, P889, DOI 10.1161/01.CIR.71.5.889; ARORA RR, 1987, J AM COLL CARDIOL, V9, P1255, DOI 10.1016/S0735-1097(87)80464-3; BARRY WH, 1974, CIRCULATION, V49, P255, DOI 10.1161/01.CIR.49.2.255; BLAUSTEIN AS, 1983, AM J PHYSIOL, V244, pH417, DOI 10.1152/ajpheart.1983.244.3.H417; BONOW RO, 1985, CIRCULATION, V72, P853, DOI 10.1161/01.CIR.72.4.853; BONOW RO, 1988, J AM COLL CARDIOL, V11, P50, DOI 10.1016/0735-1097(88)90166-0; BONOW RO, 1991, CIRCULATION, V84, pI208; BONOW RO, 1981, CIRCULATION, V64, P787, DOI 10.1161/01.CIR.64.4.787; BOURDILLON PD, 1983, CIRCULATION, V67, P316, DOI 10.1161/01.CIR.67.2.316; BRUSH JE, 1989, J AM COLL CARDIOL, V14, P515, DOI 10.1016/0735-1097(89)90210-6; BRUSH JE, 1988, NEW ENGL J MED, V319, P1302, DOI 10.1056/NEJM198811173192002; BRUTSAERT DL, 1980, CIRC RES, V47, P637, DOI 10.1161/01.RES.47.5.637; BRUTSAERT DL, 1984, CIRCULATION, V69, P190, DOI 10.1161/01.CIR.69.1.190; CAPASSO JM, 1983, AM J PHYSIOL, V245, pH72, DOI 10.1152/ajpheart.1983.245.1.H72; CARROLL JD, 1983, CIRCULATION, V67, P521, DOI 10.1161/01.CIR.67.3.521; CARROLL JD, 1982, AM J CARDIOL, V49, P9, DOI 10.1016/0002-9149(82)90270-3; CHOI B W, 1990, Journal of the American College of Cardiology, V15, p7A; CHOI BW, 1989, CIRCULATION, V80, P11; CLYNE CA, 1991, AM J CARDIOL, V68, P1469, DOI 10.1016/0002-9149(91)90281-O; CUOCOLO A, 1990, CIRCULATION, V81, P978, DOI 10.1161/01.CIR.81.3.978; CUOCOLO A, 1989, Journal of Nuclear Medicine, V30, P780; DOUGHERTY AH, 1984, AM J CARDIOL, V54, P778, DOI 10.1016/S0002-9149(84)80207-6; FALK RH, 1987, AM J CARDIOL, V59, P418, DOI 10.1016/0002-9149(87)90948-9; FOUAD FM, 1980, CLIN SCI, V59, pS411, DOI 10.1042/cs059411s; FOUAD FM, 1984, J AM COLL CARDIOL, V3, P1500, DOI 10.1016/S0735-1097(84)80289-2; FROEHLICH JP, 1978, J MOL CELL CARDIOL, V10, P427, DOI 10.1016/0022-2828(78)90364-4; GAASCH WH, 1976, AM J CARDIOL, V38, P645, DOI 10.1016/S0002-9149(76)80015-X; GAASCH WH, 1980, AM J PHYSIOL, V239, pH1, DOI 10.1152/ajpheart.1980.239.1.H1; GERSTENBLITH G, 1976, PROG CARDIOVASC DIS, V19, P1, DOI 10.1016/0033-0620(76)90005-0; GERSTENBLITH G, 1977, CIRCULATION, V56, P273, DOI 10.1161/01.CIR.56.2.273; GIVEN BD, 1985, ARCH INTERN MED, V145, P281, DOI 10.1001/archinte.145.2.281; GROSSMAN W, 1976, ANN INTERN MED, V84, P316, DOI 10.7326/0003-4819-84-3-316; GROSSMAN W, 1991, NEW ENGL J MED, V325, P1557; GWATHMEY JK, 1985, CIRC RES, V57, P836, DOI 10.1161/01.RES.57.6.836; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; HANRATH P, 1980, AM J CARDIOL, V45, P1258, DOI 10.1016/0002-9149(80)90487-7; HANRATH P, 1983, AM J CARDIOL, V52, P544, DOI 10.1016/0002-9149(83)90023-1; HENRY PD, 1977, AM J PHYSIOL, V233, pH677, DOI 10.1152/ajpheart.1977.233.6.H677; INOUYE I, 1984, AM J CARDIOL, V53, P120, DOI 10.1016/0002-9149(84)90695-7; ISHIDA Y, 1986, CIRCULATION, V74, P187, DOI 10.1161/01.CIR.74.1.187; ITO Y, 1974, J MOL CELL CARDIOL, V6, P237, DOI 10.1016/0022-2828(74)90053-4; KATZ AM, 1983, J AM COLL CARDIOL, V2, P143, DOI 10.1016/S0735-1097(83)80387-8; KITZMAN DW, 1991, J AM COLL CARDIOL, V17, P1065, DOI 10.1016/0735-1097(91)90832-T; LAKATTA EG, 1975, J CLIN INVEST, V55, P61, DOI 10.1172/JCI107918; LAKATTA EG, 1982, AM J PHYSIOL, V242, pH927, DOI 10.1152/ajpheart.1982.242.6.H927; LAKATTA EG, 1987, CIRCULATION, V75, P69; LECARPENTIER Y, 1982, AM J PHYSIOL, V242, pH855, DOI 10.1152/ajpheart.1982.242.5.H855; LORELL BH, 1987, J AM COLL CARDIOL, V9, P1189, DOI 10.1016/S0735-1097(87)80326-1; LORELL BH, 1986, CIRC RES, V58, P653, DOI 10.1161/01.RES.58.5.653; LORELL BH, 1988, CIRC RES, V63, P457, DOI 10.1161/01.RES.63.2.457; LORELL BH, 1982, CIRCULATION, V65, P499, DOI 10.1161/01.CIR.65.3.499; MANN T, 1977, CIRCULATION, V55, P761, DOI 10.1161/01.CIR.55.5.761; MANN T, 1979, CIRCULATION, V59, P14, DOI 10.1161/01.CIR.59.1.14; MCLAURIN LP, 1973, AM J CARDIOL, V32, P751, DOI 10.1016/S0002-9149(73)80002-5; MILLER TR, 1986, AM J CARDIOL, V58, P531, DOI 10.1016/0002-9149(86)90028-7; MIYATAKE K, 1984, AM J CARDIOL, V53, P586, DOI 10.1016/0002-9149(84)90035-3; NAYLER WG, 1979, J MOL CELL CARDIOL, V11, P683, DOI 10.1016/0022-2828(79)90381-X; NAYLER WG, 1978, EUR J CARDIOL, V7, P35; OPHERK D, 1984, CIRCULATION, V69, P1, DOI 10.1161/01.CIR.69.1.1; PARFREY PS, 1988, ARCH INTERN MED, V148, P1519, DOI 10.1001/archinte.148.7.1519; PAULUS WJ, 1983, J AM COLL CARDIOL, V2, P879, DOI 10.1016/S0735-1097(83)80235-6; PAULUS WJ, 1982, CIRC RES, V50, P218, DOI 10.1161/01.RES.50.2.218; SCHAUB MC, 1964, GERONTOLOGY, V10, P38, DOI 10.1159/000211372; SCHULMAN SP, 1990, NEW ENGL J MED, V322, P1350, DOI 10.1056/NEJM199005103221904; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; SERIZAWA T, 1980, CIRC RES, V46, P430, DOI 10.1161/01.RES.46.3.430; SETARO JF, 1990, AM J CARDIOL, V66, P981, DOI 10.1016/0002-9149(90)90937-V; SMITH VE, 1985, J AM COLL CARDIOL, V5, P869, DOI 10.1016/S0735-1097(85)80425-3; SMITH VE, 1986, J AM COLL CARDIOL, V8, P1449, DOI 10.1016/S0735-1097(86)80322-9; SORDAHL LA, 1973, AM J PHYSIOL, V224, P497, DOI 10.1152/ajplegacy.1973.224.3.497; SOUFER R, 1985, AM J CARDIOL, V55, P1032, DOI 10.1016/0002-9149(85)90741-6; SPIRITO P, 1988, ANN INTERN MED, V109, P122, DOI 10.7326/0003-4819-109-2-122; TOPOL EJ, 1985, NEW ENGL J MED, V312, P277, DOI 10.1056/NEJM198501313120504; TRIMARCO B, 1989, AM J CARDIOL, V64, P745, DOI 10.1016/0002-9149(89)90758-3; TYBERG JV, 1970, CARDIOVASC RES, V4, P423, DOI 10.1093/cvr/4.4.423; UDELSON JE, 1990, CIRCULATION, V82, P1174, DOI 10.1161/01.CIR.82.4.1174; WEBER A, 1968, J GEN PHYSIOL, V52, P750, DOI 10.1085/jgp.52.5.750; WEBER KT, 1987, CIRCULATION, V75, P40; WEI JY, 1984, AM J PHYSIOL, V246, pH784, DOI 10.1152/ajpheart.1984.246.6.H784; WEISFELDT ML, 1971, AM J PHYSIOL, V220, P1921, DOI 10.1152/ajplegacy.1971.220.6.1921; WEISFELDT ML, 1974, J CLIN INVEST, V53, P1626, DOI 10.1172/JCI107713; WEXLER LF, 1988, CIRC RES, V62, P766, DOI 10.1161/01.RES.62.4.766; WILENS S. L., 1938, AMER JOUR PATH, V14, P177; ZUSMAN RM, 1989, AM J CARDIOL, V64, pF51, DOI 10.1016/0002-9149(89)90747-9	85	312	326	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					502	510		10.7326/0003-4819-117-6-502	http://dx.doi.org/10.7326/0003-4819-117-6-502			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503353				2022-12-28	WOS:A1992JN25700010
J	ALLISON, MC; HOWATSON, AG; TORRANCE, CJ; LEE, FD; RUSSELL, RI				ALLISON, MC; HOWATSON, AG; TORRANCE, CJ; LEE, FD; RUSSELL, RI			GASTROINTESTINAL DAMAGE ASSOCIATED WITH THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-INFLAMMATORY DRUGS; SMALL-BOWEL ULCERATION; SMALL-INTESTINE; PEPTIC-ULCER; RHEUMATOID-ARTHRITIS; ELDERLY PERSONS; DISEASE; PERMEABILITY; THERAPY; PERFORATION	Background. Long-term use of nonsteroidal antiinflammatory drugs (NSAIDs) may lead to inflammation of the small intestine associated with occult blood and protein loss. The aim of this study was to investigate the prevalence and structural correlates of this enteropathy. Methods. We examined the stomach, duodenum, and small intestine of 713 patients post mortem. Of these patients, 249 had had NSAIDs prescribed during the six months before death and 464 patients had not. All visible small intestinal lesions were removed for histologic examination, and specific etiologic factors were sought. The prevalence of nonspecific small-intestinal ulcers and ulcers of the stomach and duodenum was compared in the two groups of patients. Results. Nonspecific small-intestinal ulceration was found in 21 (8.4 percent) of the users of NSAIDs and 3 (0.6 percent) of the nonusers (difference, 7.8 percent; 95 percent confidence interval, 5.0 to 10.6 percent; P<0.001). Three patients who were long-term users of NSAIDs were found to have died of perforated nonspecific small-intestinal ulcers. Ulcers of the stomach or duodenum were found in 54 (21.7 percent) of the patients who used these drugs and 57 (12.3 percent) of those who had not (difference, 9.4 percent; 95 percent confidence interval, 3.9 to 15.1 percent; P<0.001). Conclusions. Patients who take NSAIDs have an increased risk of nonspecific ulceration of the small-intestinal mucosa. These ulcers are less common than ulcers ot the stomach or duodenum, but can lead to life-threatening complications.	GLASGOW ROYAL INFIRM,DEPT PATHOL,GLASGOW G4 0SF,SCOTLAND; GLASGOW ROYAL INFIRM,GASTROENTEROL UNIT,GLASGOW G4 0SF,SCOTLAND	University of Glasgow; University of Glasgow								ARMSTRONG CP, 1987, GUT, V28, P527, DOI 10.1136/gut.28.5.527; BEARDON PHG, 1989, Q J MED, V71, P497; BJARNASON I, 1986, GUT, V27, P1292, DOI 10.1136/gut.27.11.1292; BJARNASON I, 1988, GASTROENTEROLOGY, V94, P1070, DOI 10.1016/0016-5085(88)90568-9; BJARNASON I, 1987, GASTROENTEROLOGY, V93, P480, DOI 10.1016/0016-5085(87)90909-7; BJARNASON I, 1984, LANCET, V2, P1171; BJARNASON I, 1987, LANCET, V2, P711; Bjarnason I., 1988, RECENT ADV GASTROENT, P23; BOYDSTUN JS, 1981, DIGEST DIS SCI, V26, P911, DOI 10.1007/BF01309496; COLLINS AJ, 1987, BRIT J RHEUMATOL, V26, P295; DAY TK, 1983, BRIT MED J, V287, P1671, DOI 10.1136/bmj.287.6406.1671-a; DEAKIN M, 1988, BRIT MED J, V297, P488, DOI 10.1136/bmj.297.6646.488-b; GRAHAM DY, 1988, LANCET, V2, P1277; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HOLVOET J, 1991, GUT, V32, P730, DOI 10.1136/gut.32.7.730; JENKINS RT, 1987, BRIT J RHEUMATOL, V26, P103; LANG J, 1988, J CLIN PATHOL, V41, P516, DOI 10.1136/jcp.41.5.516; LANGMAN MJS, 1985, BRIT MED J, V290, P347, DOI 10.1136/bmj.290.6465.347; LEIJONMARCK CE, 1985, ACTA CHIR SCAND, V151, P273; MADHOK R, 1986, Q J MED, V58, P53; MORRIS AJ, 1991, LANCET, V337, P520, DOI 10.1016/0140-6736(91)91300-J; NEOPTOLEMOS JP, 1983, BRIT J SURG, V70, P244, DOI 10.1002/bjs.1800700422; SAVERYMUTTU SH, 1986, POSTGRAD MED J, V62, P967, DOI 10.1136/pgmj.62.732.967; SAW KC, 1990, J ROY SOC MED, V83, P114, DOI 10.1177/014107689008300219; SILVOSO GR, 1979, ANN INTERN MED, V91, P517, DOI 10.7326/0003-4819-91-4-517; SOLL AH, 1991, ANN INTERN MED, V114, P307, DOI 10.7326/0003-4819-114-4-307; SOMERVILLE K, 1986, LANCET, V1, P462; STURGES HF, 1973, AM J GASTROENTEROL, V59, P162; UPADHYAY R, 1990, ANN RHEUM DIS, V49, P359, DOI 10.1136/ard.49.6.359; WAYTE DM, 1968, AM J CLIN PATHOL, V49, P26	31	847	885	1	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					749	754		10.1056/NEJM199209103271101	http://dx.doi.org/10.1056/NEJM199209103271101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501650	Bronze			2022-12-28	WOS:A1992JL66100001
J	INGLESE, J; KOCH, WJ; CARON, MG; LEFKOWITZ, RJ				INGLESE, J; KOCH, WJ; CARON, MG; LEFKOWITZ, RJ			ISOPRENYLATION IN REGULATION OF SIGNAL TRANSDUCTION BY G-PROTEIN-COUPLED RECEPTOR KINASES	NATURE			English	Article							GAMMA SUBUNITS CONTAIN; RAS PROTEINS; TRANSLOCATION; FARNESYL; FAMILY; CELLS; ACID; P21	RHODOPSIN kinase1 and beta-adrenergic receptor kinase (beta-ARK)2 are related members of a serine/threonine kinase family that specifically initiate deactivation of G-protein-coupled receptors. After stimulus-mediated receptor activation, these cytoplasmic kinases translocate to the plasma membrane3,4. Here we show that the molecular basis for this event involves a class of unsaturated lipids called isoprenoids. Covalent modification in vivo of rhodopsin kinase by a 15-C (farnesyl) isoprenoid5 enables the kinase to anchor to photon-activated rhodopsin. Mutations that alter or eliminate the isoprenoid, fully disable light-specific Rhodopsin kinase translocation. Other receptor kinases (such as beta-ARK), which lack an intrinsic lipid, are activated6 on exposure to brain beta-gamma-subunits of the signal-transducing G proteins, the gamma-subunit of which bears a 20-C (geranylgeranyl) isoprenoid7,8. Using chimaeric beta-ARKs that undergo isoprenylation in vitro, we demonstrate that membrane association and activation of these kinases can occur in the absence of beta-gamma. These results indicate that rhodopsin kinase (by means of an integral isoprenoid) and beta-ARK (through its association with beta-gamma) both rely on the function of isoprenyl moieties for their translocation and activity, illustrating distinct, though related, modes of biological regulation of receptor function.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021					ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARRIZA JL, IN PRESS J NEUROSCI; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, NATURE, V322, P869; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; COX AD, IN PRESS CRIT REV ON; FARNSWORTH C C, 1990, Methods (Orlando), V1, P231, DOI 10.1016/S1046-2023(05)80322-6; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAGA K, 1992, J BIOL CHEM, V267, P2222; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PITCHER J, IN PRESS SCIENCE; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	26	269	274	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1992	359	6391					147	150		10.1038/359147a0	http://dx.doi.org/10.1038/359147a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JM494	1522899				2022-12-28	WOS:A1992JM49400052
J	DAVIS, DA; THOMSON, MA; OXMAN, AD; HAYNES, RB				DAVIS, DA; THOMSON, MA; OXMAN, AD; HAYNES, RB			EVIDENCE FOR THE EFFECTIVENESS OF CME - A REVIEW OF 50 RANDOMIZED CONTROLLED TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTINUING MEDICAL-EDUCATION; PRIMARY-CARE PHYSICIANS; TEST-ORDERING BEHAVIOR; QUALITY ASSURANCE; SMOKING CESSATION; CLINICAL-TRIAL; TRAINING PHYSICIANS; PATIENT OUTCOMES; COST AUDITS; FEEDBACK	Objective.-To assess the impact of diverse continuing medical education (CME) interventions on physician performance and health care outcomes. Data Sources.-Using continuing medical education and related phrases, we performed regular searches of the indexed literature (MEDLINE, Social Science Index, the National Technical Information Service, and Educational Research Information Clearinghouse) from 1975 through 1991. In addition, for these years, we used manual searches, key informants, and requests to authors to locate other indexed articles and the nonindexed literature of adult and continuing professional education. Study Selection.-From the resulting database we selected studies that met the following criteria: randomized controlled trials; educational programs, activities, or other interventions; studies that included 50% or more physicians; follow-up assessments of at least 75% of study subjects; and objective assessments of either physician performance or health care outcomes. Data Extraction.-Studies were reviewed for data related to physician specialty and setting. Continuing medical education interventions were classified by their mode(s) of activity as being predisposing, enabling, or facilitating. Using the statistical tests supplied by the original investigators, physician performance outcomes and patient outcomes were classified as positive, negative, or inconclusive. Data Synthesis.-We located 777 CME studies, of which 50 met all criteria. Thirty-two of these analyzed physician performance; seven evaluated patient outcomes; 11 examined both measures. The majority of the 43 studies of physician performance showed positive results in some important measures of resource utilization, counseling strategies, and preventive medicine. Of the 18 studies of health care outcomes, eight demonstrated positive changes in patients' health care outcomes. Conclusion.-Broadly defined CME interventions using practice-enabling or reinforcing strategies consistently improve physician performance and, in some instances, health care outcomes.	MCMASTER UNIV,FAC ENGN,DEPT MED,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,FAC ENGN,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,SCH OCCUPAT THERAPY & PHYSIOTHERAPY,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; McMaster University; McMaster University	DAVIS, DA (corresponding author), MCMASTER UNIV,FAC HLTH SCI,DEPT FAMILY MED,1200 MAIN ST W,CHEDOKE CAMPUS,BLDG 74,HAMILTON L8N 3Z5,ONTARIO,CANADA.		Oxman, Andrew/Y-3004-2019	Oxman, Andrew/0000-0002-5608-5061; Haynes, Robert Brian/0000-0002-1453-3196				AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Beaudry JS, 1989, J CONTIN EDUC HEALTH, V9, P285, DOI DOI 10.1002/CHP.4750090414; BERTRAM DA, 1977, HEALTH EDUC QUART, V5, P330, DOI 10.1177/109019817700500404; BERWICK DM, 1986, JAMA-J AM MED ASSOC, V255, P1450, DOI 10.1001/jama.255.11.1450; Carter W B, 1981, Med Care Rev, V38, P195, DOI 10.1177/107755878103800401; CHAMBERS L, 1979, IMPACT CME ANNOTATED; CHASSIN MR, 1986, JAMA-J AM MED ASSOC, V256, P1012, DOI 10.1001/jama.256.8.1012; COHEN DI, 1982, MED CARE, V20, P286, DOI 10.1097/00005650-198203000-00005; COHEN SJ, 1985, SOC SCI MED, V21, P909, DOI 10.1016/0277-9536(85)90147-9; COHEN SJ, 1989, ANN INTERN MED, V110, P648, DOI 10.7326/0003-4819-110-8-648; CUMMINGS SR, 1989, ANN INTERN MED, V110, P640, DOI 10.7326/0003-4819-110-8-640; CUMMINGS SR, 1989, J GEN INTERN MED, V4, P482, DOI 10.1007/BF02599545; CURRY L, 1981, CAN MED ASSOC J, V124, P563; DAVIDOFF F, 1989, MED CARE, V27, P45, DOI 10.1097/00005650-198901000-00005; DAVIS DA, 1990, JAMA-J AM MED ASSOC, V263, P2041, DOI 10.1001/jama.263.15.2041; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; Elstein AS, 1978, MED PROBLEM SOLVING; EVANS CE, 1986, JAMA-J AM MED ASSOC, V255, P501; EVERETT GD, 1983, ARCH INTERN MED, V143, P942, DOI 10.1001/archinte.143.5.942; Fishbein M, 1968, BELIEF ATTITUDE INTE; FOX RD, 1989, CHANGE LEARNING LIVE; FRECHETTE AL, 1983, NEW ENGL J MED, V308, P97; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GEHLBACH SH, 1984, MED CARE, V22, P193, DOI 10.1097/00005650-198403000-00002; Green LW., 1980, HLTH ED PLANNING DIA, V1; GULLION DS, 1988, J CONTIN EDUC HEALTH, V8, P239; HAYNES RB, 1984, JAMA-J AM MED ASSOC, V251, P61, DOI 10.1001/jama.251.1.61; HEALE J, 1988, P ANN C RES MED ED, V27, P72; HERSHEY CO, 1986, MED CARE, V24, P472, DOI 10.1097/00005650-198606000-00002; HERSHEY CO, 1988, MED CARE, V26, P88, DOI 10.1097/00005650-198801000-00010; HISS RG, 1978, P 17 ANN C RES MED E, V17, P283; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JENNETT PA, 1988, MED EDUC, V22, P139, DOI 10.1111/j.1365-2923.1988.tb00424.x; Knowles M., 1980, MODERN PRACTICE ADUL; KOTTKE TE, 1989, JAMA-J AM MED ASSOC, V261, P2101, DOI 10.1001/jama.261.14.2101; LINN BS, 1980, JAMA-J AM MED ASSOC, V244, P565, DOI 10.1001/jama.244.6.565; Lloyd J S, 1979, Eval Health Prof, V2, P251, DOI 10.1177/016327877900200301; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; MAGRUDERHABIB K, 1990, MED CARE, V28, P239, DOI 10.1097/00005650-199003000-00004; MAIMAN LA, 1988, AM J DIS CHILD, V142, P773, DOI 10.1001/archpedi.1988.02150070087033; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; MARTON KI, 1985, ARCH INTERN MED, V145, P816, DOI 10.1001/archinte.145.5.816; MAZZUCA SA, 1990, AM EDUC RES J, V27, P473, DOI 10.3102/00028312027003473; MCCONNELL TS, 1982, WESTERN J MED, V137, P448; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCLAUGHLIN PJ, 1991, J CONTIN EDUC HEALTH, V11, P65; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; MEYER TJ, 1991, J GEN INTERN MED, V6, P133, DOI 10.1007/BF02598309; MILLER GE, 1976, J MED EDUC, V42, P320; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PALMER RH, 1985, MED CARE, V23, P751, DOI 10.1097/00005650-198506000-00001; PARBOOSINGH J, 1987, P C RES MED ED, V26, P103; PERERA DR, 1983, J FAM PRACTICE, V16, P785; PUTNAM RW, 1989, CAN MED ASSOC J, V140, P806; PUTNAM RW, 1985, CAN MED ASSOC J, V132, P1025; RESTUCCIA JD, 1982, MED CARE, V20, P46, DOI 10.1097/00005650-198201000-00004; RICHARDSON K, 1986, DANA-J FISH MAR RES, V6, P1; ROGERS JL, 1982, MED CARE, V20, P63, DOI 10.1097/00005650-198201000-00005; RUBENSTEIN LV, 1989, ANN INTERN MED, V111, P836, DOI 10.7326/0003-4819-111-10-836; SANAZARO PJ, 1978, NEW ENGL J MED, V298, P1171, DOI 10.1056/NEJM197805252982104; SIBLEY JC, 1982, NEW ENGL J MED, V305, P511; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; STEIN LS, 1980, J MED EDUC, V56, P103; STINSON ER, 1980, JAMA-J AM MED ASSOC, V243, P140, DOI 10.1001/jama.243.2.140; STROSS JK, 1980, ARTHRITIS RHEUM, V23, P846, DOI 10.1002/art.1780230711; STROSS JK, 1983, AM REV RESPIR DIS, V127, P739; STROSS JK, 1985, ARTHRITIS RHEUM, V28, P108, DOI 10.1002/art.1780280119; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; Tugwell P, 1985, ASSESSING CLIN COMPE, P142; VINICOR F, 1987, J CHRON DIS, V40, P345, DOI 10.1016/0021-9681(87)90050-6; WATTS MSM, 1989, J CONTIN ED HLTH PRO, V9, P129; WHITE CW, 1985, ANN INTERN MED, V102, P689; WHITE PT, 1989, J ROY COLL GEN PRACT, V39, P182; WILLIAMS DD, 1986, NEW DIRECTIONS PROGR, P30; WILSON DM, 1988, JAMA-J AM MED ASSOC, V260, P1570, DOI 10.1001/jama.260.11.1570; WINICKOFF RN, 1984, MED CARE, V22, P527, DOI 10.1097/00005650-198406000-00003; WONES RG, 1987, MED CARE, V25, P78, DOI 10.1097/00005650-198701000-00009; 1991, ANN REPORT RES DEV R	81	765	769	0	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1111	1117		10.1001/jama.268.9.1111	http://dx.doi.org/10.1001/jama.268.9.1111			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK681	1501333				2022-12-28	WOS:A1992JK68100008
J	MACASKIE, LE; EMPSON, RM; CHEETHAM, AK; GREY, CP; SKARNULIS, AJ				MACASKIE, LE; EMPSON, RM; CHEETHAM, AK; GREY, CP; SKARNULIS, AJ			URANIUM BIOACCUMULATION BY A CITROBACTER SP AS A RESULT OF ENZYMATICALLY MEDIATED GROWTH OF POLYCRYSTALLINE HUO2PO4	SCIENCE			English	Article							URANYL PHOSPHATE TETRAHYDRATE; P-31 NMR; ACCUMULATION; WASTES	A Citrobacter sp. accumulates heavy deposits of metal phosphate, derived from an enzymatically liberated phosphate ligand. The cells are not subject to saturation constraints and can accumulate several times their own weight of precipitated metal. This high capacity is attributable to biomineralization; uranyl phosphate accumulates as polycrystalline HUO2PO4 at the cell surface. The precipitated metal is indistinguishable from crystalline HUO2PO4.4H2O grown by chemical methods.	ST MARYS HOSP,SCH MED,LONDON W2 1NY,ENGLAND; UNIV OXFORD,CHEM CRYSTALLOG LAB,OXFORD OX1 3PD,ENGLAND	Imperial College London; University of Oxford	MACASKIE, LE (corresponding author), UNIV BIRMINGHAM,SCH BIOL SCI,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Grey, Clare P/Q-8860-2017	Grey, Clare P/0000-0001-5572-192X; Empson, Ruth/0000-0002-0415-6083				AICKIN RM, 1979, MICROBIOS LETT, V9, P7; CHEETHAM AK, 1986, J CHEM SOC CHEM COMM, P195, DOI 10.1039/c39860000195; CLIFF G, 1975, J MICROSC-OXFORD, V103, P203, DOI 10.1111/j.1365-2818.1975.tb03895.x; DUNCAN TM, 1984, CHEM PHYS, V87, P339, DOI 10.1016/0301-0104(84)85115-0; DUNN HW, 1956, ORNL PUBL, V2092; GREAVES C, 1973, INORG CHEM, V12, P3003, DOI 10.1021/ic50130a054; GRIMMER AR, 1983, CHEM PHYS LETT, V99, P487, DOI 10.1016/0009-2614(83)80180-8; HERZFELD J, 1980, J CHEM PHYS, V73, P6021, DOI 10.1063/1.440136; HOWE AT, 1980, J SOLID STATE CHEM, V34, P149, DOI 10.1016/0022-4596(80)90217-0; Macaskie L E, 1989, Adv Biotechnol Processes, V12, P159; MACASKIE LE, 1988, FEMS MICROBIOL LETT, V55, P157, DOI 10.1111/j.1574-6968.1988.tb13926.x; MACASKIE LE, 1987, J GEN MICROBIOL, V133, P539; MACASKIE LE, 1991, CRIT REV BIOTECHNOL, V11, P41, DOI 10.3109/07388559109069183; MACASKIE LE, 1990, J CHEM TECHNOL BIOT, V49, P357; MOROSIN B, 1978, ACTA CRYSTALLOGR B, V34, P3732, DOI 10.1107/S0567740878011991; PLUMMER EJ, 1990, B ENVIRON CONTAM TOX, V44, P173, DOI 10.1007/BF01700133; ROTHWELL WP, 1980, J AM CHEM SOC, V102, P2637, DOI 10.1021/ja00528a020; STRACHAN L, 1991, 201ST P AM CHEM SOC, V31, P128; WEIGEL F, 1976, J LESS-COMMON MET, V44, P99, DOI 10.1016/0022-5088(76)90121-1	19	230	242	4	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					782	784		10.1126/science.1496397	http://dx.doi.org/10.1126/science.1496397			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496397				2022-12-28	WOS:A1992JG85100029
J	CARDE, P				CARDE, P			CURRENT ISSUES IN CANCER .11. HODGKINS LYMPHOMA .2. TREATMENT AND DELAYED MORBIDITY	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL STAGE-I; PROGNOSTIC FACTORS; MOPP CHEMOTHERAPY; PLUS RADIOTHERAPY; DISEASE; MANAGEMENT; THERAPY; RADIATION; TRANSPLANTATION; TRIALS				CARDE, P (corresponding author), INST GUSTAVE ROUSSY,SERV MED,CS AXEL UNIT,F-94805 VILLEJUIF,FRANCE.							BONADONNA G, 1985, CANCER SURV, V4, P439; BONADONNA G, 1985, MALIGNANT LYMPHOMAS, P299; BONADONNA G, 1991, ANN ONCOL, V1, P9; CANNELLOS GP, 1988, P AM SOC ONCOLOGY, V8, P230; CARDE P, 1988, J CLIN ONCOL, V6, P239, DOI 10.1200/JCO.1988.6.2.239; CARDE P, 1983, J CLIN ONCOL, V1, P146, DOI 10.1200/JCO.1983.1.2.146; CARDE P, 1992, IN PRESS CLIN STAGIN; CARDE P, 1985, P AM SOC CLIN ONCOL, V4, P212; CIMINO G, 1989, J CLIN ONCOL, V7, P732, DOI 10.1200/JCO.1989.7.6.732; CONNORS JM, 1992, P AN M AM SOC CLIN, V11, P317; Cosset J M, 1984, Hematol Oncol, V2, P33; COSSET JM, 1991, ANN ONCOL, V2, P77, DOI 10.1093/annonc/2.suppl_2.77; COSSET JM, 1990, INT J RADIAT ONCOL, V21, P447; DEVITA VT, 1970, ANN INTERN MED, V73, P891; DIONET C, 1988, INT J RADIAT ONCOL, V15, P341, DOI 10.1016/S0360-3016(98)90013-X; EKERT H, 1988, J CLIN ONCOL, V6, P1845, DOI 10.1200/JCO.1988.6.12.1845; GOLDSTONE AH, 1992, RECENT ADV HAEMATOLO, V6, P149; HAYBITTLE JL, 1985, LANCET, V1, P967; HENRYAMAR M, 1990, SEMIN ONCOL, V17, P758; HOERNI B, 1990, B CANCER PARIS, V75, P789; HOHL RJ, 1989, HEMATOL ONCOL CLIN N, V3, P331, DOI 10.1016/S0889-8588(18)30560-4; Hoppe R T, 1989, Recent Results Cancer Res, V117, P182; HOPPE RT, 1990, SEMIN ONCOL, V17, P704; HORNING SJ, 1988, J CLIN ONCOL, V6, P1822, DOI 10.1200/JCO.1988.6.12.1822; HORWICH A, 1990, BLOOD REV, V4, P181, DOI 10.1016/0268-960X(90)90046-U; JAGANNATH S, 1986, ANN INTERN MED, V104, P163, DOI 10.7326/0003-4819-104-2-163; JEGOU B, 1991, P NATL ACAD SCI USA, V88, P8710, DOI 10.1073/pnas.88.19.8710; Kaplan H.S., 1980, HODGKINS DISEASE; KESSINGER A, 1989, BLOOD, V74, P1260; LONGO DL, 1991, J CLIN ONCOL, V9, P906, DOI 10.1200/JCO.1991.9.6.906; LONGO DL, 1991, J CLIN ONCOL, V9, P227, DOI 10.1200/JCO.1991.9.2.227; LONGO DL, 1986, J CLIN ONCOL, V4, P1296; MAUCH P, 1988, J CLIN ONCOL, V6, P1576, DOI 10.1200/JCO.1988.6.10.1576; MEAD GM, 1982, CANCER, V50, P829, DOI 10.1002/1097-0142(19820901)50:5<829::AID-CNCR2820500504>3.0.CO;2-R; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; OREILLY SE, 1991, ANN ONCOL, V2, P17, DOI 10.1093/annonc/2.suppl_1.17; PAVLOVSKY S, 1988, JNCI-J NATL CANCER I, V80, P1466, DOI 10.1093/jnci/80.18.1466; PECKHAM MJ, 1975, BRIT J CANCER, V32, P391, DOI 10.1038/bjc.1975.239; RATAIN MJ, 1992, ANN ONCOL, V3, P107, DOI 10.1093/oxfordjournals.annonc.a058121; ROSENBERG SA, 1985, INT J RADIAT ONCOL, V11, P5, DOI 10.1016/0360-3016(85)90357-8; SANTORO A, 1987, J CLIN ONCOL, V5, P27, DOI 10.1200/JCO.1987.5.1.27; SANTORO A, 1982, ANN INTERN MED, V96, P139, DOI 10.7326/0003-4819-96-2-139; SANTORO A, 1983, P AN M AM SOC CLIN, V2, P223; SELBY P, 1990, BRIT J CANCER, V62, P279, DOI 10.1038/bjc.1990.278; SOMERS R, 1990, TREATMENT SURGERY HO; SOMERS R, 1988, P AM SOC CLIN ONCOL, V914, P236; SPECHT L, 1991, CANCER TREAT REV, V18, P21, DOI 10.1016/0305-7372(91)90003-I; SPEYER JL, 1992, J CLIN ONCOL, V10, P117, DOI 10.1200/JCO.1992.10.1.117; TUBIANA M, 1989, BLOOD, V73, P47; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; ZITTOUN R, 1987, B CANC, V74, P1515	51	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					173	176		10.1136/bmj.305.6846.173	http://dx.doi.org/10.1136/bmj.305.6846.173			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1489407	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JF06300032
J	THORP, JM; BOWES, WA				THORP, JM; BOWES, WA			PROLIFE PERINATOLOGIST - PARADOX OR POSSIBILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MORTALITY				THORP, JM (corresponding author), UNIV N CAROLINA,SCH MED,CB 7570,214 MACNIDER BLDG,CHAPEL HILL,NC 27599, USA.							Cates WJ, 1981, ABORTION STERILIZATI, P155; GRIMES DA, 1985, J REPROD MED, V30, P505; HOOK EB, 1989, AM J HUM GENET, V45, P855; MARTEAU TM, 1991, BRIT J OBSTET GYNAEC, V98, P282, DOI 10.1111/j.1471-0528.1991.tb13394.x; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; ROCHAT RW, 1988, OBSTET GYNECOL, V72, P91; SHULMAN LP, 1990, OBSTET GYNECOL, V75, P1037; TIETZE C, 1983, INDUCED ABORTION WOR	8	10	10	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 30	1992	326	18					1217	1219		10.1056/NEJM199204303261810	http://dx.doi.org/10.1056/NEJM199204303261810			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR008	1472178				2022-12-28	WOS:A1992HR00800010
J	GOLDOFT, M				GOLDOFT, M			ANOTHER LANGUAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3482	3482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460742				2022-12-28	WOS:A1992KC83900042
J	CAMPS, M; CAROZZI, A; SCHNABEL, P; SCHEER, A; PARKER, PJ; GIERSCHIK, P				CAMPS, M; CAROZZI, A; SCHNABEL, P; SCHEER, A; PARKER, PJ; GIERSCHIK, P			ISOZYME-SELECTIVE STIMULATION OF PHOSPHOLIPASE C-BETA-2 BY G-PROTEIN BETA-GAMMA-SUBUNITS	NATURE			English	Article							ADENYLYL CYCLASE; SIGNAL TRANSDUCTION; RECEPTOR; CELLS	HYDROLYSIS by phospholipase C (PLC) of phosphatidylinositol 4,5-bisphosphate is a key mechanism by which many extracellular signalling molecules regulate functions of their target cells1,2. At least eight distinct isozymes of PLC are recognized in mammalian cells3,4. Receptor-controlled PLC is often regulated by G proteins, which can be modified by pertussis toxin in some cells but not in others5,6. In the latter cells, PLC-beta1, but not PLC-gamma1 or PLC-delta1, may be activated by members of the alpha(q)-subfamily of the G protein alpha-subunits7-10. An unidentified PLC in soluble fractions of cultured human HL-60 granulocytes is specifically stimulated by G protein betagamma subunits purified from retina and brain11. Identification of a second PLC-beta complementary DNA (PLC-beta2) in an HL-60 cell cDNA library9 prompted us to investigate the effect of purified G protein betagamma subunits on the activities of PLC-beta1 and PLC-beta2 transiently expressed in cultured mammalian cells. We report here that PLC-beta1 and PLC-beta2 were stimulated by free betagamma subunits and that PLC-beta2 was the most sensitive to betagamma stimulation. Thus stimulation of PLC by betagamma subunits is isozyme-selective and PLC-beta2 is a prime target of betagamma stimulation. Activation of PLC-beta2 by betagamma subunits may be an important mechanism by which pertussis toxin-sensitive G proteins stimulate PLC.	GERMAN CANC RES CTR, DIV MOLEC PHARMACOL, W-6900 HEIDELBERG, GERMANY; IMPERIAL CANC RES FUND, PROT PHOSPHORYLAT LAB, LONDON WC2A 3PX, ENGLAND	Helmholtz Association; German Cancer Research Center (DKFZ); Cancer Research UK			Parker, Peter j/D-5192-2013	Camps, Montserrat/0000-0002-9849-8657; parker, peter/0000-0002-6218-2933				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; DEVIVO M, 1990, ADP RIBOSYLATING TOX, P267; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; LEE CH, 1992, J BIOL CHEM, V267, P16044; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARK D, 1992, J BIOL CHEM, V267, P16048; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q	24	572	576	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1992	360	6405					684	686		10.1038/360684a0	http://dx.doi.org/10.1038/360684a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465133				2022-12-28	WOS:A1992KD08200060
J	WHITE, RJ; JACKSON, SP				WHITE, RJ; JACKSON, SP			MECHANISM OF TATA-BINDING PROTEIN RECRUITMENT TO A TATA-LESS CLASS-III PROMOTER	CELL			English	Article							RNA POLYMERASE-III; TRANSCRIPTION FACTOR-IIIB; HUMAN U6 GENE; ACCURATE TRANSCRIPTION; MULTIPLE FACTORS; TFIID COMPLEX; INITIATION; ACTIVATION; PURIFICATION; COMPONENTS	The TATA-binding protein (TBP) is required for transcription by RNA polymerase III (pol III), even though many pol III templates, such as the adenovirus VA(I) gene, lack a consensus TATA box. We show that TBP alone does not form a stable, productive interaction with VA(I) DNA. However, it can be incorporated into an initiation complex if the other class III basal factors, TFIIIB and TFIIIC, are also present. TFIIIB can associate with the evolutionarily conserved C-terminal domain of TBP in the absence of DNA or TFIIIC, suggesting that TFIIIB exists in solution as a complex with TBP. The stable association of TBP with an essential component of the pol III transcription apparatus may account for the ability of TATA-less class III genes to recruit TBP.			WHITE, RJ (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURKE DJ, 1985, J BIOL CHEM, V260, P816; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CAREY MF, 1986, J BIOL CHEM, V261, P4309; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FUHRMAN SA, 1984, J BIOL CHEM, V259, P1934; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; WHITE RJ, 1990, EMBO J, V9, P3713, DOI 10.1002/j.1460-2075.1990.tb07584.x; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WHITE RJ, 1992, IN PRESS J CELL SCI; Wolffe AP, 1991, CURR OPIN CELL BIOL, V3, P461, DOI 10.1016/0955-0674(91)90074-9; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	60	109	111	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1041	1053		10.1016/0092-8674(92)90398-V	http://dx.doi.org/10.1016/0092-8674(92)90398-V			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458535				2022-12-28	WOS:A1992KB99000015
J	[Anonymous]				[Anonymous]			MERGING FOR STRENGTH	NATURE			English	Editorial Material																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					515	515						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461272				2022-12-28	WOS:A1992KB95900028
J	LLEWELYN, MB; HAWKINS, RE; RUSSELL, SJ				LLEWELYN, MB; HAWKINS, RE; RUSSELL, SJ			MONOCLONAL-ANTIBODIES IN MEDICINE - DISCOVERY OF ANTIBODIES .3.	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Passive immunisation has been used in clinical practice since the end of last century, mainly for prophylaxis. Success of early treatments was marred by anaphylactic reactions and serum sickness because antibodies or antitoxins were not raised in humans. Recombination of gene segments during antibody synthesis means that specific antibodies for numerous antigens can be produced from a limited gene pool. Killer lymphocytes, phagocytes, and complement then bind to the constant region of the antibody facilitating elimination of the pathogen. Development of a method of obtaining large quantities of antibodies against a specific antigen (monoclonal antibodies) offers the possibility of initiating host defence mechanisms against any unwanted antigen, though some problems still remain in preventing the body from attacking the monoclonal antibody.	MRC, CAMBRIDGE CB2 2QH, ENGLAND; ADDENBROOKES HOSP, CAMBRIDGE CB2 2QQ, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Llewelyn, Martin/A-7194-2011	Llewelyn, Martin/0000-0002-6811-1124				BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BROWNING CH, 1955, NATURE, V175, P570, DOI 10.1038/175570a0; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; DALE H, 1954, BRIT MED J, V1, P659, DOI 10.1136/bmj.1.4863.659; DREYER WJ, 1965, P NATL ACAD SCI USA, V54, P864, DOI 10.1073/pnas.54.3.864; GRONSKI P, 1991, MOL IMMUNOL, V28, P1321, DOI 10.1016/0161-5890(91)90034-H; KARPAS A, 1988, P NATL ACAD SCI USA, V85, P9234, DOI 10.1073/pnas.85.23.9234; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; MACNALTY AS, 1954, BRIT MED J, V1, P668, DOI 10.1136/bmj.1.4863.668; Nisonoff A, 1975, ANTIBODY MOL; PASCUAL V, 1991, ADV IMMUNOL, V49, P1; POLJAK RJ, 1973, P NATL ACAD SCI USA, V70, P3305, DOI 10.1073/pnas.70.12.3305; Singer C., 1962, SHORT HIST MED, V2nd ed.; STEINITZ M, 1980, NATURE, V287, P443, DOI 10.1038/287443a0; Stokes J, 1944, J CLIN INVEST, V23, P531, DOI 10.1172/JCI101518; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Von Behring E, 1890, DEUT MED WOCHENSCHR, V16, P1113, DOI [DOI 10.1055/S-0029-1207589, 10.1055/s-0029-1207589]; WILLIAMS AF, 1977, CELL, V12, P663, DOI 10.1016/0092-8674(77)90266-5; ZWISTER O, 1990, GELBEN HEFTE, V4, P153; 1990, IMMUNISATION INFECTI	21	35	36	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 21	1992	305	6864					1269	1272		10.1136/bmj.305.6864.1269	http://dx.doi.org/10.1136/bmj.305.6864.1269			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477573	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JZ52100028
J	OCALLAGHAN, E; GIBSON, T; COLOHAN, HA; BUCKLEY, P; WALSHE, DG; LARKIN, C; WADDINGTON, JL				OCALLAGHAN, E; GIBSON, T; COLOHAN, HA; BUCKLEY, P; WALSHE, DG; LARKIN, C; WADDINGTON, JL			RISK OF SCHIZOPHRENIA IN ADULTS BORN AFTER OBSTETRIC COMPLICATIONS AND THEIR ASSOCIATION WITH EARLY ONSET OF ILLNESS - A CONTROLLED-STUDY	BRITISH MEDICAL JOURNAL			English	Article							PERINATAL COMPLICATIONS; PREGNANCY; DISORDER; PSYCHOSIS; DELIVERY; BIRTH; LIFE	Objective-To determine whether obstetric complications occur to excess in the early histories of individuals who go on to develop schizophrenia when compared with controls, and to seek clinical correlates of any such excess. Design-Contemporaneous maternity hospital records were identified and extracted verbatim, and these extracts evaluated for obstetric complications by two independent assessors who were blind to subjects' status. Subjects-65 patients having an ICD-9 diagnosis of schizophrenia, the records of the previous same sex live birth being deemed to be those of a control subject. Main outcome measure-Presence of one or more obstetric complications recorded in maternity notes of patients and controls. Results-When two recognised scales for specifying obstetric complications were used the patients with schizophrenia were significantly more likely than controls to have experienced at least one obstetric complication (odds ratio 2.44, 95% confidence interval 1.08 to 6.03). Patients also showed a greater number and severity of and total score for obstetric complications, fetal distress being the only complication to occur to significant individual excess (present in five (8%) patients, absent in controls). There was a marked sex effect, male patients being more vulnerable (odds ratio 4.24, 1.39 to 12.90) to such complications. Obstetric complications in patients were unrelated to family history or season of birth but were associated with a significantly younger age at onset of illness (mean difference -4.5 years, -1.2 to -7.8 years). Conclusions-Patients with schizophrenia, particularly males, have an excess of obstetric complications in their early developmental histories, and such complications are associated with a younger age at onset of their disease. Though the data are not conclusive, they also suggest that obstetric complications may be secondary to yet earlier events.	ST JOHN GOD PSYCHIAT SERV,BLACKROCK,DUBLIN,IRELAND; ROYAL COLL SURG IRELAND,DUBLIN 2,IRELAND	Royal College of Surgeons - Ireland								CHAMBERLAIN GVP, 1987, DEWHURSTS TXB OBSTET, P101; CHITKARA B, 1988, BRIT J PSYCHIAT, V152, P391, DOI 10.1192/bjp.152.3.391; DONE DJ, 1991, BRIT MED J, V302, P1576, DOI 10.1136/bmj.302.6792.1576; EAGLES JM, 1990, LANCET, V335, P1139, DOI 10.1016/0140-6736(90)91136-X; GARDNER MJ, 1989, BRIT MED J; GOLDSTEIN JM, 1990, SCHIZOPHRENIA BULL, V16, P179, DOI 10.1093/schbul/16.2.179; JACOBSEN B, 1980, ACTA PSYCHIAT SCAND, V62, P337, DOI 10.1111/j.1600-0447.1980.tb07709.x; KERWIN R, 1991, BRIT MED J, V303, P188, DOI 10.1136/bmj.303.6795.188-b; LANE EA, 1966, J PSYCHOL, V64, P227, DOI 10.1080/00223980.1966.10544847; LEWIS S, 1991, BRIT MED J, V303, P582, DOI 10.1136/bmj.303.6802.582-b; LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4; Lewis SW, 1989, SCHIZOPHRENIA, P56; McNeil TF, 1978, NATURE SCHIZOPHRENIA, P401; MURRAY RM, 1991, CONCEPTS OF MENTAL DISORDER, P48; MURRAY RM, 1987, BRIT MED J, V295, P681, DOI 10.1136/bmj.295.6600.681; OCALLAGHAN E, 1991, BRIT J PSYCHIAT, V158, P764, DOI 10.1192/bjp.158.6.764; OCALLAGHAN E, 1991, AM J PSYCHIAT, V148, P479; OCALLAGHAN E, 1990, BRIT J PSYCHIAT, V157, P578, DOI 10.1192/bjp.157.4.578; OCALLAGHAN E, 1990, PSYCHOL MED, V20, P89, DOI 10.1017/S0033291700013258; PARNAS J, 1982, BRIT J PSYCHIAT, V140, P416, DOI 10.1192/bjp.140.4.416; POLLACK M, 1966, AM J ORTHOPSYCHIAT, V36, P510, DOI 10.1111/j.1939-0025.1966.tb02394.x; POLLACK M, 1968, AM J ORTHOPSYCHIAT, V38, P94, DOI 10.1111/j.1939-0025.1968.tb00560.x; WADDINGTON JL, 1991, ARCH GEN PSYCHIAT, V48, P271; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; WILLIAMS MA, 1991, OBSTET GYNECOL, V78, P14; WOERNER MG, 1973, ACTA PSYCHIAT SCAND, V49, P712, DOI 10.1111/j.1600-0447.1973.tb04460.x; 1978, WHO ICD9; 1987, CENSUS 86	28	160	162	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1256	1259		10.1136/bmj.305.6864.1256	http://dx.doi.org/10.1136/bmj.305.6864.1256			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JZ521	1477568	Green Submitted, Green Published			2022-12-28	WOS:A1992JZ52100022
J	OGG, J; BENNETT, G				OGG, J; BENNETT, G			ELDER ABUSE IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Article											OGG, J (corresponding author), ROYAL LONDON TRUST,DEPT HLTH CARE ELDERLY,LONDON E1 4DG,ENGLAND.							BENNETT G, 1990, GERIATRIC MED    APR, P53; HOMER AC, 1990, BRIT MED J, V301, P1359, DOI 10.1136/bmj.301.6765.1359; PILLEMER K, 1988, GERONTOLOGIST, V28, P51, DOI 10.1093/geront/28.1.51; PODNIEKS E, 1989, NATIONAL SURVEY ABUS; 1992, CONFRONTING ELDER AB	5	109	112	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					998	999		10.1136/bmj.305.6860.998	http://dx.doi.org/10.1136/bmj.305.6860.998			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV776	1458149	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JV77600029
J	BILOUS, RW; MURTY, G; PARKINSON, DB; THAKKER, RV; COULTHARD, MG; BURN, J; MATHIAS, D; KENDALLTAYLOR, P				BILOUS, RW; MURTY, G; PARKINSON, DB; THAKKER, RV; COULTHARD, MG; BURN, J; MATHIAS, D; KENDALLTAYLOR, P			AUTOSOMAL DOMINANT FAMILIAL HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DYSPLASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HUMAN PARATHYROID-HORMONE; IDIOPATHIC HYPOPARATHYROIDISM; RECESSIVE INHERITANCE; GENE; NEPHROPATHY		UNIV NEWCASTLE UPON TYNE,DEPT EAR NOSE & THROAT SURG,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT PAEDIAT,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT HUMAN GENET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; MRC,CLIN RES CTR,DIV MOLEC MED,HARROW HA1 3UJ,MIDDX,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Medical Research Council Clinical Trials Unit				Thakker, Rajesh/0000-0002-1438-3220; Burn, John/0000-0002-9823-2322				AHN TG, 1986, MEDICINE, V65, P73, DOI 10.1097/00005792-198603000-00001; AHONEN P, 1985, CLIN GENET, V27, P535, DOI 10.1111/j.1399-0004.1985.tb02037.x; Albright F, 1929, J CLIN INVEST, V7, P183, DOI 10.1172/JCI100224; ARNOLD A, 1990, J CLIN INVEST, V86, P1084, DOI 10.1172/JCI114811; BARAKAT AY, 1977, J PEDIATR-US, V91, P61, DOI 10.1016/S0022-3476(77)80445-9; BOONSTRA CE, 1965, ANN INTERN MED, V63, P468, DOI 10.7326/0003-4819-63-3-468; BRONSKY D, 1968, J CLIN ENDOCR METAB, V28, P61, DOI 10.1210/jcem-28-1-61; CHU HY, 1964, CHINESE MED J-PEKING, V83, P723; COUNAHAN R, 1976, ARCH DIS CHILD, V51, P875, DOI 10.1136/adc.51.11.875; DAHLBERG PJ, 1983, AM J MED GENET, V16, P99, DOI 10.1002/ajmg.1320160115; DECAMPO C, 1988, J ENDOCRINOL INVEST, V11, P91, DOI 10.1007/BF03350111; EDWARDS BD, 1989, J MED GENET, V26, P289, DOI 10.1136/jmg.26.5.289; ELLIS HA, 1969, PEDIATRICS, V44, P225; GEERTINGER P, 1967, PEDIATRICS, V39, P43; GEERTINGER P, 1969, ACTA PATHOL MIC SC, V75, P270; HUNTER AGW, 1981, J MED GENET, V18, P431, DOI 10.1136/jmg.18.6.431; IKEDA K, 1987, LARYNGOSCOPE, V97, P1075; KRUSE K, 1987, EUR J PEDIATR, V146, P373, DOI 10.1007/BF00444941; KUNSTADTER RH, 1963, AM J DIS CHILD, V105, P499, DOI 10.1001/archpedi.1963.02080040501014; LEHNHARDT E, 1986, CLIN ASPECTS INNER E, P57; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCELDUFF A, 1989, AUST NZ J MED, V19, P22, DOI 10.1111/j.1445-5994.1989.tb01668.x; MILLER M J, 1972, Henry Ford Hospital Medical Journal, V20, P3; NAYLOR SL, 1983, SOMAT CELL GENET, V9, P609, DOI 10.1007/BF01574261; NUSYNOWITZ ML, 1976, MEDICINE, V55, P105, DOI 10.1097/00005792-197603000-00001; PARKINSON DB, 1992, NAT GENET, V1, P149, DOI 10.1038/ng0592-149; PEDEN VH, 1960, AM J HUM GENET, V12, P323; PHILIPSON B, 1978, ACTA MED SCAND, V203, P223; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAO SD, 1981, ANN INTERN MED, V95, P655, DOI 10.7326/0003-4819-95-5-655_1; RICHTER PL, 1968, NEUROLOGY, V18, P75, DOI 10.1212/WNL.18.1_Part_1.75; SHAW NJ, 1991, ARCH DIS CHILD, V66, P1191, DOI 10.1136/adc.66.10.1191; THAKKER RV, 1990, J CLIN INVEST, V86, P40, DOI 10.1172/JCI114712; VALDESDAPENA MA, 1971, ACTA PATH MICRO IM A, VA 79, P228; WEIDAUER H, 1981, ARCH OTO-RHINO-LARYN, V231, P677, DOI 10.1007/BF00501699; WHYTE MP, 1981, J PEDIATR-US, V99, P608, DOI 10.1016/S0022-3476(81)80272-7; WINTER WE, 1983, J PEDIATR-US, V103, P387, DOI 10.1016/S0022-3476(83)80408-9; YUMITA S, 1986, TOHOKU J EXP MED, V148, P135, DOI 10.1620/tjem.148.135	38	118	121	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1992	327	15					1069	1074		10.1056/NEJM199210083271506	http://dx.doi.org/10.1056/NEJM199210083271506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR321	1522843				2022-12-28	WOS:A1992JR32100006
J	BUCHWALD, H; MATTS, JP; FITCH, LL; CAMPOS, CT; SANMARCO, ME; AMPLATZ, K; CASTANEDAZUNIGA, WR; HUNTER, DW; PEARCE, MB; BISSETT, JK; EDMISTON, WA; SAWIN, HS; WEBER, FJ; VARCO, RL; CAMPBELL, GS; YELLIN, AE; SMINK, RD; LONG, JM; HANSEN, BJ; CHALMERS, TC; MEIER, P; STAMLER, J				BUCHWALD, H; MATTS, JP; FITCH, LL; CAMPOS, CT; SANMARCO, ME; AMPLATZ, K; CASTANEDAZUNIGA, WR; HUNTER, DW; PEARCE, MB; BISSETT, JK; EDMISTON, WA; SAWIN, HS; WEBER, FJ; VARCO, RL; CAMPBELL, GS; YELLIN, AE; SMINK, RD; LONG, JM; HANSEN, BJ; CHALMERS, TC; MEIER, P; STAMLER, J			CHANGES IN SEQUENTIAL CORONARY ARTERIOGRAMS AND SUBSEQUENT CORONARY EVENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERLIPIDEMIAS POSCH; SURGICAL CONTROL; ARTERY DISEASE; ATHEROSCLEROSIS; REGRESSION; PROGRAM; THERAPY; HYPERCHOLESTEROLEMIA; PROGRESSION; DESIGN	Objective.-Assessment of the relationship between changes in sequential coronary arteriograms and subsequent clinical coronary events. Design.-The Program on the Surgical Control of the Hyperlipidemias, a randomized secondary atherosclerosis intervention trial, obtained coronary arteriograms at baseline, 3, 5, and 7 or 10 years of follow-up. Assessments of changes between pairs of coronary arteriograms were made by two-member panels blinded to the patients' assigned treatment and to the temporal sequence of the films. The relationship of changes between the baseline and the 3-year follow-up arteriograms and subsequent clinical coronary events was examined. Setting.-Three university hospitals and one private primary care facility. Patients.-A total of 838 patients, with 417 patients randomized to the control group and 421 to the intervention group. Of all patients, 695 had baseline and 3-year arteriograms. Intervention.-The control group received American Heart Association Phase II diet instruction and the intervention group received identical dietary instruction plus a partial ileal bypass operation. Main Outcome Measure.-The use of arteriographic changes as a predictor of subsequent clinical coronary events. Results.-Changes between the baseline and the 3-year coronary arteriographic overall disease assessment were significantly associated with subsequent overall and atherosclerotic coronary heart disease mortality (P<.01). For the combined end point of atherosclerotic coronary heart disease mortality or confirmed nonfatal myocardial infarction, a significant relationship between the overall disease assessment and subsequent clinical events was found in the control group (P<.0001) and in the surgery group (P=.04). For this combined end point, however, the control and the surgery groups were different with respect to clinical coronary events after 3 years, stratified by the baseline to 3-year overall disease assessment (P<.001, unadjusted; P=.06, adjusted for 3-year clinical covariates). Conclusions.-Coronary arteriographic changes can be used in atherosclerosis intervention trials as a limited surrogate end point for certain clinical coronary events. This relationship is statistically compelling for overall mortality and atherosclerotic coronary heart disease mortality. For an individual patent, changes in the severity of coronary atherosclerosis seen on sequential coronary arteriograms can serve as prognostic indicators for subsequent overall or atherosclerotic coronary heart disease mortality.	BOSTON VET AFFAIRS HOSP,BOSTON,MA; LANKENAU HOSP & RES CTR,DEPT MED,PHILADELPHIA,PA; LANKENAU HOSP & RES CTR,DEPT SURG,PHILADELPHIA,PA; UNIV MINNESOTA,DEPT RADIOL,MINNEAPOLIS,MN 55455; UNIV ARKANSAS MED SCI HOSP,DEPT MED,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT SURG,LITTLE ROCK,AR 72205; NORTHWESTERN UNIV,DEPT MED,CHICAGO,IL 60611; UNIV SO CALIF,DEPT MED,LOS ANGELES,CA 90089; UNIV SO CALIF,DEPT SURG,LOS ANGELES,CA 90089; UNIV CHICAGO,DEPT STAT,CHICAGO,IL 60637	Lankenau Medical Center; Lankenau Institute for Medical Research; Lankenau Medical Center; Lankenau Institute for Medical Research; University of Minnesota System; University of Minnesota Twin Cities; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Northwestern University; University of Southern California; University of Southern California; University of Chicago	BUCHWALD, H (corresponding author), UNIV MINNESOTA,DEPT SURG,BOX 290 UMHC,MINNEAPOLIS,MN 55455, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015265] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL15265] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BLANKENHORN DH, 1987, CONTROL CLIN TRIALS, V8, P354, DOI 10.1016/0197-2456(87)90156-5; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1987, CONTROL CLIN TRIALS, V8, pS94; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BUCHWALD H, 1989, J CLIN EPIDEMIOL, V42, P1111, DOI 10.1016/0895-4356(89)90109-1; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; CONOVER WJ, 1971, PRACTICAL NONPARAMET, P247; COX DR, 1972, J R STAT SOC B, V34, P187; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; MATTS JP, 1991, CONTROL CLIN TRIALS, V12, P314, DOI 10.1016/0197-2456(91)90028-K; MOISE A, 1985, AM J CARDIOL, V55, P941, DOI 10.1016/0002-9149(85)90722-2	14	163	166	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1429	1433		10.1001/jama.268.11.1429	http://dx.doi.org/10.1001/jama.268.11.1429			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512911				2022-12-28	WOS:A1992JM84900025
J	ROSENBLATT, WH; SILVERMAN, DG				ROSENBLATT, WH; SILVERMAN, DG			RECOVERY, RESTERILIZATION, AND DONATION OF UNUSED SURGICAL SUPPLIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISPOSABLE MEDICAL DEVICES; DEVELOPING-COUNTRIES; HOSPITALS; REUSE				ROSENBLATT, WH (corresponding author), YALE UNIV,SCH MED,DEPT ANESTHESIOL,NEW HAVEN,CT 06510, USA.							BRYSON TK, 1979, ANESTHESIOLOGY, V50, P370, DOI 10.1097/00000542-197904000-00020; CAMPBELL BA, 1987, AM J INFECT CONTROL, V15, P196, DOI 10.1016/0196-6553(87)90095-2; CROW S, 1986, INFECT CONT HOSP EP, V7, P561, DOI 10.1017/S0195941700065346; DECKER R, 1989, HOSP MATER MANAGE, V14, P20; EYREBROOK AL, 1986, INT ORTHOP, V10, P5; FISHMAN RL, 1991, ANESTH ANALG, V72, P266, DOI 10.1213/00000539-199102000-00031; Gaynor E, 1984, J Hosp Supply Process Distrib, V2, P48; GITLIN L, 1992, RECYCLING TODAY  JAN, P66; MAYHALL CG, 1986, INFECT CONT HOSP EP, V7, P491, DOI 10.1017/S0195941700065103; RANDOLPH E, 1991, WASHINGTON POST 1118, pA1; REMIS R, 1983, TROP DOCT, V13, P89, DOI 10.1177/004947558301300216; WESTON PM, 1987, BR J ACCIDENT SURG, V18, P267; 1982, J TROP MED HYG, V85, P183; 1992, NY TIMES        0225, pA21; 1984, LANCET, V2, P34; 1991, NEW EMERGENCY HLTH K, P9	16	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1441	1443		10.1001/jama.268.11.1441	http://dx.doi.org/10.1001/jama.268.11.1441			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512913				2022-12-28	WOS:A1992JM84900027
J	Scott, HD; Shapiro, HB				Scott, HD; Shapiro, HB			Universal Insurance for American Health-Care - A Proposal of the American-College-of-Physicians	ANNALS OF INTERNAL MEDICINE			English	Article						Insurance, Health; Health Services Accessibility; National Health Insurance, United-States; Delivery of Health Care; Cost Control; Ethics, Medical		The American College of Physicians calls for major reform of the American health care system. The College proposes universal health insurance covering everyone. 1) Assuring access to care through a universal insurance system that relies on employer and publicly sponsored insurance plans- All public programs for health care would be consolidated, and everyone would be guaranteed coverage, funded through a combination of private premiums and public revenues. 2) Assuring high-quality and comprehensive health care through coverage of all medically effective services that are appropriate for a particular patient. 3) Promoting innovation and excellence through enhancing the crucial institutional underpinnings of excellence in medical care-research, education, and medeical information management. 4) Controlling costs through a national health care budget, with a mixture of centralized and decentralized mechanisms to influence the price, volume, supply, and demand for health care services. The College offers a conceptual outline for reform; important details such as financial projections must be developed and tested over the next several years	Amer Coll Physicians, Div Hlth & Publ Policy, Independence Mall W, 6th St & Race, Philadelphia, PA 19106 USA	American College of Physicians	Scott, HD (corresponding author), Amer Coll Physicians, Div Hlth & Publ Policy, Independence Mall W, 6th St & Race, Philadelphia, PA 19106 USA.							American College of Physicians, 1990, ANN INTERN MED, V112, P641; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; IGLEHART JK, 1986, NEW ENGL J MED, V315, P778, DOI 10.1056/NEJM198609183151238; KIRKMANLIFF BL, 1989, INQUIRY-J HEALTH CAR, V26, P468; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; Reinhardt U.E., 1989, W GERMANYS HLTH CARE; SCHWARTZ JS, 1982, ANN INTERN MED, V96, P246, DOI 10.7326/0003-4819-96-2-246; SNYDER L, 1990, ANN INTERN MED, V113, P789, DOI 10.7326/0003-4819-113-10-789; 1991, HLTH CARE FINANCING, V13, P1; 1992, 1991 GRADUATING STUD; 1988, HOSPITAL CLIN PRIVIL; 1988, PROPOSED ALTERNATIVE; 1992, MANAGING CARE RHETOR, P313	13	34	34	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					511	519		10.7326/0003-4819-117-6-511	http://dx.doi.org/10.7326/0003-4819-117-6-511			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503354				2022-12-28	WOS:A1992JN25700011
J	GURSOY, S; STEURER, G; BRUGADA, J; ANDRIES, E; BRUGADA, P				GURSOY, S; STEURER, G; BRUGADA, J; ANDRIES, E; BRUGADA, P			THE HEMODYNAMIC MECHANISM OF POUNDING IN THE NECK IN ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							SUPRAVENTRICULAR TACHYCARDIA		ONZE LIEVE VROUW HOSP, CTR CARDIOVASC, MOORSELBAAN 164, B-9300 AALST, BELGIUM; UNIV BARCELONA, HOSP CLIN, ARRHYTHMIA UNIT, BARCELONA 7, SPAIN	University of Barcelona; Hospital Clinic de Barcelona				BRUGADA, JOSEP/0000-0002-5662-8302				AKHTAR M, 1978, AM HEART J, V95, P22, DOI 10.1016/0002-8703(78)90394-0; FERRER MI, 1949, AM J MED, V6, P725, DOI 10.1016/0002-9343(49)90308-3; GOLDREYER BN, 1976, CIRCULATION, V54, P783, DOI 10.1161/01.CIR.54.5.783; NAITO M, 1983, AM HEART J, V105, P295, DOI 10.1016/0002-8703(83)90530-6; SGANZERLA P, 1989, EUR HEART J, V10, P32, DOI 10.1093/oxfordjournals.eurheartj.a059378; SWINSCOW TDV, 1980, STATISTICS SQUARE ON	6	51	53	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					772	774		10.1056/NEJM199209103271105	http://dx.doi.org/10.1056/NEJM199209103271105			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501653				2022-12-28	WOS:A1992JL66100005
J	WALENT, JH; PORTER, BW; MARTIN, TFJ				WALENT, JH; PORTER, BW; MARTIN, TFJ			A NOVEL 145-KD BRAIN CYTOSOLIC PROTEIN RECONSTITUTES CA2+-REGULATED SECRETION IN PERMEABLE NEUROENDOCRINE CELLS	CELL			English	Article							SEMI-INTACT CELLS; KINASE-C; VESICULAR TRANSPORT; MEMBRANE-FUSION; GOLGI-COMPLEX; MAST-CELLS; PC12 CELLS; EXOCYTOSIS; PURIFICATION; COMPONENTS	The regulated secretory pathway is activated by elevated cytoplasmic Ca2+; however, the components mediating Ca2+ regulation have not been identified. In semi-intact neuroendocrine cells, Ca2+-activated secretion is ATP- and cytosol protein-dependent. We have identified a novel brain protein, p145, as a cytosolic factor that reconstitutes Ca2+-activated secretion in two neuroendocrine cell types. The protein is a dimer of 145 kd subunits, exhibits Ca2+-dependent interaction with a hydrophobic matrix, and binds phospholipid vesicles, suggesting a membrane-associated function. A p145-specific antibody inhibits the reconstitution of Ca2+-activated secretion by cytosol, indicating an essential role for p145. The restricted expression of p145 in tissues exhibiting a regulated secretory pathway suggests a key role for this protein in the transduction of Ca2+ signals into vectorial membrane fusion events.			WALENT, JH (corresponding author), UNIV WISCONSIN,DEPT ZOOL,MADISON,WI 53706, USA.				NIDDK NIH HHS [DK 40428] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040428] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; AUNIS D, 1988, J EXP BIOL, V139, P253; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGOYNE RD, 1990, ANNU REV PHYSIOL, V52, P647; CHURCHER Y, 1990, CELL REGUL, V1, P337, DOI 10.1091/mbc.1.4.337; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DELISLE RC, 1986, ANNU REV PHYSIOL, V48, P225; DUNPHY WG, 1986, P NATL ACAD SCI USA, V83, P1622, DOI 10.1073/pnas.83.6.1622; FRICKER LD, 1990, NEUROENDOCRINOLOGY, V51, P658, DOI 10.1159/000125407; GODA Y, 1989, FASEB J, V3, P2488, DOI 10.1096/fasebj.3.13.2680705; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HARLOW E, 1988, ANTIBODIES LABORATOR; HAY JC, 1992, IN PRESS J CELL BIOL; KOFFER A, 1989, J CELL SCI, V94, P585; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; Miller SG, 1990, CURR OPIN CELL BIOL, V2, P642, DOI 10.1016/0955-0674(90)90105-N; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; OBENDORF D, 1988, NEUROSCIENCE, V25, P343, DOI 10.1016/0306-4522(88)90030-9; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PEPPERS SC, 1986, J BIOL CHEM, V261, P4665; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; ROSSIER J, 1989, ANAL BIOCHEM, V178, P27, DOI 10.1016/0003-2697(89)90350-3; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WATTENBERG BW, 1986, J BIOL CHEM, V261, P2208; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	37	237	241	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					765	775		10.1016/0092-8674(92)90310-9	http://dx.doi.org/10.1016/0092-8674(92)90310-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516133				2022-12-28	WOS:A1992JL66300008
J	DINNEEN, S; GERICH, J; RIZZA, R				DINNEEN, S; GERICH, J; RIZZA, R			CARBOHYDRATE-METABOLISM IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ORAL GLUCOSE-LOAD; POSTPRANDIAL HYPERGLYCEMIA; HEPATIC GLYCOGEN; SKELETAL-MUSCLE; CONSCIOUS DOG; MIXED-MEAL; EXOGENOUS INSULIN; NIDDM PATIENTS; GLUCONEOGENESIS; LIVER		MAYO CLIN & MAYO FDN, DEPT MED,ENDOCRINE RES UNIT,RM 5-164, W JOSEPH BLDG, ROCHESTER, MN 55905 USA; WHITTIER INST DIABET & ENDOCRINOL, DEPT BIOCHEM, LA JOLLA, CA USA	Mayo Clinic				Dinneen, Sean/0000-0002-6636-0493	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029953, R37DK020411, R01DK029953, R01DK020411] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20411, DK29953] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRES R, 1956, J CLIN INVEST, V35, P671, DOI 10.1172/JCI103324; BASSO L V, 1970, Journal of Clinical Investigation, V49, P537, DOI 10.1172/JCI106264; BODEN G, 1983, DIABETES, V32, P982, DOI 10.2337/diabetes.32.11.982; BODEN G, 1991, DIABETES, V40, P686, DOI 10.2337/diabetes.40.6.686; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; BROSNAN JT, 1982, FED PROC, V41, P91; BRUCE DG, 1988, DIABETES, V37, P736, DOI 10.2337/diabetes.37.6.736; BUTLER PC, 1991, DIABETES, V40, P73, DOI 10.2337/diabetes.40.1.73; BUTLER PC, 1990, DIABETES, V39, P1373, DOI 10.2337/diabetes.39.11.1373; CHERRINGTON AD, 1981, DIABETES, V30, P180, DOI 10.2337/diabetes.30.3.180; CHERRINGTON AD, 1978, METABOLISM, V27, P787, DOI 10.1016/0026-0495(78)90213-5; CONSOLI A, 1989, DIABETES, V38, P550, DOI 10.2337/diabetes.38.5.550; CONSOLI A, 1990, J CLIN INVEST, V86, P2038, DOI 10.1172/JCI114940; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; CONSOLI A, 1990, AM J PHYSIOL, V259, pE677, DOI 10.1152/ajpendo.1990.259.5.E677; DAGENAIS GR, 1976, J CLIN INVEST, V58, P421, DOI 10.1172/JCI108486; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DIETZE G, 1976, DIABETOLOGIA, V12, P555, DOI 10.1007/BF01220631; EDELMAN SV, 1990, DIABETES, V39, P955, DOI 10.2337/diabetes.39.8.955; EFENDIC S, 1985, P NATL ACAD SCI USA, V82, P2965, DOI 10.1073/pnas.82.9.2965; ESTRICH D, 1967, DIABETES, V16, P232, DOI 10.2337/diab.16.4.232; FELBER JP, 1987, DIABETES, V36, P1341, DOI 10.2337/diabetes.36.11.1341; FELIG P, 1973, METABOLISM, V22, P179, DOI 10.1016/0026-0495(73)90269-2; FERRANNINI E, 1989, DIABETES METAB REV, V5, P711, DOI 10.1002/dmr.5610050806; FERRANNINI E, 1985, DIABETES, V34, P580, DOI 10.2337/diabetes.34.6.580; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; FERRANNINI E, 1988, METABOLISM, V37, P79, DOI 10.1016/0026-0495(88)90033-9; FIRTH R, 1987, DIABETES, V36, P1130, DOI 10.2337/diabetes.36.10.1130; FIRTH RG, 1986, J CLIN INVEST, V77, P1525, DOI 10.1172/JCI112467; FIRTH RG, 1986, NEW ENGL J MED, V314, P1280, DOI 10.1056/NEJM198605153142003; GANNON MC, 1988, METABOLISM, V37, P1081, DOI 10.1016/0026-0495(88)90072-8; GOLD M, 1964, AM J PHYSIOL, V206, P153, DOI 10.1152/ajplegacy.1964.206.1.153; HALL SEH, 1979, DIABETES, V28, P737; HETENYI G, 1982, FED PROC, V41, P104; JACKSON RA, 1986, J CLIN ENDOCR METAB, V63, P541, DOI 10.1210/jcem-63-3-541; KATZ J, 1984, J CLIN INVEST, V74, P1901, DOI 10.1172/JCI111610; KELLEY D, 1988, J CLIN INVEST, V81, P1563, DOI 10.1172/JCI113489; LANG CH, 1986, AM J PHYSIOL, V251, pE584, DOI 10.1152/ajpendo.1986.251.5.E584; MCMAHON M, 1989, J CLIN ENDOCR METAB, V68, P647, DOI 10.1210/jcem-68-3-647; MCMAHON M, 1989, DIABETES, V38, P291, DOI 10.2337/diabetes.38.3.291; MITRAKOU A, 1992, NEW ENGL J MED, V326, P22, DOI 10.1056/NEJM199201023260104; MITRAKOU A, 1990, DIABETES, V39, P1381, DOI 10.2337/diabetes.39.11.1381; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MOORE MC, 1991, J CLIN INVEST, V88, P578, DOI 10.1172/JCI115342; MOST AS, 1969, J CLIN INVEST, V48, P1177, DOI 10.1172/JCI106082; NATHAN DM, 1992, DIABETES CARE, V15, P270, DOI 10.2337/diacare.15.2.270; NURJHAN N, 1992, J CLIN INVEST, V89, P169, DOI 10.1172/JCI115558; OSEI K, 1986, DIABETOLOGIA, V29, P100, DOI 10.1007/BF00456118; OWEN OE, 1969, J CLIN INVEST, V48, P574, DOI 10.1172/JCI106016; PAGLIASSOTTI MJ, 1991, DIABETES, V40, P1659, DOI 10.2337/diabetes.40.12.1659; PETERS AL, 1991, ANN INTERN MED, V115, P45, DOI 10.7326/0003-4819-115-1-45; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; PUHAKAINEN I, 1991, DIABETES, V40, P1319, DOI 10.2337/diabetes.40.10.1319; RADZIUK J, 1978, METABOLISM, V27, P657, DOI 10.1016/0026-0495(78)90003-3; RADZIUK J, 1989, AM J PHYSIOL, V257, pE145, DOI 10.1152/ajpendo.1989.257.2.E145; RANDLE PJ, 1963, LANCET, V1, P785; ROTHMAN DL, 1991, SCIENCE, V254, P573, DOI 10.1126/science.1948033; RUDENSKI AS, 1991, METABOLISM, V40, P908, DOI 10.1016/0026-0495(91)90065-5; SACCA L, 1978, J CLIN ENDOCR METAB, V47, P1160, DOI 10.1210/jcem-47-5-1160; SERVICE FJ, 1983, DIABETOLOGIA, V25, P316, DOI 10.1007/BF00253193; SHAPIRO ET, 1989, J CLIN ENDOCR METAB, V69, P571, DOI 10.1210/jcem-69-3-571; WELLE S, 1990, INT J OBESITY, V14, P701; WILLIAMSON JR, 1966, P NATL ACAD SCI USA, V56, P247, DOI 10.1073/pnas.56.1.247; WRIGHT KS, 1988, DIABETES, V37, P436, DOI 10.2337/diabetes.37.4.436; YOUN JH, 1990, AM J PHYSIOL, V258, pE899, DOI 10.1152/ajpendo.1990.258.6.E899	65	227	231	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					707	713		10.1056/NEJM199209033271007	http://dx.doi.org/10.1056/NEJM199209033271007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1495524				2022-12-28	WOS:A1992JL23500007
J	GUPTA, GC; KONRAD, TR				GUPTA, GC; KONRAD, TR			ALLIED HEALTH-EDUCATION IN RURAL HEALTH PROFESSIONAL SHORTAGE AREAS OF THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASSISTANTS				GUPTA, GC (corresponding author), AMER MED ASSOC,DEPT INFORMAT ANAL & PUBLICAT,515 N STATE ST,CHICAGO,IL 60610, USA.		Konrad, Thomas R./AAT-9276-2020	Konrad, Thomas R/0000-0002-5269-0440	AHRQ HHS [R01-HS-06544-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BLADWIN F, 1991, J APPALACHIAN REG CO, V24, P12; BURROWS WR, 1989, ALLIED HLTH ED DIREC, P259; COCOWITCH V, 1991, BIBLIO LISTING RURAL; CORDES SM, 1989, REV ALLIED HLTH ED, V5; FOWKES VK, 1983, J MED EDUC, V58, P194; GOLDBERG H, 1984, MED CARE, V22, P760, DOI 10.1097/00005650-198408000-00008; GORDON IT, 1991, 119TH ANN M AM PUBL; GORDON MS, 1971, J AMER MED ASSOC, V218, P1192; GUPTA GC, 1992, ALLIED HLTH ED DIREC, P275; HAFFERTY FW, 1986, HEALTH SERV RES, V21, P107; HEWITT M, 1992, HLTH RURAL N AM GEOG, P25; 1989, 789 US DEP HLTH HUM; 1987, WORLDWIDE GEOGRAPHIC; 1989, ALLIED HLTH SERVICES, P3; 1970, HIGHER ED NATIONS HL; IN PRESS RURAL HLTH; 1991, FED REGISTER, V56, P41363; 1992, INFORMATION STATEMEN, P1; 1988, RURAL HLTH CARE CHAL, P47; 1990, OTAH434 OFF TECHN AS, P5	20	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1127	1130		10.1001/jama.268.9.1127	http://dx.doi.org/10.1001/jama.268.9.1127			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK681	1501336				2022-12-28	WOS:A1992JK68100011
J	MARSTON, RQ				MARSTON, RQ			THE ROBERT-WOOD-JOHNSON-FOUNDATION COMMISSION ON MEDICAL-EDUCATION - THE SCIENCES OF MEDICAL-PRACTICE, SUMMARY REPORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											MARSTON, RQ (corresponding author), ROBERT WOOD JOHNSON FDN,COLL RD,POB 2316,PRINCETON,NJ 08543, USA.							CANTOR JC, 1991, JAMA-J AM MED ASSOC, V265, P1002, DOI 10.1001/jama.265.8.1002; MARSTON RQ, 1992, MED ED TRANSITION	2	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1144	1145						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK681	1501341				2022-12-28	WOS:A1992JK68100016
J	GARDNER, JM; NAKATSU, Y; GONDO, Y; LEE, S; LYON, MF; KING, RA; BRILLIANT, MH				GARDNER, JM; NAKATSU, Y; GONDO, Y; LEE, S; LYON, MF; KING, RA; BRILLIANT, MH			THE MOUSE PINK-EYED DILUTION GENE - ASSOCIATION WITH HUMAN PRADER-WILLI AND ANGELMAN SYNDROMES	SCIENCE			English	Article							PARENTAL ORIGIN; CDNA CLONES; P-LOCUS; HYPOPIGMENTATION; IDENTIFICATION; DELETION; MUTANTS; ABNORMALITIES; CHROMOSOME-7; EXPRESSION	Complementary DNA clones from the pink-eyed dilution (p) locus of mouse chromosome 7 were isolated from murine melanoma and melanocyte libraries. The transcript from this gene is missing or altered in six independent mutant alleles of the p locus, suggesting that disruption of this gene results in the hypopigmentation phenotype that defines mutant p alleles. Characterization of the human homolog revealed that it is localized to human chromosome 15 at q11.2-q12, a region associated with Prader-Willi and Angelman syndromes, suggesting that altered expression of this gene may be responsible for the hypopigmentation phenotype exhibited by certain individuals with these disorders.	FOX CHASE CANC INST,INST CANC RES,PHILADELPHIA,PA 19111; MRC,RADIOBIOL UNIT,DIDCOT 0X11 0RD,OXON,ENGLAND; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455	Fox Chase Cancer Center; University of Minnesota System; University of Minnesota Twin Cities			Gondo, Yoichi/A-5375-2016	Gondo, Yoichi/0000-0003-2184-6489; Nakatsu, Yoshimichi/0000-0001-7408-7071	NCI NIH HHS [CA06927] Funding Source: Medline; NIGMS NIH HHS [GM43840, GM22167] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM022167, R01GM043840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APKARIAN P, 1989, DOC OPHTHALMOL, V71, P355, DOI 10.1007/BF00152762; BRAY GA, 1983, MEDICINE, V62, P59, DOI 10.1097/00005792-198303000-00001; BRILLIANT MH, 1992, MAMM GENOME, V3, P187, DOI 10.1007/BF00355717; BRILLIANT MH, 1991, SCIENCE, V252, P566, DOI 10.1126/science.1673574; BRILLIANT MH, UNPUB; BUTLER MG, 1989, AM J HUM GENET, V45, P140; CHAILLET JR, 1991, GENOMICS, V11, P773, DOI 10.1016/0888-7543(91)90090-2; CREEL DJ, 1986, NEW ENGL J MED, V314, P1606, DOI 10.1056/NEJM198606193142503; DONLON TA, 1986, P NATL ACAD SCI USA, V83, P4408, DOI 10.1073/pnas.83.12.4408; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FRYBURG JS, 1991, AM J MED GENET, V38, P58, DOI 10.1002/ajmg.1320380114; GONDO Y, UNPUB; Green MC., 1989, GENETIC VARIANTS STR, P12; HAMABE J, 1991, AM J MED GENET, V41, P54, DOI 10.1002/ajmg.1320410116; HEARING VJ, 1973, J ULTRA MOL STRUCT R, V43, P88, DOI 10.1016/S0022-5320(73)90072-5; HITTNER HM, 1982, AM J OPHTHALMOL, V94, P328, DOI 10.1016/0002-9394(82)90358-0; HUNT DM, 1971, J EMBRYOL EXP MORPH, V26, P111; JOHNSON DR, 1975, J REPROD FERTIL, V42, P51, DOI 10.1530/jrf.0.0420051; KNOLL JHM, 1990, AM J HUM GENET, V47, P149; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LARUE L, 1990, SOMAT CELL MOLEC GEN, V16, P361, DOI 10.1007/BF01232464; LYON MF, IN PRESS P NATL ACAD; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MARKERT CL, 1956, GENETICS, V41, P429; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; MELVOLD RW, 1974, GENET RES, V23, P319, DOI 10.1017/S0016672300014956; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NAKATSU Y, 1992, MAMM GENOME, V2, P69, DOI 10.1007/BF00570442; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; NICHOLLS RD, 1989, AM J MED GENET, V33, P66, DOI 10.1002/ajmg.1320330109; NICHOLLS RD, 1989, MOUSE NEWS LETT, V84, P87; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHILLIPS RJS, 1977, MOUSE NEWS LETT, V57, P18; PHILLIPS RJS, 1977, MOUSE NEWS LETT, V56, P38; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; ROBINSON WP, 1991, AM J HUM GENET, V49, P1219; RUSSELL ES, 1949, GENETICS, V34, P146; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVERS WK, 1979, COAT COLORS MICE, P90; STEPHENSON DA, 1985, J EMBRYOL EXP MORPH, V87, P65; TANTRAVAHI U, 1989, AM J MED GENET, V33, P78, DOI 10.1002/ajmg.1320330110; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WAGSTAFF J, 1991, GENOMICS, V11, P1071, DOI 10.1016/0888-7543(91)90034-C; WALLIS CE, 1989, J MED GENET, V26, P337, DOI 10.1136/jmg.26.5.337; WIESNER GL, 1987, AM J HUM GENET, V40, P431; WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308; WOLFE HG, 1963, 11TH P INT C GEN, P251	50	198	200	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1121	1124		10.1126/science.257.5073.1121	http://dx.doi.org/10.1126/science.257.5073.1121			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509264				2022-12-28	WOS:A1992JJ88400034
J	HARRIS, B; OTHMAN, S; DAVIES, JA; WEPPNER, GJ; RICHARDS, CJ; NEWCOMBE, RG; LAZARUS, JH; PARKES, AB; HALL, R; PHILLIPS, DIW				HARRIS, B; OTHMAN, S; DAVIES, JA; WEPPNER, GJ; RICHARDS, CJ; NEWCOMBE, RG; LAZARUS, JH; PARKES, AB; HALL, R; PHILLIPS, DIW			ASSOCIATION BETWEEN POSTPARTUM THYROID-DYSFUNCTION AND THYROID ANTIBODIES AND DEPRESSION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ORGANIC AFFECTIVE-DISORDER; PSYCHIATRIC-DISORDER; POSTNATAL DEPRESSION; IMMUNE-SYSTEM; LIFE EVENTS; THYROTOXICOSIS; HYPOTHYROIDISM; CHILDBIRTH; PREVALENCE; DISEASE	Objective-To define the relation between mood and autoimmune thyroid dysfunction during the eight months after delivery. Design-Double blind comparison of the psychiatric status of women positive and negative for thyroid antibodies. Clinical examination and blood sampling for free triiodothyronine and thyroxine, thyroid stimulating hormone, and thyroid antibody concentrations at four weekly intervals. Psychiatric assessment at six, eight, 12, 20, and 28 weeks post partum. Setting-Outpatient department of district hospital. Patients-145 antibody positive women and 229 antibody negative women delivering between August 1987 and December 1989. Main outcome measures-Thyroid status. Number of cases of mental ill health by the general health questionnaire, research diagnostic criteria, Hamilton 17 item depression scale, hospital anxiety and depression scale, and Edinburgh postnatal depression scale. Results-Six weeks after delivery the general health questionnaire showed 62 (43%) antibody positive women and 65 (28%) antibody negative women had mental ill health (chi-2=8.18, p<0.005). Follow up of 110 antibody positive and 132 antibody negative women showed significantly greater depression by research diagnostic criteria in antibody positive women (47%) than antibody negative women (32%) regardless of thyroid dysfunction. Antibody positive women showed higher mean scores for depression on the Hamilton (6-01 v 3.89, p=0.0002), Edinburgh (7.45 v 5.92, p=0.031), and hospital depression scales (4.95 v 3.79, p=0.003). Conclusion-Depressive symptoms are associated with positive thyroid antibody status in the postpartum period.	UNIV WALES COLL MED, DEPT MED, CARDIFF CF4 4XN, S GLAM, WALES; UNIV WALES COLL MED, DEPT MED COMP & STAT, CARDIFF CF4 4XN, S GLAM, WALES; CAERPHILLY & DIST MINERS HOSP, DEPT OBSTET & GYNAECOL, CAERPHILLY, M GLAM, WALES	Cardiff University; Cardiff University	HARRIS, B (corresponding author), UNIV WALES COLL MED, DEPT PSYCHOL MED, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES.		Newcombe, Robert G/B-4897-2009; Lazarus, John H/H-5108-2017	Lazarus, John H/0000-0001-8852-704X				AMINO N, 1976, J CLIN ENDOCR METAB, V42, P296, DOI 10.1210/jcem-42-2-296; AMINO N, 1982, NEW ENGL J MED, V306, P849, DOI 10.1056/NEJM198204083061405; AMINO N, 1983, AUTOIMMUNE ENDOCRINE, P247; COOPER PJ, 1988, BRIT J PSYCHIAT, V152, P799, DOI 10.1192/bjp.152.6.799; COX JL, 1982, BRIT J PSYCHIAT, V140, P111, DOI 10.1192/bjp.140.2.111; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; DANTZER R, 1989, LIFE SCI, V44, P1995, DOI 10.1016/0024-3205(89)90345-7; FOLKS DG, 1984, PSYCHOSOMATICS, V25, P243, DOI 10.1016/S0033-3182(84)73070-2; FUNG HYM, 1988, BRIT MED J, V296, P241, DOI 10.1136/bmj.296.6617.241; Goldberg D.P., 1972, MAUDSLEY MONOGRAPH, V21; GOLDMAN JM, 1986, ARCH INTERN MED, V146, P1296, DOI 10.1001/archinte.146.7.1296; GROVES CJ, 1990, J CLIN LAB IMMUNOL, V32, P147; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; HARRIS B, 1989, J AFFECT DISORDERS, V17, P243, DOI 10.1016/0165-0327(89)90006-2; HARRIS B, 1989, BRIT J PSYCHIAT, V154, P660, DOI 10.1192/bjp.154.5.660; HAYSLIP CC, 1988, AM J OBSTET GYNECOL, V159, P203, DOI 10.1016/0002-9378(88)90522-4; JANSSON R, 1984, J CLIN ENDOCR METAB, V58, P681, DOI 10.1210/jcem-58-4-681; JANSSON R, 1987, ACTA ENDOCRINOL-COP, V116, P321, DOI 10.1530/acta.0.1160321; JOHN R, 1984, CLIN CHEM, V30, P1396; KATHOL RG, 1986, PSYCHOSOMATICS, V27, P501, DOI 10.1016/S0033-3182(86)72656-X; KUMAR R, 1984, BRIT J PSYCHIAT, V144, P35, DOI 10.1192/bjp.144.1.35; LAZARUS JH, 1990, LANCET, V336, P315, DOI 10.1016/0140-6736(90)91853-3; LIPOWSKI ZJ, 1980, AM J PSYCHIAT, V137, P674; MACKENZIE TB, 1983, AM J PSYCHIAT, V140, P342; NEMEROFF CB, 1985, AM J PSYCHIAT, V142, P840; NOTT PN, 1982, PSYCHOL MED, V12, P557, DOI 10.1017/S0033291700055653; PAYKEL ES, 1980, BRIT J PSYCHIAT, V136, P339, DOI 10.1192/bjp.136.4.339; PAYKEL ES, 1971, ARCH GEN PSYCHIAT, V25, P340, DOI 10.1001/archpsyc.1971.01750160052010; PITT B, 1991, HOSPITAL UPDATE, V17, P133; PRENTICE LM, 1990, ACTA ENDOCRINOL-COP, V123, P493, DOI 10.1530/acta.0.1230493; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; STEIN M, 1991, ARCH GEN PSYCHIAT, V48, P171; STEWART DE, 1988, AM J PSYCHIAT, V145, P1579; THOMAS FB, 1970, ANN INTERN MED, V72, P679, DOI 10.7326/0003-4819-72-5-679; VANUITERT RL, 1979, AM J PSYCHIAT, V136, P1208; WATSON JP, 1984, BRIT J PSYCHIAT, V144, P453, DOI 10.1192/bjp.144.5.453; YOUNG LD, 1984, PSYCHOSOMATICS, V25, P490, DOI 10.1016/S0033-3182(84)73023-4; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1987, DIAGNOSTIC STATISTIC	39	181	189	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 18	1992	305	6846					152	156		10.1136/bmj.305.6846.152	http://dx.doi.org/10.1136/bmj.305.6846.152			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515829	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JF06300021
J	BUNTINX, F; KNOTTNERUS, JA; CREBOLDER, HFJM; ESSED, GGM; SCHOUTEN, H				BUNTINX, F; KNOTTNERUS, JA; CREBOLDER, HFJM; ESSED, GGM; SCHOUTEN, H			RELATION BETWEEN QUALITY OF CERVICAL SMEARS AND PROBABILITY OF ABNORMAL RESULTS	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIMBURG,DEPT GYNAECOL,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT MED STAT,6200 MD MAASTRICHT,NETHERLANDS	Hasselt University; Hasselt University	BUNTINX, F (corresponding author), UNIV LIMBURG,DEPT GEN PRACTICE,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Buntinx, Frank/E-4950-2011; Knottnerus, Andre/F-4866-2013; Knottnerus, Johannes A/A-3829-2009					BUNTINX F, 1991, ACTA CYTOL, V35, P64; MITCHELL H, 1991, LANCET, V337, P265, DOI 10.1016/0140-6736(91)90870-U; STEINER C, 1989, ACTA CYTOL, V33, P471; VOOIJS GP, 1988, NEW FRONTIERS CYTOLO, P412; ZUNA RE, 1984, POSTGRAD MED, V76, P36, DOI 10.1080/00325481.1984.11698775	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1224	1224		10.1136/bmj.304.6836.1224	http://dx.doi.org/10.1136/bmj.304.6836.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515793	Bronze, Green Published			2022-12-28	WOS:A1992HT96400024
J	PAPAVASSILIOU, AG; TREIER, M; CHAVRIER, C; BOHMANN, D				PAPAVASSILIOU, AG; TREIER, M; CHAVRIER, C; BOHMANN, D			TARGETED DEGRADATION OF C-FOS, BUT NOT V-FOS, BY A PHOSPHORYLATION-DEPENDENT SIGNAL ON C-JUN	SCIENCE			English	Article							DNA-BINDING DOMAIN; ACTIVATION; TRANSCRIPTION; ONCOGENES; CELLS	The proto-oncogene products c-Fos and c-Jun heterodimerize through their leucine zippers to form the AP-1 transcription factor. The transcriptional activity of the heterodimer is regulated by signal-dependent phosphorylation and dephosphorylation events. The stability of c-Fos was found to also be controlled by intracellular signal transduction. In transient expression and in vitro degradation experiments, the stability of c-Fos was decreased when the protein was dimerized with phosphorylated c-Jun. c-Jun protein isolated from phorbol ester-induced cells did not target c-Fos for degradation, which suggests that c-Fos is transiently stabilized after stimulation of cell growth. v-Fos protein, the retroviral counterpart of c-Fos, was not susceptible to degradation targeted by c-Jun.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAM, POSTFACH 102209, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Karamouzis, Michalis/AAD-2860-2020; Treier, Mathias/AAD-6388-2021					BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOHMANN D, UNPUB; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CURRAN T, 1987, ONCOGENE, V2, P79; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; PAPAVASSILIOU AG, UNPUB; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0	25	104	104	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1992	258	5090					1941	1944		10.1126/science.1470918	http://dx.doi.org/10.1126/science.1470918			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470918				2022-12-28	WOS:A1992KD08800033
J	CHEN, J; KANAI, Y; COWAN, NJ; HIROKAWA, N				CHEN, J; KANAI, Y; COWAN, NJ; HIROKAWA, N			PROJECTION DOMAINS OF MAP2 AND TAU DETERMINE SPACINGS BETWEEN MICROTUBULES IN DENDRITES AND AXONS	NATURE			English	Article							POLARITY ORIENTATION; MOLECULAR-STRUCTURE; BINDING DOMAIN; PROTEIN TAU; EXPRESSION; BRAIN; CDNA; PHOSPHORYLATION; ORGANIZATION; SEQUENCES	NEURONS develop a highly polarized morphology consisting of dendrites and a long axon. Both axons and dendrites contain microtubules and microtubule-associated proteins (MAPs) with characteristic structures1. Among MAPs, MAP2 is specifically expressed in dendrites2 whereas MAP2C and tau are abundant in the axon2-5. But the influence of MAP2, MAP2C and tau on the organization of microtubule domains in dendrites versus axons is unknown. Both MAP2 and tau induce microtubule bundle formation in fibroblasts after transfection of complementary DNAs6,7 and a long process resembling an axon is extended in Sf9 cells infected with recombinant baculovirus expressing tau8,9. We have now expressed MAP2 and MAP2C in Sf9 cells in order to compare their morphology and the arrangement of their microtubules to that found in Sf9 cells expressing tau. We report here that the spacing between microtubules depends on the MAP expressed: in cells expressing MAP2, the distance is similar to that found in dendrites, whereas the spacing between microtubules in cells expressing MAP2C or tau is similar to that found in axons.	UNIV TOKYO,SCH MED,DEPT ANAT & CELL BIOL,BUNKYO KU,TOKYO 113,JAPAN; NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	University of Tokyo; New York University			Kanai, Yoshimitsu/W-3486-2019	Kanai, Yoshimitsu/0000-0002-0375-6853				AIZAWA H, 1988, J BIOL CHEM, V263, P7703; BAAS PW, 1991, J CELL BIOL, V115, P1333, DOI 10.1083/jcb.115.5.1333; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; HEIDEMANN SR, 1981, J CELL BIOL, V91, P661, DOI 10.1083/jcb.91.3.661; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1988, J NEUROSCI, V8, P285; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; NUNEZ J, 1988, TRENDS NEUROSCI, V11, P477, DOI 10.1016/0166-2236(88)90004-5; PAPANDRIKOPOULOU A, 1989, NATURE, V340, P650, DOI 10.1038/340650a0; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; TAKEUCHI M, 1992, J NEUROCHEM, V58, P1510, DOI 10.1111/j.1471-4159.1992.tb11372.x; UMEYAMA T, IN PRESS J CELL BIOL; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; WEBB NR, 1990, MAXBAC BACULOVIRUS E; WILLE H, 1992, J STRUCT BIOL, V108, P49, DOI 10.1016/1047-8477(92)90006-V	28	477	495	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					674	676		10.1038/360674a0	http://dx.doi.org/10.1038/360674a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465130				2022-12-28	WOS:A1992KD08200056
J	LAWN, RM; WADE, DP; HAMMER, RE; CHIESA, G; VERSTUYFT, JG; RUBIN, EM				LAWN, RM; WADE, DP; HAMMER, RE; CHIESA, G; VERSTUYFT, JG; RUBIN, EM			ATHEROGENESIS IN TRANSGENIC MICE EXPRESSING HUMAN APOLIPOPROTEIN(A)	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; ATHEROSCLEROSIS SUSCEPTIBILITY; PLASMINOGEN ACTIVATION; HUMAN AORTA; QUANTIFICATION; LESIONS; FIBRIN; ACCUMULATION; MACROPHAGES; INHIBITION	ELEVATED plasma levels of the lipoprotein Lp(a) are associated with increased risk for atherosclerosis and its manifestations, myocardial infarction, stroke and restenosis (for reviews, see refs 1-3). Lp(a) differs from low-density lipoprotein by the addition of the glycoprotein apolipoprotein(a), a homologue of plasminogen that contains many tandemly repeated units which resemble the fourth kringle domain of plasminogen, and single homologues of its kringle-5 and protease domain4. As plasma Lp(a) concentration is strongly influenced by heritable factors and is refractory to most drug and dietary manipulation, the effects of modulating it are difficult to mimic experimentally. In addition, the absence of apolipoprotein(a) from virtually all species other than primates precludes the use of convenient animal models. Here we show that transgenic mice expressing human apolipoprotein(a) are more susceptible than control mice to the development of lipid-staining lesions in the aorta, and that apolipoprotein(a) co-localizes with lipid deposition in the artery walls.	UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235; LAWRENCE BERKELEY LAB,DIV CELL & MOLEC BIOL,BERKELEY,CA 94720; UNIV TEXAS,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LAWN, RM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CARDIOVASC MED,STANFORD,CA 94305, USA.		Chiesa, Giulia/G-8987-2012	Chiesa, Giulia/0000-0001-5553-1210; Hammer, Robert E./0000-0001-5487-7551				BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; CHIESA G, IN PRESS J BIOL CHEM; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; EDELBERG JM, 1990, THROMB RES, V57, P155, DOI 10.1016/0049-3848(90)90203-O; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MCCONATHY WJ, 1990, FASEB J, V4, pA1019; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MEHRABIAN M, 1991, ARTERIOSCLER THROMB, V11, P947, DOI 10.1161/01.ATV.11.4.947; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; NIENDORF A, 1990, VIRCHOWS ARCH A, V417, P105, DOI 10.1007/BF02190527; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PEPIN JM, 1991, J LIPID RES, V32, P317; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; ROUY D, 1991, ARTERIOSCLER THROMB, V11, P629, DOI 10.1161/01.ATV.11.3.629; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SALONEN EM, 1989, EMBO J, V8, P4035, DOI 10.1002/j.1460-2075.1989.tb08586.x; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209; SMITH EB, 1990, ATHEROSCLEROSIS, V84, P173, DOI 10.1016/0021-9150(90)90088-Z; STEWARTPHILLIPS JL, 1991, ATHEROSCLEROSIS, V90, P211, DOI 10.1016/0021-9150(91)90117-L; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZIONCHECK TF, 1991, J CLIN INVEST, V87, P767, DOI 10.1172/JCI115079	30	264	273	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					670	672		10.1038/360670a0	http://dx.doi.org/10.1038/360670a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465128				2022-12-28	WOS:A1992KD08200054
J	WORKMAN, JL; KINGSTON, RE				WORKMAN, JL; KINGSTON, RE			NUCLEOSOME CORE DISPLACEMENT INVITRO VIA A METASTABLE TRANSCRIPTION FACTOR NUCLEOSOME COMPLEX	SCIENCE			English	Article							POLYMERASE-II TRANSCRIPTION; XENOPUS-LAEVIS OOCYTES; TUMOR VIRUS PROMOTER; SACCHAROMYCES-CEREVISIAE; POSITIONED NUCLEOSOMES; HYPERSENSITIVE SITES; DNA-REPLICATION; PHO5 PROMOTER; GAL4; ACTIVATION	In order to function, transcription factors must compete for DNA binding with structural components of chromatin, including nucleosomes. Mechanisms that could be used in this competition have been characterized with the use of the DNA binding domain of the yeast GAL4 protein. The binding of GAL4 to a nucleosome core resulted in a ternary complex containing GAL4, the core histone proteins, and DNA. This ternary complex was unstable; upon the addition of nonspecific competitor DNA, it dissociated into either the original nucleosome core particle or GAL4 bound to naked DNA. Nucleosome core destabilization by GAL4 did not require a transcriptional activation domain. These data demonstrate the displacement of nucleosome cores as a direct result of binding by a regulatory factor. Similar mechanisms might affect the establishment of factor occupancy of promoters and enhancers in vivo.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1989, TRENDS GENET, V5, P268, DOI 10.1016/0168-9525(89)90100-5; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chen H. M., UNPUB; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; JUAN LJ, UNPUB; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAPP M, 1990, J BIOL CHEM, V265, P9357; SCHMID A, IN PRESS CELL; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; WOLFFE AP, 1991, J CELL SCI, V99, P201; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	36	171	174	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1780	1784		10.1126/science.1465613	http://dx.doi.org/10.1126/science.1465613			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465613				2022-12-28	WOS:A1992KB96400035
J	ELREFAEY, H; HINSHAW, K; HENSHAW, R; SMITH, N; TEMPLETON, A				ELREFAEY, H; HINSHAW, K; HENSHAW, R; SMITH, N; TEMPLETON, A			MEDICAL-MANAGEMENT OF MISSED ABORTION AND ANEMBRYONIC PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article									ABERDEEN MATERN HOSP,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen				Hinshaw, Kim/0000-0003-0468-4326				NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; 1990, BRIT J OBSTET GYNAEC, V97, P480; 1990, FERTIL STERIL, V56, P132; 1989, HUM REPROD, V4, P718	4	63	64	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1399	1399		10.1136/bmj.305.6866.1399	http://dx.doi.org/10.1136/bmj.305.6866.1399			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486304	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992KB85600022
J	THORNICROFT, G; STRATHDEE, G				THORNICROFT, G; STRATHDEE, G			HOW TO JOB SHARE A CONSULTANT POST	BRITISH MEDICAL JOURNAL			English	Article								Job sharing offers advantages to both employer and employee but it is still uncommon in medicine. Based on the experiences of two psychiatrists sharing a consultant post this article describes some of the problems in obtaining a job share. The most difficult part can be getting an interview, and once a post has been obtained the terms and conditions of service may have to be modified to suit job sharing. Getting on well with your job sharing partner and good communication will not only help overcome the obstacles but ensure that the sharing is successful.			THORNICROFT, G (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,LONDON SE5 8AZ,ENGLAND.		Thornicroft, Graham/B-4027-2010	Thornicroft, Graham/0000-0003-0662-0879				ALLEN I, 1988, ANY ROOM TOP STUDY D; BOLTONMAGGS P, 1988, BR J HOSP MED, V5, P413; Boyle Adrienne, 1980, JOB SHARING STUDY CO; LEMPP H, 1987, SENIOR NURSE, V7, P24; MEAGER N, 1989, 174 I MANP STUD REP; Walton Pam., 1990, JOB SHARING PRACTICA; 1989, EMPLOYMENT TRENDS, V6, P441; 1981, JOB SHARING IMPROVIN; 1987, JOB SHARING HLTH SER	9	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1413	1415		10.1136/bmj.305.6866.1413	http://dx.doi.org/10.1136/bmj.305.6866.1413			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486308	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KB85600027
J	BROWN, MM; HUMPHREY, PRD				BROWN, MM; HUMPHREY, PRD			CAROTID ENDARTERECTOMY - RECOMMENDATIONS FOR MANAGEMENT OF TRANSIENT ISCHEMIC ATTACK AND ISCHEMIC STROKE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANGIOGRAPHY		WALTON HOSP, DEPT NEUROL, LIVERPOOL L9 1AE, MERSEYSIDE, ENGLAND	Walton Centre	BROWN, MM (corresponding author), ST GEORGE HOSP, SCH MED, DIV CLIN NEUROSCI, LONDON SW17 0RE, ENGLAND.		Brown, Martin M/B-3288-2009	Brown, Martin M/0000-0002-3273-1356				BORGSTEIN RL, 1991, CLIN RADIOL, V44, P402, DOI 10.1016/S0009-9260(05)80659-2; CAPLAN LR, 1991, AM J NEURORADIOL, V12, P593; DENNIS M, 1991, BRIT MED J, V303, P636, DOI 10.1136/bmj.303.6803.636; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HUMPHREY P, 1990, J NEUROL NEUROSUR PS, V53, P966, DOI 10.1136/jnnp.53.11.966; KRETSCHMER G, 1990, ANN SURG, V211, P317, DOI 10.1097/00000658-199003000-00002; MURIE J, 1991, HOSPTIAL UPDATE  JUL, P557; MURIE JA, 1986, BRIT J SURG, V73, P867, DOI 10.1002/bjs.1800731103; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; 1988, BMJ, V296, P320	12	39	39	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 31	1992	305	6861					1071	1074		10.1136/bmj.305.6861.1071	http://dx.doi.org/10.1136/bmj.305.6861.1071			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467689	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JW70100022
J	BROWN, CG; MARTIN, DR; PEPE, PE; STUEVEN, H; CUMMINS, RO; GONZALEZ, E; JASTREMSKI, M				BROWN, CG; MARTIN, DR; PEPE, PE; STUEVEN, H; CUMMINS, RO; GONZALEZ, E; JASTREMSKI, M			A COMPARISON OF STANDARD-DOSE AND HIGH-DOSE EPINEPHRINE IN CARDIAC-ARREST OUTSIDE THE HOSPITAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL BLOOD-FLOW; CARDIOPULMONARY-RESUSCITATION; SWINE MODEL; METHOXAMINE; PRESSURE; BALANCE; DEMAND; DOGS; CPR	Background. Experimental and uncontrolled clinical evidence suggests that intravenous epinephrine in doses higher than currently recommended may improve outcome after cardiac arrest. We conducted a prospective, multicenter study comparing standard-dose epinephrine with high-dose epinephrine in the management of cardiac arrest outside the hospital. Methods. Adult patients were enrolled in the study if they remained in ventricular fibrillation, or if they had asystole or electromechanical dissociation, at the time the first drug was to be administered to treat the cardiac arrest. Patients were randomly assigned to receive either 0.02 mg of epinephrine per kilogram of body weight (standard-dose group, 632 patients) or 0.2 mg per kilogram (high-dose group, 648 patients), both given intravenously. Results. In the standard-dose group 190 patients (30 percent) had a return of spontaneous circulation, as compared with 217 patients (33 percent) in the high-dose group; 136 patients (22 percent) in the standard-dose group and 145 patients (22 percent) in the high-dose group survived to be admitted to the hospital. Twenty-six patients (4 percent) in the standard-dose group and 31 (5 percent) in the high-dose group survived to discharge from the hospital. Ninety-two percent of the patients discharged in the standard-dose group and 94 percent in the high-dose group were conscious at the time of hospital discharge. None of the differences in outcome between the groups were statistically significant. Conclusions. In this study, we were unable to demonstrate any difference in the overall rate of return of spontaneous circulation, survival to hospital admission, survival to hospital discharge, or neurologic outcome between patients treated with a standard dose of epinephrine and those treated with a high dose.	CITY OF HOUSTON EMERGENCY MED SERV,HOUSTON,TX; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT SURG,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; MED COLL WISCONSIN,DEPT EMERGENCY MED,MILWAUKEE,WI 53226; UNIV WASHINGTON,EMERGENCY MED SERV,SEATTLE,WA 98195; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,EMERGENCY MED SERV SECT,RICHMOND,VA 23298; SUNY HLTH SCI CTR,PROGRAM MULTIDISCIPLINARY CRIT CARE,SYRACUSE,NY	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Medical College of Wisconsin; University of Washington; University of Washington Seattle; Virginia Commonwealth University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	BROWN, CG (corresponding author), OHIO STATE UNIV,DEPT EMERGENCY MED,108 MEANS HALL,1654 UPHAM DR,COLUMBUS,OH 43210, USA.							BARTON CW, 1990, ANN EMERG MED, V19, P490; BROWN CG, 1988, ANN EMERG MED, V17, P302, DOI 10.1016/S0196-0644(88)80767-4; BROWN CG, 1987, AM J EMERG MED, V5, P362, DOI 10.1016/0735-6757(87)90382-2; BROWN CG, 1987, CRIT CARE MED, V15, P682, DOI 10.1097/00003246-198707000-00011; BROWN CG, 1986, RESUSCITATION, V14, P171, DOI 10.1016/0300-9572(86)90122-X; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; DITCHEY RV, 1988, CIRCULATION, V78, P382, DOI 10.1161/01.CIR.78.2.382; EMERMAN CL, 1990, AM J EMERG MED, V8, P190, DOI 10.1016/0735-6757(90)90319-U; GOETTING MG, 1989, CRIT CARE MED, V17, P1258, DOI 10.1097/00003246-198912000-00004; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; KOSCOVE EM, 1988, JAMA-J AM MED ASSOC, V259, P3031, DOI 10.1001/jama.259.20.3031; KOSNIK JW, 1985, ANN EMERG MED, V14, P204, DOI 10.1016/S0196-0644(85)80440-6; KULLER L, 1972, ARCH INTERN MED, V129, P714, DOI 10.1001/archinte.129.5.714; LINDNER KH, 1991, ACTA ANAESTH SCAND, V35, P253, DOI 10.1111/j.1399-6576.1991.tb03283.x; LIVESAY JJ, 1978, J THORAC CARDIOV SUR, V76, P244; NETER J, 1985, APPLIED LINEAR STATI; PARADIS NA, 1991, JAMA-J AM MED ASSOC, V265, P1139, DOI 10.1001/jama.265.9.1139; SAFAR P, 1983, AM J EMERG MED, V2, P198; 1986, JAMA-J AM MED ASSOC, V255, P2905; 1986, NEW ENGL J MED, V314, P397	21	312	323	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1992	327	15					1051	1055		10.1056/NEJM199210083271503	http://dx.doi.org/10.1056/NEJM199210083271503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR321	1522841	Green Published			2022-12-28	WOS:A1992JR32100003
J	STIELL, IG; HEBERT, PC; WEITZMAN, BN; WELLS, GA; RAMAN, S; STARK, RM; HIGGINSON, LAJ; AHUJA, J; DICKINSON, GE				STIELL, IG; HEBERT, PC; WEITZMAN, BN; WELLS, GA; RAMAN, S; STARK, RM; HIGGINSON, LAJ; AHUJA, J; DICKINSON, GE			HIGH-DOSE EPINEPHRINE IN ADULT CARDIAC-ARREST	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY PERFUSION-PRESSURE; MYOCARDIAL BLOOD-FLOW; CARDIOPULMONARY-RESUSCITATION; VENTRICULAR-FIBRILLATION; DOGS; STANDARD; THERAPY; BALANCE; DEMAND; SWINE	Background. Recent studies suggest that doses of epinephrine of 0.1 mg per kilogram of body weight or higher may improve myocardial and cerebral blood flow as well as survival in cardiac arrest. Such studies have called into question the traditional dose of epinephrine (0.007 to 0.014 mg per kilogram) recommended for advanced cardiac life support. Methods. We randomly assigned 650 patients who had had cardiac arrest either in or outside the hospital to receive up to five doses of high-dose (7 mg) or standard-dose (1 mg) epinephrine at five-minute intervals according to standard protocols for advanced cardiac life support. Patients who collapsed outside the hospital received no advanced-life-support measures other than defibrillation before reaching the hospital. Results. There was no significant difference between the high-dose group (n = 317) and the standard-dose group (n = 333) in the proportions of patients who survived for one hour (18 percent vs. 23 percent, respectively) or who survived until hospital discharge (3 percent vs. 5 percent). Among the survivors, there was no significant difference in the proportions who remained in the best category of cerebral performance (90 percent vs. 94 percent) and no significant difference in the median Mini-Mental State score (36 vs. 37). The exploration of clinically important subgroups, including those with out-of-hospital arrest (n = 335) and those with in-hospital arrest (n = 315), failed to identify any patients who appeared to benefit from high-dose epinephrine and suggested that some patients may have worse outcomes after high-dose epinephrine. Conclusions. High-dose epinephrine was not found to improve survival or neurologic outcomes in adult victims of cardiac arrest.	UNIV OTTAWA,DIV EMERGENCY MED,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV OTTAWA,DEPT MED,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV OTTAWA,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV OTTAWA,CLIN EPIDEMIOL UNIT,OTTAWA K1N 6N5,ONTARIO,CANADA	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa				Stiell, Ian/0000-0002-2583-6408				BAROLDI G, 1979, AM HEART J, V98, P20, DOI 10.1016/0002-8703(79)90316-8; BROWN CG, 1991, ANN EMERG MED, V20, P104, DOI 10.1016/S0196-0644(05)81136-9; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; BRUNETTE DD, 1990, ANN EMERG MED, V19, P8, DOI 10.1016/S0196-0644(05)82130-4; CALLAHAM M, 1991, JAMA-J AM MED ASSOC, V265, P1117, DOI 10.1001/jama.265.9.1117; CALLAHAN M, 1989, ANN EMERG MED, V18, P1011, DOI 10.1016/S0196-0644(89)80483-4; DEBARD ML, 1981, ANN EMERG MED, V10, P408, DOI 10.1016/S0196-0644(81)80307-1; DITCHEY RV, 1988, CIRCULATION, V78, P382, DOI 10.1161/01.CIR.78.2.382; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; GOETTING MG, 1991, ANN EMERG MED, V20, P22, DOI 10.1016/S0196-0644(05)81112-6; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; HBERT P, 1991, J EMERGENCY MED, V9, P487; HOSMER DW, 1989, APPLIED LOGISTIC REG, V7; JACKSON RE, 1984, ANN EMERG MED, V13, P657, DOI 10.1016/S0196-0644(84)80721-0; KERN KB, 1990, AM HEART J, V120, P324, DOI 10.1016/0002-8703(90)90076-A; KOSCOVE EM, 1988, JAMA-J AM MED ASSOC, V259, P3031, DOI 10.1001/jama.259.20.3031; KOSNIK JW, 1985, ANN EMERG MED, V14, P204, DOI 10.1016/S0196-0644(85)80440-6; LINDNER KH, 1991, ACTA ANAESTH SCAND, V35, P253, DOI 10.1111/j.1399-6576.1991.tb03283.x; LIVESAY JJ, 1978, J THORAC CARDIOV SUR, V76, P244; MAHA RJ, 1990, ANN EMERG MED, V19, P956; MARTIN D, 1990, ANN EMERG MED, V19, P322, DOI 10.1016/S0196-0644(05)82055-4; MCKEEVER WP, 1958, CIRC RES, V6, P612, DOI 10.1161/01.RES.6.5.612; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; MIDEI MG, 1990, J AM COLL CARDIOL, V16, P489, DOI 10.1016/0735-1097(90)90608-R; MONROE RG, 1960, CIRC RES, V8, P260, DOI 10.1161/01.RES.8.1.260; MORADY F, 1988, J AM COLL CARDIOL, V11, P1235, DOI 10.1016/0735-1097(88)90287-2; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; ORNATO JP, 1991, JAMA-J AM MED ASSOC, V265, P1160, DOI 10.1001/jama.265.9.1160; OTTO CW, 1985, AM J EMERG MED, V3, P285, DOI 10.1016/0735-6757(85)90048-8; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; PARADIS NA, 1990, ANN EMERG MED, V19, P1288, DOI 10.1016/S0196-0644(05)82289-9; PARADIS NA, 1991, JAMA-J AM MED ASSOC, V265, P1139, DOI 10.1001/jama.265.9.1139; PEARSON JW, 1965, ANESTH ANAL CURR RES, V44, P746; PEARSON JW, 1963, AM HEART J, V66, P210, DOI 10.1016/0002-8703(63)90036-X; REDDING JS, 1963, ANESTHESIOLOGY, V24, P203, DOI 10.1097/00000542-196303000-00008; SCHLEIEN CL, 1986, CIRCULATION, V73, P809, DOI 10.1161/01.CIR.73.4.809; SHERMAN BW, 1991, ANN EMERG MED, V20, P949; TANG W, 1991, CIRCULATION, V84, P2101, DOI 10.1161/01.CIR.84.5.2101; TEASDALE G, 1974, LANCET, V2, P81; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Zar JH., 1999, BIOSTAT ANAL; 1991, CONTROLLED CLIN TRIA, V12, P525; 1986, JAMA-J AM MED ASSOC, V255, P2905	44	248	255	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1992	327	15					1045	1050		10.1056/NEJM199210083271502	http://dx.doi.org/10.1056/NEJM199210083271502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR321	1522840				2022-12-28	WOS:A1992JR32100002
J	SESSO, R; KLAG, M				SESSO, R; KLAG, M			PLASMAPHERESIS FOR LUPUS NEPHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											SESSO, R (corresponding author), JOHNS HOPKINS HLTH INST,BALTIMORE,MD 21287, USA.		schroeder, Johann O/D-5601-2011; Sesso, Ricardo C C/B-4767-2013	Sesso, Ricardo/0000-0002-1062-0073				CAMPION EW, 1992, NEW ENGL J MED, V326, P1425, DOI 10.1056/NEJM199205213262109	1	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					1029	1029						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1518540				2022-12-28	WOS:A1992JQ22500015
J	ENTHOVEN, AC				ENTHOVEN, AC			MEASURING THE CANDIDATES ON HEALTH-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROMOTE QUALITY; INSURANCE; ECONOMY; 1990S; PLAN				ENTHOVEN, AC (corresponding author), STANFORD UNIV,STANFORD,CA 94305, USA.							ELLWOOD P, IN PRESS HLTH EC; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN A, 1992, WALL STREET J   0124, pA12; 1962, PRESIDENTS COMPREHEN; 1992, B CLINTONS AM HLTH C	6	13	13	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					807	809		10.1056/NEJM199209103271113	http://dx.doi.org/10.1056/NEJM199209103271113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JL661	1501658				2022-12-28	WOS:A1992JL66100013
J	SANDEMAN, DD; SHORE, AC; TOOKE, JE				SANDEMAN, DD; SHORE, AC; TOOKE, JE			RELATION OF SKIN CAPILLARY-PRESSURE IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS TO COMPLICATIONS AND METABOLIC CONTROL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPAIRED AUTO-REGULATION; BLOOD-FLOW; MICROANGIOPATHY; PERMEABILITY; NEPHROPATHY; PREVALENCE; DURATION; RATS	Background. Microvascular disease is a major problem in patients with diabetes mellitus. It has been suggested that diabetic microangiopathy may result from an increase in capillary blood flow and capillary hypertension, but direct evidence of capillary hypertension in such patients is lacking. Methods. We measured capillary pressure at the summit of the capillary loop by direct microcannulation of skin nail-fold capillaries and a dynamic method of pressure measurement in 29 patients with insulin-dependent (Type 1) diabetes and 29 normal subjects matched for age and sex. Among the diabetic patients, 7 had had diabetes for less than one year, 12 had incipient nephropathy (albumin excretion, 20 to 200-mu-g per minute), and 10 had overt nephropathy (albumin excretion, >200-mu-g per minute). In addition, seven patients with no evidence of nephropathy were studied before and after three months of improved glycemic control. Results. The median capillary pressure in the diabetic patients was 20.4 mm Hg (range, 13.6 to 25.3), as compared with 16.7 mm Hg (range, 12.8 to 22.8; P<0.001) in the normal subjects. The values were higher in each subgroup of diabetic patients than in the corresponding group of normal subjects, but the values did not differ among the three subgroups of diabetic patients. In the seven patients who were studied before and after three months of improved glycemic control, the median capillary pressure fell from 20.0 mm Hg (range, 18.5 to 21.7) to 17.8 mm Hg (range, 14.1 to 20.3; P = 0.02). Conclusions. Nail-fold capillary hypertension may develop early in the course of diabetes, before the emergence of microvascular disease, and may be influenced by changes in metabolic control.			SANDEMAN, DD (corresponding author), UNIV EXETER,POSTGRAD MED SCH,BARRACK RD,EXETER EX2 5EQ,ENGLAND.			Shore, Angela/0000-0003-3039-308X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTURA BM, 1979, ADV MICROCIRCULAT, V8, P118; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; Christiansen J S, 1985, Diabet Med, V2, P235; DARTON K, 1991, RAYNAUDS SYNDROME, P69; DITZEL J, 1968, DIABETES, V17, P388, DOI 10.2337/diab.17.6.388; FLAVELL HJ, 1988, CLIN CHEM, V34, P1506; FOLKOW B, 1983, CIBA F SYMP, V100, P56; GATLING W, 1988, DIABETIC MED, V5, P343, DOI 10.1111/j.1464-5491.1988.tb01002.x; GUNDERSEN HJ, 1974, DIABETOLOGIA, V10, P225, DOI 10.1007/BF00423039; HANSSEN KF, 1986, DIABETOLOGIA, V29, P901; HILL MA, 1990, FRONT DIABETES, V9, P118; KALEY G, 1989, AM J PHYSIOL, V256, pH720, DOI 10.1152/ajpheart.1989.256.3.H720; KASTRUP J, 1985, DIABETOLOGIA, V28, P711; KOHNER EM, 1975, DIABETOLOGIA, V11, P27, DOI 10.1007/BF00422814; LANSMAN JB, 1988, NATURE, V331, P481, DOI 10.1038/331481a0; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MCMILLAN DE, 1983, DIABETES, V32, P56, DOI 10.2337/diab.32.2.S56; MOGENSEN CE, 1988, TOPICS RENAL MED, V6, P7; MOGENSEN CE, 1989, DIABETES NUTR METAB, V2, P227; ORCHARD TJ, 1990, DIABETES, V39, P1116, DOI 10.2337/diabetes.39.9.1116; OSTERGREN J, 1982, INT J MICROCIRC, V1, P300; PARVING HH, 1984, DIABETOLOGIA, V27, P547, DOI 10.1007/BF00276965; PARVING HH, 1983, METABOLISM, V32, P943, DOI 10.1016/0026-0495(83)90210-X; RAYMAN G, 1984, INT J MICROCIRC, V3, P285; RIPPE B, 1977, ACTA PHYSIOL SCAND, V101, P72, DOI 10.1111/j.1748-1716.1977.tb05985.x; SANDEMAN DD, 1991, CLIN SCI S24, V80, pP13; SHORE AC, 1990, INT J MICROCIRC CLIN, V9, P136; SINCLAIR SH, 1982, OPHTHALMOLOGY, V89, P748, DOI 10.1016/s0161-6420(82)34720-x; TOOKE JE, 1980, DIABETES, V29, P815, DOI 10.2337/diabetes.29.10.815; TOOKE JE, 1986, CLIN SCI, V70, P119, DOI 10.1042/cs0700119; TOOKE JE, 1986, PROG APPL MICROCIRC, V11, P60; WILLIAMS SA, 1988, CLIN SCI, V74, P507, DOI 10.1042/cs0740507; WILLIAMSON JR, 1977, DIABETES, V26, P65, DOI 10.2337/diab.26.1.65; WILLIAMSON JR, 1985, DIABETES, V34, P703, DOI 10.2337/diabetes.34.7.703; WILLIAMSON JR, 1980, NEW ENGL J MED, V302, P399, DOI 10.1056/NEJM198002143020710; WILLIAMSON JR, 1990, J CLIN INVEST, V85, P1167, DOI 10.1172/JCI114549; YOSHIDA Y, 1989, KIDNEY INT, V35, P654, DOI 10.1038/ki.1989.35; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; ZATZ R, 1986, AM J MED, V80, P443, DOI 10.1016/0002-9343(86)90719-9; ZIEGLER D, 1988, KLIN WOCHENSCHR, V66, P1085, DOI 10.1007/BF01711924	40	162	165	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					760	764		10.1056/NEJM199209103271103	http://dx.doi.org/10.1056/NEJM199209103271103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501652				2022-12-28	WOS:A1992JL66100003
J	SAUER, MV; PAULSON, RJ; LOBO, RA				SAUER, MV; PAULSON, RJ; LOBO, RA			REVERSING THE NATURAL DECLINE IN HUMAN-FERTILITY - AN EXTENDED CLINICAL-TRIAL OF OOCYTE DONATION TO WOMEN OF ADVANCED REPRODUCTIVE AGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INVITRO FERTILIZATION; OVARIAN FAILURE; MATERNAL AGE; PREGNANCY; IMPLANTATION	Objective.-To evaluate the effect of age on pregnancy success rates in functionally agonadal women undergoing oocyte donation. Design.-A prospective study of 100 consecutive patients using oocyte donation for the treatment of infertility. Patients.-Women aged 40 years and above requesting oocyte donation (N=104) were required to undergo medical, reproductive, and psychological screening. Suitable candidates (n=65) were matched with an oocyte donor whose cycle was synchronized with that of the potential recipient, prior to the donor's undertaking ovarian hyperstimulation and transvaginal ultrasound-directed follicle aspiration. Outcomes were compared with those of two groups undergoing therapy at the same time: (1) women below 40 years of age undergoing oocyte donation for premature ovarian failure (n=35) and (2) women 40 years of age and above undergoing standard in vitro fertilization and embryo transfer using their own oocytes (n=57). Main Outcome Measures.-Embryo implantation and pregnancy rates. Setting.-The in vitro fertilization program of the University of Southern California and the California Medical Center, Los Angeles. Results.-Improved outcomes were observed with regard to fertilization rates in vitro, number of embryos transferred, embryo implantation rate, clinical pregnancy rates, and ongoing or successfully completed pregnancy rates when women undergoing oocyte donation regardless of age were compared with women 40 years of age and above using their own oocytes. No age-related decline in fertility was demonstrable when oocyte donation was used, with a mean age of 44.3+/-3.1 years for those successfully conceiving (range, 40 to 52 years). Perinatal outcomes (n=27) were generally uncomplicated, with a mean gestational age at delivery of 38.4+/-2.1 weeks (range, 34 to 42 weeks), although multiple births occurred in 24.1% of cases. Conclusions.-The age-related decline in female fertility may be reversed in couples electing to use donated oocytes from a younger woman, and women of advanced reproductive age may conceive, carry, and give birth to infants with success rates similar to those of their younger counterparts using assisted reproductive methods.	UNIV SO CALIF, DEPT OBSTET & GYNECOL, DIV REPROD ENDOCRINOL, LOS ANGELES, CA 90089 USA	University of Southern California								ASCH RH, 1988, FERTIL STERIL, V49, P263; BALMACEDA JP, 1992, FERTIL STERIL, V57, P362; BUSTILLO M, 1984, JAMA-J AM MED ASSOC, V251, P1171, DOI 10.1001/jama.251.9.1171; CONNORS TJ, 1972, BIOL REPROD, V6, P131, DOI 10.1093/biolreprod/6.1.131; FRIEDE A, 1988, OBSTET GYNECOL, V72, P152; HARTZ SC, 1991, FERTIL STERIL, V55, P14; HARTZ SC, 1990, FERTIL STERIL, V53, P13; HARTZ SC, 1989, FERTIL STERIL, V51, P13; HARTZ SC, 1992, FERTIL STERIL, V57, P15; HARTZ SC, 1988, FERTIL STERIL, V49, P212; HOLINKA CF, 1979, BIOL REPROD, V20, P1201, DOI 10.1095/biolreprod20.5.1201; JUNCA AM, 1988, HUM REPROD, V3, P121, DOI 10.1093/oxfordjournals.humrep.a136643; KENNARD EAD, 1989, FERTIL STERIL, V51, P655; LUTJEN P, 1984, NATURE, V307, P174, DOI 10.1038/307174a0; MAROULIS GB, 1991, SEMIN REPROD ENDOCR, V9, P165, DOI 10.1055/s-2007-1019407; NAEYE RL, 1983, OBSTET GYNECOL, V61, P210; NAVOT D, 1991, LANCET, V337, P1375, DOI 10.1016/0140-6736(91)93060-M; PAULSON RJ, 1990, AM J OBSTET GYNECOL, V163, P2020, DOI 10.1016/0002-9378(90)90790-E; SAUER MV, 1990, AM J OBSTET GYNECOL, V163, P1421, DOI 10.1016/0002-9378(90)90599-3; SAUER MV, 1990, NEW ENGL J MED, V323, P1157, DOI 10.1056/NEJM199010253231702; SERHAL PF, 1989, LANCET, V1, P1185; STENE J, 1977, ANN HUM GENET, V40, P299, DOI 10.1111/j.1469-1809.1977.tb00194.x; THORNEYCROFT IH, 1969, ANAT RECORD, V165, P343, DOI 10.1002/ar.1091650303; 1991, HLTH US 1990	24	164	164	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1275	1279		10.1001/jama.268.10.1275	http://dx.doi.org/10.1001/jama.268.10.1275			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507373				2022-12-28	WOS:A1992JL60800027
J	COHN, JN				COHN, JN			THE PREVENTION OF HEART-FAILURE - A NEW AGENDA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MORTALITY; CELLS				COHN, JN (corresponding author), UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA.							ACETO JF, 1990, AM J PHYSIOL, V258, pH806, DOI 10.1152/ajpheart.1990.258.3.H806; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1982, NEW ENGL J MED, V306, P1129, DOI 10.1056/NEJM198205133061902; FRANCIS GS, 1990, FASEB J, V4, P3068, DOI 10.1096/fasebj.4.13.2210153; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	12	84	84	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					725	727		10.1056/NEJM199209033271010	http://dx.doi.org/10.1056/NEJM199209033271010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1495526				2022-12-28	WOS:A1992JL23500010
J	FRIEDHOFF, AJ; BALLENGER, J; BELLACK, AS; CARPENTER, WT; CHUI, HC; DOBROF, R; FITZPATRICK, JJ; FREEMAN, R; HENINGER, GR; LAVORI, PW; MERIKANGAS, KR; RASCHKO, R; STORANDT, M; WILLIAMS, ME				FRIEDHOFF, AJ; BALLENGER, J; BELLACK, AS; CARPENTER, WT; CHUI, HC; DOBROF, R; FITZPATRICK, JJ; FREEMAN, R; HENINGER, GR; LAVORI, PW; MERIKANGAS, KR; RASCHKO, R; STORANDT, M; WILLIAMS, ME			DIAGNOSIS AND TREATMENT OF DEPRESSION IN LATE LIFE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MED UNIV S CAROLINA,INST PSYCHIAT,DEPT PSYCHIAT & BEHAV SCI,CHARLESTON,SC 29425; MED COLL PENN,E PENN PSYCHIAT INST,PHILADELPHIA,PA 19129; UNIV MARYLAND,SCH MED,MARYLAND PSYCHIAT RES CTR,DEPT PSYCHIAT,BALTIMORE,MD 21201; UNIV SO CALIF,RANCHO LOS AMIGOS MED CTR,CTR GERIATR NEUROBEHAV & ALZHEIMER,LOS ANGELES,CA 90089; CUNY HUNTER COLL,BROOKDALE CTR AGING,NEW YORK,NY 10021; CASE WESTERN RESERVE UNIV,FRANCES PAYNE BOLTON SCH NURSING,CLEVELAND,OH 44106; RIVERSIDE REG MED CTR,ADULT INPATIENT UNIT,NEWPORT NEWS,VA; YALE UNIV,SCH MED,GENET EPIDEMIOL RES UNIT,NEW HAVEN,CT 06510; BROWN UNIV,DEPT PSYCHIAT & HUMAN BEHAV,PROVIDENCE,RI 02912; SPOKANE COMMUNITY MENTAL HLTH CTR,ELDERLY SERV,SPOKANE,WA; WASHINGTON UNIV,DEPT PSYCHOL,ST LOUIS,MO 63130; UNIV N CAROLINA,SCH MED,PROGRAM AGING,CHAPEL HILL,NC 27514	Medical University of South Carolina; Drexel University; University System of Maryland; University of Maryland Baltimore; University of Southern California; City University of New York (CUNY) System; Hunter College (CUNY); Case Western Reserve University; Yale University; Brown University; Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	FRIEDHOFF, AJ (corresponding author), NYU,SCH MED,DEPT PSYCHIAT,MILLHAUSER LABS,NEW YORK,NY 10003, USA.								0	353	362	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1018	1024		10.1001/jama.1992.03490080092032	http://dx.doi.org/10.1001/jama.1992.03490080092032			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501308				2022-12-28	WOS:A1992JK12900029
J	HANKINSON, SE; WILLETT, WC; COLDITZ, GA; SEDDON, JM; ROSNER, B; SPEIZER, FE; STAMPFER, MJ				HANKINSON, SE; WILLETT, WC; COLDITZ, GA; SEDDON, JM; ROSNER, B; SPEIZER, FE; STAMPFER, MJ			A PROSPECTIVE-STUDY OF CIGARETTE-SMOKING AND RISK OF CATARACT-SURGERY IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTERIOR SUBCAPSULAR CATARACTS; EPIDEMIOLOGY; ALCOHOL; NUCLEAR; PLASMA	Objective.-To examine prospectively the association between cigarette smoking and the risk of cataract extraction in women. Design.-Prospective cohort study beginning in 1980 with 8 years of follow-up. Setting.-United States, multistate. Participants.-Registered nurses 45 to 67 years of age and free of diagnosed cancer. There were 50 828 women included in 1980 and others were added as they became 45 years of age. Main Outcome Measure.-Incidence of senile cataract extraction. Results.-We documented 493 incident senile cataracts diagnosed and extracted during 470302 person-years of follow-up. The age-adjusted relative risk (RR) among women who smoked at least 65 pack-years was 1.63 (95% confidence interval [CI], 1.18 to 2.26; P for trend, .02). A similar increase in RR was noted when smoking was assessed in terms of number of cigarettes currently smoked or number of cigarettes smoked by past smokers. Results were also similar after adjusting for other potential risk factors for cataract. Smoking was also strongly associated with posterior subcapsular cataract specifically (RR, 2.59; 95% CI, 1.49 to 4.50 for greater-than-or-equal-to 65-pack-year smokers relative to nonsmokers). Conclusion.-Smoking appears to increase the risk of cataract extraction.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, BOSTON, MA 02115 USA; MASSACHUSETTS EYE & EAR INFIRM, BOSTON, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	HANKINSON, SE (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline; PHS HHS [5T32 E507069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLACKMAN BC, 1984, ANN NY ACAD SCI, V435, P385, DOI 10.1111/j.1749-6632.1984.tb13828.x; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; BUNCE GE, 1990, ANNU REV NUTR, V10, P233, DOI 10.1146/annurev.nu.10.070190.001313; BUNCE GE, 1988, NUTR TODAY, V4, P6; CHRISTEN WG, 1991, INVEST OPHTH VIS SCI, V32, P1244; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408; COX DR, 1972, J R STAT SOC B, V34, P187; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; FLAYE DE, 1989, EYE, V3, P379, DOI 10.1038/eye.1989.56; HANKINSON SE, IN PRESS BMJ; HARDING JJ, 1987, EYE, V1, P537, DOI 10.1038/eye.1987.82; HARDING JJ, 1988, BRIT J OPHTHALMOL, V72, P809, DOI 10.1136/bjo.72.11.809; HILLER R, 1986, AM J EPIDEMIOL, V124, P916, DOI 10.1093/oxfordjournals.aje.a114481; KLEIN BEK, 1985, OPHTHALMOLOGY, V92, P1191; LESKE MC, 1983, AM J EPIDEMIOL, V118, P152, DOI 10.1093/oxfordjournals.aje.a113625; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MARAINI G, 1991, AM J EPIDEMIOL, V133, P541; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; ROBERTSON JM, 1989, ANN NY ACAD SCI, V570, P372; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P87; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SCHWAB IR, 1988, ARCH OPHTHALMOL-CHIC, V106, P1062, DOI 10.1001/archopht.1988.01060140218027; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; VARMA SD, 1991, AM J CLIN NUTR, V53, pS335, DOI 10.1093/ajcn/53.1.335S; WEST S, 1989, ARCH OPHTHALMOL-CHIC, V107, P1166, DOI 10.1001/archopht.1989.01070020232031; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	29	124	124	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					994	998		10.1001/jama.268.8.994	http://dx.doi.org/10.1001/jama.268.8.994			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501325				2022-12-28	WOS:A1992JK12900023
J	MORSE, RM; FLAVIN, DK				MORSE, RM; FLAVIN, DK			THE DEFINITION OF ALCOHOLISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENCE; ABUSE	To establish a more precise use of the term alcoholism, a 23-member multidisciplinary committee of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine conducted a 2-year study of the definition of alcoholism in the light of current concepts. The goals of the committee were to create by consensus a revised definition that is (1) scientifically valid, (2) clinically useful, and (3) understandable by the general public. Therefore, the committee agreed to define alcoholism as a primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic.	NATL COUNCIL ALCOHOLISM & DRUG DEPENDENCE,12 W 21ST ST,NEW YORK,NY 10010									CAMPBELL EJM, 1979, BMJ-BRIT MED J, V2, P757, DOI 10.1136/bmj.2.6193.757; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; EDWARDS G, 1976, BRIT MED J, V1, P1058, DOI 10.1136/bmj.1.6017.1058; GORDIS E, 1989, ALCOHOL HLTH RES WOR, V13, P298; GRANT BF, 1989, INT REV PSYCHIATR, V1, P21; JELLINEK EM, 1960, DIS CONCEPT ALCOHOL, P33; KLEBER HD, 1990, J PSYCHIAT RES, V24, P57, DOI 10.1016/0022-3956(90)90036-P; LE AD, 1981, PSYCHOPHARMACOLOGY, V75, P231, DOI 10.1007/BF00432429; MEYER RE, 1988, ALCOHOLISM ORIGINS O, P1; MORSE RM, 1989, SUBST ABUSE, V10, P75; NARANJO CA, 1986, J CLIN PSYCHIAT, V47, P16; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611; 1972, ANN INTERN MED, V77, P249; 1978, MENTAL DISORDERS GLO; 1976, ANN INTERN MED, V85, P764; 1972, AM J PSYCHIAT, V129, P127; 1980, DIAGNOSTIC STATISTIC; 1990, 7TH SPECF REP US C A; 1987, DIAGNOSTIC STATISTIC; 1981, B WORLD HEALTH ORGAN, V59, P225	21	155	162	1	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1012	1014		10.1001/jama.268.8.1012	http://dx.doi.org/10.1001/jama.268.8.1012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK129	1501306				2022-12-28	WOS:A1992JK12900027
J	HORIUCHI, S				HORIUCHI, S			STAGNATION IN THE DECLINE OF THE WORLD-POPULATION GROWTH-RATE DURING THE 1980S	SCIENCE			English	Article							FERTILITY; CHINA; TRENDS; POLICY; INDIA	The world human population growth rate after World War II passed through three phases: the rise in the 1950s and 1960s, the fall (though still at a positive level) in the 1970s, and the plateau in the 1980s. The rise was produced by the global decline in death rates, the fall was mainly due to the reduction of fertility in a number of developing countries, and the stagnation of growth rate decline was attributable to three major factors. First, substantial fertility declines started around 1970 and stalled around 1980 in both China and India. Second, the age structure of population changed in favor of higher birth rates. Third, although fertility started to decline significantly around 1970 mainly in East Asia, Southeast Asia, and Latin America, few countries have begun fertility declines since then. Many countries in sub-Saharan Africa and South Asia have not started substantial fertility reductions, deepening the gap between developing countries that are moving to lower fertility levels and those that are left behind.			HORIUCHI, S (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							Bhat P. M., 1984, VITAL RATES INDIA 19; BOHUA L, 1990, ASIA PAC POPUL J, V5, P3; CHAUDHURY MD, 1989, POPULATION TRANSITIO, P89; COALE AJ, 1991, SCIENCE, V251, P389, DOI 10.1126/science.251.4992.389; FEENEY G, 1989, POPUL DEV REV, V15, P297, DOI 10.2307/1973706; GREENHALGH S, 1986, POPUL DEV REV, V12, P491, DOI 10.2307/1973220; Horiuchi S, 1991, Popul Bull UN, P106; JAIN AK, 1989, EC POLIT WKLY, V49, P2729; KAUFMAN J, 1989, POPUL DEV REV, V15, P707, DOI 10.2307/1972596; KEYFITZ N, 1988, 1988 P IIASA C FUT C; KITAGAWA EM, 1955, J AM STAT ASSOC, V50, P1168, DOI 10.2307/2281213; MAULDIN WP, 1966, STUD FAM PLAN, V1, P1; NESS GD, 1991, GLOBAL POPULATION AS; PRESTON SH, 1984, POPUL DEV REV, V10, P481, DOI 10.2307/1973516; RELE JR, 1987, POPUL DEV REV, V13, P513, DOI 10.2307/1973137; WHYTE MK, 1987, POPUL DEV REV, V13, P471, DOI 10.2307/1973135; 1991, SEX AGE DISTRIBUTION; 1992, 1990 DEMOGRAPHIC YB; 1979, DEMOGRAPHICYB HIST S; 1984, 1982 DEMOGRAPHIC YB; 1983, REPORT INTENSIVE ENQ; 1991, WORLD POPULATION PRO; 1990, WORLD DEV REPORT 199, pCH1; 1987, LEAST DEV COUNTRIES; 1991, DEMOGR HLTH SURV NEW, V5, P12; 1992, WORLD POPULATION MON	26	15	15	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					761	765		10.1126/science.1496396	http://dx.doi.org/10.1126/science.1496396			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JG851	1496396				2022-12-28	WOS:A1992JG85100025
J	FINGERHUT, LA; INGRAM, DD; FELDMAN, JJ				FINGERHUT, LA; INGRAM, DD; FELDMAN, JJ			FIREARM HOMICIDE AMONG BLACK TEENAGE MALES IN METROPOLITAN COUNTIES - COMPARISON OF DEATH RATES IN 2 PERIODS, 1983 THROUGH 1985 AND 1987 THROUGH 1989	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - To identify US counties (1) that had either significantly high or significantly low firearm homicide rates among black males 15 through 19 years of age in 1983 through 1985 and in 1987 through 1989, and/or (2) that experienced a significant increase in the firearm homicide rate between 1983 through 1985 and 1987 through 1989. Design. - Using the Compressed Mortality File, a county-level mortality and population database maintained by the National Center for Health Statistics, Centers for Disease Control, Hyattsville, Md, county-level firearm homicide rates are analyzed. Setting. - Eighty counties with a population of at least 10 000 black males 15 through 19 years of age in 1987 through 1989. Subjects. - Black males 15 through 19 years of age whose underlying cause of death was classified as firearm homicide (E965.0 through E965.4, or E970) in the ICD-9 (International Statistical Classification of Diseases, Injuries, and Causes of Death, Ninth Revision). Main Outcome Measure. - County-specific firearm homicide rate. Results. - In 1983 through 1985 and in 1987 through 1989, seven and 13 counties, respectively, were identified that had significantly high firearm homicide rates. Firearm homicide rates were significantly high in both time periods in the following counties: Los Angeles, California; Wayne, Michigan; Kings, New York; St Louis City, Missouri; and Baltimore City, Maryland. Firearm homicide rates increased significantly between 1983 through 1985 and 1987 through 1989 in 34 of the 80 counties. Twenty counties had significantly low rates in both time periods. Several counties with low rates in 1983 through 1985 experienced significant increases and by 1987 through 1989 were among those with high rates. Conclusions. - Surveillance of firearm homicide rates at the county level in counties with high and with low rates is a necessary first step in the development of successful violence prevention programs. Those counties where rates are high and increasing are the counties that are in greatest need for intervention strategies. Knowledge of the incidence of nonfatal firearm injuries is also needed.			FINGERHUT, LA (corresponding author), CTR DIS CONTROL,NATL CTR HLTH STAT,OFF ANAL & EPIDEMIOL,ROOM 1080,6525 BELCREST RD,HYATTSVILLE,MD 20782, USA.							FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; 1990, NCJ122024 US BUR JUS; [No title captured]	3	63	63	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3054	3058		10.1001/jama.267.22.3054	http://dx.doi.org/10.1001/jama.267.22.3054			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1514955				2022-12-28	WOS:A1992HW97000026
J	HAY, SM; ALLEN, MJ; BARNES, MR				HAY, SM; ALLEN, MJ; BARNES, MR			ACUTE COMPARTMENT SYNDROMES RESULTING FROM ANTICOAGULANT TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									LEICESTER ROYAL INFIRM,LEICESTER LE1 5WW,ENGLAND	University of Leicester	ALLEN, MJ (corresponding author), LEICESTER ROYAL INFIRM,LEICESTER LE1 5WW,ENGLAND.							BARNES MR, 1985, J BIOMED ENG, V7, P35, DOI 10.1016/0141-5425(85)90006-8; HALPERN AA, 1978, J BONE JOINT SURG AM, V60, P1136, DOI 10.2106/00004623-197860080-00026; LUCE EA, 1976, J TRAUMA, V160, P717; MACON WL, 1973, NEW ENGL J MED, V288, P1396, DOI 10.1056/NEJM197306282882609; NEVIASER RJ, 1976, J BONE JOINT SURG AM, V58, P218, DOI 10.2106/00004623-197658020-00009	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1474	1475		10.1136/bmj.305.6867.1474	http://dx.doi.org/10.1136/bmj.305.6867.1474			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493394	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992KC91800024
J	CARMAN, GJ; WELCH, L				CARMAN, GJ; WELCH, L			3-DIMENSIONAL ILLUSORY CONTOURS AND SURFACES	NATURE			English	Article							SUBJECTIVE CONTOURS; PERCEPTION; DEPTH; INTERPOLATION	UNDER general viewing conditions, objects are often partially camouflaged, obscured or occluded, thereby limiting information about their three-dimensional position, orientation and shape to incomplete and variable image cues. When presented with such partial cues, observers report perceiving 'illusory' contours and surfaces (forms) in regions having no physical image contrast1-7. Here we report that three-dimensional illusory forms share three fundamental properties with 'real' forms: (1) the same forms are perceived using either stereo or motion parallax cues (cue invariance8,9); (2) they retain their shape over changes in position and orientation relative to an observer (view stability10); and (3) they can take the shape of general contours and surfaces in three dimensions11 (morphic generality). We hypothesize that illusory contours and surfaces are manifestations of a previously unnoticed visual process which constructs a representation of three-dimensional position, orientation and shape of objects from available image cues.	UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093	University of California System; University of California San Diego	CARMAN, GJ (corresponding author), SALK INST VCL,POB 85800,SAN DIEGO,CA 92186, USA.							ALBRIGHT TD, 1992, SCIENCE, V255, P1141, DOI 10.1126/science.1546317; CARMAN GJ, 1992, INVEST OPHTH VIS SCI, V33, P1333; CARMAN GJ, 1990, MAPPINGS CEREBRAL CO, P48; COLLETT TS, 1985, PROC R SOC SER B-BIO, V224, P43, DOI 10.1098/rspb.1985.0020; COREN S, 1972, PSYCHOL REV, V79, P359, DOI 10.1037/h0032940; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; Ehrenstein W, 1941, Z PSYCHOLOGIE, V150, P83; GIBSON JJ, 1950, AM J PSYCHOL, V63, P376; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GROSOF DH, 1992, INVEST OPHTH VIS SCI, V33, P1257; HARRIS JP, 1973, PERCEPTION, V2, P235, DOI 10.1068/p020235; Hilbert D., 1952, GEOMETRY IMAGINATION; IDESAWA M, 1991, JPN J APPL PHYS 2, V30, pL751, DOI 10.1143/JJAP.30.L751; KANIZSA G, 1976, SCI AM, V234, P48, DOI 10.1038/scientificamerican0476-48; Kanizsa G., 1955, RIV PSICOL, V49, P7; KANIZSA G, 1979, ORG VISION ESSAYS GE; KELLMAN PJ, 1984, PERCEPT PSYCHOPHYS, V35, P237, DOI 10.3758/BF03205937; KELLMAN PJ, 1991, COGNITIVE PSYCHOL, V23, P141, DOI 10.1016/0010-0285(91)90009-D; KLYMENKO V, 1981, PERCEPTION, V10, P627, DOI 10.1068/p100627; KOCH C, 1986, P NATL ACAD SCI USA, V83, P4263, DOI 10.1073/pnas.83.12.4263; KOENDERINK JJ, 1976, BIOL CYBERN, V24, P51, DOI 10.1007/BF00365595; LAWSON RB, 1967, VISION RES, V7, P271, DOI 10.1016/0042-6989(67)90091-0; MITCHISON GJ, 1985, NATURE, V315, P402, DOI 10.1038/315402a0; MUSTILLO P, 1986, PERCEPT PSYCHOPHYS, V40, P362, DOI 10.3758/BF03203029; NAKAYAMA K, 1989, PERCEPTION, V18, P55, DOI 10.1068/p180055; PRAZDNY K, 1986, PERCEPT PSYCHOPHYS, V39, P175, DOI 10.3758/BF03212488; RICHARDS WA, 1987, J OPT SOC AM A, V4, P1168, DOI 10.1364/JOSAA.4.001168; RODGERS B, 1982, VISION RES, V22, P261; SAIDPOUR A, 1992, PERCEPT PSYCHOPHYS, V51, P105, DOI 10.3758/BF03212235; SCHUMANN F, 1904, PSYCHOLOGISCHE STUDI, V1, P1; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501	31	41	41	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					585	587		10.1038/360585a0	http://dx.doi.org/10.1038/360585a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KB959	1461281				2022-12-28	WOS:A1992KB95900085
J	HOSOBUCHI, M; KREIS, T; SCHEKMAN, R				HOSOBUCHI, M; KREIS, T; SCHEKMAN, R			SEC21 IS A GENE REQUIRED FOR ER TO GOLGI PROTEIN-TRANSPORT THAT ENCODES A SUBUNIT OF A YEAST COATOMER	NATURE			English	Article							SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE; COATED VESICLES; CLATHRIN; STACK; COMPLEX; COMPLEMENTATION; IDENTIFICATION; BINDING; VECTORS	NON-CLATHRIN coated vesicles have been implicated in early steps of intercompartmental transport1-4. A distinct set of coat proteins are peripherally associated with the exterior of purified mammalian intra-Golgi transport vesicles5. The 'coatomer', a cytosolic complex containing a similar subunit composition to and sharing at least one subunit (beta-COP) with the coat found on vesicles, has been postulated to be the precursor of this non-clathrin coat6. Here we describe the characterization of SEC21, an essential gene required for protein transport from the endoplasmic reticulum to the Golgi in the yeast Saccharomyces cerevisiae. The 105K product of this gene, Sec21p, participates in a cytosolic complex that we show to be a yeast homologue of the mammalian coatomer. These observations demonstrate that a non-clathrin coat protein plays an essential role in intercompartmental transport.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA; UNIV GENEVA, DEPT BIOL CELLULAIRE, CH-1211 GENEVA 4, SWITZERLAND	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Geneva	HOSOBUCHI, M (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 401 BARKER HALL, BERKELEY, CA 94720 USA.							BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; DUNN B, 1989, CURRENT PROTOCOLS MO, V2; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; HARLOW E, 1988, ANTIBODIES LABORATOR, V98, P100; HARLOW E, 1988, ANTIBODIES LABORATOR, V98, P114; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PAYNE GS, 1987, MOL CELL BIOL, V7, P3888, DOI 10.1128/MCB.7.11.3888; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHERMAN F, 1991, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVEIRA LA, 1990, J CELL BIOL, V111, P1437, DOI 10.1083/jcb.111.4.1437; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	31	171	175	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 10	1992	360	6404					603	605		10.1038/360603a0	http://dx.doi.org/10.1038/360603a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461285				2022-12-28	WOS:A1992KB95900091
J	ALBERT, T; CHADWICK, S				ALBERT, T; CHADWICK, S			HOW READABLE ARE PRACTICE LEAFLETS	BRITISH MEDICAL JOURNAL			English	Article									MONTPELIER HLTH CTR,BRISTOL BS6 5PT,ENGLAND									ALBERT T, 1992, MED JOURNALISM WRITE; BHOPAL RS, 1990, FAM PRACT, V7, P132, DOI 10.1093/fampra/7.2.132; GOODMAN NW, 1991, MED WRITING PRESCTIP; HENNESSY B, 1989, WRITING FEATURE ARTI, P19; LEVY P, 1972, J I HLTH ED, V10, P47; MORRELL DC, 1980, BRIT MED J, V280, P769, DOI 10.1136/bmj.280.6216.769; NEVILLE R G, 1987, Health Bulletin (Edinburgh), V45, P185; SIMPOSON M, 1991, BMJ, V303, P1358; 1989, WORKING PATIENTS; 1990, MAKING PRINT LEGIBLE	11	61	61	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1266	1268		10.1136/bmj.305.6864.1266	http://dx.doi.org/10.1136/bmj.305.6864.1266			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477572	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JZ52100027
J	GLASIER, A; THONG, KJ; DEWAR, M; MACKIE, M; BAIRD, DT				GLASIER, A; THONG, KJ; DEWAR, M; MACKIE, M; BAIRD, DT			MIFEPRISTONE (RU-486) COMPARED WITH HIGH-DOSE ESTROGEN AND PROGESTOGEN FOR EMERGENCY POSTCOITAL CONTRACEPTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MENSTRUAL-CYCLE; EARLY-PREGNANCY; LUTEAL PHASE; ETHINYLESTRADIOL; INTERRUPTION; COMBINATION; NORGESTREL; INDUCTION; OVULATION; RU486	Background. Mifepristone (RU 486) is a synthetic steroid with potent antiprogestational and antiglucocorticoid properties that provides an effective medical method of inducing abortion in early pregnancy. Since progesterone is essential for implantation, we tested the use of mifepristone for emergency postcoital contraception. Methods. We studied 800 women and adolescents requesting emergency postcoital contraception who had had unprotected intercourse within the preceding 72 hours. A total of 398 women and adolescents were randomly assigned to treatment with 100 mug of ethinyl estradiol and 1 mg of norgestrel, each given twice 12 hours apart (standard therapy), and 402 women and adolescents were randomly assigned to receive 600 mg of mifepristone. Results. None of the women and adolescents who received mifepristone became pregnant, as compared with four of those who received standard therapy; the difference in failure rates between the two regimens was not statistically Significant. The number of pregnancies in each group was significantly lower than the number expected according to calculations based on the day of the cycle during which intercourse had taken place (P<0.001). In many subjects the stage of the cycle as calculated by menstrual history was inconsistent with measurements of plasma progesterone or urinary pregnanediol excretion. The subjects treated with mifepristone reported less nausea (40 percent vs. 60 percent) and vomiting (3 percent vs. 17 percent) on the day of treatment, as well as lower rates of other side effects, than the subjects treated with the standard regimen, but they were more likely to have a delay in the onset of the next menstrual period (42 percent vs. 13 percent). Conclusions. Mifepristone is a highly effective postcoital contraceptive agent that, if used more widely, could help reduce the number of unplanned and unwanted pregnancies.	UNIV EDINBURGH,CTR REPROD BIOL,DEPT OBSTET & GYNAECOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Edinburgh	GLASIER, A (corresponding author), LOTHIAN HLTH BOARD,DEAN TERRACE CTR,18 DEAN TERR,EDINBURGH EH4 1NL,SCOTLAND.							DIXON GW, 1980, JAMA-J AM MED ASSOC, V244, P1336, DOI 10.1001/jama.244.12.1336; FASOLI M, 1989, CONTRACEPTION, V39, P699; FLEISSIG A, 1991, BRIT MED J, V302, P147, DOI 10.1136/bmj.302.6769.147; FRYDMAN R, 1991, LANCET, V337, P488, DOI 10.1016/0140-6736(91)93421-5; GARZO VG, 1988, J CLIN ENDOCR METAB, V66, P508, DOI 10.1210/jcem-66-3-508; GLASIER A, 1991, LANCET, V337, P1414, DOI 10.1016/0140-6736(91)93097-S; HERRMANN W, 1982, CR ACAD SCI III-VIE, V294, P933; HODGEN GD, 1991, FERTIL STERIL, V56, P394; LIU JH, 1987, J CLIN ENDOCR METAB, V65, P1135, DOI 10.1210/jcem-65-6-1135; LUUKKAINEN T, 1988, FERTIL STERIL, V49, P961; NIEMAN LK, 1987, NEW ENGL J MED, V316, P187, DOI 10.1056/NEJM198701223160404; RATCLIFFE WA, 1982, CLIN CHEM, V28, P1314; RODGER MW, 1987, LANCET, V2, P1415; ROWLANDS S, 1983, CONTRACEPTION, V27, P39, DOI 10.1016/0010-7824(83)90054-9; SILVESTRE L, 1990, NEW ENGL J MED, V322, P645, DOI 10.1056/NEJM199003083221001; SILVESTRE L, 1991, LANCET, V338, P39, DOI 10.1016/0140-6736(91)90018-K; SWAHN ML, 1990, HUM REPROD, V5, P402, DOI 10.1093/oxfordjournals.humrep.a137111; VANLOOK PFA, 1989, OXF REV REPROD BIOL, V11, P2; YONG EL, 1992, HUM REPROD, V7, P39, DOI 10.1093/oxfordjournals.humrep.a137553; YUZPE AA, 1977, FERTIL STERIL, V28, P932; 1987, CONTRACEPTION, V36, P275	21	249	254	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1992	327	15					1041	1044		10.1056/NEJM199210083271501	http://dx.doi.org/10.1056/NEJM199210083271501			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR321	1522839				2022-12-28	WOS:A1992JR32100001
J	BUTKUS, DE; MEYDRECH, EF; RAJU, SS				BUTKUS, DE; MEYDRECH, EF; RAJU, SS			RACIAL-DIFFERENCES IN THE SURVIVAL OF CADAVERIC RENAL-ALLOGRAFTS - OVERRIDING EFFECTS OF HLA MATCHING AND SOCIOECONOMIC-FACTORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSPLANT RECIPIENTS; BLACKS; RACE; NONCOMPLIANCE	Background. The long-term survival of cadaveric renal allografts is lower in black recipients than in white recipients, although the one-year graft survival is similar in these racial groups. We sought to determine what factors account for this disparity. Methods. We studied 100 consecutive recipients of primary cadaveric renal allografts (57 were black and 43 white) at least 1 year after transplantation (mean, 40 months); all had received identical immunosuppressive therapy. We evaluated differences in the cause and duration of end-stage renal disease, the number of pretransplantation transfusions, age, matching for HLA-A, B, and DR antigens, race of the donor, insurance coverage, and compliance to assess their effect on graft survival in both groups. Results. Allograft survival after one year was significantly lower in black than in white patients (P = 0.025). According to univariate analysis, only the recipient's age at transplantation, the number of mismatches for HLA antigens, the type of insurance coverage, the source of referral for transplantation, and the degree of compliance correlated significantly with the rate of graft survival. The frequency of all variables that reduced graft survival was higher among the blacks. According to proportional-hazards analysis, the only factors contributing to a lower rate of graft survival were age of less than 30 years at transplantation (relative risk, 2.3; 95 percent confidence interval, 1.3 to 4.6), mismatches for all six HLA antigens as compared with three or fewer mismatches (relative risk, 5.6; 95 percent confidence interval, 3.3 to 9.6), and coverage by Medicaid or Medicare (relative risk, 2.2; 95 percent confidence interval, 1.5 to 3.2). Race had no additional effect. Noncompliance was more frequent among blacks (16 percent vs. 2 percent) and could substitute for insurance status in the model. Conclusions. When immunosuppression is equivalent in black and white transplant recipients, apparently race-related differences in the long-term survival of renal cadaveric allografts appear to be related to other factors that affect graft survival unfavorably, notably poor HLA matching and unfavorable socioeconomic factors.	UNIV MISSISSIPPI, MED CTR, DEPT PREVENT MED, JACKSON, MS 39216 USA; UNIV MISSISSIPPI, MED CTR, DEPT SURG, JACKSON, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center	BUTKUS, DE (corresponding author), UNIV MISSISSIPPI, MED CTR, DEPT MED, 2500 N STATE ST, JACKSON, MS 39216 USA.							[Anonymous], 1908, BIOMETRIKA, V6, P1; Barger B O, 1987, Clin Transpl, P217; BUTKUS DE, 1991, CLIN TRANSPLANT, V5, P411; BUTKUS DE, 1991, TRANSPLANT REV, V5, P91; COX DR, 1972, J R STAT SOC B, V34, P187; DELONE P, 1989, TRANSPLANT P, V21, P3982; DIDLAKE RH, 1988, TRANSPLANT P, V20, P63; Evans R W, 1990, Clin Transpl, P343; FIRST MR, 1989, TRANSPLANT P, V21, P3949; GASTON RS, 1992, TRANSPLANTATION, V53, P103, DOI 10.1097/00007890-199201000-00020; GREENSTEIN SM, 1989, TRANSPLANT P, V21, P3874; KALIL RSN, 1992, AM J KIDNEY DIS, V20, P63, DOI 10.1016/S0272-6386(12)80318-0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNECHTLE SJ, 1989, TRANSPLANT P, V21, P3931; MatasCallies AJAL, 1991, TRANSPLANT REV, V5, P173, DOI 10.1016/S0955-470X(10)80022-9; Matthews DE, 1985, USING UNDERSTANDING, P39; MCDONALD JC, 1989, TRANSPLANT P, V21, P3411; OPELZ G, 1977, TRANSPLANT P, V9, P137; OPELZ G, 1989, TRANSPLANT P, V21, P3918; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PIRSCH JD, 1989, TRANSPLANT P, V21, P3926; ROVELLI M, 1989, TRANSPLANT P, V21, P3979; SHAVELSON RJ, 1988, STATISTICAL REASONIN, P572; WARD HJ, 1987, TRANSPLANT P, V19, P1546; Wilks SS, 1932, BIOMETRIKA, V24, P471; Yuge J, 1989, Clin Transpl, P407; Zhou Y C, 1990, Clin Transpl, P447; 1990, CONT DIALYSIS NEPHRO, V11, P14	28	215	216	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					840	845		10.1056/NEJM199209173271203	http://dx.doi.org/10.1056/NEJM199209173271203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1508243	Bronze			2022-12-28	WOS:A1992JN12000003
J	REINHARDT, UE				REINHARDT, UE			POLITICS AND THE HEALTH-CARE SYSTEM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											REINHARDT, UE (corresponding author), PRINCETON UNIV,PRINCETON,NJ 08544, USA.							Butler S. M., 1992, POLICY MAKERS GUID 2; REINHARDT UE, 1987, HEALTH AFFAIR, V6, P101, DOI 10.1377/hlthaff.6.1.101; 1992, PRESIDENTS COMPREHEN; 1971, HLTH MESSAGE PRESIDE	4	11	11	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					809	811		10.1056/NEJM199209103271114	http://dx.doi.org/10.1056/NEJM199209103271114			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JL661	1501659				2022-12-28	WOS:A1992JL66100014
J	COOPER, JR; CZECHOWICZ, DJ; PETERSEN, RC; MOLINARI, SP				COOPER, JR; CZECHOWICZ, DJ; PETERSEN, RC; MOLINARI, SP			PRESCRIPTION DRUG DIVERSION CONTROL AND MEDICAL-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CATCHMENT-AREA SITES; UNITED-STATES; CHRONIC PAIN; BENZODIAZEPINES; ABUSE; PREVALENCE; DEPRESSION; DISORDER; PROGRAM; QUALITY	Concern about the role of prescription drug diversion in drug abuse has led to demands for more stringent regulation and for better ways to detect prescription drug diversion. Advances in technology now allow point-of-sale computer systems to report prescriptions filled by pharmacies to state agencies rapidly and possibly more economically. However, the advantages of more comprehensive control systems must be balanced against their possible effects on medical practice and patient care. Our limited knowledge about prescription drug diversion and the impact of diversion control systems on medical practice is summarized. Needed research is outlined together with the components of a diversion control program that balances reducing drug diversion with minimizing adverse effects on medical practice and patient care. We stress the need for broadly defined practice parameters and peer review by medical experts thoroughly familiar with the complexities of medical practice.	NIDA,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)								ADAMS EH, 1991, NEW YORK STATE J MED, V91, P337; AMBRE JJ, 1991, MAY NAT I DRUG AB TE; BAIRD WP, 1990, BALANCING RESPONSE P, P65; BALTER MB, 1992, J PSYCHOACTIVE DRUGS, V24, P63, DOI 10.1080/02791072.1992.10471620; BARNETT GO, 1978, MED CARE, V16, P962, DOI 10.1097/00005650-197811000-00007; BATTEN HL, 1991, DRUG SERVICES RES SO; BERINA LF, 1985, AM J HOSP PHARM, V42, P857, DOI 10.1093/ajhp/42.4.857; Burton B T, 1991, NIDA Res Monogr, V115, P47; CHIARELLO RJ, 1987, ARCH GEN PSYCHIAT, V44, P286; CLEELAND CS, 1989, ADV PAIN RES THER, P81; COLE JO, 1990, J PSYCHIAT RES, V24, P135, DOI 10.1016/0022-3956(90)90045-R; DAHL J, 1991, MAY NAT I DRUG AB TE; Du Pont R.L., 1988, AM J DRUG ALCOHOL S1, V14, P1; DUBE CE, 1990, CURRICULUM PRIMARY C; EDWARDS CC, 1972, FED REG         0815, V37, P16503; FARNSWORTH P, 1990, BALANCING RESPONSE P, P103; FDA Drug Bulletin, 1982, FDA DRUG B, V12, P4; FRANCE RD, 1984, SOC SCI MED, V19, P1379, DOI 10.1016/0277-9536(84)90027-3; GARVEY MJ, 1986, AM J PSYCHIAT, V143, P1601; GLASS RM, 1991, JAMA-J AM MED ASSOC, V266, P2431, DOI 10.1001/jama.266.17.2431; Green J, 1989, PAIN MANAGE, V2, P241; HAISLIP GR, 1982, SUBST ABUS, V4, P4; HASH BM, 1984, J CLIN PSYCHOPHARM, V4, P298, DOI 10.1097/00004714-198410000-00022; HECHTMAN L, 1984, AM J ORTHOPSYCHIAT, V54, P415, DOI 10.1111/j.1939-0025.1984.tb01507.x; HILL CS, 1987, JAMA-J AM MED ASSOC, V257, P2081; HOLLISTER AS, 1991, SCIENCE, V252, P11, DOI 10.1126/science.252.5002.11-a; HOLLISTER AS, 1990, SUBST ABUSE, V11, P69; HORGAN C, 1991, REV PRESCRIPTION DRU; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; IRVINE GD, 1991, METHAMPHETAMINE ABUS, P33; Joranson D E, 1990, J Pain Symptom Manage, V5, pS12; JORANSON DE, 1992, B J MED LICENSURE DI, V79, P15; KALES A, 1983, J CLIN PSYCHOPHARM, V3, P140, DOI 10.1097/00004714-198304000-00038; KLEIN LE, 1981, J MED EDUC, V56, P504; LEVIN AA, 1992, JAMA-J AM MED ASSOC, V268, P473, DOI 10.1001/jama.268.4.473; LONEY J, 1988, ADOLESCENT DRUG ABUS, P19; LURIE P, 1992, JAMA-J AM MED ASSOC, V268, P472; MARKOWITZ JS, 1989, ARCH GEN PSYCHIAT, V46, P984; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; MELLINGER GD, 1984, JAMA-J AM MED ASSOC, V251, P375, DOI 10.1001/jama.251.3.375; Mellinger Glen, 1981, EPIDEMIOLOGICAL IMPA, P117; MORGAN JP, 1986, AM OPIOPHOBIA CUSTOM, P163; NAGY A, 1987, ACTA PSYCHIAT SCAND, V765, P47; Nemeroff C B, 1990, N C Med J, V51, P240; PERRY S, 1982, PAIN, V13, P267, DOI 10.1016/0304-3959(82)90016-1; PISCOPO JA, 1991, MAY NAT I DRUG AB TE; PORTENOY R, 1990, J PAIN SYMPTOM MA S1, V5, P546; PORTER J, 1980, NEW ENGL J MED, V302, P123; PROTTAS J, 1991, MAY NAT I DRUG AB TE; PUDER KS, 1988, AM J DRUG ALCOHOL AB, V14, P463, DOI 10.3109/00952998809001564; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; RICHARD BW, 1988, J CLIN PHARMACOL, V28, P395, DOI 10.1002/j.1552-4604.1988.tb05747.x; RICKELS K, 1972, CLIN PHARMACOL THER, V13, P595; RICKELS K, 1991, MAY NAT I DRUG AB TE; ROCK N, 1991, MAY AM AC CHILD AD P; SALZMAN C, 1991, NOV NIH CONS DEV C D; Sanders J H Jr, 1989, N C Med J, V50, P105; SATEL SL, 1989, J CLIN PSYCHIAT, V50, P241; SCHWARTZ HI, 1991, GEN HOSP PSYCHIAT, V13, P219, DOI 10.1016/0163-8343(91)90122-D; SCHWEIZER E, 1990, ARCH GEN PSYCHIAT, V47, P908; SHADER RI, 1991, J CLIN PHARMACOL, V31, P781, DOI 10.1002/j.1552-4604.1991.tb01910.x; SHAPIRO S, 1984, ARCH GEN PSYCHIAT, V41, P971; SIGLER KA, 1984, AM J HOSP PHARM, V41, P108, DOI 10.1093/ajhp/41.1.108; SMITH MC, 1983, SOC MED CONFLICTING, P259; STROSS JK, 1980, ARTHRITIS RHEUM, V23, P846, DOI 10.1002/art.1780230711; TEMIN P, 1981, DRUGS HLTH, P173; TENNANT FS, 1983, POSTGRAD MED, V73, P81, DOI 10.1080/00325481.1983.11698315; UHLENHUTH EH, 1988, J CLIN PSYCHOPHARM, V8, P161; UHLENHUTH EH, 1987, CURR MED RES OPIN, V765, P47; UNGERLEIDER JT, 1980, ARCH GEN PSYCHIAT, V37, P106; WEBB CE, 1991, MAY NAT I DRUG AB TE; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; Weissman D E, 1991, Wis Med J, V90, P671; WILFORD BB, 1991, J PSYCHOACTIVE DRUGS, V23, P343, DOI 10.1080/02791072.1991.10471605; WILFORD BB, 1983, NEW ENGL J MED, V308, P1457; WOLFE SM, 1990, HLTH LETT, V6, P6; WOODS JH, 1991, LANCET, V337, P295, DOI 10.1016/0140-6736(91)90902-2; WOODS JH, 1988, JAMA-J AM MED ASSOC, V260, P3476, DOI 10.1001/jama.260.23.3476; ZULLICH SG, 1992, ANN PHARMACOTHER, V26, P539; 1991, US DHHS ADM901839 PU; 1985, FED REG         1018, V50, P42184; 1991, J AM ACAD CHILD ADOL, V30, P1; 1991, US DHHS ADM911732 PU; 1982, GAOGGD832 GEN ACC OF; 1978, GAOGGD7822 GEN ACC O; 1990, PLAN CURB PRESCRIPTI; 1986, FED REG         0513, V51, P17476; 1992, OHIO STATE BOARD FEB, V13, P3; 1992, J NIH RES, V4, P27; 1990, EPIDEMIOL NOTES, V5, P1; 1990, BENZODIAZEPINE DEPEN; 1992, GAOHRD92115 GEN ACC	93	26	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1306	1310		10.1001/jama.268.10.1306	http://dx.doi.org/10.1001/jama.268.10.1306			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JL608	1507377				2022-12-28	WOS:A1992JL60800032
J	LEGERSKI, R; PETERSON, C				LEGERSKI, R; PETERSON, C			EXPRESSION CLONING OF A HUMAN DNA-REPAIR GENE INVOLVED IN XERODERMA-PIGMENTOSUM GROUP-C	NATURE			English	Article							HIGH-EFFICIENCY TRANSFORMATION; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; EXCISION REPAIR; RAD4 GENE; CELLS; COMPLEMENTATION; MUTANTS; DEFECT	XERODERMA pigmentosum (XP) is a rare human autosomal recessive disease characterized by solar sensitivity, high predisposition for developing cancers on areas exposed to sunlight, and, in some cases, neurological abnormalities1,2. XP cells are defective in DNA repair3, and complementation of this defect has been used to identify eight genetic groups (A-G and variant)4. We have developed a simple, highly efficient complementary DNA expression system for use in human cells5. Here we use this system to isolate a cDNA clone that restores the ultraviolet sensitivity and unscheduled DNA synthesis of XP-C cells to normal levels. The XP-C complementing clone XPCC encodes a highly hydrophilic protein which is composed of a predicted 823 amino acids and shares limited homology with the product of the yeast DNA repair gene RAD4. The XPCC transcript is undetectable by northern blotting in most XP-C cell lines examined.			LEGERSKI, R (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CLEAVER JE, 1975, REV GENET, V26, P365; COUTO LB, 1989, J BACTERIOL, V171, P1862, DOI 10.1128/jb.171.4.1862-1869.1989; DAYAGROSJEAN L, 1987, MUTAT RES, V183, P185, DOI 10.1016/0167-8817(87)90061-7; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; GIETZ RD, 1988, GENE, V74, P535, DOI 10.1016/0378-1119(88)90186-2; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LEGERSKI RJ, 1984, P NATL ACAD SCI-BIOL, V81, P5676, DOI 10.1073/pnas.81.18.5676; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STORMO GD, 1987, NUCLEIC ACID PROTEIN, P231; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5512, DOI 10.1073/pnas.86.14.5512; THOMPSON LH, 1981, P NATL ACAD SCI-BIOL, V78, P3734, DOI 10.1073/pnas.78.6.3734; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WEBER CA, 1988, MOL CELL BIOL, V8, P1137, DOI 10.1128/MCB.8.3.1137; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	25	208	211	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					70	73		10.1038/359070a0	http://dx.doi.org/10.1038/359070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522891				2022-12-28	WOS:A1992JL66200056
J	LOUIE, GV; BROWNLIE, PD; LAMBERT, R; COOPER, JB; BLUNDELL, TL; WOOD, SP; WARREN, MJ; WOODCOCK, SC; JORDAN, PM				LOUIE, GV; BROWNLIE, PD; LAMBERT, R; COOPER, JB; BLUNDELL, TL; WOOD, SP; WARREN, MJ; WOODCOCK, SC; JORDAN, PM			STRUCTURE OF PORPHOBILINOGEN DEAMINASE REVEALS A FLEXIBLE MULTIDOMAIN POLYMERASE WITH A SINGLE CATALYTIC SITE	NATURE			English	Article							HYDROXYMETHYLBILANE SYNTHASE; DIPYRROMETHANE COFACTOR; RESOLUTION STRUCTURE; NUCLEOTIDE-SEQUENCE; SUBSTRATE BINDING; ARGININE RESIDUES; 2.3-A RESOLUTION; ACTIVE-TRANSPORT; PROTEIN; REFINEMENT	The three-domain structure of porphobilinogen deaminase, a key enzyme in the biosynthetic pathway of tetrapyrroles, has been defined by X-ray analysis at 1.9 angstrom resolution. Two of the domains structurally resemble the transferrins and periplasmic binding proteins. The dipyrromethane cofactor is covalently linked to domain 3 but is bound by extensive salt-bridges and hydrogen-bonds within the cleft between domains 1 and 2, at a position corresponding to the binding sites for small-molecule ligands in the analogous proteins. The X-ray structure and results from site-directed mutagenesis provide evidence for a single catalytic site. Interdomain flexibility may aid elongation of the polypyrrole product in the active-site cleft of the enzyme.	UNIV LONDON BIRKBECK COLL, IMPERIAL CANC RES FUND, STRUCT MOLEC BIOL UNIT, LONDON WC1E 7HX, ENGLAND; UNIV LONDON, QUEEN MARY & WESTFIELD COLL, SCH BIOL SCI, LONDON E1 4NS, ENGLAND	Cancer Research UK; University of London; Birkbeck University London; University of London; Queen Mary University London	LOUIE, GV (corresponding author), UNIV LONDON BIRKBECK COLL, DEPT CRISTALLOG, MOLEC BIOL LAB, MALET ST, LONDON WC1E 7HX, ENGLAND.		Wood, Stephen P/B-1438-2009	Warren, Martin/0000-0002-6028-6456				ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DELFAU MH, 1990, J CLIN INVEST, V86, P1511, DOI 10.1172/JCI114869; EVANS SV, IN PRESS J MOL GRAPH; HADENER A, 1990, BIOCHEM J, V271, P487; HANEEF I, 1985, ACTA CRYSTALLOGR A, V41, P426, DOI 10.1107/S0108767385000915; HART GJ, 1987, J CHEM SOC CHEM COMM, P1762, DOI 10.1039/c39870001762; JONES C, 1984, J CHEM SOC PERK T 1, P2625, DOI 10.1039/p19840002625; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Jordan P.M., 1991, NEW COMPREHENSIVE BI, V19, P1, DOI DOI 10.1016/S0167-7306(08)60108-8; JORDAN PM, 1987, FEBS LETT, V225, P87, DOI 10.1016/0014-5793(87)81136-5; JORDAN PM, 1992, J MOL BIOL, V224, P269, DOI 10.1016/0022-2836(92)90590-G; JORDAN PM, 1991, BIOCHEM J, V280, P445, DOI 10.1042/bj2800445; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; LANDER M, 1991, BIOCHEM J, V275, P447, DOI 10.1042/bj2750447; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MAUZERALL D, 1960, J AM CHEM SOC, V82, P2605, DOI 10.1021/ja01495a053; MGONE CS, IN PRESS HUM GENET; PETRICEK M, 1990, J BACTERIOL, V172, P2250, DOI 10.1128/jb.172.5.2250-2258.1990; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; RAICH N, 1986, NUCLEIC ACIDS RES, V14, P5955, DOI 10.1093/nar/14.15.5955; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SARRA R, 1990, ACTA CRYSTALLOGR B, V46, P763, DOI 10.1107/S0108768190006450; SCHAUDER JR, 1987, J CHEM SOC CHEM COMM, P436, DOI 10.1039/c39870000436; SCOTT AI, 1989, FEBS LETT, V242, P319, DOI 10.1016/0014-5793(89)80493-4; SHARIF AL, 1989, EUR J BIOCHEM, V184, P353, DOI 10.1111/j.1432-1033.1989.tb15026.x; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STUBNICER AC, 1988, NUCLEIC ACIDS RES, V16, P3102, DOI 10.1093/nar/16.7.3102; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P377, DOI 10.1093/protein/1.5.377; THOMAS SD, 1986, NUCLEIC ACIDS RES, V14, P6215, DOI 10.1093/nar/14.15.6215; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WARREN MJ, 1988, BIOCHEMISTRY-US, V27, P9020, DOI 10.1021/bi00425a021	38	177	181	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					33	39		10.1038/359033a0	http://dx.doi.org/10.1038/359033a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522882				2022-12-28	WOS:A1992JL66200044
J	DICKINSON, LA; JOH, T; KOHWI, Y; KOHWISHIGEMATSU, T				DICKINSON, LA; JOH, T; KOHWI, Y; KOHWISHIGEMATSU, T			A TISSUE-SPECIFIC MAR/SAR DNA-BINDING PROTEIN WITH UNUSUAL BINDING-SITE RECOGNITION	CELL			English	Article							SCAFFOLD-ATTACHED REGIONS; CHROMOSOMAL LOOP ANCHORAGE; BETA-GLOBIN GENE; ESCHERICHIA-COLI; TOPOISOMERASE-II; NUCLEAR SCAFFOLD; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; CONSENSUS SEQUENCE; CRYSTAL-STRUCTURE	A human cDNA was cloned that encodes a DNA-binding protein (SATB1) that is expressed predominantly in thymus and binds selectively to the nuclear matrix/scaffold-associating DNAs (MARs/SARs). Missing nucleoside experiments showed that SATB1 selectively binds in a special AT-rich sequence context where one strand consists of mixed A's, T's, and C's, excluding G's (ATC sequences). When this feature is destroyed by mutation, SATB1 binding is greatly reduced even if the direct contact sequence remains intact. Conjunctional SATB1-binding sequences become stably unpaired in supercoiled DNA. Specific mutations that diminish the unwinding potential greatly reduce SATB1 binding. However, SATB1 does not bind single-stranded DNA. Chemical interference assays show that SATB1 binds along the minor groove with very little contact with the bases. This suggests that SATB1 recognizes the ATC sequence indirectly through the altered sugar-phosphate backbone structure present in the double-stranded DNA.			DICKINSON, LA (corresponding author), LA JOLLA CANC RES FDN,LA JOLLA,CA 92037, USA.				NCI NIH HHS [R01 CA51377, R01 CA39681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039681, R01CA051377] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; BARRIO JR, 1972, BIOCHEM BIOPH RES CO, V46, P597, DOI 10.1016/S0006-291X(72)80181-5; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROTHERTON T, 1991, BIOCHEMISTRY-US, V30, P5845, DOI 10.1021/bi00238a006; BROWN DG, 1990, EMBO J, V9, P1329, DOI 10.1002/j.1460-2075.1990.tb08242.x; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEDOROFF NV, 1978, CELL, V13, P701, DOI 10.1016/0092-8674(78)90220-9; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; HOFMANN MC, 1989, CANCER RES, V49, P4696; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KOCHETKOV N K, 1971, Tetrahedron Letters, V22, P1993; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KOHWISHIGEMATSU T, 1983, P NATL ACAD SCI-BIOL, V80, P4389, DOI 10.1073/pnas.80.14.4389; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; KOO HS, 1987, BIOCHEMISTRY-US, V26, P3745, DOI 10.1021/bi00386a070; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STOCKHAUS J, 1987, NUCLEIC ACIDS RES, V15, P3479, DOI 10.1093/nar/15.8.3479; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	77	448	489	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					631	645		10.1016/0092-8674(92)90432-C	http://dx.doi.org/10.1016/0092-8674(92)90432-C			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505028				2022-12-28	WOS:A1992JJ88600012
J	CARTWRIGHT, K; REILLY, S; WHITE, D; STUART, J				CARTWRIGHT, K; REILLY, S; WHITE, D; STUART, J			EARLY TREATMENT WITH PARENTERAL PENICILLIN IN MENINGOCOCCAL DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE BACTERIAL-MENINGITIS; ANTIBIOTICS; ASSOCIATION; INFECTIONS; ENDOTOXIN; CHILDHOOD; SERUM	Objective-To measure the effect of parenteral antibiotics given before admission to hospital on mortality and on bacteriological investigations in meningococcal disease. Design-Retrospective review of hospital notes and laboratory and public health medicine department records. Setting-Three health districts in south west England. Subjects-Patients with meningococcal disease in Gloucester district presenting between 1 January 1982 and 31 December 1991 (n=190); patients with meningococcal disease in Plymouth (n=118) and Bath (n=73) districts presenting between 1 January 1988 and 31 December 1991 (total=381). Main outcome measure-Number of deaths from meningococcal disease. Results-Parenteral antibiotic given by general practitioners was associated with a substantial reduction in mortality (from 9% to 5%; relative risk 0.6, 95% confidence interval 0.2 to 1.5); patients with a rash were more likely to be given parenteral antibiotics, and mortality was further reduced (from 12% to 5%; 0.5, 0.2 to 1.4). In a district where such treatment was regularly encouraged its use increased from 5% to 40% of cases over 10 years (p=0.00001). Treatment with parenteral antibiotics before admission made isolation of meningococci from blood and cerebrospinal fluid less likely but did not affect nasopharyngeal cultures. Conclusions-General practitioners should carry benzylpenicillin in their emergency bags at all times and should administer it promptly, preferably intravenously, whenever meningococcal disease is suspected, unless the patient has had an anaphylactic reaction to penicillin. Specimens for culture should include a nasopharyngeal swab.	DERRIFORD HOSP, PUBL HLTH LAB, PLYMOUTH PL6 8DH, ENGLAND; ROYAL UNITED HOSP, PUBL HLTH LAB, BATH BA1 3NG, ENGLAND; GLOUCESTER HLTH AUTHOR, COMMUNICABLE DIS CONTROL, GLOUCESTER GL1 1LY, ENGLAND	Derriford Hospital	CARTWRIGHT, K (corresponding author), GLOUCESTERSHIRE ROYAL HOSP, PUBL HLTH LAB, GLOUCESTER GL1 3NN, ENGLAND.							ABBOTT JD, 1985, J INFECTION, V11, P241, DOI 10.1016/S0163-4453(85)93294-3; ABRAMSON JS, 1985, J INFECT DIS, V151, P370, DOI 10.1093/infdis/151.2.370; ANDERSEN BM, 1980, ACTA PATH MICRO IM B, V88, P231; BANKS HS, 1948, LANCET, V252, P677, DOI 10.1016/S0140-6736(48)91113-1; BANKS HS, 1948, LANCET, V255, P635; BAXTER P, 1988, LANCET, V1, P1166; BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; CARTWRIGHT KAV, 1986, LANCET, V2, P558; CARTWRIGHT KAV, 1990, J CLIN PATHOL, V43, P438, DOI 10.1136/jcp.43.5.438-a; CONVERSE GM, 1973, J PEDIATR-US, V83, P220, DOI 10.1016/S0022-3476(73)80479-2; Dean A. G., 1990, EPI INFO VERSION 5 W; DEVOE IW, 1982, MICROBIOL REV, V46, P162, DOI 10.1128/MMBR.46.2.162-190.1982; EDWARDS EA, 1977, SCAND J INFECT DIS, V9, P105, DOI 10.3109/inf.1977.9.issue-2.09; FALLON RJ, 1984, J HYG-CAMBRIDGE, V93, P167, DOI 10.1017/S0022172400064688; GEDDE-DAHL T W, 1990, NIPH (National Institute of Public Health) Annals (Oslo), V13, P45; GOLDACRE MJ, 1977, ARCH DIS CHILD, V52, P501, DOI 10.1136/adc.52.6.501; GOLDACRE MJ, 1976, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.6034.501; HARVEY IM, 1989, HLTH TRENDS, V21, P73; JARVIS CW, 1972, CLIN PEDIATR, V11, P201, DOI 10.1177/000992287201100406; Jones D M, 1992, Commun Dis Rep CDR Rev, V2, pR61; Jones D M, 1991, CDR (Lond Engl Rev), V1, pR76; Lieberman J M, 1990, Infect Dis Clin North Am, V4, P703; MELLADO MC, 1991, EPIDEMIOL INFECT, V106, P283, DOI 10.1017/S0950268800048421; NIKLASSON P-M, 1971, Scandinavian Journal of Infectious Diseases, V3, P17, DOI 10.3109/inf.1971.3.issue-1.03; OAKLEY JR, 1979, BRIT MED J, V2, P468, DOI 10.1136/bmj.2.6188.468; ONG ELC, 1988, BRIT MED J, V297, P901, DOI 10.1136/bmj.297.6653.901; SIPPEL JE, 1990, J CLIN PATHOL, V43, P610, DOI 10.1136/jcp.43.7.610-c; SLACK J, 1982, J ROY COLL PHYS LOND, V16, P40; STEPHENS DS, 1991, REV INFECT DIS, V13, P22; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; SURTEES SJ, 1991, BRIT MED J, V302, P1051, DOI 10.1136/bmj.302.6784.1051; TALAN DA, 1989, ANN EMERG MED, V18, P856, DOI 10.1016/S0196-0644(89)80213-6; TALAN DA, 1988, REV INFECT DIS, V10, P365; TOEWS WH, 1974, AM J DIS CHILD, V127, P173, DOI 10.1001/archpedi.1974.02110210023003; TONJUM T, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P175; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WAAGE A, 1987, LANCET, V1, P355; 1990, IMMUNISATION INFECTI, P166; 1974, LANCET, V1, P55; 1988, MENINGOCOCCAL INFECT; 1989, DRUG THER B, V27, P17	42	205	207	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 18	1992	305	6846					143	147		10.1136/bmj.305.6846.143	http://dx.doi.org/10.1136/bmj.305.6846.143			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515827	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JF06300019
J	SENDTNER, M; HOLTMANN, B; KOLBECK, R; THOENEN, H; BARDE, YA				SENDTNER, M; HOLTMANN, B; KOLBECK, R; THOENEN, H; BARDE, YA			BRAIN-DERIVED NEUROTROPHIC FACTOR PREVENTS THE DEATH OF MOTONEURONS IN NEWBORN RATS AFTER NERVE-SECTION	NATURE			English	Article							SPINAL-CORD MOTONEURONS; GROWTH-FACTOR; MESSENGER-RNA; EXPRESSION; SURVIVAL; NGF; NEURONS; AXOTOMY; CNTF; BDNF	MOTONEURONS innervating the skeletal musculature were among the first neurons shown to require the presence of their target cells to develop appropriately1,2. But the characterization of molecules allowing motoneuron survival has been difficult. Ciliary neurotrophic factor prevents the death of motoneurons3-6, but its gene is not expressed during development7. Although the presence of a neurotrophin receptor on developing motoneurons8-10 has suggested a role for neurotrophins, none could be shown to promote motoneuron survival in vitro3. We report here that brain-derived neurotrophic factor can prevent the death of axotomized motoneurons in newborn rats, suggesting a role for this neurotrophin for motoneuron survival in vivo.			SENDTNER, M (corresponding author), MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM & NEUROBIOCHEM,W-8033 MARTINSRIED,GERMANY.		Sendtner, Michael/M-8137-2014; Sendtner, Michael/J-1542-2012; Barde, Yves/F-6019-2011	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Barde, Yves/0000-0002-7627-461X				ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; ERNFORS P, 1989, NEURON, V2, P1605, DOI 10.1016/0896-6273(89)90049-4; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; Gudden B., 1870, ARCHIV PSYCHIAT NERV, V2, P693; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; MAGAL E, 1991, DEV BRAIN RES, V63, P141, DOI 10.1016/0165-3806(91)90074-S; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; Oppenheim R. W., 1981, STUDIES DEV NEUROBIO, P74; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; RAIVICH G, 1985, EMBO J, V4, P637, DOI 10.1002/j.1460-2075.1985.tb03677.x; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SCHMALBRUCH H, 1984, J COMP NEUROL, V224, P252, DOI 10.1002/cne.902240206; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; Shorey ML, 1909, J EXP ZOOL, V7, P25, DOI 10.1002/jez.1400070103; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; SUDA K, 1978, P NATL ACAD SCI USA, V75, P4042, DOI 10.1073/pnas.75.8.4042; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1988, NEURON, V1, P335	23	682	704	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					757	759		10.1038/360757a0	http://dx.doi.org/10.1038/360757a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465147	Green Submitted			2022-12-28	WOS:A1992KE47200039
J	YANG, G; MASLAND, RH				YANG, G; MASLAND, RH			DIRECT VISUALIZATION OF THE DENDRITIC AND RECEPTIVE-FIELDS OF DIRECTIONALLY SELECTIVE RETINAL GANGLION-CELLS	SCIENCE			English	Article							CHOLINERGIC AMACRINE CELLS; RABBIT RETINA; MAMMALIAN RETINA; GABA-LIKE; NEURONS; ACETYLCHOLINE; MORPHOLOGY; IMMUNOREACTIVITY; DECARBOXYLASE; RESPONSES	Optical methods were used to locate the cell bodies of directionally selective ganglion cells in isolated rabbit retinas. These neurons detect the direction in which images move across the retinal surface and transmit that information to the brain. The receptive field of each identified cell was determined, after which the cell was injected with Lucifer yellow. An image of the receptive field border was then projected onto the fluorescent image of the dendrites, allowing precise comparison between them. The size of the receptive field matched closely the size of the dendritic arbor of that cell. This result restricts the types of convergence that can be postulated in modeling the mechanism of retinal directional selectivity.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROSURG,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NEI NIH HHS [R37-EY01075] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY001075] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES A, 1981, J NEUROCHEM, V37, P867, DOI 10.1111/j.1471-4159.1981.tb04473.x; AMTHOR FR, 1989, J COMP NEUROL, V280, P97, DOI 10.1002/cne.902800108; AMTHOR FR, 1984, BRAIN RES, V298, P187, DOI 10.1016/0006-8993(84)91167-3; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P161, DOI 10.1113/jphysiol.1982.sp014105; BARLOW HB, 1965, J PHYSIOL-LONDON, V178, P477, DOI 10.1113/jphysiol.1965.sp007638; BLOOMFIELD SA, 1992, J NEUROPHYSIOL, V68, P711, DOI 10.1152/jn.1992.68.3.711; BLOOMFIELD SA, 1991, NATURE, V350, P347, DOI 10.1038/350347a0; BLOOMFIELD SA, 1992, INVEST OPHTH VIS SCI, V33, P1173; BORGGRAHAM L, 1991, SINGLE NEURON COMPUT; BRANDON C, 1987, BRAIN RES, V401, P385, DOI 10.1016/0006-8993(87)91426-0; BRECHA N, 1988, P NATL ACAD SCI USA, V85, P6187, DOI 10.1073/pnas.85.16.6187; FAMIGLIETTI EV, 1983, BRAIN RES, V261, P138, DOI 10.1016/0006-8993(83)91293-3; FAMIGLIETTI EV, 1991, J COMP NEUROL, V309, P40, DOI 10.1002/cne.903090105; KOCH C, 1982, PHILOS T R SOC B, V298, P227, DOI 10.1098/rstb.1982.0084; KOSAKA T, 1988, EXP BRAIN RES, V70, P605; LEVICK WR, 1983, PROGR RETINAL RES, V2, P267; MASLAND RH, 1976, J NEUROPHYSIOL, V39, P1220, DOI 10.1152/jn.1976.39.6.1220; MASLAND RH, 1984, PROC R SOC SER B-BIO, V223, P121, DOI 10.1098/rspb.1984.0086; MASLAND RH, 1979, J CELL BIOL, V83, P159, DOI 10.1083/jcb.83.1.159; MILLER RF, 1983, P NATL ACAD SCI-BIOL, V80, P3069, DOI 10.1073/pnas.80.10.3069; OMALLEY DM, 1989, P NATL ACAD SCI USA, V86, P3414, DOI 10.1073/pnas.86.9.3414; OYSTER CW, 1968, J PHYSIOL-LONDON, V199, P613, DOI 10.1113/jphysiol.1968.sp008671; PEICHL L, 1979, J PHYSIOL-LONDON, V291, P117, DOI 10.1113/jphysiol.1979.sp012803; TAUCHI M, 1985, J NEUROSCI, V5, P2494; TAUCHI M, 1984, PROC R SOC SER B-BIO, V223, P101, DOI 10.1098/rspb.1984.0085; TORRE V, 1978, PROC R SOC SER B-BIO, V202, P409, DOI 10.1098/rspb.1978.0075; VANEY DI, 1988, BRAIN RES, V438, P369, DOI 10.1016/0006-8993(88)91366-2; VANEY DI, 1984, PROC R SOC SER B-BIO, V220, P501, DOI 10.1098/rspb.1984.0016; VANEY DI, 1989, NEUROBIOLOGY INNER R, P154; VANEY DI, 1990, PROGR RETINAL RES, V9, P1; WYATT HJ, 1975, J NEUROPHYSIOL, V38, P613, DOI 10.1152/jn.1975.38.3.613	31	75	78	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1949	1952		10.1126/science.1470920	http://dx.doi.org/10.1126/science.1470920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470920				2022-12-28	WOS:A1992KD08800036
J	CITRON, M; OLTERSDORF, T; HAASS, C; MCCONLOGUE, L; HUNG, AY; SEUBERT, P; VIGOPELFREY, C; LIEBERBURG, I; SELKOE, DJ				CITRON, M; OLTERSDORF, T; HAASS, C; MCCONLOGUE, L; HUNG, AY; SEUBERT, P; VIGOPELFREY, C; LIEBERBURG, I; SELKOE, DJ			MUTATION OF THE BETA-AMYLOID PRECURSOR PROTEIN IN FAMILIAL ALZHEIMERS-DISEASE INCREASES BETA-PROTEIN PRODUCTION	NATURE			English	Article							IDENTIFICATION; RECEPTOR; GENE	PROGRESSIVE cerebral deposition of the 39-43-amino-acid amyloid beta-protein (Abeta) is an invariant feature of Alzheimer's disease which precedes symptoms of dementia by years or decades. The only specific molecular defects that cause Alzheimer's disease which have been identified so far are missense mutations in the gene encoding the beta-amyloid precursor protein (beta-APP) in certain families with an autosomal dominant form of the disease (familial Alzheimer's disease, or FAD)1-5. These mutations are located within or immediately flanking the Abeta region of beta-APP, but the mechanism by which they cause the pathological phenotype of early and accelerated Abeta deposition is unknown. Here we report that cultured cells which express a beta-APP complementary DNA bearing a double mutation (Lys to Asn at residue 595 plus Met to Leu at position 596) found in a Swedish FAD family5 produce approximate 6-8-fold more Abeta than cells expressing normal beta-APP. The Met 596 to Leu mutation is principally responsible for the increase. These data establish a direct link between a FAD genotype and the clinicopathological phenotype. Further, they confirm the relevance of the continuous Abeta production by cultured cells6-8 for elucidating the fundamental mechanism of Alzheimer's disease.	ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080; HARVARD UNIV,SCH MED,NEUROSCI PROGRAM,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	CITRON, M (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.							CHEN WJ, 1990, J BIOL CHEM, V265, P3116; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, IN PRESS J BIOL CHEM; HARLIN MCC, 1991, NATURE, V353, P844; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, IN PRESS NATURE; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	19	1556	1665	1	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					672	674		10.1038/360672a0	http://dx.doi.org/10.1038/360672a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465129				2022-12-28	WOS:A1992KD08200055
J	HERD, RM; HUNTER, JAA; MCLAREN, KM; CHETTY, U; WATSON, ACH; GOLLOCK, JM				HERD, RM; HUNTER, JAA; MCLAREN, KM; CHETTY, U; WATSON, ACH; GOLLOCK, JM			EXCISION BIOPSY OF MALIGNANT-MELANOMA BY GENERAL-PRACTITIONERS IN SOUTH EAST SCOTLAND 1982-91	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	Objective-To examine the management of patients who had a malignant melanoma excised initially by general practitioners in south east Scotland over the past 10 years and to assess the impact of the April 1990 contract on this. Design-A retrospective case-control study. Setting-South east Scotland. Subjects-All patients in south east Scotland who had malignant melanomas excised by general practitioners in 1982-91. Outcome measures-Demographic details of patients; Breslow thickness, clearance of excision. Results-42 patients had malignant melanomas excised by general practitioners in 1982-91: 15 in 1982-9 and 27 in 1990-1. These patients were significantly younger than those who had their tumours excised initially in hospital. Although the longest diameter of melanomas excised by general practitioners was significantly less than of those excised in hospital, the Breslow thicknesses were similar. Completeness of initial excision was doubtful or incomplete in nine (23%) general practitioner excisions compared with 4/o of hospital excisions, but the time interval between excision biopsy and wide excision was similar. Pathology requests accompanying excision biopsies mentioned melanoma as a possible diagnosis in 15% (6/40) of general practitioner cases compared with 79% of hospital cases. Thirty nine general practitioners responded to a questionnaire and only 12 had considered melanoma in the differential diagnosis. Conclusions-General practitioners need to think more often of malignant melanoma when they excise pigmented lesions and when they consider this tumour a possibility should perform an excision biopsy with a lateral clearance of at least 2 mm.	UNIV EDINBURGH, ROYAL INFIRM, DEPT PATHOL, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, DEPT SURG, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; ST JOHNS HOSP, PLAST SURG UNIT, Livingston, ENGLAND; BORDERS GEN HOSP, DEPT SURG, BORDERS, SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	HERD, RM (corresponding author), UNIV EDINBURGH, ROYAL INFIRM, DEPT DERMATOL, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND.							BAGLEY FH, 1981, CANCER-AM CANCER SOC, V47, P2126, DOI 10.1002/1097-0142(19810501)47:9<2126::AID-CNCR2820470904>3.0.CO;2-C; BRAZIER JE, 1991, BRIT MED J, V303, P1472, DOI 10.1136/bmj.303.6815.1472-a; COX NH, 1992, BMJ-BRIT MED J, V304, P1177; ELLWOOD JM, 1988, PIGMENT CELL, V9, P118; HILLAN KJ, 1991, BRIT MED J, V303, P1180, DOI 10.1136/bmj.303.6811.1180; LANDTHALER M, 1989, CANCER-AM CANCER SOC, V64, P1612, DOI 10.1002/1097-0142(19891015)64:8<1612::AID-CNCR2820640810>3.0.CO;2-7; LEDERMAN JS, 1985, J AM ACAD DERMATOL, V13, P983, DOI 10.1016/S0190-9622(85)70249-6; Mackie R. M., 1989, MALIGNANT MELANOMA G; MCWILLIAM LJ, 1991, BRIT MED J, V303, P1177, DOI 10.1136/bmj.303.6811.1177; Pitcher R., 1991, BR J DERMATOL S38, V125, P93; RAMPEN FHJ, 1984, BRIT J DERMATOL, V111, P431, DOI 10.1111/j.1365-2133.1984.tb06605.x; SHRANK AB, 1991, BRIT J DERMATOL, V125, P599, DOI 10.1111/j.1365-2133.1991.tb14804.x; URIST MM, 1985, CUTANEOUS MELANOMA C, P71; WHIMSTER WF, 1991, BRIT MED J, V303, P1149, DOI 10.1136/bmj.303.6811.1149; WILLIAMS RB, 1991, BRIT MED J, V303, P1179, DOI 10.1136/bmj.303.6811.1179; 1989, GENERAL PRACTICE NAT	16	26	26	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 12	1992	305	6867					1476	1478		10.1136/bmj.305.6867.1476	http://dx.doi.org/10.1136/bmj.305.6867.1476			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493395	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KC91800025
J	MORRELL, JE; ROBERTS, AJ				MORRELL, JE; ROBERTS, AJ			HOW TO MAKE AN APPLICATION FOR PART TIME SENIOR REGISTRAR TRAINING	BRITISH MEDICAL JOURNAL			English	Article							WOMEN DOCTORS		TAVISTOCK CLIN,LONDON NW2,ENGLAND		MORRELL, JE (corresponding author), COMMUNITY & MENTAL HLTH UNIT,HOUNSLOW,ENGLAND.							ALLEN I, 1991, DOCTORS THEIR CAREER; BOLTONMAGGS PH, 1988, BRIT J HOSP MED, V39, P413; GATH A, 1988, B ROYAL COLLEGE PSYC, V12, P368; PROCTOR S, 1987, MED EDUC, V21, P260, DOI 10.1111/j.1365-2923.1987.tb00700.x; WARREN VJ, 1989, J ROY SOC MED, V82, P528, DOI 10.1177/014107688908200907	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1411	1413		10.1136/bmj.305.6866.1411	http://dx.doi.org/10.1136/bmj.305.6866.1411			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486307	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KB85600026
J	KINMONTH, AL; FULTON, Y; CAMPBELL, MJ				KINMONTH, AL; FULTON, Y; CAMPBELL, MJ			MANAGEMENT OF FEVERISH CHILDREN AT HOME	BRITISH MEDICAL JOURNAL			English	Article							YOUNG-CHILDREN	Objectives-To compare the acceptability and effects on temperature of advice to unwrap children and give paracetamol or warm sponging treatments in the management of feverish illness at home. Design-A randomised, open, parallel group study using factorial design comparison of unwrapping, warm sponging plus unwrapping, paracetamol plus unwrapping, and paracetamol and warm sponging plus unwrapping. Setting-Homes of willing families with a feverish child recruited after consulting one of 21 participating general practitioners in Southampton. Subjects-52 children aged from 3 months to 5 years with axillary temperatures before treatment of greater-than-or-equal-to 37.8-degrees-C and < 40-degrees-C. Main outcome measures-Response to advice assessed over four hours; temperature assessed by continuous data logging from an axillary thermistor; acceptability of treatment to child and parent scored on Likert scales immediately after treatment and on return to health. Results-Response to treatment advice varied; unwrapping alone had little effect on temperature. Paracetamol increased the time below 37.2-degrees-C in four hours by 109 (95% confidence interval 74 to 145) minutes compared with unwrapping; warm sponging caused the fastest reduction in temperature. Parents discriminated between treatments, preferring paracetamol. Conclusion-Advice to give paracetamol is more effective than sponging or unwrapping in controlling temperature in children at home and is more acceptable to parents. Warm sponging has an additive effect and reduces fever more quickly than paracetamol.	SOUTHAMPTON GEN HOSP,COLL NURSING,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton; University of Southampton	KINMONTH, AL (corresponding author), UNIV SOUTHAMPTON,ALDERMOOR HEALTH CTR,SOUTHAMPTON SO1 6ST,ENGLAND.							AYRES R, 1986, THESIS U SOUTHAMPTON; BAIN J, 1986, THESIS U ABERDEEN; HUNTER J, 1973, ARCH DIS CHILD, V48, P313, DOI 10.1136/adc.48.4.313; ILLINGWORTH RS, 1971, TREATMENT CHILD HOME, P171; KLUGER MJ, 1980, PEDIATRICS, V66, P720; KRAMER MS, 1991, LANCET, V337, P591, DOI 10.1016/0140-6736(91)91648-E; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; NEWMAN J, 1985, CAN MED ASSOC J, V132, P641; PANTELL RH, 1980, CLIN PEDIATR, V19, P77, DOI 10.1177/000992288001900201; RYLANCE GW, 1988, BMJ-BRIT MED J, V297, P445, DOI 10.1136/bmj.297.6646.445; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SOMAN M, 1985, J FAM PRACTICE, V21, P117; STEELE RW, 1970, J PEDIATR-US, V77, P824, DOI 10.1016/S0022-3476(70)80242-6; TAYLOR JP, 1985, AM J DIS CHILD, V139, P486, DOI 10.1001/archpedi.1985.02140070060034; 1986, MORBIDITY STATISTICS	15	31	32	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1134	1136		10.1136/bmj.305.6862.1134	http://dx.doi.org/10.1136/bmj.305.6862.1134			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463951	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JX84100025
J	DAYSON, D; GOOCH, C; THORNICROFT, G				DAYSON, D; GOOCH, C; THORNICROFT, G			THE TAPS PROJECT .16. DIFFICULT TO PLACE, LONG-TERM PSYCHIATRIC-PATIENTS - RISK-FACTORS FOR FAILURE TO RESETTLE LONG STAY PATIENTS IN COMMUNITY FACILITIES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To identify patients who could not be resettled in the community as part of the closure plans of two psychiatric hospitals and to determine their numbers and risk factors for failure. Design and setting-Prospective study of the closure of Friern and Claybury psychiatric hospitals. Patients-The first third (369) of long stay psychiatric patients to be resettled. Outcome measures-Reasons for patients being readmitted to hospital and not leaving the patients' service needs. Results-22-6% of both hospitals' long stay patients-were not successfully resettled in the community. Eighteen continuing care places per 100 000 of catchment area population seem to be required for this group. Patients whose placements were unsuccessful were usually readmitted because of a deterioration of their mental state and aggressive behavior, both of which persisted and necessitated their continuing stay in hospital, often in a locked ward. Risk factors associated with failure were a high level of psychosis; a diagnosis of paranoid psychosis; incontinence; and being male. But having a social network, especially a large one, seemed to aid successful placement in the community. Conclusion-Rehabilitation efforts should be focused on the characteristics of these patients that put them at risk of failing to succeed in community placements.	INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London	DAYSON, D (corresponding author), FRIERN HOSP,TAPS RES UNIT,LONDON N11 3BP,ENGLAND.		Thornicroft, Graham/B-4027-2010	Thornicroft, Graham/0000-0003-0662-0879				ANDERSON J, IN PRESS BR J PSYCHI; CHRISTIEBROWN JRW, 1977, PSYCHOL MED, V7, P113; COID JW, 1991, BRIT MED J, V302, P603, DOI 10.1136/bmj.302.6777.603; DAYSON D, IN PRESS BR J PSYCHI; DUNN M, 1990, BRIT J PSYCHIAT, V157, P842, DOI 10.1192/bjp.157.6.842; HERXHEIMER A, 1991, DRUG THERAPEUTIC B, V29, P41; KENDELL RE, 1989, BRIT MED J, V299, P1237, DOI 10.1136/bmj.299.6710.1237; LEFF J, 1990, BRIT J PSYCHIAT, V157, P848, DOI 10.1192/bjp.157.6.848; STURT E, 1986, BRIT J PSYCHIAT, V148, P1; THORNICROFT G, 1989, BRIT J PSYCHIAT, V155, P739, DOI 10.1192/bjp.155.6.739; THORNICROFT G, IN PRESS TAPS PROJEC; WING JK, 1990, BRIT J PSYCHIAT, V157, P822, DOI 10.1192/bjp.157.6.822; Wing JK, 1974, DESCRIPTION CLASSIFI; 1992, HLTH NATION; 1991, HLTH NATION	15	26	27	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					993	995		10.1136/bmj.305.6860.993	http://dx.doi.org/10.1136/bmj.305.6860.993			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV776	1458147	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JV77600027
J	BUSIS, SN				BUSIS, SN			TREATMENT OF TINNITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							VENOUS ANGIOMAS; LIDOCAINE				BUSIS, SN (corresponding author), UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA 15261, USA.							AMEDEE RG, 1991, J RESPIR DIS S4, V12, pS22; BILLER J, 1985, ARCH NEUROL-CHICAGO, V42, P367, DOI 10.1001/archneur.1985.04060040077016; BUSIS SN, 1985, JAMA-J AM MED ASSOC, V253, P2119; GARNER TB, 1991, J NEUROSURG, V75, P715, DOI 10.3171/jns.1991.75.5.0715; JACKSON P, 1985, J LARYNGOL OTOL, V99, P667, DOI 10.1017/S0022215100097450; KONDZIOLKA D, 1991, CAN J NEUROL SCI, V18, P295, DOI 10.1017/S031716710003184X; MOLLER AR, 1984, ANN OTO RHINOL LARYN, V93, P39; PORTMANN M, 1983, ANN OTO RHINOL LARYN, V92, P621, DOI 10.1177/000348948309200617; SHULMAN A, 1991, TINNITUS DIAGNOSIS T	9	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1467	1467		10.1001/jama.268.11.1467	http://dx.doi.org/10.1001/jama.268.11.1467			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512918				2022-12-28	WOS:A1992JM84900034
J	FAHS, MC; MANDELBLATT, J; SCHECHTER, C; MULLER, C				FAHS, MC; MANDELBLATT, J; SCHECHTER, C; MULLER, C			COST-EFFECTIVENESS OF CERVICAL-CANCER SCREENING FOR THE ELDERLY	ANNALS OF INTERNAL MEDICINE			English	Article						CERVIX NEOPLASMS; COST-BENEFIT ANALYSIS; VAGINAL SMEARS; MASS SCREENING; MEDICARE	PREVENTIVE HEALTH-CARE; PNEUMOCOCCAL IMMUNIZATION; NATIONAL TRENDS; FOLLOW-UP; WOMEN; CYTOLOGY; SMEARS; VACCINATION; MAMMOGRAPHY; PHYSICIANS	Objective: To analyze the costs and benefits of alternate cervical cancer screening schedules among elderly women. Setting: Population-based screening programs. Design: A Markov model predicts the outcomes of periodic screening, diagnosis, and treatment for cervical cancer among women from 65 to 109 years of age. Patients: A hypothetical cohort of one million 65-year-old women, representative of the U.S. population. Measurements: The costs and yields of screening. Results: Triennial screening reduced mortality from cervical cancer among the elderly by 74% at a cost of $2254 per year of life saved. Annual screening increased costs to $7345 per year of life saved; less frequent schedules yielded lower costs but decreased savings in life. These results were most sensitive to the quality of the Papanicolaou smear and the characteristics of the women using the benefit. If the sensitivity of the Papanicolaou smear was reduced from a baseline estimate of 75% to 50% and the specificity was decreased to 87% from 95%, the cost effectiveness ratio increased by nearly $7000 per year of life saved. If triennial screening is targeted to women who have not had regular screening, the program will save money as well as years of life; however, screening women who have been screened regularly is considerably less efficient, increasing costs to $33 572 per year of life saved. Conclusion: The success of the new Medicare benefit depends substantially on physicians assuring that their elderly patients, particularly women without regular prior screening, obtain high quality Papanicolaou smears. The data also show that after a woman 65 years of age or older has a history of regular negative smears, screening is inefficient and can cease.	MEM SLOAN KETTERING CANC CTR, DEPT EPIDEMIOL & BIOSTAT, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	FAHS, MC (corresponding author), MT SINAI MED CTR, DEPT COMMUNITY MED, BOX 1043, 1 GUSTAVE LEVY PL, NEW YORK, NY 10029 USA.				PHS HHS [J3-4130.0] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAQUET C, 1987, MILBANK Q, V65, P322, DOI 10.2307/3349994; BATTISTA RN, 1983, AM J PUBLIC HEALTH, V73, P1036, DOI 10.2105/AJPH.73.9.1036; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BEILBY JOW, 1982, OBSTET GYNECOL, V60, P46; BERGET A, 1977, DAN MED BULL, V24, P26; BOYES DA, 1982, CLIN INVEST MED, V5, P1; CAMPION MJ, 1986, LANCET, V2, P237; CELENTANO DD, 1989, PREV MED, V18, P411, DOI 10.1016/0091-7435(89)90001-7; CELENTANO DD, 1982, PREV MED, V11, P454, DOI 10.1016/0091-7435(82)90048-2; CHRISTOPHERSON WM, 1969, CANCER-AM CANCER SOC, V24, P64, DOI 10.1002/1097-0142(196907)24:1<64::AID-CNCR2820240108>3.0.CO;2-Y; COPPLESON LW, 1974, AM J OBSTET GYNECOL, V119, P953, DOI 10.1016/0002-9378(74)90013-1; COPPLESON LW, 1975, AM J OBSTET GYNECOL, V122, P127, DOI 10.1016/0002-9378(75)90627-4; CREASMAN WT, 1981, GYNECOL ONCOL, V12, pS306, DOI 10.1016/0090-8258(81)90084-6; DAVIS JR, 1981, ACTA CYTOL, V25, P533; DICKINSON L, 1972, MAYO CLIN PROC, V47, P534; DUNN JE, 1959, J NATL CANCER I, V23, P507; DUNN JE, 1981, AM J OBSTET GYNECOL, V139, P868, DOI 10.1016/0002-9378(81)90951-0; EDDY D, 1987, BREAST CANCER SCREEN; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; FAHS MC, 1991, WOMEN POPULATION AGI, P1; FEDSON DS, 1987, CHEST, V91, P436, DOI 10.1378/chest.91.3.436; FIDLER H. K., 1968, J OBSTET GYNAECOL BRIT COMMONW, V75, P392; FINK DJ, 1988, CA-CANCER J CLIN, V38, P127, DOI 10.3322/canjclin.38.2.127; FOX CH, 1967, AM J OBSTET GYNECOL, V99, P960, DOI 10.1016/0002-9378(67)90251-7; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; GAY JD, 1985, ACTA CYTOL, V29, P1043; GILES JA, 1988, BRIT MED J, V296, P1099, DOI 10.1136/bmj.296.6629.1099; HARLAN LC, 1991, AM J PUBLIC HEALTH, V81, P885, DOI 10.2105/AJPH.81.7.885; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; HUSAIN OAN, 1974, J CLIN PATHOL, V27, P935, DOI 10.1136/jcp.27.12.935; HUSAIN OAN, 1984, BRIT MED J, V289, P50, DOI 10.1136/bmj.289.6436.50; KASHGARI.M, 1970, AM J EPIDEMIOL, V92, P211, DOI 10.1093/oxfordjournals.aje.a121201; KINLEN LJ, 1978, LANCET, V2, P463; KLEINMAN JC, 1981, AM J PUBLIC HEALTH, V71, P73, DOI 10.2105/AJPH.71.1.73; MACCORMAC L, 1988, MED J AUSTRALIA, V149, P530, DOI 10.5694/j.1326-5377.1988.tb120761.x; MAKUC DM, 1989, AM J PUBLIC HEALTH, V79, P21, DOI 10.2105/AJPH.79.1.21; MAMON JA, 1990, PREV MED, V19, P363, DOI 10.1016/0091-7435(90)90036-J; MANDELBLATT J, 1991, AM J OBSTET GYNECOL, V164, P644, DOI 10.1016/S0002-9378(11)80040-2; MANDELBLATT J, 1986, JAMA-J AM MED ASSOC, V256, P367, DOI 10.1001/jama.256.3.367; MANDELBLATT JS, 1988, JAMA-J AM MED ASSOC, V259, P2409, DOI 10.1001/jama.259.16.2409; MCPHEE SJ, 1987, AM J PUBLIC HEALTH, V77, P780, DOI 10.2105/AJPH.77.7.780; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; MILLER AB, 1991, CAN MED ASSOC J, V145, P1301; MORRISON EAB, 1991, INT J CANCER, V49, P6, DOI 10.1002/ijc.2910490103; MULLER C, 1990, COSTS EFFECTIVENESS; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NELSON JH, 1989, CA-CANCER J CLIN, V39, P157, DOI 10.3322/canjclin.39.3.157; PETERSEN O, 1956, AM J OBSTET GYNECOL, V72, P1063, DOI 10.1016/0002-9378(56)90072-2; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; RIDDIOUGH MA, 1983, JAMA-J AM MED ASSOC, V249, P3189; RIOTTON G, 1986, COMMUNICATION   0306; ROBERTSON JH, 1988, RISK CERVICAL CANCER; RYLANDER E, 1977, ACTA OBSTET GYN SCAN, V56, P115, DOI 10.3109/00016347709158352; SCHWARTZ B, 1990, JAMA-J AM MED ASSOC, V264, P1154; SILVERBERG E, 1984, CA-CANCER J CLIN, V34, P7; SPRIGGS AI, 1977, BRIT MED J, V1, P1516; STAUB JJ, 1976, NEW ENGL J MED, V294, P223; STENKVIST B, 1984, JAMA-J AM MED ASSOC, V252, P1423, DOI 10.1001/jama.252.11.1423; STERN E, 1959, CANCER, V12, P933, DOI 10.1002/1097-0142(195909/10)12:5<933::AID-CNCR2820120513>3.0.CO;2-2; Stern E, 1969, Obstet Gynecol Surv, V24, P711, DOI 10.1097/00006254-196907001-00005; WEISMAN CS, 1989, PUBLIC HEALTH REP, V104, P209; WILLEMS JS, 1980, NEW ENGL J MED, V303, P553, DOI 10.1056/NEJM198009043031004; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1987, NATIONAL HOSPITAL DI; 1989, GUIDE CLIN PREVENTIV, P26; 1990, JAMA-J AM MED ASSOC, V264, P54; 1985, CHEM ABSTR, V35, P197; 1976, VITAL STATISTICS US, V2; 1989, WASHINGTON REPORT, V7, P1; 1985, CANCER INCIDENCE 197; 1976, CAN MED ASSOC J, V114, P1003; 1980, CHEM ABSTR, V30, P215; 1988, PRESS RELEASE; 1981, SO MED J, V74, P87; 1984, VITAL STATISTICS U A, V2; 1991, NCI912789 NIH DIV CA; 1988, 2ND P C STAT ART QUA	77	110	111	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					520	527		10.7326/0003-4819-117-6-520	http://dx.doi.org/10.7326/0003-4819-117-6-520			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503355				2022-12-28	WOS:A1992JN25700012
J	HARTIGAN, PM; HAMILTON, JD; SIMBERKOFF, MS				HARTIGAN, PM; HAMILTON, JD; SIMBERKOFF, MS			EARLY ZIDOVUDINE AND SURVIVAL IN HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											HARTIGAN, PM (corresponding author), VET AFFAIRS MED CTR,W HAVEN,CT 06516, USA.							HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; 1987, NEW ENGL J MED, V317, P185	2	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					814	815						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501668				2022-12-28	WOS:A1992JL66100026
J	VOGELMANN, AM; ACKERMAN, TP; TURCO, RP				VOGELMANN, AM; ACKERMAN, TP; TURCO, RP			ENHANCEMENTS IN BIOLOGICALLY EFFECTIVE ULTRAVIOLET-RADIATION FOLLOWING VOLCANIC-ERUPTIONS	NATURE			English	Article							HETEROGENEOUS CHEMISTRY; PALMER-STATION; EL-CHICHON; OZONE; ANTARCTICA; SKIN	AEROSOLS injected into the stratosphere by large volcanic eruptions may induce ozone destruction through processes including heterogeneous chemical reactions. The effect of ozone reductions on surface ultraviolet irradiation is not obvious, however, because aerosols also increase the reflection of sunlight. Here we use a radiative transfer model to estimate the changes in biologically effective ultraviolet radiation (UV-BE) at the Earth's surface produced by the El Chichon (1982) and Mount Pinatubo (1991) eruptions. We find that in both cases surface UV-BE intensity can increase because the effect of ozone depletion outweighs the increased scattering.	UNIV CALIF LOS ANGELES,DEPT ATMOSPHER SCI,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	VOGELMANN, AM (corresponding author), PENN STATE UNIV,DEPT METEOROL,UNIV PK,PA 16802, USA.		Vogelmann, Andrew M/M-8779-2014	Vogelmann, Andrew M/0000-0003-1918-5423				ACKERMAN TP, 1976, J APPL METEOROL, V15, P28, DOI 10.1175/1520-0450(1976)015<0028:IRTIPA>2.0.CO;2; ANGELL JK, 1985, MON WEATHER REV, V113, P641, DOI 10.1175/1520-0493(1985)113<0641:GBASEF>2.0.CO;2; ANGELL JK, 1988, J APPL METEOROL, V27, P91, DOI 10.1175/1520-0450(1988)027<0091:AUTOTV>2.0.CO;2; BERGER DS, 1976, PHOTOCHEM PHOTOBIOL, V24, P587, DOI 10.1111/j.1751-1097.1976.tb06877.x; BLUMTHALER M, 1988, PHOTOCHEM PHOTOBIOL, V48, P85, DOI 10.1111/j.1751-1097.1988.tb02790.x; BLUTH GJS, 1992, GEOPHYS RES LETT, V19, P151, DOI 10.1029/91GL02792; BOJKOV RD, 1987, MON WEATHER REV, V115, P2187, DOI 10.1175/1520-0493(1987)115<2187:TAAIOD>2.0.CO;2; BRASSEUR GP, 1990, NATURE, V348, P626, DOI 10.1038/348626a0; CALDWELL MM, 1986, STRATOSPHERIC OZONE, P87; CHANDRA S, 1991, GEOPHYS RES LETT, V18, P2277, DOI 10.1029/91GL02779; COOHILL TP, 1991, IMPACT GLOBAL CLIMAT; CUZZI JN, 1982, J ATMOS SCI, V39, P917, DOI 10.1175/1520-0469(1982)039<0917:TDFSAF>2.0.CO;2; FREDERICK JE, 1988, PHOTOCHEM PHOTOBIOL, V47, P571, DOI 10.1111/j.1751-1097.1988.tb08846.x; Goody R., 1964, ATMOSPHERIC RAD, V1; HOFMANN DJ, 1989, J GEOPHYS RES-ATMOS, V94, P5029, DOI 10.1029/JD094iD04p05029; HOFMANN DJ, 1987, REV GEOPHYS, V25, P743, DOI 10.1029/RG025i004p00743; Hunter J. R., 1982, ROLE SOLAR ULTRAVIOL, P459; LUBIN D, 1989, GEOPHYS RES LETT, V16, P783, DOI 10.1029/GL016i008p00783; LUBIN D, 1990, J GEOPHYS RES-ATMOS, V95, P13883, DOI 10.1029/JD095iD09p13883; MADRONICH S, 1992, GEOPHYS RES LETT, V19, P37, DOI 10.1029/91GL02954; McCormick M. P., 1984, GEOFISICA INT, V23, P187; MICHELANGELI DV, 1989, J GEOPHYS RES-ATMOS, V94, P18429, DOI 10.1029/JD094iD15p18429; MICHELANGELI DV, 1992, J GEOPHYS RES-ATMOS, V97, P865, DOI 10.1029/91JD01308; MOLINA LT, 1986, J GEOPHYS RES-ATMOS, V91, P14501, DOI 10.1029/JD091iD13p14501; PARRISH JA, 1982, PHOTOCHEM PHOTOBIOL, V36, P187, DOI 10.1111/j.1751-1097.1982.tb04362.x; PINTO JP, 1989, J GEOPHYS RES-ATMOS, V94, P11165, DOI 10.1029/JD094iD08p11165; PRATHER M, 1992, J GEOPHYS RES-ATMOS, V97, P10187, DOI 10.1029/92JD00845; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; SHETTLE EP, 1979, ADA085951; SMITH RC, 1992, SCIENCE, V255, P952, DOI 10.1126/science.1546292; STAMNES K, 1990, GEOPHYS RES LETT, V17, P2181, DOI 10.1029/GL017i012p02181; TERAMURA AH, 1987, AM J BOT, V74, P975, DOI 10.2307/2443936; TOON OB, 1976, J APPL METEOROL, V15, P225, DOI 10.1175/1520-0450(1976)015<0225:AGAMOA>2.0.CO;2; TURCO RP, 1992, BER BUNSEN PHYS CHEM, V96, P323, DOI 10.1002/bbpc.19920960319; VALERO FPJ, 1992, GEOPHYS RES LETT, V19, P163, DOI 10.1029/92GL00074; Worrest R, 1982, ROLE SOLAR ULTRAVIOL, V7, P429; 1991, ENV EFFECTS OZONE DE; 1986, 16 WORLD MET ORG REP, V1; 1976, NOAAST761562 US STAN	39	34	34	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					47	49		10.1038/359047a0	http://dx.doi.org/10.1038/359047a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522884				2022-12-28	WOS:A1992JL66200048
J	TROTTER, Y; CELEBRINI, S; STRICANNE, B; THORPE, S; IMBERT, M				TROTTER, Y; CELEBRINI, S; STRICANNE, B; THORPE, S; IMBERT, M			MODULATION OF NEURAL STEREOSCOPIC PROCESSING IN PRIMATE AREA-V1 BY THE VIEWING DISTANCE	SCIENCE			English	Article							BINOCULAR INTERACTION; VISUAL-CORTEX; PERCEPTION; DISPARITIES; STRIATE; NEURONS; MONKEY; LIGHT	Accurate binocular depth perception requires information about both stereopsis (relative depth) and distance (absolute depth). It is unclear how these two types of information are integrated in the visual system. In alert, behaving monkeys the responsiveness of a large majority of neurons in the primary visual cortex (area V1) was modulated by the viewing distance. This phenomenon affected particularly disparity-related activity and background activity and was not dependent on the pattern of retinal stimulation. Therefore, extraretinal factors, probably related to ocular vergence or accommodation, or both, can affect processing early in the visual pathway. Such modulations could be useful for (i) judging true distance and (ii) scaling retinal disparity to give information about three-dimensional shape.			TROTTER, Y (corresponding author), UNIV PARIS 06,INST NEUROSCI,NEUROSCI VIS LAB,9 QUAI ST BERNARD,F-75230 PARIS 05,FRANCE.		Trotter, Yves/G-7333-2011; THORPE, Simon J/A-5661-2008; celebrini, simona/H-2169-2011	THORPE, Simon J/0000-0003-4997-3367; 				ANDERSEN RA, 1983, J NEUROSCI, V3, P532; BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; CUMMING BG, 1991, NATURE, V349, P411, DOI 10.1038/349411a0; FOLEY JM, 1980, PSYCHOL REV, V87, P411, DOI 10.1037/0033-295X.87.5.411; GAUTHIER GM, 1990, SCIENCE, V249, P58, DOI 10.1126/science.2367852; GNADT JW, 1991, SOC NEUR ABSTR, V2, P1113; JOSHUA DE, 1970, EXP BRAIN RES, V10, P389, DOI 10.1007/BF02324766; JULESZ B, 1960, AT&T TECH J, V39, P1125, DOI 10.1002/j.1538-7305.1960.tb03954.x; LEHKY SR, 1990, COLD SH Q B, V55, P765; MAZZONI P, 1991, P NATL ACAD SCI USA, V88, P4433, DOI 10.1073/pnas.88.10.4433; MORRISON JD, 1984, PERCEPTION, V13, P555, DOI 10.1068/p130555; NIKARA T, 1968, EXP BRAIN RES, V6, P353; POGGIO GF, 1984, ANNU REV NEUROSCI, V7, P379, DOI 10.1146/annurev.ne.07.030184.002115; POGGIO GF, 1988, J NEUROSCI, V8, P4531; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; POGGIO GF, 1985, VISION RES, V25, P397, DOI 10.1016/0042-6989(85)90065-3; Wheatstone C., 1838, 18 CONTRIBUTIONS PHY, P371	17	112	112	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1279	1281		10.1126/science.1519066	http://dx.doi.org/10.1126/science.1519066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519066				2022-12-28	WOS:A1992JL05000034
J	VOSS, JW; ROSENFELD, MG				VOSS, JW; ROSENFELD, MG			ANTERIOR-PITUITARY DEVELOPMENT - SHORT TALES FROM DWARF MICE	CELL			English	Review							HORMONE-RELEASING FACTOR; GROWTH-HORMONE; TRANSGENIC MICE; POU-DOMAIN; SYNERGISTIC INTERACTIONS; TRANSCRIPTION FACTORS; HOMEODOMAIN PROTEIN; PROLACTIN GENE; CELL-TYPES; PIT-1		UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,DEPT MED,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego	VOSS, JW (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093, USA.							BEGEOT M, 1984, SCIENCE, V226, P566, DOI 10.1126/science.6208610; BEGEOT M, 1982, NEUROENDOCRINOLOGY, V35, P255, DOI 10.1159/000123391; BEHRINGER RR, 1988, GENE DEV, V2, P543; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BORRELLI E, 1989, NATURE, V339, P538, DOI 10.1038/339538a0; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CARBAJOPEREZ E, 1990, CELL TISSUE RES, V261, P333, DOI 10.1007/BF00318674; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; DROUIN J, 1989, GENOME, V31, P510, DOI 10.1139/g89-099; DUBOIS PM, 1991, J ELECTRON MICR TECH, V19, P2, DOI 10.1002/jemt.1060190103; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; HEMMING FJ, 1984, ENDOCRINOLOGY, V114, P2107, DOI 10.1210/endo-114-6-2107; HOEFFLER JP, 1985, ENDOCRINOLOGY, V117, P187, DOI 10.1210/endo-117-1-187; IKEDA H, 1991, CELL TISSUE RES, V263, P41, DOI 10.1007/BF00318398; INGRAHAM HA, 1990, ANNU REV PHYSIOL, V52, P773; KENDALL SK, 1991, MOL ENDOCRINOL, V5, P2025, DOI 10.1210/mend-5-12-2025; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; Schwind JL, 1928, AM J ANAT, V41, P295, DOI 10.1002/aja.1000410206; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SLAUGHBAUGH MB, 1981, ENDOCRINOLOGY, V109, P1040; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	30	202	203	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					527	530		10.1016/0092-8674(92)90422-9	http://dx.doi.org/10.1016/0092-8674(92)90422-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505020				2022-12-28	WOS:A1992JJ88600002
J	SCHINDLER, C; SHUAI, K; PREZIOSO, VR; DARNELL, JE				SCHINDLER, C; SHUAI, K; PREZIOSO, VR; DARNELL, JE			INTERFERON-DEPENDENT TYROSINE PHOSPHORYLATION OF A LATENT CYTOPLASMIC TRANSCRIPTION FACTOR	SCIENCE			English	Article							HUMAN LYMPHOCYTES-T; PROTEIN-KINASE; ALPHA-INTERFERON; GAMMA-INTERFERON; CYCLIC-AMP; RECEPTOR; GENE; EXPRESSION; CELLS; ISGF3	The interferon-alpha (IFN-alpha)-stimulated gene factor 3 (ISGF3), a transcriptional activator, contains three proteins, termed ISGF3-alpha-proteins,that reside in the cell cytoplasm until they are activated in response to IFN-alpha. Treatment of cells with IFN-alpha caused these three proteins to be phosphorylated on tyrosine and to translocate to the cell nucleus where they stimulate transcription through binding to IFN-alpha-stimulated response elements in DNA. IFN-gamma, which activates transcription through a different receptor and different DNA binding sites, also caused tyrosine phosphorylation of one of these proteins. The ISGF3-alpha-proteins may be substrates for one or more kinases activated by ligand binding to the cell surface and may link occupation of a specific polypeptide receptor with activation of transcription of a set of specific genes.	ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021	Rockefeller University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32489] Funding Source: Medline; NIGMS NIH HHS [GM07982-10] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Bourne H.D., 1990, ONCOGENES MOL ORIGIN, P97; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, IN PRESS P NATL ACAD; Gill G., 1990, ONCOGENES MOL ORIGIN, P67; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLENNY JR, 1991, J IMMUNOCHEM, V5, P1; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; Hunter T., 1990, ONCOGENES MOL ORIGIN, P142; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; MURDOCH GH, 1982, SCIENCE, V218, P1315, DOI 10.1126/science.6293056; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHINDLER C, IN PRESS P NATL ACAD; SCHINDLER C, UNPUB; SHUAI K, UNPUB; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS S, IN PRESS MOL CELL BI; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897	35	792	820	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					809	813		10.1126/science.1496401	http://dx.doi.org/10.1126/science.1496401			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496401				2022-12-28	WOS:A1992JG85100039
J	CULLITON, BJ				CULLITON, BJ			OPTIMISTIC, INDEPENDENT, AGGRESSIVE - TEXAS SHOOTS FOR THE TOP IN SCIENCE	NATURE			English	Editorial Material																		1992, NATURE, V355, P573	1	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					623	624		10.1038/357623a0	http://dx.doi.org/10.1038/357623a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1489398				2022-12-28	WOS:A1992JA43000020
J	RASMUSSEN, BF; STOCK, AM; RINGE, D; PETSKO, GA				RASMUSSEN, BF; STOCK, AM; RINGE, D; PETSKO, GA			CRYSTALLINE RIBONUCLEASE-A LOSES FUNCTION BELOW THE DYNAMIC TRANSITION AT 220-K	NATURE			English	Article							TEMPERATURE-DEPENDENCE; NEUTRON-SCATTERING; MYOGLOBIN	WHEN the dynamic properties of many different proteins are plotted as a function of temperature, biphasic behaviour is observed, with a broad transition centred around 220 K. Atomic mean-square displacements from X-ray crystallography 1 and Mossbauer scattering 2-3 show this behaviour, as do electron transfer rates 4 and dynamic information from inelastic neutron scattering 5. Molecular dynamics simulations over a range of temperatures also exhibit a transition at about 220 K: high-temperature atomic fluctuations are dominated by anharmonic collective motions of bonded and nonbonded groups of atoms, but below 220 K the predominant dynamic behaviour is harmonic vibration of individual atoms 6. Here we show by high-resolution X-ray diffraction that crystalline ribonuclease A does not bind substrate or inhibitor at 212 K but will bind either rapidly at 228 K. Once bound at the higher temperature, inhibitor cannot be washed off after the enzyme is cooled to below the transition temperature. These results suggest that enzyme flexibility is required for catalytic function.	BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT CHEM,WALTHAM,MA 02254	Brandeis University; Brandeis University	RASMUSSEN, BF (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,STRUCT BIOL LAB,WALTHAM,MA 02254, USA.		Petsko, Gregory/AAO-7962-2020					CARLISLE CH, 1974, J MOL BIOL, V85, P1, DOI 10.1016/0022-2836(74)90125-9; DOSTER W, 1986, BIOPHYS J, V50, P213, DOI 10.1016/S0006-3495(86)83455-5; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; Douzou P, 1977, CRYOBIOCHEMISTRY; FINK AL, 1987, BIOCHEMISTRY-US, V26, P8571, DOI 10.1021/bi00400a012; GILBERT WA, 1982, J RAMAN SPECTROSC, V12, P173, DOI 10.1002/jrs.1250120217; HOWLIN B, 1987, J MOL BIOL, V196, P159, DOI 10.1016/0022-2836(87)90518-3; KARTHA G, 1973, SCIENCE, V179, P495, DOI 10.1126/science.179.4072.495; KELLER H, 1980, PHYS REV LETT, V45, P68, DOI 10.1103/PhysRevLett.45.68; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; NOCEK JM, 1991, J AM CHEM SOC, V113, P6822, DOI 10.1021/ja00018a017; PARAK F, 1980, FEBS LETT, V117, P368, DOI 10.1016/0014-5793(80)80982-3; PETSKO GA, 1985, METHOD ENZYMOL, V114, P141; RASMUSSEN BF, UNPUB J APPL CRYSTAL; RICHARDS FM, 1971, ENZYMES, V4, P647; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; TILTON RF, 1992, BIOCHEMISTRY-US, V31, P2469, DOI 10.1021/bi00124a006	17	507	511	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					423	424		10.1038/357423a0	http://dx.doi.org/10.1038/357423a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1463484				2022-12-28	WOS:A1992HX17200070
J	ROSENBERG, DR; PAJER, K; RANCURELLO, M				ROSENBERG, DR; PAJER, K; RANCURELLO, M			NEUROPSYCHIATRIC ASSESSMENT OF ORPHANS IN ONE ROMANIAN ORPHANAGE FOR UNSALVAGEABLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									UNIV PITTSBURGH,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	ROSENBERG, DR (corresponding author), WESTERN PSYCHIAT INST & CLIN,3811 OHARA ST,PITTSBURGH,PA 15213, USA.							ALMOND M, 1988, DECLINE FALL ROMANIA; FISCHER ME, 1989, N CEAUSESCU STUDY PO; GALLOWAY G, 1991, DOWNFALL CEAUSESCUS; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; MOSKOFF W, 1980, ECON DEV CULT CHANGE, V28, P597, DOI 10.1086/451199; RADHARKRISHNAN G, 1991, PSYCHIATR B, V15, P621; 1990, NEWS HELSINKI WA DEC; 1987, DIAGNOSTIC STATISTIC; 1948, A810 GEN ASS UN DOC	9	15	15	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3489	3490		10.1001/jama.268.24.3489	http://dx.doi.org/10.1001/jama.268.24.3489			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460743				2022-12-28	WOS:A1992KC83900044
J	LLOYD, AM; WALBOT, V; DAVIS, RW				LLOYD, AM; WALBOT, V; DAVIS, RW			ARABIDOPSIS AND NICOTIANA ANTHOCYANIN PRODUCTION ACTIVATED BY MAIZE REGULATOR-R AND REGULATOR-C1	SCIENCE			English	Article							TISSUE-SPECIFIC EXPRESSION; CHALCONE SYNTHASE; TRANSCRIPTIONAL ACTIVATORS; GENE; HOMOLOGY; MYB; TRANSFORMATION; INDUCTION; INFECTION; ELICITOR	Anthocyanin pathway-specific transcriptional activators Rand C1 from the monocot maize were expressed in two dicots, Arabidopsis thaliana and Nicotiana tabacum. Expression of R caused augmented anthocyanin pigmentation in both plant species and augmented trichome (hair) production in Arabidopsis. Alone, C1 had no effect. Hybrid transgenic Arabidopsis expressing both C1 and R produced anthocyanins in root, petal, and stamen tissues that normally never express anthocyanins. When R was expressed in the transparent testa glabrous (without anthocyanins and trichomes) mutant of Arabidopsis, the deficiency was complemented and both anthocyanins and trichomes were restored.	STANFORD UNIV,DEPT BIOL,STANFORD,CA 94305	Stanford University	LLOYD, AM (corresponding author), STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305, USA.			Walbot, Virginia/0000-0002-1596-7279	NIGMS NIH HHS [GM 32422] Funding Source: Medline; PHS HHS [R37-H600198] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bateson W., 1901, J R HORT SOC, V26, P1; BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; Coe E. H. Jr., 1988, Corn and corn improvement. Third edition., P81; DAMIANI RD, UNPUB; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; DRUMMHERREL H, 1981, PHOTOCHEM PHOTOBIOL, V33, P391, DOI 10.1111/j.1751-1097.1981.tb05435.x; FEINBAUM RL, 1988, MOL CELL BIOL, V8, P1985, DOI 10.1128/MCB.8.5.1985; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; GOODRICH J, 1992, CELL, V68, P955, DOI 10.1016/0092-8674(92)90038-E; HABEREDER H, 1989, PLANTA, V177, P58, DOI 10.1007/BF00392154; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Hunt A. G., UNPUB; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Koornneef M., 1981, ARABID INF SERV, V18, P45; Koornneef M., 1990, ARABIDOPSIS INFO SER, V27, P1; KUBASEK W, UNPUB; LLOYD AL, UNPUB; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; LUDWIG SR, 1990, SCIENCE, V247, P449, DOI 10.1126/science.247.4941.449; McClure J.W., 1975, FLAVONOIDS, P970, DOI DOI 10.1007/978-1-4899-2909-9_18; MEHDY MC, 1987, EMBO J, V6, P1527, DOI 10.1002/j.1460-2075.1987.tb02396.x; Mendel JG., 1865, VERHANDLUNGEN NATURF, V4, P3, DOI DOI 10.1093/OXFORDJOURNALS.JHERED.A106151; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; ROTH BA, 1991, PLANT CELL, V3, P317, DOI 10.1105/tpc.3.3.317; RYDER TB, 1987, MOL GEN GENET, V210, P219, DOI 10.1007/BF00325687; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SHIRLEY BW, 1992, PLANT CELL, V4, P333, DOI 10.1105/tpc.4.3.333; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201	30	404	451	3	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1773	1775		10.1126/science.1465611	http://dx.doi.org/10.1126/science.1465611			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465611				2022-12-28	WOS:A1992KB96400033
J	LOBO, SM; TANAKA, M; SULLIVAN, ML; HERNANDEZ, N				LOBO, SM; TANAKA, M; SULLIVAN, ML; HERNANDEZ, N			A TBP COMPLEX ESSENTIAL FOR TRANSCRIPTION FROM TATA-LESS BUT NOT TATA-CONTAINING RNA POLYMERASE-III PROMOTERS IS PART OF THE TFIIIB FRACTION	CELL			English	Article							HUMAN U6 GENE; SACCHAROMYCES-CEREVISIAE; ACCURATE TRANSCRIPTION; MULTIPLE FACTORS; BINDING-PROTEIN; SNRNA PROMOTER; FACTOR-TAU; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL DOMAINS; FACTOR-EPSILON	The TATA box-binding protein TBP directs transcription by all three eukaryotic RNA polymerases. In mammalian cells, TBP is found in at least three different complexes: SL1, D-TFIID, and B-TFIID. While SL1 and D-TFIID are involved in RNA polymerase I and II transcription, respectively, no unique function has been assigned to the B-TFIID complex. Here we show that the TFIIIB fraction required for RNA polymerase III transcription contains two separable components, one of which is a TBP-containing complex that may correspond to B-TFIID. For transcription of TATA-less RNA polymerase III genes such as the VAI, 5S, and 7SL genes, this complex cannot be replaced by either TBP alone or the D-TFIID complex. In contrast, TBP alone is active for basal transcription from the TATA-containing U6 promoter. This indicates different requirements for recruiting TBP to TATA-less and TATA-containing RNA polymerase III promoters.			LOBO, SM (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Hernandez, Nouria/0000-0003-1465-4585	NCI NIH HHS [CA13106] Funding Source: Medline; NIGMS NIH HHS [R01 GM38810] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CILIBERTO G, 1987, NUCLEIC ACIDS RES, V15, P2403, DOI 10.1093/nar/15.6.2403; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAHLBERG JE, 1988, NUCLEIC ACIDS RES, V16, P5827, DOI 10.1093/nar/16.13.5827; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P583; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GEIDUSCHEK EP, 1992, IN PRESS TRANSCRIPTI; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HARLOW E, 1988, ANTIBODIES LABORATOR; HERNANDEZ N, 1992, IN PRESS COLD SPRING; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LITTLE RD, 1989, GENOMICS, V4, P376, DOI 10.1016/0888-7543(89)90345-5; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHASTRY BS, 1982, J BIOL CHEM, V257, P2979; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3584	65	147	148	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1029	1040		10.1016/0092-8674(92)90397-U	http://dx.doi.org/10.1016/0092-8674(92)90397-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458534				2022-12-28	WOS:A1992KB99000014
J	MATSUMURA, K; ERVASTI, JM; OHLENDIECK, K; KAHL, SD; CAMPBELL, KP				MATSUMURA, K; ERVASTI, JM; OHLENDIECK, K; KAHL, SD; CAMPBELL, KP			ASSOCIATION OF DYSTROPHIN-RELATED PROTEIN WITH DYSTROPHIN-ASSOCIATED PROTEINS IN MDX MOUSE MUSCLE	NATURE			English	Article							SKELETAL-MUSCLE; NEUROMUSCULAR-JUNCTIONS; GLYCOPROTEIN COMPLEX; GENE; MICE; LOCALIZATION; SARCOLEMMA; EXPRESSION; FIBERS	DYSTROPHIN is associated with a complex of muscle membrane (sarcolemmal) glycoproteins that provide a linkage to the extracellular matrix protein, laminin1-8. The absence of dystrophin leads to a dramatic reduction of the dystrophin-associated proteins (156DAG, 59DAP, 50DAG, 43DAG and 35DAG) in the sarcolemma of patients with Duchenne muscular dystrophy and mdx mice2,6-8. Here we demonstrate that dystrophin-related protein (DRP, utrophin), an autosomal homologue of dystrophin9-17, is associated with an identical or antigenically similar complex of sarcolemmal proteins and that DRP and the dystrophin/DRP-associated proteins colocalize to the neuromuscular junction in Duchenne muscular dystrophy and mdx muscle. The DRP and dystrophin/DRP-associated proteins are found throughout the sarcolemma in small-calibre skeletal muscles and cardiac muscle of adult mdx mice. Because these muscles show minimal pathological changes18-20, our results could provide a basis for the upregulation of DRP as a potential therapeutic approach.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa	MATSUMURA, K (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242, USA.		Ervasti, James/AAZ-4786-2020	Ohlendieck, Kay/0000-0002-6266-4510; Campbell, Kevin/0000-0003-2066-5889; Kahl, Steven/0000-0001-7085-9556				BUCKLE VJ, 1990, HUM GENET, V85, P324; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KARPATI G, 1986, AM J MED GENET, V25, P653, DOI 10.1002/ajmg.1320250407; KARPATI G, 1988, MUSCLE NERVE, V11, P795, DOI 10.1002/mus.880110802; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MAN NT, 1991, J CELL BIOL, V115, P1695; MATSUMURA K, 1988, MUSCLE NERVE, V11, P97, DOI 10.1002/mus.880110202; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; OHLENDIECK K, IN PRESS NEUROLOGY; PONS F, 1991, FEBS LETT, V282, P161, DOI 10.1016/0014-5793(91)80468-I; TAKEMITSU M, 1991, BIOCHEM BIOPH RES CO, V180, P1179, DOI 10.1016/S0006-291X(05)81320-8; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269	21	451	457	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					588	591		10.1038/360588a0	http://dx.doi.org/10.1038/360588a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461282				2022-12-28	WOS:A1992KB95900086
J	FITZPATRICK, R; FLETCHER, A; GORE, S; JONES, D; SPIEGELHALTER, D; COX, D				FITZPATRICK, R; FLETCHER, A; GORE, S; JONES, D; SPIEGELHALTER, D; COX, D			QUALITY-OF-LIFE MEASURES IN HEALTH-CARE .1. APPLICATIONS AND ISSUES IN ASSESSMENT	BRITISH MEDICAL JOURNAL			English	Article							RHEUMATOID-ARTHRITIS; FUNCTIONAL DISABILITY; CLINICAL-TRIALS; PATIENT; IMPACT; PHYSICIANS; VARIABLES; PROFILE; DISEASE; SCALES	Many clinicians remain unsure of the relevance of measuring quality of life to their clinical practice. In health economics quality of life measures have become the standard means of assessing the results of health care interventions and, more controversially, the means of prioritising funding; but they have many other applications. This article-the first of three on measuring quality of life-reviews the instruments available and their application in screening programmes, audit, health care research, and clinical trials. Using the appropriate instrument is essential if outcome measures are to be valid and clinically meaningful.	ROYAL POSTGRAD MED SCH,LONDON W12 0HS,ENGLAND; UNIV LEICESTER,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE1 7RH,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND	Imperial College London; University of Leicester; MRC Biostatistics Unit	FITZPATRICK, R (corresponding author), UNIV OXFORD NUFFIELD COLL,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX1 1NF,ENGLAND.							Aaronson N K, 1988, Recent Results Cancer Res, V111, P231; AARONSON NK, 1989, CONTROL CLIN TRIALS, V10, pS195; Anderson R., 1988, LIVING CHRONIC ILLNE; Bardsley M J, 1992, Qual Health Care, V1, P124, DOI 10.1136/qshc.1.2.124; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BINDMAN AB, 1990, MED CARE, V28, P1142, DOI 10.1097/00005650-199012000-00003; COX DR, 1992, J ROY STAT SOC A STA, V155, P353, DOI 10.2307/2982889; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DEYO RA, 1984, HEALTH SERV RES, V19, P275; FEINSTEIN AR, 1977, CLIN PHARMACOL THER, V22, P485; Fitzpatrick R, 1992, Qual Health Care, V1, P89, DOI 10.1136/qshc.1.2.89; Fitzpatrick R, 1991, Int Disabil Stud, V13, P34; FITZPATRICK R, 1992, BRIT J RHEUMATOL, V31, P87; FITZPATRICK R, 1989, BRIT J RHEUMATOL, V28, P201; Fitzpatrick R M, 1987, Int Disabil Stud, V9, P161; FRANKEL S, 1991, J EPIDEMIOL COMMUN H, V45, P257, DOI 10.1136/jech.45.4.257; FRATER A, 1992, BRIT MED J, V304, P519, DOI 10.1136/bmj.304.6826.519; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; Hunt SM, 1986, MEASURING HLTH STATE; JENKINSON C, 1990, FAM PRACT, V7, P121, DOI 10.1093/fampra/7.2.121; Karnofsky D., 1949, CLIN EVALUATION CHEM, P191; KAZIS LE, 1990, J CLIN EPIDEMIOL, V43, P1243, DOI 10.1016/0895-4356(90)90025-K; LANSKY D, 1992, MED CARE, V30, pMS57, DOI 10.1097/00005650-199205001-00006; LEIGH JP, 1991, J RHEUMATOL, V18, P1307; LOHR KN, 1992, MED CARE, V30, pMS1, DOI 10.1097/00005650-199205001-00001; LOMAS J, 1987, MED CARE, V25, P764, DOI 10.1097/00005650-198708000-00009; MEENAN RF, 1982, ARTHRITIS RHEUM, V25, P1048, DOI 10.1002/art.1780250903; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; NELSON EC, 1990, MED CARE, V28, P1111, DOI 10.1097/00005650-199012000-00001; PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018; PEARLMAN R, 1988, J GERONTOL, V643, P25; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; RUBENSTEIN LV, 1989, ANN INTERN MED, V111, P836, DOI 10.7326/0003-4819-111-10-836; SCHUMACHER M, 1991, STAT MED, V10, P1915, DOI 10.1002/sim.4780101207; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; Spilker B, 1990, Med Care, V28, pDS1; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; SUTHERLAND HJ, 1990, J CLIN EPIDEMIOL, V43, P661, DOI 10.1016/0895-4356(90)90036-O; TANDON PK, 1989, J CLIN EPIDEMIOL, V42, P955, DOI 10.1016/0895-4356(89)90160-1; TUGWELL P, 1990, ARCH INTERN MED, V150, P59, DOI 10.1001/archinte.150.1.59; WARE J, 1986, LANCET, V848, P1017; WASSON J, 1992, MED CARE, V30, pMS42, DOI 10.1097/00005650-199205001-00004; WILKIN D, 1992, MEASURES NEED OUTCOM; WOLFE F, 1991, J RHEUMATOL, V18, P1298	49	511	526	1	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1074	1077		10.1136/bmj.305.6861.1074	http://dx.doi.org/10.1136/bmj.305.6861.1074			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467690	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JW70100023
J	NASHEF, SAM; CAREY, F; SILCOCK, MM; OOMMEN, PK; LEVY, RD; JONES, MT				NASHEF, SAM; CAREY, F; SILCOCK, MM; OOMMEN, PK; LEVY, RD; JONES, MT			RISK STRATIFICATION FOR OPEN-HEART-SURGERY - TRIAL OF THE PARSONNET SYSTEM IN A BRITISH HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							QUALITY		WYTHENSHAWE HOSP,CARDIOTHORAC SURG,MANCHESTER M23 9LT,LANCS,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital								ALDERMAN EL, 1983, CIRCULATION, V68, P785, DOI 10.1161/01.CIR.68.4.785; DUBOIS RW, 1987, AM J PUBLIC HEALTH, V77, P1162, DOI 10.2105/AJPH.77.9.1162; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; PARSONNET V, 1989, CIRCULATION S, V701, P13; SANDERSON H, 1992, BRIT MED J, V304, P1067, DOI 10.1136/bmj.304.6834.1067	5	50	51	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1066	1067		10.1136/bmj.305.6861.1066	http://dx.doi.org/10.1136/bmj.305.6861.1066			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JW701	1467687	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JW70100020
J	EULER, HH; SCHROEDER, JO				EULER, HH; SCHROEDER, JO			PLASMAPHERESIS FOR LUPUS NEPHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											EULER, HH (corresponding author), UNIV KIEL,LUPUS PLASMAPHERESIS STUDY GRP,W-2300 KIEL 1,GERMANY.			Sesso, Ricardo/0000-0002-1062-0073				Clark W F, 1991, J Clin Apher, V6, P40, DOI 10.1002/jca.2920060109; EULER HH, 1992, TRANSFUS SCI, V3, P167; LEWIS EJ, 1992, NEW ENGL J MED, V326, P1373, DOI 10.1056/NEJM199205213262101; SCHROEDER JO, 1987, ANN INTERN MED, V107, P344, DOI 10.7326/0003-4819-107-2-344	4	14	14	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					1028	1028						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1518539				2022-12-28	WOS:A1992JQ22500012
J	DECOCK, KM; SORO, B; COULIBALY, IM; LUCAS, SB				DECOCK, KM; SORO, B; COULIBALY, IM; LUCAS, SB			TUBERCULOSIS AND HIV-INFECTION IN SUB-SAHARAN AFRICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY-SYNDROME; NON-HAITIAN PATIENTS; SYNDROME AIDS; OPPORTUNISTIC INFECTIONS; PULMONARY TUBERCULOSIS; DEVELOPING-COUNTRIES; BCG VACCINATION; ZAIRE; ASSOCIATION	Objectives.-To review the epidemiologic, clinical, and pathological characteristics and the public health implications of human immunodeficiency virus (HIV)-associated tuberculosis in sub-Saharan Africa. Data Sources.-Published medical literature (English and French) and proceedings of international and African conferences on the acquired immunodeficiency syndrome (AIDS). Study Selection.-Selection by the authors of articles most pertinent to HIV infection and tuberculosis in Africa and internationally. Data Extraction.-Direct reporting of quantitative data (eg, HIV seroprevalence levels) and of qualitative descriptions and conclusions from selected literature. Data Synthesis.-High rates (20% to 67%) of HIV infection in patients with tuberculosis have been reported from East, West, Central, and Southern Africa. An increase in tuberculosis cases has been reported at the same time as the emergence of AIDS in several countries. Autopsies in Abidjan, Ivory Coast (Cote d'Ivoire), have shown tuberculosis as the most frequent opportunistic infection in patients dying of AIDS. Clinical differences in patients with tuberculosis who were HIV-positive and HIV-negative are reviewed, the most important being a greatly increased mortality rate in HIV-associated disease. Access to HIV testing is required for firm diagnosis, for clinical care and counseling, and for public health surveillance. Conclusions.-The epidemiology of tuberculosis has been profoundly influenced by the epidemic of HIV infection in sub-Saharan Africa. Greatly increased human and material resources are required for this neglected problem in international health.	INST NATL SANTE PUBL,ABIDJAN,COTE IVOIRE; CTR ANTITUBERCULEUX,ABIDJAN,COTE IVOIRE; UNIV COLL & MIDDLESEX SCH MED,DEPT HISTOPATHOL,LONDON,ENGLAND; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333	University of London; University College London; Centers for Disease Control & Prevention - USA	DECOCK, KM (corresponding author), PROJET RETRO CI,ABIDJAN,COTE IVOIRE.							ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; ARMBRUSTER C, 1990, J INFECT DIS, V162, P1216, DOI 10.1093/infdis/162.5.1216; BARBER TW, 1990, MEDICINE, V69, P375, DOI 10.1097/00005792-199011000-00005; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BATUNGWANAYO J, 1990, 5TH INT C AIDS AFR K; BOUDES P, 1989, JAMA-J AM MED ASSOC, V262, P2386, DOI 10.1001/jama.1989.03430170046020; BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501, DOI 10.1164/ajrccm/143.3.501; CATHEBRAS P, 1988, INT C SER, V810, P66; CEGIELSKI JP, 1990, LANCET, V335, P209, DOI 10.1016/0140-6736(90)90288-G; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96; CHIN J, 1990, AIDS S, V4, pS227; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1083; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DECOCK KM, 1991, BMJ-BRIT MED J, V303, P1185, DOI 10.1136/bmj.303.6811.1185; DIPERRI G, 1989, LANCET, V2, P1502; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; ERIKI PP, 1991, AM REV RESPIR DIS, V143, P185, DOI 10.1164/ajrccm/143.1.185; FINE PEM, 1990, LANCET, V335, P1016, DOI 10.1016/0140-6736(90)91074-K; GILKS CF, 1990, AIDS, V4, P981, DOI 10.1097/00002030-199010000-00006; GOODGAME RW, 1990, NEW ENGL J MED, V323, P283; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; HOUDE C, 1988, PEDIATR INFECT DIS J, V7, P810, DOI 10.1097/00006454-198811000-00016; JESSURUN J, 1990, J ACQ IMMUN DEF SYND, V3, P579; KELLY P, 1990, T ROY SOC TROP MED H, V84, P725, DOI 10.1016/0035-9203(90)90165-B; LALLEMANTLECOEUR S, 1991, AIDS, V5, P195, DOI 10.1097/00002030-199102000-00010; LONG R, 1991, AM REV RESPIR DIS, V143, P69, DOI 10.1164/ajrccm/143.1.69; LOUIE E, 1986, CHEST, V90, P542, DOI 10.1378/chest.90.4.542; LUCAS SB, 1991, LANCET, V337, P428; MAHARI M, 1990, 6TH INT C AIDS SAN F; MALKIN JE, 1990, 6TH INT C AIDS SAN F; MANGIAROTTI V, 1990, 5TH INT C AIDS AFR K; MANN J, 1986, JAMA-J AM MED ASSOC, V256, P346, DOI 10.1001/jama.1986.03380030048011; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MCLEOD DT, 1989, T ROY SOC TROP MED H, V83, P694, DOI 10.1016/0035-9203(89)90400-8; MONIZ A, 1989, 4TH INT C AIDS ASS C; MUKADI Y, 1990, 6TH INT C AIDS SAN F; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; MURRAY JF, 1989, AM REV RESPIR DIS, V140, P1788, DOI 10.1164/ajrccm/140.6.1788; NAMBUYA A, 1988, J CLIN PATHOL, V41, P93, DOI 10.1136/jcp.41.1.93; NAUCLER A, 1991, AIDS, V5, P301, DOI 10.1097/00002030-199103000-00009; NEMIR RL, 1991, PEDIATRICS, V88, P236; NINANE J, 1988, ARCH DIS CHILD, V63, P1268, DOI 10.1136/adc.63.10.1268; NUNN P, 1991, LANCET, V337, P627; NUNN P, 1991, ANN INTERN MED, V114, P252, DOI 10.7326/0003-4819-114-3-252_2; NUNN P, 1990, LANCET, V335, P1044, DOI 10.1016/0140-6736(90)91115-Q; NUNN PP, 1989, 4TH INT C AIDS ASS C; PAPE JW, 1983, NEW ENGL J MED, V309, P945, DOI 10.1056/NEJM198310203091603; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; PIOT P, 1984, LANCET, V2, P65; PIOT P, 1990, J ACQ IMMUN DEF SYND, V3, P403; PITCHENIK AE, 1990, ANN INTERN MED, V113, P89, DOI 10.7326/0003-4819-113-2-89; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1990, LANCET, V336, P440, DOI 10.1016/0140-6736(90)91987-L; PITCHENIK AE, 1983, ANN INTERN MED, V98, P277, DOI 10.7326/0003-4819-98-3-277; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; REYNES J, 1989, J INFECT DIS, V160, P727, DOI 10.1093/infdis/160.4.727; RIDLEY DS, 1974, B WORLD HEALTH ORGAN, V51, P451; RODRIGUES LC, 1990, T ROY SOC TROP MED H, V84, P739, DOI 10.1016/0035-9203(90)90172-B; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SORIANO E, 1988, AIDS, V2, P429, DOI 10.1097/00002030-198812000-00003; SORO BN, 1990, J ACQ IMMUN DEF SYND, V3, P1193; STANDAERT B, 1989, AIDS RES HUM RETROV, V5, P247, DOI 10.1089/aid.1989.5.247; STANFORD JL, 1991, LANCET, V338, P557, DOI 10.1016/0140-6736(91)91113-9; Styblo K, 1990, Bull Int Union Tuberc Lung Dis, V65, P28; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; SYABBALO NC, 1987, CHEST, V92, P383, DOI 10.1378/chest.92.2.383-a; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; VALWAY SE, 1991, 41ST EP INT SERV ANN; VANDEPERRE P, 1984, LANCET, V2, P62; VOETBERG A, 1991, LANCET, V337, P56, DOI 10.1016/0140-6736(91)93380-R; WADHAWAN D, 1991, 7 INT C AIDS FLOR; WRIGHT J, 1991, BRIT MED J, V302, P1603, DOI 10.1136/bmj.302.6792.1603; YESSO G, 1990, 6TH INT C AIDS SAN F; 1991, MMWR, V40, P649; 1989, MMWR, V38, P236; 1990, EPIDEMIOL B, V4, P9; 1990, MMWR, V39, P718; 1991, MMWR, V40, P585; 1986, WKLY EPIDEMIOL REC, V61, P72; 1986, MMWR, V35, P74; 1991, 1992 REVISED CLASSIF; 1987, WKLY EPIDEMIOL REC, V62, P297; 1987, MMWR S, V36, P1; 1990, MMWR, V39, P1; 1985, MMWR, V34, P227	93	354	356	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1581	1587		10.1001/jama.1992.03490120095035	http://dx.doi.org/10.1001/jama.1992.03490120095035			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1518113				2022-12-28	WOS:A1992JN25600030
J	ONEIL, EH				ONEIL, EH			EDUCATION AS PART OF THE HEALTH-CARE SOLUTION - STRATEGIES FROM THE PEW-HEALTH-PROFESSIONS-COMMISSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											ONEIL, EH (corresponding author), PEW HLTH PROFESS COMMISS,1388 SUTTER ST,SUITE 805,SAN FRANCISCO,CA 94109, USA.								0	32	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1146	1148		10.1001/jama.268.9.1146	http://dx.doi.org/10.1001/jama.268.9.1146			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK681	1501342				2022-12-28	WOS:A1992JK68100017
J	MARKOWITZ, N; QUINN, EL; SARAVOLATZ, LD				MARKOWITZ, N; QUINN, EL; SARAVOLATZ, LD			TRIMETHOPRIM-SULFAMETHOXAZOLE COMPARED WITH VANCOMYCIN FOR THE TREATMENT OF STAPHYLOCOCCUS-AUREUS INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VANCOMYCIN; STAPHYLOCOCCUS-AUREUS; SUBSTANCE ABUSE	IMPAIRED RENAL-FUNCTION; METHICILLIN-RESISTANT; ANTIBIOTIC-TREATMENT; PLUS RIFAMPIN; THERAPY; ENDOCARDITIS; COMBINATION; CIPROFLOXACIN; MENINGITIS; OXACILLIN	Objective: To compare trimethoprim-sulfamethoxazole (TMP-SMZ) and vancomycin regarding efficacy and safety in the therapy of serious Staphylococcus aureus infections. Design: Randomized, double-blind comparative trial. Setting: A tertiary-care hospital. Patients: One hundred and one intravenous drug users hospitalized with S. aureus infection. Measurements: Cure and failure rates; blood and wound cultures; minimum inhibitory and bactericidal concentrations; serum inhibitory and bactericidal titers; temperature; leukocyte count; durations of treatment and hospitalization; and toxicity. Results: Of 228 intravenous drug users, 101 had S. aureus infection and were included in the efficacy analysis (43 received TMP-SMZ and 58 received vancomycin). Methicillin-resistant S. aureus (MRSA) accounted for 47% of S. aureus isolates, and 65% of patients were bacteremic. Infections were cured in 57 of 58 vancomycin recipients and in 37 of 43 TMP-SMZ recipients (P < 0.02). Failure occurred mostly in patients with tricuspid valve endocarditis and only in those with infection caused by methicillin-sensitive S. aureus (MSSA). The mean duration of bacteremia was 6.7 days in TMP-SMZ recipients and 4.3 days in vancomycin recipients. Among 222 subjects hospitalized for at least 24 hours, toxicity rates were similar for TMP-SMZ (23%) and vancomycin (20%) recipients; nausea and vomiting were associated with TMP-SMZ and inflammation at the intravenous site was associated with vancomycin. Forty-four percent of TMP-SMZ recipients and 29% of vancomycin recipients experienced side effects in the efficacy cohort (P > 0.05). Conclusions: Vancomycin is superior to TMP-SMZ in efficacy and safety when treating intravenous drug users who have staphylococcal infections. However, all treatment failures occurred in patients with MSSA infection at any site. Therefore, TMP-SMZ may be considered as an alternative to vancomycin in selected cases of MRSA infection.			MARKOWITZ, N (corresponding author), HENRY FORD HOSP, DIV INFECT DIS, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.							ARCHER GL, 1986, ANTIMICROB AGENTS CH, V29, P733, DOI 10.1128/AAC.29.5.733; ARDATI KO, 1979, J PEDIATR-US, V95, P801, DOI 10.1016/S0022-3476(79)80740-4; BAJPAI J, 1977, INT SURG, V62, P172; BENGTSSON E, 1974, SCAND J INFECT DIS, V6, P177, DOI 10.3109/inf.1974.6.issue-2.13; Bernstein-Hahn L, 1969, Paraplegia, V7, P96; BERNSTEINHAHN L, 1971, INT SURG, V46, P8; BRAINE HG, 1982, REV INFECT DIS, V4, P586; BUSHBY SRM, 1973, J INFECT DIS, V128, pS442, DOI 10.1093/infdis/128.Supplement_3.S442; CRAIG WA, 1973, ANN INTERN MED, V78, P491, DOI 10.7326/0003-4819-78-4-491; CRAVEN DE, 1983, J INFECT DIS, V147, P137, DOI 10.1093/infdis/147.1.137; CRAVEN JL, 1970, BRIT MED J, V3, P201, DOI 10.1136/bmj.3.5716.201; CROSSLEY K, 1979, J INFECT DIS, V139, P273, DOI 10.1093/infdis/139.3.273; DAUM TE, 1990, ANTIMICROB AGENTS CH, V34, P1862, DOI 10.1128/AAC.34.9.1862; FARBER BF, 1983, ANTIMICROB AGENTS CH, V23, P138, DOI 10.1128/AAC.23.1.138; FRIMODTMOLLER N, 1987, ACTA MED SCAND, V222, P175; Gavan T. L., 1980, MANUAL CLIN MICROBIO, P459; GOODWIN NM, 1973, S AFR MED J, V47, P2159; HALEY RW, 1982, ANN INTERN MED, V97, P297, DOI 10.7326/0003-4819-97-3-297; HUGHES DTD, 1973, J INFECT DIS, V128, pS701, DOI 10.1093/infdis/128.Supplement_3.S701; KIANI R, 1983, JAMA-J AM MED ASSOC, V249, P2812; KOCH UJ, 1973, CHEMOTHERAPY, V19, P314, DOI 10.1159/000221470; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; LAMBERTUS MW, 1990, ANTIMICROB AGENTS CH, V34, P1453, DOI 10.1128/AAC.34.7.1453; LEGGETT JE, 1989, J INFECT DIS, V160, P616, DOI 10.1093/infdis/160.4.616; LEVINE DP, 1991, ANN INTERN MED, V115, P674, DOI 10.7326/0003-4819-115-9-674; LEVITZ RE, 1984, ANN INTERN MED, V100, P881, DOI 10.7326/0003-4819-100-6-881; LEWIS E, 1985, AM J INFECT CONTROL, V13, P109, DOI 10.1016/S0196-6553(85)80011-0; MARKOWITZ N, 1987, REV INFECT DIS, V9, pS218; MARKOWITZ N, 1983, ANTIMICROB AGENTS CH, V23, P450, DOI 10.1128/AAC.23.3.450; MOELLERING RC, 1981, ANN INTERN MED, V94, P343, DOI 10.7326/0003-4819-94-3-343; MOELLERING RC, 1984, J ANTIMICROB CHEMOTH, V14, P43, DOI 10.1093/jac/14.suppl_D.43; MUANGMAN V, 1973, J MED ASSOC THAILAND, V56, P448; PEACOCK JE, 1980, ANN INTERN MED, V93, P526, DOI 10.7326/0003-4819-93-4-526; PELLETIER LL, 1988, ANTIMICROB AGENTS CH, V32, P374, DOI 10.1128/AAC.32.3.374; PETERSON LR, 1990, ARCH INTERN MED, V150, P2151, DOI 10.1001/archinte.150.10.2151; PINES A, 1973, J INFECT DIS, V128, pS706, DOI 10.1093/infdis/128.Supplement_3.S706; POLK RE, 1988, J INFECT DIS, V157, P502, DOI 10.1093/infdis/157.3.502; PUGSLEY DJ, 1969, POSTGRAD MED J, VS, P95; QUICK CA, 1973, J INFECT DIS, V128, pS696, DOI 10.1093/infdis/128.Supplement_3.S696; RAVIGLIONE MC, 1990, ANTIMICROB AGENTS CH, V34, P2050, DOI 10.1128/AAC.34.11.2050; ROSASCHINO F, 1973, TRIMETHOPRIM SULPHAM, P165; RUTENBURG AM, 1960, NEW ENGL J MED, V263, P1174, DOI 10.1056/NEJM196012082632305; SABEL KG, 1975, ACTA PAEDIATR SCAND, V64, P25; SALTER AJ, 1982, REV INFECT DIS, V4, P338; SARAVOLATZ LD, 1982, ANN INTERN MED, V96, P11, DOI 10.7326/0003-4819-96-1-11; SCHELD WM, 1987, J ANTIMICROB CHEMOTH, V19, P647, DOI 10.1093/jac/19.5.647; SCHMIDT U, 1982, REV INFECT DIS, V4, P332; SELIGMAN SJ, 1973, J INFECT DIS, V128, pS754, DOI 10.1093/infdis/128.Supplement_3.S754; SHAFQAT SH, 1971, BRIT HEART J, V33, P974; SMALL PM, 1990, ANTIMICROB AGENTS CH, V34, P1227, DOI 10.1128/AAC.34.6.1227; SORRELL TC, 1982, ANN INTERN MED, V97, P344, DOI 10.7326/0003-4819-97-3-344; STRATFORD BC, 1978, MED J AUSTRALIA, V2, P37, DOI 10.5694/j.1326-5377.1978.tb131329.x; TAMER MA, 1982, CLIN PEDIATR, V21, P125, DOI 10.1177/000992288202100211; WOLFSON JS, 1985, NEW ENGL J MED, V312, P968, DOI 10.1056/NEJM198504113121507; WORMSER GP, 1979, ANN INTERN MED, V91, P420, DOI 10.7326/0003-4819-91-3-420; 1973, J INFECT DIS, V128, pS629	57	267	273	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					390	398		10.7326/0003-4819-117-5-390	http://dx.doi.org/10.7326/0003-4819-117-5-390			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503330				2022-12-28	WOS:A1992JK67800007
J	IZUMI, Y; CLIFFORD, DB; ZORUMSKI, CF				IZUMI, Y; CLIFFORD, DB; ZORUMSKI, CF			INHIBITION OF LONG-TERM POTENTIATION BY NMDA-MEDIATED NITRIC-OXIDE RELEASE	SCIENCE			English	Article							RAT HIPPOCAMPUS; L-ARGININE; INTERCELLULAR MESSENGER; SYNAPTIC TRANSMISSION; RECEPTOR ACTIVATION; RELAXING FACTOR; AMINO-ACIDS; INDUCTION; BRAIN; ENHANCEMENT	Activation of N-methyl-D-aspartate (NMDA) receptors before tetanic stimulation blocks long-term potentiation (LTP) in the CA1 region of the hippocampus. This NMDA-mediated inhibition of LTP can be reversed by the nitric oxide (NO) inhibitors L-N(G)-monomethyl-arginine or hemoglobin and mimicked by sodium nitroprusside. These results indicate that the timing of NO release relative to high-frequency activation of CA1 synapses may be an important determinant of LTP generation and suggest that NO may play a positive or negative modulatory role in LTP depending on prior events at the tetanized synapse and the ambient concentration of excitatory amino acids.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	IZUMI, Y (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH000964, R01MH045493, R29MH045493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005681] Funding Source: NIH RePORTER; NIA NIH HHS [AG05681] Funding Source: Medline; NIMH NIH HHS [MH00964, MH45493] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; ERRINGTON ML, 1987, NEUROSCIENCE, V20, P279, DOI 10.1016/0306-4522(87)90019-4; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; IZUMI Y, 1992, NEUROSCI LETT, V135, P227, DOI 10.1016/0304-3940(92)90442-A; IZUMI Y, 1992, NEUROSCI LETT, V137, P245, DOI 10.1016/0304-3940(92)90414-3; IZUMI Y, UNPUB; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; LERMA J, 1986, BRAIN RES, V384, P145, DOI 10.1016/0006-8993(86)91230-8; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; MARTIN W, 1986, BRIT J PHARMACOL, V89, P563, DOI 10.1111/j.1476-5381.1986.tb11157.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORE PK, 1990, BRIT J PHARMACOL, V99, P408, DOI 10.1111/j.1476-5381.1990.tb14717.x; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; van Sande M, 1970, J Neurochem, V17, P125	33	217	219	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1273	1276		10.1126/science.1519065	http://dx.doi.org/10.1126/science.1519065			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519065				2022-12-28	WOS:A1992JL05000032
J	KRAUSE, RM				KRAUSE, RM			THE ORIGIN OF PLAGUES - OLD AND NEW	SCIENCE			English	Article							SHOCK-LIKE SYNDROME; EMERGING VIRUSES; VIRAL DISEASES; LYME-DISEASE; AIDS; AGENT; HIV-1	Viruses and bacteria emerge in new and old forms to cause disease epidemics. Some microorganisms recur when changing life-styles (including increased international travel) offer new opportunities; others arise from new genetic variations. These various epidemics connect the future with the past, offering lessons for guarding the health of generations to come-lessons learned from diseases such as tuberculosis, toxic shock syndrome, Lyme disease, streptococcal infection, influenza, and acquired immunodeficiency syndrome (AIDS). The public must be vigilant to the possibility of new epidemics, learn more about the biology and epidemiology of microbes, and strengthen systems of surveillance and detection.			KRAUSE, RM (corresponding author), NIH,FOGARTY INT CTR ADV STUDY HLTH SCI,BETHESDA,MD 20892, USA.							ANDERSON RM, 1992, SCI AM, V266, P58, DOI 10.1038/scientificamerican0592-58; ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0; ARAL SO, 1991, SCI AM, V264, P62, DOI 10.1038/scientificamerican0291-62; BLOOM B, 1992, SCIENCE, V257; BROOME CV, 1989, REV INFECT DIS S1, V11, P14; BROWN RN, 1992, SCIENCE, V256, P1439, DOI 10.1126/science.1604318; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; BURGDORFER W, 1991, NOV C EM MICR MICR D; BURNET M, 1963, NATURAL HIST INFECTI; CLEARY PP, 1992, LANCET, V339, P518, DOI 10.1016/0140-6736(92)90339-5; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; Dubos R, 1952, WHITE PLAGUE TUBERCU; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; FIKRIG E, 1992, P NATL ACAD SCI USA, V89, P5418, DOI 10.1073/pnas.89.12.5418; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HUET T, 1990, NATURE, V345, P356, DOI 10.1038/345356a0; JACOBY GA, 1991, NEW ENGL J MED, V324, P601, DOI 10.1056/NEJM199102283240906; KILBOURNE ED, 1981, PERSPECT BIOL MED, V25, P66; KILBOURNE ED, 1990, JAMA-J AM MED ASSOC, V264, P68, DOI 10.1001/jama.264.1.68; Krause Richard M., 1981, RESTLESS TIDE PERSIS; KRAUSE RM, 1984, REV INFECT DIS, V6, P270; KRAUSE RM, 1989, EMORY U J MED, V3, P77; KRAUSE RM, 1991, COSMOS, V1, P15; LEDERBERG J, 1988, JAMA-J AM MED ASSOC, V260, P684, DOI 10.1001/jama.260.5.684; MALAWISTA SE, 1991, CECIL TXB MED, P1772; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; MCNEILL WH, 1991, NOV C EM MICR MICR D; MEKALANOS J, 1991, NOV C EM MICR MICR D; MORSE SS, 1990, J INFECT DIS, V162, P1, DOI 10.1093/infdis/162.1.1; MORSE SS, 1991, PERSPECT BIOL MED, V34, P387; MUSSER JM, 1991, P NATL ACAD SCI USA, V88, P2668, DOI 10.1073/pnas.88.7.2668; MYERS G, 1989, HUMAN RETROVIRUSES A; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PEETERS M, 1989, AIDS, V3, P625, DOI 10.1097/00002030-198910000-00001; SCHNEIDER J, 1988, AIDS, V2, P1, DOI 10.1097/00002030-198802000-00001; SHANDS KN, 1980, NEW ENGL J MED, V303, P1436, DOI 10.1056/NEJM198012183032502; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; 1991, NIH911261 DEP HLTH H; 1991, NIH891261 DEP HLTH H; 1969, MORB MORTAL WKLY R S, V18, P50	41	80	83	3	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1073	1078		10.1126/science.257.5073.1073	http://dx.doi.org/10.1126/science.257.5073.1073			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509258				2022-12-28	WOS:A1992JJ88400022
J	KILEY, TD				KILEY, TD			PATENTS ON RANDOM COMPLEMENTARY-DNA FRAGMENTS	SCIENCE			English	Article								The proposal by the National Institutes of Health (NIH) to patent products resulting merely from sequencing the human genome is a mistake: at worst, it is wrong in patent law; at best, it relies on deficiencies in law concerning what is "useful" as a requirement for patents. The proposal is symptomatic of a problem besieging biotechnology-attempts to control the raw material of scientific experimentation before research has determined the practical value of such material-that needs curing on many fronts. Corrective measures are proposed for adoption by the Executive branch, the Congress, and the courts.										ROBERTS L, 1991, SCIENCE, V254, P184, DOI 10.1126/science.1925568; ROBERTS L, 1991, SCIENCE, V254, P1104, DOI 10.1126/science.1957160; USDIN S, 1992, BIOWORLD TODAY, V3, P1	3	26	26	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					915	918		10.1126/science.1502558	http://dx.doi.org/10.1126/science.1502558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1502558				2022-12-28	WOS:A1992JH82700023
J	BEAUDRY, AA; JOYCE, GF				BEAUDRY, AA; JOYCE, GF			DIRECTED EVOLUTION OF AN RNA ENZYME	SCIENCE			English	Article							GROUP-I INTRON; SITE-SPECIFIC MUTAGENESIS; SELF-SPLICING INTRON; TETRAHYMENA RIBOZYME; RIBOSOMAL-RNA; CATALYTIC ACTIVITY; DNA-POLYMERASE; SATURATION MUTAGENESIS; SECONDARY STRUCTURE; STRANDED-DNA	An in vitro evolution procedure was used to obtain RNA enzymes with a particular catalytic function. A population of 10(13) variants of the, Tetrahynena ribozyme, a group I ribozyme that catalyzes sequence-specific cleavage of RNA via a phosphoester transfer mechanism, was generated. This enzyme has a limited ability to cleave DNA under conditions of high temperature or high MgCl2 concentration, or both. A selection constraint was imposed on the population of ribozyme variants such that only those individuals that carried out DNA cleavage under physiologic conditions were amplified to produce "progeny" ribozymes. Mutations were introduced during amplification to maintain heterogeneity in the population. This process was repeated for ten successive generations, resulting in enhanced (100 times) DNA cleavage activity.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	BEAUDRY, AA (corresponding author), SCRIPPS RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA.				NIAID NIH HHS [AI30882] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030882] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARFOD ET, 1988, GENE DEV, V2, P652, DOI 10.1101/gad.2.6.652; BEAUDRY AA, 1990, BIOCHEMISTRY-US, V29, P6534, DOI 10.1021/bi00479a027; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; Chamberlin M., 1982, ENZYMES, V15, P87; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; CHU CT, 1979, VIROLOGY, V98, P168, DOI 10.1016/0042-6822(79)90535-X; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DERBYSHIRE KM, 1986, GENE, V46, P145, DOI 10.1016/0378-1119(86)90398-7; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; Eadie GS, 1942, J BIOL CHEM, V146, P85; EIGEN M, 1988, J PHYS CHEM-US, V92, P6881, DOI 10.1021/j100335a010; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GUATELLI JC, 1990, P NATL ACAD SCI USA, V87, P1874, DOI 10.1073/pnas.87.5.1874; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HOFSTEE BHJ, 1952, J BIOL CHEM, V199, P357; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; JOHNSON KA, 1990, ENZYMES, V19, P159; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; JOYCE GF, 1987, NUCLEIC ACIDS RES, V15, P9825, DOI 10.1093/nar/15.23.9825; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P711, DOI 10.1093/nar/17.12.4885; JOYCE GF, 1992, ANTISENSE RNA DNA, P353; JOYCE GF, 1989, MOL BIOL RNA, P361; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KNOWLES JR, 1987, SCIENCE, V236, P1252; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; KWOH DY, 1989, P NATL ACAD SCI USA, V86, P1173, DOI 10.1073/pnas.86.4.1173; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEHTOVAARA PM, 1988, PROTEIN ENG, V2, P63, DOI 10.1093/protein/2.1.63; Leung DW, 1989, TECHNIQUE, V1, P11; MATTEUCCI MD, 1983, NUCLEIC ACIDS RES, V11, P3113, DOI 10.1093/nar/11.10.3113; MCNEIL JB, 1985, MOL CELL BIOL, V5, P3545, DOI 10.1128/MCB.5.12.3545; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PRICE JV, 1985, NUCLEIC ACIDS RES, V13, P1871, DOI 10.1093/nar/13.6.1871; Robertson D. W., UNPUB; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; SZOSTAK JW, 1986, NATURE, V322, P83, DOI 10.1038/322083a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1; ZAKOUR RA, 1982, NATURE, V295, P708, DOI 10.1038/295708a0; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	75	348	444	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1992	257	5070					635	641		10.1126/science.1496376	http://dx.doi.org/10.1126/science.1496376			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496376				2022-12-28	WOS:A1992JF85200026
J	WORMALD, RPL; WRIGHT, LA; COURTNEY, P; BEAUMONT, B; HAINES, AP				WORMALD, RPL; WRIGHT, LA; COURTNEY, P; BEAUMONT, B; HAINES, AP			VISUAL PROBLEMS IN THE ELDERLY POPULATION AND IMPLICATIONS FOR SERVICES	BRITISH MEDICAL JOURNAL			English	Article							EYE DISEASE; PREVALENCE	Objective - To determine the prevalence of visual disability and common eye disease among elderly people in inner London. Design - Cross sectional random sample survey. Setting - Inner London health centre. Subjects - Random sample of people aged 65 and over taken from practice's computerised age-sex register. Main outcome measures - Presenting binocular Snellen 6 m distance acuity and best monocular 3 m Sonksen-Silver acuity to classify prevalence of blindness by World Health Organisation criteria (less than 3/60 in better eye) and American criteria for legal blindness (better eye equal to 6/60 or less) and of low vision by WHO criteria (best acuity 6/18) and visual impairment by American criteria (less than 6/12 or 20/40 but greater than 6/60 or 20/200 in better eye). Principal cause of visual loss by diagnosis, referral indication by cause to hospital eye service, and proportion of cases known to primary care. Results - 207 of 288 (72%) eligible people were examined. 17 (8%) housebound subjects were examined at home. The prevalence of blindness was 1% by WHO criteria and 3.9% by American criteria. The prevalence of low vision (WHO criteria) was 7.7%. The prevalence of visual impairment (American criteria) was 10.6%. Cataract accounted for 75% of cases of low vision. Only eight out of 16 patients with low vision were known by their general practitioner to have an eye problem. 56 subjects (27%) would probably have benefited from refraction. Comparisons with studies in the United States and Finland suggested higher rates in this sample, mainly due to the prevalence of disabling cataract. Conclusion - There seems to be a considerable amount of undetected ocular disease in elderly people in the community.	INST OPHTHALMOL,DEPT PREVENT MED,LONDON EC1V 9EJ,ENGLAND; WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,LONDON N19 5NF,ENGLAND	University of London; University College London; University of London; University College London				Haines, Andy/0000-0002-8053-4605				BRENNAN ME, 1973, BRIT J PREV SOC MED, V27, P154; CULLINAN TR, 1977, 28 HLTH SERV RES UN; FREER CB, 1990, BRIT MED J, V300, P1447, DOI 10.1136/bmj.300.6737.1447; GARDNER S, 1989, CONFIDENCE INTERVAL; GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196; HAKKINEN L, 1984, SCAND J SOC MED S, V35; HITCHINGS RA, 1989, BRIT MED J, V298, P1126, DOI 10.1136/bmj.298.6681.1126; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MARTINEZ GS, 1982, AM J OPHTHALMOL, V94, P181, DOI 10.1016/0002-9394(82)90073-3; PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191; SANDERSON D, 1986, CANADIAN NURSE   FEB, P19; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; 1988, 1 OFF POP CENS SURV; 1980, SURV OPHTHALMOL S, V24, P335	14	116	118	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1226	1229		10.1136/bmj.304.6836.1226	http://dx.doi.org/10.1136/bmj.304.6836.1226			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515797	Green Published, Bronze			2022-12-28	WOS:A1992HT96400028
J	BULTMAN, SJ; MICHAUD, EJ; WOYCHIK, RP				BULTMAN, SJ; MICHAUD, EJ; WOYCHIK, RP			MOLECULAR CHARACTERIZATION OF THE MOUSE AGOUTI LOCUS	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LIMB DEFORMITY; SEQUENCE-ANALYSIS; GENE; RECOMBINATION; MUTATIONS; MICE; ORGANIZATION; TRANSCRIPTS; CLEAVAGE	The agouti (a) locus acts within the microenvironment of the hair follicle to regulate coat color pigmentation in the mouse. We have characterized a gene encoding a novel 131 amino acid protein that we propose is the one gene associated with the agouti locus. This gene is normally expressed in a manner consistent with a locus function, and, more importantly, its structure and expression are affected by a number of representative alleles in the agouti dominance hierarchy. In addition, we found that the pleiotropic effects associated with the lethal yellow (A(y)) mutation, which include pronounced obesity, diabetes, and the development of neoplasms, are accompanied by deregulated overexpression of the agouti gene in numerous tissues of the adult animal.	UNIV TENNESSEE,SCH BIOMED SCI,DIV BIOL,OAK RIDGE NATL LAB,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville	BULTMAN, SJ (corresponding author), OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831, USA.		Woychik, Richard P/C-8345-2019	Woychik, Richard P/0000-0001-8196-1732	NIEHS NIH HHS [IAG 222Y01-ES-10067] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R13ES010067] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BATES PF, 1983, GENE, V26, P137, DOI 10.1016/0378-1119(83)90183-X; BULTMAN SJ, 1991, P NATL ACAD SCI USA, V88, P8062, DOI 10.1073/pnas.88.18.8062; CALARCO PG, 1976, J EMBRYOL EXP MORPH, V35, P73; CARPENTER KJ, 1958, AM J PHYSIOL, V193, P499, DOI 10.1152/ajplegacy.1958.193.3.499; Castle WE, 1910, SCIENCE, V32, P868, DOI 10.1126/science.32.833.868; Cuenot L., 1905, ARCH ZOOL EXP GEN, V3, P123; DERINGER MK, 1970, J NATL CANCER I, V45, P1205; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEXTER TM, 1977, NATURE, V269, P412, DOI 10.1038/269412a0; DICKERSON GE, 1947, SCIENCE, V105, P496, DOI 10.1126/science.105.2732.496-a; Dunn LC, 1928, P NATL ACAD SCI USA, V14, P816, DOI 10.1073/pnas.14.10.816; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; EATON GJ, 1963, GENETICA, V34, P155, DOI 10.1007/BF01664187; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FENTON PF, 1951, P SOC EXP BIOL MED, V77, P420, DOI 10.3181/00379727-77-18800; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GRANHOLM NH, 1986, J REPROD FERTIL, V76, P279, DOI 10.1530/jrf.0.0760279; Green M. C., 1989, GENETIC VARIANTS STR, P17; HELLERSTROM C, 1963, METABOLISM, V12, P527; HESTON WE, 1961, J NATL CANCER I, V26, P969; Heston WE, 1942, J NATL CANCER I, V3, P303; HESTON WE, 1962, J NATL CANCER I, V29, P197; HESTON WE, 1947, J NATL CANCER I, V7, P463; HESTON WE, 1963, J NATL CANCER I, V31, P189; HOLLANDER W. F., 1956, JOUR HEREDITY, V47, P221; KOBORI JA, 1986, SCIENCE, V234, P173, DOI 10.1126/science.3018929; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBO RV, 1983, P NATL ACAD SCI-BIOL, V80, P4808, DOI 10.1073/pnas.80.15.4808; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; PAPAIOANNOU V, 1979, J EMBRYOL EXP MORPH, V52, P153; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLOCHER TA, 1976, METABOLISM, V25, P593, DOI 10.1016/0026-0495(76)90013-5; Robertson GG, 1942, J EXP ZOOL, V89, P197, DOI 10.1002/jez.1400890203; RUSSELL LB, 1963, GENETICS, V48, P907; SAKURAI T, 1975, DEV BIOL, V47, P466, DOI 10.1016/0012-1606(75)90301-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; Silvers W. K., 1979, COAT COLORS MICE, P6; SILVERS WK, 1961, SCIENCE, V134, P368, DOI 10.1126/science.134.3476.368; SILVERS WK, 1958, J EXP ZOOL, V137, P189, DOI 10.1002/jez.1401370110; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; SILVERS WK, 1958, J EXP ZOOL, V137, P181, DOI 10.1002/jez.1401370109; SIRACUSA LD, 1987, GENETICS, V117, P93; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKEUCHI T, 1989, Journal of Investigative Dermatology, V92, p239S, DOI 10.1111/1523-1747.ep13075730; TRECO D, 1985, MOL CELL BIOL, V5, P2029, DOI 10.1128/MCB.5.8.2029; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WOLFF GL, 1986, J HERED, V77, P151, DOI 10.1093/oxfordjournals.jhered.a110206; WOYCHIK RP, 1990, P NATL ACAD SCI USA, V87, P2588, DOI 10.1073/pnas.87.7.2588; WOYCHIK RP, 1985, NATURE, V318, P36, DOI 10.1038/318036a0; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0	65	673	711	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1195	1204		10.1016/S0092-8674(05)80067-4	http://dx.doi.org/10.1016/S0092-8674(05)80067-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473152				2022-12-28	WOS:A1992KE60400013
J	SHERMAN, DR; GUINN, B; PERDOK, MM; GOLDBERG, DE				SHERMAN, DR; GUINN, B; PERDOK, MM; GOLDBERG, DE			COMPONENTS OF STEROL BIOSYNTHESIS ASSEMBLED ON THE OXYGEN-AVID HEMOGLOBIN OF ASCARIS	SCIENCE			English	Article							SQUALENE EPOXIDASE; RAT-LIVER	The parasitic nematode Ascaris infests a billion people worldwide. Much of its proliferative success is due to prodigious egg production, up to 10(6) sterol-replete eggs per day. Sterol synthesis requires molecular oxygen for squalene epoxidation, yet oxygen is scarce in the intestinal folds the worms inhabit. Ascaris has an oxygen-avid hemoglobin in the perienteric fluid that bathes its reproductive organs. Purified hemoglobin contained tightly bound squalene and functioned as an NADPH-dependent, ferrihemoprotein reductase. All components of the squalene epoxidation reaction-squalene, oxygen, NADPH, and NADPH-dependent reductase-are assembled on the hemoglobin. This molecule may thus function in sterol biosynthesis.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)					NCRR NIH HHS [RR-00954] Funding Source: Medline; NIADDK NIH HHS [AM-20579] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020579] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barrett J., 1981, BIOCH PARASITIC HELM; BRYANT C, 1978, ADV PARASIT, V16, P3111; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CHEAH KS, 1975, BIOCHIM BIOPHYS ACTA, V387, P107, DOI 10.1016/0005-2728(75)90055-9; CROMPTON DWT, 1986, T ROY SOC TROP MED H, V80, P697, DOI 10.1016/0035-9203(86)90368-8; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; Dresselhaus M., 1974, Getreide, Mehl und Brot, V28, P137; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; HAMADA K, 1963, J BIOCHEM-TOKYO, V53, P484, DOI 10.1093/oxfordjournals.jbchem.a127727; HAMADA K, 1962, J BIOCHEM-TOKYO, V52, P290, DOI 10.1093/oxfordjournals.jbchem.a127616; Keilin D, 1925, P R SOC LOND B-CONTA, V98, P312, DOI 10.1098/rspb.1925.0039; LEE DL, 1965, EXP PARASITOL, V16, P392, DOI 10.1016/0014-4894(65)90062-7; MBAYA B, 1987, BIOCHEM BIOPH RES CO, V147, P556, DOI 10.1016/0006-291X(87)90967-3; OKAZAKI T, 1967, BIOCHIM BIOPHYS ACTA, V140, P258, DOI 10.1016/0005-2795(67)90466-7; ONO T, 1985, METHOD ENZYMOL, V110, P375; PAWLOWSKI ZS, 1982, REV INFECT DIS, V4, P806; SHERMAN DH, UNPUB; SMITH MH, 1963, PROC R SOC SER B-BIO, V157, P234, DOI 10.1098/rspb.1963.0007; STEPHENSON LS, 1980, PARASITOLOGY, V81, P221, DOI 10.1017/S0031182000055177; WARREN K, 1988, BIOL PARASITISM; Warren K, 1989, TROPICAL GEOGRAPHICA; WEBER RE, 1980, AM ZOOL, V20, P79; WITTENBE.BA, 1965, BIOCHIM BIOPHYS ACTA, V111, P485, DOI 10.1016/0304-4165(65)90058-9; YAMAMOTO S, 1970, J BIOL CHEM, V245, P1670	25	23	24	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1930	1932		10.1126/science.1470914	http://dx.doi.org/10.1126/science.1470914			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470914				2022-12-28	WOS:A1992KD08800029
J	BRUZIK, JP; MANIATIS, T				BRUZIK, JP; MANIATIS, T			SPLICED LEADER RNAS FROM LOWER EUKARYOTES ARE TRANSSPLICED IN MAMMALIAN-CELLS	NATURE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; PRE-MESSENGER-RNA; 2'-OME RNA; C-ELEGANS; INVITRO; SEQUENCES; U2; OLIGONUCLEOTIDES; IDENTIFICATION; PRECURSORS	EXON sequences present on separate RNA molecules can be joined by trans-splicing in trypanosomatids, Euglena, and in the nematode and trematode worms1-3. Trans-splicing involves an interaction between a 5' splice site present in a spliced leader RNA and a 3' splice site located near the 5' end of pre-messenger RNAs. In vitro trans-splicing of artificial mammalian pre-mRNAs has been reported, but the efficiency of splicing appears to depend on sequence complementarity between the two substrates4-7. There has been speculation that some natural pre-mRNAs can be trans-spliced in mammalian cells in vivo8,9, but alternative interpretations have not been ruled out. Here we show that spliced leader RNAs can be accurately trans-spliced in mammalian cells in vivo and in vitro. Both nematode and mammalian 3' splice sites can function as acceptors for trans-splicing in vivo. These results reveal functional conservation in the splicing machinery between lower eukaryotes and mammals, and they directly demonstrate the potential for trans-splicing in mammalian cells.			BRUZIK, JP (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BEKTESH SL, 1988, NUCLEIC ACIDS RES, V16, P5692, DOI 10.1093/nar/16.12.5692; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; Huang X Y, 1992, Genet Eng (N Y), V14, P211; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; MANGIN M, 1986, EMBO J, V5, P987, DOI 10.1002/j.1460-2075.1986.tb04313.x; MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; SHARP PA, 1987, CELL, V50, P147, DOI 10.1016/0092-8674(87)90207-8; SHARP PA, 1986, CELL, V44, P211, DOI 10.1016/0092-8674(86)90753-1; SHIMIZU A, 1989, P NATL ACAD SCI USA, V86, P8020, DOI 10.1073/pnas.86.20.8020; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SOLNICK D, 1986, CELL, V44, P211, DOI 10.1016/0092-8674(86)90752-X; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; SUREAU A, 1991, CR ACAD SCI III-VIE, V312, P323; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	36	66	84	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					692	695		10.1038/360692a0	http://dx.doi.org/10.1038/360692a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465136				2022-12-28	WOS:A1992KD08200063
J	BORST, P; NUSSENZWEIG, V				BORST, P; NUSSENZWEIG, V			MOLECULAR PARASITOLOGY AT WOODS HOLE	CELL			English	Editorial Material							PLASMODIUM-FALCIPARUM; GLYCOPROTEIN GENE; RESISTANCE; LEISHMANIA; DNA		NYU MED CTR,MICHAEL HEIDELBERGER DIV IMMUNOL,DEPT PATHOL,NEW YORK,NY 10016	New York University	BORST, P (corresponding author), NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS.							BARNES DA, 1992, EMBO J, V11, P3067, DOI 10.1002/j.1460-2075.1992.tb05378.x; BLATTNER J, 1992, IN PRESS J CELL BIOL; BORST P, 1991, TRENDS GENET, V7, P307, DOI 10.1016/0168-9525(91)90406-G; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; HENDERSON DM, 1992, MOL CELL BIOL, V12, P2855, DOI 10.1128/MCB.12.6.2855; JOINER K, 1985, J EXP MED, V161, P1196, DOI 10.1084/jem.161.5.1196; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; OUELLETTE M, 1991, EMBO J, V10, P1009, DOI 10.1002/j.1460-2075.1991.tb08035.x; Pfefferkorn E.R., 1990, P26; RICEFICHT AC, 1982, NATURE, V298, P676, DOI 10.1038/298676a0; ROSENTHAL PJ, 1992, MOL BIOCHEM PARASIT, V51, P143, DOI 10.1016/0166-6851(92)90209-3; SCHENKMAN S, 1988, CELL, V55, P157, DOI 10.1016/0092-8674(88)90018-9; SHERMAN DR, 1992, IN PRESS P NATL ACAD; SIMPSON AM, 1976, J PROTOZOOL, V23, P583, DOI 10.1111/j.1550-7408.1976.tb03846.x; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; TARDIEUX I, 1992, IN PRESS CELL, V71; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	23	3	3	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					895	899		10.1016/0092-8674(92)90386-Q	http://dx.doi.org/10.1016/0092-8674(92)90386-Q			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458539				2022-12-28	WOS:A1992KB99000003
J	SETTE, A; CEMAN, S; KUBO, RT; SAKAGUCHI, K; APPELLA, E; HUNT, DF; DAVIS, TA; MICHEL, H; SHABANOWITZ, J; RUDERSDORF, R; GREY, HM; DEMARS, R				SETTE, A; CEMAN, S; KUBO, RT; SAKAGUCHI, K; APPELLA, E; HUNT, DF; DAVIS, TA; MICHEL, H; SHABANOWITZ, J; RUDERSDORF, R; GREY, HM; DEMARS, R			INVARIANT CHAIN PEPTIDES IN MOST HLA-DR MOLECULES OF AN ANTIGEN-PROCESSING MUTANT	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I; BINDING SITE; T-CELLS; REGION; GENE; SPECIFICITY; MUTATIONS; MHC	Class II major histocompatibility complexes bind peptides in an endosome-like compartment. When the class II null cell line 721.174 was transfected with class II DR3 genes, DR molecules were produced in normal amounts. However, the DR molecules were abnormally conformed and unstable because deletion of an antigen-processing gene had impaired intracellular formation of most class II-peptide complexes. Yet, 70 percent of the DR molecules still bore peptides, 80 percent of which were 21- to 24-amino acid fragments of the class II-associated invariant chain. These peptides were rare on DR3 from control cells. Thus, a defect in the main antigen-processing pathway revealed a process in which DR molecules bind long peptides derived from proteins present in the same compartment.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; NCI,BETHESDA,MD 20892; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Virginia	SETTE, A (corresponding author), CYTEL,3525 JOHN HOPKINS COURT,SAN DIEGO,CA 92121, USA.		Sette, Alessandro/AFO-8916-2022; Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Sakaguchi, Kazuyasu/0000-0002-8434-4171	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015486, R01AI018634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18634, AI15486] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER JG, 1992, TISSUE ANTIGENS, V39, P161, DOI 10.1111/j.1399-0039.1992.tb01932.x; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; Brodsky F M, 1992, Trends Cell Biol, V2, P109, DOI 10.1016/0962-8924(92)90015-F; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CEMAN S, 1992, J IMMUNOL, V149, P754; CEMAN S, UNPUB; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; COTNER T, 1991, J IMMUNOL, V146, P414; DeMars R, 1992, Trends Cell Biol, V2, P81, DOI 10.1016/0962-8924(92)90077-Z; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEMARS R, 1983, HUM IMMUNOL, V8, P123, DOI 10.1016/0198-8859(83)90008-3; DENAGEL DC, 1992, IMMUNOL TODAY, V13, P86, DOI 10.1016/0167-5699(92)90147-Y; ERLICH H, 1986, HUM IMMUNOL, V16, P205, DOI 10.1016/0198-8859(86)90049-2; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; LAMB CA, 1992, J IMMUNOL, V148, P3478; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LONG EO, 1992, NEW BIOL, V4, P274; MALNATI MS, 1992, NATURE, V357, P702, DOI 10.1038/357702a0; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; RIBERBY JM, 1992, J IMMUNOL, V148, P2856; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1992, IMMUNOL TODAY, V13, P43, DOI 10.1016/0167-5699(92)90131-P; SETTE A, 1989, J IMMUNOL, V142, P35; SETTE A, 1992, J IMMUNOL, V148, P844; SIDNEY J, 1992, J IMMUNOL, V149, P2634; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; TROWSDALE J, 1991, IMMUNOL TODAY, V12, P443, DOI 10.1016/0167-5699(91)90017-N; VANSCHOOTEN WCA, 1989, EUR J IMMUNOL, V19, P2075, DOI 10.1002/eji.1830191116; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0	39	216	222	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1801	1804		10.1126/science.1465617	http://dx.doi.org/10.1126/science.1465617			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465617				2022-12-28	WOS:A1992KB96400041
J	RICHARDS, RI; SUTHERLAND, GR				RICHARDS, RI; SUTHERLAND, GR			DYNAMIC MUTATIONS - A NEW CLASS OF MUTATIONS CAUSING HUMAN-DISEASE	CELL			English	Article							FRAGILE-X; GENE; DNA				RICHARDS, RI (corresponding author), ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA.		Sutherland, Grant Robert/D-2606-2012; Richards, Robert/ABE-6423-2020	Richards, Robert Ian/0000-0002-5978-6453				ALBERTS B, 1983, MOL BIOL CELL, P214; Biancalana V., 1992, Human Molecular Genetics, V1, P255, DOI 10.1093/hmg/1.4.255; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARPER PS, 1992, AM J HUM GENET, V51, P10; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; OBERLE I, 1991, SCIENCE, V252, P1087; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; SUTHERLAND GR, 1991, LANCET, V338, P289, DOI 10.1016/0140-6736(91)90426-P; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; YU S, 1992, AM J HUM GENET, V50, P968; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; ZHU QS, 1990, NUCLEIC ACIDS RES, V18, P7119, DOI 10.1093/nar/18.23.7119	19	297	306	3	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					709	712		10.1016/0092-8674(92)90302-S	http://dx.doi.org/10.1016/0092-8674(92)90302-S			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516128				2022-12-28	WOS:A1992JL66300002
J	LEWIS, SM				LEWIS, SM			EXAMINED AT 40	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						CERTIFICATION; SPECIALTY BOARDS; KNOWLEDGE, ATTITUDES; PRACTICE; EDUCATION, MEDICAL		A physician's experience with a board examination after 10 years of private practice provokes an examination of the process of becoming an internist.										OSLER W, 1932, AEQUANIMITAS OTHER A, P133	1	0	0	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					433	435		10.7326/0003-4819-117-5-433	http://dx.doi.org/10.7326/0003-4819-117-5-433			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503335				2022-12-28	WOS:A1992JK67800014
J	WILKES, MS; KRAVITZ, RL				WILKES, MS; KRAVITZ, RL			MEDICAL RESEARCHERS AND THE MEDIA - ATTITUDES TOWARD PUBLIC DISSEMINATION OF RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To study the experience of recently published authors with the news media. Design.-A self-administered questionnaire. Participants.-All first authors of scientific articles published in JAMA and The New England Journal of Medicine during a 6-month period. Of 397 surveyed, 92% responded. Main Outcome Measures.-Researchers were asked about (1) their experience with the news media, (2) their attitudes toward the dissemination of health-related research to the general public, and (3) their attitudes toward the lay press. Results.-Of respondents, 65% stated that their research was discussed in the lay press, and 60% reported that they were directly contacted by the press. Researchers had positive attitudes toward the press; 86% reported that news reports based on their research were accurate and 44% felt that media coverage would help them achieve their overall professional goals. Positive aspects of media coverage most frequently endorsed were that (1) it improves the image of the profession, (2) it informs the professional community of their research, and (3) it allows the public to understand the topic better. Negative aspects of media coverage were (1) it gives the impression that the researcher is seeking publicity, (2) it creates jealousy among colleagues, and (3) it takes too much time. Researchers were not eager to change the existing dissemination process, yet they endorsed the need for uniform standards concerning relations with the press. Conclusions.-The majority of first authors in two leading medical journals reported substantial media coverage of their research, expressed generally positive sentiments about the press coverage of their work, and expressed a need for consensus on interactions involving the press.			WILKES, MS (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DIV GEN INTERNAL MED & HLTH SERV RES,LOS ANGELES,CA 90024, USA.		Kravitz, Richard/AAF-7425-2021	Kravitz, Richard/0000-0001-5575-529X				ALTMAN LK, 1976, B AM COLL PHYSICIANS, V8, P6; ANGELL M, 1991, NEW ENGL J MED, V325, P1371, DOI 10.1056/NEJM199111073251910; CANIANO DA, 1985, J PEDIATR SURG, V20, P566, DOI 10.1016/S0022-3468(85)80002-6; COHEN L, 1988, CAN MED ASSOC J, V139, P657; DEVRIES WC, 1988, JAMA-J AM MED ASSOC, V259, P886, DOI 10.1001/jama.259.6.886; FOWLER FJ, 1988, APPLIED SOCIAL RES M, V1, P92; GRACE J, 1980, CAN MED ASSOC J, V122, P450; HAYNESROBINSON E, 1989, JAMA-J AM MED ASSOC, V261, P1280; HAYS RD, 1989, EDUC PSYCHOL MEAS, V49, P629, DOI 10.1177/001316448904900315; HOFFMAN B, 1982, CAN MED ASSOC J, V126, P408; LUNDBERG GD, 1991, JAMA-J AM MED ASSOC, V265, P400, DOI 10.1001/jama.265.3.400; MCGUIRE R, 1989, AM MED NEWS     0528, P4; MERTON RK, 1957, DOCTORING STUDIES SO; MIZES JS, 1984, PUBLIC OPIN QUART, V48, P794, DOI 10.1086/268885; NELKIN D, 1985, SOC RES, V52, P625; OSLER W, 1905, AEQUANIMITAS OTHER A; PHILLIPS DF, 1988, JAMA-J AM MED ASSOC, V260, P751; Reiser SJ, 1977, ETHICS MED HIST PERS, P7; RELMAN AS, 1981, NEW ENGL J MED, V305, P824, DOI 10.1056/NEJM198110013051408; RELMAN AS, 1984, CLIN RES, V32, P119; ROGERS EM, 1971, COMMUN INNOVATION, P30; STEINBROOK R, 1986, LOS ANGELES TIM 1025, P31; STEINBROOK R, 1986, LOS ANGELES TIM 1025, P1; STEINBROOK R, 1986, LOS ANGELES TIM 1025, P30	24	42	42	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					999	1003		10.1001/jama.268.8.999	http://dx.doi.org/10.1001/jama.268.8.999			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK129	1501326				2022-12-28	WOS:A1992JK12900024
J	LINSLEY, PS; WALLACE, PM; JOHNSON, J; GIBSON, MG; GREENE, JL; LEDBETTER, JA; SINGH, C; TEPPER, MA				LINSLEY, PS; WALLACE, PM; JOHNSON, J; GIBSON, MG; GREENE, JL; LEDBETTER, JA; SINGH, C; TEPPER, MA			IMMUNOSUPPRESSION INVIVO BY A SOLUBLE FORM OF THE CTLA-4 T-CELL ACTIVATION MOLECULE	SCIENCE			English	Article							COSTIMULATORY SIGNAL; ANTIGEN-B7; INTERLEUKIN-2; EXPRESSION; ANTIBODIES; RECEPTOR; ADHESION	In vitro, when the B7 molecule on the surface of antigen-presenting cells binds to the T cell surface molecules CD28 and CTLA-4, a costimulatory signal for T cell activation is generated. CTLA4Ig is a soluble form of the extracellular domain of CTLA-4 and binds B7 with high avidity. CTLA4Ig treatment in vivo suppressed T cell-dependent antibody responses to sheep erythrocytes or keyhole limpet hemocyanin. Large doses of CTLA4Ig suppressed responses to a second immunization. Thus, costimulation by B7 is important for humoral immune responses in vivo, and interference with costimulation may be useful for treatment of antibody-mediated autoimmune disease.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, WALLINGFORD, CT 06492 USA	Bristol-Myers Squibb	LINSLEY, PS (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA.							BIERER BE, 1991, ADV CANCER RES, V56, P49; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; BURSTEIN HJ, 1992, J IMMUNOL, V148, P3687; DAMLE NK, 1991, EUR J IMMUNOL, V21, P1277, DOI 10.1002/eji.1830210527; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GUCKEL B, 1991, J EXP MED, V174, P957, DOI 10.1084/jem.174.5.957; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; JENKINS MK, 1991, J IMMUNOL, V147, P2461; Jerne N.K., 1963, CELL BOUND ANTIBODIE, P109; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LENSCHOW DJ, UNPUB; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; LIU Y, IN PRESS CURR OPIN I; LIU YJ, IN PRESS EUR J IMMUN; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TAN PH, UNPUB; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; WALDMANN H, 1989, ANNU REV IMMUNOL, V7, P407, DOI 10.1146/annurev.iy.07.040189.002203	28	766	849	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					792	795		10.1126/science.1496399	http://dx.doi.org/10.1126/science.1496399			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496399				2022-12-28	WOS:A1992JG85100033
J	STICHER, L; HOFSTEENGE, J; MILANI, A; NEUHAUS, JM; MEINS, F				STICHER, L; HOFSTEENGE, J; MILANI, A; NEUHAUS, JM; MEINS, F			VACUOLAR CHITINASES OF TOBACCO - A NEW CLASS OF HYDROXYPROLINE-CONTAINING PROTEINS	SCIENCE			English	Article							TRIPLE-HELIX; CONFORMATION; COLLAGEN; PLANTS	The fungicidal type I chitinases contribute to the defense response of plants against pathogens. Two tobacco chitinases represent a different class of hydroxyproline-containing proteins. Hydroxyproline-rich proteins are predominantly extracellular, structural glycoproteins that lack enzymatic activity and contain many hydroxyproline residues. In contrast, type I chitinases are vacuolar enzymes. They are not glycosylated and contain a small number of hydroxyproline residues restricted to a single, short peptide sequence.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; BOT INST,PFLANZENPHYSIOL ABT,CH-4056 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; Boller T., 1988, Oxford Surveys of Plant Molecular and Cell Biology, V5, P145; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; GROSS J, 1973, HARVEY LECT, V68, P351; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOFSTEENGE J, 1990, EUR J BIOCHEM, V188, P55, DOI 10.1111/j.1432-1033.1990.tb15370.x; HOMER RB, 1979, PLANTA, V46, P217; JONES RL, 1989, NEW PHYTOL, V111, P567, DOI 10.1111/j.1469-8137.1989.tb02352.x; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; LAMPORT DTA, 1969, BIOCHEMISTRY-US, V8, P1155, DOI 10.1021/bi00831a049; LINTHORST HJM, 1991, CRIT REV PLANT SCI, V10, P123, DOI 10.1080/07352689109382309; MATSUZAKI T, 1974, ACTA CRYSTALLOGR B, V30, P1029, DOI 10.1107/S0567740874004213; MEINS F, IN PRESS GENES INVOL; NEUHAUS JM, 1991, P NATL ACAD SCI USA, V88, P10362, DOI 10.1073/pnas.88.22.10362; Robinson D G, 1990, ORG ASSEMBLY PLANT A, P283; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; SCHAR M, 1991, RAPID COMMUN MASS SP, V5, P319, DOI 10.1002/rcm.1290050705; SHEN H, 1991, J BIOL CHEM, V266, P11335; SHINSHI H, 1987, P NATL ACAD SCI USA, V84, P89, DOI 10.1073/pnas.84.1.89; SHINSHI H, 1990, PLANT MOL BIOL, V14, P357, DOI 10.1007/BF00028772; SHOWALTER AM, 1989, BIOCH PLANTS, V15, P485; Showalter AM, 1990, ORG ASSEMBLY PLANT A, P247; TANAKA M, 1981, J BIOL CHEM, V256, P1397; VANBUUREN M, 1992, MOL GEN GENET, V232, P460, DOI 10.1007/BF00266251; VANHOLST GJ, 1984, PLANT PHYSIOL, V74, P247, DOI 10.1104/pp.74.2.247; VANHOLST GJ, 1984, PLANT PHYSIOL, V75, P1163, DOI 10.1104/pp.75.4.1163; WAITE JH, 1983, J BIOL CHEM, V258, P2911	28	44	46	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					655	657		10.1126/science.1496378	http://dx.doi.org/10.1126/science.1496378			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496378				2022-12-28	WOS:A1992JF85200032
J	MILLER, FW; LEITMAN, SF; CRONIN, ME; HICKS, JE; LEFF, RL; WESLEY, R; FRASER, DD; DALAKAS, M; PLOTZ, PH				MILLER, FW; LEITMAN, SF; CRONIN, ME; HICKS, JE; LEFF, RL; WESLEY, R; FRASER, DD; DALAKAS, M; PLOTZ, PH			CONTROLLED TRIAL OF PLASMA-EXCHANGE AND LEUKAPHERESIS IN POLYMYOSITIS AND DERMATOMYOSITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; INFLAMMATORY MYOPATHIES; RANDOMIZED TRIAL; PLASMAPHERESIS; LYMPHOPLASMAPHERESIS; RECOGNITION; MYOSITIS; THERAPY; SUBSETS	Background. The therapeutic options for patients with polymyositis or dermatomyositis that is resistant to corticosteroids are limited, unproved, and often toxic. Uncontrolled trials concluded that both plasma exchange and leukapheresis are beneficial, but despite the considerable use of these approaches, proof of their efficacy is lacking. Methods. Thirty-nine patients with definite polymyositis or dermatomyositis were randomly assigned to receive plasma exchange (replacement of one volume of plasma with 5 percent albumin in saline), leukapheresis (removal of 5 x 10(9) to 10 x 10(9) lymphocytes), or sham apheresis in a double-blind manner, with 12 treatments given over a one-month period. Muscle strength, functional capacity, and serum levels of muscle-associated enzymes were measured before and after the 12 procedures. Results. In each group 3 of 13 patients had improvements in strength and functional capacity. The condition of 3 patients treated with leukapheresis and 1 treated with plasma exchange deteriorated, and it was unchanged in the other 26 patients. Adverse effects of apheresis included the need for a central venous catheter (9 patients), major vasovagal episodes (3 patients), and severe citrate reactions (2 patients). Despite the occurrence of significant reductions in the serum levels of muscle enzymes with plasma exchange (P < 0.001) and significant decreases in lymphocyte counts with leukapheresis (P = 0.002), there were no significant differences among the three treatment groups in the final muscle strength or functional capacity of the patients. Conclusions. As treatments for corticosteroid-resistant polymyositis or dermatomyositis, leukapheresis and plasma exchange are no more effective than sham apheresis.	NIH,DEPT TRANSFUS MED,BETHESDA,MD 20892; NIH,DEPT REHABIL MED,BETHESDA,MD 20892; NIH,CTR CLIN,BETHESDA,MD 20892; NINCDS,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)			Miller, Frederick/D-2431-2019	Miller, Frederick/0000-0003-2831-9593				BOHAN A, 1975, NEW ENGL J MED, V292, P403, DOI 10.1056/NEJM197502202920807; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; CECERE FA, 1982, PLASMA THER TRANSFUS, V3, P401; CLARKE CR, 1988, J CLIN LAB IMMUNOL, V27, P149; CONVERY FR, 1977, ARCH PHYS MED REHAB, V58, P494; Daniels L, 1972, MUSCLE TESTING TECHN, P2; Dau P C, 1987, J Clin Apher, V3, P167, DOI 10.1002/jca.2920030308; DAU PC, 1981, ARCH NEUROL-CHICAGO, V38, P544, DOI 10.1001/archneur.1981.00510090038003; DWOSH IL, 1983, NEW ENGL J MED, V308, P1124, DOI 10.1056/NEJM198305123081903; ENGEL AG, 1990, RES P ARNMD, V68, P141; ENGEL AG, 1986, HUM PATHOL, V17, P704, DOI 10.1016/S0046-8177(86)80180-0; HERSON S, 1989, ANN MED INTERNE, V140, P453; HOLLANDER M, 1973, NONPARAMETRIC STAT M, P120; KARSH J, 1981, ARTHRITIS RHEUM, V24, P867, DOI 10.1002/art.1780240701; KHATRI BO, 1982, MUSCLE NERVE, V5, P568, DOI 10.1002/mus.880050710; LOVE LA, 1991, MEDICINE, V70, P360, DOI 10.1097/00005792-199111000-00002; MIKOL J, 1986, MYOLOGY, P1423; MILLER FW, 1990, CLIN EXP IMMUNOL, V81, P373; ODDIS CV, 1990, J RHEUMATOL, V17, P1329; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; ROTHWELL RS, 1980, ARTHRITIS RHEUM, V23, P785, DOI 10.1002/art.1780230702; Schumacher H.R., 1988, PRIMER RHEUMATIC DIS; TARGOFF IN, 1990, J IMMUNOL, V144, P1737; TARGOFF IN, 1990, ARTHRITIS RHEUM, V33, P1361, DOI 10.1002/art.1780330908; VERDICKT W, 1983, ARTHRITIS RHEUM, V26, P1419, DOI 10.1002/art.1780261202; WALLACE D, 1982, NEW ENGL J MED, V306, P1406, DOI 10.1056/NEJM198206103062307; WEI N, 1983, LANCET, V1, P17	27	221	226	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1992	326	21					1380	1384		10.1056/NEJM199205213262102	http://dx.doi.org/10.1056/NEJM199205213262102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU890	1472183				2022-12-28	WOS:A1992HU89000002
J	SPIRO, H				SPIRO, H			WHAT IS EMPATHY AND CAN IT BE TAUGHT	ANNALS OF INTERNAL MEDICINE			English	Article						EMPATHY; HUMANITIES; EDUCATION, MEDICAL; PHILOSOPHY, MEDICAL; PHYSICIAN-PATIENT RELATIONS		Empathy is the "almost magical" emotion that persons or objects arouse in us as projections of our feelings. Empathy requires passion, more so than does equanimity, so long cherished by physicians. Medical students lose some of their empathy as they learn science and detachment, and hospital residents lose the remainder in the weariness of overwork and in the isolation of the intensive care units that modern hospitals have become. Conversations about experiences, discussions of patients and their human stories, more leisure and unstructured contemplation of the humanities help physicians to cherish empathy and to retain their passion. Physicians need rhetoric as much as knowledge, and they need stories as much as journals if they are to be more empathetic than computers.			SPIRO, H (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.							ARISTOTLE, 1938, POETICS; BARON RJ, 1981, J MED PHILOS, V6, P5, DOI 10.1093/jmp/6.1.5; Berger J., 1971, LOOK THINGS; BOOK HE, 1988, AM J PSYCHIAT, V145, P420; BROTHERS L, 1989, AM J PSYCHIAT, V146, P10; DONNELLY WJ, 1988, JAMA-J AM MED ASSOC, V260, P823, DOI 10.1001/jama.260.6.823; FREUD S, 1955, COMPLETE WORKS S FRE, V18; GAUSS CE, 1973, DICT HIST IDEAS, V2, P85; HARRIES K, 1973, DICT HIST IDEAS, V2; HAWKINS AH, IN PRESS YALE J BIOL; HOGENSON GB, 1981, J MED PHILOS, V6, P67, DOI 10.1093/jmp/6.1.67; HUNTER KM, 1986, PERSPECT BIOL MED, V29, P619; Nagel E., 1961, STRUCTURE SCI; PAYER L, 1988, MED CULTURE; Spiro HM, 1986, DOCTORS PATIENTS PLA; Thomas L, 1974, LIVES CELL NOTES BIO; Updike John, 1990, RABBIT REST	17	188	191	0	40	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					843	846		10.7326/0003-4819-116-10-843	http://dx.doi.org/10.7326/0003-4819-116-10-843			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1482433				2022-12-28	WOS:A1992HT80200010
J	CAPLAN, AJ; CYR, DM; DOUGLAS, MG				CAPLAN, AJ; CYR, DM; DOUGLAS, MG			YDJ1P FACILITATES POLYPEPTIDE TRANSLOCATION ACROSS DIFFERENT INTRACELLULAR MEMBRANES BY A CONSERVED MECHANISM	CELL			English	Article							HEAT-SHOCK PROTEINS; PREPRO-ALPHA-FACTOR; MITOCHONDRIAL PRECURSOR POLYPEPTIDES; POST-TRANSLATIONAL TRANSLOCATION; YEAST SECRETORY PATHWAY; ESCHERICHIA-COLI DNAJ; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CARBOXYPEPTIDASE-Y; STRESS PROTEINS	The role of S. cerevisiae YDJ1 protein (YDJ1p) in polypeptide translocation across membranes has been examined. A conditional ydj1 mutant strain (ydj1-151TS) is defective for import of several polypeptides into mitochondria and alpha factor into the endoplasmic reticulum at 37-degrees-C. These defects are suppressed by E. coli dnaJ or overexpression of S. cerevisiae SIS1 proteins. A different ydj1 mutant, which cannot be farnesylated (ydj1-S406), displays similar transport defects to the ydj1-151 strain. Furthermore, the ability of purified ydj1-151p to stimulate the ATPase activity of hsp70SSA1 was greatly diminished compared with the wild-type protein. Together, these data suggest that YDJ1p functions in polypeptide translocation in a conserved manner, probably acting at organelle membranes and in association with hsp70 proteins.			CAPLAN, AJ (corresponding author), UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA.		Caplan, Avrom/GPT-0824-2022	Cyr, Douglas/0000-0002-4928-3414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041758] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41758, GM35367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10699; ALTMAN E, 1991, EMBO J, V10, P239, DOI 10.1002/j.1460-2075.1991.tb07943.x; ANG D, 1991, J BIOL CHEM, V266, P24233; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CYR DM, 1992, J BIOL CHEM, V267, P20927; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIMURA T, 1989, J BIOL CHEM, V264, P3183; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Leung DW, 1989, TECHNIQUE, V1, P11; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; REID GA, 1982, J BIOL CHEM, V257, P3056; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; Sherman F., 1986, METHODS YEAST GENETI; SHERMAN MY, 1992, EMBO J, V11, P71; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	65	233	236	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1143	1155		10.1016/S0092-8674(05)80063-7	http://dx.doi.org/10.1016/S0092-8674(05)80063-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473150				2022-12-28	WOS:A1992KE60400009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PRESCRIPTION DRUG-USER FEE STATUTE ENACTED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3418	3418		10.1001/jama.268.24.3418	http://dx.doi.org/10.1001/jama.268.24.3418			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460725				2022-12-28	WOS:A1992KC83900006
J	VAUX, DL; WEISSMAN, IL; KIM, SK				VAUX, DL; WEISSMAN, IL; KIM, SK			PREVENTION OF PROGRAMMED CELL-DEATH IN CAENORHABDITIS-ELEGANS BY HUMAN BCL-2	SCIENCE			English	Article							CHROMOSOMAL BREAKPOINT; GENE-EXPRESSION; B-CELLS; NEMATODE; TRANSLOCATION; SURVIVAL; CLONING; PROTEIN; LOCUS	Programmed cell death is a physiological process that eliminates unwanted cells. The bcl-2 gene regulates programmed cell death in mammalian cells, but the way it functions is not known. Expression of the human bcl-2 gene in the nematode Caenorhabditis elegans reduced the number of programmed cell deaths, suggesting that the mechanism of programmed cell death controlled by bcl-2 in humans is the same as that in nematodes.			VAUX, DL (corresponding author), STANFORD UNIV, MED CTR, DEPT DEV BIOL, STANFORD, CA 94305 USA.		Vaux, David L/C-7249-2013	Vaux, David L/0000-0003-2703-1651				ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAUX DL, 1992, INT IMMUNOL, V4, P821; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOLDSTEIN P, 1991, IMMUNOL REV, V121, P29; HAMBURGER V, 1949, J EXP ZOOL, V111, P457, DOI 10.1002/jez.1401110308; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JONES D, 1986, J BIOL CHEM, V261, P2006; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	27	517	545	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1992	258	5090					1955	1957		10.1126/science.1470921	http://dx.doi.org/10.1126/science.1470921			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470921				2022-12-28	WOS:A1992KD08800038
J	ROYDEN, CS; BANKS, MS; CROWELL, JA				ROYDEN, CS; BANKS, MS; CROWELL, JA			THE PERCEPTION OF HEADING DURING EYE-MOVEMENTS	NATURE			English	Article							OPTICAL-FLOW; MOTION; IMAGE; DIRECTION	WHEN a person walks through a rigid environment while holding eyes and head fixed, the pattern of retinal motion flows radially away from a point, the focus of expansion (Fig. 1a)1,2. Under such conditions of translation, heading corresponds to the focus of expansion and people identify it readily3. But when making an eye/head movement to track an object off to the side, retinal motion is no longer radial (Fig. 1b)4. Heading perception in such situations has been modelled in two ways. Extra-retinal models monitor the velocity of rotational movements through proprioceptive or efference information from the extraocular and neck muscles and use that information to discount rotation effects5. Retinal-image models determine (and eliminate) rotational components from the retinal image alone6-12. These models have been tested13,14 by measuring heading perception under two conditions. First, observers judged heading while tracking a point on a simulated ground plane. Second, they fixated a stationary point and the How field simulated the effects of a tracking eye movement. Extra-retinal models5 predict poorer performance in the simulated condition because the eyes do not move. Retinal-image models6-12 predict no difference in performance because the two conditions produce identical patterns of retinal motion. Warren and Hannon13,14 observed similar performance and concluded that people do not require extra-retinal information to judge heading with eye/head movements present, but they used extremely slow tracking eye movements of 0.2-1.2 deg s-1; a moving observer frequently tracks objects at much higher rates (L. Stark, personal communication). Here we examine heading judgements at higher, more typical eye movement velocities and find that people require extra-retinal information about eye position15 to perceive heading accurately under many viewing conditions.	UNIV CALIF BERKELEY,SCH OPTOMETRY,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT PSYCHOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley								BRUSS AR, 1983, COMPUT VISION GRAPH, V21, P3, DOI 10.1016/S0734-189X(83)80026-7; DROULEZ J, 1990, BIOL CYBERN, V62, P211, DOI 10.1007/BF00198096; Gibson J.J., 1966, SENSES CONSIDERED PE; Gibson JJ, 1950, PERCEPTION VISUAL WO; HEEGER DJ, IN PRESS INT J COMP; LONGUETHIGGINS HC, 1980, PROC R SOC SER B-BIO, V208, P385, DOI 10.1098/rspb.1980.0057; MATIN L, 1981, S STUDY MOTON PERCEP; REGAN D, 1982, SCIENCE, V215, P194, DOI 10.1126/science.7053572; RIEGER JH, 1985, J OPT SOC AM A, V2, P354, DOI 10.1364/JOSAA.2.000354; von Holst E, 1954, BRIT J ANIM BEHAV, V2, P89, DOI DOI 10.1016/S0950-5601(54)80044-X; WARREN WH, 1988, J EXP PSYCHOL HUMAN, V14, P646, DOI 10.1037/0096-1523.14.4.646; WARREN WH, 1990, J OPT SOC AM A, V7, P160, DOI 10.1364/JOSAA.7.000160; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0; WARREN WH, 1991, BIOL CYBERN, V65, P311, DOI 10.1007/BF00216964; WAXMAN AM, 1985, INT J ROBOT RES, V4, P72, DOI 10.1177/027836498500400306	16	261	262	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					583	587		10.1038/360583a0	http://dx.doi.org/10.1038/360583a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461280				2022-12-28	WOS:A1992KB95900084
J	DELUZE, C; BOSIA, L; ZIRBS, A; CHANTRAINE, A; VISCHER, TL				DELUZE, C; BOSIA, L; ZIRBS, A; CHANTRAINE, A; VISCHER, TL			ELECTROACUPUNCTURE IN FIBROMYALGIA - RESULTS OF A CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							ACUPUNCTURE ANALGESIA; CEREBROSPINAL-FLUID; PAIN PATIENTS; DOUBLE-BLIND; STIMULATION; RELIEF; REHABILITATION; FIBROSITIS; INHIBITION; RESPONSES	Objective-To determine the efficacy of electroacupuncture in patients with fibromyalgia, a syndrome of unknown origin causing diffuse musculoskeletal pain. Design-Three weeks' randomised study with blinded patients and evaluating physician. Setting-University divisions of physical medicine and rehabilitation and rheumatology, Geneva. Patients-70 patients (54 women) referred to the division for fibromyalgia as defined by the American College of Rheumatology. Interventions-Patients were randomised to electroacupuncture (n=36) or a sham procedure (n=34) by means of an electronic numbers generator. Main outcome measures-Pain threshold, number of analgesic tablets used, regional pain score, pain recorded on visual analogue scale, sleep quality, morning stiffness, and patient's and evaluating physician's appreciation. Results-Seven of the eight outcome parameters showed a significant improvement in the active treatment group whereas none were improved in the sham treatment group. Differences between the groups were significant for five of the eight outcome measures after treatment. Conclusions-Electroacupuncture is effective in relieving symptoms of fibromyalgia. Its potential in long term management should now be studied.	UNIV HOSP GENEVA,DIV RHEUMATOL,CH-1211 GENEVA 14,SWITZERLAND; UNIV HOSP GENEVA,DIV PHYS MED & REHABIL,CH-1211 GENEVA 14,SWITZERLAND	University of Geneva; University of Geneva								BENNETT RM, 1988, ARTHRITIS RHEUM, V31, P1535, DOI 10.1002/art.1780311210; BENNETT RM, 1989, TXB RHEUMATOLOGY, P541; BING Z, 1991, PAIN, V47, P71, DOI 10.1016/0304-3959(91)90013-N; BUCKELEW SP, 1989, AM J PHYS MED REHAB, V68, P37, DOI 10.1097/00002060-198902000-00010; CARETTE S, 1986, ARTHRITIS RHEUM-US, V29, P655, DOI 10.1002/art.1780290510; CHENG RSS, 1989, SCI BASES ACUPUNCTUR, P119; CLEMENTJONES V, 1980, LANCET, V2, P946; EADIE MJ, 1990, MED J AUSTRALIA, V153, P180, DOI 10.5694/j.1326-5377.1990.tb136855.x; Fields H.L., 1989, TXB PAIN, P206; HAN JS, 1986, INT J NEUROSCI, V29, P79; HAN JS, 1989, SCI BASES ACUPUNCTUR, P7; HANSEN PE, 1983, HEADACHE, V23, P66, DOI 10.1111/j.1526-4610.1983.hed2302066.x; HE LF, 1991, PAIN, V44, P89; HO WKK, 1989, NEUROPHARMACOLOGY, V28, P961, DOI 10.1016/0028-3908(89)90196-2; KISER RS, 1983, LANCET, V2, P1394; LAUTENSCHAGER J, 1989, DTSCH ZSCHR AKUP, V6, P122; Le Bars D., 1989, SCI BASES ACUPUNCTUR, P79, DOI 10.1007/978-3-642-73757-2_5; LEE KH, 1985, J NEUROSURG, V62, P276, DOI 10.3171/jns.1985.62.2.0276; LEHMANN TR, 1986, PAIN, V26, P277, DOI 10.1016/0304-3959(86)90057-6; LEWIT K, 1979, PAIN, V6, P83, DOI 10.1016/0304-3959(79)90142-8; MacDonald A., 1989, TXB PAIN, P906; MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5; MELZACK R, 1977, PAIN, V3, P2; MOORE ME, 1976, ANN INTERN MED, V84, P381, DOI 10.7326/0003-4819-84-4-381; PAIK KS, 1988, EXP NEUROL, V99, P498, DOI 10.1016/0014-4886(88)90166-5; POMMERANZ B, 1979, EXP NEUROL, V64, P327; PRICE DD, 1984, PAIN, V19, P27, DOI 10.1016/0304-3959(84)90062-9; REEVES JL, 1986, PAIN, V24, P313, DOI 10.1016/0304-3959(86)90117-X; RIET GT, 1990, J CLIN EPIDEMIOL, V43, P1191; TODA K, 1978, EXP NEUROL, V61, P465, DOI 10.1016/0014-4886(78)90261-3; VINCENT CA, 1986, PAIN, V24, P1, DOI 10.1016/0304-3959(86)90022-9; Waylonis G W, 1977, Ohio State Med J, V73, P299; WILLER JC, 1982, PAIN, V14, P267, DOI 10.1016/0304-3959(82)90133-6; 1990, ARTHRITIS RHEUM, V33, P160	34	167	171	0	27	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1249	1252		10.1136/bmj.305.6864.1249	http://dx.doi.org/10.1136/bmj.305.6864.1249			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477566	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JZ52100020
J	HUHTASAARI, F; ASPLUND, K; LUNDBERG, V; STEGMAYR, B; WESTER, PO				HUHTASAARI, F; ASPLUND, K; LUNDBERG, V; STEGMAYR, B; WESTER, PO			TOBACCO AND MYOCARDIAL-INFARCTION - IS SNUFF LESS DANGEROUS THAN CIGARETTES	BRITISH MEDICAL JOURNAL			English	Article							SMOKELESS TOBACCO; RISK-FACTORS; NICOTINE; SMOKING; CONSUMPTION; MECHANISMS; ABSORPTION; PATTERNS; CANCER	Objective-To estimate the risk of myocardial infarction in snuff users, cigarette smokers, and non-tobacco users in northern Sweden, where using snuff is traditional. Design-Case-control study. Setting-Northern Sweden. Subjects-All 35-64 year old men who had had a first myocardial infarction and a population based sample of 35-64 year old men who had not had an infarction in the same geographical area. Main outcome measure-Tobacco consumption (regular snuff dipping, regular cigarette smoking, non-tobacco use) and risk of acute myocardial infarction. Results-59 of 585 (10%) patients who had a first myocardial infarction and 87 of 589 (15%) randomly selected men without myocardial infarction were non-smokers who used snuff daily. The age adjusted odds ratio for myocardial infarction was 0.89 (95% confidence interval 0.62 to 1.29) for exposure to snuff and 1.87 (1.40 to 2.48) for cigarette smoking compared with non-tobacco users, showing an increased risk in smokers but not in snuff dippers. Regular cigarette smokers had a significantly higher risk of myocardial infarction than regular snuff dippers (age adjusted odds ratio 2.09; 1.39 to 3.15). Smoking, but not snuff dipping, predicted myocardial infarction in a multiple logistic regression model that included age and level of education. Conclusions-In middle aged men snuff dipping is associated with a lower risk of myocardial infarction than cigarette smoking.	UMEA UNIV HOSP,DEPT MED,S-90185 UMEA,SWEDEN; LULEA BODEN HOSP,DEPT MED,S-95128 LULEA,SWEDEN; KALIX HOSP,DEPT MED,S-95282 KALIX,SWEDEN	Umea University								ASPLUND K, IN PRESS CARDIOVASC; BENOWITZ NL, 1988, CLIN PHARMACOL THER, V44, P23, DOI 10.1038/clpt.1988.107; BOLINDER G, 1992, European Heart Journal, V13, P393; BOLINDER G, 1988, LAKARTIDNINGEN, V85, P1248; BROCKIE RE, 1990, SEMIN RESPIR MED, V11, P5, DOI 10.1055/s-2007-1006191; BROWNSON RC, 1990, PREV MED, V19, P170, DOI 10.1016/0091-7435(90)90018-F; CHRISTEN AG, 1987, AVIAT SPACE ENVIR MD, V58, P97; CONNOLLY GN, 1986, NEW ENGL J MED, V314, P1020, DOI 10.1056/NEJM198604173141605; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; ELIASSON M, 1991, J INTERN MED, V230, P17, DOI 10.1111/j.1365-2796.1991.tb00401.x; ERNSTER VL, 1989, NATL CANCER I MONOGR, V8, P87; GLOVER ED, 1989, AM J PUBLIC HEALTH, V79, P207, DOI 10.2105/AJPH.79.2.207; HATSUKAMI DK, 1987, CLIN PHARMACOL THER, V41, P103, DOI 10.1038/clpt.1987.17; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; MCGILL HC, 1988, AM HEART J, V115, P250, DOI 10.1016/0002-8703(88)90645-X; NORDGREN P, 1990, BRIT J ADDICT, V85, P1107; ORLANDI MA, 1989, NCI MONOGRAPHS, V8, P5; Peterson J S, 1990, Arctic Med Res, V49 Suppl 2, P32; ROBERTSON D, 1988, AM HEART J, V115, P258, DOI 10.1016/0002-8703(88)90646-1; RUSSELL MAH, 1985, LANCET, V2, P1370; SCHEI E, 1990, PREV MED, V19, P667, DOI 10.1016/0091-7435(90)90063-P; SCHROEDER KL, 1988, ADDICT BEHAV, V13, P395, DOI 10.1016/0306-4603(88)90047-0; SCHROEDER KL, 1985, NEW ENGL J MED, V312, P919; SQUIRES WG, 1984, PREV MED, V13, P195, DOI 10.1016/0091-7435(84)90051-3; STAVENOW L, 1988, ARTERY, V15, P94; STEGMAYR B, 1991, HYGIEA, V100, P252; VENITT S, 1990, BRIT J ADDICT, V85, P1100; WEST R, 1990, BRIT J ADDICT, V85, P1097; WILKINSON L, 1989, SYSTAT SYSTEM STATIS; WILLIAMS RR, 1977, JNCI-J NATL CANCER I, V58, P525, DOI 10.1093/jnci/58.3.525; WRIGHT BM, 1970, LANCET, V1, P337; 1989, WORLD HLTH STATISTIC, P27; 1986, HLTH CONSEQUENCES US; 1976, PUBLIC HLTH EUROPE, V5; 1988, WHO TECH REPORTS SER, V773	35	122	124	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1252	1256		10.1136/bmj.305.6864.1252	http://dx.doi.org/10.1136/bmj.305.6864.1252			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477567	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JZ52100021
J	SAUNDERS, CJP				SAUNDERS, CJP			DRIVING AND DIABETES-MELLITUS	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEEDS,ACAD UNIT PUBL HLTH MED,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND	University of Leeds								DAVIS TG, 1973, OKLAHOMA STATE MED A, V66, P322; DEKLERK NH, 1983, J EPIDEMIOL COMMUN H, V37, P232, DOI 10.1136/jech.37.3.232; FRIER BM, 1980, LANCET, V1, P1232; STEEL JM, 1981, LANCET, V2, P354; WILLIAMS DRR, 1990, DIABETIC MED, V7, P74, DOI 10.1111/j.1464-5491.1990.tb01312.x	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1265	1265		10.1136/bmj.305.6864.1265	http://dx.doi.org/10.1136/bmj.305.6864.1265			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477571	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JZ52100026
J	ARONSON, JK; HARDMAN, M; REYNOLDS, DJM				ARONSON, JK; HARDMAN, M; REYNOLDS, DJM			ABC OF MONITORING DRUG-THERAPY - PHENYTOIN	BRITISH MEDICAL JOURNAL			English	Article									ICI PLC,DIV MED RES,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND		ARONSON, JK (corresponding author), RADCLIFFE INFIRM,OXFORD OX2 6HE,ENGLAND.							KUTT H, 1964, ARCH NEUROL-CHICAGO, V11, P642, DOI 10.1001/archneur.1964.00460240074010; LUND, 1983, 2ND P WORLD C CLIN P, P40; RICHENS A, 1975, LANCET, V2, P247	3	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1992	305	6863					1215	1218		10.1136/bmj.305.6863.1215	http://dx.doi.org/10.1136/bmj.305.6863.1215			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467727	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JY77700029
J	MOSS, F; MCNICOL, M				MOSS, F; MCNICOL, M			LONDON AFTER TOMLINSON .3. SECONDARY CARE BEYOND TOMLINSON - AN OPPORTUNITY TO BE SEIZED OR SQUANDERED	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SPECIALIST OUTPATIENT CLINICS; GENERAL-PRACTITIONERS; REFERRALS	The Tomlinson report's emphasis on primary care and its essentially quantitative analysis of hospital care in London leaves little space for a picture of how secondary care for Londoners should look. In this article Fiona Moss and Martin McNicol argue that most outpatient work does not need to be done in hospitals. With proper organisation and better premises a genuinely specialist consultative service can be provided in primary health care centres, with benefit to patients and communication between primary and secondary care doctors. Hospitals would then house those outpatient services that needed major investigative facilities and much reduced inpatient capacity. It may no longer be necessary for each acute unit to offer a full range of services. Such a pattern of secondary care will have implications for the organisation of accident and emergency services and for postgraduate training. Above all Moss and McNicol argue that Tomlinson's recommendations demand that general practitioners and specialists should re-examine the services hospitals provide and agree on the best settings for different sorts of health care and the most appropriate skills to provide it.			MOSS, F (corresponding author), CENT MIDDLESEX HOSP, NHS TRUST, LONDON NW10 7NS, ENGLAND.							BRADLOW J, 1992, PATTERNS REFERRAL ST; COULTER A, 1989, BMJ-BRIT MED J, V299, P304, DOI 10.1136/bmj.299.6694.304; COULTER A, 1991, BRIT J OBSTET GYNAEC, V98, P789, DOI 10.1111/j.1471-0528.1991.tb13484.x; COULTER A, 1991, BRIT J GEN PRACT, V41, P450; DAY JL, 1988, DIABETIC MED, V5, P372, DOI 10.1111/j.1464-5491.1988.tb01008.x; DOWIE R, 1983, GENERAL PRACTITIONER; GRACE JF, 1986, FAM PRACT, V3, P143, DOI 10.1093/fampra/3.3.143; HAYNES SE, 1991, THORAX, V46, P753; LESSING D, 1991, ARCH DIS CHILD, V66, P994, DOI 10.1136/adc.66.8.994; Tatman M A, 1992, Qual Health Care, V1, P98, DOI 10.1136/qshc.1.2.98; TAYLOR D, 1989, HOSPITAL HOME COMING; YOUNG JB, 1992, BRIT MED J, V304, P1085, DOI 10.1136/bmj.304.6834.1085; 1992, HLTH PERSONAL SOCIAL; 1991, EFFECTIVE HLTH CARE, V2; 1992, WELFARE CHILDREN YOU	15	9	9	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1992	305	6863					1211	1214		10.1136/bmj.305.6863.1211	http://dx.doi.org/10.1136/bmj.305.6863.1211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467726	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JY77700028
J	MACFARLANE, GJ; BOYLE, P; SCULLY, C				MACFARLANE, GJ; BOYLE, P; SCULLY, C			ORAL-CANCER IN SCOTLAND - CHANGING INCIDENCE AND MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							TOBACCO; ALCOHOL; PHARYNX; TONGUE; CAVITY; DIET	Objectives-To determine the incidence of oral cancer in Scotland between 1960 and 1989 and oral cancer mortality from 1911 to 1989. Setting-Data were obtained on oral cancer incidence from the information and statistics division of the Common Services Agency of the Scottish Health Service and mortality data from the office of the registrar general for Scotland. Results-Mortality from intraoral cancers in Scotland substantially declined throughout this century until the mid-1970s. This trend, however, was then reversed, and fourfold increases in incidence were observed in younger age groups after 1960. Death rates in these younger age groups increased to levels previously recorded in the 1940s. These increases seemed to be cohort based and may therefore continue into the future. Conclusions-Reasons for increasing rates among younger age groups are speculative and rely on combining knowledge about risk factors and available ecological data. Though increases in incidence at younger ages do not result in a large change in the number of cases diagnosed, possible similar increases continuing into older ages, when oral cancer is more common, will correspond to a much larger increase in the actual number of cases. Given that such a large attributable risk is associated with tobacco and alcohol, however, these increases may be preventable.	BRISTOL DENT HOSP & SCH,DEPT ORAL MED SURG & PATHOL,CTR STUDY ORAL DIS,BRISTOL BS1 2LY,ENGLAND	University of Bristol	MACFARLANE, GJ (corresponding author), EUROPEAN INST ONCOL,DIV EPIDEMIOL & BIOSTAT,VIA RIPAMONTI 332-10,I-20141 MILAN,ITALY.		Macfarlane, Gary J/I-9521-2014; Boyle, Peter/A-4380-2014	Macfarlane, Gary J/0000-0003-2322-3314; Boyle, Peter/0000-0001-6251-0610				[Anonymous], 1988, IARC MONOGR EVAL CAR, V44, P41; [Anonymous], 1990, ANN REPORT; BINNIE WH, 1972, OPCS STUDIES MED POP; BLOT WJ, 1988, CANCER RES, V48, P3282; BRUGERE J, 1986, CANCER, V57, P391, DOI 10.1002/1097-0142(19860115)57:2<391::AID-CNCR2820570235>3.0.CO;2-Q; CASE RAM, 1976, SERIAL MORTALITY TAB, V4; DAVIS S, 1987, LANCET, V1, P910; DEPUE RH, 1986, NEW ENGL J MED, V315, P647; DOLL R, 1967, INT J CANCER, V2, P269, DOI 10.1002/ijc.2910020310; DOLL R, 1966, CANCER INCIDENCE 5 C, V1; Easson E C, 1976, Clin Oncol, V2, P191; GRAHAM S, 1977, J NATL CANCER I, V59, P1611, DOI 10.1093/jnci/59.6.1611; HAKULINEN T, 1986, ACTA PATHOLOGIC S228, V94, P30; KELLER AZ, 1965, AM J PUBLIC HEALTH N, V55, P1578, DOI 10.2105/AJPH.55.10.1578; LAVECCHIA C, 1992, EUR J CANCER, V28A, P132; MACFARLANE GJ, 1987, LANCET, V2, P1912; MERLETTI F, 1989, CANCER RES, V49, P4919; MOLLER H, 1989, J ORAL PATHOL MED, V18, P224, DOI 10.1111/j.1600-0714.1989.tb00767.x; MUIR CS, 1987, IARC SCI PUBLICATION, V88; RUSSELL MH, 1955, BRIT MED J, V2, P823, DOI 10.1136/bmj.2.4943.823; SCHIFFLERS E, 1985, STAT MED, V4, P63, DOI 10.1002/sim.4780040110; SPRING JA, 1977, NATURE, V270, P567, DOI 10.1038/270567a0; SVEJDA J, 1971, NEOPLASMA, V18, P193; TAN K N, 1969, Australian Dental Journal, V14, P50; WALD NJ, 1985, CANCER RISKS PREVENT, P44; WINN DM, 1981, NEW ENGL J MED, V304, P745, DOI 10.1056/NEJM198103263041301; WYNDER EL, 1957, CANCER, V10, P1300, DOI 10.1002/1097-0142(195711/12)10:6&lt;1300::AID-CNCR2820100628&gt;3.0.CO;2-2; [No title captured]	28	82	84	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1121	1123		10.1136/bmj.305.6862.1121	http://dx.doi.org/10.1136/bmj.305.6862.1121			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463946	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992JX84100020
J	WILKIE, ME; ALMOND, MK; MARSH, FP				WILKIE, ME; ALMOND, MK; MARSH, FP			DIAGNOSIS AND MANAGEMENT OF URINARY-TRACT INFECTION IN ADULTS	BRITISH MEDICAL JOURNAL			English	Article							VESICOURETERAL REFLUX; RENAL-TRANSPLANT; GENERAL-PRACTICE; NATURAL-HISTORY; YOUNG-WOMEN; PYELONEPHRITIS; PROPHYLAXIS; PREGNANCY; INJURY		ROYAL LONDON TRUST,DEPT NEPHROL,LONDON E1 1BB,ENGLAND									ANDRIOLE VT, 1991, MED CLIN N AM, V75, P359, DOI 10.1016/S0025-7125(16)30459-X; [Anonymous], 1991, DRUG THER B, V29, P37; ARANT BS, 1991, AM J KIDNEY DIS, V17, P491, DOI 10.1016/S0272-6386(12)80490-2; BAILEY RR, 1990, INFECTION S2, V18, P53; BALDASSARRE JS, 1991, MED CLIN N AM, V75, P375, DOI 10.1016/S0025-7125(16)30460-6; BROOKS D, 1990, BRIT J GEN PRACT, V40, P399; BRUMFITT W, 1991, BRIT MED J, V303, P1, DOI 10.1136/bmj.303.6793.1; COHEN J, 1988, J HOSP INFECT, V11, P357, DOI 10.1016/0195-6701(88)90089-8; DUNN SP, 1987, J PEDIATR SURG, V22, P1095, DOI 10.1016/S0022-3468(87)80716-9; GORDON I, 1990, BRIT J RADIOL, V63, P507, DOI 10.1259/0007-1285-63-751-507; HANEVOLD CD, 1987, AM J DIS CHILD, V141, P982, DOI 10.1001/archpedi.1987.04460090059024; HANSEN BL, 1988, SCAND J INFECT DIS, V20, P425, DOI 10.3109/00365548809032480; HOOTON TM, 1991, MED CLIN N AM, V75, P339, DOI 10.1016/S0025-7125(16)30458-8; HOOTON TM, 1991, MED CLIN N AM, V75, P375; HSU CCS, 1990, INFECTION, V18, P280, DOI 10.1007/BF01647004; HUSTINX WNM, 1991, J HOSP INFECT, V18, P45, DOI 10.1016/0195-6701(91)90092-M; IRAVANI A, 1991, UROLOGY, V37, P503, DOI 10.1016/0090-4295(91)80312-U; JOHNSON JR, 1991, CLIN MICROBIOL REV, V4, P80, DOI 10.1128/CMR.4.1.80-128.1991; KEANE EM, 1989, DIABETES CARE, V11, P708; MCNICHOLAS MMJ, 1991, BRIT J RADIOL, V64, P221, DOI 10.1259/0007-1285-64-759-221; MERENICH WM, 1991, MED CLIN N AM, V75, P425, DOI 10.1016/S0025-7125(16)30463-1; MICHAELS EK, 1988, J UROLOGY, V140, P254, DOI 10.1016/S0022-5347(17)41576-X; PAPPAS PG, 1991, MED CLIN N AM, V75, P213; PATTON JP, 1991, MED CLIN N AM, V75, P495, DOI 10.1016/S0025-7125(16)30466-7; ROCCO F, 1991, EUR UROL, V19, P7; RONALD AR, 1990, CHEMOTHERAPY, V36, P2, DOI 10.1159/000238807; RUBIN RH, 1991, KIDNEY, V2, P1369; SANDBERG T, 1991, SCAND J INFECT DIS, V23, P221, DOI 10.3109/00365549109023404; SANDERSON PJ, 1991, J HOSP INFECT, V18, P1; SCHAEFFER AJ, 1991, EUR UROL, V19, P2; STAMM WE, 1991, REV INFECT DIS, V13, P77; STAMM WE, 1988, UROLOGY, V32, P6; WYNDAELE JJ, 1990, PARAPLEGIA, V28, P76, DOI 10.1038/sc.1990.9; 1986, DRUG THER B, V24, P101; 1986, MMWR-MORBID MORTAL W, P159; 1986, DRUG THER B, V24, P17	36	24	27	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1137	1141		10.1136/bmj.305.6862.1137	http://dx.doi.org/10.1136/bmj.305.6862.1137			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463952	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JX84100026
J	DAU, PC				DAU, PC			PLASMA-EXCHANGE IN POLYMYOSITIS AND DERMATOMYOSITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							PLASMAPHERESIS				DAU, PC (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611, USA.		Miller, Frederick/D-2431-2019	Miller, Frederick/0000-0003-2831-9593				BENNINGTON JL, 1981, ARCH NEUROL-CHICAGO, V38, P553, DOI 10.1001/archneur.1981.00510090047005; CAMPION EW, 1992, NEW ENGL J MED, V326, P1425, DOI 10.1056/NEJM199205213262109; Clark W F, 1991, J Clin Apher, V6, P40, DOI 10.1002/jca.2920060109; DAU PC, 1990, J NEUROIMMUNOL, V30, P15, DOI 10.1016/0165-5728(90)90048-R; DAU PC, 1981, ARCH NEUROL-CHICAGO, V38, P544, DOI 10.1001/archneur.1981.00510090038003; MILLER FW, 1992, NEW ENGL J MED, V326, P1380, DOI 10.1056/NEJM199205213262102	6	7	7	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					1030	1030						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1518542				2022-12-28	WOS:A1992JQ22500017
J	LOCKSHIN, MD				LOCKSHIN, MD			ANTIPHOSPHOLIPID ANTIBODY SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; CLINICAL ASPECTS; FETAL DEATH; ANTICOAGULANTS; VASCULOPATHY; MICE				LOCKSHIN, MD (corresponding author), NATL INST ARTHRIT & MUSCULOSKELETAL & SKIN DIS, EXTRAMURAL PROGRAM, BLDG 31, ROOM 4C32, BETHESDA, MD 20892 USA.							ALARCONSEGOVIA D, 1992, SEMIN ARTHRITIS RHEU, V21, P275, DOI 10.1016/0049-0172(92)90021-5; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; BAKIMER R, 1992, J CLIN INVEST, V89, P1558, DOI 10.1172/JCI115749; BEVERS EM, 1992, LUPUS, V1, P51, DOI 10.1177/096120339200100201; BLANK M, 1991, P NATL ACAD SCI USA, V88, P3069, DOI 10.1073/pnas.88.8.3069; BRANCH DW, 1990, AM J OBSTET GYNECOL, V163, P210, DOI 10.1016/S0002-9378(11)90700-5; COWCHOCK FS, 1992, AM J OBSTET GYNECOL, V166, P1318, DOI 10.1016/0002-9378(92)91596-3; DERKSEN RHWM, 1988, ANN RHEUM DIS, V47, P364, DOI 10.1136/ard.47.5.364; GHARAVI AE, 1989, CLIN EXP IMMUNOL, V78, P233; GHARAVI AE, 1992, STROKE, V23, pI7; GREISMAN SG, 1991, ARCH INTERN MED, V151, P389, DOI 10.1001/archinte.151.2.389; HARRIS EN, 1991, ARCH INTERN MED, V151, P231, DOI 10.1001/archinte.151.2.231; HUNT JE, 1992, LUPUS, V1, P75, DOI 10.1177/096120339200100204; INFANTERIVARD C, 1991, NEW ENGL J MED, V325, P1063, DOI 10.1056/NEJM199110103251503; LEVY RA, 1990, J RHEUMATOL, V17, P1036; LOCKSHIN MD, 1989, AM J OBSTET GYNECOL, V160, P439, DOI 10.1016/0002-9378(89)90468-7; LOCKSHIN MD, 1992, NEW ENGL J MED, V326, P951; LOCKSHIN MD, IN PRESS ARTHRITIS R; MCNEIL HP, 1989, BRIT J HAEMATOL, V73, P506, DOI 10.1111/j.1365-2141.1989.tb00289.x; MCNEIL HP, 1991, ADV IMMUNOL, V49, P193; ROSOVE M H, 1991, Arthritis and Rheumatism, V34, pS42; SAMMARITANO LR, 1990, SEMIN ARTHRITIS RHEU, V20, P81, DOI 10.1016/0049-0172(90)90021-7; SAMMARITANO LR, IN PRESS J CLIN INVE	23	54	55	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1451	1453						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512915				2022-12-28	WOS:A1992JM84900030
J	LOCKE, SE; KOWALOFF, HB; HOFF, RG; SAFRAN, C; POPOVSKY, MA; COTTON, DJ; FINKELSTEIN, DM; PAGE, PL; SLACK, WV				LOCKE, SE; KOWALOFF, HB; HOFF, RG; SAFRAN, C; POPOVSKY, MA; COTTON, DJ; FINKELSTEIN, DM; PAGE, PL; SLACK, WV			COMPUTER-BASED INTERVIEW FOR SCREENING BLOOD-DONORS FOR RISK OF HIV TRANSMISSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HISTORIES; ANTIBODIES; HEADACHE; SYSTEM; AIDS	Objective.-To test the ability of a computer-based interview to detect factors related to the risk of the human immunodeficiency virus (HIV) among potential blood donors and to determine donor reactions to the use of the interview. Design.-A comparison of the rate of detection of HIV-related factors elicited by a computer interview with that obtained by standard American Red Cross procedures for assessment of donor suitability, including a randomized crossover trial in which the order of the two methods was reversed. Information obtained by the computer was not available to influence the use of blood components for transfusion. Setting.-The computer interview was administered to donors at an American Red Cross blood donor center and at a mobile blood drive at a hospital. Subjects.-Consecutive sample of 294 male and female blood donors 18 to 75 years of age. Main Outcome Measures.-Subjects' responses to the computer-based interview as well as responses to the standard Red Cross written questionnaires and face-to-face interviews were used for donor assessment. Results.-The interview took an average of 8 minutes to complete. From among 272 donors who provided complete data, the computer identified 12 donors who reported either behaviors associated with a risk of HIV acquisition or symptoms compatible with the acquired immunodeficiency syndrome; none of these donors had been so identified either by routine written questionnaires or by face-to-face interviews used to screen potential blood donors. Only one of the 12 identified donors used the confidential unit exclusion procedure to prevent use of his donated unit. The rate of elicitation of HIV-related factors by the computer interview was 12 (4.4%) of 272 (95% confidence interval [CI], 2.3% to 7.6%), compared with two (0.13%) of 1536 (95% confidence upper bound, 0.28%) using the standard Red Cross procedure (P<.0001). Tests for antibodies to HIV were negative in blood samples from all of the 272 subjects studied. The subjects enjoyed the computer interview and judged it to be more private than the standard donor assessment method. They also predicted that donors would be more honest with the computer interview than with a human interviewer. Conclusions.-Computer-based screening elicits more HIV-related factors in the health histories of blood donors than do the standard questionnaire and interviewing methods currently in use. Computer-based screening is also acceptable to blood donors.	BETH ISRAEL HOSP, CTR CLIN COMP, 350 LONGWOOD AVE, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT PSYCHIAT, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT PATHOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, CTR BIOSTAT, BOSTON, MA 02114 USA; TUFTS UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA; AMER RED CROSS, BLOOD SERV, DEDHAM, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Tufts University; American Red Cross					AHRQ HHS [HS06288] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BANA DS, 1980, HEADACHE, V20, P85, DOI 10.1111/j.1526-4610.1980.hed2002085.x; BLOOM SM, 1978, COMPUT BIOMED RES, V11, P167, DOI 10.1016/0010-4809(78)90028-9; CARR AC, 1983, PSYCHOL MED, V13, P151, DOI 10.1017/S0033291700050157; COOMBS GJ, 1970, COMPUT BIOMED RES, V3, P178, DOI 10.1016/0010-4809(70)90024-8; EVANS SN, 1973, J AM DIET ASSOC, V63, P397; FARZADEGAN H, 1988, ANN INTERN MED, V108, P785, DOI 10.7326/0003-4819-108-6-785; FISHER LA, 1977, AM J PUBLIC HEALTH, V67, P640, DOI 10.2105/AJPH.67.7.640; GREIST JH, 1973, ARCH GEN PSYCHIAT, V29, P247; GREIST JH, 1980, TECHNOLOGY MENTAL HL, P161; GROSSMAN JH, 1971, J AMER MED ASSOC, V215, P1286, DOI 10.1001/jama.215.8.1286; LEITMAN SF, 1989, NEW ENGL J MED, V321, P917, DOI 10.1056/NEJM198910053211401; Locke S. E., 1990, Fourteenth Annual Symposium on Computer Applications in Medical Care. Standards in Medical Informatics. A Conference of the American Medical Informatics Association, P835; LUCAS RW, 1977, BRIT J PSYCHIAT, V131, P160, DOI 10.1192/bjp.131.2.160; MAULTSBY MC, 1971, ARCH GEN PSYCHIAT, V25, P570; MAYNE JG, 1968, MAYO CLIN PROC, V43, P1; MENITOVE JE, 1989, NEW ENGL J MED, V321, P966, DOI 10.1056/NEJM198910053211409; MILLSTEIN SG, 1983, J PEDIATR-US, V103, P815, DOI 10.1016/S0022-3476(83)80493-4; SCHMIDT PJ, 1988, AM ASS BLOOD BANKS P; SILVERGLEID AJ, 1989, TRANSFUSION, V29, P362, DOI 10.1046/j.1537-2995.1989.29489242806.x; SLACK WV, 1972, NEW ENGL J MED, V286, P1304; SLACK WV, 1966, NEW ENGL J MED, V274, P194, DOI 10.1056/NEJM196601272740406; SLACK WV, 1984, M D COMPUT, V1, P52; SLACK WV, 1968, POSTGRAD MED, V43, P68, DOI 10.1080/00325481.1968.11693177; SLACK WV, 1968, COMPUT BIOMED RES, V1, P527, DOI 10.1016/0010-4809(68)90018-9; SLACK WV, 1990, M D COMPUT, V7, P37; SNYDER AJ, 1988, NEW ENGL J MED, V319, P374; STEAD WW, 1972, ARCH INTERN MED, V129, P950, DOI 10.1001/archinte.129.6.950; VANCURA LJ, 1975, AM J PUBLIC HEALTH, V65, P1159, DOI 10.2105/AJPH.65.11.1159; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; WITSCHI J, 1976, J AM DIET ASSOC, V69, P385; ZUCK TF, 1987, TRANSFUSION, V27, P447, DOI 10.1046/j.1537-2995.1987.27688071691.x; 1991, STATXACT STATISTICAL; 1991, AM RED CROSS BLOOD S	33	161	162	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1301	1305		10.1001/jama.268.10.1301	http://dx.doi.org/10.1001/jama.268.10.1301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507376				2022-12-28	WOS:A1992JL60800031
J	DAVIES, K				DAVIES, K			MULLING OVER MOUSE MODELS	NATURE			English	Editorial Material																		BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; COLLINS FS, 1992, NATURE, V358, P708, DOI 10.1038/358708a0; GARDNER JM, 1992, SCIENCE, V257, P1121, DOI 10.1126/science.257.5073.1121; GASCHEN PP, 1992, J NEUROL SCI, V110, P149; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; Morell Robert, 1992, Human Molecular Genetics, V1, P243, DOI 10.1093/hmg/1.4.243; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; STEEL KP, 1992, NAT GENET, V2, P75, DOI 10.1038/ng0992-75; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TATSUMI K, 1992, NAT GENET, V1, P56, DOI 10.1038/ng0492-56	13	4	4	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					86	86		10.1038/359086a0	http://dx.doi.org/10.1038/359086a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522893	Bronze			2022-12-28	WOS:A1992JL66200062
J	MACKENZIE, WR; DAVIS, JP; PETERSON, DE; HIBBARD, AJ; BECKER, G; ZARVAN, BS				MACKENZIE, WR; DAVIS, JP; PETERSON, DE; HIBBARD, AJ; BECKER, G; ZARVAN, BS			MULTIPLE FALSE-POSITIVE SEROLOGIC TESTS FOR HIV, HTLV-1, AND HEPATITIS-C FOLLOWING INFLUENZA VACCINATION, 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-(1) To assess factors associated with the occurrence of multiple false-positive viral enzyme-linked immunosorbent assays (ELISAs) for human immunodeficiency virus (HIV), human T-cell lymphotrophic virus type 1 (HTLV-1), and hepatitis C virus (HCV) among individual blood donors and (2) to determine the frequency and time course of this phenomenon. Design.-Case-control study. Setting.-A regional blood center. Participants.-Blood donors found to have multiple false-positive viral ELISAs (case donors) and randomly selected seronegative controls (control donors) who donated between October 31, 1991, and December 15, 1991. An additional random sample of 262 donation records was reviewed to calculate the proportion of donors who received influenza vaccine. Main Outcome Measures.-Multiple false-positive viral ELISAs, receipt of influenza vaccination formulated for the 1991-1992 influenza season, and follow-up ELISA results on serum samples obtained from case donors. Results.-Among 17941 donors, 10 case donors were identified. Nine of the 10 case donors received influenza vaccine, compared with three of 30 control donors (odds ratio [OR]=81; 95% confidence interval [CI], 6 to 3670; P<.001). Among nine case donors, the mean time between vaccination and blood donation was 26 days (range, 9 to 68 days). Follow-up ELISAs of serum samples from seven case donors obtained 52 to 130 days (mean, 75 days) after vaccination demonstrated reversion to HIV and HTLV-1 seronegativity in all but one specimen, with persistence of positive HCV ELISAs in four specimens. We estimate between 0.6% and 1.7% of blood donors who received influenza vaccine this season had multiple false-positive viral ELISAs. Conclusions.-The occurrence of multiple false-positive viral ELISAs among blood donors was associated with influenza vaccination, but was infrequent among vaccinees. This phenomenon is of short duration for HIV and HTLV-1, but may persist longer for HCV. We recommend influenza vaccinees not be deferred from blood donation. Blood donors with multiple false-positive viral ELISAs should be considered for future reentry as blood donors.	CTR DIS CONTROL,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333; AMER RED CROSS,BLOOD SERV,BADGER REG,MADISON,WI	Centers for Disease Control & Prevention - USA; American Red Cross	MACKENZIE, WR (corresponding author), WISCONSIN DEPT HLTH & SOCIAL SERV,BUR PUBL HLTH,1400 & WASHINGTON AVE,ROOM 96,MADISON,WI 53703, USA.		Kenzie, William R Mac/F-1528-2013	Kenzie, William R Mac/0000-0001-7723-0339				Colton T, 1974, STAT MED, P160; FANG CT, 1988, TRANSFUSION, V28, P179, DOI 10.1046/j.1537-2995.1988.28288179027.x; MENTA CR, 1985, J AM STAT ASSOC, V78, P969; 1985, MMWR, V34, P1; 1991, MMWR, V40, P1	5	58	60	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1015	1017		10.1001/jama.268.8.1015	http://dx.doi.org/10.1001/jama.268.8.1015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501307				2022-12-28	WOS:A1992JK12900028
J	WRIGHT, JL				WRIGHT, JL			SUNDAY ROUNDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					955	955						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501311				2022-12-28	WOS:A1992JK12900002
J	DEMERS, C; GINSBERG, JS; HIRSH, J; HENDERSON, P; BLAJCHMAN, MA				DEMERS, C; GINSBERG, JS; HIRSH, J; HENDERSON, P; BLAJCHMAN, MA			THROMBOSIS IN ANTITHROMBIN-III-DEFICIENT PERSONS - REPORT OF A LARGE KINDRED AND LITERATURE-REVIEW	ANNALS OF INTERNAL MEDICINE			English	Review						ANTITHROMBIN-III; THROMBOPHLEBITIS; THROMBOEMBOLISM; ANTICOAGULANTS; VASCULITIS; DEATH, SUDDEN	HEPARIN-COFACTOR ACTIVITIES; AT-III; VENOUS THROMBOSIS; CROSSED IMMUNOELECTROPHORESIS; RECURRENT THROMBOPHLEBITIS; FAMILIAL THROMBOSIS; CEREBRAL THROMBOSIS; HOMOZYGOUS VARIANT; AFFINITY; BINDING	. Purpose: To estimate the prevalence of objectively proven thrombotic complications in antithrombin-III-deficient persons. . Study Design: Cross-sectional study and a critical review of the literature. . Data Sources and Extraction: The prevalence of thrombosis in antithrombin III-deficient and -nondeficient family members of a large kindred was estimated by history, review of diagnostic tests, and examination for venous reflux by Doppler ultrasonography, as an indicator of previous venous thrombosis. A MEDLINE search and literature review of the published English- and French-language literature from 1966 to 1990 that described antithrombin-III-deficient families was done, and the following information was obtained: the prevalence of thrombosis in deficient and nondeficient family members, the presence or absence of risk factors for thrombosis (surgery, pregnancy, the postpartum state, use of oral contraceptives, immobilization, metastatic cancer, major trauma) at the time of the thrombotic event, and age of onset of the first episode of thrombosis. The validity of the studies was assessed according to predetermined criteria. . Results: Sixty-seven research subjects were evaluated. Six of 31 (19.4%) antithrombin-III-deficient subjects compared with none of 36 (0%) nondeficient subjects had had one or more thrombotic events. The initial episode in five of six subjects had occurred in association with risk factors for thrombosis. The literature search indicated that the pooled prevalence of symptomatic venous thrombosis among the deficient subjects was 51%, but objective testing was done in only 17% of these subjects at the time of presentation. . Conclusion: Based on the data from this antithrombin-III-deficient kindred, lifelong anticoagulant prophylaxis does not appear to be warranted in asymptomatic carriers, and prophylaxis could be limited to periods of high risk for thrombosis.	MCMASTER UNIV, MED CTR, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA; CANADIAN RED CROSS SOC, HAMILTON, ONTARIO, CANADA	McMaster University			ginsberg, jeffrey s/ABC-1065-2020					AIACH M, 1988, THROMB HAEMOSTASIS, V60, P94; AIACH M, 1985, THROMB RES, V39, P559, DOI 10.1016/0049-3848(85)90236-1; AIACH M, 1987, BRIT J HAEMATOL, V66, P515, DOI 10.1111/j.1365-2141.1987.tb01337.x; AMBRUSO DR, 1980, PEDIATRICS, V65, P125; BARBUI T, 1983, BRIT J HAEMATOL, V54, P561, DOI 10.1111/j.1365-2141.1983.tb02134.x; BARNES RW, 1975, JAMA-J AM MED ASSOC, V234, P605, DOI 10.1001/jama.234.6.605; BAUER KA, 1983, BLOOD, V62, P1242; BESSOT JC, 1978, NOUV PRESSE MED, V7, P999; BEUKES CA, 1980, S AFR MED J, V58, P528; BORG JY, 1988, J CLIN INVEST, V81, P1292, DOI 10.1172/JCI113447; BOYER C, 1980, THROMB RES, V20, P207, DOI 10.1016/0049-3848(80)90386-2; BOYER C, 1986, THROMB HAEMOSTASIS, V56, P18; BRENNER B, 1988, AM J HEMATOL, V27, P209, DOI 10.1002/ajh.2830270311; CANDRINA R, 1985, HAEMATOLOGICA, V70, P399; CARVALHO A, 1976, AM J MED, V61, P179, DOI 10.1016/0002-9343(76)90167-4; CHAMONTIN B, 1984, ARCH MAL COEUR VAISS, V77, P1064; CONCANNON AJ, 1981, MED J AUSTRALIA, V1, P521, DOI 10.5694/j.1326-5377.1981.tb135779.x; COSGRIFF TM, 1983, MEDICINE, V62, P209, DOI 10.1097/00005792-198307000-00002; DALY M, 1989, THROMB RES, V56, P503, DOI 10.1016/0049-3848(89)90234-X; DEMOERLOOSE PA, 1987, THROMB HAEMOSTASIS, V57, P154; DEVRAJKIZUK R, 1988, BLOOD, V72, P1518; DSOUZA S, 1984, AUST NZ J MED, V14, P835, DOI 10.1111/j.1445-5994.1984.tb03784.x; DUCHANGE N, 1987, THROMB RES, V45, P115, DOI 10.1016/0049-3848(87)90263-5; EGEBERG O, 1965, THROMB DIATH HAEMOST, V13, P516, DOI 10.1055/s-0038-1656297; FERNANDEZRACHUB.F, IN PRESS THROMB RES; FISCHER AM, 1983, THROMB HAEMOSTASIS, V50, P358; FISCHER AM, 1986, THROMB HAEMOSTASIS, V55, P218; FONTCUBERTA J, 1988, THROMB RES, V51, P75, DOI 10.1016/0049-3848(88)90284-8; GINSBERG JS, 1989, ARCH INTERN MED, V149, P2255, DOI 10.1001/archinte.149.10.2255; GIROLAMI A, 1983, Folia Haematologica (Leipzig), V110, P98; GIROLAMI A, 1983, BLUT, V47, P93, DOI 10.1007/BF02482643; GIROLAMI A, 1984, ACTA HAEMATOL-BASEL, V72, P73, DOI 10.1159/000206364; GIROLAMI A, 1985, Folia Haematologica (Leipzig), V112, P594; GRAU E, 1988, THROMB HAEMOSTASIS, V59, P13; GRIFFITH MJ, 1983, BLOOD, V61, P111; GYDE OHB, 1978, BRIT MED J, V1, P621, DOI 10.1136/bmj.1.6113.621; HOFMAN KJ, 1980, S AFR MED J, V58, P531; HOWARTH DJ, 1985, THROMB HAEMOSTASIS, V53, P314; HULL RD, 1984, CLIN CHEST MED, V5, P439; JOHANSSON L, 1978, ACTA MED SCAND, V204, P491; JOHNSON EJ, 1990, THROMB HAEMOSTASIS, V63, P13; JUILLET Y, 1979, ANN MED INTERNE, V130, P53; KAHLE LH, 1978, THROMB RES, V12, P1003, DOI 10.1016/0049-3848(78)90056-7; LANE DA, 1989, BRIT J HAEMATOL, V71, P91, DOI 10.1111/j.1365-2141.1989.tb06280.x; LANE DA, 1987, BRIT J HAEMATOL, V66, P523, DOI 10.1111/j.1365-2141.1987.tb01338.x; LEE M, 1986, ACTA HAEMATOL JAPON, V49, P980; LEONE G, 1987, BRIT J HAEMATOL, V65, P187, DOI 10.1111/j.1365-2141.1987.tb02263.x; LEONE G, 1983, HAEMATOLOGICA, V68, P765; LEONE G, 1980, THROMB HAEMOSTASIS, V43, P74; MANOTTI C, 1982, HAEMOSTASIS, V12, P300; MARCINIA.E, 1974, BLOOD, V43, P219, DOI 10.1182/blood.V43.2.219.219; MATSUO T, 1979, THROMB RES, V16, P815, DOI 10.1016/0049-3848(79)90224-X; MENDELSOHN G, 1976, THROMB HAEMOSTASIS, V36, P495, DOI 10.1055/s-0038-1648068; MURAMATSU S, 1990, THROMB RES, V57, P593, DOI 10.1016/0049-3848(90)90076-O; ODEGARD OR, 1977, SCAND J HAEMATOL, V18, P86; OKAJIMA K, 1989, THROMB HAEMOSTASIS, V61, P20; OWEN MC, 1987, BLOOD, V69, P1275; PERRY DJ, 1989, FEBS LETT, V254, P174, DOI 10.1016/0014-5793(89)81033-6; PEWARCHUK WJ, 1990, THROMB RES, V59, P793, DOI 10.1016/0049-3848(90)90061-G; PHIFER TJ, 1990, J VASC SURG, V11, P586, DOI 10.1067/mva.1990.17918; PITNEY WR, 1980, BRIT J HAEMATOL, V46, P147; REY JL, 1979, ARCH MAL COEUR VAISS, V72, P919; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; ROUSSEL B, 1991, AM J HEMATOL, V36, P25, DOI 10.1002/ajh.2830360106; SAKURAGAWA N, 1983, THROMB RES, V31, P305, DOI 10.1016/0049-3848(83)90333-X; SAMBRANO JE, 1986, J CLIN INVEST, V77, P887, DOI 10.1172/JCI112386; SAS G, 1980, THROMB HAEMOSTASIS, V43, P133; SCULLY MF, 1981, BRIT J HAEMATOL, V47, P235, DOI 10.1111/j.1365-2141.1981.tb02784.x; SORENSEN PJ, 1980, SCAND J HAEMATOL, V24, P105; STATHAKIS NE, 1977, ACTA HAEMATOL-BASEL, V57, P47, DOI 10.1159/000207859; TENGBORN L, 1985, SCAND J HAEMATOL, V34, P412; THALER E, 1981, CLIN HAEMATOL, V10, P369; THUOT C, 1977, UNION MED CAN, V106, P673; TRAN TH, 1980, THROMB HAEMOSTASIS, V44, P87; TRIPODI A, 1980, RES CLIN LAB, V10, P521, DOI 10.1007/BF02938798; TRIPODI A, 1986, THROMB HAEMOSTASIS, V56, P349; VANDERMEER J, 1973, J CLIN PATHOL, V26, P532, DOI 10.1136/jcp.26.7.532; WINTER JH, 1982, Q J MED, V51, P373; WOLF M, 1985, BLOOD, V65, P496; WOLF M, 1982, BRIT J HAEMATOL, V51, P285, DOI 10.1111/j.1365-2141.1982.tb02782.x; WOLF M, 1990, THROMB HAEMOSTASIS, V63, P215; ZUCKER ML, 1976, S AFR MED J, V50, P1743	82	160	161	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1992	116	9					754	761		10.7326/0003-4819-116-9-754	http://dx.doi.org/10.7326/0003-4819-116-9-754			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ623	1489375				2022-12-28	WOS:A1992HQ62300010
J	ERNST, P; SPITZER, WO; SUISSA, S; COCKCROFT, D; HABBICK, B; HORWITZ, RI; BOIVIN, JF; MCNUTT, M; BUIST, AS				ERNST, P; SPITZER, WO; SUISSA, S; COCKCROFT, D; HABBICK, B; HORWITZ, RI; BOIVIN, JF; MCNUTT, M; BUIST, AS			RISK OF FATAL AND NEAR-FATAL ASTHMA IN RELATION TO INHALED CORTICOSTEROID USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							LONG-TERM TREATMENT; BUDESONIDE; RESPONSIVENESS; TERBUTALINE	Objective.-To examine the relationship between patterns of use of inhaled beclomethasone dipropionate and the risk of fatal and near-fatal asthma. Design.-Nested case-control analysis of a historical cohort; a further analysis. Setting.-The 12 301 residents of Saskatchewan aged 5 to 54 years who were dispensed 10 or more asthma drugs from 1978 to 1987. Patients.-The 129 persons who experienced asthma death (n=44) and near-death (n=85) and their 655 controls matched as to age and date of entry into the cohort, with the additional matching criteria of at least one hospitalization for asthma in the prior 2 years, region of residence, and having received social assistance. Main Outcome.-Life-threatening attacks of asthma defined as death due to asthma or the occurrence of hypercarbia, intubation, and mechanical ventilation during an acute attack of asthma. Results.-After accounting for the risk associated with use of other medications and adjustment for markers of risk of adverse events related to asthma, subjects who had been dispensed, on average, one or more metered-dose inhalers of beclomethasone per month over a 1-year period had a significantly lower risk of fatal and near-fatal asthma (odds ratio, 0.1; 95% confidence interval, 0.02 to 0.6). Conclusion.-These data support recent guidelines from several countries that recommend the use of inhaled corticosteroids in moderate and severe asthma.	MONTREAL GEN HOSP,DEPT EPIDEMIOL & BIOSTAT,MONTREAL H3G 1A4,QUEBEC,CANADA; MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,MONTREAL H3A 2T5,QUEBEC,CANADA; UNIV SASKATCHEWAN,DEPT MED,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; UNIV SASKATCHEWAN,DEPT COMMUNITY HLTH & EPIDEMIOL,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; YALE UNIV,SCH MED,NEW HAVEN,CT 06510; SASKATCHEWAN DEPT HLTH,LAB & DIS CONTROL SERV BRANCH,HE ROBERTSON LAB,REGINA,SASKATCHEWAN,CANADA; OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PHYSIOL,PORTLAND,OR 97201	McGill University; McGill University; McGill University; University of Saskatchewan; University of Saskatchewan; Yale University; Oregon Health & Science University; Oregon Health & Science University	ERNST, P (corresponding author), RESP EPIDEMIOL UNIT,1110 PINE AVE W,MONTREAL H3A 1A3,QUEBEC,CANADA.							[Anonymous], 1990, BMJ, V301, P651; BRESLOW NE, 1980, STATISTICAL METHODS, P1; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; JENKINS CR, 1988, THORAX, V43, P378, DOI 10.1136/thx.43.5.378; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STRAND LM, 1989, PHARMACOEPIDEM DR S, P189; TOOGOOD JH, 1985, BRONCHIAL ASTHMA MEC, P698; WEST R, 1987, AM J PREV MED S2, V4, P25; 1991, 913042 DEP HLTH HUM	15	210	214	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3462	3464		10.1001/jama.268.24.3462	http://dx.doi.org/10.1001/jama.268.24.3462			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460737				2022-12-28	WOS:A1992KC83900035
J	ASHBURNER, M				ASHBURNER, M			FROSTED FLIES	SCIENCE			English	Editorial Material							CRYOPRESERVATION; EMBRYOS				ASHBURNER, M (corresponding author), UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND.							BRUSCHWEILER W, 1973, EXPERIENTIA, V29, P135; LIMBOURG B, 1973, DEV BIOL, V35, P382, DOI 10.1016/0012-1606(73)90034-1; LYNCH DV, 1989, CRYOBIOLOGY, V26, P445, DOI 10.1016/0011-2240(89)90069-2; MAZUR P, 1992, CRYOBIOLOGY, V29, P210, DOI 10.1016/0011-2240(92)90021-S; MAZUR P, 1992, CRYOBIOLOGY, V29, P39, DOI 10.1016/0011-2240(92)90005-M; RALL WF, 1985, NATURE, V313, P573, DOI 10.1038/313573a0; STEPONKUS PL, 1990, NATURE, V345, P170, DOI 10.1038/345170a0; DROSOPHILA INFORMATI	8	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1896	1897		10.1126/science.1470912	http://dx.doi.org/10.1126/science.1470912			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470912				2022-12-28	WOS:A1992KD08800020
J	GUSTAFSSON, C; ASPLUND, K; BRITTON, M; NORRVING, B; OLSSON, B; MARKE, LA				GUSTAFSSON, C; ASPLUND, K; BRITTON, M; NORRVING, B; OLSSON, B; MARKE, LA			COST-EFFECTIVENESS OF PRIMARY STROKE PREVENTION IN ATRIAL-FIBRILLATION - SWEDISH NATIONAL PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article							RISK	Objective-To assess the potential effects of primary prevention with anticoagulants or aspirin in atrial fibrillation on Swedish population. Design-Analysis of cost effectiveness based on the following assumptions: about 83 000 people have atrial fibrillation in Sweden, of whom 22 000 would be potential candidates for treatment with anticoagulants and 55 000 for aspirin treatment; the annual 5% stroke rate is reduced by 64% (with anticoagulants) and 25% (with aspirin); incidence of intracranial haemorrhage of 0.3%, 1.3%, or 2.0% per year; direct and indirect costs of a stroke of Kr180 000 and Kr90 000; estimated annual cost of treatment is Kr5030 for anticoagulants and Kr100 for aspirin. Setting-Total Swedish population. Main outcome measures-Direct and indirect costs of stroke saved, number of strokes prevented, and cost of preventive treatment. Results-Depending on the rate of haemorrhagic complications 34 to 83 patients would need to be treated annually with anticoagulants to prevent one stroke; 83 patients would need to be treated with aspirin. Giving anticoagulant treatment only would reduce costs by Kr60 million if the incidence of intracranial haemorrhage were 0.3% but would imply a net expense if the complication rate exceeded 1.3%. The total savings from giving anticoagulant (22 000 patients) and aspirin (55 000 patients) treatment would be Kr175 million per year corresponding to 2 million Pounds per million inhabitants each year. Conclusions-Treatment with anticoagulants and, if contraindications exist, with aspirin is cost effective provided that the risk of serious haemorrhage complications due to anticoagulants is kept low.	UMEA REG HOSP,DEPT MED,UMEA,SWEDEN; ST GORANS UNIV HOSP,DEPT MED,S-11281 STOCKHOLM,SWEDEN; LUND HOSP,DEPT NEUROL,LUND,SWEDEN; SWEDISH COUNCIL TECHNOL ASSESSMENT HLTH CARE,STOCKHOLM,SWEDEN; LUND HOSP,DEPT CARDIOL,LUND,SWEDEN	Saint Goran's Hospital	GUSTAFSSON, C (corresponding author), MARIESTAD HOSP,DEPT MED,BOX 411,S-54224 MARIESTAD,SWEDEN.			Norrving, Bo/0000-0002-8024-5096				ALBERS GW, 1991, ANN INTERN MED, V115, P727, DOI 10.7326/0003-4819-115-9-727; CAIRNS JA, 1991, CIRCULATION, V84, P469, DOI 10.1161/01.CIR.84.2.469; CONOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; LANDAHL S, 1984, EUR HEART J, V5, P326, DOI 10.1093/oxfordjournals.eurheartj.a061659; PETERSEN P, 1989, LANCET, V1, P175; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; 1991, CIRCULATION, V84, P527; 1988, BMJ, V296, P320; 1990, NEW ENGL J MED, V323, P1505	10	126	126	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1457	1460		10.1136/bmj.305.6867.1457	http://dx.doi.org/10.1136/bmj.305.6867.1457			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493390	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992KC91800019
J	DARMIENTO, J; DALAL, SS; OKADA, Y; BERG, RA; CHADA, K				DARMIENTO, J; DALAL, SS; OKADA, Y; BERG, RA; CHADA, K			COLLAGENASE EXPRESSION IN THE LUNGS OF TRANSGENIC MICE CAUSES PULMONARY-EMPHYSEMA	CELL			English	Article							CONNECTIVE-TISSUE; HEPATIC-FIBROSIS; ANIMAL-MODELS; PATHOGENESIS; ELASTASE; DISEASE; GENE; METALLOPROTEINASES; INHIBITORS; EFFICIENT	Transgenic mice were generated that expressed a human collagenase transgene in their lungs under the direction of the haptoglobin promoter. Histological analysis demonstrated disruption of the alveolar walls and coalescence of the alveolar spaces with no evidence of fibrosis or inflammation. This pathology is strikingly similar to the morphological changes observed in human emphysema and therefore implicates interstitial collagenase as a possible etiological agent in the disease process. Although elastase has been proposed as the primary enzyme responsible for emphysematous lung damage, this study provides evidence that other extracellular matrix proteases could play a role in emphysema. In addition, these transgenic mice are a defined genetic animal model system to study the pathogenesis of emphysema.	KANAZAWA UNIV, SCH MED, DEPT PATHOL, KANAZAWA, ISHIKAWA 920, JAPAN	Kanazawa University	DARMIENTO, J (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA.		Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038731] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38731] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG RA, 1989, THERAPEUTIC APPROACHES TO INFLAMMATORY DISEASES, P84; BERMAN M, 1980, COLLAGENASE NORMAL P, P141; CHADA K, 1985, NATURE, V314, P377, DOI 10.1038/314377a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; CLEWELL DB, 1972, J BACTERIOL, V110, P1135, DOI 10.1128/JB.110.3.1135-1146.1972; CORRIN B, 1990, LUNGS, V5, P167; EMONARD H, 1989, HEPATOLOGY, V10, P77, DOI 10.1002/hep.1840100116; Gibbs AR, 1984, OCCUPATIONAL LUNG DI, P129; GOLDRING IP, 1968, ARCH ENVIRON HEALTH, V16, P59, DOI 10.1080/00039896.1968.10665015; GROSS P, 1965, ARCH ENVIRON HEALTH, V11, P50, DOI 10.1080/00039896.1965.10664169; HANCE AJ, 1975, AM REV RESPIR DIS, V112, P657; HARRIS ED, 1974, NEW ENGL J MED, V291, P652, DOI 10.1056/NEJM197409262911305; HARRIS ED, 1977, MAMMALIAN COLLAGENAS, P249; HOGAN B, 1986, MANIPULATING MOUSE E; HOIDAL JR, 1983, CHEST, V83, P679, DOI 10.1378/chest.83.4.679; HOIDAL JR, 1989, HDB ANIMAL MODELS PU; JANOFF A, 1983, J APPL PHYSIOL, V55, P285, DOI 10.1152/jappl.1983.55.2.285; JANOFF A, 1977, AM REV RESPIR DIS, V115, P461; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; JOHANSON WG, 1972, J CLIN INVEST, V51, P288, DOI 10.1172/JCI106813; KARLINSKY JB, 1978, AM REV RESPIR DIS, V117, P1109; KESSLER S, 1975, LAB INVEST, V32, P71; KILBURN KH, 1971, ARCH INTERN MED, V127, P884, DOI 10.1001/archinte.127.5.884; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUSHNER I, 1987, DIS MARKERS, V5, P1; LAROS CD, 1976, RESPIRATION, V33, P325, DOI 10.1159/000193748; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCLAUGHLIN RF, 1971, CHEST, V59, P592, DOI 10.1378/chest.59.6.592; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHAELI D, 1974, CLIN IMMUNOL IMMUNOP, V3, P187, DOI 10.1016/0090-1229(74)90004-X; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; OKAZAKI I, 1974, NATURE, V252, P49, DOI 10.1038/252049a0; OLIVIERO S, 1987, EMBO J, V6, P1905, DOI 10.1002/j.1460-2075.1987.tb02450.x; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; PINNELL SR, 1972, NEW ENGL J MED, V286, P1013, DOI 10.1056/NEJM197205112861901; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; PUTT F, 1972, MANUAL HISTOPATHOLOG, P111; RILEY DJ, 1987, AM REV RESPIR DIS, V135, P441; RUBIN E, 1988, PATHOLOGY, P542; Sambrook J, 1989, MOL CLONING LABORATO; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469, DOI 10.1164/arrd.1977.116.3.469; SNIDER GL, 1989, ANNU REV MED, V40, P411; SNIDER GL, 1986, AM REV RESPIR DIS, V133, P149, DOI 10.1164/arrd.1986.133.1.149; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STACEY A, 1988, NATURE, V332, P131, DOI 10.1038/332131a0; UITTO J, 1987, CONNECTIVE TISSUE DI, V12; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YU SY, 1978, EXP MOL PATHOL, V29, P37, DOI 10.1016/0014-4800(78)90024-2; [No title captured]	55	281	301	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					955	961		10.1016/0092-8674(92)90391-O	http://dx.doi.org/10.1016/0092-8674(92)90391-O			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458541				2022-12-28	WOS:A1992KB99000008
J	KANIS, JA; JOHNELL, O; GULLBERG, B; ALLANDER, E; DILSEN, G; GENNARI, C; VAZ, AAL; LYRITIS, GP; MAZZUOLI, G; MIRAVET, L; PASSERI, M; CANO, RP; RAPADO, A; RIBOT, C				KANIS, JA; JOHNELL, O; GULLBERG, B; ALLANDER, E; DILSEN, G; GENNARI, C; VAZ, AAL; LYRITIS, GP; MAZZUOLI, G; MIRAVET, L; PASSERI, M; CANO, RP; RAPADO, A; RIBOT, C			EVIDENCE FOR EFFICACY OF DRUGS AFFECTING BONE METABOLISM IN PREVENTING HIP FRACTURE	BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; CALCIUM SUPPLEMENTATION; REPLACEMENT THERAPY; WOMEN; RISK; ESTROGEN; DIET	Objective-To examine the effects of taking drugs affecting bone metabolism on the risk of hip fracture in women aged over 50 years. Design-Retrospective, population based, case-control study by questionnaire. Setting-14 centres in six countries in southern Europe. Subjects-2086 women with hip fracture and 3532 control women matched for age. Main outcome measures-Number of drugs affecting bone metabolism taken and length taken for. Results-Women taking drugs affecting bone metabolism had a significantly decreased risk of hip fracture. After adjustment for differences in other risk factors, the relative risk of hip fractures was 0.55 (95% confidence interval 0.31 to 0.85) in women taking oestrogens, 0.75 (0.60 to 0.94) in those taking calcium, and 0.69 (0.51 to 0.92) in those taking calcitonin. The fall in risk was not significant for anabolic steroids (0.6 (0.29 to 1.22)). Neither vitamin D nor fluorides were associated with a significant decrease in the risk of hip fracture. The effect on hip fracture risk increased significantly with increasing duration of exposure (risk ratio 0.8 (0.61 to 1.05) for less than median exposure v 0.66 (0.5 to 0.88) for greater than median exposure). Drugs were equally effective in older and younger women, with the exception of oestrogen. Conclusions-Oestrogen, calcium, and calcitonins significantly decrease the risk of hip fracture. Short term intervention late in the natural course of osteoporosis may have significant effects on the incidence of hip fracture.	MALMO GEN HOSP,ORTHOPAED,S-21401 MALMO,SWEDEN; MALMO GEN HOSP,MED STAT,S-21401 MALMO,SWEDEN; HUDDINGE UNIV HOSP,DEPT SOCIAL MED,S-14186 HUDDINGE,SWEDEN; ISTANBUL UNIV,FAK CAPA TIP,ISTANBUL,TURKEY; UNIV SIENA,I-53100 SIENA,ITALY; ACCIDENT HOSP,T GAROFALIDIS RES,GR-14561 KIFISIA,GREECE; POLICLIN UMBERTO 1,MED CLIN 2,I-00161 ROME,ITALY; CTR ANDRE LICHTWITZ,INSERM,U18,F-75010 PARIS,FRANCE; IST CLIN MED GEN TERAPIA MED,I-43100 PARMA,ITALY; FDN JIMENEZ DIAZ,DEPT INTERNAL MED,E-28040 MADRID,SPAIN; CHU TOULOUSE PURPAN,SERV ENDOCRINOL,F-31059 TOULOUSE,FRANCE	Karolinska Institutet; Istanbul University; University of Siena; Sapienza University Rome; University Hospital Sapienza Rome; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	KANIS, JA (corresponding author), UNIV SHEFFIELD,DEPT HUMAN METAB & CLIN BIOCHEM,WHO,COLLABORATING CTR METAB BONE DIS,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; CHESNUT CH, 1983, METABOLISM, V32, P571, DOI 10.1016/0026-0495(83)90027-6; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; DEQUEKER J, 1991, CLIN RHEUMATOL, V10, P49, DOI 10.1007/BF02208033; DEQUEKER J, 1991, CLIN RHEUMATOL, P54; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; GEUSENS P, 1977, OSTEOPOROSIS, P966; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUTCHINSON TA, 1979, LANCET, V2, P705; Kanis J A, 1991, Osteoporos Int, V1, P182, DOI 10.1007/BF01625451; KANIS JA, 1991, CALCIFIED TISSUE INT, V49, pS33, DOI 10.1007/BF02555086; KANIS JA, 1989, BRIT MED J, V298, P137, DOI 10.1136/bmj.298.6667.137; KANIS JA, 1989, BRIT MED J, V298, P205, DOI 10.1136/bmj.298.6668.205; KANIS JA, 1984, LANCET, V1, P27; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; MACINTYRE I, 1988, LANCET, V1, P900; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; 1991, OSTEOPOROSIS INT, V1, P114	24	262	268	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1124	1128		10.1136/bmj.305.6862.1124	http://dx.doi.org/10.1136/bmj.305.6862.1124			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463947	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JX84100021
J	ARONSON, JK; HARDMAN, M				ARONSON, JK; HARDMAN, M			ABC OF MONITORING DRUG-THERAPY - MEASURING PLASMA DRUG CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article									ICI PLC,DIV MED RES,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND		ARONSON, JK (corresponding author), RADCLIFFE INFIRM,CLIN PHARMACOL,OXFORD OX2 6HE,ENGLAND.							ARONSON JK, 1976, BRIT J CLIN PHARMACO, V3, P1045, DOI 10.1111/j.1365-2125.1976.tb00356.x; HOOPER WD, 1974, AUST NZ J MED, V4, P449, DOI 10.1111/j.1445-5994.1974.tb03216.x; LLOYD, 1978, AM J CARDIOL, V42, P129	3	22	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1078	1080		10.1136/bmj.305.6861.1078	http://dx.doi.org/10.1136/bmj.305.6861.1078			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467691	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JW70100025
J	RIMPELA, AH; RIMPELA, MK; KOSUNEN, EAL				RIMPELA, AH; RIMPELA, MK; KOSUNEN, EAL			USE OF ORAL-CONTRACEPTIVES BY ADOLESCENTS AND ITS CONSEQUENCES IN FINLAND 1981-91	BRITISH MEDICAL JOURNAL			English	Article							TEENAGE PREGNANCY; UNITED-STATES; WOMEN; COUNTRIES; DISEASE; AGE	Objectives-To study use of oral contraceptives among Finnish teenagers during 1981-91 and how abortions, childbirths, sexually transmitted diseases, and cardiovascular diseases changed during this period. Design-Biannual cross sectional surveys with mailed questionnaires from 1981 onwards and analysis of national statistics. Setting-Finland. Subjects-A nationwide sample of 14, 16, and 18 year olds. Sample size varied from 1249 to 3887 and response rate from 85% to 94%. Main outcome measures-Proportion taking oral contraceptive, fertility and abortion rates, hospital discharge rates, rates of sexually transmitted diseases. Results-The proportion of teenagers taking oral contraceptives increased steadily. In 1991 the percentages among 14, 16, and 18 year olds were 2%, 18%, and 41%,compared with 0.2%, 7% and 22% in 1981. Most users had a steady partner (80% of 16 year olds and 85% of 18 year olds). By 1989 rates of abortion had fallen from 12/1000 to 9.3/1000 in 16 year olds and from 25/1000 to 19.2/1000 in 18 year olds; fertility rates had fallen from 4.5/1000 to 2.3/1000 and from 23.5/1000 to 15.3/1000 respectively. Rates in 14 year olds fell only slightly. Gonorrhoea infection fell and HIV infection remained rare. Rates of hospital discharge after thromboembolic venous disease rose slightly. Conclusions-The increased use of oral contraceptives is the most likely explanation for decreasing abortion and fertility rates among teenagers. Increased reliance on the condom because of the threat of AIDS may increase unwanted pregnancies.	UNIV HELSINKI,DEPT PUBL HLTH,SF-00250 HELSINKI,FINLAND; UNIV TURKU,DEPT PUBL HLTH,SF-20520 TURKU 52,FINLAND; UNIV TAMPERE,DEPT PUBL HLTH,SF-33101 TAMPERE,FINLAND	University of Helsinki; University of Turku; Tampere University			Rimpela, Arja/J-3910-2014					ARMITAGE P, 1971, STATISTICAL METHODS; BERAL V, 1988, LANCET, V2, P1331; BRINTON LA, 1991, CONTRACEPTION, V43, P581, DOI 10.1016/0010-7824(91)90005-Z; BROOKSGUNN J, 1991, B NY ACAD MED, V76, P527; DAVANZO J, 1991, JAMA-J AM MED ASSOC, V265, P2692; DEBUONO BA, 1990, NEW ENGL J MED, V322, P821, DOI 10.1056/NEJM199003223221206; HARRIS C, 1983, NEW ENGL J MED, V308, P1181, DOI 10.1056/NEJM198305193082001; HIRVONEN E, 1990, AM J OBSTET GYNECOL, V163, P281, DOI 10.1016/0002-9378(90)90568-R; HOFMANN A D, 1984, Bulletin of the World Health Organization, V62, P331; Holmgren K, 1990, Nord Med, V105, P46; JONES EF, 1985, FAM PLANN PERSPECT, V17, P53, DOI 10.2307/2135261; KONTULA O, 1992, HEALTH EDUC RES, V7, P69, DOI 10.1093/her/7.1.69; KONTULA O, 1988, HLTH ED SERIES ORIGI, V9; KONTULA O, 1991, SUKUPUOLIELAMAN ALOI; MAKKONEN K, 1991, SCAND J SOC MED, V19, P32, DOI 10.1177/140349489101900106; Mandelin M, 1990, Nord Med, V105, P41; PIKE MC, 1983, LANCET, V2, P926; REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P2094, DOI 10.1001/jama.254.15.2094; RIMPELA M, 1988, HLTH BEHAVIOUR RES H; RUUSUVAARA L, 1983, THESIS U HELSINKI HE; SHAW RW, 1987, BRIT J OBSTET GYNAEC, V94, P724, DOI 10.1111/j.1471-0528.1987.tb03716.x; THOROGOOD M, 1990, AM J OBSTET GYNECOL, V163, P274, DOI 10.1016/0002-9378(90)90567-Q; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; Tikkanen J, 1988, Hygie, V7, P28; TURETSKY RA, 1983, CLIN PEDIATR, V22, P337, DOI 10.1177/000992288302200503; TYRER L B, 1977, Clinical Obstetrics and Gynecology, V20, P651, DOI 10.1097/00003081-197709000-00013; WALLACE HM, 1989, J ADOLESCENT HEALTH, V10, P231, DOI 10.1016/0197-0070(89)90239-8; 1987, OFFICIAL STATISTICS, P4; 1991, HLTH STATISTICS NORD, P36; 1980, OFFICIAL STATISTIC A, V4, P145; 1990, OFFICIAL STATISTICS, P1; OFFICIAL STATISTICS, V11, P77; 1980, OFFICIAL STATISTIC B, V6, P136; 1991, TILASTOJULKAISU 1991; 1988, POPULATION STUDIES, V109, P1	35	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1053	1057		10.1136/bmj.305.6861.1053	http://dx.doi.org/10.1136/bmj.305.6861.1053			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467684	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JW70100017
J	GURWITZ, JH; COL, NF; AVORN, J				GURWITZ, JH; COL, NF; AVORN, J			THE EXCLUSION OF THE ELDERLY AND WOMEN FROM CLINICAL-TRIALS IN ACUTE MYOCARDIAL-INFARCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE; PROPHYLACTIC LIDOCAINE; MORTALITY; AGE; HYPERTENSION; MORBIDITY; PATTERNS; THERAPY; MEN	Objective.-To determine the extent to which the elderly have been excluded from trials of drug therapies used in the treatment of acute myocardial infarction, to identify factors associated with such exclusions, and to explore the relationship between the exclusion of elderly and the representation of women. Data Sources.-We conducted a systematic search of the English-language literature from January 1960 through September 1991 to identify all relevant studies of specific pharmacotherapies employed in the treatment of acute myocardial infarction. To accomplish this, we searched MEDLINE, major cardiology textbooks, meta-analyses, reviews, editorials, and the bibliographies of all identified articles. Study Selection.-Only trials in which patients were randomly allocated to receive a specific therapeutic regimen or a placebo or nonplacebo control regimen were included for review. Data Extraction.-Studies were abstracted for year of publication, source of support, performance location, drug therapies to which patients were randomized, use of invasive diagnostic tests or therapeutic procedures, exclusion criteria, size and demographic characteristics of the randomized study population, and principal outcome measures. Data Synthesis.-A total of 214 trials met inclusion criteria, involving 150 920 study subjects. Over 60% of trials excluded persons over the age of 75 years. Studies published after 1980 were more likely to have age-based exclusions compared with studies published before 1980 (adjusted odds ratio, 4.92; 95% confidence interval, 2.33 to 10.54). Trials of thrombolytic therapy involving an invasive procedure were more likely to exclude elderly patients compared with other studies (adjusted odds ratio, 2.45; 95% confidence interval, 1.10 to 5.47). Studies with age-based exclusions had a smaller percentage of women compared with those without such exclusions (18% vs 23%; P=.0002), with the mean age of the study population significantly associated with the proportion of women participants (P=.0001, R2=.29). Conclusions.-Age-based exclusions are frequently used in clinical trials of medications used in the treatment of acute myocardial infarction. Such exclusions limit the ability to generalize study findings to the patient population that experiences the most morbidity and mortality from acute myocardial infarction.	HARVARD RES & TRAINING CTR, BOSTON, MA USA; HEBREW REHABIL CTR AGED, BOSTON, MA USA; UNIV MASSACHUSETTS, SCH MED, DEPT FAMILY & COMMUNITY MED, WORCESTER, MA 01605 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	GURWITZ, JH (corresponding author), BRIGHAM & WOMENS HOSP, DIV GERONTOL, PROGRAM ANAL CLIN STRATEGIES, 221 LONGWOOD AVE, BOSTON, MA 02115 USA.		Col, Nananda/AAE-3445-2019	Col, Nananda/0000-0001-7106-662X	NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER; NIA NIH HHS [KO8 AG00510-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADOLPH RJ, 1990, J AM COLL CARDIOL, V16, P793, DOI 10.1016/S0735-1097(10)80323-7; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1990, Lancet, V336, P65; [Anonymous], 1986, Lancet, V1, P397; [Anonymous], 1989, GUIDELINE STUDY DRUG; COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P1049, DOI 10.1001/jama.263.8.1049; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DOUGLAS PS, 1986, CIRCULATION, V74, P917, DOI 10.1161/01.CIR.74.5.917; DUNN HM, 1985, AM HEART J, V110, P353, DOI 10.1016/0002-8703(85)90156-5; EVEMY KL, 1978, EUR J CARDIOL, V7, P391; FISHER LD, 1989, INT J CARDIOL, V24, P317, DOI 10.1016/0167-5273(89)90011-9; FULTON JP, 1989, VITAL HLTH STAT 10, V167; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GRAVES EJ, 1991, VITAL HLTH STAT, V13; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; JECKER NS, 1991, JAMA-J AM MED ASSOC, V266, P3012, DOI 10.1001/jama.266.21.3012; KAPANTAIS G, 1989, ADV DATA VITAL HLTH, V172; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KLINKENBERGKNOL EC, 1987, LANCET, V1, P349; LAKATTA EG, 1982, AM J PHYSIOL, V242, pH927, DOI 10.1152/ajpheart.1982.242.6.H927; LEVEY BA, 1991, CLIN PHARMACOL THER, V50, P641, DOI 10.1038/clpt.1991.201; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MANOLIO TA, 1992, AM J MED, V92, P1, DOI 10.1016/0002-9343(92)90007-X; MONTAGUE TJ, 1991, AM J CARDIOL, V68, P843, DOI 10.1016/0002-9149(91)90397-4; MONTAMAT SC, 1989, NEW ENGL J MED, V321, P303; RICH MW, 1992, AM J MED, V92, P7, DOI 10.1016/0002-9343(92)90008-Y; ROSS AM, 1990, J MYO ISCH, V2, P65; SMITH SC, 1990, J AM COLL CARDIOL, V16, P784, DOI 10.1016/S0735-1097(10)80322-5; WARNES CA, 1984, AM HEART J, V108, P431, DOI 10.1016/0002-8703(84)90404-6; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WILHELMSEN L, 1988, EUR HEART J, V9, P207, DOI 10.1093/oxfordjournals.eurheartj.a062484; WILHELMSSON C, 1974, LANCET, V2, P1157; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1990, STAT MED, V9, P73, DOI 10.1002/sim.4780090114; YUSUF S, 1991, AM J CARDIOL, V68, P954, DOI 10.1016/0002-9149(91)90416-I; YUSUF S, 1988, LANCET, V1, P1088; 1991, VITAL STATISTICS U A, V2; 1987, SAS RELEAS 604; 1987, VITAL HLTH STAT, V3; 1990, STATISTICAL ABSTRACT	42	381	388	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1417	1422		10.1001/jama.1992.03490110055029	http://dx.doi.org/10.1001/jama.1992.03490110055029			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512909				2022-12-28	WOS:A1992JM84900023
J	HOULE, D; HOFFMASTER, DK; ASSIMACOPOULOS, S; CHARLESWORTH, B				HOULE, D; HOFFMASTER, DK; ASSIMACOPOULOS, S; CHARLESWORTH, B			THE GENOMIC MUTATION-RATE FOR FITNESS IN DROSOPHILA	NATURE			English	Article							AFFECTING VIABILITY; MELANOGASTER; POPULATIONS; EVOLUTION	THE mutation rate per genome for local affecting fitness is crucial in theories of the evolution of sex and recombination1,2 and of outbreeding mechanisms3. Mutational variation in fitness may also be important in the evolution of mate choice in animals2,4,5. No information is available on the rate at which spontaneous mutations with small effects on fitness arise, although viability (probability of survival to adulthood) has been studied in Drosophila melanogaster6-9. These experiments involved the accumulation of spontaneous mutations in the virtual absence of natural selection, in a set of independently maintained lines with a common origin. The rates of decline in mean and increase in variance among lines permit estimation of limits to the mean number of new mutations arising per generation (U) and the average homozygous effect of a new mutation of minor effect (s)7,9,10. For the second chromosome of D. melanogaster, the value of U is at least 0.17 (ref. 7), and (1 - h)s is less than 0.02, where hs is the average decline in fitness of heterozygotes. As the second chromosome is about 40% of the genome, these data indicate a mutation rate per haploid genome of at least 0.42 for viability. Here we present similar data on the effects of homozygous spontaneous mutations on a measure of fitness in D. melanogaster.	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637	University of Chicago								ASHBURNER M, 1989, DROSOPHILA LABORATOR; BATEMAN A, 1959, INT J RADIAT BIOL, V2, P170; CARLSSON BG, 1987, ORNIS SCAND, V18, P237, DOI 10.2307/3676890; CHARLESWORTH B, 1990, NATURE, V347, P380, DOI 10.1038/347380a0; CHARLESWORTH B, 1985, HEREDITY, V54, P71, DOI 10.1038/hdy.1985.10; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; Lindsley D.L., 1968, GENETIC VARIATIONS D; MUKAI T, 1969, GENETICS, V61, P749; MUKAI T, 1971, GENETICS, V69, P385; MUKAI T, 1972, GENETICS, V72, P335; MUKAI T, 1964, GENETICS, V50, P1; OHNISHI O, 1977, GENETICS, V87, P529; SIMMONS MJ, 1980, GENETICS, V94, P467; Sokal R. R, 1981, BIOMETRY; SVED JA, 1971, GENET RES, V18, P97, DOI 10.1017/S0016672300012453; YOSHIMARU H, 1985, JPN J GENET, V60, P307, DOI 10.1266/jjg.60.307	20	108	108	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1992	359	6390					58	60		10.1038/359058a0	http://dx.doi.org/10.1038/359058a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522887				2022-12-28	WOS:A1992JL66200052
J	WENTZ, DK; OSTEEN, AM; CANNON, MI				WENTZ, DK; OSTEEN, AM; CANNON, MI			CONTINUING MEDICAL-EDUCATION - UNABATED DEBATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											WENTZ, DK (corresponding author), AMER MED ASSOC,DIV CONTINUING MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							WENTZ DK, 1991, JAMA-J AM MED ASSOC, V266, P953; 1992, GUIDELINES FACULTY I; 1992, UNIFORM GUIDELINES F; 1992, PHYSICIANS RECOGNITI; 1992, STANDARDS COMMERCIAL; 1991, WHITE PAPER PROPRIET; 1990, GUIDELINES DEALING F; 1991, ANNOTATED GUIDELINES	8	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1118	1120		10.1001/jama.268.9.1118	http://dx.doi.org/10.1001/jama.268.9.1118			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK681	1501334				2022-12-28	WOS:A1992JK68100009
J	WHITCOMB, M				WHITCOMB, M			THE ORGANIZATION AND FINANCING OF GRADUATE MEDICAL-EDUCATION IN CANADA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								1988, 1ST US DEP HLTH HUM; 1978, MANPOWER POLICY PRIM; 1990, SUPPLYING PHYSICIANS; 1985, FINANCING GRADUATE M; 1978, REPORT C ARE ENOUGH; 1985, PRESCRIPTION CHANGE; 1980, GRADUATE MED ED NATI	7	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1106	1109		10.1001/jama.268.9.1106	http://dx.doi.org/10.1001/jama.268.9.1106			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK681	1501332				2022-12-28	WOS:A1992JK68100007
J	NEU, HC				NEU, HC			THE CRISIS IN ANTIBIOTIC-RESISTANCE	SCIENCE			English	Article							PENICILLIN-BINDING PROTEINS; BETA-LACTAM ANTIBIOTICS; HIGH-LEVEL RESISTANCE; COAGULASE-NEGATIVE STAPHYLOCOCCI; D-ALANINE LIGASE; STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; VANCOMYCIN RESISTANCE; ENTEROCOCCUS-FAECIUM; UNITED-STATES	The synthesis of large numbers of antibiotics over the past three decades has caused complacency about the threat of bacterial resistance. Bacteria have become resistant to antimicrobial agents as a result of chromosomal changes or the exchange of genetic material via plasmids and transposons. Streptococcus pneumoniae, Streptococcus pyogenes, and staphylococci, organisms that cause respiratory and cutaneous infections, and members of the Enterobacteriaceae and Pseudomonas families, organisms that cause diarrhea, urinary infection, and sepsis, are now resistant to virtually all of the older antibiotics. The extensive use of antibiotics in the community and hospitals has fueled this crisis. Mechanisms such as antibiotic control programs, better hygiene, and synthesis of agents with improved antimicrobial activity need to be adopted in order to limit bacterial resistance.			NEU, HC (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, 630 W 168 ST, NEW YORK, NY 10032 USA.							APPELBAUM P C, 1992, Clinical Microbiology Newsletter, V14, P49, DOI 10.1016/0196-4399(92)90053-C; APPELBAUM PC, 1987, EUR J CLIN MICROBIOL, V6, P367, DOI 10.1007/BF02013089; ARTHUR M, 1991, GENE, V103, P133, DOI 10.1016/0378-1119(91)90405-Z; ARTHUR M, 1987, J ANTIMICROB CHEMOTH, V20, P783, DOI 10.1093/jac/20.6.783; BANERJEE SN, 1991, AM J MED, V91, pS86, DOI 10.1016/0002-9343(91)90349-3; BAUERNFEIND A, 1990, INFECTION, V18, P48, DOI 10.1007/BF01644185; BLUMBERG HM, 1991, J INFECT DIS, V163, P1279, DOI 10.1093/infdis/163.6.1279; Boyce J M, 1989, Infect Dis Clin North Am, V3, P901; BOYCE JM, 1983, JAMA-J AM MED ASSOC, V249, P2803, DOI 10.1001/jama.249.20.2803; BRISSONNOEL A, 1988, J BACTERIOL, V170, P1739, DOI 10.1128/jb.170.4.1739-1745.1988; BRUTON J, 1986, J BACTERIOL, V168, P374; BRUTON J, 1986, REV INFECT DIS, V8, P713; Bryan L. E., 1984, ANTIMICROBIAL DRUG R, P241; BRYAN LE, 1988, J ANTIMICROB CHEMOTH, V22, P1; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; BUSH K, 1989, ANTIMICROB AGENTS CH, V33, P339; BUUHOI AY, 1988, J ANTIMICROB CHEMOTH, V22, P41, DOI 10.1093/jac/22.Supplement_B.41; CHAMBERS H F, 1988, Clinical Microbiology Reviews, V1, P173; CHAMBERS HF, 1987, ANTIMICROB AGENTS CH, V31, P1919, DOI 10.1128/AAC.31.12.1919; CHAMBERS HF, 1990, J INFECT DIS, V161, P1170, DOI 10.1093/infdis/161.6.1170; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; COFFEY TJ, 1991, MOL MICROBIOL, V5, P2255, DOI 10.1111/j.1365-2958.1991.tb02155.x; COURVALIN P, 1990, ANTIMICROB AGENTS CH, V34, P2291, DOI 10.1128/AAC.34.12.2291; CROKSON BD, 1990, J APPL BACTERIOL, V69, P55; CUNDY KV, 1991, J ANTIMICROB CHEMOTH, V28, P491, DOI 10.1093/jac/28.4.491; DARFEUILLE-MICHAUD A, 1992, INFECT IMMUN, V60, P44, DOI 10.1128/IAI.60.1.44-55.1992; DAVON RS, 1988, J INFECT DIS, V157, P450; DEGUCHI K, 1990, JPN J ANTIBIOT, V42, P2133; DIVER JM, 1991, ANTIMICROB AGENTS CH, V35, P1538, DOI 10.1128/AAC.35.8.1538; DUTKAMALEN S, 1990, MOL GEN GENET, V224, P364, DOI 10.1007/BF00262430; ELIOPOULOS GM, 1988, ANTIMICROB AGENTS CH, V32, P1528, DOI 10.1128/AAC.32.10.1528; FASCHING CE, 1991, J INFECT DIS, V164, P976, DOI 10.1093/infdis/164.5.976; FENOLL A, 1991, REV INFECT DIS, V13, P56; FINLAND M, 1979, REV INFECT DIS, V1, P4; FISHER M, 1990, NEW ANTIBACTERIAL ST, P177; GAYNES RP, 1992, INFECT CONT HOSP EP, V13, P10, DOI 10.1086/646417; HAKENBECK R, 1991, J INFECT DIS, V164, P307, DOI 10.1093/infdis/164.2.307; HAKENBECK R, 1991, J INFECT DIS, V164, P313, DOI 10.1093/infdis/164.2.313; HAKENBECK R, 1991, J CHEMOTHERAPY, V3, P86; HANDSFIELD HH, 1982, NEW ENGL J MED, V306, P950, DOI 10.1056/NEJM198204223061602; HIGGINS CF, 1990, FR INFEC D, P193; HOLMSTROM L, 1990, SCAND J INFECT DIS, V22, P179, DOI 10.3109/00365549009037900; JACOBUS NV, 1989, J ANTIMICROB CHEMOTH, V24, P675, DOI 10.1093/jac/24.5.675; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JOHNSON AP, 1990, CLIN MICROBIOL REV, V3, P280, DOI 10.1128/CMR.3.3.280-291.1990; JORGENSEN JH, 1990, ANTIMICROB AGENTS CH, V34, P2075, DOI 10.1128/AAC.34.11.2075; KAPLAN EL, 1991, EUR J CLIN MICROBIOL, V10, P55, DOI 10.1007/BF01964407; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; KHADORI N, 1990, REV INFECT DIS, V12, P996; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; LABILE G, 1991, MOL MICROBIOL, V5, P1933; LAIBLE G, 1991, J BACTERIOL, V173, P6986, DOI 10.1128/jb.173.21.6986-6990.1991; LECLERCQ R, 1991, ANTIMICROB AGENTS CH, V35, P1267, DOI 10.1128/AAC.35.7.1267; LECLERCQ R, 1989, ANTIMICROB AGENTS CH, V33, P10, DOI 10.1128/AAC.33.1.10; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; LEE EH, 1991, ANTIMICROB AGENTS CH, V35, P1093, DOI 10.1128/AAC.35.6.1093; LUJAN R, 1990, REV ESP QUIM, V3, P323; LYON BR, 1987, MICROBIOL REV, V51, P88, DOI 10.1128/MMBR.51.1.88-134.1987; MACHKA K, 1988, EUR J CLIN MICROBIOL, V7, P14, DOI 10.1007/BF01962165; MALMBORG AS, 1986, J ANTIMICROB CHEMOTH, V18, P293, DOI 10.1093/jac/18.3.293; MANYAMA S, 1979, AM J DIS CHILD, V133, P1143; MARTON A, 1991, J INFECT DIS, V163, P542, DOI 10.1093/infdis/163.3.542; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MILATOVIC D, 1987, EUR J CLIN MICROBIOL, V6, P234, DOI 10.1007/BF02017607; MITSUHASHI S, 1982, AMINOGLYCOSIDES MICR, P97; MOELLERING RC, 1991, J ANTIMICROB CHEMOTH, V28, P1, DOI 10.1093/jac/28.1.1; MORAKAMI K, 1989, J BACTERIOL, V171, P864; MORSE SA, 1986, ANTIMICROB AGENTS CH, V30, P664, DOI 10.1128/AAC.30.5.664; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; MUDER RR, 1987, ARCH INTERN MED, V147, P1672, DOI 10.1001/archinte.147.9.1672; MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302; MURRAY BE, 1983, J CLIN INVEST, V72, P1168, DOI 10.1172/JCI111042; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; MURRAY BE, 1983, ANTIMICROB AGENTS CH, V23, P799, DOI 10.1128/AAC.23.6.799; Nafziger D A, 1989, Infect Dis Clin North Am, V3, P915; NEU HC, 1984, AM J MED, V76, P11, DOI 10.1016/0002-9343(84)90240-7; NEU HC, 1992, INFECT CONT HOSP EP, V13, P7, DOI 10.2307/30146961; NEU HC, 1992, ANNU REV MED, V43, P465, DOI 10.1146/annurev.me.43.020192.002341; NEU HC, 1986, REV INFECT DIS, V8, pS237; NEU HC, 1992, ANN INTERN MED, V116, P517, DOI 10.7326/0003-4819-116-6-517; NEU HC, 1991, HUMAN PHARM, P613; NEU HC, 1985, AM J MED S5B, V7, P2; NICAS TI, 1989, ANTIMICROB AGENTS CH, V33, P1121, DOI 10.1128/AAC.33.7.1121; NIKAIDO H, 1988, J ANTIMICROB CHEMOTH, V22, P17, DOI 10.1093/jac/22.Supplement_A.17; NORMARK S, 1990, FR INFEC D, P161; OBRIEN TF, 1987, REV INFECT DIS, V9, pS244; PATTERSON JE, 1988, J INFECT DIS, V158, P212, DOI 10.1093/infdis/158.1.212; PHILIPPON A, 1989, ANTIMICROB AGENTS CH, V33, P1131, DOI 10.1128/AAC.33.8.1131; PHILLIPS G, 1990, J ANTIMICROB CHEMOTH, V25, P723, DOI 10.1093/jac/25.4.723; PIERRE J, 1990, ANTIMICROB AGENTS CH, V34, P1691, DOI 10.1128/AAC.34.9.1691; RAIMONDI A, 1991, ANTIMICROB AGENTS CH, V35, P1174, DOI 10.1128/AAC.35.6.1174; REEVES DS, 1991, J ANTIMICROB CHEMOTH, V27, P469, DOI 10.1093/jac/27.4.469; RICE LB, 1989, ANTIMICROB AGENTS CH, V33, P470, DOI 10.1128/AAC.33.4.470; SANDERS CC, 1991, ANN INTERN MED, V115, P650, DOI 10.7326/0003-4819-115-8-650; SANDERS WE, 1988, REV INFECT DIS, V10, P830; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; SCHABERG DR, 1981, AM J MED, V70, P445, DOI 10.1016/0002-9343(81)90786-5; SCHWALBE RS, 1987, NEW ENGL J MED, V316, P927, DOI 10.1056/NEJM198704093161507; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; Shapiro JA, 1983, MOBILE GENETIC ELEME; SHLAES DM, 1989, ANTIMICROB AGENTS CH, V33, P198, DOI 10.1128/AAC.33.2.198; SIROT DL, 1992, ANTIMICROB AGENTS CH, V36, P1677, DOI 10.1128/AAC.36.8.1677; SIROT J, 1988, REV INFECT DIS, V10, P850; SKURRAY RA, 1988, J ANTIMICROB CHEMOTH, V21, P9, DOI 10.1093/jac/21.suppl_C.19; SLOCOMBE B, 1991, J HOSP INFECT, V19, P19, DOI 10.1016/0195-6701(91)90198-H; SMITH AL, 1992, INFECT DIS CLIN N AM, V6, P177; SPIKA JS, 1991, J INFECT DIS, V163, P1273, DOI 10.1093/infdis/163.6.1273; SPRATT BG, 1988, REV INFECT DIS, V10, P699; STINGEMORE N, 1989, MED J AUSTRALIA, V150, P626, DOI 10.5694/j.1326-5377.1989.tb136725.x; SUZUKI E, 1992, ANTIMICROB AGENTS CH, V36, P429, DOI 10.1128/AAC.36.2.429; TENOVER F, COMMUNICATION; TENOVER FC, 1991, AM J MED, V91, pS76, DOI 10.1016/0002-9343(91)90347-Z; TESCH W, 1988, ANTIMICROB AGENTS CH, V32, P1494, DOI 10.1128/AAC.32.10.1494; TOMASZ A, 1986, REV INFECT DIS, V8, pS260; UBUKATA K, 1985, ANTIMICROB AGENTS CH, V27, P851, DOI 10.1128/AAC.27.5.851; UTTLEY AHC, 1988, LANCET, V1, P57; VILLARINO ME, 1992, INFECT CONT HOSP EP, V13, P201, DOI 10.1086/646510; WALLACE RJ, 1990, AM J MED, V88, pS46, DOI 10.1016/0002-9343(90)90262-C; WALLACE RJ, 1989, ANTIMICROB AGENTS CH, V33, P1845, DOI 10.1128/AAC.33.11.1845; WARD J, 1981, REV INFECT DIS, V3, P254; WELLS VD, 1992, ANN INTERN MED, V116, P285, DOI 10.7326/0003-4819-116-4-285; WILLIAMSON R, 1989, J INFECT DIS, V159, P1095, DOI 10.1093/infdis/159.6.1095; ZACKRISSON G, 1988, SCAND J INFECT DIS, V20, P419, DOI 10.3109/00365548809032478; ZEROS MJ, 1987, ANN INTERN MED, V106, P687; 1991, AM J MED S3B, V91; 1987, REV INFECT DIS S3, V9	127	2112	2211	24	1405	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1992	257	5073					1064	1073		10.1126/science.257.5073.1064	http://dx.doi.org/10.1126/science.257.5073.1064			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509257				2022-12-28	WOS:A1992JJ88400021
J	ADLER, RG				ADLER, RG			GENOME RESEARCH - FULFILLING THE PUBLICS EXPECTATIONS FOR KNOWLEDGE AND COMMERCIALIZATION	SCIENCE			English	Article							BIOTECHNOLOGY; PROJECT; PATENTS	This article provides a historical perspective for the patenting of gene sequences and describes the fundamentals and evolution of patent law. It summarizes federal technology transfer law and policy and assesses the impacts of patenting on academic research. The patentability of gene sequences is then considered along with potential impacts that published sequence data may have on obtaining patent protection for downstream products. Industry's position on gene patenting is summarized and perspectives from the emerging public record on these issues are presented. The article discussing points at which the filing of patent applications and the licensing of patents may be appropriate. It concludes that technology transfer policies for genome research must be adopted carefully so that they remain viable in a time of rapid technological change.			ADLER, RG (corresponding author), NIH,OFF TECHNOL TRANSFER,BETHESDA,MD 20892, USA.			Adler, Reid/0000-0002-4998-4034				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ADLER R, 1988, HARVARD J LAW TECH, V1, P1; ADLER R, 1989, AM INTELECT PROP LAW, V16, P287; ADLER RG, 1984, SCIENCE, V224, P357, DOI 10.1126/science.6584975; Beier David, 1991, DENVER U LAW REV, V68, P173; BENT S, 1992, GENET ENG NEWS   JAN, P4; BURRILL GS, 1990, BIOTECH 91 CHANGING, P5; Cohen Stanley N, 1980, US Patent, Patent No. [4,237,224, 4237224]; CURIEN H, 1991, SCIENCE, V254, P1710; Eisenberg Rebecca S, 1990, Emory Law J, V39, P721; EISENBERG RS, 1989, U CHICAGO LAW REV, V56, P1017, DOI 10.2307/1599761; FEIT, 1989, J PAT TRADEMARK OFF, V71, P819; GREENLEE LL, 1991, DENVER U LAW REV, V68, P127; HEALY B, 1992, IN PRESS N ENGL J ME; ISRAELSEN N, 1988, AM INTELECT PROP L A, V16, P457; JARJALA DS, 1992, JURIMETRICS, V32, P121; KELLY PD, 1992, BIO-TECHNOL, V10, P52, DOI 10.1038/nbt0192-52; KOSHLAND DE, 1992, SCIENCE, V255, P1189, DOI 10.1126/science.255.5049.1189; MANSFIELD E, 1979, REV EC STATISTIC FEB, P49; MERGES RP, 1990, COLUMBIA LAW REV, V90, P839, DOI 10.2307/1122920; MOSSINGHOFF GJ, 1992, COMMUNICATION   0528; Pasteur L., 1871, REV SCI; RAINES L, 1992, MAY PUBL M FCCSET CO; RAINES LJ, 1991, ISSUES SCI TECHNOL, V8, P33; Santayana George, 1905, LIFE REASON, VII; Schwaab Richard L., 1987, INTELLECTUAL PROPERT; Solzhenitsyn Aleksandr, 1978, NAT REV, V30; VAGELOS PR, 1991, SCIENCE, V252, P1080, DOI 10.1126/science.252.5009.1080; WATSON JD, 1981, DNA STORY DOCUMENTAR, pCH16; Winslow Ron, WALL STREET J; 1992, OTATCT527E OFF TECHN; 1991, OTABA495 OFF TECHN A, P203; 1991, REPORT NATIONAL BIOT, P17; 1984, OTAB2218 US C OFF TE; 1988, OTABA373 US C OFF TE, pCH16; 1991, OTABA494 US C OFF TE, P17; 1992, WASHINGTON POST 0501; [No title captured]; 1988, IMPLICATIONS SOC, P91	40	32	32	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					908	914		10.1126/science.1502557	http://dx.doi.org/10.1126/science.1502557			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JH827	1502557				2022-12-28	WOS:A1992JH82700022
J	KURLANDER, RJ; SHAWAR, SM; BROWN, ML; RICH, RR				KURLANDER, RJ; SHAWAR, SM; BROWN, ML; RICH, RR			SPECIALIZED ROLE FOR A MURINE CLASS-I-B MHC MOLECULE IN PROKARYOTIC HOST DEFENSES	SCIENCE			English	Article							N-FORMYLATED PEPTIDES; LISTERIA-MONOCYTOGENES; T-CELLS; LYMPHOCYTES-T; ANTIGEN; RECEPTOR; MICE; PROTECTION; IMMUNITY; PROTEINS	Although nonclassical (class I-b) gene products represent the majority of murine major histocompatibility complex (MHC) genes, the role of these relatively nonpolymorphic molecules remains uncertain. Recently, one such protein, H-2M3 (formerly designated Hmt), was shown to bind and specifically present N-formylated peptides to cytotoxic T lymphocytes. Because N-formylation is characteristic of prokaryotic proteins, this MHC molecule may be especially adapted for a role in the mammalian defense against bacterial attack. The current studies demonstrate that an MHC molecule, indistinguishable from H-2M3, presents antigens derived from the intracellular pathogen Listeria monocytogenes to Listeria-specific CD8+ cells.	BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	KURLANDER, RJ (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA.			Shawar, Said/0000-0002-5281-1783	NIAID NIH HHS [R01 AI18882, R01 AI18073] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018073, R01AI018882] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN ML, 1992, J IMMUNOL, V148, P555; BRUNT LM, 1990, J IMMUNOL, V145, P3540; Buetow D E, 1978, Subcell Biochem, V5, P1; COLLINGE J, 1991, NATURE, V353, P802, DOI 10.1038/353802a0; CZUPRYNSKI CJ, 1987, IMMUNOLOGY, V60, P287; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; DELIBERO G, 1986, J IMMUNOL, V137, P2688; FISCHERLINDAHL K, 1985, TRENDS GENET, V1, P135; FISCHERLINDAHL K, 1983, NATURE, V306, P383; IMANI F, 1991, P NATL ACAD SCI USA, V88, P10475, DOI 10.1073/pnas.88.23.10475; KAUFMANN SHE, 1987, REV INFECT DIS, V9, pS650; KAUFMANN SHE, 1988, J IMMUNOL, V140, P3173; KLEIN J, 1990, IMMUNOGENETICS, V32, P147, DOI 10.1007/BF02114967; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LINDAHL KF, 1991, ANNU REV IMMUNOL, V9, P351, DOI 10.1146/annurev.iy.09.040191.002031; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LUKACS K, 1989, J IMMUNOL, V142, P2879; LUKACS K, 1989, J IMMUNOL, V143, P3731; MIELKE MEA, 1988, INFECT IMMUN, V56, P1920, DOI 10.1128/IAI.56.8.1920-1925.1988; MILLIGAN GN, 1991, J EXP MED, V174, P133, DOI 10.1084/jem.174.1.133; PARISH CR, 1983, J IMMUNOL METHODS, V58, P225, DOI 10.1016/0022-1759(83)90277-6; Rodgers J R, 1986, Adv Immunol, V38, P313, DOI 10.1016/S0065-2776(08)60010-3; SHAWAR SM, 1991, J EXP MED, V174, P941, DOI 10.1084/jem.174.4.941; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; SHAWAR SM, 1991, IMMUNOL RES, V10, P365, DOI 10.1007/BF02919723; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7	27	140	141	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1992	257	5070					678	679		10.1126/science.1496381	http://dx.doi.org/10.1126/science.1496381			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496381				2022-12-28	WOS:A1992JF85200039
J	ZHANG, K; PAPAGEORGE, AG; LOWY, DR				ZHANG, K; PAPAGEORGE, AG; LOWY, DR			MECHANISTIC ASPECTS OF SIGNALING THROUGH RAS IN NIH-3T3 CELLS	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; NUCLEOTIDE BINDING; CYCLASE PATHWAY; GROWTH-FACTOR; KINASE-C; GENE; P21RAS; GAP	Serum and growth factors can increase the proportion of Ras in the active guanosine triphosphate (GTP)-bound form. Growth factors might stimulate guanine nucleotide exchange or decrease the activity of the guanosine triphosphatase-activating proteins GAP and neurofibromin (NF1). In NIH 3T3 cells that overexpress the mutant Ras protein His116, which releases bound guanine nucleotide at a constitutively high rate and retains sensitivity to GAP and NF1, the proportion of GTP bound to the His116 protein was not altered by serum or platelet-derived growth factor. However, these mitogens increased the proportion of Ras in the GTP-bound form in cells that overexpressed control Ras proteins with a normal intrinsic rate of guanine nucleotide release. The amount of GTP-bound His116 or control Ras proteins was higher in cells at low density than in cells at high density, which have more GAP-like activity. The lower proportion of GTP-bound Ras in NIH 3T3 cells at high density may result from increased GAP-like activity. By contrast, serum and platelet-derived growth factors appear to stimulate guanine nucleotide exchange.			ZHANG, K (corresponding author), NCI,CELLULAR ONCOL LAB,BLDG 37,ROOM 1B-26,BETHESDA,MD 20892, USA.							BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DER CJ, 1988, ONCOGENE, V3, P105; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HOSHINO M, 1988, MOL CELL BIOL, V8, P4169, DOI 10.1128/MCB.8.10.4169; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PAPAGEORGE AG, UNPUB; PATEL G, 1992, ONCOGENE, V7, P283; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	34	83	83	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					671	674		10.1126/science.1496380	http://dx.doi.org/10.1126/science.1496380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496380				2022-12-28	WOS:A1992JF85200037
J	LITTLECHILD, P; MACMILLAN, A; WHITE, MM; STEEDMAN, DJ				LITTLECHILD, P; MACMILLAN, A; WHITE, MM; STEEDMAN, DJ			CONTAMINATION OF SKIN AND CLOTHING OF ACCIDENT AND EMERGENCY PERSONNEL	BRITISH MEDICAL JOURNAL			English	Article									ROYAL INFIRM,DEPT ACCID & EMERGENCY MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh								SKINNER D, 1991, ABC MAJOR TRAUMA; WONG D, 1991, BRIT MED J, V303, P1602, DOI 10.1136/bmj.303.6817.1602; 1989, CHOICE REUSABLE FABR; 1987, MMWR, V36, P285; 1987, MMWR S2S, V36, pS5	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					156	157		10.1136/bmj.305.6846.156	http://dx.doi.org/10.1136/bmj.305.6846.156			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515830	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JF06300022
J	GOURLAY, GK; BOAS, RA				GOURLAY, GK; BOAS, RA			LESSON OF THE WEEK - FATAL OUTCOME WITH USE OF RECTAL MORPHINE FOR POSTOPERATIVE PAIN CONTROL IN AN INFANT	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL PHARMACOKINETIC CONSIDERATIONS; METHADONE; INFUSION; CANCER		UNIV AUCKLAND,SCH MED,DEPT PHARMACOL & CLIN PHARMACOL,ANAESTHET SECT,AUCKLAND,NEW ZEALAND	University of Auckland	GOURLAY, GK (corresponding author), FLINDERS UNIV,MED CTR,PAIN MANAGEMENT UNIT,BEDFORD PK,BEDFORD PK,SA 5042,AUSTRALIA.							DEBOER AG, 1982, CLIN PHARMACOKINET, V7, P285, DOI 10.2165/00003088-198207040-00002; GOURLAY GK, 1986, PAIN, V25, P297, DOI 10.1016/0304-3959(86)90234-4; GOURLAY GK, 1987, HDB CHRONIC PAIN MAN, P163; KOREN G, 1985, J PEDIATR-US, V107, P963, DOI 10.1016/S0022-3476(85)80205-5; KOREN G, 1983, VET HUM TOXICOL, V27, P519; LINDAHL S, 1981, ANAESTHESIA, V36, P376, DOI 10.1111/j.1365-2044.1981.tb10241.x; LYNN AM, 1984, CRIT CARE MED, V12, P863, DOI 10.1097/00003246-198410000-00005; MCRORIE TI, 1990, CLIN PHARMACOL THER, V47, P132; SAWE J, 1986, CLIN PHARMACOKINET, V11, P87; WESTERLING D, 1982, EUR J CLIN PHARMACOL, V23, P59, DOI 10.1007/BF01061378	10	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1992	304	6829					766	767		10.1136/bmj.304.6829.766	http://dx.doi.org/10.1136/bmj.304.6829.766			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK800	1489382	Green Published, Bronze			2022-12-28	WOS:A1992HK80000028
J	SPACH, DH; STAPLETON, AE; STAMM, WE				SPACH, DH; STAPLETON, AE; STAMM, WE			LACK OF CIRCUMCISION INCREASES THE RISK OF URINARY-TRACT INFECTION IN YOUNG MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIMBRIATED ESCHERICHIA-COLI; DECREASED INCIDENCE; MALE INFANTS; DIAGNOSIS; PYELONEPHRITIS; URETHRITIS; WOMEN	Objective. - To determine whether lack of circumcision increases the risk of urinary tract infection (UTI) in adult men. Design and Setting. - Retrospective case-control study (1987-1990) at a sexually transmitted disease clinic in Seattle, Wash. Patients. - Twenty-six men (median age, 30 years) who had microbiologically confirmed symptomatic UTIs (cases) compared with 52 men (median age, 32 years) who had urinary symptoms but negative urine cultures (controls). Main Outcome Measure. - Circumcision status among bacteriuric and nonbacteriuric men. Results. - The bacteriuric and nonbacteriuric groups were similar in age, race, sexual activity, and sexual preference. Eight (31%) of the 26 bacteriuric men were uncircumcised compared with 6 (12%) of the 52 nonbacteriuric men (P =.037; odds ratio, 3.4; 95% confidence interval, 1.0 to 11.2). Among 19 patients infected with gram-negative bacilli, 8 (42%) of 19 were uncircumcised vs 6 (12%) of 52 nonbacteriuric men (P = .004; odds ratio, 5.6; 95% confidence interval, 1.6 to 19.4). Escherichia coli was the most common urinary isolate (15 of 26 isolates), and the majority of E coli strains possessed urovirulence determinants, including mannose-resistant hemagglutination (10 of 14 isolates), F fimbriae (11 of 14 isolates), P fimbriae (6 of 14 isolates), hemolysin (10 of 14 isolates), and aerobactin (8 of 14 isolates). Although all 26 bacteriuric men had urethral cultures negative for Chlamydia trachomatis and Neisseria gonorrhoeae, Gram-stained urethral smears showed evidence of urethritis in 17 (68%) of 25 men. Conclusions. - (1) Lack of circumcision increases the risk of UTI in young adult men. (2) The majority of these infections result from urovirulent strains of E coli. (3) Clinically, these infections often produce urethritis as well as UTI.	UNIV WASHINGTON,MED CTR,DIV INFECT DIS,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Stapleton, Ann E/N-2428-2015	Stapleton, Ann E/0000-0003-0130-8659	NIDDK NIH HHS [DK 40045] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040045] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNES RC, 1986, LANCET, V1, P171; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BOWIE WR, 1978, SEX TRANSM DIS, V5, P39, DOI 10.1097/00007435-197804000-00001; BURBIGE KA, 1984, J UROLOGY, V132, P541, DOI 10.1016/S0022-5347(17)49727-8; DEPINHO AMF, 1990, 6TH INT C AIDS SAN F, P209; FIHN SD, 1988, J INFECT DIS, V157, P196, DOI 10.1093/infdis/157.1.196; GINSBURG CM, 1982, PEDIATRICS, V69, P409; HERZOG LW, 1989, AM J DIS CHILD, V143, P348, DOI 10.1001/archpedi.1989.02150150106026; JACOBSON SH, 1985, J INFECT DIS, V152, P426, DOI 10.1093/infdis/152.2.426; JOHNSON JR, 1987, J INFECT DIS, V156, P225, DOI 10.1093/infdis/156.1.225; KALLENIUS G, 1981, LANCET, V2, P1369; KIELY B, 1984, IRISH MED J, V77, P384; LIPSKY BA, 1987, J INFECT DIS, V155, P847, DOI 10.1093/infdis/155.5.847; LIPSKY BA, 1989, ANN INTERN MED, V110, P138, DOI 10.7326/0003-4819-110-2-138; Maniatis T., 1982, MOL CLONING; SCHWATZ SL, 1978, J INFECT DIS, V138, P445; STAMM WE, 1983, J CLIN MICROBIOL, V17, P666, DOI 10.1128/JCM.17.4.666-668.1983; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STAPLETON A, 1991, J INFECT DIS, V163, P773, DOI 10.1093/infdis/163.4.773; VAISANEN V, 1981, LANCET, V2, P1366; VAISANENRHEN V, 1984, INFECT IMMUN, V43, P149; VANBUREN M, 1990, 30TH INT C ANT AG CH, P106; WISWELL TE, 1985, PEDIATRICS, V75, P901; WISWELL TE, 1986, PEDIATRICS, V78, P96	24	88	89	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1992	267	5					679	681		10.1001/jama.267.5.679	http://dx.doi.org/10.1001/jama.267.5.679			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB354	1472171				2022-12-28	WOS:A1992HB35400025
J	TARDIEUX, I; WEBSTER, P; RAVESLOOT, J; BORON, W; LUNN, JA; HEUSER, JE; ANDREWS, NW				TARDIEUX, I; WEBSTER, P; RAVESLOOT, J; BORON, W; LUNN, JA; HEUSER, JE; ANDREWS, NW			LYSOSOME RECRUITMENT AND FUSION ARE EARLY EVENTS REQUIRED FOR TRYPANOSOME INVASION OF MAMMALIAN-CELLS	CELL			English	Article							PLASMA-MEMBRANE; ACTIN-FILAMENTS; LISTERIA-MONOCYTOGENES; TOXOPLASMA-GONDII; HUMAN-NEUTROPHILS; EPITHELIAL-CELLS; XENOPUS OOCYTES; PROTEIN-KINASE; CYCLE CONTROL; HELA-CELLS	Trypanosoma cruzi invades most nucleated cells by a mechanism distinct from classical phagocytosis. Although parasites enter at the lysosome-poor peripheral cell margins, lysosomal markers are immediately incorporated into the parasitophorous vacuole. No accumulation of polymerized actin was detected around recently internalized parasites, and disruption of microfilaments significantly facilitated invasion. Lysosomes were observed to aggregate at the sites of trypanosome attachment and to fuse with the vacuole at early stages of its formation. Experimentally induced, microtubule-dependent movement of lysosomes from the perinuclear area to the cell periphery enhanced entry. Conditions that deplete cells of peripheral lysosomes or interfere with lysosomal fusion capacity inhibited invasion. These observations reveal a novel mechanism for cell invasion: recruitment of lysosomes for fusion at the site of parasite internalization.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Yale University; Yale University; Washington University (WUSTL)	TARDIEUX, I (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,INFECT DIS SECT,NEW HAVEN,CT 06510, USA.		Heuser, John/H-5940-2012; Boron, Walter/ABI-1564-2020; Tardieux, Isabelle/G-4733-2014	Tardieux, Isabelle/0000-0002-5677-7463; Andrews, Norma/0000-0002-0611-2412; Boron, Walter/0000-0003-4741-7287; Webster, Paul/0000-0002-1980-6931	NIAID NIH HHS [R01AI32056, R29AI27260] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027260, R01AI032056] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; ALLAN VJ, 1991, J CELL BIOL, V113, P347, DOI 10.1083/jcb.113.2.347; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; BARON R, 1990, J CELL SCI, V97, P439; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BOYLES J, 1981, CELL, V24, P905, DOI 10.1016/0092-8674(81)90116-1; CARVALHO T M U D, 1989, Cell Structure and Function, V14, P383; CERIOTTI A, 1989, J CELL BIOL, V109, P1439, DOI 10.1083/jcb.109.4.1439; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; COHN ZA, 1969, J EXP MED, V129, P201, DOI 10.1084/jem.129.1.201; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; DECOURCY K, 1991, EXP CELL RES, V192, P52, DOI 10.1016/0014-4827(91)90156-O; DVORAK JA, 1981, SCIENCE, V214, P1034, DOI 10.1126/science.7029713; FERRIS AL, 1987, J CELL BIOL, V105, P2703, DOI 10.1083/jcb.105.6.2703; FINLAY BB, 1991, J CELL SCI, V99, P283; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; FORSCHER P, 1987, J NEUROSCI, V7, P3600; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HALL BF, 1992, J EXP MED, V176, P313, DOI 10.1084/jem.176.2.313; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JACONI MEE, 1990, J CELL BIOL, V110, P1555, DOI 10.1083/jcb.110.5.1555; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; KNAPP PE, 1990, J CELL SCI, V95, P433; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEY V, 1990, J EXP MED, V171, P401, DOI 10.1084/jem.171.2.401; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LYNCH TJ, 1986, J BIOL CHEM, V261, P4212; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MEIRELLES MNL, 1983, J SUBMICR CYTOL PATH, V17, P327; MILDER R, 1980, PARASITOLOGY, V80, P139, DOI 10.1017/S0031182000000597; MONTGOMERY RR, 1991, J IMMUNOL, V147, P3087; MUNDY DI, 1992, J CELL BIOL, V116, P135, DOI 10.1083/jcb.116.1.135; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NOGUEIRA N, 1976, J EXP MED, V143, P1402, DOI 10.1084/jem.143.6.1402; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; PERRIN D, 1992, J CELL BIOL, V116, P127, DOI 10.1083/jcb.116.1.127; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; PRYZWANSKY KB, 1979, CELL, V18, P1025, DOI 10.1016/0092-8674(79)90215-0; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; SALAS PJI, 1986, J CELL BIOL, V102, P1853, DOI 10.1083/jcb.102.5.1853; SCHENKMAN S, 1988, CELL, V55, P157, DOI 10.1016/0092-8674(88)90018-9; SCHENKMAN S, 1991, INFECT IMMUN, V59, P645, DOI 10.1128/IAI.59.2.645-654.1991; SCHENKMAN S, 1992, J CELL SCI, V101, P895; SHROER TA, 1989, CELL, V56, P937; SHROER TR, 1988, J CELL BIOL, V107, P1785; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197	64	314	323	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1117	1130		10.1016/S0092-8674(05)80061-3	http://dx.doi.org/10.1016/S0092-8674(05)80061-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473148	hybrid			2022-12-28	WOS:A1992KE60400007
J	NEUBERGER, J				NEUBERGER, J			LONDON AFTER TOMLINSON .7. COMMUNITY-HEALTH SERVICES	BRITISH MEDICAL JOURNAL			English	Article								The Tomlinson report, with its emphasis on primary and community care, offers great scope to community health services, for long the poor relation of the NHS, and particularly poorly resourced in London. The aim is to create services that break down the barriers between primary, secondary, and tertiary health care and concentrate on providing high quality care tailored to individual patients' needs. Thus a range of flexible options needs to be developed between acute hospital based care and the standard home care arrangements currently provided by district nurses. Examples include hospital at home schemes, nursing beds, and rehabilitation beds. Together community and primary care services need to consider weekend coverage, to conduct research, and to become a setting for education. The infrastructure for primary and community care must, however, be put in place before acute facilities are shut.			NEUBERGER, J (corresponding author), CAMDEN & ISLINGTON COMMUNITY,HLTH SERV TRUST,LONDON,ENGLAND.							COSTAIN D, 1992, HOSPITAL HOMECARE PO; KARMI G, 1992, BRIT MED J, V305, P205, DOI 10.1136/bmj.305.6847.205; MARKS L, 1991, HOME HOSPITAL CARE R; MARTIN P, 1992, LONDON ACUTE HLTH SE; SCHEUER M, 1991, HOMELESSNESS UTILISA; TAYLOR D, 1991, DEV PRIMARY CARE OPP; THORNICROFT G, 1992, BRIT J PSYCHIAT, V161, P621, DOI 10.1192/bjp.161.5.621; Tomlinson B., 1992, REPORT INQUIRY LONDO; 1992, LONDON HLTH CARE, V2010	9	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1486	1488		10.1136/bmj.305.6867.1486	http://dx.doi.org/10.1136/bmj.305.6867.1486			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493399	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992KC91800030
J	ADDINGTONHALL, JM; MACDONALD, LD; ANDERSON, HR; CHAMBERLAIN, J; FREELING, P; BLAND, JM; RAFTERY, J				ADDINGTONHALL, JM; MACDONALD, LD; ANDERSON, HR; CHAMBERLAIN, J; FREELING, P; BLAND, JM; RAFTERY, J			RANDOMIZED CONTROLLED TRIAL OF EFFECTS OF COORDINATING CARE FOR TERMINALLY ILL CANCER-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							DEPRESSION; FAMILIES; ANXIETY	Objectives-To measure effects on terminally ill cancer patients and their families of coordinating the services available within the NHS and from local authorities and the voluntary sector. Design-Randomised controlled trial. Setting-Inner London health district. Patients-Cancer patients were routinely notified from 1987 to 1990. 554 patients expected to survive less than one year entered the trial and were randomly allocated to a coordination or a control group. Intervention-All patients received routinely available services. Coordination group patients received the assistance of two nurse coordinators, whose role was to ensure that patients received appropriate and well coordinated services, tailored to their individual needs and circumstances. Main outcome measures-Patients and carers were interviewed at home on entry to the trial and at intervals until death. Interviews after bereavement were also conducted. Outcome measures included the presence and severity of physical symptoms, psychiatric morbidity, use of and satisfaction with services, and carers' problems. Results from the baseline interview, the interview closest to death, and the interview after bereavement were analysed. Results-Few differences between groups were significant. Coordination group patients were less likely to suffer from vomiting, were more likely to report effective treatment for it, and less likely to be concerned about having an itchy skin. Their carers were more likely to report that in the last week of life the patient had had a cough and had had effective treatinent for constipation, and they were less likely to rate the patient's difficulty swallowing as severe or to report effective treatment for anxiety. Coordination group patients were more likely to have seen a chiropodist and their carers were more likely to contact a specialist nurse in a night time emergency. These carers were less likely to feel angry about the death of the patient. Conclusions-This coordinating service made little difference to patiept or family outcomes, perhaps because the service did not have a budget with which it could obtain services or because the professional skills of the nurse-coordinators may have conflicted with the requirements of the coordinating role.	ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND; ROYAL MARSDEN HOSP,S W THAMES REG CANC ORG,SUTTON SM2 5PT,SURREY,ENGLAND; ST GEORGE HOSP,SCH MED,DIV GEN PRACTICE & PRIMARY CARE,LONDON SW17 0RE,ENGLAND	St Georges University London; Royal Marsden NHS Foundation Trust; St Georges University London								ADDINGTON-HALL J M, 1991, Palliative Medicine, V5, P207, DOI 10.1177/026921639100500305; Altman DG, 1991, PRACTICAL STATISTICS; ARMITAGE P, 1987, STATISTICAL METHODS; CARTWRIGHT A, 1973, LIFE DEATH; HIGGINSON I, 1990, BRIT MED J, V301, P277, DOI 10.1136/bmj.301.6746.277; HOCKLEY JM, 1988, BRIT MED J, V296, P1715, DOI 10.1136/bmj.296.6638.1715; HOUTS PS, 1988, CANCER, V62, P627, DOI 10.1002/1097-0142(19880801)62:3<627::AID-CNCR2820620331>3.0.CO;2-1; HURLEY RE, 1986, SOC SCI MED, V23, P82; KANE RL, 1984, LANCET, V1, P890; LUNT B, 1981, BRIT MED J, V283, P595, DOI 10.1136/bmj.283.6291.595; MORRIS JN, 1987, J CHRON DIS, V40, P545, DOI 10.1016/0021-9681(87)90012-9; RAPP CA, 1985, SOC WORK, V30, P417; SEALE CF, 1989, SOC SCI MED, V28, P551, DOI 10.1016/0277-9536(89)90249-9; Shepherd G, 1990, Health Trends, V22, P59; SMILKSTEIN G, 1982, J FAM PRACTICE, V15, P303; SNAITH RP, 1976, BRIT J PSYCHIAT, V128, P156, DOI 10.1192/bjp.128.2.156; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; WILKES E, 1984, LANCET, V1, P950; WILKES E, 1980, TERMINAL CARE REPORT; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1992, DIRECTORY HOSPICE SE	21	142	143	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1317	1322		10.1136/bmj.305.6865.1317	http://dx.doi.org/10.1136/bmj.305.6865.1317			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483075	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KA77300019
J	GODDARD, C; PATON, C				GODDARD, C; PATON, C			HYPONATREMIA ASSOCIATED WITH PAROXETINE	BRITISH MEDICAL JOURNAL			English	Letter							FLUOXETINE; SIADH				GODDARD, C (corresponding author), BEXLEY HOSP,KENT DA5 2BW,ENGLAND.							COHEN BJ, 1990, AM J PSYCHIAT, V147, P948; HWANG AS, 1989, AM J PSYCHIAT, V146, P339; MUCKLOW J, 1991, PRESCRIBERS J, V31, P61; SANDIFER MG, 1983, J CLIN PSYCHIAT, V44, P301; STAAB JP, 1990, AM J PSYCHIAT, V147, P1569; VISHWANATH BM, 1991, AM J PSYCHIAT, V148, P542	6	43	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1332	1332		10.1136/bmj.305.6865.1332-b	http://dx.doi.org/10.1136/bmj.305.6865.1332-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483080	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KA77300026
J	CAMPBELL, LV; ASHWELL, SM; BORKMAN, M; CHISHOLM, DJ				CAMPBELL, LV; ASHWELL, SM; BORKMAN, M; CHISHOLM, DJ			WHITE COAT HYPERGLYCEMIA - DISPARITY BETWEEN DIABETES CLINIC AND HOME BLOOD-GLUCOSE CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To identify patients with discrepantly high clinic blood glucose concentrations compared with self reported values and to assess whether such patients have errors in self monitoring technique. To determine whether, in patients with good technique, the discrepancy is a transient phenomenon related to clinic attendance. Design-Prospective study of diabetes clinic patients recruited over six months. Setting-Outpatient diabetes clinic of a teaching hospital. Subjects-34 consecutive patients with noninsulin dependent diabetes who had had at least two consecutive clinic blood glucose concentrations more than 5 mmol/l higher than the mean self reported concentration. Main outcome measures-Assessment of monitoring technique; presence of cognitive or physical impairment; serum fructosamine concentration; home and clinic blood glucose concentrations. Results-15 of 34 patients had errors in monitoring technique, 12 of whom had cognitive or physical impairment. In the remaining 19, the mean (SD) blood glucose concentrations of capillary and venous samples taken at home (10.2 (0.6) and 12.2 (1.1) mmol/l respectively) were significantly lower than in those taken at the clinic (16.8 (1.6) mmol/l, p<0.0002). The fructosamine concentration was significantly higher in patients with monitoring errors than those without (2.4 (0.4) v 1.8 (0.4) mmol/l, p<0.0001). Conclusions-"White coat" hyperglycaemia was detected in about half the patients but errors in technique accounted for the rest of the discrepancies. Patients' ability should be assessed before teaching self monitoring and the technique checked regularly.	ST VINCENTS HOSP,GARVAN INST MED RES,SYDNEY,NSW 2010,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney	CAMPBELL, LV (corresponding author), ST VINCENTS HOSP,CTR DIABET,SYDNEY,NSW 2010,AUSTRALIA.		Chisholm, Donald J/J-9332-2013; Campbell, Lesley V/B-2271-2008	Chisholm, Donald J/0000-0002-5349-5735; 				[Anonymous], 1987, DIABETES CARE, V10, P95; BURGESS E, 1991, DIABETOLOGIA, V34, P684, DOI 10.1007/BF00401000; CAMPBELL LV, 1991, DIABETES, V40, P140; FELL LR, 1985, AUST VET J, V62, P403, DOI 10.1111/j.1751-0813.1985.tb14120.x; Long J, 1990, Md Med J, V39, P555; MCLAY J, 1987 P AUSTR DIAB ED, pE3; MOLNAR GD, 1974, DIABETOLOGIA, V10, P139, DOI 10.1007/BF01219670; ROSE RM, 1981, TXB ENDOCRINOLOGY, P654; SCHLEICHER ED, 1990, CLIN CHEM, V36, P136; SURWIT RS, 1983, DIABETES CARE, V6, P176, DOI 10.2337/diacare.6.2.176	10	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1992	305	6863					1194	1196		10.1136/bmj.305.6863.1194	http://dx.doi.org/10.1136/bmj.305.6863.1194			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467722	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JY77700021
J	OSTERGAARD, JR; KRAFT, M				OSTERGAARD, JR; KRAFT, M			NATURAL COURSE OF BENIGN COITAL HEADACHE	BRITISH MEDICAL JOURNAL			English	Article									PRIVATE CLIN NEUROL,NEUROL,DK-8240 RIISKOV,DENMARK		OSTERGAARD, JR (corresponding author), AARHUS UNIV HOSP,DEPT PEDIAT A,DK-8000 AARHUS,DENMARK.							Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; JOHS DR, 1986, ARCH NEUROL-CHICAGO, V43, P1158; KRITZ K, 1970, CESK NEUROL NEUROCHI, V33, P162; LANCE JW, 1976, J NEUROL NEUROSUR PS, V39, P1226, DOI 10.1136/jnnp.39.12.1226; PAULSON GW, 1974, HEADACHE, V13, P181, DOI 10.1111/j.1526-4610.1974.hed1304181.x	5	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1129	1129		10.1136/bmj.305.6862.1129	http://dx.doi.org/10.1136/bmj.305.6862.1129			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463949	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JX84100023
J	MILES, SH; LURIE, N; QUAM, L; CAPLAN, A				MILES, SH; LURIE, N; QUAM, L; CAPLAN, A			HEALTH-CARE REFORM IN MINNESOTA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									UNITED HEALTH CARE CORP,MINNEAPOLIS,MN 55343; UNIV MINNESOTA,MINNEAPOLIS,MN 55455	UnitedHealth Group Incorporated; University of Minnesota System; University of Minnesota Twin Cities	MILES, SH (corresponding author), UNIV MINNESOTA,HENNEPIN CTY MED CTR,MINNEAPOLIS,MN 55415, USA.							FOX DM, 1991, HEALTH AFFAIR, V10, P7, DOI 10.1377/hlthaff.10.2.7; GOLDBERGER SA, 1990, J HEALTH POLIT POLIC, V15, P857, DOI 10.1215/03616878-15-4-857; MCLAUGHLIN CG, 1992, HEALTH AFFAIR, V11, P28, DOI 10.1377/hlthaff.11.2.28; REINHARDT UE, 1991, HEALTH AFFAIR, V10, P96, DOI 10.1377/hlthaff.10.2.96; SAGER A, 1988, HASTINGS CENT REP, V18, P21, DOI 10.2307/3562198; STEINBROOK R, 1992, NEW ENGL J MED, V326, P340, DOI 10.1056/NEJM199201303260511; 1991, FINAL REPORT LEGISLA; HF2800 C COMM REP	8	14	14	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1992	327	15					1092	1095		10.1056/NEJM199210083271511	http://dx.doi.org/10.1056/NEJM199210083271511			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JR321	1522847				2022-12-28	WOS:A1992JR32100011
J	BERGER, CJ; MURABITO, JM; EVANS, JC; ANDERSON, KM; LEVY, D				BERGER, CJ; MURABITO, JM; EVANS, JC; ANDERSON, KM; LEVY, D			PROGNOSIS AFTER 1ST MYOCARDIAL-INFARCTION - COMPARISON OF Q-WAVE AND NON-Q-WAVE MYOCARDIAL-INFARCTION IN THE FRAMINGHAM HEART-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM PROGNOSIS; CLINICAL-SIGNIFICANCE; NATURAL-HISTORY; QRS COMPLEX; ST SEGMENT; PREVALENCE; LOCATION; EXTENSION; MORTALITY; ANTERIOR	Objective.-To compare the short- and long-term prognosis following a first Q-wave or non-Q-wave myocardial infarction. Design.-Cohort study with a mean follow-up period of 5.1+/-4.9 years. Setting.-Population-based. Participants.-Framingham (Mass) Heart Study subjects with an initial recognized myocardial infarction during a 17-year period were studied, including 227 men and 136 women with a mean age of 67.2 years. Seventy-seven percent of first infarctions were Q-wave infarctions and 23% were non-Q-wave infarctions. Main Outcome Measures.-Reinfarction and death from coronary heart disease. Results.-During the follow-up period, subjects with non-Q-wave infarctions had a significantly higher rate of reinfarction than subjects in the Q-wave group (P=.02 for the entire follow-up). The 10-year reinfarction rates were 44.8% vs 27.4%. When analyzed separately by age and sex, differences in reinfarction rates were only noted in men and in those under the age of 65 years. There were no differences in coronary heart disease death rates based on Q-wave status, even when examined separately by age and sex. Multivariate analysis revealed a 1.8-fold higher risk of reinfarction in the non-Q-wave group (95% confidence interval, 1.1 to 3.1), and also demonstrated that baseline hypertension was an independent risk factor for predicting reinfarction (relative risk, 1.8; 95% confidence interval, 1.1 to 3.2). There were no differences in the rates of sudden death or all-cause mortality following the two types of myocardial infarction. Additionally, subjects with a first Q-wave infarction had a higher rate of subsequent congestive heart failure, while those with non-Q-wave infarctions had a significantly higher rate of coronary insufficiency (unstable angina with transient ST-T wave abnormalities). Conclusions.-These results confirm and extend findings from prior studies that have identified patients with first non-Q-wave myocardial infarctions as potentially unstable, with greater subsequent morbidity and similar mortality to their counter-parts with Q-wave infarctions.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY,5 THURBER ST,FRAMINGHAM,MA 01701; BETH ISRAEL HOSP,DIV CARDIOVASC,BOSTON,MA 02215; BETH ISRAEL HOSP,DIV CLIN EPIDEMIOL,BOSTON,MA 02215; NHLBI,DIV EPIDEMIOL & CLIN APPLICAT,BETHESDA,MD 20892; BOSTON UNIV,SCH MED,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA 02118	Framingham Heart Study; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University			Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021	Levy, Daniel/0000-0003-1843-8724; Murabito, Joanne/0000-0002-0192-7516				AHNVE S, 1988, AM HEART J, V116, P925, DOI 10.1016/0002-8703(88)90142-1; BENHORIN J, 1990, J AM COLL CARDIOL, V15, P1201, DOI 10.1016/S0735-1097(10)80001-4; BISSETT JK, 1987, BRIT HEART J, V58, P460; CANNOM DS, 1976, AM J MED, V61, P452, DOI 10.1016/0002-9343(76)90322-3; COLL S, 1983, AM J CARDIOL, V51, P1584, DOI 10.1016/0002-9149(83)90191-1; CONNOLLY DC, 1985, MAYO CLIN PROC, V60, P375, DOI 10.1016/S0025-6196(12)60846-5; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; DEWOOD MA, 1986, NEW ENGL J MED, V315, P417, DOI 10.1056/NEJM198608143150703; FABRICIUSBJERRE N, 1979, AM J MED, V66, P986, DOI 10.1016/0002-9343(79)90454-6; FOX JP, 1990, BRIT HEART J, V63, P151; FRIEFELD AG, 1983, AM J MED, V75, P423; GELTMAN EM, 1979, CIRCULATION, V60, P805, DOI 10.1161/01.CIR.60.4.805; GIBSON RS, 1986, CIRCULATION, V73, P1186, DOI 10.1161/01.CIR.73.6.1186; GIBSON RS, 1988, CURR PROB CARDIOLOGY, V13, P8; GOLDBERG RJ, 1987, AM HEART J, V113, P273, DOI 10.1016/0002-8703(87)90265-1; HANDS ME, 1986, CIRCULATION, V73, P885, DOI 10.1161/01.CIR.73.5.885; HOLLANDER G, 1984, AM HEART J, V108, P1412, DOI 10.1016/0002-8703(84)90685-9; HUEY BL, 1987, J AM COLL CARDIOL, V9, P18, DOI 10.1016/S0735-1097(87)80076-1; HUTTER AM, 1981, AM J CARDIOL, V48, P595, DOI 10.1016/0002-9149(81)90136-3; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KLEIN LW, 1986, PROG CARDIOVASC DIS, V29, P205, DOI 10.1016/0033-0620(86)90042-3; KRONE RJ, 1983, AM J CARDIOL, V52, P234, DOI 10.1016/0002-9149(83)90114-5; MADIAS JE, 1974, CIRCULATION, V49, P498, DOI 10.1161/01.CIR.49.3.498; MAHONY C, 1980, AM J MED, V69, P183, DOI 10.1016/0002-9343(80)90377-0; MAISEL AS, 1985, CIRCULATION, V71, P211, DOI 10.1161/01.CIR.71.2.211; MARMOR A, 1981, AM J CARDIOL, V48, P603, DOI 10.1016/0002-9149(81)90137-5; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; OGAWA H, 1986, AM HEART J, V111, P513, DOI 10.1016/0002-8703(86)90056-6; PHIBBS B, 1983, J AM COLL CARDIOL, V1, P561, DOI 10.1016/S0735-1097(83)80090-4; RAUNIO H, 1979, AM HEART J, V98, P176, DOI 10.1016/0002-8703(79)90219-9; RIGO P, 1975, CIRCULATION, V51, P1064, DOI 10.1161/01.CIR.51.6.1064; SCHEINMAN MM, 1973, AM J MED, V55, P602, DOI 10.1016/0002-9343(73)90181-2; SPODICK DH, 1983, AM J CARDIOL, V51, P913, DOI 10.1016/S0002-9149(83)80160-X; STONE PH, 1988, J AM COLL CARDIOL, V11, P453, DOI 10.1016/0735-1097(88)91517-3; THANAVARO S, 1980, CIRCULATION, V61, P29, DOI 10.1161/01.CIR.61.1.29; ULVENSTAM G, 1985, EUR HEART J, V6, P294, DOI 10.1093/oxfordjournals.eurheartj.a061856; ZEMA MJ, 1985, AM J MED, V78, P391, DOI 10.1016/0002-9343(85)90329-8; [No title captured]	45	94	97	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1545	1551		10.1001/jama.268.12.1545	http://dx.doi.org/10.1001/jama.268.12.1545			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1518109				2022-12-28	WOS:A1992JN25600024
J	EPSTEIN, WV; CRISWELL, LA; HENKE, CJ				EPSTEIN, WV; CRISWELL, LA; HENKE, CJ			METHOTREXATE FOR JUVENILE RHEUMATOID-ARTHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											EPSTEIN, WV (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.							GIANNINI EH, 1992, NEW ENGL J MED, V326, P1043, DOI 10.1056/NEJM199204163261602; WEINBLATT ME, 1992, ARTHRITIS RHEUM, V35, P129, DOI 10.1002/art.1780350202; WHITE PH, 1992, NEW ENGL J MED, V326, P1077, DOI 10.1056/NEJM199204163261608	3	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					893	893						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1508256				2022-12-28	WOS:A1992JN12000025
J	CLINTON, B				CLINTON, B			THE CLINTON HEALTH-CARE PLAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		CLINTON B, 1992, PUTTING PEOPLE 1ST N; CLINTON B, 1992, CINCINNATI J ME 0731, P9; Sonnefeld S T, 1991, Health Care Financ Rev, V13, P1; 1990, CURRENT POPULATI P70, V17; 1992, B CLINTON AM HLTH CA; 1991, INCOME SECURITY HLTH; 1992, ANAL PRESIDENTS BUDG	7	43	43	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					804	807		10.1056/NEJM199209103271112	http://dx.doi.org/10.1056/NEJM199209103271112			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JL661	1501657				2022-12-28	WOS:A1992JL66100012
J	HIRSCHEL, B				HIRSCHEL, B			EARLY ZIDOVUDINE AND SURVIVAL IN HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											HIRSCHEL, B (corresponding author), HOP CANTONAL GENEVA, CH-1211 GENEVA 4, SWITZERLAND.			Zeger, Scott/0000-0001-8907-1603				GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703	2	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					814	814		10.1056/NEJM199209103271116	http://dx.doi.org/10.1056/NEJM199209103271116			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501667				2022-12-28	WOS:A1992JL66100025
J	PHILEN, RM; ORTIZ, DI; AUERBACH, SB; FALK, H				PHILEN, RM; ORTIZ, DI; AUERBACH, SB; FALK, H			SURVEY OF ADVERTISING FOR NUTRITIONAL SUPPLEMENTS IN HEALTH AND BODYBUILDING MAGAZINES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EOSINOPHILIA-MYALGIA SYNDROME; L-TRYPTOPHAN	The use of food supplements by the general public is poorly quantified, and little information on this subject is available in the medical literature. We surveyed 12 recent issues of popular health and bodybuilding magazines (1) to quantify the number of advertisements for food supplements, the number of products advertised, and the number and type of ingredients in these products; (2) to identify the purported health benefits of these products; and (3) as a preliminary effort to identify areas for future research. We counted 89 brands, 311 products, and 235 unique ingredients, the most frequent of which were unspecified amino acids; the most frequently promoted health benefit was muscle growth. We also found many unusual or unidentifiable ingredients, and 22.2% of the products had no ingredients listed in their advertisements. Health professionals may not be aware of how popular food supplements are or of a particular supplement's potential effects or side effects. In addition, patients may be reluctant to discuss their use of these products with traditional medical practitioners. We recommend that routine history taking include specific questions about patients' use of food supplements and that any possible adverse effects or side effects be reported to public health authorities.	UNIV TURABO, DEPT CIENCIAS & TECHNOL, UNIV STN, PR USA		PHILEN, RM (corresponding author), CTR DIS CONTROL, NATL CTR ENVIRONM HLTH & INJURY CONTROL, ATLANTA, GA 30333 USA.							AMOS RJ, 1987, J AM DIET ASSOC, V87, P1063; ARENA JM, 1979, POISONING; BLUHM R, 1990, JAMA-J AM MED ASSOC, V264, P1141, DOI 10.1001/jama.264.9.1141; CHERNOFF N, 1988, TOXICOLOGY, V51, P57, DOI 10.1016/0300-483X(88)90080-7; CLARK HW, 1988, J PSYCHOACTIVE DRUGS, V20, P355, DOI 10.1080/02791072.1988.10472505; EIDSON M, 1990, LANCET, V335, P645, DOI 10.1016/0140-6736(90)90421-Z; Ellenhorn M.J., 1988, MED TOXICOLOGY DIAGN; GIANNINI JA, 1982, HDB OVERDOSE DETOXIF; Gilman A., 1985, PHARM BASIS THERAPEU, Vseventh; HENDEE WR, 1987, JAMA-J AM MED ASSOC, V257, P1929; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAMB ML, 1992, JAMA-J AM MED ASSOC, V267, P77, DOI 10.1001/jama.267.1.77; KAUFMAN J, 1983, OVER COUNTER PILLS D; KESSLER DA, 1992, NEW ENGL J MED, V326, P70; KURMUKOV A G, 1991, Farmakologiya i Toksikologiya (Moscow), V54, P27; Lentner C, 1981, GEIGY SCI TABLES, V1; LENTNER C, 1986, GEIGY SCI TABLES, V4; LUBY S, 1992, AM J PUBLIC HEALTH, V82, P128, DOI 10.2105/AJPH.82.1.128-a; Mahler H.R., 1971, BIOL CHEM, V2nd; MAIRESSE M, 1981, HLTH SECRETS MED HER; MIRKIN G, 1991, JAMA-J AM MED ASSOC, V265, P912; Mirkin G, 1987, Semin Adolesc Med, V3, P177; ROBINSON T, 1975, ORGANIC CONSTITUENTS; SCHNEIDERHELMERT D, 1986, PSYCHOPHARMACOLOGY, V89, P1; SHIFF CJ, 1991, TROP MED PARASITOL, V42, P11; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; TAKEI M, 1991, J PHARM SCI, V80, P309, DOI 10.1002/jps.2600800403; WIDGER NH, 1979, WIDGER GUIDE OVER CO; ZHU DPQ, 1987, AM J CHINESE MED, V15, P117, DOI 10.1142/S0192415X87000151; ZIMMERMAN DR, 1983, ESSENTIAL GUIDE NONP; 1990, MMWR, V39, P789; 1991, MUSCLE MAG INT   AUG, P49; 1991, MUSCLE MAG INT   AUG, P121; 1990, MMWR, V39, P47; 1991, NATURES WAY HLTH CAR, P13; 1991, MUSCLE MAG INT   AUG, P163; 1990, NATURAL PHYSIQUE JUL, P92; 1989, MMWR, V38, P765; 1982, HDB NONPRESCRIPTION	39	41	42	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1008	1011		10.1001/jama.268.8.1008	http://dx.doi.org/10.1001/jama.268.8.1008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501305				2022-12-28	WOS:A1992JK12900026
J	GRUENEBERG, DA; NATESAN, S; ALEXANDRE, C; GILMAN, MZ				GRUENEBERG, DA; NATESAN, S; ALEXANDRE, C; GILMAN, MZ			HUMAN AND DROSOPHILA HOMEODOMAIN PROTEINS THAT ENHANCE THE DNA-BINDING ACTIVITY OF SERUM RESPONSE FACTOR	SCIENCE			English	Article							YEAST TRANSCRIPTION ACTIVATOR; TERNARY COMPLEX-FORMATION; C-FOS PROMOTER; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MAT-ALPHA-1 PROTEIN; ANTIRRHINUM-MAJUS; RECOGNITION HELIX; CRYSTAL-STRUCTURE; HOMEOBOX GENES	Cells with distinct developmental histories can respond differentially to identical signals, suggesting that signals are interpreted in a fashion that reflects a cell's identity. How this might occur is suggested by the observation that proteins of the homeodomain family, including a newly identified human protein, enhance the DNA-binding activity of serum response factor, a protein required for the induction of genes by growth and differentiation factors. Interaction with proteins of the serum response factor family may allow homeodomain proteins to specify the transcriptional response to inductive signals. Moreover, because the ability to enhance the binding of serum response factor to DNA resides within the homeodomain but is independent of homeodomain DNA-binding activity, this additional activity of the homeodomain may account for some of the specificity of action of homeodomain proteins in development.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [R01CA045642] Funding Source: NIH RePORTER; NCI NIH HHS [CA08968, CA45642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; ATTAR RM, UNPUB; BENDER A, 1986, CELL, V47, P929, DOI 10.1016/0092-8674(86)90808-1; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; COLICELLI J, 1991, P NATL ACAD SCI USA, V88, P2913, DOI 10.1073/pnas.88.7.2913; CSERJESI P, IN PRESS DEVELOPMENT; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GRUENEBERG DA, UNPUB; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HAWKINS NC, 1990, NUCLEIC ACIDS RES, V18, P6101, DOI 10.1093/nar/18.20.6101; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HENIKOFF S, 1990, NUCLEIC ACIDS RES, V18, P2961, DOI 10.1093/nar/18.10.2961; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; JARVIS EE, 1988, MOL CELL BIOL, V8, P309, DOI 10.1128/MCB.8.1.309; JOSTES B, 1991, MECH DEVELOP, V33, P27; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURET J, 1988, J BIOL CHEM, V263, P9149; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NAKAYAMA N, 1987, EMBO J, V6, P249, DOI 10.1002/j.1460-2075.1987.tb04746.x; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OPSTELTEN DJE, 1991, MECH DEVELOP, V34, P29, DOI 10.1016/0925-4773(91)90089-O; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; RYAN WE, UNPUB; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; SIMON K, UNPUB; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Sprague G F Jr, 1990, Adv Genet, V27, P33; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRUHL K, 1982, P NATL ACAD SCI-BIOL, V79, P7385, DOI 10.1073/pnas.79.23.7385; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; TREISMAN J, 1989, CELL, V59, P553; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERSHON AK, COMMUNICATION; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YUAN YLO, 1991, MOL CELL BIOL, V11, P5910, DOI 10.1128/MCB.11.12.5910	90	299	305	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1089	1095		10.1126/science.257.5073.1089	http://dx.doi.org/10.1126/science.257.5073.1089			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509260				2022-12-28	WOS:A1992JJ88400025
J	HAAF, T; WARBURTON, PE; WILLARD, HF				HAAF, T; WARBURTON, PE; WILLARD, HF			INTEGRATION OF HUMAN ALPHA-SATELLITE DNA INTO SIMIAN CHROMOSOMES - CENTROMERE PROTEIN-BINDING AND DISRUPTION OF NORMAL CHROMOSOME SEGREGATION	CELL			English	Article							DOUBLE MINUTE CHROMOSOMES; SYRIAN-HAMSTER CELLS; ADRENAL-TUMOR CELLS; ANTIGEN CENP-B; MAMMALIAN CHROMOSOMES; GENE AMPLIFICATION; LOCATED BENEATH; Y-CHROMOSOME; CAD GENES; SEQUENCES	Centromeres of mammalian and other complex eukaryotic chromosomes are dominated by one or more classes of satellite DNA. To test the hypothesis that alpha-satellite DNA, the major centromeric satellite of primate chromosomes, is involved in centromere structure and/or function, human alpha-satellite DNA was introduced into African green monkey (AGM) cells. Centromere protein binding was apparent at the sites of integrated human alpha-satellite DNA. In the presence of an AGM centromere on the same chromosome, human alpha-satellite was associated with bridges between the separating sets of chromatids at anaphase and an increased number of lagging chromosomes at meta-phase, both features consistent with the integrated alpha-satellite disrupting normal chromosome segregation. These experiments suggest that alpha-satellite DNA provides the primary sequence information for centromere protein binding and for at least some functional aspect(s) of a mammalian centromere, playing a role either in kinetochore formation or in sister chromatid apposition.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto	HAAF, T (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT GENET,STANFORD,CA 94305, USA.				NHGRI NIH HHS [HG00107] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BERNAT RL, 1991, CELL, V66, P1229, DOI 10.1016/0092-8674(91)90045-Z; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; Brinkley B.R., 1989, MITOSIS MOL MECHANIS, P77; BROWN PC, 1981, MOL CELL BIOL, V1, P1077, DOI 10.1128/MCB.1.12.1077; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; EARNSHAW WC, 1987, P NATL ACAD SCI USA, V84, P4979, DOI 10.1073/pnas.84.14.4979; EARNSHAW WC, 1991, J CELL SCI, V99, P1; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; FORD JH, 1989, MECHANISMS CHROMOSOM, P231; GEORGE DL, 1982, P NATL ACAD SCI-BIOL, V79, P1597, DOI 10.1073/pnas.79.5.1597; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GRADY DL, 1992, P NATL ACAD SCI USA, V89, P1695, DOI 10.1073/pnas.89.5.1695; GROSVELD FG, 1982, NUCLEIC ACIDS RES, V10, P6715, DOI 10.1093/nar/10.21.6715; HAAF T, 1988, CANCER GENET CYTOGEN, V30, P73, DOI 10.1016/0165-4608(88)90094-5; HAAF T, 1990, EXP CELL RES, V191, P157, DOI 10.1016/0014-4827(90)90051-B; HAAF T, 1990, CYTOGENET CELL GENET, V53, P40, DOI 10.1159/000132892; HAAF T, 1990, HUM GENET, V85, P486; HAAF T, 1991, P223; HADLACZKY G, 1991, P NATL ACAD SCI USA, V88, P8106, DOI 10.1073/pnas.88.18.8106; HAMKALO BA, 1985, P NATL ACAD SCI USA, V82, P1126, DOI 10.1073/pnas.82.4.1126; HEARTLEIN MW, 1988, MOL CELL BIOL, V8, P3611, DOI 10.1128/MCB.8.9.3611; HSU TC, 1975, CYTOGENET CELL GENET, V15, P41, DOI 10.1159/000130497; KAUFMAN RJ, 1983, MOL CELL BIOL, V3, P699, DOI 10.1128/MCB.3.4.699; LIN CC, 1990, CANCER GENET CYTOGEN, V48, P271, DOI 10.1016/0165-4608(90)90131-S; MANUELIDIS L, 1976, NUCLEIC ACIDS RES, V3, P3063, DOI 10.1093/nar/3.11.3063; MASUMOTO H, 1989, EXP CELL RES, V181, P181, DOI 10.1016/0014-4827(89)90192-4; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; Miklos GLG, 1985, MOL EVOLUTIONARY GEN, P241; MOLEBAJER J, 1990, P NATL ACAD SCI USA, V87, P3599, DOI 10.1073/pnas.87.9.3599; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; MURO Y, 1992, J CELL BIOL, V116, P585, DOI 10.1083/jcb.116.3.585; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; OAKEY R, 1990, GENOMICS, V7, P325, DOI 10.1016/0888-7543(90)90165-Q; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; PERETTI D, 1986, HUM GENET, V73, P12, DOI 10.1007/BF00292655; PERUCHO M, 1980, CELL, V22, P9; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; PRAZNOVSZKY T, 1991, P NATL ACAD SCI USA, V88, P11042, DOI 10.1073/pnas.88.24.11042; ROSENBERG H, 1978, SCIENCE, V200, P394, DOI 10.1126/science.205944; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SIMERLY C, 1990, J CELL BIOL, V111, P1491, DOI 10.1083/jcb.111.4.1491; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; STARK GR, 1990, FRONTIERS MOL BIOL, P99; STENMAN S, 1975, EXP CELL RES, V90, P87, DOI 10.1016/0014-4827(75)90360-2; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; THERMAN E, 1986, HUM GENET, V72, P191, DOI 10.1007/BF00291876; TYLERSMITH C, 1987, J MOL BIOL, V195, P457, DOI 10.1016/0022-2836(87)90175-6; VISSING H, 1987, NUCLEIC ACIDS RES, V15, P1363, DOI 10.1093/nar/15.4.1363; WAHL GM, 1983, MOL CELL BIOL, V3, P2066, DOI 10.1128/MCB.3.11.2066; WARBURTON PE, 1990, J MOL BIOL, V216, P3, DOI 10.1016/S0022-2836(05)80056-7; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; WAYE JS, 1989, P NATL ACAD SCI USA, V86, P6250, DOI 10.1073/pnas.86.16.6250; WAYE JS, 1986, MOL CELL BIOL, V6, P315; WEVRICK R, 1990, MOL CELL BIOL, V10, P6374, DOI 10.1128/MCB.10.12.6374; WEVRICK R, 1989, P NATL ACAD SCI USA, V86, P9394, DOI 10.1073/pnas.86.23.9394; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; WILLARD HF, 1990, TRENDS GENET, V6, P410, DOI 10.1016/0168-9525(90)90302-M; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; YUNIS JJ, 1971, SCIENCE, V174, P1200, DOI 10.1126/science.174.4015.1200	66	191	206	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					681	696		10.1016/0092-8674(92)90436-G	http://dx.doi.org/10.1016/0092-8674(92)90436-G			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505032				2022-12-28	WOS:A1992JJ88600016
J	OVERDUIN, M; RIOS, CB; MAYER, BJ; BALTIMORE, D; COWBURN, D				OVERDUIN, M; RIOS, CB; MAYER, BJ; BALTIMORE, D; COWBURN, D			3-DIMENSIONAL SOLUTION STRUCTURE OF THE SRC HOMOLOGY-2 DOMAIN OF C-ABL	CELL			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PROTEIN STRUCTURES; SH2 DOMAIN; ACTIVATION; P60C-SRC; BINDING; SITE; GAP	SH2 regions are protein motifs capable of binding target protein sequences that contain a phosphotyrosine. The solution structure of the abl SH2 product, a protein of 109 residues and 12.1 kd, has been determined by multidimensional nuclear magnetic resonance spectroscopy. It is a compact spherical domain with a pair of three-stranded antiparallel beta-sheets and a C-terminal alpha-helix enclosing the hydrophobic core. Three arginines project from a short N-terminal alpha-helix and one beta-sheet into the putative phosphotyrosine-binding site, which lies on a face distal from the termini. Comparison with other SH2 sequences supports a common global fold and mode of phosphotyrosine binding for this family.			OVERDUIN, M (corresponding author), ROCKEFELLER UNIV LABS, NEW YORK, NY 10021 USA.			Overduin, Michael/0000-0002-3114-6585; Cowburn, David/0000-0001-6770-7172	NCI NIH HHS [CA-51462] Funding Source: Medline; NIDDK NIH HHS [DK-20357] Funding Source: Medline; NIGMS NIH HHS [GM-47021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BRUNGER AT, 1992, XPLOR VERSION 3 0 MA; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; DALEY GQ, 1991, ADV CANCER RES, V57, P151; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OVERDUIN M, 1992, IN PRESS P NATL ACAD; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WUTHRICK K, 1986, NMR PROTEINS NUCLEIC	29	163	170	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1992	70	4					697	704		10.1016/0092-8674(92)90437-H	http://dx.doi.org/10.1016/0092-8674(92)90437-H			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505033				2022-12-28	WOS:A1992JJ88600017
J	ECKER, DJ; VICKERS, TA; BRUICE, TW; FREIER, SM; JENISON, RD; MANOHARAN, M; ZOUNES, M				ECKER, DJ; VICKERS, TA; BRUICE, TW; FREIER, SM; JENISON, RD; MANOHARAN, M; ZOUNES, M			PSEUDO HALF-KNOT FORMATION WITH RNA	SCIENCE			English	Article							TAR RNA; BINDING; PROTEIN; SEQUENCE	A pseudo-half-knot can be formed by binding an oligonucleotide asymmetrically to an RNA hairpin loop. This binding motif was used to target the human immunodeficiency virus TAR element, an important viral RNA structure that is the receptor for Tat, the major viral transactivator protein. Oligonucleotides complementary to different halves of the TAR structure bound with greater affinity than molecules designed to bind symmetrically around the hairpin. The pseudo-half-knot-forming oligonucleotides altered the TAR structure so that specific recognition and binding of a Tat-derived peptide was disrupted. This general binding motif may be used to disrupt the structure of regulatory RNA hairpins.			ECKER, DJ (corresponding author), ISIS PHARMACEUT, 2280 FARADAY AVE, CARLSBAD, CA 92008 USA.			Ecker, David/0000-0003-4350-9037				CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHEN CHB, 1988, J AM CHEM SOC, V110, P6570, DOI 10.1021/ja00227a052; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; ECKER D, UNPUB ANTISENSE RES; ECKER DJ, UNPUB; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; PLEIJ CWA, 1989, METHOD ENZYMOL, V180, P289; PLEIJ CWA, 1990, TRENDS BIOCHEM SCI, V15, P143, DOI 10.1016/0968-0004(90)90214-V; PUGLISI JD, 1991, ACCOUNTS CHEM RES, V24, P152, DOI 10.1021/ar00005a005; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WITHERELL GW, 1990, BIOCHEMISTRY-US, V29, P11051, DOI 10.1021/bi00502a006	19	89	94	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	1992	257	5072					958	961		10.1126/science.1502560	http://dx.doi.org/10.1126/science.1502560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1502560				2022-12-28	WOS:A1992JH82700033
J	LOCKHART, DJ; KIM, PS				LOCKHART, DJ; KIM, PS			INTERNAL STARK-EFFECT MEASUREMENT OF THE ELECTRIC-FIELD AT THE AMINO TERMINUS OF AN ALPHA-HELIX	SCIENCE			English	Article							DIELECTRIC-CONSTANT; DIPOLE MODEL; PROTEINS; STABILITY; STABILIZATION; RESONANCE; PEPTIDES; ALANINE; CHARGE	The strengths of electrostatic interactions in biological molecules are difficult to calculate or predict because they occur in complicated, inhomogeneous environments. The electric field at the amino terminus of an alpha-helix in water has been determined by measuring the shift in the absorption band for a covalently attached, neutral probe molecule with an electric dipole moment difference between the ground and excited electronic states (an internal Stark effect). The field at the interface between the helix and the solvent is found to be an order of magnitude stronger than expected from the dielectric properties of bulk water. Furthermore, although the total electric dipole moment of the helix increases with length, the electric field at the amino terminus does not.			LOCKHART, DJ (corresponding author), MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142, USA.							AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; FIELDS C G, 1991, Peptide Research, V4, P95; GILSON MK, 1986, BIOPOLYMERS, V25, P2097, DOI 10.1002/bip.360251106; GILSON MK, 1988, PROTEINS, V3, P32, DOI 10.1002/prot.340030104; GILSON MK, 1985, J MOL BIOL, V183, P503; HEMANT SK, 1991, J AM CHEM SOC, V113, P6062; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; LIFF MI, 1991, J AM CHEM SOC, V113, P1014, DOI 10.1021/ja00003a041; Liptay W., 1974, Excited states. Vol.1, P129; LOCKHART DJ, 1987, BIOCHEMISTRY-US, V26, P664, DOI 10.1021/bi00377a001; LOCKHART DJ, UNPUB; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MATHIES R, 1976, P NATL ACAD SCI USA, V73, P2169, DOI 10.1073/pnas.73.7.2169; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P1591, DOI 10.1021/bi00220a021; MIICK SM, 1991, BIOCHEMISTRY-US, V30, P9498, DOI 10.1021/bi00103a016; NICHOLSON H, 1991, BIOCHEMISTRY-US, V30, P9816, DOI 10.1021/bi00105a002; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; REES DC, 1980, J MOL BIOL, V141, P323, DOI 10.1016/0022-2836(80)90184-9; RODGERS KK, 1991, J AM CHEM SOC, V113, P9419, DOI 10.1021/ja00024a087; ROHL CA, 1992, BIOCHEMISTRY-US, V31, P1263, DOI 10.1021/bi00120a001; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; Wada A, 1976, Adv Biophys, P1; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15	34	189	192	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 14	1992	257	5072					947	951		10.1126/science.1502559	http://dx.doi.org/10.1126/science.1502559			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH827	1502559				2022-12-28	WOS:A1992JH82700030
J	TIMMINS, PA; POLIKS, B; BANASZAK, L				TIMMINS, PA; POLIKS, B; BANASZAK, L			THE LOCATION OF BOUND LIPID IN THE LIPOVITELLIN COMPLEX	SCIENCE			English	Article							CONTRAST VARIATION; RESOLUTION; LIPOPROTEIN; PHOSVITIN	The location of the bound lipid in the soluble lipoprotein lipovitellin has been determined by neutron crystallographic techniques. With the use ot the contrast variation method, whereby the crystals are soaked in different H2O-D2O mixtures, the lipid has been found to occupy a large cavity in the protein whose structure had previously been determined by x-ray crystallography. The lipid appears to be bound in the form of a bilayer with the major protein-lipid interactions being hydrophobic and with the lipid headgroups projecting into the bulk solvent and into a solvent-filled space in the cavity.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; WASHINGTON UNIV,SCH MED,DEPT BIOL CHEM,ST LOUIS,MO 63110	University of Minnesota System; University of Minnesota Twin Cities; Washington University (WUSTL)	TIMMINS, PA (corresponding author), INST LAUE LANGEVIN,156X,F-38042 GRENOBLE 9,FRANCE.							BANASZAK L, 1991, ANNU REV BIOPHYS BIO, V20, P221, DOI 10.1146/annurev.biophys.20.1.221; BANASZAK LJ, 1982, BIOCHEMISTRY-US, V21, P2436, DOI 10.1021/bi00539a024; MEININGER T, 1984, J MOL BIOL, V179, P759, DOI 10.1016/0022-2836(84)90167-0; POLIKS B, UNPUB; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; ROCHE CT, 1985, IEEE T NUCL SCI, V32, P373, DOI 10.1109/TNS.1985.4336858; ROTH M, 1987, ACTA CRYSTALLOGR A, V43, P780, DOI 10.1107/S0108767387098520; ROTH M, 1984, J APPL CRYSTALLOGR, V17, P77, DOI 10.1107/S0021889884011031; ROTH M, IN PRESS CRYSTALLOGR, V5; TIMMINS PA, 1988, EUR BIOPHYS J BIOPHY, V15, P257, DOI 10.1007/BF00256476; WORCESTER DL, 1976, J MOL BIOL, V100, P359, DOI 10.1016/S0022-2836(76)80068-X	11	34	36	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					652	655		10.1126/science.1496377	http://dx.doi.org/10.1126/science.1496377			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496377				2022-12-28	WOS:A1992JF85200031
J	YANG, XO; HUBBARD, EJA; CARLSON, M				YANG, XO; HUBBARD, EJA; CARLSON, M			A PROTEIN-KINASE SUBSTRATE IDENTIFIED BY THE 2-HYBRID SYSTEM	SCIENCE			English	Article							YEAST TRANSCRIPTIONAL ACTIVATORS; SACCHAROMYCES-CEREVISIAE; SNF4 PROTEIN; GENE	A genetic method, the two-hybrid system, was used to identify four genes encoding proteins that interact with the SNF1 protein kinase from yeast. One of the genes, SIP1, was independently isolated as a multicopy suppressor of defects caused by reduced SNF1 kinase activity, and genetic evidence supports its function in the SNF1 pathyway. The SIP1 protein co-immunoprecipitated with SNF1 and was phosphorylated in vitro. Thus, the two-hybrid system, which is applicable to any cloned gene, can be used to detect physical interactions between protein kinases and functionally related substrate proteins.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032	Columbia University; Columbia University				Hubbard, E. Jane Albert/0000-0001-5893-7232	NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034095, R01GM034095] Funding Source: NIH RePORTER; NCI NIH HHS [CA09503] Funding Source: Medline; NIGMS NIH HHS [GM34095] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDERSON A, 1991, P NATL ACAD SCI USA, V88, P8602, DOI 10.1073/pnas.88.19.8602; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HUBBARD EJA, 1992, GENETICS, V130, P71; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Miller J.H., 1972, EXPT MOL GENETICS; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; Rose MD., 1990, METHODS YEAST GENETI; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMPSONJAEGER S, 1991, GENETICS, V129, P697	19	180	212	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					680	682		10.1126/science.1496382	http://dx.doi.org/10.1126/science.1496382			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496382				2022-12-28	WOS:A1992JF85200040
J	KOLLERBENZ, G; FRITZSCHE, A; KRAPF, R				KOLLERBENZ, G; FRITZSCHE, A; KRAPF, R			NIFEDIPINE INDUCED GINGIVAL ABSCESSES	BRITISH MEDICAL JOURNAL			English	Letter							HYPERPLASIA				KOLLERBENZ, G (corresponding author), UNIV BERN,INSELSPITAL,CH-3010 BERN,SWITZERLAND.							LUCAS RM, 1985, J PERIODONTOL, V56, P211, DOI 10.1902/jop.1985.56.4.211; SHAFTIC AA, 1986, DRUG INTEL CLIN PHAR, V20, P602, DOI 10.1177/106002808602000724; VANDERWALL EE, 1985, ORAL SURG ORAL MED O, V60, P38, DOI 10.1016/0030-4220(85)90212-9	3	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1225	1225		10.1136/bmj.304.6836.1225-a	http://dx.doi.org/10.1136/bmj.304.6836.1225-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515795	Bronze, Green Published			2022-12-28	WOS:A1992HT96400026
J	WHITE, JM; GILLAM, SJ; BEGG, NT; FARRINGTON, CP				WHITE, JM; GILLAM, SJ; BEGG, NT; FARRINGTON, CP			VACCINE COVERAGE - RECENT TRENDS AND FUTURE-PROSPECTS	BRITISH MEDICAL JOURNAL			English	Article							ENGLAND	Objective - To assess the feasibility of achieving the target of 95% coverage for the childhood immunisation schedule by 1995 and to determine the influence of sociodemographic factors and information systems on recent trends. Design - Analyses of trends in quarterly vaccination data for diphtheria, pertussis, and measles in health districts between February 1988 and February 1991. Setting - District health authorities in England and Wales, and health and social services boards in Northern Ireland. Subjects - Cohorts of children whose youngest member had reached the target age of 18 months for receiving the third doses of diphtheria and pertussis vaccines and 2 years for receiving measles vaccine. Results - Predicted coverage levels for mid-1995 were in excess of 95% for diphtheria, pertussis, and measles vaccines. In the 118 districts that continuously reported between February 1988 and February 1991 the increase in coverage was 6% for diphtheria and 13% for pertussis and measles vaccines. 1991 coverage depended primarily on 1988 coverage. The additional effects of deprivation, change in computer system, and child population size achieved at most only marginal statistical significance. Conclusions - The government's target of 95% coverage by 1995 is realistic, although projections should be viewed with caution. Several national vaccination initiatives are likely to have contributed to the recent steady increase in coverage. Updating and validation exercises are likely to improve recorded coverage.	NW THAMES REG HLTH AUTHOR,LONDON W2 3QR,ENGLAND		WHITE, JM (corresponding author), PUBL HLTH LAB SERV,COMMUNICABLE DIS SURVEILLANCE CTR,LONDON NW9 5EQ,ENGLAND.			Farrington, Conor Patrick/0000-0002-7148-2612; White, Joanne/0000-0001-7786-4462				AITKIN M, 1989, STATISTICAL MODELLIN; BEGG NT, 1989, PUBLIC HEALTH, V103, P81, DOI 10.1016/S0033-3506(89)80021-6; JAMES J, 1986, ARCH DIS CHILD, V61, P251; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; JARMAN B, 1988, BRIT MED J, V296, P1775, DOI 10.1136/bmj.296.6639.1775; LAKHANI A, 1986, REPORT INVESTIGATION; LAWRENCE M, 1989, BRIT MED J, V299, P389, DOI 10.1136/bmj.299.6695.389-a; MANT D, 1986, BMJ, V293, P955; NICOLL A, 1989, BMJ, V299, P423; ROSS S K, 1986, Health Bulletin (Edinburgh), V44, P370; WILLIAMS DA, 1982, J R STAT SOC C-APPL, V31, P144; 1990, IMMUNISATION INFECTI; 1991, CM1523; 1987, CHILD HLTH SYSTEM SY; 1988, IMMUNISATION INFECTI	15	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					682	684		10.1136/bmj.304.6828.682	http://dx.doi.org/10.1136/bmj.304.6828.682			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK761	1510759	Green Published, Bronze			2022-12-28	WOS:A1992HK76100022
J	VINE, SJ; PRYSDAVIES, A; PEARSON, JF				VINE, SJ; PRYSDAVIES, A; PEARSON, JF			TRANSVERSE POSTERIOR CERVICOISTHMIC RUPTURE AFTER GEMEPROST PESSARIES FOR TERMINATION	BRITISH MEDICAL JOURNAL			English	Letter							VAGINAL PESSARIES; UTERINE RUPTURE; PREGNANCY				VINE, SJ (corresponding author), UNIV HOSP WALES,CARDIFF CF4 4XN,S GLAM,WALES.							BYRNE P, 1991, BRIT MED J, V302, P852, DOI 10.1136/bmj.302.6780.852-c; CAMERON IT, 1987, PROSTAGLANDINS, V34, P111, DOI 10.1016/0090-6980(87)90268-1; LOWENSOHN R, 1974, AM J OBSTET GYNECOL, V119, P1057, DOI 10.1016/0002-9378(74)90258-0; WENTZ AC, 1973, AM J OBSTET GYNECOL, V115, P1107, DOI 10.1016/0002-9378(73)90560-7; WIENER JJ, 1990, BRIT J OBSTET GYNAEC, V97, P1061, DOI 10.1111/j.1471-0528.1990.tb02484.x	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1332	1332		10.1136/bmj.305.6865.1332	http://dx.doi.org/10.1136/bmj.305.6865.1332			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483081	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992KA77300024
J	LOWRY, S				LOWRY, S			MEDICAL-EDUCATION .1. WHATS WRONG WITH MEDICAL-EDUCATION IN BRITAIN .1.	BRITISH MEDICAL JOURNAL			English	Article							HOUSE OFFICERS											ALLEN I, 1988, ANY ROOM TOP STUDY D; DILLNER L, 1992, BRIT MED J, V305, P1103; ELTON L, 1992, TEACHING STANDARDS E; FIRTHCOZENS J, 1989, BRIT J HOSP MED, V41, P161; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; Harden R M, 1984, Med Educ, V18, P284; MCMANUS C, 1992, BEST HLTH STATUS FUT; STOCKING B, 1992, MED ADV FUTURE SHAPE; TOWLE A, 1991, CRITICAL THINKING FU; 1992, STRESS MED PROFESSIO; 1991, 1ST REPORT EFFECTS N; 1992, 2ND REPORT EFFECTS N; 1980, RECOMMENDATIONS MED; 1989, CMND555; 1957, RECOMMENDATIONS MED; 1991, UNDERGRADUATE MED ED	16	42	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1277	1280		10.1136/bmj.305.6864.1277	http://dx.doi.org/10.1136/bmj.305.6864.1277			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477575	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JZ52100031
J	ROBINSON, JA				ROBINSON, JA			PLASMAPHERESIS FOR LUPUS NEPHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											ROBINSON, JA (corresponding author), LOYOLA UNIV,MED CTR,MAYWOOD,IL 60153, USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					1028	1029						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1472252				2022-12-28	WOS:A1992JQ22500013
J	MCINNES, J; LARSON, MG; DALTROY, LH; BROWN, T; FOSSEL, AH; EATON, HM; SHULMANKIRWAN, B; STEINDORF, S; POSS, R; LIANG, MH				MCINNES, J; LARSON, MG; DALTROY, LH; BROWN, T; FOSSEL, AH; EATON, HM; SHULMANKIRWAN, B; STEINDORF, S; POSS, R; LIANG, MH			A CONTROLLED EVALUATION OF CONTINUOUS PASSIVE MOTION IN PATIENTS UNDERGOING TOTAL KNEE ARTHROPLASTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-STATUS INSTRUMENTS; REPLACEMENT; ARTHRITIS; RABBIT	Objective.-To evaluate the efficacy of continuous passive motion (CPM) in the postoperative management of patients undergoing total knee arthroplasty. Design.-A randomized controlled single-blind trial of CPM plus standardized rehabilitation vs standard rehabilitation alone. Setting.-A referral hospital for arthritis and musculoskeletal care. Patients.-Consecutive patients with end-stage osteoarthritis or rheumatoid arthritis undergoing primary total knee arthroplasty who had at least 90-degrees of passive knee flexion. One hundred fifty-four patients were eligible and 102 patients agreed to participate and were randomized. Ninety-three patients completed the study protocol. Intervention.-Continuous passive motion machines programmed for rate and specified arc of motion within 24 hours of surgery with range increased daily as tolerated with standardized rehabilitation program compared with standardized rehabilitation program alone. Main Outcome Measures.-Primary outcomes were pain, active and passive knee range of motion, swelling (or circumference), quadriceps strength at postoperative day 7, as well as complications, length of stay, and active and passive range of motion and function at 6 weeks. Results.-Use of CPM increased active flexion and decreased swelling and the need for manipulations but did not significantly affect pain, active and passive extension, quadriceps strength, or length of hospital stay. At 6 weeks there were no differences between the two groups in either range of motion or function. In this series, use of CPM resulted in a net savings of $6764 over conventional rehabilitation in achieving these results. Conclusion.-For the average patient undergoing total knee arthroplasty, CPM is more effective in improving range of motion, decreasing swelling, and reducing the need for manipulation than is conventional therapy and lowers cost.	BRIGHAM & WOMENS HOSP,DEPT REHABIL SERV,75 FRANCIS ST,PBB-B2,BOSTON,MA 02115; HARVARD UNIV,SCH MED,ROBERT B BRIGHAM MULTIPURPOSE ARTHRIT CTR,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,ROBERT B BRIGHAM MULTIPURPOSE ARTHRIT CTR,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,ROBERT B BRIGHAM MULTIPURPOSE ARTHRIT CTR,DEPT ORTHOPED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School				Larson, Martin/0000-0002-9631-1254	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36308, AR05669] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BASSO DM, 1987, PHYS THER, V67, P360, DOI 10.1093/ptj/67.3.360; BOHANNON RW, 1986, PHYS THER, V6, P206; COUTTS R D, 1982, Orthopaedic Transactions, V6, P277; Coutts R D, 1986, Orthop Rev, V15, P126; Coutts RD, 1984, TOTAL KNEE ARTHROPLA, P126; Fisher R L, 1985, Conn Med, V49, P498; FOX JL, 1981, J BONE JOINT SURG AM, V63, P357, DOI 10.2106/00004623-198163030-00005; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; GOLL SR, 1987, TOTAL ARTHROPLASTY K, P399; GOOMDAN LS, 1985, PHARM BASICS THERAPE, P505; GOSE JC, 1987, PHYS THER, V67, P39, DOI 10.1093/ptj/67.1.39; INSALL JN, 1982, J BONE JOINT SURG AM, V64, P1317, DOI 10.2106/00004623-198264090-00006; JOHNSON DP, 1990, J BONE JOINT SURG AM, V72A, P421, DOI 10.2106/00004623-199072030-00016; Kleinbaum DG, 1988, APPLIED REGRESSION A, P181; LIANG MH, 1990, MED CARE, V28, P632, DOI 10.1097/00005650-199007000-00008; LIANG MH, 1985, ARTHRITIS RHEUM, V28, P542, DOI 10.1002/art.1780280513; Lynch JA, 1984, ORTHOP T, V8, P400; MALONEY WJ, 1990, CLIN ORTHOPAEDICS, V256, P162; MOERTEL CG, 1972, NEW ENGL J MED, V286, P813, DOI 10.1056/NEJM197204132861504; ODRISCOL SW, 1983, CLIN ORTHOP RELAT R, V176, P305; ODRISCOLL SW, 1983, J RHEUMATOL, V10, P360; ROPES MW, 1959, ARTHRITIS RHEUM-US, V2, P16, DOI 10.1002/1529-0131(195902)2:1<16::AID-ART1780020104>3.0.CO;2-9; SALTER R B, 1984, Journal of Orthopaedic Research, V1, P325; SALTER RB, 1980, J BONE JOINT SURG AM, V62, P1232, DOI 10.2106/00004623-198062080-00002; SALTER RB, 1981, CLIN ORTHOP RELAT R, V159, P223; SNEDECOR GW, 1967, STATISTICAL METHODS, P100; Vince K G, 1987, J Arthroplasty, V2, P281, DOI 10.1016/S0883-5403(87)80060-8; WASILEWSKI SA, 1990, ORTHOPEDICS, V13, P291; 1988, SAS STAT USERS GUIDE, P549	29	71	79	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1423	1428		10.1001/jama.268.11.1423	http://dx.doi.org/10.1001/jama.268.11.1423			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512910				2022-12-28	WOS:A1992JM84900024
J	LIN, AN; FROST, J; DENG, TL; SMEAL, T; ALALAWI, N; KIKKAWA, U; HUNTER, T; BRENNER, D; KARIN, M				LIN, AN; FROST, J; DENG, TL; SMEAL, T; ALALAWI, N; KIKKAWA, U; HUNTER, T; BRENNER, D; KARIN, M			CASEIN KINASE-II IS A NEGATIVE REGULATOR OF C-JUN DNA-BINDING AND AP-1 ACTIVITY	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; TRANS-ACTING FACTOR; TRANSCRIPTIONAL ACTIVATION; STIMULATE TRANSCRIPTION; PROTO-ONCOGENE; PHOSPHORYLATION; GENE; ELEMENT; SERUM; FIBROBLASTS	c-Jun, a major component of the inducible transcription factor AP-1, is a phosphoprotein. In nonstimulated fibroblasts and epithelial cells, c-Jun is phosphorylated on a cluster of two to three sites abutting its DNA-binding domain. Phosphorylation of these sites inhibits DNA binding, and their dephosphorylation correlates with increased AP-1 activity. We show that two of these sites, Thr-231 and Ser-249, are phosphorylated by casein kinase II (CKII). Substitution of the third site, Ser-243, by Phe interferes with phosphorylation of the inhibitory sites in vivo and by purified CKII in vitro. Microinjection into living cells of synthetic peptides that are specific competitive substrates or inhibitors of CKII results in induction of AP-1 activity and c-Jun expression. Microinjection of CKII supresses induction of AP-1 by either phorbol ester or an inhibitory peptide. These results suggest that one of the roles of CKII, a major nuclear protein kinase with no known functions, is to attenuate AP-1 activity through phosphorylation of c-Jun.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT BIOL, LA JOLLA, CA 92093 USA; SALK INST BIOL RES, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, CTR CANC, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute; University of California System; University of California San Diego	LIN, AN (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA.			Frost, Jeffrey/0000-0001-9722-1536; Brenner, David/0000-0003-2573-525X	NATIONAL CANCER INSTITUTE [R01CA039811, P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151, R01ES004151] Funding Source: NIH RePORTER; NCI NIH HHS [CA50528, CA39811] Funding Source: Medline; NIEHS NIH HHS [ES04151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; DENG T, 1992, IN PRESS P NATL ACAD, V89; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; FERAMISCO JR, 1986, MICROINJECTION ORGAN, P40; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FIRZLAFF J M, 1989, New Biologist, V1, P44; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GLINEUR C, 1989, ONCOGENE, V4, P1247; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KARIN M, 1991, MOL ASPECTS CELLULAR, V6, P143; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; Tooze J, 1980, DNA TUMOR VIRUSES; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANG-YEN H-F, 1990, New Biologist, V2, P351	65	368	374	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1992	70	5					777	789		10.1016/0092-8674(92)90311-Y	http://dx.doi.org/10.1016/0092-8674(92)90311-Y			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516134				2022-12-28	WOS:A1992JL66300009
J	ENARSON, C; BURG, FD				ENARSON, C; BURG, FD			AN OVERVIEW OF REFORM INITIATIVES IN MEDICAL-EDUCATION - 1906 THROUGH 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV PENN,SCH MED,PHILADELPHIA,PA 19104	University of Pennsylvania	ENARSON, C (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.							BANE F, 1959, PHYSICIANS GROWING A; BLOOM SW, 1989, MED EDUC, V23, P228, DOI 10.1111/j.1365-2923.1989.tb01538.x; CANTOR JC, 1991, JAMA-J AM MED ASSOC, V265, P1002, DOI 10.1001/jama.265.8.1002; COGGESHALL LT, 1965, PLANNING PROGR MED E; DEITRICK JE, 1953, MED SCH US MIDCENTUR; Flexner A., 1910, FLEXNER REPORT; GASTEL B, 1989, CLIN ED DOCTOR TOMOR; JOHNSON, 1992, SCI MED PRACTICE; KASSEBAUM DG, 1990, ACAD MED, V65, P293, DOI 10.1097/00001888-199005000-00003; Kaufman Martin, 1976, AM MED ED FORMATIVE; KELLOGG WK, 1991, ANN REPROT TRANSITIO; LEVIT EJ, 1973, EVALUATION CONTINUUM; MACY J, 1991, ANN REPORT J MACY JR; MANNING TE, 1992, SOURCEBOOK OUTCOME A; MILLIS JS, 1966, GRADUATE ED PHYSICIA; RAPPLEYE W, 1932, MED ED; Shugars DA, 1991, HLTH AM PRACTITIONER; Weiskotten HG, 1940, MED ED US 1934 1939; 1984, PHYSICIANS 21ST CENT; 1970, HIGHER ED NATIONS HL; 1959, HIST COUNCIL MED ED; 1982, FUTURE DIRECTIONS ME	22	44	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1141	1143		10.1001/jama.268.9.1141	http://dx.doi.org/10.1001/jama.268.9.1141			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK681	1501340				2022-12-28	WOS:A1992JK68100015
J	STRAUS, DB; WEISS, A				STRAUS, DB; WEISS, A			GENETIC-EVIDENCE FOR THE INVOLVEMENT OF THE ICK TYROSINE KINASE IN SIGNAL TRANSDUCTION THROUGH THE T-CELL ANTIGEN RECEPTOR	CELL			English	Article							PROTEIN-KINASE; ZETA-CHAIN; PHOSPHOLIPASE C-GAMMA-1; SURFACE MOLECULES; CROSS-LINKING; CD4 RECEPTOR; SRC FAMILY; ACTIVATION; P56LCK; PHOSPHORYLATION	Signaling through the T cell antigen receptor (TCR) results both in rapid increases in tyrosine phosphorylation on a number of proteins and in the activation of the phosphatidylinositol pathway. It is not clear how stimulation of the TCR leads to these signaling events. Mutants of the Jurkat T cell line have been previously isolated that fail to show increases in calcium following receptor stimulation. Analysis of one of these mutants, JCaM1, which is defective in the induction of tyrosine phosphorylation, revealed a defect in the expression of functional lck tyrosine kinase. The lack of lck activity was caused in part by a splicing defect. Expression of the lck cDNA in JCaM1 restores the ability of the cell to respond to TCR stimulation. These results indicate that lck is required for normal signal transduction through the TCR.			STRAUS, DB (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MED,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.				NIGMS NIH HHS [GM39553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ANSOTEGUI IJ, 1991, SCAND J IMMUNOL, V33, P375, DOI 10.1111/j.1365-3083.1991.tb01784.x; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDSMITH MA, 1988, P NATL ACAD SCI USA, V85, P8613, DOI 10.1073/pnas.85.22.8613; GOLDSMITH MA, 1989, J BIOL CHEM, V264, P17190; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARA T, 1985, J EXP MED, V161, P641, DOI 10.1084/jem.161.4.641; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JONGSTRA J, 1987, J EXP MED, V165, P601, DOI 10.1084/jem.165.3.601; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1741, DOI 10.1073/pnas.88.5.1741; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; TESTI R, 1989, J IMMUNOL, V142, P1854; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISS A, 1989, FUNDAMENTAL IMMUNOLO, P359; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	57	1010	1047	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					585	593		10.1016/0092-8674(92)90428-F	http://dx.doi.org/10.1016/0092-8674(92)90428-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505025				2022-12-28	WOS:A1992JJ88600008
J	WULCZYN, FG; NAUMANN, M; SCHEIDEREIT, C				WULCZYN, FG; NAUMANN, M; SCHEIDEREIT, C			CANDIDATE PROTOONCOGENE BCL-3 ENCODES A SUBUNIT-SPECIFIC INHIBITOR OF TRANSCRIPTION FACTOR NF-KAPPA-B	NATURE			English	Article							DNA-BINDING PROTEIN; REL-ASSOCIATED PP40; C-REL; GENE; CLONING; DORSAL; PURIFICATION; DROSOPHILA; COMPLEX; MOTIFS	THE NF-kappa-B subunits p50 and p65 and the product of the rel proto-oncogene are members Of a growing class of transcription factors with a unique DNA-binding and dimerization domain1-13. Nuclear transfer of each of these factors is controlled by cytoplasmic inhibitors, and regulated by specific stimuli. The inhibitors I-kappa-B-alpha and -beta and pp40 recognize either p65 or the c-rel protein14-16. We show here that the proto-oncogene bcl-3, believed to be involved in certain human B-cell leukaemias17, encodes a protein that functions as an I-kappa-B-like molecule for native NF-kappa-B but is specific for the p50 subunit. The ankyrin repeat domain of the bcl-3 product is shown to mediate complex formation with NF-kappa-B dimers by contacting the conserved dimerization domain of NF-kappa-B.	MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society			Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOSH S, 1990, CELL, V62, P1019; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1991, CELL, V64, P439; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	29	214	215	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					597	599		10.1038/358597a0	http://dx.doi.org/10.1038/358597a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1501714				2022-12-28	WOS:A1992JH82900064
J	ZHANG, Y; HEYM, B; ALLEN, B; YOUNG, D; COLE, S				ZHANG, Y; HEYM, B; ALLEN, B; YOUNG, D; COLE, S			THE CATALASE PEROXIDASE GENE AND ISONIAZID RESISTANCE OF MYCOBACTERIUM-TUBERCULOSIS	NATURE			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; EXPRESSION; TRANSFORMATION; SUPEROXIDE; EXTRACTS; CLONING; STRAINS	TUBERCULOSIS is responsible for one in four of all avoidable adult deaths in developing countries1. Increased frequency and accelerated fatality of the disease among individuals infected with human immunodeficiency virus has raised worldwide concern that control programmes may be inadequate2, and the emergence of multidrug-resistant strains of Mycobacterium tuberculosis has resulted in several recent fatal outbreaks in the United States3. Isonicotinic acid hydrazide (isoniazid, INH) forms the core of antituberculosis regimens; however, clinical isolates that are resistant to INH show reduced catalase activity and a relative lack of virulence in guinea-pigs4-7. Here we use mycobacterial genetics8,9 to study the molecular basis of INH resistance. A single M. tuberculosis gene, katG, encoding both catalase and peroxidase, restored sensitivity to INH in a resistant mutant of Mycobacterium smegmatis, and conferred INH susceptibility in some strains of Escherichia coli. Deletion of katG from the chromosome was associated with INH resistance in two patient isolates of M. tuberculosis.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT BACTERIOL,LONDON W12 0HS,ENGLAND; INST PASTEUR,GENET MOLEC BACTERIENNE LAB,F-75724 PARIS 15,FRANCE; CHU PITIE SALPETRIERE,SERV BACTERIOL VIROL,F-75634 PARIS 13,FRANCE	Imperial College London; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	ZHANG, Y (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,TB & RELATED INFECT UNIT,LONDON W12 0HS,ENGLAND.							COHN ML, 1954, AM REV TUBERC PULM, V70, P641; DEVI BG, 1975, BIOCHEM J, V149, P187, DOI 10.1042/bj1490187; HEYM B, IN PRESS RES MICROBI; JACKETT PS, 1978, J GEN MICROBIOL, V104, P37, DOI 10.1099/00221287-104-1-37; LOPRASERT S, 1989, J BACTERIOL, V171, P4871, DOI 10.1128/jb.171.9.4871-4875.1989; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V70, P852; MITCHISON DA, 1963, J PATHOL BACTERIOL, V86, P377, DOI 10.1002/path.1700860213; MULVEY MR, 1988, GENE, V73, P337, DOI 10.1016/0378-1119(88)90498-2; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; SNAPPER SB, 1988, P NATL ACAD SCI USA, V85, P6987, DOI 10.1073/pnas.85.18.6987; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; TRIGGSRAINE BL, 1988, J BACTERIOL, V170, P4415, DOI 10.1128/jb.170.9.4415-4419.1988; WAYNE LG, 1986, ANAL BIOCHEM, V157, P89, DOI 10.1016/0003-2697(86)90200-9; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; YOUATT J, 1969, AM REV RESPIR DIS, V99, P729; ZHANG Y, 1992, INFECT IMMUN, V60, P2160, DOI 10.1128/IAI.60.6.2160-2165.1992; ZHANG Y, 1991, MOL MICROBIOL, V5, P381, DOI 10.1111/j.1365-2958.1991.tb02120.x	21	1042	1117	2	99	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					591	593		10.1038/358591a0	http://dx.doi.org/10.1038/358591a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1501713				2022-12-28	WOS:A1992JH82900062
J	EMSON, HE				EMSON, HE			MEDICINE AND HISTORY - FOR THE WANT OF AN HEIR - THE OBSTETRICAL HISTORY OF QUEEN-ANNE	BRITISH MEDICAL JOURNAL			English	Article							LUPUS-ANTICOAGULANT; INTRAUTERINE DEATH; ABORTION				EMSON, HE (corresponding author), UNIV SASKATCHEWAN,ROYAL HOSP,SASKATOON S7N 0X0,SASKATCHEWAN,CANADA.							CARRERAS LO, 1981, BRIT J OBSTET GYNAEC, V88, P890, DOI 10.1111/j.1471-0528.1981.tb02224.x; FIRKIN BG, 1980, LANCET, V2, P366; GREEN D, 1970, ANNE; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; LUBBE WF, 1984, NEW ZEAL MED J, V97, P398; MCALPINE I, 1966, BRIT MED J, V1, P65; NILSSON IM, 1975, ACTA MED SCAND, V197, P153; QMAR T, 1990, ARTHRITIS RHEUM, V33, P501; Roberts Philip, 1975, DIARY D HAMILTON 170; SAXBE WB, 1972, PEDIATRICS, V49, P97	10	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1365	1366		10.1136/bmj.304.6838.1365	http://dx.doi.org/10.1136/bmj.304.6838.1365			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1463487	Bronze, Green Published			2022-12-28	WOS:A1992HW41700031
J	BLACK, J				BLACK, J			2ND LETTER FROM ERITREA	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON KINGS COLL HOSP,LONDON SE5 8RX,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	BLACK, J (corresponding author), 54 RUSKIN PK HOUSE,CHAMP HILL,LONDON SE5 8TQ,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1480	1481		10.1136/bmj.305.6867.1480	http://dx.doi.org/10.1136/bmj.305.6867.1480			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493397	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992KC91800028
J	ZACHARY, I; ROZENGURT, E				ZACHARY, I; ROZENGURT, E			FOCAL ADHESION KINASE (P125(FAK)) - A POINT OF CONVERGENCE IN THE ACTION OF NEUROPEPTIDES, INTEGRINS, AND ONCOGENES	CELL			English	Review							TYROSINE PHOSPHORYLATION; PROTEIN				ZACHARY, I (corresponding author), IMPERIAL CANC RES FUND,GROWTH REGULAT LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, IN PRESS J BIOL CHEM; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SETHI T, 1992, CANCER RES, V52, pS2737; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	17	453	457	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					891	894		10.1016/0092-8674(92)90385-P	http://dx.doi.org/10.1016/0092-8674(92)90385-P			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458538				2022-12-28	WOS:A1992KB99000002
J	FORSBLOM, CM; GROOP, PH; EKSTRAND, A; GROOP, LC				FORSBLOM, CM; GROOP, PH; EKSTRAND, A; GROOP, LC			PREDICTIVE VALUE OF MICROALBUMINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES OF LONG DURATION	BRITISH MEDICAL JOURNAL			English	Article							NEPHROPATHY	Objective-To investigate the predictive value of microalbuminuria (albumin excretion rate 30-300 mg/24 h) as a risk factor for overt diabetic nephropathy in patients with longstanding insulin dependent diabetes. Design-10 year follow up of patients with normoalbuminuria (albumin excretion rate < 30 mg/24 h), microalbuminuria (30-300 mg/24 h), and macroalbuminuria (> 300 mg/24 h) based on two out of three timed overnight urine samples. Setting-Outpatient clinic of Helsinki University Hospital. Subjects-72 consecutive patients who had had insulin dependent diabetes for over 15 years. Main outcome measures-Urinary albumin excretion rate, mortality, and prevalence of diabetic complications after 10 years. Results-56 patients were re-examined at 10 year follow up, 10 had died, five were lost to follow up, and one was excluded because of non-diabetic kidney disease. At initial screening 22 patients had macroalbuminuria, 18 had microalbuminuria, and 26 had normal albumin excretion. Only five (28%, 95% confidence interval 10% to 54%) of the microalbuminuric patients developed macroalbuminuria during the 10 year follow up and none developed end stage renal failure. Two (8%, 1% to 25%) normoalbuminuric patients developed macroalbuminuria and four (15%, 4% to 35%) became microalbuminuric. Seven (32%, 14% to 55%) of the macroalbuminuric patients developed end stage renal failure and six (27%, 11% to 50%) died of cardiovascular complications. Conclusion-Microalbuminuria is not a good predictor of progression to overt nephropathy in patients with longstanding insulin dependent diabetes.	HELSINKI UNIV HOSP,DEPT MED 4,UNIONINKATU 38,SF-00170 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital								ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; TEPPO AM, 1982, CLIN CHEM, V28, P1359; VIBERTI GC, 1982, LANCET, V1, P1430	6	137	140	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1051	1053		10.1136/bmj.305.6861.1051	http://dx.doi.org/10.1136/bmj.305.6861.1051			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467683	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JW70100016
J	COBB, DK; HIGH, KP; SAWYER, RG; SABLE, CA; ADAMS, RB; LINDLEY, DA; PRUETT, TL; SCHWENZER, KJ; FARR, BM				COBB, DK; HIGH, KP; SAWYER, RG; SABLE, CA; ADAMS, RB; LINDLEY, DA; PRUETT, TL; SCHWENZER, KJ; FARR, BM			A CONTROLLED TRIAL OF SCHEDULED REPLACEMENT OF CENTRAL VENOUS AND PULMONARY-ARTERY CATHETERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TOTAL-PARENTERAL-NUTRITION; 200 CONSECUTIVE PATIENTS; CRITICALLY ILL PATIENTS; TRIPLE-LUMEN; SINGLE-LUMEN; RISK-FACTORS; INFECTION; SEPSIS; COMPLICATIONS; COLONIZATION	Background. The incidence of infection increases with the prolonged use of central vascular catheters, but it is unclear whether changing catheters every three days, as some recommend, will reduce the rate of infection. It is also unclear whether it is safer to change a catheter over a guide wire or insert it at a new site. Methods. We conducted a controlled trial in adult patients in intensive care units who required central venous or pulmonary-artery catheters for more than three days. Patients were assigned randomly to undergo one of four methods of catheter exchange: replacement every three days either by insertion at a new site (group 1) or by exchange over a guide wire (group 2), or replacement when clinically indicated either by insertion at a new site (group 3) or by exchange over a guide wire (group 4). Results. Of the 160 patients, 5 percent had catheter-related bloodstream infections, 16 percent had catheters that became colonized, and 9 percent had major mechanical complications. The incidence rates (per 1000 days of catheter use) of bloodstream infection were 3 in group 1, 6 in group 2, 2 in group 3, and 3 in group 4; the incidence rates of mechanical complications were 14, 4, 8, and 3, respectively. Patients randomly assigned to guide-wire-assisted exchange were more likely to have bloodstream infection after the first three days of catheterization (6 percent vs. 0, P = 0.06). Insertions at new sites were associated with more mechanical complications (5 percent vs. 1 percent, P = 0.005). Conclusions. Routine replacement of central vascular catheters every three days does not prevent infection. Exchanging catheters with the use of a guide wire increases the risk of bloodstream infection, but replacement involving insertion of catheters at new sites increases the risk of mechanical complications.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MED,BOX 473,CHARLOTTESVILLE,VA 22908	University of Virginia				Sawyer, Robert/0000-0002-8155-2661				ARMSTRONG CW, 1983, CHEST, V84, P231, DOI 10.1378/chest.84.2.231; ARMSTRONG CW, 1986, J INFECT DIS, V154, P808, DOI 10.1093/infdis/154.5.808; BJORNSON HS, 1982, SURGERY, V92, P720; BLEWETT JH, 1974, ARCH SURG-CHICAGO, V108, P241; Borja A R, 1972, Ann Thorac Surg, V13, P615; BOZZETTI F, 1983, ANN SURG, V198, P48, DOI 10.1097/00000658-198307000-00009; CLERI DJ, 1980, J INFECT DIS, V141, P781, DOI 10.1093/infdis/141.6.781; CRONIN WA, 1990, INFECT CONT HOSP EP, V11, P301; DAMEN J, 1988, CRIT CARE MED, V16, P221, DOI 10.1097/00003246-198803000-00003; DELEON SP, 1984, CRIT CARE MED, V12, P856, DOI 10.1097/00003246-198410000-00003; EISENHAUER ED, 1982, ANN SURG, V196, P560, DOI 10.1097/00000658-198211000-00008; EYER S, 1990, CRIT CARE MED, V18, P1073, DOI 10.1097/00003246-199010000-00005; FLOWERS RH, 1989, JAMA-J AM MED ASSOC, V261, P878, DOI 10.1001/jama.261.6.878; FRIED DA, 1980, AM J SURG, V139, P454, DOI 10.1016/0002-9610(80)90316-5; GIL RT, 1989, ARCH INTERN MED, V149, P1139, DOI 10.1001/archinte.149.5.1139; GRAEVE AH, 1981, AM J SURG, V142, P752, DOI 10.1016/0002-9610(81)90327-5; GREGORY JA, 1985, AM SURGEON, V51, P534; HILTON E, 1988, AM J MED, V84, P667, DOI 10.1016/0002-9343(88)90102-7; JARVIS WR, 1991, AM J MED S3B, V91; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE RB, 1988, J TRAUMA, V28, P1472, DOI 10.1097/00005373-198810000-00012; LINARES J, 1985, J CLIN MICROBIOL, V21, P357; MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MAKI DG, 1990, 30 INT C ANT AG CHEM, P205; MAKI DG, 1991, 31ST INT C ANT AG CH, P176; MAKI DG, 1989, 29 INT C ANT AG CHEM, P284; MALMVALL BE, 1980, ACTA CHIR SCAND, V146, P155; MANTESE VA, 1987, AM J SURG, V154, P597, DOI 10.1016/0002-9610(87)90224-8; MICHEL L, 1981, JAMA-J AM MED ASSOC, V245, P1032, DOI 10.1001/jama.245.10.1032; MICHEL LA, 1988, INT SURG, V73, P180; MILLER JJ, 1984, CRIT CARE MED, V12, P634, DOI 10.1097/00003246-198408000-00005; MITCHELL SE, 1979, AM J ROENTGENOL, V133, P467, DOI 10.2214/ajr.133.3.467; NEWSOME HH, 1984, JPEN-PARENTER ENTER, V8, P560, DOI 10.1177/0148607184008005560; PADBERG FT, 1981, ANN SURG, V193, P264, DOI 10.1097/00000658-198103000-00002; PEMBERTON LB, 1986, ARCH SURG-CHICAGO, V121, P591; PETTIGREW RA, 1985, BRIT J SURG, V72, P52, DOI 10.1002/bjs.1800720121; RAVINDRAN RS, 1981, ANESTH ANALG, V60, P229; RYAN JA, 1974, NEW ENGL J MED, V290, P757, DOI 10.1056/NEJM197404042901401; SCHWARTZ AJ, 1981, CRIT CARE MED, V9, P347, DOI 10.1097/00003246-198104000-00014; SENAGORE A, 1987, CRIT CARE MED, V15, P35, DOI 10.1097/00003246-198701000-00007; SHOUM S, 1980, ANESTH ANALG, V59, P455; SIMMONS BP, 1982, GUIDELINES PREVENTIO; SINGH S, 1982, CRIT CARE MED, V10, P736, DOI 10.1097/00003246-198211000-00007; SITZMANN JV, 1985, ANN SURG, V202, P766, DOI 10.1097/00000658-198512000-00017; SNYDER RH, 1988, ANN SURG, V208, P651, DOI 10.1097/00000658-198811000-00018; SNYDMAN DR, 1982, AM J MED, V73, P695, DOI 10.1016/0002-9343(82)90412-0; SNYDMAN DR, 1982, LANCET, V2, P1385; STENZEL JP, 1989, CRIT CARE MED, V17, P981; ULLMAN RF, 1990, AM J INFECT CONTROL, V18, P201, DOI 10.1016/0196-6553(90)90185-U; WENZEL RP, 1976, AM J EPIDEMIOL, V103, P251, DOI 10.1093/oxfordjournals.aje.a112223; YEUNG C, 1988, INFECT CONT HOSP EP, V9, P154; 1983, LANCET, V1, P37; 1985, SAS USERS GUIDE STAT; 1981, STATISTICAL METHODS, P38	55	271	280	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1992	327	15					1062	1068		10.1056/NEJM199210083271505	http://dx.doi.org/10.1056/NEJM199210083271505			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR321	1522842				2022-12-28	WOS:A1992JR32100005
J	CARMELLI, D; SWAN, GE; ROBINETTE, D; FABSITZ, R				CARMELLI, D; SWAN, GE; ROBINETTE, D; FABSITZ, R			GENETIC INFLUENCE ON SMOKING - A STUDY OF MALE TWINS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; NICOTINE; PERSPECTIVE; ALCOHOL; STRAINS	Background. The results of twin and family studies suggest that heredity has a small influence on smoking behavior. Methods. We conducted a genetic analysis of several aspects of smoking behavior among subjects in the National Academy of Sciences-National Research Council Twin Registry. The registry includes male twins who were born in the United States between 1917 and 1927 and who were members of the armed forces during World War II. Information on smoking history was available for 4775 pairs of twins, who were first surveyed in 1967 through 1969, when they were 40 to 50 years old, and then resurveyed in 1983 through 1985, when they were 56 to 66. Eighty percent of the subjects in this cohort had smoked at some time in their lives, 60 percent were smokers in 1967 through 1969, and 39 percent were smoking in 1983 through 1985. Similarities between twins in smoking habits at base line and at the second follow-up 16 years later were examined. The comparison of concordance for smoking between monozygotic and dizygotic twins was used to assess the relative contribution of familial and genetic factors. Results. In the 1967-1969 survey the ratio of observed to expected concordance for smoking was higher among the monozygotic twins than among the dizygotic twins for those who had never smoked (overall rate ratio, 1.38; 95 percent confidence interval, 1.25 to 1.54), for former smokers (overall rate ratio, 1.59; 95 percent confidence interval, 1.35 to 1.85), for current cigarette smokers (overall rate ratio, 1.18; 95 percent confidence interval, 1.11 to 1.26), and for current cigar or pipe smokers (overall rate ratio, 1.60; 95 percent confidence interval, 1.22 to 2.06). The data also suggest genetic influences on quitting smoking. Monozygotic twins were more likely than dizygotic twins to be concordant for quitting smoking (overall rate ratio, 1.24; 95 percent confidence interval, 1.06 to 1.45). Conclusions. In this cohort of adult male twins, there were moderate genetic influences on lifetime smoking practices.	NATL ACAD SCI,MED FOLLOW VP AGCY,WASHINGTON,DC 20418; NHLBI,BETHESDA,MD 20892	National Academies of Sciences, Engineering & Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	CARMELLI, D (corresponding author), SRI INT,HLTH SCI PROGRAM,333 RAVENSWOOD AVE,MENLO PK,CA 94025, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL046115] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46115-01] Funding Source: Medline; PHS HHS [4504-9] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAILAR JC, 1964, BIOMETRICS, V20, P639; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; CARMELLI D, 1990, ACTA GENET MED GEMEL, V39, P91, DOI 10.1017/S0001566000005602; CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; CEDERLOF R, 1971, ACTA MED SCAND S, P523; CLARKE PBS, 1987, PSYCHOPHARMACOLOGY, V92, P135; HRUBEC Z, 1978, TWIN RES B, P153; HUGHES JR, 1986, BEHAV THER, V17, P335, DOI 10.1016/S0005-7894(86)80066-1; JABLON S, 1967, AM J HUM GENET, V19, P133; KAPRIO J, 1987, ALCOHOL CLIN EXP RES, V11, P349, DOI 10.1111/j.1530-0277.1987.tb01324.x; KAPRIO J, 1982, INT J EPIDEMIOL, V411, P378; Kaprio J. M., 1981, TWIN RES C, P37; KOZLOWSKI LT, 1991, BRIT J ADDICT, V86, P517; KOZLOWSKI LT, 1976, J ABNORM PSYCHOL, V85, P433, DOI 10.1037/0021-843X.85.4.433; MARKS MJ, 1986, J PHARMACOL EXP THER, V239, P358; MARKS MJ, 1983, J PHARMACOL EXP THER, V226, P291; PEDERSEN N, 1981, TWIN RES C, V3, P53; PEDERSEN NL, 1984, ACTA GENET MED GEMEL, V33, P413, DOI 10.1017/S0001566000005869; SAN GE, 1990, J SUBST ABUSE, V2, P39; SWAN GE, 1988, ADDICT BEHAV, V13, P51, DOI 10.1016/0306-4603(88)90025-1; 1908, DHHS CDC888406 PUBL; 1989, DHHS CDC898411 PUBL	22	270	274	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					829	833		10.1056/NEJM199209173271201	http://dx.doi.org/10.1056/NEJM199209173271201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JN120	1508241				2022-12-28	WOS:A1992JN12000001
J	SCHWARZ, MR				SCHWARZ, MR			LIAISON-COMMITTEE-ON-MEDICAL-EDUCATION - PAST SUCCESSES, FUTURE CHALLENGES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											SCHWARZ, MR (corresponding author), AMER MED ASSOC,MED EDUC & SCI GRP,515 N STATE ST,CHICAGO,IL 60610, USA.								0	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1091	1092						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK681	1501330				2022-12-28	WOS:A1992JK68100004
J	LU, H; ZAWEL, L; FISHER, L; EGLY, JM; REINBERG, D				LU, H; ZAWEL, L; FISHER, L; EGLY, JM; REINBERG, D			HUMAN GENERAL TRANSCRIPTION FACTOR-IIH PHOSPHORYLATES THE C-TERMINAL DOMAIN OF RNA POLYMERASE-II	NATURE			English	Article							PREINITIATION COMPLEX; LARGEST SUBUNIT; REPEAT DOMAIN; INITIATION; PURIFICATION; PROTEIN; PROMOTER; INVITRO; KINASE; FORM	Phosphorylation of the carboxy-terminal domain of the largest subunit of RNA polymerase II is believed to control the transition from transcription initiation to elongation. The general transcription factor IIH (TFIIH) contains a kinase activity capable of phosphorylating this domain. Factors that promote the association of RNA polymerase II with the preinitiation complex stimulate this activity. The transcription factor IIE, which is required for the stable association of TFIIH with the preinitiation complex, affects the processivity of TFIIH kinase.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, 675 HOES LANE, PISCATAWAY, NJ 08854 USA; FAC MED STRASBOURG, CNRS, GENET MOLEC LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE	Rutgers State University New Brunswick; Rutgers State University Medical Center; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Reinberg, Danny/0000-0003-4288-2016				ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHO KWY, 1985, J BIOL CHEM, V260, P5204; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DAHMUS M, IN PRESS TRANSCRIPTI; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FISCHER L, IN PRESS SCIENCE; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; KIM WY, 1989, J BIOL CHEM, V264, P3169; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON MG, 1991, NATURE, V354, P369; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; STONE N, 1992, J BIOL CHEM, V267, P6353; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, IN PRESS PROG NUCLEI; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	35	367	370	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 20	1992	358	6388					641	645		10.1038/358641a0	http://dx.doi.org/10.1038/358641a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1495560				2022-12-28	WOS:A1992JJ88200045
J	CHOI, GH; NUSS, DL				CHOI, GH; NUSS, DL			HYPOVIRULENCE OF CHESTNUT BLIGHT FUNGUS CONFERRED BY AN INFECTIOUS VIRAL CDNA	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; ENDOTHIA-PARASITICA; BIOLOGICAL-CONTROL; CRYPHONECTRIA-PARASITICA; VEGETATIVE COMPATIBILITY; TRANSMISSIBLE HYPOVIRULENCE; GENE-EXPRESSION; VIRUS; AUTOPROTEOLYSIS; STRAINS	Strains of the chestnut blight fungus Cryphonectria parasitica that contain viral double-stranded RNAs often exhibit reduced virulence. Such hypovirulent strains act as biocontrol agents by virtue of their ability to convert virulent strains to hypovirulence after anastomosis. Transformation of virulent C. parasitica strains with a full-length complementary DNA copy of a hypovirulence-associated viral RNA conferred the complete hypovirulence phenotype. Cytoplasmic double-stranded RNA was resurrected from the chromosomally integrated complementary DNA copy and was able to convert compatible virulent strains to hypovirulence. These results establish viral double-stranded RNA as the causal agent of hypovirulence and demonstrate the feasibility of engineering hypovirulent fungal strains.	ROCHE RES CTR,ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	Roche Holding								ANAGNOSTAKIS SL, 1977, EXP MYCOL, V1, P306, DOI 10.1016/S0147-5975(77)80006-6; ANAGNOSTAKIS SL, 1986, PLANT DIS, V70, P536, DOI 10.1094/PD-70-536; ANAGNOSTAKIS SL, 1982, SCIENCE, V215, P466, DOI 10.1126/science.215.4532.466; ANAGNOSTAKIS SL, 1982, GENETICS, V102, P25; ANAGNOSTAKIS SL, 1983, MYCOLOGIA, V75, P777, DOI 10.2307/3792770; ANAGNOSTAKIS SL, 1984, ECOLOGY PHYSL FUNGAL, P499; Buck K.W., 1986, FUNGAL VIROLOGY, P1, DOI [10.1201/9781351072205-1, DOI 10.1201/9781351072205-1]; CHOI GH, 1992, EMBO J, V11, P473, DOI 10.1002/j.1460-2075.1992.tb05077.x; CHOI GH, 1991, VIROLOGY, V183, P747, DOI 10.1016/0042-6822(91)91004-Z; CHOI GH, 1991, P NATL ACAD SCI USA, V88, P1167, DOI 10.1073/pnas.88.4.1167; CULLEN D, 1987, GENE, V57, P21, DOI 10.1016/0378-1119(87)90172-7; DAY PR, 1977, PHYTOPATHOLOGY, V67, P1393, DOI 10.1094/Phyto-67-1393; Elliston JE, 1978, P AM CHESTNUT S, P95; ELSHERBEINI M, 1984, MOL CELL BIOL, V4, P2818, DOI 10.1128/MCB.4.12.2818; Grente J, 1978, P AM CHESTNUT S, P30; GRENTE M. J., 1965, COMPT REND HEBD SEANCES ACAD AGR FRANCE, V51, P1033; Griffin G. J., 1986, Horticultural Reviews, V8, P291, DOI 10.1002/9781118060810.ch8; HILLMAN BI, 1992, J GEN VIROL, V73, P681, DOI 10.1099/0022-1317-73-3-681; HILLMAN BI, 1990, PHYTOPATHOLOGY, V80, P950, DOI 10.1094/Phyto-80-950; HIREMATH S, 1986, NUCLEIC ACIDS RES, V14, P9877; JAYNES RA, 1980, PHYTOPATHOLOGY, V70, P453, DOI 10.1094/Phyto-70-453; KOONIN EV, 1991, P NATL ACAD SCI USA, V88, P10647, DOI 10.1073/pnas.88.23.10647; MACDONALD WL, 1991, PLANT DIS, V75, P656, DOI 10.1094/PD-75-053; Roane MK, 1986, CHESTNUT BLIGHT OTHE, P1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHAPIRA R, 1991, EMBO J, V10, P731, DOI 10.1002/j.1460-2075.1991.tb08004.x; SHAPIRA R, 1991, EMBO J, V10, P741, DOI 10.1002/j.1460-2075.1991.tb08005.x; SHAPIRA R, 1991, J BIOL CHEM, V266, P19419; VANALFEN NK, 1975, SCIENCE, V189, P890, DOI 10.1126/science.189.4206.890; WICKNER RB, 1989, FASEB J, V3, P2257, DOI 10.1096/fasebj.3.11.2550303	30	267	296	3	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 7	1992	257	5071					800	803		10.1126/science.1496400	http://dx.doi.org/10.1126/science.1496400			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496400				2022-12-28	WOS:A1992JG85100036
J	EZEKOWITZ, RAB; MULLIKEN, JB; FOLKMAN, J				EZEKOWITZ, RAB; MULLIKEN, JB; FOLKMAN, J			INTERFERON ALFA-2A THERAPY FOR LIFE-THREATENING HEMANGIOMAS OF INFANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; VASCULAR MALFORMATIONS; KAPOSIS SARCOMA; CHILDREN; MANAGEMENT; CYCLOPHOSPHAMIDE; CLASSIFICATION; EMBOLIZATION; INHIBITION; DISEASE	Background and Methods. Most hemangiomas are small, harmless birthmarks that appear soon after birth, proliferate for 8 to 18 months, and then slowly regress over the next 5 to 8 years, leaving normal or slightly blemished skin. In rare cases, hemangiomas can endanger vital structures, with a mortality of up to 60 percent. About a third of these life-threatening hemangiomas respond to treatment with corticosteroids, but for the others there is no safe and effective treatment. We evaluated the effects of daily subcutaneous injections of interferon alfa-2a (up to 3 million units per square meter of body-surface area) in 20 neonates and infants with life-threatening or vision-threatening hemangiomas that failed to respond to corticosteroid therapy. Results. In 18 of the 20 patients the hemangiomas regressed by 50 percent or more after an average of 7.8 months of treatment (range, 2 to 13). One infant died of refractory proliferation of a lesion and consumptive coagulopathy. The condition of three other patients who had large hemangiomas associated with consumptive coagulopathies that were unresponsive to conventional therapies stabilized after seven days of treatment with interferon alfa-2a alone. Transient side effects of treatment with interferon alfa-2a included fever, neutropenia (one patient), and skin necrosis (one patient). No long-term toxicity has been observed after a mean follow-up of 16 months. Conclusions. Interferon alfa-2a appears to induce the early regression of life-threatening corticosteroid-resistant hemangiomas of infancy.	CHILDRENS HOSP MED CTR,DANA FARBER CANC INST,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DANA FARBER CANC INST,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DANA FARBER CANC INST,DIV PLAST SURG,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DANA FARBER CANC INST,DIV HEMATOL & ONCOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute	EZEKOWITZ, RAB (corresponding author), CHILDRENS HOSP MED CTR,DANA FARBER CANC INST,DEPT PEDIAT,ENDERS BLDG,7TH FL,BOSTON,MA 02115, USA.				NCRR NIH HHS [M01 RR02172] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALRASHID RA, 1971, CANCER, V27, P364, DOI 10.1002/1097-0142(197102)27:2<364::AID-CNCR2820270219>3.0.CO;2-V; Amir J, 1986, Pediatr Dermatol, V3, P331, DOI 10.1111/j.1525-1470.1986.tb00535.x; ARGENTA LC, 1982, PLAST RECONSTR SURG, V70, P739, DOI 10.1097/00006534-198212000-00015; BARTOSHESKY LE, 1978, CLIN PEDIATR, V17, P625, DOI 10.1177/000992287801700807; Berman B, 1978, J Dermatol Surg Oncol, V4, P869; BOWERS RE, 1960, ARCH DERMATOL, V82, P667, DOI 10.1001/archderm.1960.01580050009002; BROUTYBOYE D, 1980, SCIENCE, V208, P516, DOI 10.1126/science.6154315; DETHLEFSEN SM, 1986, ULTRASTRUCT PATHOL, V10, P175, DOI 10.3109/01913128609014593; ELDESSOUKY M, 1988, J PEDIATR SURG, V23, P109, DOI 10.1016/S0022-3468(88)80135-0; ENJOLRAS O, 1990, PEDIATRICS, V85, P491; FINN MC, 1983, J PEDIATR SURG, V18, P894; FOLKMAN J, 1989, NEW ENGL J MED, V320, P1211, DOI 10.1056/NEJM198905043201811; FOLKMAN J, 1984, PEDIATRICS, V74, P850; GLOWACKI J, 1982, PEDIATRICS, V70, P48; GROOPMAN JE, 1984, ANN INTERN MED, V100, P671, DOI 10.7326/0003-4819-100-5-671; HIDANO A, 1972, BRIT J DERMATOL, V87, P138, DOI 10.1111/j.1365-2133.1972.tb16188.x; HOLMDAHL K, 1955, Acta Paediatr, V44, P370, DOI 10.1111/j.1651-2227.1955.tb04151.x; HOPFELKREINER I, 1980, PATHOL RES PRACT, V170, P70; HURVITZ CH, 1986, J PEDIATR-US, V109, P360, DOI 10.1016/S0022-3476(86)80405-X; Kasabach HH, 1940, AM J DIS CHILD, V59, P1063, DOI 10.1001/archpedi.1940.01990160135009; KUSHNER BJ, 1985, PLAST RECONSTR SURG, V76, P517, DOI 10.1097/00006534-198510000-00005; LARCHER VF, 1981, ARCH DIS CHILD, V56, P7, DOI 10.1136/adc.56.1.7; Lister WA, 1938, LANCET, V1, P1429; MARGILETH AM, 1965, J AMER MED ASSOC, V194, P523, DOI 10.1001/jama.194.5.523; MERIGAN TC, 1988, NEW ENGL J MED, V318, P1458, DOI 10.1056/NEJM198806023182208; MULLIKEN JB, 1982, PLAST RECONSTR SURG, V69, P412, DOI 10.1097/00006534-198203000-00002; Mulliken JB, 1988, VASCULAR BIRTHMARKS, P41; NIEDT G W, 1989, Pediatric Pathology, V9, P567; ORCHARD PJ, 1989, LANCET, V2, P565; PEREYRA R, 1982, PEDIATRICS, V70, P254; REAL FX, 1986, J CLIN ONCOL, V4, P544, DOI 10.1200/JCO.1986.4.4.544; RIOS A, 1985, J CLIN ONCOL, V3, P506, DOI 10.1200/JCO.1985.3.4.506; SCHILD SE, 1991, INT J RADIAT ONCOL, V21, P729, DOI 10.1016/0360-3016(91)90693-X; SIDKY YA, 1987, CANCER RES, V47, P5155; SIMPSON JR, 1959, LANCET, V2, P1057; SLOAN GM, 1989, PLAST RECONSTR SURG, V83, P459, DOI 10.1097/00006534-198903000-00009; STANLEY P, 1986, AM J PEDIAT HEMATOL, V8, P308; WHITE CW, 1989, NEW ENGL J MED, V320, P1197, DOI 10.1056/NEJM198905043201807; WHITE CW, 1991, J PEDIATR-US, V118, P59, DOI 10.1016/S0022-3476(05)81844-X	39	789	814	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1992	326	22					1456	1463		10.1056/NEJM199205283262203	http://dx.doi.org/10.1056/NEJM199205283262203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV469	1489383				2022-12-28	WOS:A1992HV46900003
J	BALARAJAN, R; YUEN, P; MACHIN, D				BALARAJAN, R; YUEN, P; MACHIN, D			DEPRIVATION AND GENERAL-PRACTITIONER WORKLOAD	BRITISH MEDICAL JOURNAL			English	Article							ETHNIC-DIFFERENCES; CARE; CONSULTATION; AREAS	Objectives - To examine general practitioner consultations by demographic and socioeconomic variables and to derive a method of measuring the impact of relative deprivation on general Practitioner workload. Design - The study was based on general practitioner consultations reported in the general household surveys of 1983-7, covering a sample of 129 987 individuals in Great Britain. Odds ratios for general practitioner consultations were obtained for selected variables among children (0-15 years), men (16-64), women (16-64), and elderly people (greater-than-or-equal-to 65). These were then used to derive deprivation indices specific to electoral wards for use in general practice. Setting - Great Britain, with particular findings illustrated by English electoral wards and the conurbations of London, Manchester, Merseyside, and the West Midlands. Results - Council tenure increased the likelihood of consultation significantly in all four groups. Odds ratios were raised in children, men and women with no access to a car. Birth in the New Commonwealth or Pakistan yielded high odds ratios in men, women, and elderly people but not in children. Marginally increased consultation rates were evident in the manual socioeconomic groups in women, elderly People, and children with a single parent mother. The deprivation indices for general practice derived using these odds ratios varied substantially among English electoral wards with, for example, anticipated general practitioner consultations in the electoral ward of Hulme, Manchester, being 24% higher than the average ward in England as a result of local attributes, and consultations in the Cheam South ward of Sutton, London, 11% lower than average. Conclusion - This deprivation index for general Practice overcomes several shortcomings expressed about the underprivileged area score, which has been adopted in the 1990 contract as a basis for allocating deprivation supplements to general practitioners. The proposed index can be applied nation wide.			BALARAJAN, R (corresponding author), UNIV SURREY,INST PUBL HLTH,GUILDFORD GU2 5XH,SURREY,ENGLAND.							Altman DG, 1991, PRACTICAL STATISTICS; BALARAJAN R, 1989, BRIT MED J, V299, P958, DOI 10.1136/bmj.299.6705.958; BALARAJAN R, 1987, J EPIDEMIOL COMMUN H, V41, P196, DOI 10.1136/jech.41.3.196; BALARAJAN R, 1987, SOCIOECONOMIC DIFFER; BALARAJAN R, 1987, 2ND U SURR EP PUBL H; BOSANQUET N, 1989, FAMILY DOCTORS EC IN; CARNEY T, 1989, BMJ-BRIT MED J, V299, P753, DOI 10.1136/bmj.299.6702.753; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; CARSTAIRS V, 1989, BRIT MED J, V299, P1462, DOI 10.1136/bmj.299.6713.1462-a; CARSTAIRS V, 1991, BRIT MED J, V302, P661, DOI 10.1136/bmj.302.6777.661-a; GILLAM SJ, 1989, BRIT MED J, V299, P953, DOI 10.1136/bmj.299.6705.953; HUTCHINSON A, 1989, BRIT MED J, V299, P1142, DOI 10.1136/bmj.299.6708.1142; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; LIVINGSTONE AE, 1989, BRIT MED J, V299, P368, DOI 10.1136/bmj.299.6695.368; PRINGLE M, 1989, BRIT MED J, V299, P470, DOI 10.1136/bmj.299.6697.470; SENIOR ML, 1991, BRIT MED J, V302, P661, DOI 10.1136/bmj.302.6777.661-b; TALBOT RJ, 1991, BRIT MED J, V302, P383, DOI 10.1136/bmj.302.6773.383; Townsend PP., 1988, HLTH DEPRIVATION INE; YUEN P, 1989, BRIT MED J, V298, P1212, DOI 10.1136/bmj.298.6682.1212; 1989, GENERAL PRACTICE NAT; 1986, ROYAL COLLEGE GE MB5, V1; 1988, LANCET, V2, P260; 1989, HLTH CHILDREN SINGLE	23	38	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 29	1992	304	6826					529	534		10.1136/bmj.304.6826.529	http://dx.doi.org/10.1136/bmj.304.6826.529			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG599	1510751	Bronze, Green Published			2022-12-28	WOS:A1992HG59900016
J	KANE, DA; WARGA, RM; KIMMEL, CB				KANE, DA; WARGA, RM; KIMMEL, CB			MITOTIC DOMAINS IN THE EARLY EMBRYO OF THE ZEBRAFISH	NATURE			English	Article							CELL LINEAGE; ENVELOPING LAYER; FUNDULUS; REARRANGEMENT; GASTRULATION; COMMITMENT	AT the midblastula transition in the zebrafish, three, and only three, spatially separate mitotic domains arise with distinctive cycle lengths and rhythms. As in Drosophila1 and at about the equivalent stage, the mitotic domains reflect the fate map, but they do so only very crudely: two are extraembryonic and the third forms the entire embryo. The domains appear not to subdivide during gastrulation, when the germ layers form and when cells probably commit to their eventual fates. The domains may signal specification of morphogenesis rather than cell fate, because, shortly after they appear, each assumes a different role during epiboly, the first morphogenetic movement of the embryo. During meroblastic cleavage, and continuing in the early blastula, zebrafish blastomeres divide rapidly and synchronously. At the time of the tenth cleavage, the beginning of the midblastula transition, the cell cycle lengthens, and, as in Xenopus2 and Drosophila3, cycle length comes under nucleocytoplasmic control (D.A.K. and C.B.K., manuscript in preparation). This nucleocytoplasmic control seems to be maintained during cycle lengthening in the next 2 or 3 cycles, comprising a midblastula transition period. We now show that functionally distinct subsets of cells that arise during this period have reproducibly different mitotic cycle lengths.	UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403	University of Oregon	KANE, DA (corresponding author), MAX PLANCK INST ENTWICKLINGSBIOL,SPEMANNSTR 35-II,W-7400 TUBINGEN,GERMANY.							ARORA K, 1992, DEVELOPMENT, V144, P1003; BETCHAKU T, 1978, J EXP ZOOL, V206, P381, DOI 10.1002/jez.1402060310; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FOE VE, 1989, DEVELOPMENT, V107, P1; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; HO RK, IN PRESS DEVELOPME S; KELLER RE, 1987, DEV BIOL, V120, P12, DOI 10.1016/0012-1606(87)90099-6; KELLER RE, 1980, J EMBRYOL EXP MORPH, V60, P201; KIMMEL CB, 1985, DEV BIOL, V108, P86, DOI 10.1016/0012-1606(85)90011-9; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1987, DEV BIOL, V124, P269, DOI 10.1016/0012-1606(87)90478-7; KIMMEL CB, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P203; KIMMEL CB, 1986, SCIENCE, V231, P356; MYERS PZ, 1991, COMPUT METH PROG BIO, V34, P27, DOI 10.1016/0169-2607(91)90079-9; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; TECHNAU GM, 1987, DEVELOPMENT, V100, P1; TRINKAUS JP, 1951, J EXP ZOOL, V118, P269, DOI 10.1002/jez.1401180204; TRINKAUS JP, 1984, AM ZOOL, V24, P673; TRINKAUS JP, IN PRESS DEVELOPME S; WARGA RM, 1990, DEVELOPMENT, V108, P569; Wilson HV., 1889, B S F C, V89, P209	22	102	106	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					735	737		10.1038/360735a0	http://dx.doi.org/10.1038/360735a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465143				2022-12-28	WOS:A1992KE47200032
J	DANIEL, MD; KIRCHHOFF, F; CZAJAK, SC; SEHGAL, PK; DESROSIERS, RC				DANIEL, MD; KIRCHHOFF, F; CZAJAK, SC; SEHGAL, PK; DESROSIERS, RC			PROTECTIVE EFFECTS OF A LIVE ATTENUATED SIV VACCINE WITH A DELETION IN THE NEF GENE	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; CONFERS PROTECTION; RHESUS-MONKEYS; CHIMPANZEES; MACAQUES; INFECTION; IMMUNIZATION; CHALLENGE	Vaccine protection against the human immunodeficiency virus (HIV) and the related simian immunodeficiency virus (SIV) in animal models is proving to be a difficult task. The difficulty is due in large part to the persistent, unrelenting nature of HIV and SIV infection once infection is initiated. SIV with a constructed deletion in the auxiliary gene nef replicates poorly in rhesus monkeys and appears to be nonpathogenic in this normally susceptible host. Rhesus monkeys vaccinated with live SIV deleted in nef were completely protected against challenge by intravenous inoculation of live, pathogenic SIV. Deletion of nef or of multiple genetic elements from HIV may provide the means for creating a safe, effective, live attenuated vaccine to protect against acquired immunodeficiency syndrome (AIDS).	HARVARD UNIV,NEW ENGLAND REG PRIMATE RES CTR,SCH MED,1 PINE HILL DR,BOX 9102,SOUTHBOROUGH,MA 01772	Harvard University			Kirchhoff, Frank/O-8367-2018	Kirchhoff, Frank/0000-0002-7052-2360	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025328, R37AI025328] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26463, AI26507, AI25328] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHUR LO, 1989, J VIROL, V63, P5046, DOI 10.1128/JVI.63.12.5046-5053.1989; Bruck C., COMMUNICATION; BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1293; Cranage M P, 1992, Nature, V355, P685, DOI 10.1038/355685a0; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DANIEL MD, UNPUB; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; EMINI EA, 1990, AIDS RES HUM RETROV, V6, P1247, DOI 10.1089/aid.1990.6.1247; GIBBS JS, UNPUB; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GIRARD M P, 1990, AIDS (London), V4, pS143; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; HU SMK, COMMUNICATION; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; LEGRAND R, 1992, NATURE, V355, P684; LEWIS MA, UNPUB; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P5407, DOI 10.1093/nar/17.13.5407; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; YILMA T, COMMUNICATION	26	964	998	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1938	1941		10.1126/science.1470917	http://dx.doi.org/10.1126/science.1470917			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470917				2022-12-28	WOS:A1992KD08800032
J	READ, SM; JONES, NMB; WILLIAMS, BT				READ, SM; JONES, NMB; WILLIAMS, BT			NURSE PRACTITIONERS IN ACCIDENT AND EMERGENCY DEPARTMENTS - WHAT DO THEY DO	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the distribution and scope of nurse practitioner schemes in accident and emergency departments in England and Wales; to describe the caseloads of doctors and nurse practitioners on two representative days; and to estimate the number of patients managed by nurse practitioners in the year to 31 March 1991. Design-A postal survey of accident and emergency departments and a content analysis of case notes of new patients attending a representative sample of accident and emergency departments on two days. Setting-All accident and emergency departments in England and Wales. Participants-Survey: 560 nurses in charge of accident and emergency departments. Census: case notes of 5814 patients in 37 accident and emergency departments. Main outcome measures-Survey: number of accident and emergency departments with nurse practitioner schemes. Census: demographic and clinical characteristics of new patients attending and whether nurse practitioner or doctor made diagnoses and ordered investigations, treatments, referrals, discharges. Results-513 replies (92%) from 465 surveyed functioning accident and emergency departments and 48 departments recently closed. 27 (6%) departments used designated nurse practitioners and 159 (34%) "unofficial" nurse practitioners. Only 530 (9%) of the 5814 patients in the census were managed entirely or mainly by nurse practitioners, with higher proportions in ophthalmic departments (nearly 30%) and minor casualty departments (over 40%) than in major departments (3%). Most patients managed by nurse practitioners (86%) had minor trauma. In the year ending 31 March 1991 an estimated 390 000 (95% confidence interval 260 000 to 520 000) patients out of a total of 12.5 million (3.1%, 2.1% to 4.1%) were clinically managed by a nurse practitioner. Conclusions-Designated nurse practitioner schemes are rare. The volume and range of nurse practitioner work in major general accident and emergency departments is small compared with those in specialised and minor accident and emergency departments.			READ, SM (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PUBL HLTH MED,MED CARE RES UNIT,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							Burgess K, 1992, Prof Nurse, V7, P301; BUTCHER B, 1990, SAMPLING ERRORS MANU; Cliff K S, 1986, Hosp Health Serv Rev, V82, P74; DAVISON AG, 1983, J ROY SOC MED, V76, P37, DOI 10.1177/014107688307600109; Dean A. G., 1990, EPI INFO VERSION 5 W; HAYDEN ML, 1982, NURS RES, V31, P294; JAMES MR, 1989, ARCH EMERG MED, V6, P241; JONES NP, 1986, BRIT MED J, V292, P188, DOI 10.1136/bmj.292.6514.188; McGaughey P, 1991, Nurs Times, V87, P51; MILNER PC, 1988, J EPIDEMIOL COMMUN H, V42, P274, DOI 10.1136/jech.42.3.274; Morris F, 1989, Health Trends, V21, P124; Potter T, 1990, Prof Nurse, V5, P586; Powers M J, 1984, Nurse Pract, V9, P44; SHAW C, 1988, GOOD PRACTICES SMALL; Waeckerle J F, 1977, J Emerg Nurs, V3, P21; Warren R, 1989, Health Serv J, V99, P232; WILDHALM SA, 1982, J EMERG NURS, V8, P67; Williams E, 1989, Nurs Times, V85, P60; YATES D, 1987, BRIT J ACCIDENT EMER, V2, P10; 1990, EMERGENCY NURSE PRAC; 1992, SCOPE PROFESSIONAL P; 1992, PLCNO92J DEP HLTH; 1992, CODE PROFESSIONAL CO; 1990, ACCIDENT EMERGENCY D; 1992, NHS ACCIDENT EMERGEN	25	29	29	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1466	1470		10.1136/bmj.305.6867.1466	http://dx.doi.org/10.1136/bmj.305.6867.1466			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493392	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KC91800021
J	KASSAVETIS, GA; JOAZEIRO, CAP; PISANO, M; GEIDUSCHEK, EP; COLBERT, T; HAHN, S; BLANCO, JA				KASSAVETIS, GA; JOAZEIRO, CAP; PISANO, M; GEIDUSCHEK, EP; COLBERT, T; HAHN, S; BLANCO, JA			THE ROLE OF THE TATA-BINDING PROTEIN IN THE ASSEMBLY AND FUNCTION OF THE MULTISUBUNIT YEAST RNA POLYMERASE-III TRANSCRIPTION FACTOR, TFIIIB	CELL			English	Article							HUMAN U6 GENE; SACCHAROMYCES-CEREVISIAE; DNA; INVITRO; PROMOTER; SUBUNIT; BACTERIOPHAGE-T4; COMPONENTS; ACTIVATION; COMPLEXES	The Saccharomyces cerevisiae RNA polymerase III transcription factor (TF)IIIB has been assembled from three components. An assembly pathway of these polypeptides, which specifies their interactions, has been determined. The TATA-binding protein, TBP, and the TFIIB-related BRF1 gene product BRF, together reconstitute the transcription factor activity and TFIIIC-dependent DNA-binding activity of the B' component of TFIIIB. BRF alone weakly binds to a TFIIIC-tRNA gene complex; TBP greatly stabilizes this interaction. B" transcription factor actitivity is recovered with its previously identified 90 kd polypeptide from SDS-polyacrylamide gels. Incorporation of the 90 kd B" protein into the transcription complex requires TBP. The heparin-resistant TFIIIB-DNA complex retains all three of its constituent proteins, TBP, BRF, and B".	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	University of California System; University of California San Diego; Fred Hutchinson Cancer Center	KASSAVETIS, GA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Pisano, Marina/C-3978-2015	Pisano, Marina/0000-0002-0649-1010	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07312] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BRAUN BR, 1992, IN PRESS J BIOL CHEM; BRAUN BR, 1992, IN PRESS J MOL BIOL; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; COLBERT T, 1992, IN PRESS GENES DEV; CORMACK BP, 1992, CELL, V69, P665; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, IN PRESS TRANSCRIPTI; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KASSAVETIS GA, 1984, P NATL ACAD SCI-BIOL, V81, P5101, DOI 10.1073/pnas.81.16.5101; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; OMAI L, 1992, CELL, V68, P965; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SIMMEN KA, 1992, J MOL BIOL, V223, P873, DOI 10.1016/0022-2836(92)90249-J; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WALDSCHMIDT R, 1992, J BIOL CHEM, V267, P16359; WEIS L, 1992, IN PRESS FASEB J; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	41	218	218	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1055	1064		10.1016/0092-8674(92)90399-W	http://dx.doi.org/10.1016/0092-8674(92)90399-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458536				2022-12-28	WOS:A1992KB99000016
J	KIELECZAWA, J; DUNN, JJ; STUDIER, FW				KIELECZAWA, J; DUNN, JJ; STUDIER, FW			DNA SEQUENCING BY PRIMER WALKING WITH STRINGS OF CONTIGUOUS HEXAMERS	SCIENCE			English	Article							SINGLE-STRANDED-DNA; BACTERIOPHAGE-T7 DNA; ESCHERICHIA-COLI; BINDING-PROTEIN; HYBRIDIZATION; POLYMERASE	When template DNA is saturated with a single-stranded DNA binding protein (SSB), strings of three or four contiguous hexanucleotides (hexamers) can cooperate through base-stacking interactions to prime DNA synthesis specifically from the 3' end of the string. Under the same conditions, priming by individual hexamers is suppressed. Strings of three or four hexamers representing more than 200 of the 4096 possible hexamers primed easily readable sequence ladders at more than 75 different sites in single-stranded or denatured double-stranded templates 6.4 kilobases to 40 kilobase pairs long, with a success rate of 60 to 90 percent. A synthesis of 1 micromole of hexamer supplies enough material for thousands of primings, so multiple libraries of all 4096 hexamers could be distributed at a reasonable cost. Such libraries would allow rapid and economical sequencing. Automating this strategy could increase the speed and efficiency of large-scale DNA sequencing by at least an order of magnitude.			KIELECZAWA, J (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.							BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; HUNKAPILLER T, 1991, SCIENCE, V254, P59, DOI 10.1126/science.1925562; Khrapko K R, 1991, DNA Seq, V1, P375, DOI 10.3109/10425179109020793; KHRAPKO KR, 1989, FEBS LETT, V256, P118, DOI 10.1016/0014-5793(89)81730-2; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; QUARTIN RS, 1989, BIOCHEMISTRY-US, V28, P1040, DOI 10.1021/bi00429a018; SHERMAN LA, 1970, J VIROL, V6, P841, DOI 10.1128/JVI.6.6.841-846.1970; STUDIER FW, 1989, P NATL ACAD SCI USA, V86, P6917, DOI 10.1073/pnas.86.18.6917; SZYBALSKI W, 1990, GENE, V90, P177, DOI 10.1016/0378-1119(90)90458-4; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447; VANWEZENBEEK PMGF, 1980, GENE, V11, P129, DOI 10.1016/0378-1119(80)90093-1; WBRIGHT R, 1992, GENE, V114, P81; WEISS B, 1971, METHODS ENZYMOLOGY D, V21, P319; 1990, UNDERSTANDING OUR GE	19	104	131	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1787	1791		10.1126/science.1465615	http://dx.doi.org/10.1126/science.1465615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465615				2022-12-28	WOS:A1992KB96400037
J	EMERY, P; SALMON, M; BRADLEY, H; WORDSWORTH, P; TUNN, E; BACON, PA; WARING, R				EMERY, P; SALMON, M; BRADLEY, H; WORDSWORTH, P; TUNN, E; BACON, PA; WARING, R			GENETICALLY-DETERMINED FACTORS AS PREDICTORS OF RADIOLOGICAL CHANGE IN PATIENTS WITH EARLY SYMMETRICAL ARTHRITIS	BRITISH MEDICAL JOURNAL			English	Article							RHEUMATOID-ARTHRITIS; SUSCEPTIBILITY; SULFOXIDATION	Objective-To determine whether genetic factors associated with established rheumatoid arthritis could, in combination with rheumatoid factor, predict the development of radiological erosions in patients with early symmetrical (rheumatoid-like) arthritis. Design-Prospective study. Setting-Teaching hospital, early arthritis clinic. Subjects-Forty nine patients with symmetrical polyarthritis attending the early arthritis clinic. Main outcome measures-Conserved sequence of DRbeta third allelic hypervariable region, sulphoxidation capacity, rheumatoid factor, and development of radiologically determined bone erosions. Results-None of the 49 patients had radiological erosions at presentation but 25 developed these by four years. Patients with the conserved class II major histocompatibility complex (third allelic hypervariable of DRbeta1) genes associated with rheumatoid arthritis had a relative risk for the development of erosions of 1.9 (95% confidence interval 0.8 to 4.5). For poor sulphoxidation the risk was 2.5 (1.1 to 5.6) and for the presence of rheumatoid factor 1.8 (0.9 to 3.7). Of the 33 patients who had two or three of these risk factors, 24 developed erosions, with a relative risk of 11.6 (1.7 to 78.5) compared with only one of the 16 individuals with no or one risk factor. Conclusions-This preliminary study shows that by using these stable markers it is possible to make clinically useful predictions of outcome in patients with early symmetrical inflammatory arthritis.	UNIV BIRMINGHAM,DEPT BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	University of Birmingham; University of Oxford	EMERY, P (corresponding author), UNIV BIRMINGHAM,DEPT RHEUMATOL,POB 363,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		emery, paul/B-3560-2013	Waring, Rosemary/0000-0001-6617-5856				EMERY P, 1992, ANN RHEUM DIS, V51, P318, DOI 10.1136/ard.51.3.318; EMERY P, 1984, J RHEUMATOL, V11, P626; GARDINER M, 1989, STATISTICS CONFIDENC; GREGERSEN PK, 1986, P NATL ACAD SCI USA, V83, P2642, DOI 10.1073/pnas.83.8.2642; Harris ED, 1989, TXB RHEUMATOLOGY; MITCHELL SC, 1984, BRIT J CLIN PHARMACO, V18, P507, DOI 10.1111/j.1365-2125.1984.tb02498.x; VANDERHEIJDE DMF, 1988, SEMIN ARTHRITIS RHEU, V17, P284; WILKENS RF, 1991, ARTHRITIS RHEUM, V34, P43; WINCHESTER RJ, 1988, SPRINGER SEMIN IMMUN, V10, P119, DOI 10.1007/BF01857219; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049; WORDSWORTH BP, 1991, BRIT J RHEUMATOL, V30, P178; YOUNG A, 1991, ARTHRITIS RHEUM, V34, P93; YOUNG A, 1991, ARTHRITIS RHEUM, V34, P48	13	79	80	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1387	1389		10.1136/bmj.305.6866.1387	http://dx.doi.org/10.1136/bmj.305.6866.1387			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486300	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992KB85600018
J	SMITH, R				SMITH, R			USING A MOCK TRIAL TO MAKE A DIFFICULT CLINICAL DECISION	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Many clinical decisions have to be taken with inadequate scientific information. Reaching a consensus among experts has been tried as one response to this problem. Another, described here, is to use legal process to dissect a difficult question. In this case a mock trial-using barristers, expert witnesses, and a jury-was conducted on whether bone marrow transplantation should be offered to all children with symptomatic sickle cell disease. Transplantation seems to offer about a 90% cure rate for a condition that may kill 15% of children before they reach 20. But transplantation carries a 10% risk of death or severe disability, and doctors cannot predict which children will suffer severly from their sickle cell disease and which will suffer little or nothing. The jury eventually reached a majority decision that transplantation should not be offered now to all symptomatic children.										CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; DAVIES SC, 1992, IN PRESS SICKLE  JUN; SMITH R, 1992, J MED ETHICS, V18, P117, DOI 10.1136/jme.18.3.117; SMITH R, 1991, BRIT MED J, V303, P798, DOI 10.1136/bmj.303.6806.798; VERMYLEN C, 1991, ARCH DIS CHILD, V66, P1195, DOI 10.1136/adc.66.10.1195; VERMYLEN C, 1988, LANCET, V1, P1427	6	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 21	1992	305	6864					1284	1287		10.1136/bmj.305.6864.1284	http://dx.doi.org/10.1136/bmj.305.6864.1284			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477577	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JZ52100033
J	CHATELLIER, G; BATTAGLIA, C; PAGNY, JY; PLOUIN, PF; MENARD, J				CHATELLIER, G; BATTAGLIA, C; PAGNY, JY; PLOUIN, PF; MENARD, J			DECISION TO TREAT MILD HYPERTENSION AFTER ASSESSMENT BY AMBULATORY MONITORING AND WORLD-HEALTH-ORGANIZATION RECOMMENDATIONS	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE	Objective-To determine if one ambulatory blood pressure recording over 12 hours could detect those patients with mild hypertension who needed treatment according to the World Health Organisation-International Society of Hypertension (ISH) guidelines based on the casual measurement of diastolic blood pressure at successive visits to a clinic. Design-Comparison of decision to treat based on one ambulatory measurement over 12 hours and standard blood pressure measurements over six months in the same patients. Setting-Outpatient hypertension clinic. Subjects-130 men and women with diastolic blood pressure of 90-104 mm Hg at second visit to clinic. Main outcome measures-Blood pressure measurements over six months. Measurement from ambulatory monitoring. Decision to treat. Results-Of the 130 patients included, 108 were followed up over the six months. Treatment was started according to WHO-ISH criteria in 44 (13 at the third visit, 13 at the fourth, 18 at the fifth). According to the selected criteria for ambulatory blood pressure monitoring 41 patients would have been treated. Both methods agreed that the same 27 patients required treatment and the same 50 did not, but they did not agree in 31 patients. When calculated at the optimal diastolic blood pressure threshold determined by a receiver operating characteristic curve, the sensitivity, specificity, and positive predictive value of ambulatory blood pressure monitoring were 71% (95% confidence interval 57% to 84%), 82% (72% to 92%), and 66% (51% to 81%), respectively. Conclusion-If the WHO-ISH criteria are accepted as the standard for deciding to treat patients with mild hypertension the predictive value of one ambulatory blood pressure recording over 12 hours is too low to detect with confidence those patients who need treatment when managed according to these criteria.	HOP BROUSSAIS,DEPT HYPERTENS,F-75674 PARIS 14,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	CHATELLIER, G (corresponding author), HOP BROUSSAIS,SERV INFORMAT MED,F-75674 PARIS 14,FRANCE.							[Anonymous], 1982, Lancet, V1, P185; ARMITAGE P, 1966, CLIN SCI, V30, P337; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BRUCE NG, 1988, J HYPERTENS, V6, P375; BURKE MJ, 1982, BRIT MED J, V285, P469, DOI 10.1136/bmj.285.6340.469; CASADEI R, 1988, J HYPERTENS, V6, P797; CLEMENT DL, 1989, J HYPERTENS, V7, pS49; CONWAY J, 1989, J HYPERTENS, V7, pS29; Fleiss JL, 1981, STAT METHODS RATES P; MANCIA G, 1990, HYPERTENSION, V16, P624, DOI 10.1161/01.HYP.16.6.624; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; PAGNY JY, 1987, PRESSE MED, V16, P1621; PAGNY JY, 1987, CARDIOVASCULAR REV R, V7, P31; PICKERING TG, 1982, JAMA-J AM MED ASSOC, V247, P992, DOI 10.1001/jama.247.7.992; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V114, P925; SMITH TDW, 1990, BMJ-BRIT MED J, V300, P74, DOI 10.1136/bmj.300.6717.74; STAESSEN JA, 1991, AM J CARDIOL, V67, P723, DOI 10.1016/0002-9149(91)90529-T; WAEBER B, 1984, J CHRON DIS, V37, P55, DOI 10.1016/0021-9681(84)90125-5; WATSON RDS, 1987, J HYPERTENS, V5, P207, DOI 10.1097/00004872-198704000-00012; WEBER MA, 1987, J HYPERTENS       S5, V4, pS325; 1985, BMJ, V291, P97; 1989, J HYPERTENS, V7, P689	22	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1062	1066		10.1136/bmj.305.6861.1062	http://dx.doi.org/10.1136/bmj.305.6861.1062			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467686	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JW70100019
J	ASCHERIO, A; CHASE, R; COTE, T; DEHAES, G; HOSKINS, E; LAAOUEJ, J; PASSEY, M; QADERI, S; SHUQAIDEF, S; SMITH, MC; ZAIDI, S				ASCHERIO, A; CHASE, R; COTE, T; DEHAES, G; HOSKINS, E; LAAOUEJ, J; PASSEY, M; QADERI, S; SHUQAIDEF, S; SMITH, MC; ZAIDI, S			EFFECT OF THE GULF-WAR ON INFANT AND CHILD-MORTALITY IN IRAQ	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Increased malnutrition and morbidity among Iraqi children after the onset of the Persian Gulf war have been reported by several fact-finding missions. The magnitude of the effect of the war and the economic embargo on child mortality remains uncertain, however. Methods. We conducted a survey of 271 clusters of 25 to 30 households each, chosen as a representative sample of the Iraqi population. The households were selected and the interviews conducted by an international team of public health professionals independent of Iraqi authorities. In each household all women 15 to 49 years of age were interviewed, and the dates of birth and death of all children born on or after January 1, 1985, were recorded. Results. The study population included 16,076 children, 768 of whom died during the period surveyed (January 1, 1985, to August 31, 1991). The age-adjusted relative mortality for the period after the war began, as compared with the period before the war, was 3.2 (95 percent confidence interval, 2.8 to 3.7). No material change in the relative risk was observed after adjustment for region of residence, maternal education, and maternal age. The increase in mortality after the onset of the war was higher among children 1 to less than 12 months old (relative risk, 4.1; 95 percent confidence interval, 3.3 to 5.2) and among those 12 to less than 60 months old (relative risk, 3.8; 95 percent confidence interval, 2.6 to 5.4) than among those less than 1 month old (relative risk, 1.8; 95 percent confidence interval, 1.4 to 2.4). The association between the war and mortality was stronger in northern Iraq (relative risk, 5.3) and southern Iraq (relative risk, 3.4) than in the central areas (relative risk, 1.9) or in Baghdad (relative risk, 1.7). Conclusions. These results provide strong evidence that the Gulf war and trade sanctions caused a threefold increase in mortality among Iraqi children under five years of age. We estimate that an excess of more than 46,900 children died between January and August 1991.	HARVARD UNIV,SCH PUBL HLTH,DEPT POPULAT SCI & INT HLTH,BOSTON,MA 02115; MED AID THIRD WORLD,BRUSSELS,BELGIUM; JORDAN UNIV SCI & TECHNOL,IRBID,JORDAN; NIH,BETHESDA,MD 20892; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; JOHNS HOPKINS UNIV,BALTIMORE,MD 21218; UNIV OXFORD,OXFORD,ENGLAND; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA; PAPUA NEW GUINEA INST MED RES,GOROKA,PAPUA N GUINEA	Harvard University; Harvard T.H. Chan School of Public Health; Jordan University of Science & Technology; National Institutes of Health (NIH) - USA; Harvard University; Harvard T.H. Chan School of Public Health; Johns Hopkins University; University of Oxford; McMaster University; PNG Institute Of Medical Research			Passey, Megan/AAC-7062-2019	Passey, Megan/0000-0001-5766-0235				ADAMCHAK DJ, 1980, POP REV, V24, P37; BAKER RJ, 1978, GLIM SYSTEM; BRESLOW NE, 1987, IARC SCI PUBL, V32, P160; DAVID PH, 1990, MEASURING CHILDHOOD, P1; DREZE J, 1991, HUNGER POVERY IRAQ, V32, P1; GARFIELD RM, 1991, JAMA-J AM MED ASSOC, V266, P688, DOI 10.1001/jama.266.5.688; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; NEWELL C, 1988, METHODS MODELS DEMOG, P71; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P171; SATO N, 1991, LANCET, V338, P1202, DOI 10.1016/0140-6736(91)92062-7; Stein Z., 1975, FAMINE HUM DEV DUTCH; 1990, NATIONAL CHILD HLTH; 1990, EVALUATION SERIES UN, V9; 1991, NEW ENGL J MED, V325, P977; 1991, MMWR MORB MORTAL WKL, V40, P443; 1983, MANUAL X INDIRECT TE; 1988, CHILDREN FRONTLINE; 1991, MED SANS FRONTIERES, P1; 1992, DEMOGRAPHIC YB 1990	19	91	91	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					931	936		10.1056/NEJM199209243271306	http://dx.doi.org/10.1056/NEJM199209243271306			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JP014	1513350				2022-12-28	WOS:A1992JP01400006
J	QUAGLIARELLO, V; SCHELD, WM				QUAGLIARELLO, V; SCHELD, WM			MECHANISMS OF DISEASE - BACTERIAL-MENINGITIS - PATHOGENESIS, PATHOPHYSIOLOGY, AND PROGRESS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TUMOR-NECROSIS-FACTOR; BLOOD-BRAIN-BARRIER; INFLUENZAE TYPE-B; LEUKOCYTE ADHESION MOLECULE-1; EXPERIMENTAL PNEUMOCOCCAL MENINGITIS; MENINGEAL INFLAMMATION; CEREBROSPINAL-FLUID; FACTOR-ALPHA; DEXAMETHASONE THERAPY; MONOCLONAL-ANTIBODIES		UNIV VIRGINIA, MED CTR, SCH MED, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22901 USA; UNIV VIRGINIA, MED CTR, SCH MED, DEPT NEUROSURG, CHARLOTTESVILLE, VA 22901 USA	University of Virginia; University of Virginia	QUAGLIARELLO, V (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, INFECT DIS SECT, 800 LCI, NEW HAVEN, CT 06510 USA.							BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOHR V, 1984, ARCH NEUROL-CHICAGO, V41, P1045, DOI 10.1001/archneur.1984.04050210043012; BROWN EJ, 1983, J IMMUNOL, V131, P409; BURROUGHS M, 1991, 31ST INT C ANT AG CH; CONHEIM J, 1889, LECTURES GENERAL PAT, V1; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DODGE PR, 1984, NEW ENGL J MED, V311, P869, DOI 10.1056/NEJM198410043111401; FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GIRGIS NI, 1989, PEDIATR INFECT DIS J, V8, P848, DOI 10.1097/00006454-198912000-00004; HUJBER AR, 1991, SCIENCE, V254, P99; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JOINER KA, 1988, ANNU REV MICROBIOL, V42, P201, DOI 10.1146/annurev.mi.42.100188.001221; KENNEDY WA, 1991, AM J DIS CHILD, V145, P1374, DOI 10.1001/archpedi.1991.02160120042016; KORHONEN TK, 1985, INFECT IMMUN, V48, P486, DOI 10.1128/IAI.48.2.486-491.1985; LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; LEIST TP, 1988, J EXP MED, V167, P1743, DOI 10.1084/jem.167.5.1743; LEVINE RP, 1983, ANN NY ACAD SCI, V421, P235, DOI 10.1111/j.1749-6632.1983.tb18112.x; MCCRACKEN GH, 1989, AM J DIS CHILD, V143, P287, DOI 10.1001/archpedi.1989.02150150041013; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; MUSTAFA MM, 1989, J PEDIATR-US, V115, P208, DOI 10.1016/S0022-3476(89)80067-8; MUSTAFA MM, 1989, J INFECT DIS, V160, P818, DOI 10.1093/infdis/160.5.818; MUSTAFA MM, 1989, J INFECT DIS, V159, P917, DOI 10.1093/infdis/159.5.917; ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201; PARKKINEN J, 1988, J CLIN INVEST, V81, P860, DOI 10.1172/JCI113395; PFISTER HW, 1990, J CEREBR BLOOD F MET, V10, P914, DOI 10.1038/jcbfm.1990.148; PLAUT AG, 1983, ANNU REV MICROBIOL, V37, P603, DOI 10.1146/annurev.mi.37.100183.003131; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; QUAGLIARELLO VJ, 1986, J CLIN INVEST, V77, P1084, DOI 10.1172/JCI112407; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; QUAGLIARELLO VJ, 1991, J EXP MED, V174, P657, DOI 10.1084/jem.174.3.657; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; ROORD JJ, 1991, 31ST INT C ANT AG CH, P251; SABLE CA, 1991, 31ST INT C ANT AG CH, P252; SAEZLLORENS X, 1991, J CLIN INVEST, V88, P2003, DOI 10.1172/JCI115527; SAEZLLORENS X, 1990, ANTIMICROB AGENTS CH, V34, P837, DOI 10.1128/AAC.34.5.837; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; SCHELD WM, 1980, J CLIN INVEST, V66, P243, DOI 10.1172/JCI109850; SCHELD WM, 1983, J CLIN INVEST, V71, P411, DOI 10.1172/JCI110785; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; SIMBERKOFF MS, 1980, J LAB CLIN MED, V95, P362; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STEPHENS DS, 1991, REV INFECT DIS, V13, P22; SULLIVAN GW, 1988, INFECT IMMUN, V56, P1722, DOI 10.1128/IAI.56.7.1722-1729.1988; SWARTZ MN, 1984, NEW ENGL J MED, V311, P913, DOI 10.1056/NEJM198410043111409; SYROGIANNOPOULOS GA, 1987, J INFECT DIS, V155, P213, DOI 10.1093/infdis/155.2.213; SYROGIANNOPOULOS GA, 1988, J INFECT DIS, V157, P237, DOI 10.1093/infdis/157.2.237; TAUBER MG, 1989, PEDIATR INFECT DIS J, V8, P842; TAUBER MG, 1985, J INFECT DIS, V151, P528, DOI 10.1093/infdis/151.3.528; TUOMANEN E, 1985, J INFECT DIS, V151, P535, DOI 10.1093/infdis/151.3.535; TUOMANEN E, 1985, J INFECT DIS, V151, P859, DOI 10.1093/infdis/151.5.859; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; TUREEN JH, 1992, J CLIN INVEST, V89, P947, DOI 10.1172/JCI115676; TUREEN JH, 1990, J CLIN INVEST, V85, P577, DOI 10.1172/JCI114475; TUREEN JH, 1991, J INFECT DIS, V163, P647, DOI 10.1093/infdis/163.3.647; VELASCO S, 1991, J CLIN INVEST, V87, P1674, DOI 10.1172/JCI115184; WAAGE A, 1989, J EXP MED, V170, P1859, DOI 10.1084/jem.170.6.1859; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WISPELWEY B, 1989, INFECT IMMUN, V57, P2559, DOI 10.1128/IAI.57.8.2559-2562.1989; WISPELWEY B, 1988, J CLIN INVEST, V82, P1339, DOI 10.1172/JCI113736; ZWAHLEN A, 1982, J INFECT DIS, V145, P635, DOI 10.1093/infdis/145.2.635	69	376	385	2	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					864	872						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1508247				2022-12-28	WOS:A1992JN12000008
J	GUILLON, JM; JOLY, P; AUTRAN, B; DENIS, M; AKOUN, G; DEBRE, P; MAYAUD, C				GUILLON, JM; JOLY, P; AUTRAN, B; DENIS, M; AKOUN, G; DEBRE, P; MAYAUD, C			MINOCYCLINE-INDUCED CELL-MEDIATED HYPERSENSITIVITY PNEUMONITIS	ANNALS OF INTERNAL MEDICINE			English	Article						ALVEOLITIS, EXTRINSIC ALLERGIC; MINOCYCLINE; SUPPRESSOR CELLS; LYMPHOCYTES-T, CYTOTOXIC; DRUG HYPERSENSITIVITY	TOXIC LYMPHOCYTES-T; BRONCHOALVEOLAR LAVAGE; TOLUENE DIISOCYANATE; PULMONARY-DISEASE; EOSINOPHILIA; AMIODARONE; EXPOSURE; ANTIGEN; VIRUS	Objective: To identify the cause of a hypersensitivity pneumonitis and to determine its pathogenesis. Design: Case study. Setting: Intensive care unit of a referral hospital. Patient: A 51-year-old man with chronic bronchitis who developed a hypersensitivity pneumonitis within 1 month after exposure to minocycline, amoxicillin, and erythromycin. Intervention: Sequential bronchoalveolar lavages after reexposure to minocycline and amoxicillin. Measurements: Immunologic analysis of the phenotype and function of alveolar lymphocytes. Results: Reexposure to minocycline but not to amoxicillin was followed by an interstitial pneumonitis. Sequential bronchoalveolar lavages showed a transient rise of eosinophils and neutrophils and a persistent alveolar lymphocytosis. Alveolar lymphocytes consisted predominantly of CD8+ but also CD4+ cells. Two CD8+ lymphocyte subsets were identified: CD8+ D44+ cytotoxic T cells that increased rapidly after the drug was resumed and CD8+ CD57+ suppressor T cells that predominated 11 days after the drug's withdrawal. In-vitro assays showed the presence of a lymphocyte-mediated specific cytotoxicity against minocycline-bearing alveolar macrophages. Conclusion: These results support the hypothesis of a central role of T lymphocytes in the pathogenesis of drug-related hypersensitivity pneumonitis.	HOP LA PITIE SALPETRIERE, IMMUNOL CELLULAIRE LAB, F-75013 PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	GUILLON, JM (corresponding author), HOP TENON, SERV PNEUMOL, 4 RUE CHINE, F-75970 PARIS 20, FRANCE.							ABRAMOV LA, 1978, ARCH INTERN MED, V138, P1156, DOI 10.1001/archinte.138.7.1156; AKOUN GM, 1991, CHEST, V99, P98, DOI 10.1378/chest.99.1.98; AKOUN GM, 1988, CHEST, V94, P1050, DOI 10.1378/chest.94.5.1050; BACK O, 1977, CLIN EXP IMMUNOL, V28, P400; BERNARDO J, 1979, AM REV RESPIR DIS, V120, P985; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CALVO CF, 1984, J IMMUNOL, V132, P2345; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; CLEMENT LT, 1984, J IMMUNOL, V133, P2461; COOPER JAD, 1986, AM REV RESPIR DIS, V133, P488; ETTENSOHN DB, 1988, CHEST, V94, P281, DOI 10.1378/chest.94.2.281; FREW AJ, 1988, J IMMUNOL, V141, P4158; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; HO D, 1979, CHEST, V76, P33, DOI 10.1378/chest.76.1.33; JOLY P, 1989, J IMMUNOL, V143, P2193; KELLER RH, 1984, AM REV RESPIR DIS, V130, P766; KROMBACH F, 1990, American Review of Respiratory Disease, V141, pA891; LEATHERMAN JW, 1984, ANN INTERN MED, V100, P390, DOI 10.7326/0003-4819-100-3-390; MCCORMICK J, 1980, AM REV RESPIR DIS, V122, P145; MEIGNAN M, 1990, AM REV RESPIR DIS, V141, P1241, DOI 10.1164/ajrccm/141.5_Pt_1.1241; OTERO M, 1983, JAMA-J AM MED ASSOC, V250, P2602, DOI 10.1001/jama.1983.03340190016010; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; POE RH, 1980, CHEST, V77, P449, DOI 10.1378/chest.77.3.449; SANDE M A, 1990, P1117; SEMENZATO G, 1986, J IMMUNOL, V137, P1164; Shigematsu T, 1988, Nihon Naika Gakkai Zasshi, V77, P1584; YOSHIZAWA Y, 1989, ANN INTERN MED, V110, P31, DOI 10.7326/0003-4819-110-1-31	27	61	63	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					476	481		10.7326/0003-4819-117-6-476	http://dx.doi.org/10.7326/0003-4819-117-6-476			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503350				2022-12-28	WOS:A1992JN25700006
J	KIMMEL, PL; PHILLIPS, TM; FERREIRACENTENO, A; FARKASSZALLASI, T; ABRAHAM, AA; GARRETT, CT				KIMMEL, PL; PHILLIPS, TM; FERREIRACENTENO, A; FARKASSZALLASI, T; ABRAHAM, AA; GARRETT, CT			BRIEF REPORT - IDIOTYPIC IGA NEPHROPATHY IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CIRCULATING IMMUNE-COMPLEXES; HIV-SEROPOSITIVE INDIVIDUALS; ANTIBODY; AIDS; ANTIGEN; DISEASE; KIDNEY; P24		GEORGE WASHINGTON UNIV,MED CTR,DEPT PATHOL,WASHINGTON,DC 20037	George Washington University	KIMMEL, PL (corresponding author), GEORGE WASHINGTON UNIV,MED CTR,DEPT MED,DIV RENAL DIS & HYPERTENS,2150 PENN AVE NW,WASHINGTON,DC 20037, USA.				NIDDK NIH HHS [1-RO1-DK-40811] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040811] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOURGOIGNIE JJ, 1990, KIDNEY INT, V37, P1571, DOI 10.1038/ki.1990.151; CANTOR ES, 1991, ARCH INTERN MED, V151, P125, DOI 10.1001/archinte.151.1.125; COHEN AH, 1989, MODERN PATHOL, V2, P125; CROCE MV, 1991, J EXP CLIN CANC RES, V10, P131; ELLAURIE M, 1990, AM J DIS CHILD, V144, P1207, DOI 10.1001/archpedi.1990.02150350039020; EMANCIPATOR SN, 1990, KIDNEY INT, V38, P1216, DOI 10.1038/ki.1990.337; FLING JA, 1988, J ALLERGY CLIN IMMUN, V82, P965, DOI 10.1016/0091-6749(88)90132-7; GARDENSWARTZ MH, 1984, CLIN NEPHROL, V21, P197; GLASSOCK RJ, 1990, ANN INTERN MED, V112, P35, DOI 10.7326/0003-4819-112-1-35; GREEN DF, 1992, KIDNEY INT, V41, P956, DOI 10.1038/ki.1992.146; GREGORY MC, 1988, LANCET, V1, P11; GUERRA IL, 1987, AM J KIDNEY DIS, V10, P385, DOI 10.1016/S0272-6386(87)80107-5; HEBERT LA, 1988, AM J KIDNEY DIS, V12, P388, DOI 10.1016/S0272-6386(88)80031-3; JACKSON S, 1988, AM J KIDNEY DIS, V12, P425, DOI 10.1016/S0272-6386(88)80039-8; JENNETTE JC, 1985, KIDNEY INT, V28, P944, DOI 10.1038/ki.1985.222; KATZ A, IN PRESS CLIN NEPHRO; KENOUCH S, 1990, NEPHRON, V54, P338, DOI 10.1159/000185891; MCDOUGAL JS, 1985, J CLIN IMMUNOL, V5, P130, DOI 10.1007/BF00915011; MCDOUGAL JS, 1987, J CLIN INVEST, V80, P316, DOI 10.1172/JCI113075; MCHUGH TM, 1988, J INFECT DIS, V158, P1088, DOI 10.1093/infdis/158.5.1088; MCHUGH TM, 1989, J INFECT DIS, V159, P602; MORROW WJW, 1986, CLIN IMMUNOL IMMUNOP, V40, P515, DOI 10.1016/0090-1229(86)90196-0; NISHANIAN P, 1990, J INFECT DIS, V162, P21, DOI 10.1093/infdis/162.1.21; OLSON JL, 1979, CLIN NEPHROL, V12, P74; OPRANDY JJ, 1989, J CLIN MICROBIOL, V27, P74, DOI 10.1128/JCM.27.1.74-77.1989; OSHEA S, 1990, J MED VIROL, V31, P291, DOI 10.1002/jmv.1890310409; PESCE AJ, 1980, J UROLOGY, V123, P486, DOI 10.1016/S0022-5347(17)55983-2; PHILLIPS TM, 1992, ANAL TECHNIQUES IMMU, P324; PHILLIPS TM, 1980, SEROLOGIC ANAL HUMAN, P643; PORTERA M, 1990, J MED VIROL, V30, P30, DOI 10.1002/jmv.1890300107; RODRIGUEZ ER, 1991, AM J CARDIOL, V68, P1511, DOI 10.1016/0002-9149(91)90288-V; SENEY FD, 1990, AM J KIDNEY DIS, V16, P1; WEIBLEN BJ, 1990, J IMMUNOL METHODS, V126, P199, DOI 10.1016/0022-1759(90)90151-K; Zollinger HU, 1978, RENAL PATHOLOGY BIOP, P8; Zubler R H, 1981, Methods Enzymol, V74 Pt C, P530	35	120	123	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					702	706		10.1056/NEJM199209033271006	http://dx.doi.org/10.1056/NEJM199209033271006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1495523				2022-12-28	WOS:A1992JL23500006
J	NICKLAS, JM; PITT, B; TIMMIS, G; BRENEMAN, G; JAFRI, SM; DUVERNOY, WFC; DAVIS, SW; GOLDBERG, MJ; BLAIR, J; MANCINI, GBJ; JOHNSON, T; LUCKOFF, C; HENRY, G; WLODKOWSKI, MB; CZAJKA, M; REINSTEIN, D; RICHARDS, J; LEWIS, R; DAVEY, DE; MALLOTTE, K; MOLL, A; QUAIN, L; THOMASMA, P; SCHREIBER, S; URSINY, E; ROGERS, WJ; ARCINIEGAS, JG; BITTNER, V; BULLE, TM; CAVENDER, JB; CHARLES, ED; DELLITALIA, LJ; HENZLOVA, MJ; MACLEAN, WA; PAPAPIETRO, SE; PAINE, TD; SALVIA, MF; SHEFFIELD, LT; STANLEY, AWH; VANTASSEL, E; TAYLOR, HA; CARLISLE, K; BAKER, A; BLACKBURN, G; BONVILLE, B; BYNUM, K; DERISO, S; KERNS, D; LAMBERT, N; MERRITT, L; NANCE, V; REDDY, E; ATKINS, F; COX, M; POULEUR, H; ROUSSEAU, MF; MELIN, J; MARCHANDISE, B; SCHROEDER, E; AHN, S; MCINTYRE, KM; TOW, D; PIETRO, D; GILLIE, E; SHARMA, GVRK; WOODS, P; DONDERO, MEC; BROWN, R; STRAUSS, W; LOSCALZO, J; SALEM, D; KONSTAM, MA; UDELSON, JE; WEINSHEL, A; GAASCH, W; DOLAN, N; HOSHINO, R; LANE, C; KELLY, S; KILCOYNE, L; KINAN, D; METHERALL, J; PARADISE, L; TOLTSIS, H; LEJEMTEL, TH; FRISHMAN, WH; WEXLER, J; GALVAO, M; MILLS, LA; JONES, M; KOHN, RM; MOREY, PD; FORTE, KE; HONG, MJ; MADDI, JL; ZIZZI, JA; BERNASKI, EJ; ROBERTS, NA; BONORA, MM; CELANO, JA; BANKS, LD; MUFFOLETTO, EM; RICH, S; BRUNDAGE, BH; SHANES, JG; PAPP, MA; MATHEW, J; BERARDUCCI, L; GHALI, JK; COOPER, R; DIERENFELDT, BJ; STANFORD, S; MUMBY, P; DAVIDSON, S; ADAMS, T; PEPINE, CJ; CONTI, CR; MEHTA, JL; LIMACHER, MC; FELDMAN, RL; GEISER, EA; HILL, JA; LAMBERT, CR; PRIDA, X; MCCOY, K; MIRANDA, A; NORVELL, NK; GREEN, JR; MILLER, AB; PERCHALSKI, DL; HANDBERG, E; HALL, B; JOHNSTONE, DE; GARDNER, MJ; MONTAGUE, TJ; LALONDE, LD; KLASSEN, GA; TEO, KK; CHANDLER, BM; CAREW, B; BLACK, S; FRANCIS, M; MARTIN, S; YOUNG, JB; PRATT, CM; QUINONES, MA; ROBERTS, R; KINGRY, C; GIBSON, D; FOREMAN, C; KOPELEN, H; GALAN, A; MILLER, L; YANG, K; MARKS, G; FRANCIS, M; KIRLIN, PC; WILLIS, PW; JONES, JW; BAIRD, WM; FRITZ, T; PERRY, B; MCNAMARA, R; MURRAY, RH; SCAFFIDI, LE; BOICHOT, H; SOLIS, N; BACHMAN, C; FOOY, C; MCKAY, K; VANDERPUY, M; HINER, K; WORDEN, E; HEARNS, P; COHN, JN; KUBO, SH; FRANCIS, GS; PETERSON, C; GOLDENBERG, IF; MCBRIDE, JW; BERMAN, D; HESSION, W; GOLDSMITH, SR; PEDERSON, WR; HOLMER, S; BJERKEN, GK; MONSON, K; PEARSON, J; OTOOLEBREHM, B; MENSING, L; BOURASSA, MG; GOULET, C; JOYAL, M; GOSSELIN, G; LABBE, M; METHE, M; BENJAMIN, H; MORTIN, S; LECLERC, D; KRONENBERG, MW; FRIESINGER, GC; BYRD, BF; CAMPBELL, WB; NADEAU, JH; SCHILLING, S; HOWE, DM; EDENS, TR; BERNARD, YD; BROWN, LA; SMITH, RF; KOSTIS, JB; SHINDLER, DM; LACY, CR; SUMATHISENA; KARSTENSEN, S; WILLIAMS, J; HILL, B; WOOD, L; STEINHAGEN, J; JESSUP, M; BROZENA, S; VICTOR, M; HAGAMAN, J; CANNON, M; MCDONOUGH, J; LUHMANN, S; SMITH, AL; KELLY, J; STINSON, D; GREENBERG, B; DEMOTS, H; GROVER, J; REINHART, S; NAUMAN, D; DUTTON, D; GUILLOTTE, M; SCHMIT, M; CAPONE, RJ; MCNULTY, C; SHARMA, S; SADANIANTZ, A; GORKIN, L; HANDSHAW, K; ERIKSON, L; LAMORE, C; REDFERN, L; RUBBERT, P; TREMBLAY, D; HOOD, WB; LIANG, CS; FITZPATRICK, PG; RICHESON, JF; ACCIARI, KJ; DIVERS, LD; STONE, TM; FARRELL, MJ; MILLER, KD; MOORE, AW; WELLINGTON, KL; EASLEY, RM; RYAN, GF; BAROLD, S; GILLESPIE, JA; COVE, L; ROACHE, MP; MALCOLM, JM; STEWART, DK; KENNEDY, JW; CALDWELL, JH; MURRAY, JA; HEGG, TD; WALLACH, R; CHAMUSCO, R; KUDENCHUCK, P; OLMSTEAD, S; DASH, H; GORHAM, J; RESNICK, A; CAHILL, L; LETTERER, R; KEMPF, T; GARDNER, P; DALQUIST, J; OLSUFKA, M; GREGORY, JJ; BROCK, DC; LAUER, R; GREENE, A; FISCHL, SJ; SLAMA, R; STEIN, E; KALISCHER, A; DIEHL, L; FACCHINEI, S; ROMANO, J; OLEARY, E; KIMBALL, G; BROCK, L; HERMAN, MV; WEISS, MB; KAY, RH; EVANS, M; LERRICK, K; UNGER, C; RIPA, S; BLAKE, J; REID, M; BRAGA, D; TREULIEB, N; CUTRONE, T; BENEDICT, C; HOLLAND, OB; BODOLA, F; CAPPOLINO, D; SHENG, WL; CHAKRAVARTHY, S; ENTEZAMI, AA; SULLIVAN, C; WU, CW; DAVIS, CE; HOSKING, JD; BANGDIWALA, SI; BARRETT, J; GARCES, C; KRAL, KM; TORETSKY, ER; YOUNGBLOOD, ME; STEWART, D; HAZARD, CJ; WEINER, DH; ADAMS, KF; EKELUND, LG; KO, WJ; JARRAD, I; WILLIAMS, G; SHELTON, BJ; JONES, D; NELSON, JJ; SMITH, V; THORN, M; PROBSTFIELD, J; VERTER, J; SCHRON, E; SCHUMACKER, S; DAVIS, P; WEBSTER, E; RAPAPORT, E; BROWN, BW; COHEN, LS; HALPERIN, M; PACKER, M; WALTERS, L; GUNNAR, R; FRIEDEWALD, W; YUSUF, S; PITT, B; DAVIS, CE; HOOD, WB; COHN, JN				NICKLAS, JM; PITT, B; TIMMIS, G; BRENEMAN, G; JAFRI, SM; DUVERNOY, WFC; DAVIS, SW; GOLDBERG, MJ; BLAIR, J; MANCINI, GBJ; JOHNSON, T; LUCKOFF, C; HENRY, G; WLODKOWSKI, MB; CZAJKA, M; REINSTEIN, D; RICHARDS, J; LEWIS, R; DAVEY, DE; MALLOTTE, K; MOLL, A; QUAIN, L; THOMASMA, P; SCHREIBER, S; URSINY, E; ROGERS, WJ; ARCINIEGAS, JG; BITTNER, V; BULLE, TM; CAVENDER, JB; CHARLES, ED; DELLITALIA, LJ; HENZLOVA, MJ; MACLEAN, WA; PAPAPIETRO, SE; PAINE, TD; SALVIA, MF; SHEFFIELD, LT; STANLEY, AWH; VANTASSEL, E; TAYLOR, HA; CARLISLE, K; BAKER, A; BLACKBURN, G; BONVILLE, B; BYNUM, K; DERISO, S; KERNS, D; LAMBERT, N; MERRITT, L; NANCE, V; REDDY, E; ATKINS, F; COX, M; POULEUR, H; ROUSSEAU, MF; MELIN, J; MARCHANDISE, B; SCHROEDER, E; AHN, S; MCINTYRE, KM; TOW, D; PIETRO, D; GILLIE, E; SHARMA, GVRK; WOODS, P; DONDERO, MEC; BROWN, R; STRAUSS, W; LOSCALZO, J; SALEM, D; KONSTAM, MA; UDELSON, JE; WEINSHEL, A; GAASCH, W; DOLAN, N; HOSHINO, R; LANE, C; KELLY, S; KILCOYNE, L; KINAN, D; METHERALL, J; PARADISE, L; TOLTSIS, H; LEJEMTEL, TH; FRISHMAN, WH; WEXLER, J; GALVAO, M; MILLS, LA; JONES, M; KOHN, RM; MOREY, PD; FORTE, KE; HONG, MJ; MADDI, JL; ZIZZI, JA; BERNASKI, EJ; ROBERTS, NA; BONORA, MM; CELANO, JA; BANKS, LD; MUFFOLETTO, EM; RICH, S; BRUNDAGE, BH; SHANES, JG; PAPP, MA; MATHEW, J; BERARDUCCI, L; GHALI, JK; COOPER, R; DIERENFELDT, BJ; STANFORD, S; MUMBY, P; DAVIDSON, S; ADAMS, T; PEPINE, CJ; CONTI, CR; MEHTA, JL; LIMACHER, MC; FELDMAN, RL; GEISER, EA; HILL, JA; LAMBERT, CR; PRIDA, X; MCCOY, K; MIRANDA, A; NORVELL, NK; GREEN, JR; MILLER, AB; PERCHALSKI, DL; HANDBERG, E; HALL, B; JOHNSTONE, DE; GARDNER, MJ; MONTAGUE, TJ; LALONDE, LD; KLASSEN, GA; TEO, KK; CHANDLER, BM; CAREW, B; BLACK, S; FRANCIS, M; MARTIN, S; YOUNG, JB; PRATT, CM; QUINONES, MA; ROBERTS, R; KINGRY, C; GIBSON, D; FOREMAN, C; KOPELEN, H; GALAN, A; MILLER, L; YANG, K; MARKS, G; FRANCIS, M; KIRLIN, PC; WILLIS, PW; JONES, JW; BAIRD, WM; FRITZ, T; PERRY, B; MCNAMARA, R; MURRAY, RH; SCAFFIDI, LE; BOICHOT, H; SOLIS, N; BACHMAN, C; FOOY, C; MCKAY, K; VANDERPUY, M; HINER, K; WORDEN, E; HEARNS, P; COHN, JN; KUBO, SH; FRANCIS, GS; PETERSON, C; GOLDENBERG, IF; MCBRIDE, JW; BERMAN, D; HESSION, W; GOLDSMITH, SR; PEDERSON, WR; HOLMER, S; BJERKEN, GK; MONSON, K; PEARSON, J; OTOOLEBREHM, B; MENSING, L; BOURASSA, MG; GOULET, C; JOYAL, M; GOSSELIN, G; LABBE, M; METHE, M; BENJAMIN, H; MORTIN, S; LECLERC, D; KRONENBERG, MW; FRIESINGER, GC; BYRD, BF; CAMPBELL, WB; NADEAU, JH; SCHILLING, S; HOWE, DM; EDENS, TR; BERNARD, YD; BROWN, LA; SMITH, RF; KOSTIS, JB; SHINDLER, DM; LACY, CR; SUMATHISENA; KARSTENSEN, S; WILLIAMS, J; HILL, B; WOOD, L; STEINHAGEN, J; JESSUP, M; BROZENA, S; VICTOR, M; HAGAMAN, J; CANNON, M; MCDONOUGH, J; LUHMANN, S; SMITH, AL; KELLY, J; STINSON, D; GREENBERG, B; DEMOTS, H; GROVER, J; REINHART, S; NAUMAN, D; DUTTON, D; GUILLOTTE, M; SCHMIT, M; CAPONE, RJ; MCNULTY, C; SHARMA, S; SADANIANTZ, A; GORKIN, L; HANDSHAW, K; ERIKSON, L; LAMORE, C; REDFERN, L; RUBBERT, P; TREMBLAY, D; HOOD, WB; LIANG, CS; FITZPATRICK, PG; RICHESON, JF; ACCIARI, KJ; DIVERS, LD; STONE, TM; FARRELL, MJ; MILLER, KD; MOORE, AW; WELLINGTON, KL; EASLEY, RM; RYAN, GF; BAROLD, S; GILLESPIE, JA; COVE, L; ROACHE, MP; MALCOLM, JM; STEWART, DK; KENNEDY, JW; CALDWELL, JH; MURRAY, JA; HEGG, TD; WALLACH, R; CHAMUSCO, R; KUDENCHUCK, P; OLMSTEAD, S; DASH, H; GORHAM, J; RESNICK, A; CAHILL, L; LETTERER, R; KEMPF, T; GARDNER, P; DALQUIST, J; OLSUFKA, M; GREGORY, JJ; BROCK, DC; LAUER, R; GREENE, A; FISCHL, SJ; SLAMA, R; STEIN, E; KALISCHER, A; DIEHL, L; FACCHINEI, S; ROMANO, J; OLEARY, E; KIMBALL, G; BROCK, L; HERMAN, MV; WEISS, MB; KAY, RH; EVANS, M; LERRICK, K; UNGER, C; RIPA, S; BLAKE, J; REID, M; BRAGA, D; TREULIEB, N; CUTRONE, T; BENEDICT, C; HOLLAND, OB; BODOLA, F; CAPPOLINO, D; SHENG, WL; CHAKRAVARTHY, S; ENTEZAMI, AA; SULLIVAN, C; WU, CW; DAVIS, CE; HOSKING, JD; BANGDIWALA, SI; BARRETT, J; GARCES, C; KRAL, KM; TORETSKY, ER; YOUNGBLOOD, ME; STEWART, D; HAZARD, CJ; WEINER, DH; ADAMS, KF; EKELUND, LG; KO, WJ; JARRAD, I; WILLIAMS, G; SHELTON, BJ; JONES, D; NELSON, JJ; SMITH, V; THORN, M; PROBSTFIELD, J; VERTER, J; SCHRON, E; SCHUMACKER, S; DAVIS, P; WEBSTER, E; RAPAPORT, E; BROWN, BW; COHEN, LS; HALPERIN, M; PACKER, M; WALTERS, L; GUNNAR, R; FRIEDEWALD, W; YUSUF, S; PITT, B; DAVIS, CE; HOOD, WB; COHN, JN			EFFECT OF ENALAPRIL ON MORTALITY AND THE DEVELOPMENT OF HEART-FAILURE IN ASYMPTOMATIC PATIENTS WITH REDUCED LEFT-VENTRICULAR EJECTION FRACTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; CLINICAL-TRIALS	Background. It is not known whether the treatment of patients with asymptomatic left ventricular dysfunction reduces mortality and morbidity. We studied the effect of an angiotensin-converting-enzyme inhibitor, enalapril, on total mortality and mortality from cardiovascular causes, the development of heart failure, and hospitalization for heart failure among patients with ejection fractions of 0.35 or less who were not receiving drug treatment for heart failure. Methods. Patients were randomly assigned to receive either placebo (n = 2117) or enalapril (n = 2111) at doses of 2.5 to 20 mg per day in a double-blind trial. Follow-up averaged 37.4 months. Results. There were 334 deaths in the placebo group, as compared with 313 in the enalapril group (reduction in risk, 8 percent by the log-rank test; 95 percent confidence interval, -8 percent [an increase of 8 percent] to 21 percent; P = 0.30). The reduction in mortality from cardiovascular causes was larger but was not statistically significant (298 deaths in the placebo group vs. 265 in the enalapril group; risk reduction, 12 percent; 95 percent confidence interval, -3 to 26 percent; P = 0.12). When we combined patients in whom heart failure developed and those who died, the total number of deaths and cases of heart failure was lower in the enalapril group than in the placebo group (630 vs. 818; risk reduction, 29 percent; 95 percent confidence interval, 21 to 36 percent; P<0.001). In addition, fewer patients given enalapril died or were hospitalized for heart failure (434 in the enalapril group vs. 518 in the placebo group; risk reduction, 20 percent; 95 percent confidence interval, 9 to 30 percent; P<0.001). Conclusions. The angiotensin-converting-enzyme inhibitor enalapril significantly reduced the incidence of heart failure and the rate of related hospitalizations, as compared with the rates in the group given placebo, among patients with asymptomatic left ventricular dysfunction. There was also a trend toward fewer deaths due to cardiovascular causes among the patients who received enalapril.	NHLBI, DIV EPIDEMIOL & CLIN APPLICAT,CLIN TRIALS BRANCH, FED BLDG,RM 5C08, BETHESDA, MD 20892 USA; UNIV MICHIGAN, MED CTR, ANN ARBOR, MI 48109 USA; UNIV ALABAMA, MED CTR, BIRMINGHAM, AL 35294 USA; CATHOLIC UNIV LOUVAIN, B-1200 BRUSSELS, BELGIUM; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, BOSTON, MA 02115 USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, BOSTON, MA USA; TUFTS UNIV, NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, WEILER HOSP, BRONX, NY 10461 USA; BUFFALO GEN HOSP, BUFFALO, NY 14203 USA; VET AFFAIRS MED CTR, BUFFALO, NY USA; UNIV ILLINOIS, SCH MED, CHICAGO, IL 60680 USA; UNIV FLORIDA, GAINESVILLE, FL 32611 USA; VET AFFAIRS MED CTR, GAINESVILLE, FL USA; VICTORIA GEN HOSP, HALIFAX B3H 2Y9, NS, CANADA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; MICHIGAN STATE UNIV, E LANSING, MI 48824 USA; UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA; MONTREAL HEART INST, MONTREAL H1T 1C8, QUEBEC, CANADA; VANDERBILT UNIV, MED CTR, SCH MED, NASHVILLE, TN 37232 USA; UNIV MED & DENT NEW JERSEY, NEW BRUNSWICK, NJ 08903 USA; UNIV MED & DENT NEW JERSEY, NEW BRUNSWICK, NJ USA; TEMPLE UNIV HOSP & MED SCH, PHILADELPHIA, PA 19140 USA; OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA; BROWN UNIV, PROVIDENCE, RI 02912 USA; UNIV ROCHESTER, MED CTR, ROCHESTER, NY 14642 USA; UNIV WASHINGTON, MED CTR, SEATTLE, WA 98195 USA; OVERLOOK HOSP, SUMMIT, NJ 07901 USA; NEW YORK MED COLL, WESTCHESTER CTY MED CTR, VALHALLA, NY 10595 USA; UNIV TEXAS, HLTH SCI CTR, NEUROHUMORAL LAB, HOUSTON, TX 77225 USA; UNIV N CAROLINA, CTR COORDINATING, CHAPEL HILL, NC 27514 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Michigan System; University of Michigan; University of Alabama System; University of Alabama Birmingham; Universite Catholique Louvain; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Tufts Medical Center; Tufts University; Yeshiva University; Albert Einstein College of Medicine; Buffalo General Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University System of Florida; University of Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); Dalhousie University; University of Victoria; Baylor College of Medicine; Michigan State University; University of Minnesota System; University of Minnesota Twin Cities; Universite de Montreal; Vanderbilt University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Oregon Health & Science University; Brown University; University of Rochester; University of Washington; University of Washington Seattle; Atlantic Health System; New York Medical College; Westchester Medical Center; University of Texas System; University of Texas Health Science Center Houston; University of North Carolina; University of North Carolina Chapel Hill			Smith, Adam/GPS-8322-2022; Reddy, E. Premkumar/F-6233-2011; Mehta, JL/AAG-7572-2020; Friedewald, William T/C-8034-2011; Loscalzo, Joseph/ABD-8980-2021; Mehta, jl/AAB-8832-2019; Jafri, Wasim/AAE-5085-2020	Mehta, jl/0000-0003-0384-2097; Yusuf, Salim/0000-0003-4776-5601				[Anonymous], 1990, Am J Cardiol, V66, P315; COHN JN, 1983, J AM COLL CARDIOL, V2, P755; FLEISS JL, 1990, CIRCULATION, V81, P684, DOI 10.1161/01.CIR.81.2.684; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; SHARPE N, 1988, LANCET, V1, P255; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1990, AM J CARDIOL, V66, P1026	11	2492	2553	1	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					685	691						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1463530				2022-12-28	WOS:A1992JL23500003
J	BARZANSKY, B; JONAS, HS				BARZANSKY, B; JONAS, HS			FINANCIAL ASSISTANCE AND EDUCATION-PROGRAMS TO ENCOURAGE CARE TO THE UNDERSERVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PHYSICIAN				BARZANSKY, B (corresponding author), AMER MED ASSOC,DIV UNDERGRAD MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							CRANFORD C, 1991, LINKING MED ED TRAIN; KINDIG DA, 1987, INQUIRY-J HEALTH CAR, V24, P136; KINDIG DA, 1989, HEALTH AFFAIR, V8, P63, DOI 10.1377/hlthaff.8.2.63; MCCLOSKEY A, 1990, STATE INITIATIVES IM; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; SCOFIELD J, 1984, NEW EXPANDED MED SCH; 1991, HTLH ED TRAINING CTR; 1991, JAMA-J AM MED ASSOC, V266, P1007; 1992, AAMC DATA BOOK	9	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1089	1089		10.1001/jama.268.9.1089	http://dx.doi.org/10.1001/jama.268.9.1089			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK681	1501329				2022-12-28	WOS:A1992JK68100003
J	PILOTE, L; THOMAS, RJ; DENNIS, C; GOINS, P; HOUSTONMILLER, N; KRAEMER, H; LEONG, C; BERGER, WE; LEW, H; HELLER, RS; ROMPF, J; DEBUSK, RF				PILOTE, L; THOMAS, RJ; DENNIS, C; GOINS, P; HOUSTONMILLER, N; KRAEMER, H; LEONG, C; BERGER, WE; LEW, H; HELLER, RS; ROMPF, J; DEBUSK, RF			RETURN TO WORK AFTER UNCOMPLICATED MYOCARDIAL-INFARCTION - A TRIAL OF PRACTICE GUIDELINES IN THE COMMUNITY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; WORK SCHEDULE TOLERANCE; PHYSICIANS PRACTICE PATTERNS; HOSPITALS; UNIVERSITY	EXERCISE TESTING SOON; CARDIOVASCULAR-RESPONSES; PROGNOSTIC VALUE; DISCHARGE; RISK	Objective: To evaluate the effectiveness of practice guidelines for return to work after acute myocardial infarction when disseminated from a university-based setting to a practice-based setting. Design: Randomized clinical trial. Patients: A total of 187 patients with uncomplicated acute myocardial infarction. Intervention: Patients were randomly assigned to the intervention (n = 95) or to usual care (n = 92). The intervention consisted of a treadmill test, a counseling session based on the test results, and a consultation letter from a cardiologist to the primary care physician. Individualized recommendations for the timing of return to work, contained in the consultation letter, were based on the patient's risk for recurrent cardiac events. Measurements: Questionnaire, chart review, and a phone interview documented the timing of return to work and the rates of cardiac death, coronary angioplasty, coronary artery surgery, and recurrent myocardial infarction. Results: Median intervals between acute myocardial infarction and return to work were similar in both groups (intervention, 54 days; usual care, 67 days; P > 0.2). Among patients without myocardial ischemia, however, the interval was shorter in the intervention group than in the usual care group (38 days compared with 65 days, respectively, P = 0.008). Among patients with myocardial ischemia, intervals were similar in both groups (80 days compared with 76 days, respectively, P > 0.2). Conclusion: Practice guidelines developed in a university-based setting were not as successful in hastening return to work after uncomplicated acute myocardial infarction when tested in a practice-based setting. Physicians' reluctance to follow guidelines for patients with myocardial ischemia reflected their concern with prognosis even though medical outcome was good.	STANFORD UNIV, MED CTR, SCH MED, STANFORD, CA 94305 USA	Stanford University				Thomas, Randal/0000-0003-1448-7182	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036734] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36734] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIDSON DM, 1980, CIRCULATION, V61, P236, DOI 10.1161/01.CIR.61.2.236; DEBUSK R, 1979, CIRCULATION, V59, P977, DOI 10.1161/01.CIR.59.5.977; DEBUSK RF, 1979, AM J CARDIOL, V43, P907, DOI 10.1016/0002-9149(79)90352-7; DEBUSK RF, 1978, CIRCULATION, V58, P368, DOI 10.1161/01.CIR.58.2.368; DEBUSK RF, 1983, AM J CARDIOL, V52, P1161, DOI 10.1016/0002-9149(83)90567-2; DENNIS C, 1988, JAMA-J AM MED ASSOC, V260, P214, DOI 10.1001/jama.260.2.214; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; EWART CK, 1983, AM J CARDIOL, V51, P1076, DOI 10.1016/0002-9149(83)90348-X; FLETCHER RH, 1990, ANN INTERN MED, V113, P645, DOI 10.7326/0003-4819-113-9-645; GARRITY TF, 1973, SOC SCI MED, V7, P705, DOI 10.1016/0037-7856(73)90004-8; HARPUR JE, 1971, LANCET, V2, P1331; HASKELL WL, 1979, CIRCULATION, V60, P1247, DOI 10.1161/01.CIR.60.6.1247; KJOLLER E, 1976, ACTA MED SCAND, V199, P379; KUSHNIR B, 1976, SCAND J REHABIL MED, V8, P155; MADSEN EB, 1985, AM J CARDIOL, V56, P839, DOI 10.1016/0002-9149(85)90766-0; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; NAUGHTON J, 1973, J SPORTS MED, V3, P201; NAYLOR CD, 1990, JAMA-J AM MED ASSOC, V264, P697, DOI 10.1001/jama.264.6.697; NICOD P, 1991, CIRCULATION, V84, P1004, DOI 10.1161/01.CIR.84.3.1004; PICARD MH, 1989, AM J CARDIOL, V63, P1308, DOI 10.1016/0002-9149(89)91040-0; SHAPIRO S, 1972, ARCH ENVIRON HEALTH, V24, P17, DOI 10.1080/00039896.1972.10666045; SMITH GR, 1988, JAMA-J AM MED ASSOC, V259, P1673, DOI 10.1001/jama.259.11.1673; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701; WEINBLATT E, 1966, AM J PUBLIC HEALTH N, V56, P169, DOI 10.2105/AJPH.56.2.169; WILLIAMS WL, 1984, J AM COLL CARDIOL, V4, P477, DOI 10.1016/S0735-1097(84)80090-X; 1985, HDB LABOR STATISTICS	28	18	18	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					383	389		10.7326/0003-4819-117-5-383	http://dx.doi.org/10.7326/0003-4819-117-5-383			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503329				2022-12-28	WOS:A1992JK67800006
J	NOVELLO, AC; SHOSKY, J				NOVELLO, AC; SHOSKY, J			UNDERAGE DRINKING - A REPORT FROM THE INSPECTOR GENERAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US PHS,OFF SURGEON GEN,ROOM 718-E,200 INDEPENDENCE AVE SW,WASHINGTON,DC 20201	United States Public Health Service								1991, OEI099100652 PUBL	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					961	961						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK129	1501315				2022-12-28	WOS:A1992JK12900006
J	NOSE, A; MAHAJAN, VB; GOODMAN, CS				NOSE, A; MAHAJAN, VB; GOODMAN, CS			CONNECTIN - A HOMOPHILIC CELL-ADHESION MOLECULE EXPRESSED ON A SUBSET OF MUSCLES AND THE MOTONEURONS THAT INNERVATE THEM IN DROSOPHILA	CELL			English	Article							MEMBRANE GLYCOPROTEIN-IB; AMINO-ACID SEQUENCE; LEUCINE-RICH ALPHA-2-GLYCOPROTEIN; SELECT APPROPRIATE PATHWAYS; VENTRAL PATTERN-FORMATION; CENTRAL-NERVOUS-SYSTEM; FACTOR-BINDING DOMAIN; GROWTH CONE GUIDANCE; GRASSHOPPER EMBRYO; VONWILLEBRAND-FACTOR	Each abdominal hemisegment in the Drosophila embryo contains a stereotyped array of 30 muscles, each specifically innervated by one or a few motoneurons. We screened 11,000 enhancer trap lines, isolated several expressing beta-galactosidase in small subsets of muscle fibers prior to innervation, and identified two of these as inserts in connectin and Toll, members of the leucine-rich repeat gene family. Connectin contains a signal sequence, ten leucine-rich repeats, and a putative phosphatidylinositol membrane linkage; in S2 cells, connectin can mediate homophilic cell adhesion. Connectin is expressed on the surface of eight muscles, the motoneurons that innervate them, and several glial cells along the pathways leading to them. During synapse formation, the protein localizes to synaptic sites; afterward, it largely disappears. Thus, connectin is a novel cell adhesion molecule whose expression suggests a role in target recognition.			NOSE, A (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.				PHS HHS [18366] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BALL EE, 1985, DEV BIOL, V111, P383, DOI 10.1016/0012-1606(85)90492-0; BALL EE, 1985, J NEUROSCI, V5, P1808; BALL EE, 1985, DEV BIOL, V111, P399, DOI 10.1016/0012-1606(85)90493-2; BALL EE, 1985, DEV BIOL, V111, P417, DOI 10.1016/0012-1606(85)90494-4; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BATE M, 1990, DEVELOPMENT, V110, P791; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CASH S, 1992, J NEUROSCI, V12, P2051; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; Crossley AC, 1978, GENETICS BIOL DROS B, V2, P499; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; EISEN JS, 1991, NEURON, V6, P767, DOI 10.1016/0896-6273(91)90173-W; EISEN JS, 1989, NEURON, V2, P1097, DOI 10.1016/0896-6273(89)90234-1; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FREDIEU JR, 1989, DEVELOPMENT, V106, P739; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GERTTULA S, 1988, GENETICS, V119, P123; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HANDA M, 1986, J BIOL CHEM, V261, P2579; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P26; HATTA K, 1990, SCIENCE, V250, P802, DOI 10.1126/science.1978412; HO RK, 1983, NATURE, V301, P66, DOI 10.1038/301066a0; HORTSCH M, 1991, ANNU REV CELL BIOL, V7, P505, DOI 10.1146/annurev.cb.07.110191.002445; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JOHANSEN J, 1989, J NEUROSCI, V9, P710; JOHANSEN J, 1989, J NEUROSCI, V9, P4318; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANDMESSER LT, 1980, ANNU REV NEUROSCI, V3, P279, DOI 10.1146/annurev.ne.03.030180.001431; LEISS D, 1988, DEVELOPMENT, V104, P525; LIU DWC, 1990, J NEUROSCI, V10, P3947, DOI 10.1523/JNEUROSCI.10-12-03947.1990; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PIKE SH, 1990, J NEUROSCI, V10, P44; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SINK H, 1991, DEVELOPMENT, V113, P701; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TOSNEY KW, 1985, J NEUROSCI, V5, P2345; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	73	269	272	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					553	567		10.1016/0092-8674(92)90426-D	http://dx.doi.org/10.1016/0092-8674(92)90426-D			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505024				2022-12-28	WOS:A1992JJ88600006
J	VOGELSTEIN, B; KINZLER, KW				VOGELSTEIN, B; KINZLER, KW			P53 FUNCTION AND DYSFUNCTION	CELL			English	Review							WILD-TYPE P53; MUTANT P53; PROTEINS BIND; MUTATIONS; TUMORIGENESIS; SEQUENCE; GENE; LINE				VOGELSTEIN, B (corresponding author), JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231, USA.							BAKER SJ, 1990, CANCER RES, V50, P7717; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILLER C W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P386; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STENGER CW, 1992, J MOL BIOL, V5, P102; STURZBECHER HW, 1987, ONCOGENE, V1, P201; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	31	1985	2045	0	60	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					523	526		10.1016/0092-8674(92)90421-8	http://dx.doi.org/10.1016/0092-8674(92)90421-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505019				2022-12-28	WOS:A1992JJ88600001
J	AFEYAN, NB; GORDON, NF; REGNIER, FE				AFEYAN, NB; GORDON, NF; REGNIER, FE			AUTOMATED REAL-TIME IMMUNOASSAY OF BIOMOLECULES	NATURE			English	Article							PERFUSION CHROMATOGRAPHY; AFFINITY-CHROMATOGRAPHY; IMMUNOGLOBULIN-G; SEPARATION		PURDUE UNIV,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	AFEYAN, NB (corresponding author), MIT,PERSEPT BIOSYST INC,UNIV PK,38 SIDNEY ST,SUITE 100,CAMBRIDGE,MA 02139, USA.							AFEYAN NB, 1990, J CHROMATOGR, V519, P1, DOI 10.1016/0021-9673(90)85132-F; AFEYAN NB, 1992, HPLC 92; DEALWIS WU, 1985, ANAL CHEM, V57, P2754; HAGE DS, 1987, J CHROMATOGR, V386, P37; OHLSON S, 1978, FEBS LETT, V93, P5, DOI 10.1016/0014-5793(78)80792-3; REGNIER FE, 1991, NATURE, V350, P634, DOI 10.1038/350634a0; REGNIER FE, 1991, 11TH INT S HPLC PROT	7	29	30	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					603	604		10.1038/358603a0	http://dx.doi.org/10.1038/358603a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1501716				2022-12-28	WOS:A1992JH82900066
J	DAVID, M; LARNER, AC				DAVID, M; LARNER, AC			ACTIVATION OF TRANSCRIPTION FACTORS BY INTERFERON-ALPHA IN A CELL-FREE SYSTEM	SCIENCE			English	Article							ISGF3; INDUCTION; GENES	The signal transduction mechanisms of interferons (IFNs) remain unclear partly because no effect of IFN has been reproducible in a cell-free system. IFN-alpha rapidly induces the transcription of a set of early response genes, and a multicomponent transcriptional activator, interferon stimulated gene factor 3 (ISGF3), is activated within minutes after binding of IFN-alpha to its receptor. A system was developed in which IFN-alpha activated ISGF3 in homogenates of HeLa cells. Subcellular fractionation revealed that incubation of a plasma membrane-enriched fraction with IFN-alpha was sufficient to activate the regulatory subcomponent of ISGF3.	CTR BIOL EVALUAT & RES, DIV CYTOKINE BIOL, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA)								DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, UNPUB; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289	13	70	72	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					813	815		10.1126/science.1496402	http://dx.doi.org/10.1126/science.1496402			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496402				2022-12-28	WOS:A1992JG85100040
J	KEENLYSIDE, RA; HAWKINS, AS; JOHNSON, AM; ADLER, MW				KEENLYSIDE, RA; HAWKINS, AS; JOHNSON, AM; ADLER, MW			FOR DEBATE - ATTITUDES TO TRACING AND NOTIFYING CONTACTS OF PEOPLE WITH HIV-INFECTION	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; PARTNER NOTIFICATION; AIDS				KEENLYSIDE, RA (corresponding author), UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON WC1 8AA,ENGLAND.			Johnson, Anne/0000-0003-1330-7100				ADLER MW, 1988, BRIT MED J, V296, P1420, DOI 10.1136/bmj.296.6634.1420; CATES W, 1988, AM J PUBLIC HEALTH, V78, P1533, DOI 10.2105/AJPH.78.12.1533; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; DROTMAN DP, 1989, ANN INTERN MED, V110, P680, DOI 10.7326/0003-4819-110-9-680; ERON J J JR, 1990, AIDS (London), V4, pS193; FEINBERG J, 1990, AIDS (London), V4, pS209; GIESECKE J, 1990, LANCET, V336, P508, DOI 10.1016/0140-6736(90)92058-P; GIESECKE J, 1991, LANCET, V338, P1096, DOI 10.1016/0140-6736(91)91962-T; GOSTIN L, 1987, AM J PUBLIC HEALTH, V77, P361, DOI 10.2105/AJPH.77.3.361; JONES JL, 1990, JAMA-J AM MED ASSOC, V264, P1284, DOI 10.1001/jama.264.10.1284; LEEN CLS, 1989, LANCET, V2, P512; MILLER D, 1989, AIDS, V3, pS187, DOI 10.1097/00002030-198901001-00027; OSBORN JE, 1988, NEW ENGL J MED, V318, P444, DOI 10.1056/NEJM198802183180710; POTTERAT JJ, 1989, AM J PUBLIC HEALTH, V29, P874; RAMSTEDT K, 1990, SEX TRANSM DIS, V17, P37, DOI 10.1097/00007435-199017010-00008; RHAME FS, 1989, NEW ENGL J MED, V320, P1249; RUTHERFORD GW, 1988, JAMA-J AM MED ASSOC, V259, P3609, DOI 10.1001/jama.259.24.3609; SESNAN K, 1989, VENEROLOGY, V2, P75; TOOMEY KE, 1989, AIDS, V3, pS57, DOI 10.1097/00002030-198901001-00009; VERNON TM, 1988, JAMA-J AM MED ASSOC, V260, P3274; WYKOFF RF, 1988, JAMA-J AM MED ASSOC, V259, P3563, DOI 10.1001/jama.259.24.3563; 1989, REPORT CONSULTATION; 1980, HDB CONTACT TRACING; 1991, AIDS HIV QUARTERLY S; 1983, MMWR, V37, P393	25	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					165	168		10.1136/bmj.305.6846.165	http://dx.doi.org/10.1136/bmj.305.6846.165			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515835	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JF06300029
J	BARNES, D; HUGHES, RAC				BARNES, D; HUGHES, RAC			GUILLAIN-BARRE-SYNDROME AFTER TREATMENT WITH STREPTOKINASE	BRITISH MEDICAL JOURNAL			English	Letter							THERAPY				BARNES, D (corresponding author), GUYS HOSP,LONDON SE1 9RT,ENGLAND.							ARROWSMITH JB, 1985, ANN INTERN MED, V103, P302, DOI 10.7326/0003-4819-103-2-302_2; CICALE MJ, 1987, SOUTHERN MED J, V80, P1068, DOI 10.1097/00007611-198708000-00047; EDEN KV, 1983, JAMA-J AM MED ASSOC, V249, P2020, DOI 10.1001/jama.1983.03330390028021; LEAF DA, 1984, ANN INTERN MED, V100, P617, DOI 10.7326/0003-4819-100-4-617_2; MCDONAGH AJG, 1987, BRIT MED J, V294, P213	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1225	1225		10.1136/bmj.304.6836.1225-b	http://dx.doi.org/10.1136/bmj.304.6836.1225-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515794	Green Published, Bronze			2022-12-28	WOS:A1992HT96400027
J	COOKE, MW; COOKE, HM; GLUCKSMAN, EE				COOKE, MW; COOKE, HM; GLUCKSMAN, EE			MANAGEMENT OF SUDDEN BEREAVEMENT IN THE ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess facilities available for the suddenly bereaved in accident and emergency departments and variations in care of bereaved relatives. Design - Postal questionnaire survey. Setting - England and Wales. Subjects - All 98 accident and emergency departments treating over 50 000 patients a year, 78 of which replied. Main outcome measures - Number of departments with specific facilities, staff training, and procedures for dealing with bereavement. Results - 60 hospitals had a specific room for bereaved relatives; the remainder used multipurpose rooms. In 49 hospitals relatives were taken to the room by a nurse with sole responsibility for caring for them. In 40 hospitals the nurse stayed with the relatives and 66 updated relatives on the patient's condition. Facilities for viewing the body privately were poor, and relatives often had to ask to be left alone. 25 departments gave no written information on bereavement and only four routinely followed up relatives. Further training was requested by staff in 44 departments. Conclusions - Although facilities could be improved, immediate care of relatives is good. Care over subsequent weeks and preparation for this period is invariably inadequate.	UNIV LONDON KINGS COLL HOSP,DEPT ACCID & EMERGENCY,LONDON SE5 8RX,ENGLAND; IAIN RENNIE HOSPICE HOME,AYLESBURY,BUCKS,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London								MCCLAUCHLAN CAJ, 1990, BMJ, V301, P1145; RAPHAEL B, 1977, ARCH GEN PSYCHIAT, V34, P1450; TACHAKRA SS, 1986, BR J A E MED, V1, P10; YATES DW, 1990, BRIT MED J, V301, P29, DOI 10.1136/bmj.301.6742.29	4	19	19	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1207	1209		10.1136/bmj.304.6836.1207	http://dx.doi.org/10.1136/bmj.304.6836.1207			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT964	1515788	Green Published, Bronze			2022-12-28	WOS:A1992HT96400017
J	DICKSON, B; SPRENGER, F; MORRISON, D; HAFEN, E				DICKSON, B; SPRENGER, F; MORRISON, D; HAFEN, E			RAF FUNCTIONS DOWNSTREAM OF RAS1 IN THE SEVENLESS SIGNAL TRANSDUCTION PATHWAY	NATURE			English	Article							RECEPTOR TYROSINE KINASE; DROSOPHILA-MELANOGASTER; PUTATIVE RECEPTOR; CELL FATE; PROTEIN; GENE; EYE; TORSO; REQUIREMENT; ACTIVATION	SPECIFICATION of the R7 cell fate in the developing Drosophila eye requires activation of the Sevenless (Sev) receptor tyrosine kinase, located on the surface of the R7 precursor cell, by its interaction with the Boss protein, expressed on the surface of the neighbouring R8 cell1-3. Four genes that participate in the intracellular transmission of this signal have so far been identified and molecularly characterized: Ras1, Sos, Gap1 and sina (refs 4-8). The Drosophila homologue of the mammalian Raf-1 serine/threonine kinase, which has been implicated in signal transduction pathways activated by many receptor tyrosine kinases (reviewed in refs 9 and 10), is encoded by the raf locus (also known as l(1)polehole11, Draf-1 12 or Draf13). Here we show that the Drosophila Raf serine/threonine kinase also plays a crucial role in the R7 pathway: the response to Sev activity is dependent on raf function, and a constitutively activated Raf protein can induce R7 cell development in the absence of sev function. We also present genetic evidence suggesting that Raf acts downstream of Ras1 and upstream of Sina in this signal transduction cascade.	MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT,W-7400 TUBINGEN,GERMANY; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	DICKSON, B (corresponding author), UNIV ZURICH,INST ZOOL,WINTERTHORERSTR 190,CH-8057 ZURICH,SWITZERLAND.			Dickson, Barry/0000-0003-0715-892X				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; KARCH F, 1981, J MOL BIOL, V148, P219, DOI 10.1016/0022-2836(81)90536-2; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KRAMERS PGN, 1983, MUTAT RES, V107, P187, DOI 10.1016/0027-5107(83)90162-8; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SPRENGER F, IN PRESS CELL; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	29	290	300	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					600	603		10.1038/360600a0	http://dx.doi.org/10.1038/360600a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461284				2022-12-28	WOS:A1992KB95900090
J	RUSSELL, SJ; LLEWELYN, MB; HAWKINS, RE				RUSSELL, SJ; LLEWELYN, MB; HAWKINS, RE			MONOCLONAL-ANTIBODIES IN MEDICINE .3. PRINCIPLES OF ANTIBODY THERAPY	BRITISH MEDICAL JOURNAL			English	Article							INTERLEUKIN-2 RECEPTOR; REMISSION INDUCTION; HUMANIZED ANTIBODY; CD4 ANTIBODY; SEPTIC SHOCK; SOLID TUMORS; LYMPHOMA; DISEASE; VIRUS; TRIAL	The success of monoclonal antibodies in clinical practice is dependent on good design. Finding a suitable target is the most important part as other properties of the antibody can be altered by genetic engineering. Antibodies that target lymphocyte antigens offer less toxic immunosuppressive treatment than currently available drugs and the first monoclonal antibody approved for human use is an immunosuppressive agent for treating rejection of renal transplants. Human trials of monoclonal antibodies to treat septic shock have been done and antibodies are also being developed to target common pathogens such as herpes simplex virus. Although monoclonal antibodies against cancer have been much heralded, their success has been limited by the poor access to the inside of tumours. Treatment of blood cancers has been more successful and a human antibody against B cell malignancies is being clinically tested. As knowledge about natural immune responses and antibody engineering increases many more monoclonals are likely to feature in clinical practice.	ADDENBROOKES HOSP,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	RUSSELL, SJ (corresponding author), MRC,CAMBRIDGE CB2 2QH,ENGLAND.		Llewelyn, Martin/A-7194-2011	Llewelyn, Martin/0000-0002-6811-1124				BAGSHAWE KD, 1989, BRIT J CANCER, V60, P275, DOI 10.1038/bjc.1989.270; BROWN PS, 1991, P NATL ACAD SCI USA, V88, P2663, DOI 10.1073/pnas.88.7.2663; BROWN SL, 1989, BLOOD, V73, P651; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; CARPENTER CB, 1990, NEW ENGL J MED, V322, P1224, DOI 10.1056/NEJM199004263221709; CO MS, 1991, P NATL ACAD SCI USA, V88, P2869, DOI 10.1073/pnas.88.7.2869; DVORAK HF, 1991, CANCER CELL-MON REV, V3, P77; DVORAK HF, 1988, AM J PATHOL, V133, P95; DYER MJS, 1990, LEUKEMIA LYMPHOMA, V2, P179, DOI 10.3109/10428199009053522; EMMRICH J, 1991, LANCET, V338, P570, DOI 10.1016/0140-6736(91)91133-F; EXLEY AR, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91337-A; GORMAN SD, 1991, P NATL ACAD SCI USA, V88, P4181, DOI 10.1073/pnas.88.10.4181; HALE G, 1988, LANCET, V2, P1394; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HAWKINS RE, 1992, BRIT MED J, V305, P1348, DOI 10.1136/bmj.305.6865.1348; HIEPE F, 1991, LANCET, V338, P1529, DOI 10.1016/0140-6736(91)92353-4; HINDS CJ, 1992, BRIT MED J, V304, P132, DOI 10.1136/bmj.304.6820.132; HORNEFF G, 1991, ARTHRITIS RHEUM, V34, P129, DOI 10.1002/art.1780340202; JANSON CH, 1989, CANCER IMMUNOL IMMUN, V28, P225; KULIG K, 1992, NEW ENGL J MED, V326, P1677; MATHIESON PW, 1990, NEW ENGL J MED, V323, P250, DOI 10.1056/NEJM199007263230407; MILENIC DE, 1991, CANCER RES, V51, P6363; NICOLAS JF, 1991, LANCET, V338, P321, DOI 10.1016/0140-6736(91)90465-2; ORDER SE, 1990, INT J RADIAT ONCOL, V18, P981, DOI 10.1016/0360-3016(90)90431-I; PRESS OW, 1989, J CLIN ONCOL, V7, P1027, DOI 10.1200/JCO.1989.7.8.1027; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; REINKE P, 1991, LANCET, V338, P702, DOI 10.1016/0140-6736(91)91285-3; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; SAVIN J, 1990, VALUE ANTIBODY ENG T; SCHLOM J, 1992, CANCER RES, V52, P1067; SOLLILOU J, 1990, NEW ENGL J MED, V322, P1175; SPICKETT GP, 1991, LANCET, V337, P281, DOI 10.1016/0140-6736(91)90882-P; TEMPEST PR, 1991, BIO-TECHNOL, V9, P266, DOI 10.1038/nbt0391-266; VANDERLUBBE PA, 1991, LANCET, V337, P1349, DOI 10.1016/0140-6736(91)93023-3; VITETTA ES, 1991, CANCER RES, V51, P4052; VRIESENDORP HM, 1991, J CLIN ONCOL, V9, P918, DOI 10.1200/JCO.1991.9.6.918; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WEBSTER ADB, 1991, BRIT MED J, V303, P375, DOI 10.1136/bmj.303.6799.375; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1985, NEW ENGL J MED, V313, P337	41	18	20	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1424	1429		10.1136/bmj.305.6866.1424	http://dx.doi.org/10.1136/bmj.305.6866.1424			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486312	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992KB85600032
J	BULSTRODE, CJK; GRAY, AJM; ANDERSON, M; HAWKE, CI				BULSTRODE, CJK; GRAY, AJM; ANDERSON, M; HAWKE, CI			NEW-DEAL FOR JUNIOR DOCTORS HOURS - HOW TO ACHIEVE IT	BRITISH MEDICAL JOURNAL			English	Article									OXFORD AREA HLTH AUTHOR,OXFORD OX3 7LF,ENGLAND		BULSTRODE, CJK (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT ORTHOPAED SURG,OXFORD OX3 9DU,ENGLAND.							1991, JUNIOR DOCTORS NEW D; 1991, BMJ, V302, P570	2	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1992	305	6863					1203	1205		10.1136/bmj.305.6863.1203	http://dx.doi.org/10.1136/bmj.305.6863.1203			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467724	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JY77700024
J	BRYAN, GT; DAUGHERTY, RM; DEAL, WB; GONNELLA, JS; HALLER, MJ; HEROLD, AD; NIXON, SA; WILSON, EA; BARZANSKY, B; JONAS, HS; SINGER, I				BRYAN, GT; DAUGHERTY, RM; DEAL, WB; GONNELLA, JS; HALLER, MJ; HEROLD, AD; NIXON, SA; WILSON, EA; BARZANSKY, B; JONAS, HS; SINGER, I			REPORT OF THE MEDICAL-SCHOOLS SECTION PRIMARY-CARE-TASK-FORCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPECIALTY; AREAS; PHYSICIANS; MINNESOTA; TRENDS		AMER MED ASSOC,OFF UNDERGRAD MED EDUC,515 N STATE ST,CHICAGO,IL 60610; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,PHILADELPHIA,PA 19107; CREIGHTON UNIV,SCH MED,OMAHA,NE 68178; UNIV S FLORIDA,SCH MED,TAMPA,FL 33620; UNIV TEXAS,SCH MED,HOUSTON,TX 77025; UNIV ALABAMA,SCH MED,BIRMINGHAM,AL 35233; UNIV KENTUCKY,COLL MED,LEXINGTON,KY 40506; UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550; UNIV NEVADA,SCH MED,RENO,NV 89557	American Medical Association; Jefferson University; Creighton University; State University System of Florida; University of South Florida; University of Texas System; University of Alabama System; University of Alabama Birmingham; University of Kentucky; University of Texas System; University of Texas Medical Branch Galveston; Nevada System of Higher Education (NSHE); University of Nevada Reno								BARNETT P, 1991, JAMA-J AM MED ASSOC, V262, P2864; CAMPOSOUTCALT D, 1989, ACAD MED, V64, P610, DOI 10.1097/00001888-198910000-00013; COFFIN SE, 1989, ACAD MED, V64, P600, DOI 10.1097/00001888-198910000-00011; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; DENNIS T, 1988, AM J PUBLIC HEALTH, V78, P1577, DOI 10.2105/AJPH.78.12.1577; HUGHES RG, 1991, NEW ENGL J MED, V325, P404, DOI 10.1056/NEJM199108083250606; KIEL J, 1991, STATE HLTH LEGISLATI, V19, P1; KINDIG DA, 1987, INQUIRY-J HEALTH CAR, V24, P136; KINDIG DA, 1989, HEALTH AFFAIR, V8, P63, DOI 10.1377/hlthaff.8.2.63; LEONARDSON G, 1985, J MED EDUC, V60, P37; LIEU TA, 1989, ACAD MED, V64, P622, DOI 10.1097/00001888-198910000-00015; LYTTLE CS, 1991, ANN INTERN MED, V114, P36, DOI 10.7326/0003-4819-114-1-36; POPE GC, 1992, HEALTH AFFAIR, V11, P181, DOI 10.1377/hlthaff.11.1.181; RABINOWITZ HK, 1988, NEW ENGL J MED, V319, P480, DOI 10.1056/NEJM198808253190805; Schmittling G, 1991, Fam Med, V23, P297; SCHROEDER SA, 1989, JAMA-J AM MED ASSOC, V262, P803, DOI 10.1001/jama.262.6.803; VERBY JE, 1988, J MED EDUC, V63, P427; WHITCOMB M, 1991, 13 WAMI RUR HLTH RES	18	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1092	1094		10.1001/jama.1992.03490090034011	http://dx.doi.org/10.1001/jama.1992.03490090034011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK681	1501331				2022-12-28	WOS:A1992JK68100005
J	RADOVICK, S; NATIONS, M; DU, YF; BERG, LA; WEINTRAUB, BD; WONDISFORD, FE				RADOVICK, S; NATIONS, M; DU, YF; BERG, LA; WEINTRAUB, BD; WONDISFORD, FE			A MUTATION IN THE POU-HOMEODOMAIN OF PIT-1 RESPONSIBLE FOR COMBINED PITUITARY-HORMONE DEFICIENCY	SCIENCE			English	Article							THYROID-STIMULATING HORMONE; TRANSCRIPTION FACTOR PIT-1; RAT GROWTH-HORMONE; BETA-SUBUNIT GENE; PROLACTIN PROMOTER; INHIBITORY ELEMENT; DOMAIN PROTEIN; EXPRESSION; ACTIVATION; RESISTANCE	Pit-1 is a pituitary-specific transcription factor responsible for pituitary development and hormone expression in mammals. Mutations in the gene encoding Pit-1 have been found in two dwarf mouse strains displaying hypoplasia of growth hormone, prolactin, and thyroid-stimulating, hormone-secreting cell types in the anterior pituitary. A point mutation in this gene was identified on one allele in a patient with combined pituitary hormone deficiency. Mutant Pit-1 binds DNA normally but acts as a dominant inhibitor of Pit-1 action in the pituitary.	RAINBOW BABIES & CHILDRENS HOSP,DEPT PEDIAT,DIV ENDOCRINOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,DEPT MED,DIV ENDOCRINOL & HYPERTENS,CLEVELAND,OH 44106; NIDDKD,MOLEC & CELLULAR ENDOCRINOL BRANCH,BETHESDA,MD 20892	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; University Hospitals of Cleveland; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BODENNER DL, 1991, J BIOL CHEM, V266, P21666; CAMPER SA, 1985, J BIOL CHEM, V260, P2246; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; DACOUVOUTETAKIS C, 1990, AM J HUM GENET, V46, P988; Dahlquist F W, 1978, Methods Enzymol, V48, P270; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAYASHIZAKI Y, 1989, EMBO J, V8, P2291, DOI 10.1002/j.1460-2075.1989.tb08355.x; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; LEW AM, 1991, NUCLEIC ACIDS RES, V19, P6329, DOI 10.1093/nar/19.22.6329; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIRA SA, 1988, P NATL ACAD SCI USA, V85, P4755, DOI 10.1073/pnas.85.13.4755; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; PHILLIPS JA, 1989, METABOLIC BASIS INHE, P1965; ROGOL AD, 1976, J PEDIATR-US, V88, P953, DOI 10.1016/S0022-3476(76)81048-7; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; STEINFELDER HJ, 1992, J CLIN INVEST, V89, P409, DOI 10.1172/JCI115600; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; STEINFELDER HJ, IN PRESS P NATL ACAD; TATSUMI K, 1992, NAT GENET, V1, P56, DOI 10.1038/ng0492-56; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; USALA SJ, 1988, MOL ENDOCRINOL, V2, P2217; WEISS J, 1992, NEW ENGL J MED, V326, P179, DOI 10.1056/NEJM199201163260306; WIT JM, 1989, HORM RES, V32, P170, DOI 10.1159/000181284; WONDISFORD FE, UNPUB; YAN GZ, 1991, MOL ENDOCRINOL, V5, P1488, DOI 10.1210/mend-5-10-1488	31	357	365	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1115	1118		10.1126/science.257.5073.1115	http://dx.doi.org/10.1126/science.257.5073.1115			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509262				2022-12-28	WOS:A1992JJ88400032
J	PAN, T; UHLENBECK, OC				PAN, T; UHLENBECK, OC			A SMALL METALLORIBOZYME WITH A 2-STEP MECHANISM	NATURE			English	Article							PHENYLALANINE TRANSFER-RNA; YEAST TRANSFER RNAPHE; SELF-SPLICING RNA; CLEAVAGE; HYDROLYSIS	An RNA molecule consisting of an asymmetric internal loop of six nucleotides can be rapidly and specifically cleaved by Pb2+ in the presence of Mg2+. The 5' cleavage product terminates with a 3' phosphomonoester generated from a 2',3'-cyclic phosphodiester reaction intermediate. This two-step reaction mechanism resembles that of many protein ribonucleases but has not previously been observed for reactions catalysed by RNA.			PAN, T (corresponding author), UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA.							Altman S., 1989, ADV ENZYMOL RAMB, V62, P1; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BROWN RS, 1983, NATURE, V303, P543, DOI 10.1038/303543a0; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CECH TR, 1990, REV BIOCH, V59, P5543; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; FARKAS WR, 1968, BIOCHIM BIOPHYS ACTA, V155, P401, DOI 10.1016/0005-2787(68)90184-6; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; KAO TH, 1980, P NATL ACAD SCI-BIOL, V77, P3360, DOI 10.1073/pnas.77.6.3360; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PACE NR, 1990, J BIOL CHEM, V265, P3587; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; RUBIN JR, 1983, J BIOMOL STRUCT DYN, V1, P639, DOI 10.1080/07391102.1983.10507471; SUNDARALINGAM M, 1984, INT J QUANTUM CHEM, P355; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0	19	205	216	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 13	1992	358	6387					560	563		10.1038/358560a0	http://dx.doi.org/10.1038/358560a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1501711				2022-12-28	WOS:A1992JH82900050
J	ARCH, R; WIRTH, K; HOFMANN, M; PONTA, H; MATZKU, S; HERRLICH, P; ZOLLER, M				ARCH, R; WIRTH, K; HOFMANN, M; PONTA, H; MATZKU, S; HERRLICH, P; ZOLLER, M			PARTICIPATION IN NORMAL IMMUNE-RESPONSES OF A METASTASIS-INDUCING SPLICE VARIANT OF CD44	SCIENCE			English	Article							ENDOTHELIAL-CELL RECOGNITION; MONOCLONAL-ANTIBODIES; RECEPTOR; ACTIVATION; TUMOR; ADHESION; MOLECULE; RAT	A variant of the glycoprotein CD44 (CD44v) that shares sequences with variants causally involved in metastasis formation is transiently expressed on B and T lymphocytes and macrophages after antigenic stimulation and in the postnatal period. Antibodies to the variant hinder in vivo activation of both B and T cells. The observation that a protein domain that is expressed on CD44 and required for the lymphatic spread of tumor cells can catalyze an essential step in the process of lymphocyte activation supports the idea that metastasizing tumor cells mimic lymphocyte behavior.	GERMAN CANC RES CTR,INST RADIOL & PATHOPHYSIOL,NEUENHEIMER FELD 280,W-6900 HEIDELBERG 1,GERMANY; KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET & TOXIKOL,W-7500 KARLSRUHE 1,GERMANY; E MERCK & CO,W-6100 DARMSTADT,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology; Merck KGaA			Hofmann-Apitius, Martin/E-6123-2018	Hofmann-Apitius, Martin/0000-0001-9012-6720				ARCH RH, UNPUB; DENNING SM, 1990, J IMMUNOL, V144, P7; ENGVALL E, 1972, J IMMUNOL, V109, P129; FIDLER JM, 1975, CELL IMMUNOL, V16, P223, DOI 10.1016/0008-8749(75)90114-8; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P4654, DOI 10.1073/pnas.86.12.4654; GOWANS JL, 1964, P ROY SOC LOND A MAT, V159, P282; GUNTHERT U, 1991, INVAS METAST, V65, P13; HOFMANN M, 1991, CANCER RES, V51, P5292; HUET S, 1989, J IMMUNOL, V143, P798; IDZERDA RL, 1989, P NATL ACAD SCI USA, V86, P4659, DOI 10.1073/pnas.86.12.4659; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; JERNE NK, 1963, SCIENCE, V140, P405, DOI 10.1126/science.140.3565.405; MATZKU S, 1983, INVAS METAST, V3, P109; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; RITTENBERG MB, 1969, P SOC EXP BIOL MED, V132, P575; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; ROBINSON AP, 1985, IMMUNOLOGY, V55, P527; RUDY W, UNPUB; SEITER S, UNPUB; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; TOLG C, UNPUB; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; ZOLLER M, 1990, SCAND J IMMUNOL, V31, P619, DOI 10.1111/j.1365-3083.1990.tb02813.x	25	444	464	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					682	685		10.1126/science.1496383	http://dx.doi.org/10.1126/science.1496383			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496383				2022-12-28	WOS:A1992JF85200041
J	STRANG, J; GRIFFITHS, P; POWIS, B; GOSSOP, M				STRANG, J; GRIFFITHS, P; POWIS, B; GOSSOP, M			1ST USE OF HEROIN - CHANGES IN ROUTE OF ADMINISTRATION OVER TIME	BRITISH MEDICAL JOURNAL			English	Article											STRANG, J (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,NATL ADDICT CTR,DRUG TRANSIT STUDY,LONDON SE5 8AF,ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725				BEWLEY TH, 1967, BRIT MED J, V2, P498, DOI 10.1136/bmj.2.5550.498; BRETTLE RP, 1987, BRIT MED J, V295, P421, DOI 10.1136/bmj.295.6595.421; GOSSOP M, 1988, BRIT J ADDICT, V83, P1159; PARKER H, 1987, BRIT J ADDICT, V82, P147; 1991, STATISTICAL B MISUSE	5	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1222	1223		10.1136/bmj.304.6836.1222	http://dx.doi.org/10.1136/bmj.304.6836.1222			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT964	1515792	Green Published, Bronze			2022-12-28	WOS:A1992HT96400022
J	HECKER, JF				HECKER, JF			REGULAR REVIEW - POTENTIAL FOR EXTENDING SURVIVAL OF PERIPHERAL INTRAVENOUS INFUSIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Review							IN-LINE FILTRATION; TRANSDERMAL GLYCERYL TRINITRATE; PROSPECTIVE CLINICAL-TRIAL; PARENTERAL-NUTRITION; POSTINFUSION PHLEBITIS; SUPERFICIAL PHLEBITIS; VENOUS CATHETERS; THROMBOPHLEBITIS; PREVENTION; COMPLICATIONS		ROYAL POSTGRAD MED SCH, DEPT SURG, LONDON W12 0HS, ENGLAND	Imperial College London								ADAMS SD, 1986, HEART LUNG, V15, P134; ALLCUTT DA, 1983, BRIT J SURG, V70, P111, DOI 10.1002/bjs.1800700219; ALPAN G, 1984, PEDIATRICS, V74, P375; ANDERSON LH, 1951, J LAB CLIN MED, V38, P585; ANSEL HC, 1971, J AMER MED ASSOC, V218, P1052, DOI 10.1001/jama.1971.03190200082033; BAILEY MJ, 1979, BRIT MED J, V1, P1671, DOI 10.1136/bmj.1.6179.1671; BASS J, 1985, CAN J SURG, V28, P124; BASSAN MM, 1983, CHEST, V84, P439, DOI 10.1378/chest.84.4.439; BERGQVIST D, 1967, NORDISK MED SCAND, V182, P93; BIVINS BA, 1979, SURGERY, V85, P388; CARRIZOSA J, 1974, ANTIMICROB AGENTS CH, V5, P192, DOI 10.1128/AAC.5.2.192; CARTER JFB, 1951, LANCET, V261, P20; CARTER JFB, 1952, LANCET, V263, P660; CHAMBERLAND ME, 1977, AM J HOSP PHARM, V34, P1068, DOI 10.1093/ajhp/34.10.1068; CLARK P B, 1960, Postgrad Med J, V36, P55; COLLIN J, 1973, BMJ-BRIT MED J, V4, P456, DOI 10.1136/bmj.4.5890.456; COX DR, 1972, J R STAT SOC B, V34, P187; DANIELL HW, 1973, JAMA-J AM MED ASSOC, V226, P1317, DOI 10.1001/jama.226.11.1317; DECOCK C, 1984, PHARM WEEKBLAD, V6, P88, DOI 10.1007/BF01953960; DELUCA PP, 1975, AM J HOSP PHARM, V32, P1001, DOI 10.1093/ajhp/32.10.1001; EEROLA R, 1964, Ann Chir Gynaecol Fenn, V53, P519; ELFVING G, 1966, LANCET, V1, P953; ENGER E, 1976, ACTA PAEDIATR SCAND, V65, P248, DOI 10.1111/j.1651-2227.1976.tb16545.x; EREMIN O, 1977, MED J AUSTRALIA, V2, P528, DOI 10.5694/j.1326-5377.1977.tb114619.x; EVANS WE, 1976, AM J HOSP PHARM, V33, P1160, DOI 10.1093/ajhp/33.11.1160; FALCHUK KH, 1985, NEW ENGL J MED, V312, P78, DOI 10.1056/NEJM198501103120203; Fleiss JL, 1981, STAT METHODS RATES P; Flores-Vega C H, 1970, Mo Med, V67, P305; FONKALSRUD EW, 1968, SURGERY, V63, P280; FONKALSRUD EW, 1971, SURG GYNECOL OBSTETR, V133, P253; FONKALSRUD EW, 1968, J SURG RES, V8, P539, DOI 10.1016/0022-4804(68)90005-X; Francombe P, 1988, Nurs Times, V84, P34; GAUKROGER PB, 1988, ANAESTH INTENS CARE, V16, P265, DOI 10.1177/0310057X8801600305; GAZITUA R, 1979, ARCH SURG-CHICAGO, V114, P897; HECKER JF, 1991, J PAEDIATR CHILD H, V27, P175, DOI 10.1111/j.1440-1754.1991.tb00381.x; HECKER JF, 1990, BRIT J CANCER, V62, P660, DOI 10.1038/bjc.1990.351; HECKER JF, 1987, BLOOD COMPATIBILITY, V2, P79; HECKER JF, 1990, PEDIATRIC REV COMMUN, V5, P51; HESSOV I, 1976, EUR J INTEN CARE MED, V2, P97, DOI 10.1007/BF01886123; ISAACS JW, 1977, AM J CLIN NUTR, V30, P552, DOI 10.1093/ajcn/30.4.552; JACQUOT C, 1989, ANN FR ANESTH, V8, P620, DOI 10.1016/S0750-7658(89)80178-9; JAKOBSEN CJ, 1986, J HOSP INFECT, V8, P217, DOI 10.1016/0195-6701(86)90116-7; KEELER C, 1987, HEART LUNG, V16, P201; KELSEY MC, 1984, J HOSP INFECT, V5, P313, DOI 10.1016/0195-6701(84)90081-1; KHAWAJA HT, 1988, BRIT J SURG, V75, P1212, DOI 10.1002/bjs.1800751223; KHAWAJA HT, 1991, J ROY SOC MED, V84, P69, DOI 10.1177/014107689108400205; KHAWAJA HT, 1988, BMJ-BRIT MED J, V299, P97; KOVACEVICH DS, 1986, JPEN-PARENTER ENTER, V10, P639, DOI 10.1177/0148607186010006639; LEBOWITZ MH, 1971, J AMER MED ASSOC, V215, P1937, DOI 10.1001/jama.215.12.1937; LEWIS GBH, 1985, BRIT J ANAESTH, V57, P220, DOI 10.1093/bja/57.2.220; LEWIS GBH, 1986, BRIT J ANAESTH, V58, P467, DOI 10.1093/bja/58.4.467-a; LEWIS GBH, 1984, ANAESTH INTENS CARE, V12, P27, DOI 10.1177/0310057X8401200106; LEWIS GBH, 1991, BRIT J SURG, V78, P500, DOI 10.1002/bjs.1800780437; LINARES J, 1985, J CLIN MICROBIOL, V21, P357; LODGE JPA, 1987, BRIT J CLIN PRACT, V41, P816; Lowe G.D., 1981, BR J INTRAVEN THER, V2, P42; MADDOX RR, 1977, AM J HOSP PHARM, V34, P29, DOI 10.1093/ajhp/34.1.29; MADDOX RR, 1983, CLIN PHARMACY, V2, P58; MAKAREWICZ PA, 1986, AM J SURG, V151, P126, DOI 10.1016/0002-9610(86)90022-X; MCNAIR TJ, 1959, LANCET, V2, P365; MESSING B, 1985, NEW ENGL J MED, V312, P1452; Moclair AE, 1991, INT J PHARM PRACT, V1, P38; MORGAN M, 1983, J PERIODONTOL, V54, P680, DOI 10.1902/jop.1983.54.11.680; MOSTERT JW, 1971, J AMER MED ASSOC, V216, P1483, DOI 10.1001/jama.1971.03180350059024; NORDELL K, 1972, ACTA MED SCAND, V192, P263; PAGE BH, 1952, LANCET, V263, P778; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RUSHO WJ, 1979, AM J HOSP PHARM, V36, P1355, DOI 10.1093/ajhp/36.10.1355; Ryan P B, 1973, Bull Parenter Drug Assoc, V27, P1; RYPINS EB, 1990, AM J SURG, V159, P222, DOI 10.1016/S0002-9610(05)80266-1; SCHAFERMEYER RW, 1974, JAMA-J AM MED ASSOC, V228, P695, DOI 10.1001/jama.1974.03230310017012; SKETCH MH, 1972, CHEST, V62, P684, DOI 10.1378/chest.62.6.684; SMALLMAN L, 1980, BRIT J SURG, V67, P861, DOI 10.1002/bjs.1800671208; STRADLING JR, 1978, BRIT MED J, V2, P1195, DOI 10.1136/bmj.2.6146.1195; SUBRAHAMANYAM M, 1988, Indian Journal of Physiology and Pharmacology, V32, P37; SWIFT RG, 1975, DRUG INTEL CLIN PHAR, V9, P76, DOI 10.1177/106002807500900202; TANNER WA, 1980, BRIT J SURG, V67, P311, DOI 10.1002/bjs.1800670503; THAYSSEN P, 1977, DAN MED BULL, V24, P160; THOMPSON DR, 1983, J HOSP INFECT, V4, P285, DOI 10.1016/0195-6701(83)90029-4; TSE RL, 1971, J AMER MED ASSOC, V215, P642, DOI 10.1001/jama.1971.03180170076025; TULLY JL, 1981, AM J MED, V70, P702, DOI 10.1016/0002-9343(81)90600-8; VERE DW, 1960, LANCET, V2, P627; WOODHOUSE CRJ, 1979, BRIT MED J, V1, P454, DOI 10.1136/bmj.1.6161.454-a; WRIGHT A, 1985, LANCET, V2, P1148; 1957, LANCET, V2, P595	85	29	29	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	1992	304	6827					619	624		10.1136/bmj.304.6827.619	http://dx.doi.org/10.1136/bmj.304.6827.619			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH733	1472179	Bronze, Green Published			2022-12-28	WOS:A1992HH73300026
J	ZHANG, Y; RAMOS, BF; JAKSCHIK, BA				ZHANG, Y; RAMOS, BF; JAKSCHIK, BA			NEUTROPHIL RECRUITMENT BY TUMOR-NECROSIS-FACTOR FROM MAST-CELLS IN IMMUNE-COMPLEX PERITONITIS	SCIENCE			English	Article							LEUKOCYTE ADHESION; MICE; INFLAMMATION; AUGMENTATION	During generalized immune complex-induced inflammation of the peritoneal cavity, two peaks of tumor necrosis factor (TNF) were observed in the peritoneal exudate of normal mice. In mast cell-deficient mice, the first peak was undetected, and the second peak of TNF and neutrophil influx were significantly reduced. Antibody to TNF significantly inhibited neutrophil infiltration in normal but not in mast cell-deficient mice. Mast cell repletion of the latter normalized TNF, neutrophil mobilization, and the effect of the antibody to TNF. Thus, in vivo, mast cells produce the TNF that augments neutrophil emigration.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031922] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31922] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS SI, 1991, J IMMUNOL, V146, P405; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; COCHRANE CG, 1984, SPRINGER SEMIN IMMUN, V7, P263, DOI 10.1007/BF01893023; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; KITAMURA Y, 1978, BLOOD, V52, P447; KLEIN LM, 1989, P NATL ACAD SCI USA, V86, P8972, DOI 10.1073/pnas.86.22.8972; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; QURESHI R, 1988, J IMMUNOL, V141, P2090; RAMOS BF, 1992, J PHARMACOL EXP THER, V262, P559; RAMOS BF, 1991, J IMMUNOL, V147, P1636; RAMOS BF, 1992, EUR J IMMUNOL, V22, P2381, DOI 10.1002/eji.1830220930; RAMOS BF, 1990, J IMMUNOL, V145, P1868; RAMOS BF, UNPUB; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SUMMERS JB, 1988, J MED CHEM, V31, P3, DOI 10.1021/jm00396a002; VANDENBROEK MF, 1988, J RHEUMATOL, V15, P544; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WERSHIL BK, 1988, J IMMUNOL, V140, P2356; YANO H, 1989, J CLIN INVEST, V84, P1276, DOI 10.1172/JCI114295; ZHANG Y, 1992, J IMMUNOL, V149, P2482; ZHANG Y, 1991, J CLIN INVEST, V88, P841, DOI 10.1172/JCI115385; ZHANG Y, 1992, IMMUNOLOGY, V77, P422	24	250	251	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1957	1959		10.1126/science.1470922	http://dx.doi.org/10.1126/science.1470922			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470922				2022-12-28	WOS:A1992KD08800039
J	HOWARD, MR; CHAPMAN, CE; DUNSTAN, JA; MITCHELL, C; LLOYD, HL				HOWARD, MR; CHAPMAN, CE; DUNSTAN, JA; MITCHELL, C; LLOYD, HL			REGIONAL TRANSFUSION CENTER PREOPERATIVE AUTOLOGOUS BLOOD DONATION PROGRAM - THE 1ST 2 YEARS	BRITISH MEDICAL JOURNAL			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN	Objective-To assess the efficacy of a regional autologous blood donation programme. Design-Clinical and laboratory data were collected and stored prospectively. Transfusion data were collected retrospectively from hospital blood bank records. Setting-Northern Region Blood Transfusion Service and 14 hospitals within the Northern Regional Health Authority. Subjects-505 patients referred for autologous blood donation before elective surgery. Main outcome measures-Patient eligibility, adverse events from donation, autologous blood units provided, and autologous and allogeneic blood units transfused within 10 days of operation. Results-Of 505 patients referred, 354 donated at least one unit. 78 of 151 referred patients who did not donate were excluded at the autologous clinic, mostly because of anaemia or ischaemic heart disease. In 73 cases the patient, general practitioner, or hospital consultant decided against donation. 363 autologous procedures were undertaken. In 213 (59%) cases all requested units were provided. The most common reasons for incomplete provision were late referral or anaemia. Adverse events accompanied 24 of 928 donations (2.6%). Transfusion data were obtained for 357 of the 363 procedures. 281 donors were transfused; autologous blood only was given to 225, autologous and allogeneic blood was given to 52, and allogeneic blood only was given to four. 648 of 902 (72%) units of autologous blood were transfused. Complete provision of requested autologous units was followed by allogeneic transfusion in 12 of 208 procedures (5.8%). Incomplete provision was followed by allogeneic transfusion in 44 of 149 procedures (30%). Conclusions-This study shows the feasibility of a regional autologous transfusion programme. Autologous donors only infrequently received allogeneic transfusion. Patients should be appropriately selected and referred early.	NO REG BLOOD TRANSFUS CTR,NEWCASTLE TYNE,ENGLAND		HOWARD, MR (corresponding author), ROYAL VICTORIA INFIRM,DEPT HAEMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							BACHON JPA, 1991, TRANSFUSION, V31, P513; BENOIT P, 1992, TRANSFUSION MED, V2, P75; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; GIBLETT ER, 1977, TRANSFUSION, V17, P299, DOI 10.1046/j.1537-2995.1977.17477216857.x; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; GRAF H, 1990, BRIT MED J, V300, P1627, DOI 10.1136/bmj.300.6740.1627; Gunson H H, 1991, CDR (Lond Engl Rev), V1, pR144; HICKMAN M, 1988, LANCET, V1, P1221; KRUSKALL MS, 1986, TRANSFUSION, V26, P335, DOI 10.1046/j.1537-2995.1986.26486262740.x; NELSON K, 1991, Transfusion (Bethesda), V31, p47S; PETERSEN LR, 1992, 5TH NAT FOR AIDS HEP, P37; PINDYCK J, 1987, JAMA-J AM MED ASSOC, V257, P1186, DOI 10.1001/jama.257.9.1186; POPOVSKY MA, 1992, TRANSFUSION, V32, P589, DOI 10.1046/j.1537-2995.1992.32692367207.x; SCHMIDT PJ, 1991, TRANSFUSION, V31, P681, DOI 10.1046/j.1537-2995.1991.31892023489.x; TASAKI T, 1992, LANCET, V339, P773, DOI 10.1016/0140-6736(92)91895-F; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; 1989, VOX SANG, V57, P278; 1986, JAMA-J AM MED ASSOC, V256, P2378; 1988, CLIN LAB HAEMATOL, V10, P193	22	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1470	1473		10.1136/bmj.305.6867.1470	http://dx.doi.org/10.1136/bmj.305.6867.1470			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493393	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KC91800022
J	GREENE, D; COOPER, J				GREENE, D; COOPER, J			WHISTLE BLOWERS	BRITISH MEDICAL JOURNAL			English	Article																		DYER C, 1992, BRIT MED J, V305, P1177; SOEKEN K, 1987, SURVEY WHISTLE BLOWE; 1992, PROFESSIONAL CONDUCT	3	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1343	1344		10.1136/bmj.305.6865.1343	http://dx.doi.org/10.1136/bmj.305.6865.1343			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483083	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992KA77300030
J	THORNICROFT, G; GOOCH, C; DAYSON, D				THORNICROFT, G; GOOCH, C; DAYSON, D			THE TAPS PROJECT .17. READMISSION TO HOSPITAL FOR LONG-TERM PSYCHIATRIC-PATIENTS AFTER DISCHARGE TO THE COMMUNITY	BRITISH MEDICAL JOURNAL			English	Article							REVOLVING-DOOR PATIENTS; NATION-WIDE COHORT; DEINSTITUTIONALIZATION; PATTERNS; SAMPLE; STAY	Objective-To identify risk factors which increase the likelihood of readmission for long stay psychiatric patients after discharge from hospital. Design-Follow up for five years of all long stay patients discharged from two large psychiatric hospitals to compare patients readmitted and not readmitted. Setting-Friern and Claybury Hospitals in north London and their surrounding catchment areas. Most patients were discharged to staffed or unstaffed group homes. Subjects-357 psychiatric patients who had been in hospital for over one year, of whom 118 were "new" long stay and 239 "old" long stay patients. Main outcome measures-Readmission to hospital and length of subsequent stay. Results-Of all discharged patients 97 (27%) were readmitted at some time during the follow up period, 57 (16%) in the first year after discharge, and 31 (9%) then remained in hospital for over a year. The best explanatory factors for readmission were: male sex, younger age group, high number of previous admissions, higher levels of symptomatic and social behavioural disturbance, a diagnosis of manic-depressive psychosis, and living in a non-staffed group home. Conclusions-During the closure of psychiatric hospitals, facilities need to be preserved for acute relapses among long term, and especially younger, discharged patients. Staffed group homes may help prevent relapse and reduce the number of admission beds required.			THORNICROFT, G (corresponding author), INST PSYCHIAT,LONDON SE5 8AF,ENGLAND.		Thornicroft, Graham/B-4027-2010	Thornicroft, Graham/0000-0003-0662-0879				AVISON WR, 1987, AM J PSYCHIAT, V144, P10; BEISER M, 1985, AM J PSYCHIAT, V142, P1047; BLUMENTAHL S, 1988, PSYCHIATR PRAX, V154, P96; CHAMBERS M, 1990, BRIT MED J, V301, P1134, DOI 10.1136/bmj.301.6761.1134; CLARKE A, 1990, BRIT MED J, V301, P1136, DOI 10.1136/bmj.301.6761.1136; COLENDA C C, 1989, Psychiatric Quarterly (New York), V60, P227, DOI 10.1007/BF01064798; DAYSON D, 1992, BRIT MED J, V305, P993, DOI 10.1136/bmj.305.6860.993; DRAKE RE, 1989, HOSP COMMUNITY PSYCH, V40, P46; FERNANDO MLD, 1990, CAN J PSYCHIAT, V35, P71, DOI 10.1177/070674379003500111; GELLER JL, 1990, AM J PSYCHIAT, V147, P988; HAEFNER H, 1989, BRIT J PSYCHIAT, V155, P12; JONES K, 1986, BRIT J PSYCHIAT, V149, P537, DOI 10.1192/bjp.149.5.537; KASTRUP M, 1987, ACTA PSYCHIAT SCAND, V76, P80, DOI 10.1111/j.1600-0447.1987.tb02865.x; KASTRUP M, 1987, ACTA PSYCHIAT SCAND, V76, P552, DOI 10.1111/j.1600-0447.1987.tb02918.x; LERNER Y, 1989, SOC PSYCH PSYCH EPID, V24, P121, DOI 10.1007/BF01788020; LEWIS T, 1990, ACTA PSYCHIAT SCAND, V82, P130, DOI 10.1111/j.1600-0447.1990.tb01369.x; MILNE R, 1990, BRIT MED J, V301, P1139, DOI 10.1136/bmj.301.6761.1139; OKIN RL, 1990, AM J PSYCHIAT, V147, P1596; POKORNY AD, 1983, AM J PSYCHIAT, V140, P1598; SETZE PJ, 1985, HOSP COMMUNITY PSYCH, V36, P521; THORNICROFT G, 1989, BRIT J PSYCHIAT, V155, P739, DOI 10.1192/bjp.155.6.739; WAN TTH, 1991, COMMUNITY MENT HLT J, V27, P3, DOI 10.1007/BF00752711; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WYKES T, 1986, BRIT J PSYCHIAT, V148, P1, DOI 10.1192/bjp.148.1.1; ZILBER N, 1990, SOC PSYCH PSYCH EPID, V25, P144, DOI 10.1007/BF00782743; 1990, 5TH ANN TAPS C LOND	26	36	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					996	998		10.1136/bmj.305.6860.996	http://dx.doi.org/10.1136/bmj.305.6860.996			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV776	1458148	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JV77600028
J	RUNYAN, CW; BANGDIWALA, SI; LINZER, MA; SACKS, JJ; BUTTS, J				RUNYAN, CW; BANGDIWALA, SI; LINZER, MA; SACKS, JJ; BUTTS, J			RISK-FACTORS FOR FATAL RESIDENTIAL FIRES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POPULATION	Background. Residential fires are the most important cause of fire-related mortality in the United States. Previous research has concentrated on fatal fires in urban areas; considerably less is known about fatal fires in rural areas. Methods. We studied fatal and nonfatal residential fires in predominantly rural areas. Using a case-control design, we compared all 151 fatal fires (cases) in single-family dwellings in North Carolina during a 13-month period with a sample of nonfatal fires (controls). Case fires were identified through the medical-examiner system, and control fires that occurred within a few weeks of the case fires were chosen from the records of randomly selected fire departments statewide. For each fire, fire officials were interviewed about the dwelling, the fire, the people involved, and the fire-response system. Results. Although heating incidents were the leading cause of fires, fatal fires were more likely to have been caused by smoking (31 percent of fatal fires vs. 6 percent of nonfatal fires). Mobile homes posed a higher risk of death if a fire occurred (odds ratio, 1.7; 95 percent confidence interval, 1.1 to 2.6), as did the absence of a smoke detector (odds ratio, 3.4; 95 percent confidence interval, 2.1 to 5.6). Smoke detectors were more protective against death in fires involving young children and when no one present was impaired by alcohol or drugs or had a physical or mental disability. The presence of an alcohol-impaired person was the strongest independent risk factor for death in the case of a fire (odds ratio, 7.5; 95 percent confidence interval, 4.4 to 12.7). Conclusions. Residential fires are most likely to be caused by heating equipment or smoking materials. The risk of death is greatest in fires in mobile homes, in those involving alcohol-impaired persons, and in those in houses without smoke detectors.	UNIV N CAROLINA,SCH PUBL HLTH,CHAPEL HILL,NC 27514; CTR DIS CONTROL,PUBL HLTH SERV,ATLANTA,GA 30333; N CAROLINA OFF CHIEF MED EXAMINER,CHAPEL HILL,NC	University of North Carolina; University of North Carolina Chapel Hill; Centers for Disease Control & Prevention - USA; United States Public Health Service	RUNYAN, CW (corresponding author), UNIV N CAROLINA,INJURY PREVENT RES CTR,CB 7400 ROSENAU HALL,CHAPEL HILL,NC 27599, USA.				PHS HHS [R49/CCR402444] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BALLARD JE, 1992, AM J EPIDEMIOL, V135, P26, DOI 10.1093/oxfordjournals.aje.a116198; Davis CE, 1986, MODERN STAT METHODS, P140; DUCIC S, 1980, ACCIDENT ANAL PREV, V12, P67, DOI 10.1016/0001-4575(80)90041-X; HALL JR, 1989, EXPERIENCE SMOKE DET; KARTER MJ, 1989, FIRE J           SEP, P24; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MCLOUGHLIN E, 1985, AM J PUBLIC HEALTH, V75, P858, DOI 10.2105/AJPH.75.8.858; MIERLEY MC, 1983, JAMA-J AM MED ASSOC, V249, P1466, DOI 10.1001/jama.249.11.1466; PATETTA MJ, 1990, AM J PUBLIC HEALTH, V80, P1116, DOI 10.2105/AJPH.80.9.1116; 1987, MMW MORB MORTAL WKLY, V36, P645; 1985, SAS USERS GUIDE STAT; 1987, JAMA-J AM MED ASSOC, V257, P1618; 1983, CENSUS POPULATION HO; 1988, MANUFACTURED HOME FI	15	211	213	1	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					859	863		10.1056/NEJM199209173271207	http://dx.doi.org/10.1056/NEJM199209173271207			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JN120	1508246				2022-12-28	WOS:A1992JN12000007
J	USALA, AL; MADIGAN, T; BURGUERA, B; SINHA, MK; CARO, JF; CUNNINGHAM, P; POWELL, JG; BUTLER, PC				USALA, AL; MADIGAN, T; BURGUERA, B; SINHA, MK; CARO, JF; CUNNINGHAM, P; POWELL, JG; BUTLER, PC			TREATMENT OF INSULIN-RESISTANT DIABETIC-KETOACIDOSIS WITH INSULIN-LIKE GROWTH FACTOR-I IN AN ADOLESCENT WITH INSULIN-DEPENDENT DIABETES	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							GLUCOSE-TRANSPORT; IGF-I; CULTURED ADIPOCYTES; RECEPTORS; MECHANISM; RATS; METABOLISM; CELLS		E CAROLINA UNIV,SCH MED,DEPT SURG,GREENVILLE,NC 27858; E CAROLINA UNIV,SCH MED,DEPT MED,ENDOCRINOL SECT,GREENVILLE,NC 27858	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	USALA, AL (corresponding author), E CAROLINA UNIV,SCH MED,DEPT PEDIAT,PEDIAT ENDOCRINOL SECT,BRODY MED SER BLDG 3E-133,GREENVILLE,NC 27858, USA.			butler, peter/0000-0002-2981-8979	NIDDK NIH HHS [DK 44341] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044341] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berson SA., 1970, DIABETES MELLITUS TH, P388; BHAUMICK B, 1991, ACTA ENDOCRINOL-COP, V125, P201, DOI 10.1530/acta.0.1250201; BHAUMICK B, 1988, BIOCHEM BIOPH RES CO, V152, P359, DOI 10.1016/S0006-291X(88)80722-8; CZECH MP, 1982, CELL, V31, P8, DOI 10.1016/0092-8674(82)90399-3; FLIER JS, 1979, NEW ENGL J MED, V300, P413; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; JACOB RJ, 1991, AM J PHYSIOL, V260, pE262, DOI 10.1152/ajpendo.1991.260.2.E262; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAHN CR, 1985, ANNU REV MED, V36, P429; KASHIWAGI A, 1983, J CLIN INVEST, V72, P1246, DOI 10.1172/JCI111080; KITABCHI AE, 1989, DIABETES METAB REV, V5, P337, DOI 10.1002/dmr.5610050403; ROSSETTI L, 1991, DIABETES, V40, P444, DOI 10.2337/diabetes.40.4.444; SCHOENLE EJ, 1991, DIABETOLOGIA, V34, P675, DOI 10.1007/BF00400998; SINHA MK, 1989, DIABETES, V38, P1217, DOI 10.2337/diabetes.38.10.1217; SINHA MK, 1987, J CLIN INVEST, V80, P1073, DOI 10.1172/JCI113163; SINHA MK, 1991, DIABETES, V40, P472, DOI 10.2337/diabetes.40.4.472; VERSPOHL EJ, 1984, J CLIN INVEST, V74, P1436, DOI 10.1172/JCI111555; WILLIAMS G, 1987, AM J MED, V82, P1247, DOI 10.1016/0002-9343(87)90234-8; ZAPF J, 1986, J CLIN INVEST, V77, P1768, DOI 10.1172/JCI112500	20	52	69	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1992	327	12					853	857		10.1056/NEJM199209173271205	http://dx.doi.org/10.1056/NEJM199209173271205			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN120	1508245				2022-12-28	WOS:A1992JN12000005
J	BREO, DL				BREO, DL			REINHARDT,UWE - THE ECONOMIST AS HEALTH EVANGELIST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1332	1336		10.1001/jama.268.10.1332	http://dx.doi.org/10.1001/jama.268.10.1332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507382				2022-12-28	WOS:A1992JL60800037
J	IGLEHART, JK				IGLEHART, JK			THE AMERICAN HEALTH-CARE SYSTEM - MANAGED CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MAINTENANCE ORGANIZATIONS; FINANCIAL INCENTIVES											BERENSON RA, 1991, HEALTH AFFAIR, V10, P106, DOI 10.1377/hlthaff.10.4.106; Brown Lawrence D., 1983, POLITICS HLTH CARE O; BROWN R, 1989, BIASED SELECTION MED; COUCH JB, 1991, HLTH CARE QUALITY MA; ENTHOVEN AC, 1991, JAMA-J AM MED ASSOC, V265, P2532, DOI 10.1001/jama.265.19.2532; ERB JC, 1992, 2 REP; Freidson E., 1970, PROFESSIONAL DOMINAN; GOLDSTEIN A, 1992, WASH POST       0710, pA1; HADLEY JP, 1991, HEALTH POLICY, V19, P91, DOI 10.1016/0168-8510(91)90001-E; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1992, MED CARE, V30, P136, DOI 10.1097/00005650-199202000-00005; HILLMAN AL, 1991, HEALTH AFFAIR, V10, P138, DOI 10.1377/hlthaff.10.4.138; HILLMAN AL, 1990, ANN INTERN MED, V112, P891, DOI 10.7326/0003-4819-112-12-891; HILLMAN AL, 1991, HEALTH AFFAIR, V10, P205, DOI 10.1377/hlthaff.10.4.207; HOY EW, 1991, HEALTH AFFAIR, V10, P18, DOI 10.1377/hlthaff.10.4.18; IGLEHART JK, 1992, NEW ENGL J MED, V326, P962, DOI 10.1056/NEJM199204023261426; IGLEHART JK, 1980, MILBANK FUND Q, V58, P656, DOI 10.2307/3349809; IGLEHART JK, 1992, NEW ENGL J MED, V326, P1715, DOI 10.1056/NEJM199206183262526; IGLEHART JK, 1984, NEW ENGL J MED, V311, P343, DOI 10.1056/NEJM198408023110536; IGLEHART JK, 1971, NAT J, V3, P1443; KASSIRER JP, 1992, NEW ENGL J MED, V326, P945, DOI 10.1056/NEJM199204023261408; LANGWELL K, 1992, CBO STAFF MEMORANDUM; LOMBARDO J, 1992, WASHIGNTON BUSI 0601, P1; LUFT HS, 1988, HEALTH AFFAIR, V7, P97, DOI 10.1377/hlthaff.7.3.97; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; Mechanic D, 1986, ADVOCACY ALLOCATION; MILLER RH, 1991, HEALTH AFFAIR, V10, P37, DOI 10.1377/hlthaff.10.4.37; MORAN DW, 1991, HEALTH AFFAIR, V10, P120, DOI 10.1377/hlthaff.10.4.120; PAULY MV, 1990, MED CARE, V28, P1013, DOI 10.1097/00005650-199011000-00004; PAWLUK W, 1992, HMO MAGAZINE, V33, P17; Schlackman N, 1989, QRB Qual Rev Bull, V15, P234; SCHWARTZ WB, 1992, HEALTH AFFAIR, V11, P100, DOI 10.1377/hlthaff.11.2.100; SMILLIE JG, 1991, STORY PERMANENTE MED; WINSLOW R, 1992, WALL STREET J   0915, pB6; 1992, NATIONALD IRECTORY H; 1992, 922 PHYS PAYM REV CO; 1991, PROVIDER PROFILING G; 1992, ANN REPORT C 1992	38	154	154	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					742	747		10.1056/NEJM199209033271029	http://dx.doi.org/10.1056/NEJM199209033271029			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1495543				2022-12-28	WOS:A1992JL23500036
J	RESCH, KL; ERNST, E; MATRAI, A; PAULSEN, HF				RESCH, KL; ERNST, E; MATRAI, A; PAULSEN, HF			FIBRINOGEN AND VISCOSITY AS RISK-FACTORS FOR SUBSEQUENT CARDIOVASCULAR EVENTS IN STROKE SURVIVORS	ANNALS OF INTERNAL MEDICINE			English	Article						CEREBROVASCULAR DISORDERS; FIBRINOGEN; RHEOLOGY; CARDIOVASCULAR DISEASES; MYOCARDIAL INFARCTION	ISCHEMIC-HEART-DISEASE; PLASMA-FIBRINOGEN; MYOCARDIAL-INFARCTION; CEREBRAL INFARCTION; BLOOD	Objective: To investigate whether abnormalities in blood viscosity predict a poor prognosis for subsequent cardiovascular events in stroke survivors. Design: Nested case-control study among a cohort of survivors of a first stroke, followed for an average of 2 years. Patients with a second stroke, myocardial infarction, or cardiovascular death were matched with patients who did not have such events (control patients). Setting: Buchberg-Klinik, Bad Tolz, Germany, a specialized center for stroke rehabilitation. Patients: A total of 625 consecutive patients. Twenty-one patients (3.5%) were lost to follow-up. Sixty pairs were matched. Measurements: Native and hematocrit-standardized blood viscosity at three shear rates, hematocrit, plasma viscosity, fibrinogen, erythrocyte sedimentation rate, total leukocyte count, and the matching variables. Results: Eighty-five patients had a second stroke, myocardial infarction, or died due to a cardiovascular event. Patients with re-events had higher blood viscosity and fibrinogen levels than the control patients. In the 60 matched pairs, the mean of the paired differences between patients with re-events and control patients was 5.03 mPa . s (95% Cl, 1.262 to 8.941; P = 0.01) for native blood viscosity at shear rate 0.7 s-1, for plasma viscosity, 0.044 mPa . s (CI, 0.006 to 0.083; P > 0.02), and for fibrinogen, 0.056 g/L (CI, 0.010 to 0.101; P > 0.02). Odds ratios were significantly increased only for plasma viscosity (odds ratio, 2.86; CI, 1.06 to 8.43) and fibrinogen (odds ratio, 3.67; CI, 1.31 to 11.69). Conclusions: Hyperfibrinogenemia is an independent risk factor for cardiovascular events in stroke survivors. Intervention trials with fibrinogen lowering measures may be warranted.	UNIV VIENNA, DEPT PHYS MED & REHABIL, WAHRINGER GURTEL 18-20, A-1097 VIENNA, AUSTRIA; BUCHBERG KLIN, W-8170 BAD TOLZ, GERMANY	University of Vienna								BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; CHIEN S, 1987, CLIN HEMORHEOL, P125; COULL BM, 1991, STROKE, V22, P162, DOI 10.1161/01.STR.22.2.162; DIMINNO G, 1990, ARTERIOSCLEROSIS, V10, P1, DOI 10.1161/01.ATV.10.1.1; ERNST E, 1990, CLIN HEMORHEOL, V10, P525; ERNST E, 1988, STROKE, V19, P634, DOI 10.1161/01.STR.19.5.634; ERNST E, 1990, J INTERN MED, V227, P365, DOI 10.1111/j.1365-2796.1990.tb00174.x; ERNST E, 1991, BRIT MED J, V303, P596, DOI 10.1136/bmj.303.6803.596; ERNST E, 1986, HERZ KREISLAUF, V18, P30; ERNST E, 1989, HAMORHEOLOGIE THEORI, P247; ERNST E, 1992, IN PRESS J CLIN PATH; FISHER M, 1991, STROKE, V22, P1164, DOI 10.1161/01.STR.22.9.1164; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GROTTA J, 1982, STROKE, V13, P296, DOI 10.1161/01.STR.13.3.296; HIER DB, 1991, STROKE, V22, P155, DOI 10.1161/01.STR.22.2.155; International Committee for Standardization in Haematology Expert Panel on Blood Cell Sizing, 1980, J CLIN PATHOL, V33, P1; JUNGQUIST G, 1991, J CLIN EPIDEMIOL, V44, P347, DOI 10.1016/0895-4356(91)90073-I; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; Lowe GDO, 1987, CLIN HEMORHEOL, P195; LOWE GOD, 1987, CEREBRAL ISCHEMIA HE, P496; MATRAD A, 1985, CLIN HEMORHEOL, V5, P622; MATRAI A, 1984, Biorheology, P99; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MERRILL EW, 1969, PHYSIOL REV, V49, P863, DOI 10.1152/physrev.1969.49.4.863; OTT EO, 1974, STROKE, V5, P330, DOI 10.1161/01.STR.5.3.330; PETERSEN WE, 1953, J LAB CLIN MED, V42, P641; RIDKER PM, 1991, CIRCULATION, V83, P1098, DOI 10.1161/01.CIR.83.3.1098; Schlesselman J. J, 1982, CASE CONTROL STUDIES, P207; SPINELLI F R, 1974, Biorheology, V11, P301; STONE MC, 1985, J ROY COLL GEN PRACT, V35, P565; SYRJANEN J, 1989, J CLIN PATHOL, V42, P63, DOI 10.1136/jcp.42.1.63; THOMAS DJ, 1987, CEREBRAL ISCHEMIA HE, P301; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; 1984, J CLIN PATHOL, V34, P1147	36	126	130	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					371	375		10.7326/0003-4819-117-5-371	http://dx.doi.org/10.7326/0003-4819-117-5-371			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503327				2022-12-28	WOS:A1992JK67800004
J	JAVIER, R; RASKA, K; SHENK, T				JAVIER, R; RASKA, K; SHENK, T			REQUIREMENT FOR THE ADENOVIRUS TYPE-9 E4 REGION IN PRODUCTION OF MAMMARY-TUMORS	SCIENCE			English	Article							E2F TRANSCRIPTION FACTOR; DNA-BINDING ACTIVITY; RETINOBLASTOMA GENE-PRODUCT; TRANSFORMED RAT-CELLS; NATURAL-KILLER CELLS; INFECTED-CELLS; NUCLEOTIDE-SEQUENCE; E1A PROTEINS; CYCLIN-A; EXPRESSION	Oncogenic viruses demonstrating a strict tropism for the mammary gland provide special opportunities to study the susceptibility of this tissue to neoplasia. In rats, human adenovirus type 9 (Ad9) elicits mammary fibroadenomas that are similar to common breast tumors in women, as well as phyllodes-like tumors and mammary sarcomas. By constructing recombinant adenoviruses between Ad9 and Ad26 (a related nontumorigenic virus), it was shown that the Ad9 E4 region was absolutely required to produce these mammary tumors. This indicates that an adenovirus gene located outside the classic transforming region (E1) can significantly influence the in vivo oncogenicity of an adenovirus. Consistent with a direct role in mammary gland oncogenesis, the Ad9 E4 region also exhibited transforming properties in vitro. Therefore, the Ad9 E4 region is a viral oncogene specifically involved in mammary gland tumorigenesis.	PRINCETON UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOL,PRINCETON,NJ 08544; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,NEW BRUNSWICK,NJ 08903; ST PETERS MED CTR,NEW BRUNSWICK,NJ 08903	Howard Hughes Medical Institute; Princeton University; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [P01CA041086, R01CA021196, T32CA009528] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21196, CA 41086, T32 CA09528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKERST J, 1974, INT J CANCER, V13, P286, DOI 10.1002/ijc.2910130303; ANKERST J, 1989, J NATL CANCER I, V81, P294, DOI 10.1093/jnci/81.4.294; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1989, J VIROL, V63, P2709, DOI 10.1128/JVI.63.6.2709-2717.1989; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BERNARDS R, 1984, J VIROL, V50, P847, DOI 10.1128/JVI.50.3.847-853.1984; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHINNADURAI G, 1979, J VIROL, V32, P623, DOI 10.1128/JVI.32.2.623-628.1979; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; GRAHAM FL, 1984, ADENOVIRUSES, P339; GREEN M, 1979, VIROLOGY, V93, P481, DOI 10.1016/0042-6822(79)90251-4; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HANAHAN D, 1984, MOL CELL BIOL, V4, P302, DOI 10.1128/MCB.4.2.302; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HEMSTROM C, 1988, J VIROL, V62, P3258; HERISSE J, 1981, NUCLEIC ACIDS RES, V9, P4023, DOI 10.1093/nar/9.16.4023; HOGENKAMP T, 1990, NUCLEIC ACIDS RES, V18, P3065, DOI 10.1093/nar/18.10.3065; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; JANNUN R, 1987, VIRUS RES, V7, P33, DOI 10.1016/0168-1702(87)90056-6; JAVIER R, 1991, J VIROL, V65, P192; JAVIER R, UNPUB; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MELLOW GH, 1984, VIROLOGY, V134, P460, DOI 10.1016/0042-6822(84)90313-1; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; SANDLER AB, 1989, J VIROL, V63, P624, DOI 10.1128/JVI.63.2.624-630.1989; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SAWADA Y, 1988, VIROLOGY, V166, P281, DOI 10.1016/0042-6822(88)90175-4; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHELLABARGER C, COMMUNICATION; SHIROKI K, 1984, J VIROL, V50, P854, DOI 10.1128/JVI.50.3.854-863.1984; STILLMAN B, 1986, CANCER SURV, V5, P389; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YODER SS, 1986, J VIROL, V60, P779, DOI 10.1128/JVI.60.2.779-781.1986	53	54	54	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1267	1271		10.1126/science.1519063	http://dx.doi.org/10.1126/science.1519063			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519063				2022-12-28	WOS:A1992JL05000030
J	LANKER, S; BUSHMAN, JL; HINNEBUSCH, AG; TRACHSEL, H; MUELLER, PP				LANKER, S; BUSHMAN, JL; HINNEBUSCH, AG; TRACHSEL, H; MUELLER, PP			AUTOREGULATION OF THE YEAST LYSYL-TRANSFER RNA-SYNTHETASE GENE GCD5/KRS1 BY TRANSLATIONAL AND TRANSCRIPTIONAL CONTROL MECHANISMS	CELL			English	Article							AMINO-ACID BIOSYNTHESIS; GCN4 MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; INITIATION-FACTOR; PROTEIN-SYNTHESIS; MUTATIONS; DNA; SPECIFICITY; EXPRESSION; REPRESSOR	We cloned the GCD5 gene of S. cerevisiae and found it to be identical to KRS1, which encodes lysyl-tRNA synthetase (LysRS). The mutation gcd5-1 changes a conserved residue in the putative lysine-binding domain of LysRS. This leads to a defect in lysine binding and, consequently, to reduced charging of tRNA(Lys). Mutant gcd5-1 cells compensate for the defect in LysRS by increasing GCN4 expression at the translational level. GCN4 protein in turn stimulates transcription of GCD5, leading to increased LysRS activity. We propose an autoregulatory model in which uncharged tRNA(Lys) stimulates the protein kinase GCN2, a translational activator of GCN4, and thereby increases transcription of GCD5 and other genes regulated by GCN4.	NICHHD,MOLEC GENET LOWER EUKARYOTES SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	LANKER, S (corresponding author), UNIV BERN,INST BIOCHEM & MOLEC BIOL,CH-3000 BERN 9,SWITZERLAND.		Mueller, Peter P./H-8656-2019	Mueller, Peter P./0000-0002-1209-7546				ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ANSELME J, 1991, FEBS LETT, V280, P163, DOI 10.1016/0014-5793(91)80228-U; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; CIRAKOGLU B, 1985, EUR J BIOCHEM, V149, P353; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DELFORGE J, 1975, EUR J BIOCHEM, V57, P231, DOI 10.1111/j.1432-1033.1975.tb02295.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HINNEBUSCH AG, 1991, TRANSLATION EUKARYOT, P243; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAST P, 1991, J MOL BIOL, V222, P99, DOI 10.1016/0022-2836(91)90740-W; MARTINEZ R, 1991, MOL GEN GENET, V227, P149, DOI 10.1007/BF00260720; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MUESSDOERFFER F, 1983, J BIOL CHEM, V258, P6293; NIEDERBERGER P, 1986, CURR GENET, V10, P657, DOI 10.1007/BF00410913; PADDON CJ, 1989, GENETICS, V122, P543; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; THIEROS B, 1984, P NATL ACAD SCI USA, V81, P5096; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WILLIAMS NP, 1989, P NATL ACAD SCI USA, V86, P7515, DOI 10.1073/pnas.86.19.7515; WOLFNER M, 1975, J MOL BIOL, V96, P273, DOI 10.1016/0022-2836(75)90348-4	39	48	52	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					647	657		10.1016/0092-8674(92)90433-D	http://dx.doi.org/10.1016/0092-8674(92)90433-D			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505029				2022-12-28	WOS:A1992JJ88600013
J	STOCK, DW; WHITT, GS				STOCK, DW; WHITT, GS			EVIDENCE FROM 18S RIBOSOMAL-RNA SEQUENCES THAT LAMPREYS AND HAGFISHES FORM A NATURAL GROUP	SCIENCE			English	Article							DNA; EVOLUTION; PHYLOGENY	Lampreys and hagfishes (cyclostomes) traditionally were considered to be a natural (monophyletic) group. Recently, the consensus of opinion, based largely on morphological analyses, has shifted to a view that lampreys are more closely related to jawed vertebrates (gnathostomes) than to hagfishes. Phylogenetic comparisons of 18S ribosomal RNA sequences from two hagfishes, two lampreys, a tunicate, a lancelet, and a number of gnathostomes support the monophyly of the cyclostomes. These data force a reassessment of several features of early vertebrate evolution.	UNIV ILLINOIS, DEPT ECOL ETHOL & EVOLUT, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign								AJUH PM, 1991, P ROY SOC B-BIOL SCI, V245, P65, DOI 10.1098/rspb.1991.0089; [Anonymous], 1966, VERTEBRATE PALEONTOL; BARDACK D, 1991, SCIENCE, V254, P701, DOI 10.1126/science.254.5032.701; CEDERGREN R, 1988, J MOL EVOL, V28, P98, DOI 10.1007/BF02143501; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J, 1989, PHYLIP MANUAL VERSIO; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Forey P.L., 1984, Journal of Vertebrate Paleontology, V4, P330; GOODMAN M, 1988, J MOL EVOL, V27, P236, DOI 10.1007/BF02100080; GOODMAN M M, 1987, P141; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hardisty M.W., 1979, BIOL CYCLOSTOMES; HARDISTY MW, 1982, BIOL LAMPREYS B, V4, pCH36; HENDY MD, 1989, SYST ZOOL, V38, P297, DOI 10.2307/2992396; JANVIER P, 1981, Journal of Vertebrate Paleontology, V1, P121; JANVIER P, 1983, Journal of Vertebrate Paleontology, V2, P407; Jarvik E., 1980, BASIC STRUCTURE EVOL, DOI [10.1126/science.214.4519.431.b, DOI 10.1126/SCIENCE.214.4519.431.B]; Jefferies R.P.S., 1986, ANCESTRY VERTEBRATES; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; Lovtrup S., 1977, PHYLOGENY VERTEBRATA; MAISEY J G, 1986, Cladistics, V2, P201, DOI 10.1111/j.1096-0031.1986.tb00462.x; MCCALLUM FS, 1985, BIOCHEM J, V232, P725, DOI 10.1042/bj2320725; Nelson J.S., 1984, FISHES WORLD, V2nd, P523; OLSEN GJ, 1991, NUCLEIC ACIDS RES, V19, P4817, DOI 10.1093/nar/19.17.4817; PATTERSON C, 1989, INT CONGR SER, V824, P471; REPETSKI JE, 1978, SCIENCE, V200, P529, DOI 10.1126/science.200.4341.529-a; SCHAEFFER B, 1987, EVOL BIOL, V21, P179; Schaeffer B., 1980, P19; SCHULTZE H.-P., 1979, HDB PALEOICHTHYOLOGY, V5; SMITH MW, 1992, J MOL EVOL, V34, P175; STOCK DW, 1991, ENVIRON BIOL FISH, V32, P99, DOI 10.1007/BF00007447; Swofford D. L., 1991, PAUP PHYLOGENETIC AN; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YALDEN DW, 1985, ZOOL J LINN SOC-LOND, V84, P291, DOI 10.1111/j.1096-3642.1985.tb01802.x	35	142	144	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1992	257	5071					787	789		10.1126/science.1496398	http://dx.doi.org/10.1126/science.1496398			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG851	1496398				2022-12-28	WOS:A1992JG85100031
J	NGUYENVANTAM, JS; BAKER, DM				NGUYENVANTAM, JS; BAKER, DM			GENERAL-PRACTICE AND ACCIDENT AND EMERGENCY DEPARTMENT CARE - DOES THE PATIENT KNOW BEST	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT ACCID & EMERGENCY,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham			Nguyen-Van-Tam, Jonathan/I-2162-2019	Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655; Baker, Daryll/0000-0002-0098-405X				DAVISON AG, 1983, J ROY SOC MED, V76, P37, DOI 10.1177/014107688307600109	1	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					157	158		10.1136/bmj.305.6846.157	http://dx.doi.org/10.1136/bmj.305.6846.157			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515831	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JF06300023
J	PONDER, BAJ				PONDER, BAJ			CURRENT ISSUES IN CANCER .1. MOLECULAR-GENETICS OF CANCER	BRITISH MEDICAL JOURNAL			English	Article											PONDER, BAJ (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,CANC RES CAMPAIGN,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 1QP,ENGLAND.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAVENEE WK, 1991, CANCER SURVEYS, V9; EASTON DF, 1991, CANCER SURV, V9, P395; GREENE MH, 1985, NEW ENGL J MED, V312, P91, DOI 10.1056/NEJM198501103120205; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MAHER ER, 1991, BRIT J CANCER, V63, P176, DOI 10.1038/bjc.1991.43; NAKACHI K, 1991, CANCER RES, V51, P5177; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OTT J, 1986, HUMAN GENETIC DISEAS; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PONDER BAJ, 1991, BRIT J CANCER, V64, P203, DOI 10.1038/bjc.1991.275; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	14	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1234	1236		10.1136/bmj.304.6836.1234	http://dx.doi.org/10.1136/bmj.304.6836.1234			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515800	Bronze, Green Published			2022-12-28	WOS:A1992HT96400031
J	GEORGE, S; READ, S; WESTLAKE, L; WILLIAMS, B; FRASERMOODIE, A; PRITTY, P				GEORGE, S; READ, S; WESTLAKE, L; WILLIAMS, B; FRASERMOODIE, A; PRITTY, P			EVALUATION OF NURSE TRIAGE IN A BRITISH ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; SATISFACTION; DEPARTMENTS	Objective-To compare formal nurse triage with an informal prioritisation process for waiting times and patient satisfaction. Setting-Accident and emergency department of a district general hospital in the midlands in 1990. Design-Patients attending between 8 00 am and 9 00 pm over six weeks were grouped for analysis according to whether triage was operating at time of presentation and by their degree of urgency as assessed retrospectively by an accident and emergency consultant. Patients-5954 patients presenting over six weeks. Main outcome measures-Time waited between first attendance in the department and obtaining medical attention, and patient satisfaction measured by questionnaire. Results-Complete data on waiting time were collected on 5037 patients (85%). Only 1213 of the 2515 (48%) patients presenting during the triage period were seen by a triage nurse. Patients in the triage group waited longer than those in the no triage group in all four retrospective priority categories, though differences were significant for only the two most urgent categories (difference in median waiting time 10.5 (95% confidence interval 3.5 to 14) min for category 1 and 8.5 (3 to 12) min for category 2). Responses to the patient satisfaction questionnaire were similar in the two groups except for the question relating to anxiety relating to pain. Conclusions-This study fails to show the benefits claimed for formal nurse triage. Nurse triage may impose additional delay for patient treatment, particularly among patients needing the most urgent attention.	DERBYSHIRE ROYAL INFIRM,DERBY DE1 2QY,ENGLAND		GEORGE, S (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PUBL HLTH MED,MED CARE RES UNIT,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							Bailey A, 1987, Nurs Times, V83, P65; Beach L, 1981, J Emerg Nurs, V7, P50; Buckles E, 1990, Nurs Stand, V4, P33; De Angelis C, 1977, J Community Health, V2, P268; ESTRADA EG, 1981, NURS CLIN N AM, V16, P13; GEORGE SL, 1991, J ADV NURS, V16, P1391, DOI 10.1111/j.1365-2648.1991.tb01570.x; Grose A, 1988, Prof Nurse, V3, P400; LEBOW JL, 1974, MED CARE, V12, P328, DOI 10.1097/00005650-197404000-00004; LOCKER D, 1978, SOC SCI MED-MED SOC, V12, P283, DOI 10.1016/0271-7123(78)90067-6; MAIDENS S, 1988, NURSING STANDAR 0206, P18; MALLETT J, 1990, J ADV NURS, V15, P1443, DOI 10.1111/j.1365-2648.1990.tb01787.x; McMillan J R, 1986, Health Care Manage Rev, V11, P21; Mills J, 1976, JACEP, V5, P877, DOI 10.1016/S0361-1124(76)80034-2; MILNER PC, 1988, J EPIDEMIOL COMMUN H, V42, P274, DOI 10.1136/jech.42.3.274; Nuttall M, 1986, Nurs Times, V82, P66; PLEDGE MN, 1988, PRIORITIES CARE WALK; RUND DA, 1981, TRIAGE; Shields J E, 1976, J Emerg Nurs, V2, P37; SLATER RR, 1970, AM J NURS, V70, P127, DOI 10.2307/3421031; WARE JE, 1978, MED CARE, V16, P327, DOI 10.1097/00005650-197804000-00005; WRIGHT R, 1985, NURS MIRROR, V161, P42; 1991, PATIENTS CHARTER	22	43	43	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1992	304	6831					876	878		10.1136/bmj.304.6831.876	http://dx.doi.org/10.1136/bmj.304.6831.876			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HM835	1472254	Green Published, Bronze			2022-12-28	WOS:A1992HM83500023
J	SKOBELOFF, EM; SPIVEY, WH; STCLAIR, SS; SCHOFFSTALL, JM				SKOBELOFF, EM; SPIVEY, WH; STCLAIR, SS; SCHOFFSTALL, JM			THE INFLUENCE OF AGE AND SEX ON ASTHMA ADMISSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe demographic data from a large population of asthmatic patients to define the role of age and sex as risk factors for asthma admission. Design.-A retrospective review of all asthma admissions as defined by international Classification of Diseases, Ninth Revision, code 493.0. Source.-All medical-surgical admissions from 67 hospitals in five counties of southeastern Pennsylvania from 1986 through 1989. Results.-Patients admitted for asthma treatment (33 269) were reviewed. In the 0- to 5-year-old and 6- to 10-year-old age groups, males were admitted nearly twice as often as age-identical females. In the 11- to 20-year-old age group, admissions for males and females were nearly identical. Between 20 and 50 years of age, the female-to-male ratio was nearly 3:1. Thereafter, females were admitted for asthma at a rate of about 2.5:1 when compared with their age-equivalent male counterparts. Length of stay increased proportionally as the patient age increased. After 30 years of age, the length of stay was slightly greater for females than males. Conclusions.-There is a much higher rate of admission for prepubertal males than females. However, there is a higher incidence of asthma admissions for adult females than adult male asthmatic patients, and female asthmatic patients experience longer hospital stays per admission as well. These data indicate that adult females are more severely affected by asthma and raise the possibility that hormonal or biochemical differences related to sex may play a role in the pathophysiology of asthma.	MED COLL PENN,DEPT EMERGENCY MED,DIV RES,3300 HENRY AVE,PHILADELPHIA,PA 19129	Drexel University	SPIVEY, WH (corresponding author), MED COLL PENN,DEPT EMERGENCY MED,DIV RES,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.							ABDULKARIM RW, 1970, AM J OBSTET GYNECOL, V107, P641, DOI 10.1016/S0002-9378(16)33953-9; ABDULKARIM RW, 1970, AM J OBSTET GYNECOL, V108, P1098, DOI 10.1016/0002-9378(70)90459-X; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; ELIASSON O, 1987, J ALLERGY CLIN IMMUN, V79, P909, DOI 10.1016/0091-6749(87)90240-5; ELIASSON O, 1985, American Review of Respiratory Disease, V131, pA110; JOHANSSON U, 1981, J PHARM PHARMACOL, V33, P353, DOI 10.1111/j.2042-7158.1981.tb13802.x; Kohler Po, 1986, CLIN ENDOCRINOLOGY; KONNO A, 1986, ORL J OTO-RHINO-LARY, V48, P45, DOI 10.1159/000275841; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MOAWAD AH, 1982, AM J OBSTET GYNECOL, V144, P608, DOI 10.1016/0002-9378(82)90235-6; ROCHE WR, 1989, LANCET, V1, P52; Rubio RL, 1988, ALLERGOL IMMUNOPATH, V16, P263; VIDIC B, 1978, CYTOBIOLOGIE, V18, P10; WILKINSON L, 1988, SYSTAT SYSTEM STATIS; 1990, 1988 SUMMARY NATIONA, V185, P1; 1991, JAMA-J AM MED ASSOC, V266, P559; 1991, 913042 DEP HLTH HUM; 1991, 1990 GENERAL POPULAT; 1980, PHS801260 DEP HLTH H	19	285	286	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3437	3440		10.1001/jama.268.24.3437	http://dx.doi.org/10.1001/jama.268.24.3437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460733				2022-12-28	WOS:A1992KC83900030
J	GREEN, R; SZOSTAK, JW				GREEN, R; SZOSTAK, JW			SELECTION OF A RIBOZYME THAT FUNCTIONS AS A SUPERIOR TEMPLATE IN A SELF-COPYING REACTION	SCIENCE			English	Article							GROUP-I INTRONS; COMPLEMENTARY-STRAND RNA; DNA; TETRAHYMENA; INVITRO; BACTERIOPHAGE-T4; POLYMERASE; LIGANDS	The sunY ribozyme is derived from a self-splicing RNA group I intron. This ribozyme was chosen as a starting point for the design of a self-replicating RNA because of its small size. As a means of facilitating the self-replication process, the size of this ribozyme was decreased by the deletion of nonconserved structural domains; however, when such deletions were made, there were severe losses of enzymatic activity. In vitro genetic selection was used to identify mutations that reactivate a virtually inactive sunY deletion mutant. A selected mutant with five substitution mutations scattered throughout the primary sequence showed greater catalytic activity than the original ribozyme under the selection conditions. The sunY ribozyme and its small selected variant can both catalyze template-directed oligonucleotide assembly. The small size and reduced secondary structure of the selected variant results in an enhancement, relative to that of the original ribozyme, of its rate of self-copying. This engineered ribozyme is able to function effectively both as a catalyst and as a template in self-copying reactions.			GREEN, R (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; DOUDNA JA, 1989, MOL CELL BIOL, V9, P5480, DOI 10.1128/MCB.9.12.5480; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; GREEN R, 1991, Methods (Orlando), V2, P75, DOI 10.1016/S1046-2023(05)80127-6; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1992, GENE DEV, V6, P1372; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MITCHELL MJ, 1990, NUCLEIC ACIDS RES, V18, P5321, DOI 10.1093/nar/18.17.5321; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SHUB DA, 1988, P NATL ACAD SCI USA, V85, P1151, DOI 10.1073/pnas.85.4.1151; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	18	108	148	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1910	1915		10.1126/science.1470913	http://dx.doi.org/10.1126/science.1470913			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470913				2022-12-28	WOS:A1992KD08800023
J	BROWNING, D				BROWNING, D			COUNTDOWN TO COMMUNITY CARE - GETTING READY FOR CHANGE	BRITISH MEDICAL JOURNAL			English	Article											BROWNING, D (corresponding author), AUDIT COMMISS,1 VINCENT SQ,LONDON SW1P 2PN,ENGLAND.							[Anonymous], 1989, CM849; BEARDSHAW V, 1988, LAST LIST COMMUNITY; HARRISON A, 1992, HLTH CARE UK 1991; Kestenbaum A., 1992, CASH CARE REPORT EXP; 1992, GENERAL PRACTITIONER; 1986, MAKING REALITY COMMU; 1992, LAINGS REV PRIVATE H; 1991, OPCS MONITOR, V1; 1989, HC895 DEP HLTH HLTH; 1989, 9 AUD COMM OCC PAP; 1992, MANAGING CASCADE CHA	11	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1415	1418		10.1136/bmj.305.6866.1415	http://dx.doi.org/10.1136/bmj.305.6866.1415			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486309	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992KB85600028
J	PRIESTLEY, KA; CAMPBELL, C; VALENTINE, CB; DENISON, DM; BULLER, NP				PRIESTLEY, KA; CAMPBELL, C; VALENTINE, CB; DENISON, DM; BULLER, NP			ARE PATIENT CONSENT FORMS FOR RESEARCH PROTOCOLS EASY TO READ	BRITISH MEDICAL JOURNAL			English	Article											PRIESTLEY, KA (corresponding author), ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT INVAS CARDIOL,LONDON SW3 6NP,ENGLAND.							Gunning R., 1971, TECHNIQUE CLEAR WRIT; 1992, NATIONAL READERSHIP; 1991, CPMP111397688EN COMM	3	41	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1263	1264		10.1136/bmj.305.6864.1263	http://dx.doi.org/10.1136/bmj.305.6864.1263			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477569	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JZ52100024
J	GARDINER, AJS; FOREY, BA; LEE, PN				GARDINER, AJS; FOREY, BA; LEE, PN			AVIAN EXPOSURE AND BRONCHOGENIC-CARCINOMA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate the association between bird keeping and risk of lung cancer. Design-Case-control study asking detailed questions on exposure to domestic birds and other pets, smoking, and various demographic and potentially confounding variables. Setting-District general hospital; current admissions interviewed in hospital or recent admissions interviewed at home. Patients-143 patients with lung cancer, 143 controls with heart disease, and 143 controls with orthopaedic conditions individually matched for age, sex, date of admission, and current or past admission. Main outcome measures-Odds ratios for lung cancer in relation to various aspects of bird keeping, after adjustment for smoking and other relevant confounding variables. Results-Risk of lung cancer was not significantly associated with household exposure to pet birds at any time or at various specific periods in life, or to keeping large numbers of birds. For specific types of birds no association was seen for living in households with budgerigars or canaries but risk was significantly associated with keeping pigeons (odds ratio 3.53, 95% confidence interval 1.56 to 7.98). This remained significant after regression analysis to account for confounding variables (3.9, 1.2 to 12.62) in both sexes and all age groups. Conclusion-Bird keeping may confer some risk of lung cancer but the relation is not as strong as previously reported.	PN LEE STAT & COMP,SUTTON SM2 5DA,SURREY,ENGLAND	PN Lee Statistics & Computing Ltd	GARDINER, AJS (corresponding author), MONKLANDS DIST GEN HOSP,MED UNIT,AIRDRIE ML6 0JS,LANARK,SCOTLAND.			Lee, Peter/0000-0002-8244-1904				Breslow N, 1980, STATISTICAL METHODS, V32; HOLST PA, 1988, BRIT MED J, V297, P1319, DOI 10.1136/bmj.297.6659.1319; HOLST PAJ, 1988, BIRD KEEPING SOURCE	3	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					989	992		10.1136/bmj.305.6860.989	http://dx.doi.org/10.1136/bmj.305.6860.989			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV776	1458146	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JV77600026
J	GAIL, MH; MARK, SD				GAIL, MH; MARK, SD			EARLY ZIDOVUDINE AND SURVIVAL IN HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											GAIL, MH (corresponding author), NCI,ROCKVILLE,MD 20892, USA.							GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703	2	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					815	815						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1472233				2022-12-28	WOS:A1992JL66100027
J	SHELHAMER, JH; TOEWS, GB; MASUR, H; SUFFREDINI, AF; PIZZO, PA; WALSH, TJ; HENDERSON, DK				SHELHAMER, JH; TOEWS, GB; MASUR, H; SUFFREDINI, AF; PIZZO, PA; WALSH, TJ; HENDERSON, DK			RESPIRATORY-DISEASE IN THE IMMUNOSUPPRESSED PATIENT	ANNALS OF INTERNAL MEDICINE			English	Article						IMMUNOSUPPRESSION; RESPIRATORY TRACT DISEASES; RESPIRATORY INSUFFICIENCY; COLONY-STIMULATING FACTORS; IMMUNIZATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS	PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED IMMUNODEFICIENCY SYNDROME; COLONY-STIMULATING FACTOR; PLACEBO-CONTROLLED TRIAL; NEUTROPHIL CHEMOTACTIC FACTOR; ACUTE NONLYMPHOCYTIC LEUKEMIA; CYTOMEGALO-VIRUS INFECTION; PLUS AMPHOTERICIN-B; OPEN LUNG-BIOPSY; BRONCHOALVEOLAR LAVAGE	Pulmonary complications, both infectious and noninfectious, are an important cause of morbidity in patients with various types of immunosuppression. The appropriate response to these clinical problems requires an understanding of pulmonary host defense and of the various types of systemic immunosuppression. Infectious and noninfectious pulmonary complications may vary according to the type of immunosuppression as well as to the degree and duration of immunosuppression. Appropriate clinical management also requires an understanding of the clinical problems commonly seen in specific groups of immunosuppressed patients and an understanding of the sensitivity, specificity, and potential complications associated with the available diagnostic approaches to those patients. Because respiratory disease in these patient groups may progress rapidly to respiratory failure, an expeditious evaluation based on the knowledge of likely causes of respiratory disease and prompt specific or empiric therapy are indicated. Specific sets of algorithms for the evaluation of both focal and diffuse pulmonary disease may facilitate such an evaluation. In addition, an aggressive approach to the prevention of pulmonary disease including immunization, prophylaxis, and immunomodulation (for example, colony stimulating factors) may be warranted in specific subgroups at risk.			SHELHAMER, JH (corresponding author), NIH, CTR CLIN, DEPT CRIT CARE MED, BETHESDA, MD 20892 USA.							ALBERT RK, 1981, NEW ENGL J MED, V304, P1465, DOI 10.1056/NEJM198106113042404; ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; ARMSTRONG D, 1984, AM J MED, V76, P685, DOI 10.1016/0002-9343(84)90295-X; BALTER MS, 1989, J IMMUNOL, V142, P602; BODEY GP, 1966, J CHRON DIS, V19, P667, DOI 10.1016/0021-9681(66)90066-X; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BROADDUS C, 1985, ANN INTERN MED, V102, P747, DOI 10.7326/0003-4819-102-6-747; BROWNE MJ, 1986, ANN INTERN MED, V104, P338, DOI 10.7326/0003-4819-104-3-338; BURCH PA, 1987, J CLIN ONCOL, V5, P1985, DOI 10.1200/JCO.1987.5.12.1985; COMMERS JR, 1984, PEDIATR INFECT DIS J, V3, P423, DOI 10.1097/00006454-198409000-00007; CRAWFORD SW, 1988, ANN INTERN MED, V108, P180, DOI 10.7326/0003-4819-108-2-180; DEKKER AW, 1981, ANN INTERN MED, V95, P555, DOI 10.7326/0003-4819-95-5-555; DEKKER AW, 1987, ANN INTERN MED, V106, P7, DOI 10.7326/0003-4819-106-1-7; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; DELIBERO G, 1986, J IMMUNOL, V137, P2688; ETTENSOHN DB, 1983, AM REV RESPIR DIS, V128, P516, DOI 10.1164/arrd.1983.128.3.516; FAGON JY, 1988, AM REV RESPIR DIS, V138, P110, DOI 10.1164/ajrccm/138.1.110; FALLOON J, 1987, 27TH INT C ANT AG CH, P1254; FANTA CH, 1989, RESPIRATORY INFECTIO, P221; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GUALTIERI RJ, 1983, AM J MED, V74, P934, DOI 10.1016/0002-9343(83)90785-4; GUIOT HFL, 1983, J INFECT DIS, V147, P615, DOI 10.1093/infdis/147.4.615; HANCE AJ, 1985, J IMMUNOL, V134, P284; HANCE AJ, 1991, LUNG SCI F, P483; HANN IM, 1982, LANCET, V1, P826; HANSON RR, 1976, AM REV RESPIR DIS, V114, P67; HATHORN JW, 1987, ANTIMICROB AGENTS CH, V31, P971, DOI 10.1128/AAC.31.7.971; HAVERKOS HW, 1983, CANCER, V52, P1093, DOI 10.1002/1097-0142(19830915)52:6<1093::AID-CNCR2820520627>3.0.CO;2-4; HENSON PM, 1988, INFLAMMATION BASIC P, P363; HOLT PG, 1987, IMMUNOLOGY, V62, P349; HOLT PG, 1988, J EXP MED, V167, P262, DOI 10.1084/jem.167.2.262; HORSBURGH CR, 1985, MEDICINE, V64, P36, DOI 10.1097/00005792-198501000-00003; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUNNINGHAKE GW, 1980, J CLIN INVEST, V66, P473, DOI 10.1172/JCI109878; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; JONES PG, 1984, ARCH INTERN MED, V144, P549, DOI 10.1001/archinte.144.3.549; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; KAHN FW, 1987, J INFECT DIS, V155, P862, DOI 10.1093/infdis/155.5.862; KARP JE, 1987, ANN INTERN MED, V106, P1, DOI 10.7326/0003-4819-106-1-1; KAUFFMAN CA, 1978, AM J MED, V64, P923, DOI 10.1016/0002-9343(78)90445-X; KAZMIEROWSKI JA, 1977, J CLIN INVEST, V59, P273, DOI 10.1172/JCI108638; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KOVACS JA, 1988, NEW ENGL J MED, V318, P589, DOI 10.1056/NEJM198803103181001; KRADIN RL, 1991, AM J RESP CELL MOL, V4, P210, DOI 10.1165/ajrcmb/4.3.210; LARSEN GL, 1982, AM REV RESPIR DIS, V126, P306; LEHNERT BE, 1985, EXP LUNG RES, V9, P177, DOI 10.3109/01902148509057522; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LEVINE SJ, 1991, AM REV RESPIR DIS, V144, P760, DOI 10.1164/ajrccm/144.4.760; LEVINE SJ, 1991, RESPIRATORY DISEASE, P73; LIPSCHIK GY, 1991, RESPIRATORY DISEASE, P64; LIPSCOMB MF, 1986, J IMMUNOL, V136, P497; LYONS CR, 1986, J IMMUNOL, V137, P1173; MASUR H, 1990, NEW ENGL J MED, V323, P1500, DOI 10.1056/NEJM199011223232131; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MCCABE RE, 1985, AM J MED, V78, P609, DOI 10.1016/0002-9343(85)90403-6; MCCABE RE, 1991, RESPIRATORY DISEASE, P105; MEUNIER F, 1989, AM J MED, V86, P668; MEUNIERCARPENTIER F, 1984, AM J MED, V76, P652, DOI 10.1016/0002-9343(84)90290-0; MEYER RD, 1973, AM J MED, V54, P6, DOI 10.1016/0002-9343(73)90077-6; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MEYERS JD, 1990, PRINCIPLES PRACTICE, P2291; MODY CH, 1990, J IMMUNOL, V144, P1472; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; NAUSEEF WM, 1981, NEW ENGL J MED, V304, P448, DOI 10.1056/NEJM198102193040802; NICOD LP, 1989, J LEUKOCYTE BIOL, V45, P458, DOI 10.1002/jlb.45.5.458; ORTBALS DW, 1977, ANN INTERN MED, V87, P552, DOI 10.7326/0003-4819-87-5-552; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; PIZZO PA, 1983, J PEDIATR-US, V102, P125, DOI 10.1016/S0022-3476(83)80310-2; PIZZO PA, 1987, REV INFECT DIS, V9, P214; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; REYNOLDS HY, 1989, CHEST, V95, pS223, DOI 10.1378/chest.95.3_Supplement.223S; ROIFMAN CM, 1987, LANCET, V1, P1075; ROTROSEN D, 1990, PRINCIPLES PRACTICE, P139; SAITO H, 1988, CHEST, V94, P745, DOI 10.1378/chest.94.4.745; SANDERS JW, 1991, J INFECT DIS, V164, P907, DOI 10.1093/infdis/164.5.907; SANDRON D, 1986, EUR J RESPIR DIS, V68, P177; SCHIMPFF S, 1971, NEW ENGL J MED, V284, P1061, DOI 10.1056/NEJM197105132841904; SCOWDEN EB, 1978, MEDICINE, V57, P527, DOI 10.1097/00005792-197811000-00004; SERTL K, 1986, J EXP MED, V163, P436, DOI 10.1084/jem.163.2.436; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; SNIDER DE, 1987, AM REV RESPIR DIS, V136, P492; SPRENT J, 1986, IMMUNOL REV, V91, P195, DOI 10.1111/j.1600-065X.1986.tb01489.x; STAHL PD, 1990, AM J RESP CELL MOL, V2, P317, DOI 10.1165/ajrcmb/2.4.317; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STOVER DE, 1984, ANN INTERN MED, V101, P1, DOI 10.7326/0003-4819-101-1-1; STRIETER RM, 1990, AM J RESP CELL MOL, V2, P321, DOI 10.1165/ajrcmb/2.4.321; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; TOEWS GB, 1984, AM REV RESPIR DIS, V129, P82; TOEWS GB, 1989, RESPIRATORY INFECTIO, P41; TRAVIS WD, 1991, RESP DIS IMMUNOSUPPR, P182; TRICOT G, 1987, REV INFECT DIS, V9, pS94; VIAL WC, 1984, AM REV RESPIR DIS, V129, P87; WALSH TJ, 1988, ANNU REV MICROBIOL, V42, P517, DOI 10.1146/annurev.mi.42.100188.002505; WALSH TJ, 1988, EUR J CLIN MICROBIOL, V7, P460, DOI 10.1007/BF01962595; WINGARD JR, 1987, AM J MED, V83, P1103, DOI 10.1016/0002-9343(87)90949-1; WINTERBAUER RH, 1983, AM REV RESPIR DIS, V128, P98, DOI 10.1164/arrd.1983.128.1.98; YOUNG RC, 1970, MEDICINE, V49, P147, DOI 10.1097/00005792-197003000-00002; YU VL, 1986, AM J MED, V81, P249, DOI 10.1016/0002-9343(86)90259-7; 1989, MMWR, V38, P297	101	61	63	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					415	431		10.7326/0003-4819-117-5-415	http://dx.doi.org/10.7326/0003-4819-117-5-415			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503334				2022-12-28	WOS:A1992JK67800012
J	GARFINKEL, A; SPANO, ML; DITTO, WL; WEISS, JN				GARFINKEL, A; SPANO, ML; DITTO, WL; WEISS, JN			CONTROLLING CARDIAC CHAOS	SCIENCE			English	Article							DYNAMICS; CELLS	The extreme sensitivity to initial conditions that chaotic systems display makes them unstable and unpredictable. Yet that same sensitivity also makes them highly susceptible to control, provided that the developing chaos can be analyzed in real time and that analysis is then used to make small control interventions. This strategy has been used here to stabilize cardiac arrhythmias induced by the drug ouabain in rabbit ventricle. By administering electrical stimuli to the heart at irregular times determined by chaos theory, the arrhythmia was converted to periodic beating.	USN,CTR SURFACE WARFARE,SILVER SPRING,MD 20903; COLL WOOSTER,DEPT PHYS,WOOSTER,OH 44691; UNIV CALIF LOS ANGELES,DEPT MED CARDIOL,LOS ANGELES,CA 90024	United States Department of Defense; United States Navy; College of Wooster; University of California System; University of California Los Angeles	GARFINKEL, A (corresponding author), UNIV CALIF LOS ANGELES,DEPT PHYSIOL SCI,LOS ANGELES,CA 90024, USA.		Ditto, William/AAK-9827-2020; Spano, Mark L/B-6883-2011	Ditto, William/0000-0002-7416-8012; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036729, K04HL001890, R01HL044880] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL44880, KO4 HL01890, R01 HL36729] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNSDORF MF, 1991, CURR OPIN CARDIOL, V6, P3, DOI 10.1097/00001573-199102000-00002; BOWEN R, 1971, T AM MATH SOC, V154, P377, DOI 10.2307/1995452; CHIALVO DR, 1990, NATURE, V343, P653, DOI 10.1038/343653a0; COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0; CRUTCHFIELD JP, 1986, SCI AM, V255, P46, DOI 10.1038/scientificamerican1286-46; DITTO WL, 1990, PHYS REV LETT, V65, P3211, DOI 10.1103/PhysRevLett.65.3211; FEDIDA D, 1987, J PHYSIOL-LONDON, V392, P523, DOI 10.1113/jphysiol.1987.sp016795; GARFINKEL AJ, 1991, LIFE SCI, V48, P2189, DOI 10.1016/0024-3205(91)90153-3; GOLLUB JP, 1975, PHYS REV LETT, V35, P927, DOI 10.1103/PhysRevLett.35.927; GREBOGI C, 1988, PHYS REV A, V37, P1711, DOI 10.1103/PhysRevA.37.1711; GUCKENHEIMER J, 1983, NONLINEAR OSCILLATIO, P105; GUEVARA MR, 1981, SCIENCE, V214, P1350, DOI 10.1126/science.7313693; HUNT ER, 1991, PHYS REV LETT, V67, P53; Kaplan JL, 1979, LECT NOTES MATH, P228; Moon F.C., 1987, CHAOTIC VIBRATIONS; OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131; OTT E, 1990, PHYS REV LETT, V64, P1196, DOI 10.1103/PhysRevLett.64.1196; ROSSLER OE, 1978, NATURE, V271, P89, DOI 10.1038/271089a0; ROY R, 1992, PHYS REV LETT, V68, P1259, DOI 10.1103/PhysRevLett.68.1259; SHINBROT T, 1992, PHYS REV LETT, V68, P2863, DOI 10.1103/PhysRevLett.68.2863; SHINBROT T, 1990, PHYS REV LETT, V65, P3215, DOI 10.1103/PhysRevLett.65.3215; WEISS J, 1982, AM J PHYSIOL, V243, pH318, DOI 10.1152/ajpheart.1982.243.2.H318; WEISS JN, 1987, CARDIAC ARRHYTHMIAS, P83	23	703	727	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1230	1235		10.1126/science.1519060	http://dx.doi.org/10.1126/science.1519060			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519060	Green Submitted			2022-12-28	WOS:A1992JL05000019
J	LI, M; JAN, YN; JAN, LY				LI, M; JAN, YN; JAN, LY			SPECIFICATION OF SUBUNIT ASSEMBLY BY THE HYDROPHILIC AMINO-TERMINAL DOMAIN OF THE SHAKER POTASSIUM CHANNEL	SCIENCE			English	Article							MUSCLE ACETYLCHOLINE-RECEPTOR; DELAYED-RECTIFIER PROPERTIES; K+ CHANNEL; FUNCTIONAL EXPRESSION; RAT-BRAIN; XENOPUS-OOCYTES; HETEROMULTIMERIC CHANNELS; EXCITABLE CELLS; MAMMALIAN BRAIN; EPSILON SUBUNIT	The functional heterogeneity of potassium channels in eukaryotic cells arises not only from the multiple potassium channel genes and splice variants but also from the combinatorial mixing of different potassium channel polypeptides to form heteromultimeric channels with distinct properties. One structural element that determines the compatibility of different potassium channel polypeptides in subunit assembly has now been localized to the hydrophilic amino-terminal domain. A Drosophila Shaker B (ShB) potassium channel truncated polypeptide that contains only the hydrophilic amino-terminal domain can form a homomultimer; the minimal requirement for the homophilic interaction has been localized to a fragment of 114 amino acids. Substitution of the amino-terminal domain of a distantly related mammalian potassium channel polypeptide (DRK1) with that of ShB permits the chimeric DRK1 polypeptide to coassemble with ShB.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LI, M (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P567; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHANDY KG, 1991, NATURE, V352, P26, DOI 10.1038/352026b0; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COPELAND BR, 1982, J BIOL CHEM, V257, P5065; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DOUGLASS J, 1990, J IMMUNOL, V144, P4841; DREWE JA, 1992, J NEUROSCI, V12, P538; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1991, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HWANG PM, 1992, NEURON, V8, P473, DOI 10.1016/0896-6273(92)90275-I; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; LATORRE R, 1984, ANNU REV PHYSIOL, V46, P485; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; Li M., UNPUB; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; LUNEAU C, 1991, FEBS LETT, V288, P163, DOI 10.1016/0014-5793(91)81026-5; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1990, BIOCHEM BIOPH RES CO, V171, P1361, DOI 10.1016/0006-291X(90)90836-C; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; PAK MD, 1991, J NEUROSCI, V11, P869; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PFAFFINGER PJ, 1991, J NEUROSCI, V11, P918; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; ROGAWSKI MA, 1985, TRENDS NEUROSCI, V8, P214, DOI 10.1016/0166-2236(85)90082-7; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	69	413	423	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1225	1230		10.1126/science.1519059	http://dx.doi.org/10.1126/science.1519059			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519059				2022-12-28	WOS:A1992JL05000018
J	COHEN, ML				COHEN, ML			EPIDEMIOLOGY OF DRUG-RESISTANCE - IMPLICATIONS FOR A POSTANTIMICROBIAL ERA	SCIENCE			English	Article							STAPHYLOCOCCUS-AUREUS; UNITED-STATES; HUMAN SALMONELLOSIS; OUTBREAK; INFECTION; PLASMIDS; ENTEROCOCCUS; TRANSMISSION; HOSPITALS; CHILDREN	In the last several years, the frequency and spectrum of antimicrobial-resistant infections have increased in both the hospital and the community. Certain infections that are essentially untreatable have begun to occur as epidemics both in the developing world and in institutional settings in the United States. The increasing frequency of drug resistance has been attributed to combinations of microbial characteristics, selective pressures of antimicrobial use, and societal and technologic changes that enhance the transmission of drug-resistant organisms. Antimicrobial resistance is resulting in increased morbidity, mortality, and health-care costs. Prevention and control of these infections will require new antimicrobial agents, prudent use of existing agents, new vaccines, and enhanced public health efforts to reduce transmission.			COHEN, ML (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333, USA.							APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77; BAINE WB, 1977, J INFECT DIS, V135, P649, DOI 10.1093/infdis/135.4.649; BHUTTA ZA, 1991, REV INFECT DIS, V13, P832; BLUMBERG HM, 1991, J INFECT DIS, V163, P1279, DOI 10.1093/infdis/163.6.1279; BRADLEY SF, 1991, ANN INTERN MED, V115, P417, DOI 10.7326/0003-4819-115-6-417; COHEN ML, 1986, SCIENCE, V234, P964, DOI 10.1126/science.3535069; COHEN ML, 1982, ANTIMICROB AGENTS CH, V21, P210, DOI 10.1128/AAC.21.2.210; FONTANALS D, 1989, EUR J CLIN MICROBIOL, V8, P90, DOI 10.1007/BF01964130; FOX JL, 1992, ASM NEWS, V58, P135; FROST JA, 1981, LANCET, V2, P1074; GAYNES RP, UNPUB; HALEY RW, 1982, ANN INTERN MED, V97, P297, DOI 10.7326/0003-4819-97-3-297; HOLMBERG SD, 1984, SCIENCE, V225, P833, DOI 10.1126/science.6382605; HOLMBERG SD, 1984, NEW ENGL J MED, V311, P617, DOI 10.1056/NEJM198409063111001; HOLMBERG SD, 1987, REV INFECT DIS, V9, P165; JACOBY GA, 1991, NEW ENGL J MED, V324, P601, DOI 10.1056/NEJM199102283240906; KNAPP JS, 1991, 31TH ICAAC, P308; LACEY RW, 1975, BACTERIOL REV, V39, P1; LEELA, 1991, 31ST INT C ANT AG CH, P186; LEVY SB, 1990, NEW ENGL J MED, V323, P335, DOI 10.1056/NEJM199008023230509; LOCKSLEY RM, 1982, ANN INTERN MED, V97, P317, DOI 10.7326/0003-4819-97-3-317; MACDONALD KL, 1987, JAMA-J AM MED ASSOC, V258, P1496, DOI 10.1001/jama.258.11.1496; MAKI DG, 1990, 3RD DEC INT C NOS IN, P26; MARX R, 1991, SEX TRANSM DIS, V18, P92, DOI 10.1097/00007435-199118020-00008; MCDERMOTT W, 1982, JOHNS HOPKINS MED J, V151, P302; MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; MURRAY BE, 1991, J INFECT DIS, V163, P118; PATTERSON JE, 1990, REV INFECT DIS, V12, P644; REICHLER M, 1991, 91ST ANN M AM SOC MI, P404; RIES AA, 1991, 31ST INT C ANT AG CH, P186; RILEY LW, 1984, J INFECT DIS, V150, P236, DOI 10.1093/infdis/150.2.236; RILEY LW, 1984, J INFECT DIS, V149, P878, DOI 10.1093/infdis/149.6.878; RYAN CA, 1987, JAMA-J AM MED ASSOC, V258, P3269, DOI 10.1001/jama.258.22.3269; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; SHLAES DM, 1992, INFECT CONT HOSP EP, V13, P193; SPIKA JS, 1987, NEW ENGL J MED, V316, P565, DOI 10.1056/NEJM198703053161001; TACKET CO, 1985, JAMA-J AM MED ASSOC, V253, P2058, DOI 10.1001/jama.253.14.2058; TAUXE RV, 1989, J INFECT DIS, V160, P1067, DOI 10.1093/infdis/160.6.1067; TAUXE RV, 1990, J INFECT DIS, V162, P1107, DOI 10.1093/infdis/162.5.1107; TAUXE RV, 1989, GENE TRANSFER ENV, P377; TOMPKINS LS, 1980, J INFECT DIS, V141, P625, DOI 10.1093/infdis/141.5.625; WATANABE T, 1963, BACTERIOL REV, V27, P87, DOI 10.1128/MMBR.27.1.87-115.1963; WEINSTEIN RA, 1982, J INFECT DIS, V145, P374, DOI 10.1093/infdis/145.3.374; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WILLIAMS RD, 1978, ANTIMICROB AGENTS CH, V14, P710, DOI 10.1128/AAC.14.5.710; YAMAMOTO T, 1992, J INFECT DIS, V165, P744, DOI 10.1093/infdis/165.4.744; 1992, NATIONAL ACTION PLAN, P8; 1991, MORB MORTAL WKLY REP, V40, P585	49	1006	1060	4	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 21	1992	257	5073					1050	1055		10.1126/science.257.5073.1050	http://dx.doi.org/10.1126/science.257.5073.1050			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509255				2022-12-28	WOS:A1992JJ88400019
J	JONES, DJ; JAMES, RD				JONES, DJ; JAMES, RD			ABC OF COLORECTAL DISEASES - ANAL CANCER	BRITISH MEDICAL JOURNAL			English	Article									CHRISTIE HOSP & HOLT RADIUM INST,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital	JONES, DJ (corresponding author), HOPE HOSP,DEPT SURG,SALFORD M6 8HD,LANCS,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					169	171		10.1136/bmj.305.6846.169	http://dx.doi.org/10.1136/bmj.305.6846.169			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515836	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JF06300030
J	ARIEFF, AI; AYUS, JC; FRASER, CL				ARIEFF, AI; AYUS, JC; FRASER, CL			HYPONATREMIA AND DEATH OR PERMANENT BRAIN-DAMAGE IN HEALTHY-CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							ANTI-DIURETIC HORMONE; WATER-INTOXICATION; NORMAL INFANTS; RAT-BRAIN; HYPONATREMIA; VASOPRESSIN; PATHOGENESIS; MORBIDITY; SURGERY; SALINE	Objective - To determine if hyponatraemia causes permanent brain damage in healthy children and, if so, if the disorder is primarily limited to females, as occurs in adults. Design - Prospective clinical case study of 16 affected children and a review of 24 412 consecutive surgical admissions at one medical centre. Patients - 16 children (nine male, seven female; age 7 (SD 5) years) with generally minor illness were electively hospitalised for primary care. Consultation was obtained for the combination of respiratory arrest with symptomatic hyponatraemia (serum sodium concentration less-than-or-equal-to 128 mmol/l). Main outcome measures - Presence, gender distribution, and classification of permanent brain damage in children with symptomatic hyponatraemia in both prospective and retrospective studies. Results - By retrospective evaluation the incidence of postoperative hyponatraemia among 24 412 patients was 0.34% (83 cases) and mortality of those afflicted was 8.4% (seven deaths). In the prospective population the serum sodium concentration on admission was 138 (SD 2) mmol/l. From three to 120 inpatient hours after hypotonic fluid administration patients developed progressive lethargy, headache, nausea, and emesis with an explosive onset of respiratory arrest. At the time serum sodium concentration was 115 (7) mmol/l and arterial oxygen tension 6 (1.5) kPa. The hyponatraemia was primarily caused by extrarenal loss of electrolytes with replacement by hypotonic fluids. All 16 patients had cerebral oedema detected at either radiological or postmortem examination. All 15 patients not treated for their hyponatraemia in a timely manner either died or were permanently incapacitated by brain damage. The only patient treated in a timely manner was alive but mentally retarded. Conclusions - Symptomatic hyponatraemia can result in a high morbidity in children of both genders, which is due in large part to inadequate brain adaptation and lack of timely treatment.	UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; BAYLOR COLL MED,HOUSTON,TX 77030	University of California System; University of California San Francisco; Baylor College of Medicine					PHS HHS [R01 08575-01A2] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abramow M, 1984, Adv Nephrol Necker Hosp, V13, P1; ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; ARIEFF AI, 1976, MEDICINE, V55, P121, DOI 10.1097/00005792-197603000-00002; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; ASHRAF N, 1981, AM J MED, V70, P1163, DOI 10.1016/0002-9343(81)90822-6; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; AYUS JC, 1982, AM J MED, V72, P43, DOI 10.1016/0002-9343(82)90575-7; AYUS JC, 1991, J AM SOC NEPHROL, V2, P278; BURROWS FA, 1983, CRIT CARE MED, V11, P527, DOI 10.1097/00003246-198307000-00009; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; COWLEY D M, 1988, Australian and New Zealand Journal of Surgery, V58, P485, DOI 10.1111/j.1445-2197.1988.tb06240.x; CRAWFORD JD, 1964, PEDIATR CLIN N AM, V11, P1029; CRUMPACK.RW, 1973, NEUROLOGY, V23, P1251, DOI 10.1212/WNL.23.11.1251; DAVID R, 1981, PEDIATRICS, V68, P349; DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410; DELCASTILLO AR, 1987, BRAIN RES, V416, P113, DOI 10.1016/0006-8993(87)91502-2; FARACI FM, 1990, AM J PHYSIOL, V258, pR94, DOI 10.1152/ajpregu.1990.258.1.R94; FRASER CL, 1989, AM J PHYSIOL, V256, pR880, DOI 10.1152/ajpregu.1989.256.4.R880; FRASER CL, 1989, AM J PHYSIOL, V257, pE284, DOI 10.1152/ajpendo.1989.257.2.E284; FRASER CL, 1990, ANN INTERN MED, V112, P113, DOI 10.7326/0003-4819-112-2-113; GARCIA JH, 1980, BRAIN EDEMA PATHOLOG, P147; GROSS PA, 1987, EUR J CLIN INVEST, V17, P123, DOI 10.1111/j.1365-2362.1987.tb02391.x; GUERRA M, 1987, NEUROSCI LETT, V78, P97, DOI 10.1016/0304-3940(87)90568-4; GUR RC, 1991, P NATL ACAD SCI USA, V88, P2845, DOI 10.1073/pnas.88.7.2845; JENNETT B, 1972, LANCET, V1, P734; JUDD BA, 1987, ACTA PAEDIATR SCAND, V76, P385; KEATING JP, 1991, AM J DIS CHILD, V145, P985, DOI 10.1001/archpedi.1991.02160090037018; MELTON JE, 1983, AM J PHYSIOL, V244, pR724, DOI 10.1152/ajpregu.1983.244.5.R724; MELTON JE, 1987, AM J PHYSIOL, V252, pF661, DOI 10.1152/ajprenal.1987.252.4.F661; NATTIE EE, 1981, J APPL PHYSIOL, V51, P1086, DOI 10.1152/jappl.1981.51.5.1086; Rosenberg G A, 1990, Adv Neurol, V52, P149; ROSOMOFF HL, 1963, ARCH NEUROL-CHICAGO, V9, P36; SARNAIK AP, 1991, CRIT CARE MED, V19, P758, DOI 10.1097/00003246-199106000-00005; TIEN R, IN PRESS AM J MED; VARAVITHYA W, 1967, J PEDIATR-US, V71, P269, DOI 10.1016/S0022-3476(67)80087-8; WIDDOWSON EM, 1960, BIOCHEM J, V77, P30, DOI 10.1042/bj0770030; WORTHLEY LIG, 1986, BRIT MED J, V292, P168, DOI 10.1136/bmj.292.6514.168; [No title captured]; 1990, STAT ABSTR US 1990, P110; 1991, AM HOSPITAL ASS HOSP, P20; 1985, SAS USERS GUIDE BASI; 1990, STAT ABSTR US 1990, P16	42	269	283	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1218	1222		10.1136/bmj.304.6836.1218	http://dx.doi.org/10.1136/bmj.304.6836.1218			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515791	Green Published, Bronze			2022-12-28	WOS:A1992HT96400021
J	HALPERN, DS; REID, J				HALPERN, DS; REID, J			EFFECT OF UNEXPECTED DEMOLITION ANNOUNCEMENT ON HEALTH OF RESIDENTS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To examine the impact of an unexpected announcement of the demolition of a housing estate on the health of the area's residents. Design - Study of general practitioner consultation rates of the estate's residents after the announcement compared with those of other areas and with those of the previous year. Setting-General practices in Runcorn, Cheshire. Patients - 17 000 patients on lists of the two group practices serving the estate and surrounding area. Main outcome measure - Relative weekly consultation rates with general practitioners. Results - The mean adjusted odds ratio for consultation was 1.12 (SD 0.12) when demolition was expected and 0.877 (0.05) when it was not (t = 5.94, p < 0.001). The difference remained after the adjustment for the fall in the estate's population was removed (t = 3.7, p < 0.01). Conclusion - Announcement of the estate's demolition adversely affected residents' health.	HALTON HLTH AUTHOR,HLTH MED,RUNCORN WA7 4TH,ENGLAND		HALPERN, DS (corresponding author), UNIV CAMBRIDGE ST JOHNS COLL,CAMBRIDGE CB2 1TP,ENGLAND.							BEALE N, 1988, BRIT MED J, V296, P1508, DOI 10.1136/bmj.296.6635.1508; FRIED M, 1963, URBAN CONDITION; KASL SV, 1974, MAN ENV SYSTEMS, V4, P207; KENNEDY S, 1990, SOCIAL SUPPORT; Lowry S., 1991, HOUSING HLTH; PEREZ M, 1988, PSYCHOL MED, V18, P11, DOI 10.1017/S0033291700001835; Young M., 1957, FAMILY KINSHIP E LON	7	3	3	2	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1229	1230		10.1136/bmj.304.6836.1229	http://dx.doi.org/10.1136/bmj.304.6836.1229			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515798	Green Published, Bronze			2022-12-28	WOS:A1992HT96400029
J	MIZOGUCHI, H; O'SHEA, JJ; LONGO, DL; LOEFFLER, CM; MCVICAR, DW; OCHOA, AC				MIZOGUCHI, H; O'SHEA, JJ; LONGO, DL; LOEFFLER, CM; MCVICAR, DW; OCHOA, AC			ALTERATIONS IN SIGNAL TRANSDUCTION MOLECULES IN LYMPHOCYTES-T FROM TUMOR-BEARING MICE	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASE; ZETA-CHAIN; FC-RECEPTORS; ACTIVATION; COMPLEX; PHOSPHORYLATION; GENERATION; EXPRESSION; CD4	Impaired immune responses occur frequently in cancer patients or in tumor-bearing mice, but the mechanisms of the tumor-induced immune defects remain poorly understood. In an in vivo murine colon carcinoma model (MCA-38), animals bearing a tumor longer than 26 days develop CD8+ T cells with impaired cytotoxic function, decreased expression of the tumor necrosis factor-alpha and granzyme B genes, and decreased ability to mediate an antitumor response in vivo. T lymphocytes from tumor-bearing mice expressed T cell antigen receptors that contained low amounts of CD3gamma and completely lacked CD3zeta, which was replaced by the Fc(epsilon) gamma-chain. Expression of the tyrosine kinases p56lck and p59fyn was also reduced. These changes could be the basis of immune defects in tumor-bearing hosts.	NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES & DEV CTR, EXPTL IMMUNOL LABS, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			McVicar, Daniel/G-1970-2015; Longo, Dan L./F-6022-2011	McVicar, Daniel/0000-0002-1112-5111	NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; ALTMAN A, 1990, CRIT REV IMMUNOL, V10, P347; BRODER S, 1978, NEW ENGL J MED, V299, P1281, DOI 10.1056/NEJM197812072992305; BUFERNE M, 1992, J IMMUNOL, V148, P657; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERSH EM, 1965, NEW ENGL J MED, V273, P1006, DOI 10.1056/NEJM196511042731903; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; LOEFFLER CM, 1992, J IMMUNOL, V149, P949; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MIZOGUCHI H, UNPUB; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NORTH RJ, 1984, J EXP MED, V159, P1295, DOI 10.1084/jem.159.5.1295; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1985, P NATL ACAD SCI USA, V82, P1969, DOI 10.1073/pnas.82.7.1969; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHMITTVERHULST AM, 1987, NATURE, V325, P628, DOI 10.1038/325628a0; SUSSMAN JJ, 1988, NATURE, V334, P625, DOI 10.1038/334625a0; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TAKASUGI M, 1977, CANCER RES, V37, P413; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1990, J CLIN INVEST, V86, P1015, DOI 10.1172/JCI114803; Weissman A M, 1989, Year Immunol, V4, P74; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; YOUNG RC, 1972, AM J MED, V52, P63, DOI 10.1016/0002-9343(72)90008-3	45	623	655	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1795	1798		10.1126/science.1465616	http://dx.doi.org/10.1126/science.1465616			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465616				2022-12-28	WOS:A1992KB96400039
J	LOWRY, S				LOWRY, S			MEDICAL-EDUCATION .3. CURRICULUM DESIGN	BRITISH MEDICAL JOURNAL			English	Article																		TOWLE A, 1991, CRITICAL THINKING FU; WALTON JN, 1977, BRIT MED J, V1, P1262, DOI 10.1136/bmj.1.6071.1262; 1991, UNDERGRADUATE MED ED	3	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1409	1411		10.1136/bmj.305.6866.1409	http://dx.doi.org/10.1136/bmj.305.6866.1409			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KB856	1486306	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KB85600025
J	PEAT, JK; HABY, M; SPIJKER, J; BERRY, G; WOOLCOCK, AJ				PEAT, JK; HABY, M; SPIJKER, J; BERRY, G; WOOLCOCK, AJ			PREVALENCE OF ASTHMA IN ADULTS IN BUSSELTON, WESTERN-AUSTRALIA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY SYMPTOMS; POPULATION; QUESTIONNAIRE; SCHOOLCHILDREN; METHACHOLINE; HISTAMINE; COMMUNITY; CHILDREN	Objective-To estimate whether the prevalence of asthma in adults increased over a nine year interval. Design-Serial cross sectional studies of the population with a protocol that included both subjective and objective measurements. Setting-Busselton, Western Australia. Subjects-A random sample of 553 subjects aged 18-55 years in 1981, and of 1028 subjects aged 18-55 years in 1990. Main outcome measures-Respiratory symptoms measured by self administered questionnaire, bronchial responsiveness measured by bronchial challenge with histamine, and allergy measured by skin prick tests. Results-Symptoms with increased prevalence were those with significant association with allergy in this population. Recent wheeze increased from 17.5% to 28.8% (p<0.001) and diagnosed asthma increased Erom 9.0% to 16.3% (p<0.001). The increase was greatest in subjects less than 30 years old. The prevalence of shortness of breath coming on at rest and of hay fever also increased significantly, but the prevalence of shortness of breath on exertion, chronic cough, bronchial hyperresponsiveness, current asthma (defined as recent wheeze plus bronchial hyperresponsiveness), and allergy did not increase. The severity of bronchial responsiveness did not change significantly in any symptom group. Conclusions-Young adults showed a significant increase in reporting of symptoms related to allergy but not in the prevalence of current asthma. The increase in symptoms may be due to increased awareness of asthma in this community, to changed treatment patterns, or to increased exposures to allergens.	UNIV SYDNEY, DEPT MED, SYDNEY, NSW 2006, AUSTRALIA; UNIV SYDNEY, DEPT PUBL HLTH, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney; University of Sydney			Haby, Michelle/AGL-3386-2022	Haby, Michelle/0000-0001-6203-9195				ABRAMSON M, 1992, AUST NZ J MED, V22, P358, DOI 10.1111/j.1445-5994.1992.tb02148.x; ABRAMSON MJ, 1991, J ASTHMA, V28, P129, DOI 10.3109/02770909109082737; BAUMAN A, 1992, MED J AUSTRALIA, V156, P827, DOI 10.5694/j.1326-5377.1992.tb136992.x; BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CAMPBELL DA, 1989, AUST NZ J MED S, V19, P657; CARMAN PG, 1990, MED J AUSTRALIA, V152, P23, DOI 10.5694/j.1326-5377.1990.tb124423.x; LEBOWITZ MD, 1976, AM REV RESPIR DIS, V113, P627; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PEARCE N, 1991, CLIN EXP ALLERGY, V21, P401, DOI 10.1111/j.1365-2222.1991.tb01679.x; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; PEAT JK, 1991, AM REV RESPIR DIS, V144, P338, DOI 10.1164/ajrccm/144.2.338; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SAMET JM, 1978, AM J EPIDEMIOL, V108, P435, DOI 10.1093/oxfordjournals.aje.a112642; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; 1966, QUESTIONNAIRE RESPIR	23	157	157	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 28	1992	305	6865					1326	1329		10.1136/bmj.305.6865.1326	http://dx.doi.org/10.1136/bmj.305.6865.1326			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483077	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992KA77300021
J	SKENE, AI; SMITH, JM; DORE, CJ; CHARLETT, A; LEWIS, JD				SKENE, AI; SMITH, JM; DORE, CJ; CHARLETT, A; LEWIS, JD			VENOUS LEG ULCERS - A PROGNOSTIC INDEX TO PREDICT TIME TO HEALING	BRITISH MEDICAL JOURNAL			English	Article							COMPRESSION; REGRESSION; MODEL; TRIAL	Objective-To evaluate the prognostic factors in uncomplicated venous leg ulcer healing. Design-Randomised parallel group controlled trial with subjects stratified by initial ulcer diameter and four months' maximum duration of follow up. Setting-Assessment at Northwick Park Hospital vascular unit with community based treatment. Patients-200 patients with clinical and objective evidence of uncomplicated venous leg ulceration and an initial ulcer diameter > 2 cm. Main outcome measure-Time to complete healing of the ulcer. Results-In the presence of graduated compression healing occurred more rapidly in patients with a smaller initial ulcer area (relative risk of healing 1.92 associated with halving of ulcer area (95% confidence interval 1.58 to 2.33)), shorter duration of ulceration (relative risk 1.35 associated with halving duration (1.17 to 1.56)), younger age (relative risk 1.34 associated with 10 year decrease (1.12 to 1.59)), and no deep vein involvement (relative risk 1.8 (1.19 to 2.78)). Conclusion-These prognostic factors used in a simple scoring system predict time to healing.	NORTHWICK PK HOSP & CLIN RES CTR,DEPT VASC SURG,HARROW HA1 3UJ,MIDDX,ENGLAND; CLIN RES CTR,MED STAT SECT,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London			Dore, Caroline J/J-4716-2012	Dore, Caroline J/0000-0001-9796-4970				BOSANQUET N, 1992, PHLEBOLOGY, V7, P44; CALLAM M, 1992, PHLEBOLOGY, V7, P6; CHRISTENSEN E, 1987, HEPATOLOGY, V7, P1346, DOI 10.1002/hep.1840070628; COLGAN MP, 1990, BRIT MED J, V300, P972, DOI 10.1136/bmj.300.6730.972; CORNWALL JV, 1986, BRIT J SURG, V73, P693, DOI 10.1002/bjs.1800730905; CORNWALL JV, 1987, BRIT MED J, V295, P1087, DOI 10.1136/bmj.295.6606.1087; CORNWALL JV, 1985, J DISTRICT NURSI SEP, P4; CORNWALL JV, 1985, J DIST NURSING  0904, P11; DEFRIEND DJ, 1992, PHLEBOLOGY, V7, P33; DIXON WJ, 1988, BMDP STATISTICAL SOF, V2; DIXON WJ, 1988, BMDP STATISTICAL SOF, V1; ERIKSSON G, 1984, ENV HEALING ROLE OCC, P45; JONES NAG, 1980, BRIT J SURG, V67, P569, DOI 10.1002/bjs.1800670814; KIKTA MJ, 1988, J VASC SURG, V7, P478, DOI 10.1067/mva.1988.avs0070478; KUK AYC, 1984, BIOMETRIKA, V71, P587; ORMISTON MC, 1985, BRIT MED J, V291, P308, DOI 10.1136/bmj.291.6491.308; SMITH JM, 1992, PHLEBOLOGY, V7, P107; Stewart AJ, 1987, PHLEBOLOGY, V2, P115; YAO ST, 1969, BRIT J SURG, V56, P676, DOI 10.1002/bjs.1800560910	19	139	141	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1119	1121		10.1136/bmj.305.6862.1119	http://dx.doi.org/10.1136/bmj.305.6862.1119			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463945	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JX84100019
J	WALLACE, DJ				WALLACE, DJ			PLASMAPHERESIS FOR LUPUS NEPHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											WALLACE, DJ (corresponding author), CEDARS SINAI MED CTR,LOS ANGELES,CA 90048, USA.							Wallace D J, 1988, J Clin Apher, V4, P30, DOI 10.1002/jca.2920040107; WALLACE DJ, 1988, 1ST P INT C WORLD AP, P855	2	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1992	327	14					1029	1029						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JQ225	1518541				2022-12-28	WOS:A1992JQ22500014
J	WORMSER, GP; FORSETER, G; COOPER, D; NOWAKOWSKI, J; NADELMAN, RB; HOROWITZ, H; SCHWARTZ, I; BOWEN, SL; CAMPBELL, GL; GOLDBERG, NS				WORMSER, GP; FORSETER, G; COOPER, D; NOWAKOWSKI, J; NADELMAN, RB; HOROWITZ, H; SCHWARTZ, I; BOWEN, SL; CAMPBELL, GL; GOLDBERG, NS			USE OF A NOVEL TECHNIQUE OF CUTANEOUS LAVAGE FOR DIAGNOSIS OF LYME-DISEASE ASSOCIATED WITH ERYTHEMA MIGRANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							NEEDLE ASPIRATION; BORRELIA-BURGDORFERI; CELLULITIS; LIDOCAINE; LESIONS; ADULTS	Objective.-Determining the microbial cause of cellulitis is often difficult. In this study, a novel two-needle lavage technique was used to culture Borrelia burgdorferi from the skin of suspected erythema migrans lesions. Design.-The yield of lavage cultures for B burgdorferi was compared with that of a 2-mm skin biopsy sample. Setting.-A Lyme disease diagnostic center located in an area in which Lyme disease is epidemic. Patients.-Forty-five patients with suspected erythema migrans who had not been treated with antimicrobial agents. Intervention.-Cutaneous lavage of the advancing edge of a suspected primary erythema migrans lesion was done for all 45 participants, 33 of whom also had a skin biopsy of the same lesion at an identical (14) or an adjacent (19) site. Main Outcome Measures.-Growth of B burgdorferi in in vitro culture. Results.-Lavage fluid cultures grew B burgdorferi in 13 (29%) of the 45 cases (95% confidence interval [CI], 16% to 44%). Among the 33 cases in which both lavage and skin biopsy cultures were done, the yield of lavage culture was less than that of biopsy culture (P<.09, 12/33 vs 20/33). If contaminated cultures are excluded, this difference is significant (P<.05, 12/30 vs 20/27). Conclusion.-Cutaneous lavage is a new diagnostic technique for recovery of B burgdorferi from erythema migrans lesions that has potential applicability to other types of cutaneous infections.	NEW YORK MED COLL,WESTCHESTER CTY MED CTR,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595; NEW YORK MED COLL,WESTCHESTER CTY MED CTR,DEPT DERMATOL,VALHALLA,NY 10595; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VECTOR BORNE INFECT DIS,FT COLLINS,CO 80522	New York Medical College; Westchester Medical Center; New York Medical College; Westchester Medical Center	WORMSER, GP (corresponding author), NEW YORK MED COLL,WESTCHESTER CTY MED CTR,DEPT MED,DIV INFECT DIS,ROOM 209SE,MACY PAVIL,VALHALLA,NY 10595, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041511] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41511] Funding Source: Medline; PHS HHS [200-91-0912] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BERGER BW, 1983, AM J DERMATOPATH, V5, P111, DOI 10.1097/00000372-198304000-00008; HOOK EW, 1986, ARCH INTERN MED, V146, P295; MILLER MA, 1985, ARCH DERMATOL, V121, P1157, DOI 10.1001/archderm.121.9.1157; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; NEWELL PM, 1988, J CLIN MICROBIOL, V26, P401, DOI 10.1128/JCM.26.3.401-404.1988; PAVIA CS, 1985, GENITOURIN MED, V61, P75; PIESMAN J, 1991, J INFECT DIS, V163, P895, DOI 10.1093/infdis/163.4.895; SCHMIDT RM, 1970, J INFECT DIS, V121, P597, DOI 10.1093/infdis/121.6.597; SCHWARTZ JJ, 1992, J BACTERIOL, V174, P3757, DOI 10.1128/JB.174.11.3757-3765.1992; SIGURDSSON AF, 1989, SCAND J INFECT DIS, V21, P537, DOI 10.3109/00365548909037882; UMAN SJ, 1975, ARCH INTERN MED, V135, P959, DOI 10.1001/archinte.135.7.959; 1990, MMWR, V39, P19	13	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1311	1313		10.1001/jama.268.10.1311	http://dx.doi.org/10.1001/jama.268.10.1311			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507378				2022-12-28	WOS:A1992JL60800033
J	JONAS, HS; ETZEL, SI; BARZANSKY, B				JONAS, HS; ETZEL, SI; BARZANSKY, B			EDUCATIONAL-PROGRAMS IN UNITED-STATES MEDICAL-SCHOOLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									AMER MED ASSOC,DEPT INFORMAT ANAL & PUBLICAT,CHICAGO,IL 60610	American Medical Association	JONAS, HS (corresponding author), AMER MED ASSOC,DIV UNDERGRAD MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							BARNETT PG, 1989, JAMA-J AM MED ASSOC, V262, P2864, DOI 10.1001/jama.262.20.2864; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; JONAS HS, 1991, JAMA-J AM MED ASSOC, V266, P913, DOI 10.1001/jama.266.7.913; KASSEBAUM DG, 1992, ACAD MED, V67, P217, DOI 10.1097/00001888-199203000-00018; Schmittling G, 1991, Fam Med, V23, P297; SCHWARZ MR, 1992, JAMA-J AM MED ASSOC, V268, P1091; WHITCOMB M, 1991, 13 WAMI RUR HLTH RES; 1992, JAMA-J AM MED ASSOC, V268, P1092	8	35	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1083	1090		10.1001/jama.268.9.1083	http://dx.doi.org/10.1001/jama.268.9.1083			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK681	1501328				2022-12-28	WOS:A1992JK68100002
J	BEAUGERIE, L; TEILHAC, MF; DELUOL, AM; FRITSCH, J; GIRARD, PM; ROZENBAUM, W; LEQUINTREC, Y; CHATELET, FP				BEAUGERIE, L; TEILHAC, MF; DELUOL, AM; FRITSCH, J; GIRARD, PM; ROZENBAUM, W; LEQUINTREC, Y; CHATELET, FP			CHOLANGIOPATHY ASSOCIATED WITH MICROSPORIDIA INFECTION OF THE COMMON BILE-DUCT MUCOSA IN A PATIENT WITH HIV-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Note						HUMAN IMMUNODEFICIENCY VIRUS; MICROSPORA INFECTIONS; CHOLANGITIS; BILE DUCT DISEASE; ENTEROCYTOZOON-BIENEUSI; ACQUIRED IMMUNODEFICIENCY SYNDROME	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AIDS	A 36-year-old homosexual man with HIV-1 infection who first developed chronic diarrhoea and then intermittent pain in the right upper quadrant of the abdomen. Microsporidia organisms were identified by light and electron microscopy in the enterocytes of duodenal biopsy specimens. Abdominal ultrasonography showed a mild dilatation of intra- and extrahepatic bile ducts. Irregularities of the intrahepatic ducts and a mild dilatation of the common bile duct were found on endoscopic retrograde cholangiography. Endoscopic sphincterotomy was done to treat the papillary stenosis. A forceps was then introduced through the sphincterotomy up to the bifurcation of the right and left hepatic ducts. Electron microscopic study of the bile duct mucosa showed plasmodial stages and spores of Enterocytozoon bieneusi in the cytoplasm of epithelial cells. Infection of the bile duct epithelium by Microsporidia organisms is possible and may play a role in the pathogenesis of the associated cholangiopathy.	HOP BICETRE, F-94270 LE KREMLIN BICETRE, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	BEAUGERIE, L (corresponding author), HOP ROTHSCHILD, DEPT HEPATOGASTROENTEROL, 33 BLVD PICPUS, F-75571 PARIS 12, FRANCE.			Rozenbaum, Willy/0000-0003-1975-3566				CELLO JP, 1989, AM J MED, V86, P539, DOI 10.1016/0002-9343(89)90381-1; DESPORTES I, 1985, J PROTOZOOL, V32, P250; FRIEDBERG DN, 1990, ARCH OPHTHALMOL-CHIC, V108, P504, DOI 10.1001/archopht.1990.01070060052047; GREENSON JK, 1991, ANN INTERN MED, V114, P366, DOI 10.7326/0003-4819-114-5-366; MARGULIS SJ, 1986, ANN INTERN MED, V105, P207, DOI 10.7326/0003-4819-105-2-207; MCWHINNEY PHM, 1991, AIDS, V5, P1394, DOI 10.1097/00002030-199111000-00024; SCHATTENKERK JKME, 1991, LANCET, V337, P895, DOI 10.1016/0140-6736(91)90215-B; TERADA S, 1987, ANN INTERN MED, V107, P61, DOI 10.7326/0003-4819-107-1-61; ZENDER HO, 1989, AM J CLIN PATHOL, V92, P352, DOI 10.1093/ajcp/92.3.352	9	54	54	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					401	402		10.7326/0003-4819-117-5-401	http://dx.doi.org/10.7326/0003-4819-117-5-401			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503332				2022-12-28	WOS:A1992JK67800009
J	KIM, SL; GEDGAUDASMCCLEES, RK; WARING, JP				KIM, SL; GEDGAUDASMCCLEES, RK; WARING, JP			SARCOIDOSIS WITH MULTIPLE HEPATIC AND SPLENIC NODULES ON DYNAMIC COMPUTED-TOMOGRAPHY	ANNALS OF INTERNAL MEDICINE			English	Note						SARCOIDOSIS; TOMOGRAPHY; X-RAY COMPUTED; LIVER DISEASE; GRANULOMA; SPLENIC DISEASES	MANIFESTATIONS; BIOPSY	Four patients with extrapulmonary manifestations of sarcoidosis were found to have diffuse hypodense lesions in the liver and spleen by dynamic computed tomography. Three patients presented with weight loss and abdominal pain and, of this group, two had hepatosplenomegaly. The fourth patient was presented with a peripheral neuropathy. The alkaline phosphatase level was elevated in all patients, with elevated transaminases seen in only one patient. Two patients had hypercalcemia. Chest radiographs showed perihilar infiltrates in two patients and were normal in two. Initial impressions of their symptoms and computed tomography findings included neoplastic, infectious, and neurologic processes. The correct diagnosis was made by liver biopsy, which revealed non-necrotizing granulomas.	EMORY UNIV HOSP, ATLANTA, GA 30322 USA	Emory University								BRITT AR, 1991, RADIOLOGY, V178, P91, DOI 10.1148/radiology.178.1.1984330; DEUTCH SJ, 1987, J ULTRAS MED, V6, P237; FOLEY WD, 1983, RADIOLOGY, V147, P797, DOI 10.1148/radiology.147.3.6844616; FRASER RG, 1991, DIAGNOSIS DIS CHEST, V4, P2604; HERCULES HD, 1984, ARCH PATHOL LAB MED, V108, P831; MATHIEU D, 1986, J COMPUT ASSIST TOMO, V10, P679, DOI 10.1097/00004728-198607000-00027; MERANZE S, 1985, J COMPUT ASSIST TOMO, V9, P50, DOI 10.1097/00004728-198501000-00010; NAKATA K, 1989, J COMPUT ASSIST TOMO, V13, P707, DOI 10.1097/00004728-198907000-00033; NEVILLE E, 1983, Q J MED, V52, P525; TAAVITSAINEN M, 1987, ACTA RADIOL, V28, P723	10	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					399	400		10.7326/0003-4819-117-5-399	http://dx.doi.org/10.7326/0003-4819-117-5-399			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503331				2022-12-28	WOS:A1992JK67800008
J	STJOHN, DJB; YOUNG, GP; MCHUTCHISON, JG; DEACON, MC; ALEXEYEFF, MA				STJOHN, DJB; YOUNG, GP; MCHUTCHISON, JG; DEACON, MC; ALEXEYEFF, MA			COMPARISON OF THE SPECIFICITY AND SENSITIVITY OF HEMOCCULT AND HEMOQUANT IN SCREENING FOR COLORECTAL NEOPLASIA	ANNALS OF INTERNAL MEDICINE			English	Article						OCCULT BLOOD; COLORECTAL NEOPLASMS; ADENOMA; HEME; PORPHYRINS	FECAL OCCULT BLOOD; CONTROLLED TRIAL; CANCER; TESTS; HEMOGLOBIN; PATTERNS; INGESTION; ASPIRIN; ASSAY; HEME	Objective: To compare the Hemoccult II and HemoQuant tests regarding their specificity and sensitivity in screening for colorectal neoplasia. Design: Cross-sectional study in which subjects underwent the two tests in parallel, after excluding dietary hemes and peroxidase-rich foods. HemoQuant results were analyzed for three different upper limits of normality (1.5, 2.0, 3.0 mg/g feces). Setting: A university hospital and the surrounding community. Participants: A total of 150 healthy volunteers, 124 patients with colorectal cancer, and 86 patients with adenoma. Main Outcome Measures: Blinded comparison of the specificity and the sensitivity of the two tests for colorectal cancer and adenoma. Results: Test specificity was 99.3% with Hemoccult and was 92.7%, 94.7%, and 97.3% with HemoQuant, depending on the cutoff point; differences between Hemoccult and HemoQuant were significant when cutoffs of 1.5 and 2.0 mg/g were used in HemoQuant testing (6.6% [95% CI, 2.3 to 11.1] and 4.7% [CI, 0.8 to 8.5], respectively). Test sensitivity for colorectal cancer at all sites was 89.5% with Hemoccult and was 83.1%, 74.2% and 62.9% with HemoQuant, for the 1.5, 2.0, and 3.0 mg/g cutoffs, respectively; differences were significant with the 2.0 and 3.0 mg/g cutoff points (6.4% [CI, 6.7 to 24.0] and 26.6% [CI, 17.4 to 35.9%], respectively). The two tests had similar levels of sensitivity for cancers proximal to the splenic flexure, but sensitivity was substantially lower with HemoQuant for the more distal cancers. For all adenomas, test sensitivity was 30.2% with Hemoccult and ranged from 45.4% to 22.1% with HemoQuant. Conclusions: Although HemoQuant provides a precise measurement of fecal heme and its porphyrin degradation products, the test's performance characteristics in the detection of colorectal neoplasia are less satisfactory than those of Hemoccult II, a qualitative test for the presence of heme.	UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT MED, MELBOURNE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; University of Melbourne	STJOHN, DJB (corresponding author), UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT GASTROENTEROL, RMH PO, MELBOURNE, VIC 3050, AUSTRALIA.			Young, Graeme/0000-0001-9458-8383				AHLQUIST DA, 1990, ARCH INTERN MED, V150, P1041, DOI 10.1001/archinte.150.5.1041; AHLQUIST DA, 1984, ANN INTERN MED, V101, P297, DOI 10.7326/0003-4819-101-3-297; AHLQUIST DA, 1985, NEW ENGL J MED, V312, P1422, DOI 10.1056/NEJM198505303122204; AHLQUIST DA, 1989, CANCER, V63, P1826; ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; BEDENNE L, 1990, GASTROEN CLIN BIOL, V14, P140; CALIGIORE P, 1982, AM J CLIN NUTR, V35, P1487, DOI 10.1093/ajcn/35.6.1487; CAMERON AD, 1960, GUT, V1, P177, DOI 10.1136/gut.1.2.177; DORAN J, 1982, BRIT J SURG, V69, P711, DOI 10.1002/bjs.1800691209; FARRANDS PA, 1983, CLIN ONCOL, V9, P217; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; FLEMING JL, 1987, MAYO CLIN PROC, V62, P159, DOI 10.1016/S0025-6196(12)62437-9; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GILBERTSEN VA, 1980, CANCER, V45, P2899, DOI 10.1002/1097-0142(19800601)45:11<2899::AID-CNCR2820451132>3.0.CO;2-M; GNAUCK R, 1984, CA-CANCER J CLIN, V34, P134, DOI 10.3322/canjclin.34.3.134; GOLDSCHMIEDT M, 1988, DIGEST DIS SCI, V33, P605, DOI 10.1007/BF01798364; GRIFFITH CDM, 1981, BRIT MED J, V283, P472, DOI 10.1136/bmj.283.6289.472; HARDCASTLE JD, 1989, LANCET, V1, P1160; HERZOG P, 1982, GASTROENTEROLOGY, V83, P957; JAFFE RM, 1975, ANN INTERN MED, V83, P824, DOI 10.7326/0003-4819-83-6-824; KEWENTER J, SCREENING RESCREENIN; KNIGHT KK, 1989, JAMA-J AM MED ASSOC, V261, P587; KRONBORG O, 1989, SCAND J GASTROENTERO, V24, P599, DOI 10.3109/00365528909093096; LYNCH NM, 1989, AUST NZ J MED, V19, P89, DOI 10.1111/j.1445-5994.1989.tb00210.x; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P899; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANDEL JS, 1989, GASTROENTEROLOGY, V97, P597, DOI 10.1016/0016-5085(89)90629-X; PETERSON WL, 1985, NEW ENGL J MED, V312, P1448, DOI 10.1056/NEJM198505303122209; PIERSON RN, 1961, AM J MED, V31, P259, DOI 10.1016/0002-9343(61)90114-0; PYE G, 1987, BRIT MED J, V294, P1510, DOI 10.1136/bmj.294.6586.1510; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; ROSE IS, 1989, CLIN CHEM, V35, P2290; Sackett D., 1985, CLIN EPIDEMIOLOGY BA, P59; SCHWARTZ S, 1983, CLIN CHEM, V29, P2061; SCHWARTZ S, 1985, GASTROENTEROLOGY, V89, P19, DOI 10.1016/0016-5085(85)90740-1; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; STJOHN DJB, 1985, GASTROENTEROLOGY, V89, P704; STJOHN DJB, 1970, BMJ-BRIT MED J, V2, P450; THOMAS WM, 1990, BRIT J SURG, V77, P277, DOI 10.1002/bjs.1800770313; TURUNEN MJ, 1984, BRIT J CANCER, V49, P141, DOI 10.1038/bjc.1984.26; WALKER AR, 1991, SCAND J GASTROENTERO, V26, P215, DOI 10.3109/00365529109025033; WINAWER SJ, 1980, CANCER, V45, P2959, DOI 10.1002/1097-0142(19800615)45:12<2959::AID-CNCR2820451212>3.0.CO;2-E; WINAWER SJ, 1990, B WORLD HEALTH ORGAN, V68, P505; YOUNG GP, 1991, FRONTIERS GASTROINTE, P135	44	32	32	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1992	117	5					376	382		10.7326/0003-4819-117-5-376	http://dx.doi.org/10.7326/0003-4819-117-5-376			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK678	1503328				2022-12-28	WOS:A1992JK67800005
J	BAJJALIEH, SM; PETERSON, K; SHINGHAL, R; SCHELLER, RH				BAJJALIEH, SM; PETERSON, K; SHINGHAL, R; SCHELLER, RH			SV2, A BRAIN SYNAPTIC VESICLE PROTEIN HOMOLOGOUS TO BACTERIAL TRANSPORTERS	SCIENCE			English	Article							DOPAMINE TRANSPORTER; CLONING; EXPRESSION; GLYCOPROTEIN; EXOCYTOSIS	Synaptic vesicle protein 2 (SV2) is a membrane glycoprotein specifically localized to secretory vesicles in neurons and endocrine cells. As a first step toward understanding the function of SV2 in neural secretion, a rat brain complementary DNA (cDNA) that encodes SV2 was isolated and characterized. Analyses of this cDNA predict that SV2 contains 12 transmembrane domains. The NH2-terminal half of the protein shows significant amino acid sequence identity to a family of bacterial proteins that transport sugars, citrate, and drugs. Expression of the SV2 cDNA in COS cells yielded a high level of SV2-like immunoreactivity distributed in a reticular and punctate pattern, which suggests localization to intracellular membranes. Its localization to vesicles, predicted membrane topology, and sequence identity to known transporters suggest that SV2 is a synaptic vesicle-specific transporter.	STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University								ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FLOOR E, 1989, J NEUROCHEM, V52, P1433, DOI 10.1111/j.1471-4159.1989.tb09190.x; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEBERER E, 1989, P NATL ACAD SCI USA, V86, P6047, DOI 10.1073/pnas.86.16.6047; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; MAYSER W, 1991, FEBS LETT, V295, P203, DOI 10.1016/0014-5793(91)81418-8; PATRENKO AG, 1991, NATURE, V353, P65; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAHAMIMOFF R, 1988, P NATL ACAD SCI USA, V85, P5310, DOI 10.1073/pnas.85.14.5310; ROUCH DA, 1990, MOL MICROBIOL, V4, P2051, DOI 10.1111/j.1365-2958.1990.tb00565.x; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; XIE XS, 1989, J BIOL CHEM, V264, P18870	23	189	201	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1271	1273		10.1126/science.1519064	http://dx.doi.org/10.1126/science.1519064			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519064				2022-12-28	WOS:A1992JL05000031
J	RAMAKRISHNAN, V; WHITE, SW				RAMAKRISHNAN, V; WHITE, SW			THE STRUCTURE OF RIBOSOMAL PROTEIN-S5 REVEALS SITES OF INTERACTION WITH 16S RIBOSOMAL-RNA	NATURE			English	Article							BACILLUS-STEAROTHERMOPHILUS RIBOSOME; ESCHERICHIA-COLI RIBOSOME; RNA-BINDING DOMAIN; CRYSTAL-STRUCTURE; SUBUNITS; S5; GENES; RECONSTITUTION; MUTATIONS; SEQUENCE	UNDERSTANDING the process whereby the ribosome translates the genetic code into protein molecules will ultimately require high-resolution structural information, and we report here the first crystal structure of a protein from the small ribosomal subunit. This protein, S5, has a molecular mass of 17,500 and is highly conserved in all lifeforms1-4. The molecule contains two distinct alpha/beta-domains that have structural similarities to several other proteins that are components of ribonucleoprotein complexes. Mutations in S5 result in several phenotypes which suggest that S5 may have a role in translational fidelity and translocation. These include ribosome ambiguity or ram5, reversion from streptomycin dependence6 and resistance to spectinomycin6. Also, a cold-sensitive, spectinomycin-resistant mutant of S5 has been identified which is defective in initiation7. Here we show that these mutations map to two distinct regions of the molecule which seem to be sites of interaction with ribosomal RNA. A structure/function analysis of the molecule reveals discrepancies with current models8,9 of the 30S subunit.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710	MRC Laboratory Molecular Biology; Duke University	RAMAKRISHNAN, V (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.		White, Stephen W/N-8164-2018	Ramakrishnan, V/0000-0002-4699-2194				ALLROBYN JA, 1990, MOL CELL BIOL, V10, P6544, DOI 10.1128/MCB.10.12.6544; APPELT K, 1983, J BIOL CHEM, V258, P3328; ARNDT UW, 1985, METHOD ENZYMOL, V114, P472; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRIMACOMBE R, 1991, BIOCHIMIE, V73, P927, DOI 10.1016/0300-9084(91)90134-M; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; DONTSOVA O, 1991, EMBO J, V10, P2613, DOI 10.1002/j.1460-2075.1991.tb07803.x; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HELD WA, 1973, J BIOL CHEM, V248, P5720; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMURA M, 1984, J BIOL CHEM, V259, P1051; LAMBERT JM, 1983, BIOCHEMISTRY-US, V22, P3913, DOI 10.1021/bi00285a029; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; LEIJONMARCK M, 1988, PROTEINS, V3, P243, DOI 10.1002/prot.340030405; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MONTANDON PE, 1986, EMBO J, V5, P3705, DOI 10.1002/j.1460-2075.1986.tb04703.x; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOMURA M, 1987, COLD SPRING HARB SYM, V52, P653, DOI 10.1101/SQB.1987.052.01.075; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; OSSWALD M, 1987, NUCLEIC ACIDS RES, V15, P3221, DOI 10.1093/nar/15.8.3221; PIEPERSBERG W, 1975, MOL GEN GENET, V143, P43, DOI 10.1007/BF00269419; PIEPERSBERG W, 1975, MOL GEN GENET, V140, P91, DOI 10.1007/BF00329777; RAMAKRISHNAN V, 1991, J BIOL CHEM, V266, P880; SCHOLZEN T, 1991, MOL GEN GENET, V228, P70, DOI 10.1007/BF00282450; SIGMUND CD, 1984, NUCLEIC ACIDS RES, V12, P4653, DOI 10.1093/nar/12.11.4653; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; WHITE SW, 1983, FEBS LETT, V163, P73, DOI 10.1016/0014-5793(83)81166-1; WILSON KS, 1986, P NATL ACAD SCI USA, V83, P7251, DOI 10.1073/pnas.83.19.7251; WITTMANNLIEBOLD B, 1978, FEBS LETT, V95, P91, DOI 10.1016/0014-5793(78)80059-3	33	147	155	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					768	771		10.1038/358768a0	http://dx.doi.org/10.1038/358768a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1508272				2022-12-28	WOS:A1992JK69900057
J	BLOOM, BR; MURRAY, CJL				BLOOM, BR; MURRAY, CJL			TUBERCULOSIS - COMMENTARY ON A REEMERGENT KILLER	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DELAYED-TYPE HYPERSENSITIVITY; TUMOR-NECROSIS-FACTOR; DRUG-RESISTANT TUBERCULOSIS; POLYMERASE CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; BCG VACCINATION; CHILDHOOD TUBERCULOSIS; PULMONARY TUBERCULOSIS; COMPLEMENT RECEPTORS	Tuberculosis remains the leading cause of death in the world from a single infectious disease, although there is little knowledge of the mechanisms of its pathogenesis and protection from it. After a century of decline in the United States, tuberculosis is increasing, and strains resistant to multiple antibiotics have emerged. This excess of cases is attributable to changes in the social structure in cities, the human immunodeficiency virus epidemic, and a failure in certain major cities to improve public treatment programs. The economic costs of not adequately addressing the problem of tuberculosis in this country are estimated from an epidemiological model.	HARVARD UNIV, SCH PUBL HLTH, CTR POPULAT & DEV STUDIES, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	BLOOM, BR (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, HOWARD HUGHES MED INST, BRONX, NY 10461 USA.							ALDOVINI A, 1991, NATURE, V351, P479, DOI 10.1038/351479a0; AMIRI P, 1992, NATURE, V356, P604, DOI 10.1038/356604a0; ANDERSEN P, 1991, INFECT IMMUN, V59, P1558, DOI 10.1128/IAI.59.4.1558-1563.1991; ANDERSON KM, 1986, CHEST, V89, P817, DOI 10.1378/chest.89.6.817; [Anonymous], 1987, Am Rev Respir Dis, V136, P1339; [Anonymous], 1927, VACCINATION PREVENTI; BARNES PF, 1989, J IMMUNOL, V142, P1114; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BARNES PF, 1990, J IMMUNOL, V145, P149; BARRETTCONNOR E, 1979, JAMA-J AM MED ASSOC, V241, P33, DOI 10.1001/jama.241.1.33; BARRY MA, 1986, PUBLIC HEALTH REP, V101, P487; Berg G., 1939, ACTA TUBERC SCAND S, V4, P1; BOOM WH, 1991, INFECT IMMUN, V59, P2737, DOI 10.1128/IAI.59.8.2737-2743.1991; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; BROWN L, 1941, STORY CLIN TUBERCULO; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BUNYAN J, 1928, LIFE DEATH BADMAN, P282; Caldwell M., 1988, LAST CRUSADE WAR CON; CANETTI G, 1965, AM REV RESPIR DIS, V92, P687; Canetti G., 1955, TUBERCLE BACILLUS PU; CASTIGLIONI A, 1933, HIST TUBERCULOSIS, V40, P1; CAUTHEN GM, 1988, WHOTTB88154; CAUTHEN GM, COMMUNICATION; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; CLEMENS JD, 1983, JAMA-J AM MED ASSOC, V249, P2362, DOI 10.1001/jama.249.17.2362; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; Comstock G W, 1985, Natl Cancer Inst Monogr, V67, P23; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; COMSTOCK GW, 1988, AM REV RESPIR DIS, V138, P479, DOI 10.1164/ajrccm/138.2.479; COMSTOCK GW, 1984, MYCOBACTERIA SOURCEB; CROSS ER, 1990, AM J PUBLIC HEALTH, V80, P435, DOI 10.2105/AJPH.80.4.435; Cummins SL, 1949, TUBERCULOSIS HIST; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DANNENBERG AM, 1991, IMMUNOL TODAY, V12, P228, DOI 10.1016/0167-5699(91)90035-R; DENIS M, 1991, CELL IMMUNOL, V132, P150, DOI 10.1016/0008-8749(91)90014-3; DEWIT D, 1990, J CLIN MICROBIOL, V28, P2437, DOI 10.1128/JCM.28.11.2437-2441.1990; DIPERRI G, 1989, LANCET, V2, P1502; DORKEN E, 1987, CHEST, V92, P237, DOI 10.1378/chest.92.2.237; DRAPER P, 1982, BIOL MYCOBACTERIA, P9; DROLET GJ, 1946, CLIN TUBERCULOSIS, pA1; DUBOS R, 1987, WHITE PLAGUE, P277; EISENACH KD, 1991, AM REV RESPIR DIS, V144, P1160, DOI 10.1164/ajrccm/144.5.1160; FINE PEM, 1989, REV INFECT DIS, V11, pS353; FINE PEM, 1988, BRIT MED BULL, V44, P691, DOI 10.1093/oxfordjournals.bmb.a072277; FOX W, 1983, BMJ-BRIT MED J, V287, P101, DOI 10.1136/bmj.287.6385.101; FOX W, 1983, BRIT MED J, V287, P33, DOI 10.1136/bmj.287.6384.33; FRIEDEN TR, 1992, 41ST ANN EP INT SERV; GARRETT L, IN PRESS SURVEY AIDS; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GAUDIER B., 1962, ANN INST PASTEUR LILLE, V13, P77; GRANGE JM, 1982, BIOL MYCOBACTERIA, P309; Graunt J, 1662, NATURAL POLITICAL OB; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; GRIGG ERN, 1958, AM REV TUBERC PULM, V78, P151; GRIGG ERN, 1958, AM REV TUBERC PULM, V78, P426; GRIGG ERN, 1958, AM REV TUBERC PULM, V78, P583; GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HART P. D'A., 1967, Tubercle, V48, P201, DOI 10.1016/S0041-3879(67)80024-2; HORWITZ O, 1969, B WORLD HEALTH ORGAN, V41, P95; ISEMAN MD, 1989, CLIN CHEST MED, V10, P341; JACOBS WR, 1987, NATURE, V327, P532, DOI 10.1038/327532a0; JACOBS WR, 1992, IMMUNOBIOLOGY, V184, P147, DOI 10.1016/S0171-2985(11)80472-9; JAMISON DT, IN PRESS DISEASE CON; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P863; KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; KOCH ROBERT, 1932, AMER REV TUBERC, V25, P285; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; KUBICA GP, 1984, MYCOBACTERIA SOURCEB, V2; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; LOPEZ A, 1992, DISEASE CONTROL PRIO, P21; LURIE MB, 1964, RESISTANCE TUBERCULO; MACHIAVELLI N, 1933, PRINCE, P1513; McDougall JB, 1949, TUBERCULOSIS GLOBAL; MCNEIL MR, 1991, RES MICROBIOL, V142, P451, DOI 10.1016/0923-2508(91)90120-Y; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; MURRAY CJL, 1990, B INT UNION TUBER, V65, P24; MURRAY CJL, 1992, DISEASE CONTROL PRIO, P50; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; ORME IM, 1988, INFECT IMMUN, V56, P3310, DOI 10.1128/IAI.56.12.3310-3312.1988; ORME IM, 1984, CELL IMMUNOL, V84, P113, DOI 10.1016/0008-8749(84)90082-0; PADUNGCHAN S, 1986, B WORLD HEALTH ORGAN, V64, P247; PALITZ LS, 1957, AM REV TUBERC PULM, V75, P461; PALMER CE, 1966, AM REV RESPIR DIS, V94, P553; PERKINS JE, 1947, AM J PUBLIC HEALTH, V37, P529; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; POWELL KE, 1981, AM J PUBLIC HEALTH, V71, P1223, DOI 10.2105/AJPH.71.11.1223; Preston SH, 1972, CAUSES DEATH LIFE TA; RATLEDGE C, 1982, BIOL MYCOBACTERIA, V2; Reichman L B, 1987, Tubercle, V68, P25, DOI 10.1016/0041-3879(87)90017-1; REICHMAN LB, 1977, AM REV RESPIR DIS, V116, P561, DOI 10.1164/arrd.1977.116.3.561; REIDER HL, 1974, HLTH SERV REP, V89, P177; REIDER HL, 1990, B INT U TUBERCULOSIS, V65, P85; Rich A., 1951, PATHOGENESIS TUBERCU, V2nd; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; RIEDER HL, 1991, MMWR-MORBID MORTAL W, V39, P944; RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; RILEY RL, 1961, AIRBORNE CONTAGION, P180; ROOK GAW, 1987, IMMUNOLOGY, V62, P229; ROOK GAW, 1988, BRIT MED BULL, V44, P611, DOI 10.1093/oxfordjournals.bmb.a072271; Rouillon A, 1991, Bull Int Union Tuberc Lung Dis, V66, P159; RUST P, 1975, AM J EPIDEMIOL, V101, P311, DOI 10.1093/oxfordjournals.aje.a112099; SBARBARO JA, 1979, CHEST, V76, P750, DOI 10.1378/chest.76.6.750; SBARBARO JA, 1990, ANN ALLERGY, V64, P325; SCHLESINGER LS, 1991, J IMMUNOL, V147, P1983; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHANKAR P, 1990, LANCET, V335, P423, DOI 10.1016/0140-6736(90)90268-A; SHAPIRO C, 1985, INT J EPIDEMIOL, V14, P441, DOI 10.1093/ije/14.3.441; Shimao T, 1987, Tubercle, V68, P5, DOI 10.1016/0041-3879(87)90014-6; SHYROCK RH, 1957, NATIONAL TUBERCULOSI; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SMITH PG, 1989, ANN NY ACAD SCI, V569, P219, DOI 10.1111/j.1749-6632.1989.tb27372.x; SNAPPER SB, 1988, P NATL ACAD SCI USA, V85, P6987, DOI 10.1073/pnas.85.18.6987; SNIDER DE, 1984, AM REV RESPIR DIS, V130, P1091; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732; SONTAG S, 1983, ILLNESS METAPHOR, P90; SPINACI S, COMMUNICATION; SRITHARAN V, 1991, MOL CELL PROBE, V5, P385, DOI 10.1016/S0890-8508(06)80011-3; STEAD WW, 1987, ANN INTERN MED, V107, P837, DOI 10.7326/0003-4819-107-6-837; Steenken W, 1934, J EXP MED, V60, P515, DOI 10.1084/jem.60.4.515; STEWART WA, CITED INDIRECTLY; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; STYBLO K, 1969, Bulletin of the International Union Against Tuberculosis, V42, P5; Styblo K., 1991, EPIDEMIOLOGY TUBERCU, V24; Sutherland I, 1991, Bull Int Union Tuberc Lung Dis, V66, P189; Sutherland I, 1976, Adv Tuberc Res, V19, P1; SUTHERLAND I, 1971, B INT UNION TUBERC, V44, P75; TAKAYAMA K, 1984, MYCOBACTERIA SOURC A, P315; TAYLOR R, 1986, SARANAC AM MAGIC MOU; ten Dam H G, 1984, Adv Tuberc Res, V21, P79; TENDAM HG, 1980, B WORLD HEALTH ORGAN, V58, P37; TIDJANI O, 1986, TUBERCLE, V67, P269, DOI 10.1016/0041-3879(86)90016-4; TRIPATHY SP, 1983, ANN NATL ACAD MED SC, V19, P12; Trudeau E.L., 1916, AUTOBIOGRAPHY; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; VENNEMA A, 1982, PUBLIC HEALTH REP, V97, P127; VILLEMIN JA, 1865, CR HEBD ACAD SCI, V61, P1012; WAKSMAN SA, 1965, CONQUEST TUBERCULOSI; WAYNE LG, 1968, J BACTERIOL, V96, P1915, DOI 10.1128/JB.96.6.1915-1919.1968; Wells W.F, 1955, AIRBORNE CONTAGION A, P423; YOUNG DB, 1992, MOL MICROBIOL, V6, P133, DOI 10.1111/j.1365-2958.1992.tb01994.x; ZHANG Y, IN PRESS NATURE; 1890, BRIT MED J, V2, P1197; 1992, NIAID INCREASE TB RE; 1990, MORB MORTAL WKLY REP, V39, P1; 1991, MORB MORTAL WKLY REP, V40, P585; 1992, WHO PROGRAMME INFORM; 1992, WHOTB91157; 1990, MORB MORTAL WKLY REP, V39, P369; 1989, JAMA-J AM MED ASSOC, V262, P3258; 1977, AM REV RESPIR DIS, V115, P3; 1990, MORB MORTAL WKLY REP, V37, P718; 1890, LANCET, V2, P1107; 1991, EXPANDED PROGRAMME I; 1890, BRIT MED J, V2, P1193; 1890, BRIT MED J, V2, P1327; 1989, JAMA-J AM MED ASSOC, V261, P436; FISCAL YEAR 1993 JUS; 1927, 1926 GILB ELL ISL CO	166	1210	1248	2	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1992	257	5073					1055	1064		10.1126/science.257.5073.1055	http://dx.doi.org/10.1126/science.257.5073.1055			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ884	1509256				2022-12-28	WOS:A1992JJ88400020
J	MORIARTY, KJ				MORIARTY, KJ			ABC OF COLORECTAL DISEASES - THE IRRITABLE-BOWEL-SYNDROME	BRITISH MEDICAL JOURNAL			English	Article											MORIARTY, KJ (corresponding author), BOLTON GEN HOSP,BOLTON,ENGLAND.								0	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1992	304	6835					1166	1169		10.1136/bmj.304.6835.1166	http://dx.doi.org/10.1136/bmj.304.6835.1166			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT232	1466670	Green Published, Bronze			2022-12-28	WOS:A1992HT23200030
J	GREER, S; MOOREY, S; BARUCH, JDR; WATSON, M; ROBERTSON, BM; MASON, A; ROWDEN, L; LAW, MG; BLISS, JM				GREER, S; MOOREY, S; BARUCH, JDR; WATSON, M; ROBERTSON, BM; MASON, A; ROWDEN, L; LAW, MG; BLISS, JM			ADJUVANT PSYCHOLOGICAL THERAPY FOR PATIENTS WITH CANCER - A PROSPECTIVE RANDOMIZED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; MASTECTOMY; RELAXATION; ADJUSTMENT; MORBIDITY; SUPPORT; IMAGERY; SCALE	Objective - To determine the effect of adjuvant psychological therapy on the quality of life of patients with cancer. Design - Prospective randomised controlled trial comparing the quality of life of patients receiving psychological therapy with that of patients receiving no therapy, measured before therapy, at eight weeks, and at four months of follow up. Setting - CRC Psychological Medicine Group of Royal Marsden Hospital. Patients - 174 patients aged 18-74 attending hospital with a confirmed diagnosis of malignant disease, a life expectancy of at least 12 months, or scores on various measures of psychological morbidity above previously defined cut off points. Intervention - Adjuvant psychological therapy, a brief, problem focused, cognitive-behavioural treatment programme specifically designed for the needs of individual cancer patients. Main outcome measures - Hospital anxiety and depression scale, mental adjustment to cancer scale, Rotterdam symptom checklist, psychosocial adjustment to illness scale. Results - 156 (90%) patients completed the eight week trial; follow up data at four months were obtained for 137 patients (79%). At eight weeks, patients receiving therapy had significantly higher scores than control patients on fighting spirit and significantly lower scores on helplessness, anxious preoccupation, and fatalism; anxiety; psychological symptoms; and on orientation towards health care. These differences indicated improvement in each case. At four months, patients receiving therapy had significantly lower scores than controls on anxiety; psychological symptoms; and psychological distress. Clinically, the proportion of severely anxious patients dropped from 46% at baseline to 20% at eight weeks and 20% at four months in the therapy group and from 48% to 41% and to 43% respectively among controls. The proportion of patients with depression was 40% at baseline, 13% at eight weeks, and 18% at four months in the therapy group and 30%, 29%, and 23% respectively in controls. Conclusions - Adjuvant psychological therapy produces significant improvement in various measures of psychological distress among cancer patients. The effect of therapy observed at eight weeks persists in some but not all measures at four month follow up.	INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5PT,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK	GREER, S (corresponding author), ROYAL MARSDEN HOSP,CANC RES CAMPAIGN PSYCHOL MED GRP,SUTTON SM2 5PT,SURREY,ENGLAND.			Law, Matthew/0000-0002-3540-8837; Bliss, Judith/0000-0001-7957-7424				[Anonymous], 1979, WHO HDB REPORTING RE; BAIDER L, 1984, J PSYCHOSOM RES, V28, P323, DOI 10.1016/0022-3999(84)90054-0; BRIDGE LR, 1988, BMJ-BRIT MED J, V297, P1169, DOI 10.1136/bmj.297.6657.1169; CAIN EN, 1986, CANCER, V57, P183, DOI 10.1002/1097-0142(19860101)57:1<183::AID-CNCR2820570135>3.0.CO;2-3; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; Derogatis LR, 1983, PSYCHOSOCIAL ADJUSTM; FARASH JL, 1979, DISS ABSTR INT B, V39, P4027; FORD MF, 1990, BRIT J CANCER, V62, P624, DOI 10.1038/bjc.1990.342; GREER S, 1991, BRIT J CANCER, V63, P257, DOI 10.1038/bjc.1991.60; GREER S, 1987, CANCER SURV, V6, P439; HUGHES JE, 1987, CANCER SURV, V6, P455; LINN MW, 1982, CANCER, V49, P1048, DOI 10.1002/1097-0142(19820301)49:5<1048::AID-CNCR2820490534>3.0.CO;2-G; MAGUIRE P, 1980, BMJ-BRIT MED J, V281, P1454, DOI 10.1136/bmj.281.6253.1454; Moorey S., 1989, PSYCHOL THERAPY PATI; SENSKY T, 1989, J R COLL PHYSICIANS, V1, P33; SPIEGEL D, 1981, ARCH GEN PSYCHIAT, V38, P527; TELCH CF, 1986, J CONSULT CLIN PSYCH, V54, P802, DOI 10.1037/0022-006X.54.6.802; WATSON M, 1988, PSYCHOL MED, V18, P203, DOI 10.1017/S0033291700002026; WATSON M, 1988, COUNSEL PSYCHOL Q, V1, P25; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	20	326	334	1	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1992	304	6828					675	680		10.1136/bmj.304.6828.675	http://dx.doi.org/10.1136/bmj.304.6828.675			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HK761	1472184	Green Published, Bronze			2022-12-28	WOS:A1992HK76100020
J	SHEN, JC; RIDEOUT, WM; JONES, PA				SHEN, JC; RIDEOUT, WM; JONES, PA			HIGH-FREQUENCY MUTAGENESIS BY A DNA METHYLTRANSFERASE	CELL			English	Article							HEAT-INDUCED DEAMINATION; CYTOSINE METHYLTRANSFERASES; CPG DINUCLEOTIDE; CELLS; 5-METHYLCYTOSINE; RESTRICTION; METHYLATION; MECHANISM; MOUSE; MODEL	Hpall methylase (M. Hpall), an example of a DNA (cytosine-5)-methyltransferase, was found to induce directly a high frequency of C-U transition mutations in double-stranded DNA. A mutant pSV2-neo plasmid, constructed with an inactivating T-->C transition mutation creating a CCGG site, was incubated with M. Hpall in the absence of S-adenosylmethionine (SAM). This caused an approximately 10(4)-fold increase in the rate of reversion when the mutant neo plasmid was transformed into bacteria lacking uracil-DNA glycosylase. The mutation frequency was very sensitive to SAM concentration and was reduced to background when the concentration of the methyl donor exceeded 300 nM. The data support current models for the formation of a covalent complex between the methyltransferase and cytosine. They also suggest that the occurrence of mutational hot spots at CpG sites may not always be due to spontaneous deamination of 5-methylcytosine, but might also be initiated by enzymatic deamination of cytosine and proceed through a C-->U-->T pathway.			SHEN, JC (corresponding author), UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033, USA.				NATIONAL CANCER INSTITUTE [R35CA049758] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA49758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DUNCAN B, 1984, ENZYMES, P565; EHRLICH M, 1986, BIOSCIENCE REP, V6, P387, DOI 10.1007/BF01116426; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FEINBERG AP, 1988, CANCER RES, V48, P1159; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; FRIEDMAN S, 1985, J BIOL CHEM, V260, P5698; GUNTHERT U, 1981, J BIOL CHEM, V256, P9346; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; Maniatis T., 1982, MOL CLONING; MONK M, 1991, DEVELOPMENT, V112, P189; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Sambrook J, 1989, MOL CLONING LABORATO; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SHAPIRO R, 1966, BIOCHEMISTRY-US, V5, P2358, DOI 10.1021/bi00871a026; SHEN JC, 1992, NUCLEIC ACIDS RES, V20, P5119, DOI 10.1093/nar/20.19.5119; SIMON D, 1978, NUCLEIC ACIDS RES, V5, P2153, DOI 10.1093/nar/5.6.2153; SINGERSAM J, 1990, NUCLEIC ACID METHYLA, V128, P285; SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744; STEINBERG RA, 1992, MOL CELL BIOL, V12, P767, DOI 10.1128/MCB.12.2.767; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; WU JC, 1987, J BIOL CHEM, V262, P4778	39	252	255	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1073	1080		10.1016/S0092-8674(05)80057-1	http://dx.doi.org/10.1016/S0092-8674(05)80057-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473145				2022-12-28	WOS:A1992KE60400003
J	KATZ, A; WU, DQ; SIMON, MI				KATZ, A; WU, DQ; SIMON, MI			SUBUNITS-BETA-GAMMA OF HETEROTRIMERIC G-PROTEIN ACTIVATE BETA-2 ISOFORM OF PHOSPHOLIPASE-C	NATURE			English	Article							ADENYLYL CYCLASE; RECEPTOR	THE activation of heterotrimeric G proteins results in the exchange of GDP bound to the alpha-subunit for GTP and the subsequent dissociation of a complex of the beta- and gamma-subunits (G(betagamma)). The alpha-subunits of different G proteins interact with a variety of effectors1-7, but less is known about the function of the free G(betagamma) complex. G(betagamma) has been implicated in the activation of a cardiac potassium channel8, a retinal phospholipase A2 (ref. 9) and a specific receptor kinase10, and in vitro reconstitution experiments indicate that the G(betagamma) complex can act with G(alpha) subunit to modulate the activity of different isoforms of adenylyl cyclase11. Of two phospholipase activities that can be separated in extracts of HL-60 cells, purified G(betagamma) is found to activate one of them12. Here we report that in co-transfection assays G(betagamma) subunits specifically activate the beta2 and not the beta1 isoform of phospholipase, which acts on phosphatidylinositol. We use transfection assays to show also that receptor-mediated release of G(betagamma) from G proteins that are sensitive to pertussis toxin can result in activation of the phospholipase. This effect may be the basis of the pertussis-toxin-sensitive phospholipase C activation seen in some cell systems (reviewed in refs 13 and 14).	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Katz, Arieh/F-5836-2012					ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DEVIVO M, 1990, ADP RIBOSYLATING TOX, P267; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAGA K, 1992, J BIOL CHEM, V267, P2222; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; LEE CH, 1992, J BIOL CHEM, V267, P16044; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PARK D, 1992, J BIOL CHEM, V267, P16048; PARKER EM, 1991, J BIOL CHEM, V266, P519; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SNYDERMAN R, 1990, ADP RIBOSYLATING TOX, P295; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOTA MR, 1987, BIOCHEMISTRY-US, V26, P8175, DOI 10.1021/bi00399a023; UI M, 1990, ADP RIBOSYLATING TOX, P45; WU DQ, 1992, J BIOL CHEM, V267, P1811; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	30	466	471	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					686	689		10.1038/360686a0	http://dx.doi.org/10.1038/360686a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465134				2022-12-28	WOS:A1992KD08200061
J	SANDERCOCK, P; BAMFORD, J; DENNIS, M; BURN, J; SLATTERY, J; JONES, L; BOONYAKARNKUL, S; WARLOW, C				SANDERCOCK, P; BAMFORD, J; DENNIS, M; BURN, J; SLATTERY, J; JONES, L; BOONYAKARNKUL, S; WARLOW, C			ATRIAL-FIBRILLATION AND STROKE - PREVALENCE IN DIFFERENT TYPES OF STROKE AND INFLUENCE ON EARLY AND LONG-TERM PROGNOSIS (OXFORDSHIRE COMMUNITY STROKE PROJECT)	BRITISH MEDICAL JOURNAL			English	Article							ACUTE CEREBROVASCULAR-DISEASE; CEREBRAL INFARCTION; RISK-FACTORS; THROMBOEMBOLIC COMPLICATIONS; BRAIN INFARCTION; FRAMINGHAM; REGISTRY; RECURRENCE; DURATION; EMBOLISM	Objective-To determine in patients with first ever stroke whether atrial fibrillation influences clinical features, the need to perform computed tomography, and prognosis. Design-Observational cohort study with maximum follow up of 6.5 years. Setting-Primary care, based on 10 general practices in urban and rural Oxfordshire. Subjects-Consecutive series of 675 patients with first ever stroke registered in the Oxfordshire community stroke project. Main outcome measures-Prevalence of atrial fibrillation by type of stroke; effect of atrial fibrillation on case fatality rate and risk of recurrent stroke, vascular death, and death from all causes. Results-Prevalence of atrial fibrillation was 17% (95% confidence interval 14% to 20%) for all stroke types (115/675), 18% (15% to 21%) for cerebral infarction (97/545), 11% (4% to 11%) for primary intercerebral haemorrhage (7/66), and 0% (0 to 11%) for subarachnoid haemorrhage (0/33). For patients with cerebral infarction the 30 day case fatality rate was significantly higher with atrial fibrillation (23%) than with sinus rhythm (8%); the risk of early recurrent stroke (within 30 days) was 1% with atrial fibrillation and 4% with sinus rhythm. In patients who survived at least 30 days the average annual risk of recurrent stroke was 8.2% (5.9% to 10.9%) with sinus rhythm and 11% (6.0% to 17.3%) with atrial fibrillation. Conclusions-After a first stroke atrial fibrillation was not associated with a definite excess risk of recurrent stroke, either within 30 days or within the first few years. Survivors with and without atrial fibrillation had a clinically important absolute risk of further serious vascular events.	ST JAMES UNIV HOSP,DEPT NEUROL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT REHABIL MED,SOUTHAMPTON S09 4XY,ENGLAND; RADCLIFFE INFIRM,GIBSON LABS,DEPT COMMUNITY MED & GEN PRACTICE,OXFORD OX2 6HE,ENGLAND; RAJAVITHI HOSP,DEPT MED,DIV NEUROL,BANGKOK 10400,THAILAND	Saint James's University Hospital; University of Southampton; Radcliffe Infirmary; Rajavithi Hospital	SANDERCOCK, P (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		sandercock, peter/GQI-3167-2022; Bamford, John/ABE-6218-2021	sandercock, peter/0000-0001-8484-0135; 				ARMITAGE P, 1971, STATISTICAL METHODS, P135; BAMFORD J, 1992, LANCET, V339, P400, DOI 10.1016/0140-6736(92)90085-H; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; BOGOUSSLAVSKY J, 1990, ACTA NEUROL SCAND, V82, P143; BOGOUSSLAVSKY J, 1990, NEUROLOGY, V40, P1046, DOI 10.1212/WNL.40.7.1046; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; BRITTON M, 1985, STROKE, V16, P182, DOI 10.1161/01.STR.16.2.182; BRITTON M, 1979, ACTA MED SCAND, V205, P425; CAMDELISE L, 1991, STROKE, V22, P169; DARLING RC, 1967, SURG GYNECOL OBSTETR, V124, P106; DAVIS PH, 1987, ANN NEUROL, V22, P319, DOI 10.1002/ana.410220307; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; DIXON WJ, 1985, BMDP STATISTICAL SOF, P576; FISHER CM, 1979, GERIATRICS, V34, P59; FLEGEL KM, 1987, LANCET, V1, P878; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; FRIEDMAN PJ, 1991, STROKE, V22, P209, DOI 10.1161/01.STR.22.2.209; GARDNER MJ, 1989, STATISTICS CONFIDENC; GUSTAFSSON C, 1986, ACTA NEUROL SCAND, V73, P520; HARRISON MJG, 1984, STROKE, V15, P441, DOI 10.1161/01.STR.15.3.441; HART RG, 1983, STROKE, V14, P827, DOI 10.1161/str.14.5.827a; HART RG, 1983, STROKE, V14, P688, DOI 10.1161/01.STR.14.5.688; HAYNES RB, 1985, EPIDEMIOLOGY SCI CLI; HIER DB, 1991, STROKE, V22, P155, DOI 10.1161/01.STR.22.2.155; KELLEY RE, 1984, NEUROLOGY, V34, P1285, DOI 10.1212/WNL.34.10.1285; KIPECKY SL, 1987, NEW ENGL J MED, V317, P669; KOLLER RL, 1982, NEUROLOGY, V32, P283; LOWE GDO, 1983, LANCET, V1, P784; MARQUARDSEN J, 1969, NATURAL HIST ACUTE C, P138; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; OLSEN T, 1990, J NEUROL, V237, P139; PETERSEN P, 1989, LANCET, V1, P175; PETERSEN P, 1990, STROKE, V21, P4, DOI 10.1161/01.STR.21.1.4; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RICCI S, 1989, STROKE, V20, P853, DOI 10.1161/01.STR.20.7.853; RICCI S, 1991, SALZBURG C CEREBROVA, P7; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SAGE JI, 1983, STROKE, V14, P537, DOI 10.1161/01.STR.14.4.537; SANTAMARIA J, 1983, NEUROLOGY, V33, P1104, DOI 10.1212/WNL.33.8.1104; SHERMAN DG, 1984, ARCH NEUROL-CHICAGO, V41, P708, DOI 10.1001/archneur.1984.04050180030011; VANMERWIJK G, 1990, J NEUROL, V237, P205; WOLF PA, 1983, STROKE, V14, P664, DOI 10.1161/01.STR.14.5.664; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; 1986, ARCH NEUROL-CHICAGO, V43, P71; 1989, ARCH NEUROL-CHICAGO, V46, P727; 1990, NEW ENGL J MED, V322, P863; 1990, NEW ENGL J MED, V323, P1505	53	188	192	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1460	1465		10.1136/bmj.305.6867.1460	http://dx.doi.org/10.1136/bmj.305.6867.1460			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493391	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992KC91800020
J	MANNING, CJ; WAKELAND, EK; POTTS, WK				MANNING, CJ; WAKELAND, EK; POTTS, WK			COMMUNAL NESTING PATTERNS IN MICE IMPLICATE MHC GENES IN KIN RECOGNITION	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MATING PREFERENCES; SYSTEMS	HOUSE mice (Mus musculus domesticus) form communal nests and appear to nurse each other's pups indiscriminately. Communal nesting probably functions to reduce infanticide1, but it also makes females vulnerable to exploitation if nursing partners fail to provide their fair share of care. Kinship theory predicts that females will preferentially form communal nests with relatives to minimize exploitation and further increase inclusive fitness2-4. Here we provide evidence from seminatural populations that females prefer communal nesting partners that share allelic forms of major histocompatibility complex genes. Such behaviour would lead to the selection of close relatives as communal nesting partners5-7. Although criteria for the demonstration of kin recognition are currently embroiled in controversy8,9, this is the first vertebrate study to meet Grafen's restrictive requirements8,10: discrimination is based on genetic similarity at highly polymorphic loci, incidental correlations due to relatedness are experimentally controlled, and strong reasons exist for expecting the assayed behaviour to be kin-selected.	UNIV FLORIDA,DEPT PATHOL & LAB MED,GAINESVILLE,FL 32610; UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195	State University System of Florida; University of Florida; University of Washington; University of Washington Seattle	MANNING, CJ (corresponding author), UNIV FLORIDA,CTR MAMMALIAN GENET,GAINESVILLE,FL 32610, USA.			Potts, Wayne/0000-0003-4137-0326				BARNARD C, 1991, TREND ECOL EVOL, V310, P312; BARNARD CJ, 1991, BIOL REV, V66, P377; BEAUCHAMP GK, 1990, CHEM SIGNAL, V5, P244; BEAUCHAMP GK, 1988, BEHAV GENET, V18, P537, DOI 10.1007/BF01065520; BEECHER MD, 1982, AM ZOOL, V22, P477; BROWN JL, 1983, ETHICAL QUESTIONS BR, P111; EGID K, 1989, ANIM BEHAV, V38, P548, DOI 10.1016/S0003-3472(89)80051-X; GETZ WM, 1981, J THEOR BIOL, V92, P209, DOI 10.1016/0022-5193(81)90288-5; GRAFEN A, 1990, ANIM BEHAV, V39, P42, DOI 10.1016/S0003-3472(05)80724-9; GROSBERG RK, 1986, NATURE, V322, P456, DOI 10.1038/322456a0; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HURST JL, 1992, BEHAV ECOL, V3, P196, DOI 10.1093/beheco/3.3.196; KLEIN J, 1986, NATURAL HIST MAJOR H; LACY RC, 1983, AM NAT, V121, P489, DOI 10.1086/284078; MANNING CJ, IN PRESS ANIM BEHAV; Oka H., 1970, PROFILES JAPANESE SC, P196; PACKER C, 1992, ANIM BEHAV, V43, P265, DOI 10.1016/S0003-3472(05)80222-2; PARTRIDGE L, 1988, PHILOS T R SOC B, V319, P525, DOI 10.1098/rstb.1988.0063; POTTS WK, 1991, NATURE, V352, P619, DOI 10.1038/352619a0; POTTS WK, 1990, TRENDS ECOL EVOL, V5, P181, DOI 10.1016/0169-5347(90)90207-T; SCOFIELD VL, 1982, NATURE, V295, P499, DOI 10.1038/295499a0; THOMAS L, 1975, IMMUNE SYSTEM INFECT, P2; Uyenoyama M. K., 1988, EVOLUTION SEX EXAMIN, P212; WILKINSON GS, 1988, ETHOLOGY, V77, P103; YAMAZAKI K, 1988, SCIENCE, V240, P1331, DOI 10.1126/science.3375818	25	197	210	0	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					581	583		10.1038/360581a0	http://dx.doi.org/10.1038/360581a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461279				2022-12-28	WOS:A1992KB95900083
J	YOONG, AFE; LIM, J; HUDSON, CN; CHARD, T				YOONG, AFE; LIM, J; HUDSON, CN; CHARD, T			AUDIT OF COMPLIANCE WITH ANTENATAL PROTOCOLS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GUIDELINES; PHYSICIANS; POLICIES; CARE	Objective-To assess the implementation of action protocols dictated by antenatal risk factors noted at the initial (booking) antenatal visit. Design-Retrospective study of 2000 women delivered between 1 March 1990 and 29 March 1991. Setting-Maternity department of a district general hospital supporting a multiethnic population in inner London. Main outcome measures-Comparison of clinical actions performed against those dictated by the department's protocols. Analysis according to clinical importance, gestation at booking, maternal age, parity, birth order, ethnic origin, and certainty of gestational age. Results-Interobserver agreement between the two auditors was good (chi statistic for risk factors detected, 0.78; for actions generated, 0.80). Of the 15 658 actions dictated by department protocols, 3673 (23.5%) were actually performed by the clinicians. The 63 combinations of risk factors and actions believed by consultants to be of particular clinical importance had an action rate of 28.3% compared with 18.6% for those considered less important (p < 0.001). Mothers who first visited the hospital antenatal clinic at or before 24 weeks' gestation had 25.2% of relevant protocols fulfilled (p < 0.001). Compliance was significantly improved in women aged 36 or over (32.4%), black women (24.9%), and cases of uncertain gestation (24.5%). Parity and birth order were not associated with an altered action rate. Ethnic origin deemed as "other" (than white, black, Asian, or oriental) or "unknown" was associated with poor compliance (19.3%). Conclusions-Compliance to a set of agreed protocols was poor even though a computer system was available and a protocol manual had been distributed. Protocols were more likely to be implemented in women who booked early and in some groups of women deemed at high risk including older mothers, black women, and those denoted as having uncertain gestational age.			YOONG, AFE (corresponding author), ST BARTHOLOMEWS HOSP & MED COLL, JOINT ACAD UNIT OBSTET GYNAECOL & REPROD PHYSIOL, LONDON EC1A 7BE, ENGLAND.							BARRETT JFR, 1990, LANCET, V336, P549, DOI 10.1016/0140-6736(90)92097-2; BODDY K, 1982, ROYAL COLLEGE OBSTET, P40; BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; CARROLL S, 1988, J OBSTET GYNAECOL, V8, P222, DOI 10.3109/01443618809012289; CHNG PK, 1980, BMJ-BRIT MED J, V281, P1184, DOI 10.1136/bmj.281.6249.1184; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1265, DOI 10.1001/jama.263.9.1265; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2239, DOI 10.1001/jama.263.16.2239; EDDY DM, 1982, NEW ENGL J MED, V307, P343, DOI 10.1056/NEJM198208053070604; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; GUTHRIE KA, 1989, BRIT J OBSTET GYNAEC, V96, P552, DOI 10.1111/j.1471-0528.1989.tb03254.x; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; ODOWD TC, 1991, BRIT MED J, V303, P450, DOI 10.1136/bmj.303.6800.450; SHAW CD, 1990, BRIT MED J, V300, P649, DOI 10.1136/bmj.300.6725.649; WOO B, 1985, JAMA-J AM MED ASSOC, V254, P1480, DOI 10.1001/jama.254.11.1480	17	11	11	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1992	305	6863					1184	1186		10.1136/bmj.305.6863.1184	http://dx.doi.org/10.1136/bmj.305.6863.1184			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467720	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1992JY77700019
J	TAYLOR, GJ; KATHOLI, RE; WOMACK, K; MOSES, HW; WOODS, WT				TAYLOR, GJ; KATHOLI, RE; WOMACK, K; MOSES, HW; WOODS, WT			INCREASED INCIDENCE OF SILENT ISCHEMIA AFTER ACUTE MYOCARDIAL-INFARCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							THROMBOLYTIC THERAPY; CORONARY-ARTERY; OCCLUSION; ELECTROCARDIOGRAM; REPERFUSION	Objective.-To determine the incidence of angina pectoris during induced myocardial ischemia in patients who have had thrombolytic therapy for acute myocardial infarction in comparison with patients with angina pectoris. Design.-During percutaneous transluminal coronary angioplasty, both study groups had coronary artery occlusion by the balloon dilatation catheter for 5 minutes. Setting.-A tertiary, cardiology referral center. Patients.-Twenty-five patients with angina pectoris who were undergoing angioplasty were compared with 30 patients having angioplasty 2 days after thrombolytic therapy for acute myocardial infarction. Outcomes.-Development of angina pectoris during balloon occlusion of the coronary artery was the primary end point; the ischemic response and muscle viability were assessed using both surface and intracoronary electrocardiograms and pulmonary artery wedge pressure. Results.-During balloon occlusion 16 (64%) of 25 patients in the angina pectoris group developed angina. In contrast, nine (30%) of 30 patients in the thrombolysis group had angina pectoris during balloon occlusion of the infarct artery (P<.01). The electrocardiographic response to ischemia and changes in pulmonary wedge pressure were similar in the two study groups. Conclusion.-After thrombolytic therapy for myocardial infarction, silent ischemia may be the rule rather than the exception.	PRAIRIE CARDIOVASC CTR,SPRINGFIELD,IL; SO ILLINOIS UNIV,SCH MED,DEPT MED,SPRINGFIELD,IL 62708	Southern Illinois University System; Southern Illinois University				Katholi, Richard/0000-0002-5625-7417				BERRY C, 1989, AM J CARDIOL, V63, P21, DOI 10.1016/0002-9149(89)91069-2; FRIEDMAN PL, 1986, CIRCULATION, V74, P330, DOI 10.1161/01.CIR.74.2.330; KAYDEN DS, 1990, J AM COLL CARDIOL, V15, P1500, DOI 10.1016/0735-1097(90)92817-L; KWON K, 1991, AM J CARDIOL, V67, P109, DOI 10.1016/0002-9149(91)90430-S; MEIJE A, 1992, J AM COLL CARDIOL, V19, P301; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; PEPINE CJ, 1990, CIRCULATION, V82, P135; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; SHEEHAN FH, 1988, J AM COLL CARDIOL, V12, P289, DOI 10.1016/0735-1097(88)90397-X; SIMOONS M L, 1988, Lancet, V1, P197; TAYLOR GJ, 1992, THROMBOLYTIC THERAPY; THAMES MD, 1989, CIRCULATION, V80, P1878, DOI 10.1161/01.CIR.80.6.1878; THOREN PN, 1976, AM J CARDIOL, V37, P1046; VANDERWALL EE, 1989, AM HEART J, V118, P655, DOI 10.1016/0002-8703(89)90575-9	14	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1448	1450		10.1001/jama.268.11.1448	http://dx.doi.org/10.1001/jama.268.11.1448			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512914				2022-12-28	WOS:A1992JM84900029
J	DITULLIO, M; SACCO, RL; GOPAL, A; MOHR, JP; HOMMA, S				DITULLIO, M; SACCO, RL; GOPAL, A; MOHR, JP; HOMMA, S			PATENT FORAMEN OVALE AS A RISK FACTOR FOR CRYPTOGENIC STROKE	ANNALS OF INTERNAL MEDICINE			English	Article						HEART SEPTAL DEFECTS, ATRIAL; CEREBROVASCULAR DISORDERS; RISK FACTORS; ECHOCARDIOGRAPHY; CEREBRAL INFARCTION	ATRIAL SEPTAL-DEFECTS; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; TRANSCRANIAL DOPPLER ULTRASOUND; CONTRAST ECHOCARDIOGRAPHY; DIAGNOSIS; EMBOLISM; EMBOLIZATION; PREVALENCE; ISCHEMIA; SHUNTS	Objective: To determine and compare the prevalence of patent foramen ovale in patients with stroke of undetermined origin (cryptogenic) and in patients with stroke of determined origin to assess the possible role of patent foramen ovale as a risk factor for cryptogenic stroke. Design: Cross-sectional study with nested case-control analysis. M Patients: A total of 146 patients (73 men, 73 women) with acute ischemic stroke referred to the echocardiography laboratory for evaluation. Setting: Neurovascular Unit and Echocardiography Laboratory, Columbia-Presbyterian Medical Center, New York, New York. Measurements: Patients were considered to have strokes of determined origin or cryptogenic strokes according to National Institute of Neurological Disorders and Stroke (NINDS) Stroke Data Bank criteria. The presence of patent foramen ovale was assessed by contrast echocardiography, performed blinded for type of stroke. The association between patent foramen ovale and type of stroke was tested after correcting for patients' demographic variables and stroke risk factors. Results: The overall prevalence of patent foramen ovale was 26 of 146 patients (18%; 95% CI, 11.4% to 24.6%). Patients with cryptogenic stroke (31%) had a significantly higher prevalence of patent foramen ovale than did patients with an identifiable cause of stroke (69%) in both the younger (< 55 years; 48% compared with 4%; P < 0.001) and the older (greater-than-or-equal-to 55 years; 38% compared with 8%; P < 0.001) age groups. Multiple logistic regression analysis was used to identify the presence of a patent foramen ovale as strongly associated with the diagnosis of cryptogenic stroke (odds ratio, 7.2; Cl, 2.4 to 21.7), irrespective of patient age and other stroke risk factors. Conclusions: Patients with cryptogenic stroke have a higher prevalence of patent foramen ovale than patients with stroke of determined cause in all age groups, even after correcting for the presence of recognized stroke risk factors. This identifies patent foramen ovale as a risk factor for cryptogenic stroke. Regardless of patient age, contrast echocardiography should be considered when the cause of stroke is unknown.	COLUMBIA PRESBYTERIAN MED CTR,DIV CARDIOL,P&S 9-441,630 W 168TH ST,NEW YORK,NY 10032	Columbia University; NewYork-Presbyterian Hospital			Mohr, J/AAO-9694-2020; Sacco, Ralph/Y-9278-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027517] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS27517] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGER M, 1985, J AM COLL CARDIOL, V6, P359, DOI 10.1016/S0735-1097(85)80172-8; BILLER J, 1987, ARCH NEUROL-CHICAGO, V44, P740, DOI 10.1001/archneur.1987.00520190046016; BOMMER WJ, 1984, J AM COLL CARDIOL, V3, P6, DOI 10.1016/S0735-1097(84)80423-4; BOROW KM, 1990, NEW ENGL J MED, V323, P1698, DOI 10.1056/NEJM199012133232409; Breslow N, 1980, STATISTICAL METHODS, V32; DITULLIO M, 1991, CIRCULATION, V84, P451; DUBOURG O, 1986, ARCH MAL COEUR VAISS, V79, P193; GROSS CR, 1986, ARCH NEUROL-CHICAGO, V43, P893, DOI 10.1001/archneur.1986.00520090031012; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HART RG, 1983, STROKE, V14, P110, DOI 10.1161/01.STR.14.1.110; HARVEY JR, 1986, ANN INTERN MED, V105, P695, DOI 10.7326/0003-4819-105-5-695; HOFMANN T, 1990, LANCET, V336, P1421; JEANRENAUD X, 1990, SCHWEIZ MED WSCHR, V120, P823; JONES HR, 1983, ANN NEUROL, V13, P314, DOI 10.1002/ana.410130315; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LOSCALZO J, 1986, AM HEART J, V112, P141, DOI 10.1016/0002-8703(86)90692-7; LYNCH JJ, 1984, AM J CARDIOL, V53, P1478, DOI 10.1016/S0002-9149(84)91617-5; MOHR JP, 1988, NEW ENGL J MED, V318, P1197, DOI 10.1056/NEJM198805053181810; MOHR JP, 1984, INT ANGIOL, V3, P431; NEMEC JJ, 1991, AM J CARDIOL, V68, P1498, DOI 10.1016/0002-9149(91)90285-S; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; ROCCHINI AP, 1990, CIRCULATION, V82, P1044, DOI 10.1161/01.CIR.82.3.1044; ROSENOW EC, 1981, MAYO CLIN PROC, V56, P161; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SHUB C, 1983, J AM COLL CARDIOL, V2, P127, DOI 10.1016/S0735-1097(83)80385-4; STRUNK BL, 1987, AM J CARDIOL, V60, P413, DOI 10.1016/0002-9149(87)90271-2; TEAGUE SM, 1991, STROKE, V22, P740, DOI 10.1161/01.STR.22.6.740; VANHARE GF, 1989, J AM COLL CARDIOL, V13, P673, DOI 10.1016/0735-1097(89)90610-4; WEBSTER MWI, 1988, LANCET, V2, P11	29	447	452	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					461	465		10.7326/0003-4819-117-6-461	http://dx.doi.org/10.7326/0003-4819-117-6-461			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503349				2022-12-28	WOS:A1992JN25700003
J	BECKSAGUE, C; DOOLEY, SW; HUTTON, MD; OTTEN, J; BREEDEN, A; CRAWFORD, JT; PITCHENIK, AE; WOODLEY, C; CAUTHEN, G; JARVIS, WR				BECKSAGUE, C; DOOLEY, SW; HUTTON, MD; OTTEN, J; BREEDEN, A; CRAWFORD, JT; PITCHENIK, AE; WOODLEY, C; CAUTHEN, G; JARVIS, WR			HOSPITAL OUTBREAK OF MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS INFECTIONS - FACTORS IN TRANSMISSION TO STAFF AND HIV-INFECTED PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe transmission of multidrug-resistant (MDR) Mycobacterium tuberculosis infection among patients and health care workers (HCWs) in a ward and clinic for human immunodeficiency virus (HIV)-infected patients in a hospital, four studies were conducted. Methods.-Case patients and control patients were persons who had been treated in the HIV ward or clinic, whose clinical course was consistent with tuberculosis and who had at least one positive culture for M tuberculosis between January 1, 1988, and January 31, 1990, resistant to at least isoniazid and rifampin (case patients), or whose isolates were susceptible to all drugs tested (control patients). In the first study, case patients and control patients were compared to identify risk factors for MDR tuberculosis. In the second study, inpatient and outpatient days of MDR tuberculosis case patients were compared to determine whether acid-fast bacillus (AFB) smear-positivity or aerosolized pentamidine use was associated with higher numbers of subsequent MDR tuberculosis cases among exposed patients. In the third study, restriction fragment length polymorphism analysis was performed on available MDR and sensitive M tuberculosis isolates. In the fourth study, skin test conversion rates among HCWs in the HIV ward and clinic were compared with those of HCWs in another ward, and the strength of the associations between skin test conversions among HCWs on the HIV ward and the number of person-days that AFB smear-positive case patients and control patients were on this ward was estimated. Results.-Case patients were more likely than control patients to have been exposed on the HIV ward or clinic to an AFB smear-positive case patient (P<.001). Inpatient and outpatient days of MDR tuberculosis case patients were associated with more subsequent cases of MDR tuberculosis if exposing case patients were smear-positive or if they received aerosolized pentamidine (P less-than-or-equal-to .01). Of 13 MDR isolates, all had one of two restriction fragment length polymorphism patterns; 10 sensitive isolates had restriction fragment length polymorphism patterns that were different from each other. The HCW skin test conversion rate was higher on the HIV ward and clinic than on the comparison ward (P<.01). The risk of occupational acquisition of infection increased in direct proportion to the number of person-days that AFB smear-positive case patients were on the HIV ward (r=.75; P=.005), but did not increase in proportion to the number of person-days that AFB smear-positive control patients were there (r=-.36; P=NS). After isolation measures for AFB smear-positive tuberculosis patients were improved, MDR tuberculosis cases decreased to seven of 214 tuberculosis patients. Conclusions.-Nosocomial transmission of MDR M tuberculosis infection to patients and HCWs occurred on the HIV ward and clinic. Infectiousness of MDR tuberculosis case patients was associated with AFB sputum-smear positivity. Case patients with MDR tuberculosis created a greater risk of skin test conversion for HCWs on the HIV ward than drug-susceptible control patients.	CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; UNIV MIAMI,MIAMI,FL 33152; VET AFFAIRS MED CTR,MIAMI,FL; JACKSON MEM HOSP,MIAMI,FL 33136	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BECKSAGUE, C (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,ATLANTA,GA 30333, USA.			Beck-Sague, Consuelo/0000-0001-9082-0165				CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; Dean A. G., 1990, EPI INFO VERSION 5 W; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; Kent PT, 1985, GUIDE LEVEL 3 LAB; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SIEGEL S, 1981, NONPARAMETRIC STAT, P184; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732; 1985, MMWR, V29, P429; 1985, SAS USERS GUIDE BASI, P861; 1990, AM REV RESPIR DIS, V142, P725; 1990, MMWR, V39, P718; 1991, MMWR, V40, P585; 1992, MMWR, V41, P61; 1991, MMWR, V40, P129; 1990, MMWR, V39, P1	17	395	401	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1280	1286		10.1001/jama.268.10.1280	http://dx.doi.org/10.1001/jama.268.10.1280			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507374				2022-12-28	WOS:A1992JL60800028
J	SWEDBERG, K; HELD, P; KJEKSHUS, J; RASMUSSEN, K; RYDEN, L; WEDEL, H				SWEDBERG, K; HELD, P; KJEKSHUS, J; RASMUSSEN, K; RYDEN, L; WEDEL, H			EFFECTS OF THE EARLY ADMINISTRATION OF ENALAPRIL ON MORTALITY IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE COOPERATIVE NEW SCANDINAVIAN ENALAPRIL SURVIVAL STUDY-II (CONSENSUS-II)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; CONVERTING ENZYME-INHIBITOR; CONGESTIVE HEART-FAILURE; CAPTOPRIL; EXPANSION; THERAPY; DILATATION; EXERCISE; RATS	Background. Long-term administration of angiotensin-converting-enzyme (ACE) inhibitors has been shown to improve survival in patients with symptomatic left ventricular failure and to attenuate left ventricular dilatation in patients with myocardial infarction. We studied whether mortality could be reduced during the 6 months after an acute myocardial infarction with use of the ACE inhibitor enalapril. Methods. At 103 Scandinavian centers patients with acute myocardial infarctions and blood pressure above 100/60 mm Hg were randomly assigned to treatment with either enalapril or placebo, in addition to conventional therapy. Therapy was initiated with an intravenous infusion of enalapril (enalaprilat) within 24 hours after the onset of chest pain, followed by administration of oral enalapril. Results. Of the 6090 patients enrolled, 3046 were assigned to placebo and 3044 to enalapril. The life-table mortality rates in the two groups at one and six months were not significantly different (6.3 and 10.2 percent in the placebo group vs. 7.2 and 11.0 percent in the enalapril group, P = 0.26). The relative risk of death in the enalapril group was 1.10 (95 percent confidence interval, 0.93 to 1.29). Death due to progressive heart failure occurred in 104 patients (3.4 percent) in the placebo group and 132 (4.3 percent) in the enalapril group (P = 0.06). Therapy had to be changed because of worsening heart failure in 30 percent of the placebo group and 27 percent of the enalapril group (P<0.006). Early hypotension (systolic pressure <90 mm Hg or diastolic pressure <50 mm Hg) occurred in 12 percent of the enalapril group and 3 percent of the placebo group (P<0.001). Conclusions. Enalapril therapy started within 24 hours of the onset of acute myocardial infarction does not improve survival during the 180 days after infarction.			SWEDBERG, K (corresponding author), GOTHENBURG UNIV, OSTRA HOSP, DEPT MED, S-41685 GOTHENBURG, SWEDEN.		Swedberg, Karl/B-2475-2008					BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; DEGRAEFF PA, 1987, J CARDIOVASC PHARM, V9, pS37, DOI 10.1097/00005344-198700002-00009; DELLBORG M, 1991, J ELECTROCARDIOL, V23, P11, DOI 10.1016/0022-0736(90)90067-C; EATON LW, 1979, NEW ENGL J MED, V300, P57, DOI 10.1056/NEJM197901113000202; ERLEBACHER JA, 1982, AM J CARDIOL, V49, P1120, DOI 10.1016/0002-9149(82)90035-2; FRANCIS GS, 1990, AM J CARDIOL, V66, pD33, DOI 10.1016/0002-9149(90)90474-F; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; HOCK CE, 1985, AM HEART J, V109, P222, DOI 10.1016/0002-8703(85)90587-3; MCALPINE HM, 1988, BRIT HEART J, V60, P117; MCKAY RG, 1986, CIRCULATION, V74, P693, DOI 10.1161/01.CIR.74.4.693; NABEL EG, 1991, J AM COLL CARDIOL, V17, P467, DOI 10.1016/S0735-1097(10)80117-2; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; OLDROYD KG, 1991, AM J CARDIOL, V68, P713, DOI 10.1016/0002-9149(91)90641-W; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; PFEFFER MA, 1985, CIRCULATION, V72, P406, DOI 10.1161/01.CIR.72.2.406; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; SCHAPER W, 1976, CIRCULATION, V53, P57; SCHOEMAKER RG, 1991, J MOL CELL CARDIOL, V23, P187, DOI 10.1016/0022-2828(91)90105-U; SHARPE N, 1988, LANCET, V1, P255; SHARPE N, 1991, LANCET, V337, P872, DOI 10.1016/0140-6736(91)90202-Z; SHATKIN BJ, 1985, CIRCULATION, V72, P316; SIGURDSSON A, 1991, INT J CARDIOL, V33, P115, DOI 10.1016/0167-5273(91)90159-M; SNAPINN SM, 1992, STAT MED, V11, P659, DOI 10.1002/sim.4780110510; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; SWEET CS, 1987, J CARDIOVASC PHARM, V10, P636, DOI 10.1097/00005344-198712000-00005; VANGILST WH, 1986, J CARDIOVASC PHARM, V8, P722; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1990, CIRCULATION, V82, P117	30	865	892	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					678	684		10.1056/NEJM199209033271002	http://dx.doi.org/10.1056/NEJM199209033271002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1495520	Bronze			2022-12-28	WOS:A1992JL23500002
J	FERRERA, VP; NEALEY, TA; MAUNSELL, JHR				FERRERA, VP; NEALEY, TA; MAUNSELL, JHR			MIXED PARVOCELLULAR AND MAGNOCELLULAR GENICULATE SIGNALS IN VISUAL AREA V4	NATURE			English	Article							MACAQUE STRIATE CORTEX; BROAD-BAND CHANNELS; REVERSIBLE INACTIVATION; INTRINSIC CONNECTIONS; GANGLION-CELLS; COLOR-OPPONENT; LAMINA 4C; PERCEPTION; VISION	VISUAL information from the retina is transmitted to the cerebral cortex by way of the lateral geniculate nucleus (LGN) in the thalamus. In primates, most of the retinal ganglion cells that project to the LGN belong to one of two classes, P and M, whose axons terminate in the parvocellular or magnocellular subdivisions of the LGN. These cell classes give rise to two channels that have been distinguished anatomically, physiologically and behaviourally1-3,16,17. The visual cortex also can be subdivided into two pathways, one specialized for motion processing and the other for colour and form information4. Several lines of indirect evidence have suggested a close correspondence between the subcortical and cortical pathways, such that the M channel provides input to the motion pathway and the P channel drives the colour/form pathway5-7. This hypothesis was tested directly by selectively inactivating either the magnocellular or parvocellular subdivision of the LGN and recording the effects on visual responses in the cortex. We have previously reported that, in accordance with the hypothesis, responses in the motion pathway in the cortex depend primarily on magnocellular LGN8. We now report that in the colour/form pathway, visual responses depend on both P and M input. These results argue against a simple correspondence between the subcortical and cortical pathways.	UNIV ROCHESTER,DEPT PHYSIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR VISUAL SCI,ROCHESTER,NY 14642	University of Rochester; University of Rochester			Maunsell, John/G-5702-2010	Maunsell, John/0000-0003-0018-4439; Ferrera, Vincent/0000-0002-6599-7740				BLASDEL GG, 1985, J NEUROSCI, V5, P3350; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FITZPATRICK D, 1985, J NEUROSCI, V5, P3329; LACHICA EA, 1992, P NATL ACAD SCI USA, V89, P3566, DOI 10.1073/pnas.89.8.3566; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MALPELI JG, 1979, J NEUROSCI METH, V1, P143, DOI 10.1016/0165-0270(79)90011-6; MALPELI JG, 1981, J NEUROPHYSIOL, V46, P1102, DOI 10.1152/jn.1981.46.5.1102; MAUNSELL JHR, 1990, J NEUROSCI, V10, P3323; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MAUNSELL JHR, 1987, MATTERS INTELLIGENCE; MERIGAN WH, 1991, J NEUROSCI, V11, P3422; MERIGAN WH, 1991, J NEUROSCI, V11, P994; NEALEY TA, 1991, INVEST OPHTH VIS SCI, V32, P1117; SCHILLER PH, 1990, VISUAL NEUROSCI, V5, P321, DOI 10.1017/S0952523800000420; SHAPLEY R, 1986, TRENDS NEUROSCI, V9, P229, DOI 10.1016/0166-2236(86)90064-0; SILVEIRA LCL, 1991, NEUROSCIENCE, V40, P217, DOI 10.1016/0306-4522(91)90186-R; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR	17	141	143	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					756	758		10.1038/358756a0	http://dx.doi.org/10.1038/358756a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1508271				2022-12-28	WOS:A1992JK69900053
J	JUVONEN, T; NIEMELA, O				JUVONEN, T; NIEMELA, O			ABO BLOOD-GROUP AND GALL STONE DISEASE	BRITISH MEDICAL JOURNAL			English	Article									OULU UNIV HOSP,DEPT CLIN CHEM,SF-90220 OULU,FINLAND	University of Oulu	JUVONEN, T (corresponding author), OULU UNIV HOSP,DEPT SURG,SF-90220 OULU,FINLAND.							BEARDMORE JA, 1983, NATURE, V303, P522, DOI 10.1038/303522a0; BUSCH N, 1991, EUR J CLIN INVEST, V21, P453, DOI 10.1111/j.1365-2362.1991.tb01394.x; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; WHINCUP PH, 1990, BMJ-BRIT MED J, V300, P1679, DOI 10.1136/bmj.300.6741.1679	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					26	27		10.1136/bmj.305.6844.26	http://dx.doi.org/10.1136/bmj.305.6844.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1489401	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JC79900025
J	REICHMANN, E; SCHWARZ, H; DEINER, EM; LEITNER, I; EILERS, M; BERGER, J; BUSSLINGER, M; BEUG, H				REICHMANN, E; SCHWARZ, H; DEINER, EM; LEITNER, I; EILERS, M; BERGER, J; BUSSLINGER, M; BEUG, H			ACTIVATION OF AN INDUCIBLE C-FOSER FUSION PROTEIN CAUSES LOSS OF EPITHELIAL POLARITY AND TRIGGERS EPITHELIAL-FIBROBLASTOID CELL CONVERSION	CELL			English	Article							CANINE KIDNEY-CELLS; ADHESION MOLECULE UVOMORULIN; HEPATOCYTE GROWTH-FACTOR; HUMAN ESTROGEN-RECEPTOR; MESENCHYME-LIKE CELLS; TRANSCRIPTIONAL ACTIVATION; CYTOSKELETAL PROTEINS; GENE-EXPRESSION; BINDING-SITE; TRANSFORMATION	As a novel approach to studying the modulation of the polarized epithelial phenotype, we have expressed c-Fos and c-Myc estrogen receptor fusion proteins (c-FosER and c-MycER) in mammary epithelial cells. The hybrid proteins could be activated by estrogen for defined time periods and after the cells had achieved their fully polarized organization. Activation of c-MycER deregulated proliferation but did not affect epithelial polarity. Short-term activation of c-FosER induced the reversible loss of morphological and functional cell polarity. In contrast, long-term stimulation of c-FosER caused the cells to depolarize irreversibly, to invade collagen gels, and to undergo epithelial-fibroblastoid cell conversion. Our data suggest that Fos proteins are important in modulating the epithelial phenotype both in normal tissue development and in invasive processes.	MAX PLANCK INST ENTWICKLUNGSBIOL,W-7400 TUBINGEN,GERMANY; ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG,GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg	REICHMANN, E (corresponding author), FORSCHUNGSINST MOLEK PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Busslinger, Meinrad J./J-1249-2016	Busslinger, Meinrad J./0000-0002-9111-9351				ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; ASCH HL, 1985, DEV BIOL, V107, P470, DOI 10.1016/0012-1606(85)90328-8; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Birchmeier W, 1991, CURR OPIN CELL BIOL, V3, P832, DOI 10.1016/0955-0674(91)90057-6; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1984, CELL, V36, P259; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FRANKE WW, 1981, EXP CELL RES, V134, P345, DOI 10.1016/0014-4827(81)90435-3; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBURG G, 1986, DEV BIOL, V115, P363, DOI 10.1016/0012-1606(86)90256-3; GREENBURG G, 1988, DEVELOPMENT, V102, P605; GRIFFITHS G, 1993, IN PRESS FINE STRUCT; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Hay E.D., 1990, Seminars in Developmental Biology, V1, P347; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; KANDJIAN EW, 1986, MOL BIOL REP, V11, P107; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; KEMLER R, 1989, BIOESSAYS, V11, P88, DOI 10.1002/bies.950110403; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MARGUET D, 1992, J BIOL CHEM, V267, P2200; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKWALD RR, 1979, DEV BIOL, V69, P634, DOI 10.1016/0012-1606(79)90317-8; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MULLIN JM, 1988, J CELL PHYSIOL, V134, P357, DOI 10.1002/jcp.1041340306; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OJAKIAN GK, 1981, CELL, V23, P95, DOI 10.1016/0092-8674(81)90274-9; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PHAM TA, 1991, P NATL ACAD SCI USA, V88, P3125, DOI 10.1073/pnas.88.8.3125; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SANFORD KK, 1961, JNCI-J NATL CANCER I, V26, P1139; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; Schoenenberger C A, 1991, Trends Cell Biol, V1, P87, DOI 10.1016/0962-8924(91)90035-8; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P873, DOI 10.1083/jcb.112.5.873; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SONNENBERG A, 1986, CANCER RES, V46, P5913; STRANGE R, 1991, CELL GROWTH DIFFER, V2, P549; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TRELSTAD RL, 1982, DEV BIOL, V92, P27, DOI 10.1016/0012-1606(82)90147-6; VESTWEBER D, 1985, DEV BIOL, V112, P213, DOI 10.1016/0012-1606(85)90135-6; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; ZUK A, 1989, J CELL BIOL, V108, P903, DOI 10.1083/jcb.108.3.903; ZURZOLO C, 1992, EMBO J, V11, P2337, DOI 10.1002/j.1460-2075.1992.tb05293.x	69	234	244	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1103	1116		10.1016/S0092-8674(05)80060-1	http://dx.doi.org/10.1016/S0092-8674(05)80060-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473147				2022-12-28	WOS:A1992KE60400006
J	DEVANE, WA; HANUS, L; BREUER, A; PERTWEE, RG; STEVENSON, LA; GRIFFIN, G; GIBSON, D; MANDELBAUM, A; ETINGER, A; MECHOULAM, R				DEVANE, WA; HANUS, L; BREUER, A; PERTWEE, RG; STEVENSON, LA; GRIFFIN, G; GIBSON, D; MANDELBAUM, A; ETINGER, A; MECHOULAM, R			ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR	SCIENCE			English	Article							RAT-BRAIN; LOCALIZATION	Arachidonylethanolamide, an arachidonic acid derivative in porcine brain, was identified in a screen for endogenous ligands for the cannabinoid receptor. The structure of this compound, which has been named "anandamide," was determined by mass spectrometry and nuclear magnetic resonance spectroscopy and was confirmed by synthesis. Anandamide inhibited the specific binding of a radiolabeled cannabinoid probe to synaptosomal membranes in a manner typical of competitive ligands and produced a concentration-dependent inhibition of the electrically evoked twitch response of the mouse vas deferens, a characteristic effect of psychotropic cannabinoids. These properties suggest that anandamide may function as a natural ligand for the cannabinoid receptor.	HEBREW UNIV JERUSALEM,FAC MED,DEPT NAT PROD,IL-91120 JERUSALEM,ISRAEL; UNIV ABERDEEN MARISCHAL COLL,DEPT BIOMED SCI,ABERDEEN AB9 1AS,SCOTLAND; TECHNION ISRAEL INST TECHNOL,DEPT CHEM,IL-32000 HAIFA,ISRAEL	Hebrew University of Jerusalem; University of Aberdeen; Technion Israel Institute of Technology			Pertwee, Roger Guy/E-1312-2011	Pertwee, Roger/0000-0003-3227-2783	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006481] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 6481] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Wellcome Trust(Wellcome TrustEuropean Commission)		BACHUR NR, 1965, J BIOL CHEM, V240, P1019; BURSTEIN S, 1992, MARIJUANA CANNABINOI, P73; CHRISTIE WW, 1982, LIPID ANAL, P81; COREY EJ, 1984, J AM CHEM SOC, V106, P1503, DOI 10.1021/ja00317a064; DEVANE WA, 1992, J MED CHEM, V35, P2065, DOI 10.1021/jm00089a018; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1989, THESIS ST LOUIS U ST; DEVANE WA, 1991, 5TH P NORD NEUR M, P198; DEVANE WA, UNPUB; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; FAIRBAIRN JW, 1981, BRIT J PHARMACOL, V72, P401, DOI 10.1111/j.1476-5381.1981.tb10990.x; FROST DJ, 1971, ANAL CHEM, V43, P1316, DOI 10.1021/ac60304a048; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Howlett A., 1992, MARIJUANA CANNABINOI, P35; KUEHL FA, 1957, J AM CHEM SOC, V79, P5577, DOI 10.1021/ja01577a066; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; MECHOULAM R, 1992, MARIJUANA CANNABINOI, P1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PERTWEE RG, 1992, BRIT J PHARMACOL, V105, P980, DOI 10.1111/j.1476-5381.1992.tb09088.x; PERTWEE RG, 1988, PHARMACOL THERAPEUT, V36, P189, DOI 10.1016/0163-7258(88)90106-4; PERTWEE RG, 1992, MARIJUANA CANNABINOI, P165; SKLENOVSKY A, 1989, Acta Universitatis Palackianae Olomucensis Facultatis Medicae, V122, P83; SWEELEY CC, 1969, METHOD ENZYMOL, V14, P254; WAKAMATSU K, 1990, BIOCHEM BIOPH RES CO, V168, P423, DOI 10.1016/0006-291X(90)92338-Z; Wenker H, 1935, J AM CHEM SOC, V57, P1079, DOI 10.1021/ja01309a034	29	4305	4475	5	289	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1946	1949		10.1126/science.1470919	http://dx.doi.org/10.1126/science.1470919			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470919				2022-12-28	WOS:A1992KD08800035
J	STEMPLE, DL; ANDERSON, DJ				STEMPLE, DL; ANDERSON, DJ			ISOLATION OF A STEM-CELL FOR NEURONS AND GLIA FROM THE MAMMALIAN NEURAL CREST	CELL			English	Article							NERVE GROWTH-FACTOR; INTERMEDIATE FILAMENT PROTEIN; FORMING SCHWANN-CELLS; NGF-RECEPTOR; SYMPATHETIC NEURONS; PROGENITOR-CELL; CLONAL ANALYSIS; MOUSE EMBRYO; AVIAN EMBRYO; DORSAL-ROOT	We have isolated mammalian neural crest cells using a monoclonal antibody to the low affinity NGF receptor, and established conditions for the serial propagation of these cells in clonal culture to assess their developmental potential. This analysis indicates that, first, single mammalian neural crest cells are multipotent, able to generate at least neurons and Schwann cells like their avian counterparts. Second, multipotent neural crest cells generate multipotent progeny, indicating that they are capable of self-renewal and therefore are stem cells. Third, multipotent neural crest cells also generate some clonal progeny that form only neurons or glia, suggesting the production of committed neuroblasts and glioblasts. Manipulation of the substrate alters the fate of the multipotent cells. These findings have implications for models of neural crest development in vivo, and establish a system for studying the generation of cellular diversity by a multipotent stem cell in vitro.			STEMPLE, DL (corresponding author), CALTECH,HOWARD HUGHES MED INST,DIV BIOL 216-76,PASADENA,CA 91125, USA.		Pillay, Nischalan/F-9536-2012	Stemple, Derek/0000-0002-8296-9928				ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BERND P, 1986, DEV BIOL, V115, P415, DOI 10.1016/0012-1606(86)90261-7; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; BRONNERFRASER M, 1989, NEURON, V3, P755, DOI 10.1016/0896-6273(89)90244-4; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; COCHARD P, 1984, J NEUROSCI, V4, P2080; COHEN AM, 1975, DEV BIOL, V46, P262, DOI 10.1016/0012-1606(75)90104-9; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DUFF RS, 1991, DEV BIOL, V147, P451, DOI 10.1016/0012-1606(91)90303-K; FRANK E, 1991, DEVELOPMENT, V111, P895; FRASER SE, 1991, DEVELOPMENT, V112, P913; FRIEDMAN B, 1990, J COMP NEUROL, V295, P43, DOI 10.1002/cne.902950105; HALL PA, 1989, DEVELOPMENT, V106, P619; Hawrot E, 1979, Methods Enzymol, V58, P574; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HUSZAR D, 1991, DEVELOPMENT, V112, P131; JESSEN KR, 1990, DEVELOPMENT, V109, P91; JESSEN KR, 1987, J NEUROSCI, V7, P3362; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; LANDIS SC, 1983, DEV BIOL, V98, P349, DOI 10.1016/0012-1606(83)90365-2; Le Douarin N.M., 1982, NEURAL CREST; LEDOUARIN N, 1991, GLIA, V4, P175; LEDOUARIN NM, 1980, NATURE, V286, P663, DOI 10.1038/286663a0; LEMKE G, 1988, DEVELOPMENT, V102, P499; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LORING J, 1982, DEV BIOL, V90, P165, DOI 10.1016/0012-1606(82)90222-6; MAXWELL GD, 1987, DEVELOPMENT, V101, P767; MAXWELL GD, 1990, DEV BIOL, V141, P233, DOI 10.1016/0012-1606(90)90118-3; MCCONNELL SK, 1991, ANNU REV NEUROSCI, V14, P269, DOI 10.1146/annurev.ne.14.030191.001413; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MIRSKY R, 1990, DEVELOPMENT, V109, P105; MIRSKY R, 1982, NEUROIMMUNOLOGY, P141; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; NEWGREEN D, 1980, CELL TISSUE RES, V211, P269; PARYSEK LM, 1988, J NEUROSCI, V8, P555; PATTERSON PH, 1977, DEV BIOL, V56, P263, DOI 10.1016/0012-1606(77)90269-X; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; ROGERS SL, 1990, DEV BIOL, V141, P173, DOI 10.1016/0012-1606(90)90112-V; ROGERS SL, 1986, DEV BIOL, V113, P429, DOI 10.1016/0012-1606(86)90177-6; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; SIEBERBLUM M, 1985, EXP CELL RES, V158, P267, DOI 10.1016/0014-4827(85)90450-1; SMITHTHOMAS LC, 1989, DEVELOPMENT, V105, P251; STEMPLE DL, 1991, NEUROSCI LETT, V124, P57, DOI 10.1016/0304-3940(91)90821-A; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; TRAPP BD, 1981, J CELL BIOL, V90, P1, DOI 10.1083/jcb.90.1.1; TRAPP BD, 1979, P NATL ACAD SCI USA, V76, P3552, DOI 10.1073/pnas.76.7.3552; WOLINSKY EJ, 1985, J NEUROSCI, V5, P1497; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387	61	673	804	1	55	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					973	985		10.1016/0092-8674(92)90393-Q	http://dx.doi.org/10.1016/0092-8674(92)90393-Q			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458542				2022-12-28	WOS:A1992KB99000010
J	GILLIS, CR; HOLE, DJ; LAMONT, DW; GRAHAM, AC; RAMAGE, S				GILLIS, CR; HOLE, DJ; LAMONT, DW; GRAHAM, AC; RAMAGE, S			THE INCIDENCES OF LUNG-CANCER AND BREAST-CANCER IN WOMEN IN GLASGOW	BRITISH MEDICAL JOURNAL			English	Article											GILLIS, CR (corresponding author), RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,SCOTLAND.							DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P44, DOI 10.1136/jech.42.1.44; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P38, DOI 10.1136/jech.42.1.38; SCHOTTENFELD D, 1982, CANCER EPIDEMIOLOGY; [No title captured]	5	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1331	1331		10.1136/bmj.305.6865.1331	http://dx.doi.org/10.1136/bmj.305.6865.1331			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483078	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992KA77300023
J	LLOYD, BW; ALI, MH				LLOYD, BW; ALI, MH			HOW USEFUL DO PARENTS FIND HOME PEAK FLOW MONITORING FOR CHILDREN WITH ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP,COMMUNITY CHILD HLTH,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	LLOYD, BW (corresponding author), N MIDDLESEX HOSP,NATL HLTH SERV TRUST,LONDON N18 1QX,ENGLAND.							[Anonymous], 1990, BMJ, V301, P797; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; 1990, BRIT MED J, V301, P651	3	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1128	1129		10.1136/bmj.305.6862.1128	http://dx.doi.org/10.1136/bmj.305.6862.1128			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463948	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JX84100022
J	GREEN, M				GREEN, M			LONDON AFTER TOMLINSON - CLINICAL RESEARCH	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN SCIENTIST; MEDICINE	Sir Bernard Tomlinson's report focuses on London's health services, but his proposals have major implications for the future of clinical research -not just in London but in the United Kingdom as a whole. They must be seen in the context of a widely perceived decline in British research and development which also threatens clinical research.12 This article examines the implications of Tomlinson's proposals and related strategis and recommends the construction of a research market for the patient costs of clinical research to complement the NHS market for patient services introduced in 1991. These arrangements would help sustain the clinical research base and guarantee excellence.			GREEN, M (corresponding author), UNIV LONDON,BRITISH POSTGRAD MED FEDERAT,LONDON WC1N 3EJ,ENGLAND.							Ahrens E.H., 1992, CRISIS CLIN RES OVER; ALDHOUS P, 1991, NATURE, V350, P546, DOI 10.1038/350546a0; FRANCE C, 1990, MED DENTAL ED 2ND RE; GLICKMAN RM, 1985, J CLIN INVEST, V76, P1293, DOI 10.1172/JCI112102; HALL M, 1992, AGENDA HLTH SUPPORTI; HARLAND SJ, 1992, J ROY SOC MED, V85, P649; HEALY B, 1988, NEW ENGL J MED, V319, P1058, DOI 10.1056/NEJM198810203191605; HICKS D, 1989, PHYSICS WORLD    DEC, P31; KINGMAN S, 1992, NEW SCI         0428, P62; KIPLING J, 1992, ASS BRIT PHARM IND E, P3; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; SMITH R, 1991, BRIT MED J, V302, P1006, DOI 10.1136/bmj.302.6783.1006; SWALES J, 1986, LANCET, V1, P1194; WEATHERALL DJ, 1991, BRIT MED J, V302, P1002, DOI 10.1136/bmj.302.6783.1002; 1992, ANATOMY EXCELLENCE L; 1992, FUTURE SCI BASE; 1989, PRIORTIES MED RES GO; 1991, LANCET, V337, P19; 1988, PRIORITIES MED RES, V1; 1992, CORPORATE PLAN; 1989, BMJ, V298, P573; 1992, CONCORDAT HLTH DEP M	22	9	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1081	1085		10.1136/bmj.305.6861.1081	http://dx.doi.org/10.1136/bmj.305.6861.1081			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467692	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JW70100026
J	LINDGREN, S; LOKSHIN, B; STROMQUIST, A; WEINBERGER, M; NASSIF, E; MCCUBBIN, M; FRASHER, R				LINDGREN, S; LOKSHIN, B; STROMQUIST, A; WEINBERGER, M; NASSIF, E; MCCUBBIN, M; FRASHER, R			DOES ASTHMA OR TREATMENT WITH THEOPHYLLINE LIMIT CHILDRENS ACADEMIC-PERFORMANCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMBULATORY PATIENTS; SCHOOL PERFORMANCE; CHILDHOOD ASTHMA; UNITED-STATES; BEHAVIOR; HOSPITALIZATION; PREVALENCE; PREDNISONE; CAFFEINE; THERAPY	Background. Asthma is a major cause of morbidity in childhood, restricting activity and causing absences from school. Theophylline, although effective in managing chronic asthma, has been reported to cause deficits in cognitive functioning and school performance. We therefore examined the effect of asthma and its treatment on academic achievement in a large, representative population of school-age children; matched sibling controls were used for comparison. Methods. We identified 255 consecutive children with asthma (mean age, 12.0 years) who had taken nationally standardized scholastic achievement tests administered routinely by the schools. One hundred one of these children had siblings without asthma with whom comparisons Gould be made in reading, mathematics, and a composite measure of achievement. Results. Academic achievement among the children with asthma was similar to normative standards in Iowa and higher than national standards, as reflected in a mean composite T-score of 57.1 (expected mean [+/-SD], 50+/-10). For the 101 children with sibling controls, composite T-scores were 58.3 for the children with asthma and 57.5 for the siblings. Eighty-five of these 101 children with asthma were receiving daily maintenance medication for chronic asthma; 72 of these were receiving theophylline. The mean composite T-scores were 58.5 for the theophylline-treated patients and 58.4 for their siblings without asthma. None of the differences between the children with asthma and the sibling controls were statistically significant. Conclusions. Academic achievement among children with asthma, at least those whose status is closely monitored in a structured treatment program, generally appears to be unaffected by asthma or by its treatment with appropriate doses of theophylline.	MCFARLAND CLIN,AMES,IA; UNIV IOWA,COLL MED,DEPT PREVENT MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT ENVIRONM HLTH,IOWA CITY,IA 52242; UNIV MISSOURI,DEPT CHILD HLTH,COLUMBIA,MO 65201; UNIV MISSOURI,DEPT PEDIAT,COLUMBIA,MO 65201	University of Iowa; University of Iowa; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	LINDGREN, S (corresponding author), UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242, USA.		Weinberger, Miles/H-6743-2019					BENDER B, 1992, JAMA-J AM MED ASSOC, V267, P2621; BENDER B G, 1991, Annals of Allergy, V66, P65; CREER TL, 1989, J PEDIATR, V15, P850; Crowder M.J., 1990, ANAL REPEATED MEASUR; EKWO E, 1978, J ALLERGY CLIN IMMUN, V61, P240, DOI 10.1016/0091-6749(78)90198-7; ELKINS RN, 1981, AM J PSYCHIAT, V138, P178; FELDT LS, 1989, IOWA TESTS ED DEV; FURUKAWA CT, 1984, LANCET, V1, P621; FURUKAWA CT, 1988, J ALLERGY CLIN IMMUN, V81, P83, DOI 10.1016/0091-6749(88)90224-2; GELLIS SS, 1986, PEDIATRIC NOTES, V10, P207; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GUTSTADT LB, 1989, AM J DIS CHILD, V143, P471, DOI 10.1001/archpedi.1989.02150160101020; HARRIS JB, 1987, J PEDIATR-US, V110, P627, DOI 10.1016/S0022-3476(87)80567-X; HIERONYMUS AN, 1989, IOWA TESTS BASIC SKI; LINDGREN SD, 1985, CHILD DEV, V56, P1404, DOI 10.1111/j.1467-8624.1985.tb00206.x; MCNEMAR Q, 1969, PSYCHOL STATISTICS; MILAVETZ G, 1986, J PEDIATR-US, V109, P351, DOI 10.1016/S0022-3476(86)80403-6; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; RACHELEFSKY GS, 1986, PEDIATRICS, V78, P1133; RAPOPORT JL, 1984, ARCH GEN PSYCHIAT, V41, P1073; RAPPAPORT L, 1989, AM J DIS CHILD, V143, P368, DOI 10.1001/archpedi.1989.02150150126032; SCHLIEPER A, 1991, J PEDIATR-US, V118, P449, DOI 10.1016/S0022-3476(05)82167-5; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SPRINGER C, 1985, J ALLERGY CLIN IMMUN, V76, P64, DOI 10.1016/0091-6749(85)90806-1; SUESS WM, 1986, J ASTHMA, V23, P291, DOI 10.3109/02770908609073175; TWAROG FJ, 1987, PEDIATR ALERT, V12, P17; WEINBERGER M, 1987, J PEDIATR-US, V111, P471, DOI 10.1016/S0022-3476(87)80483-3; WEINBERGER M, 1990, MANAGING ASTHMA; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOLKOWITZ OM, 1990, AM J PSYCHIAT, V147, P1297; 1962, AM REV RESPIR DIS, V85, P762	32	60	60	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1992	327	13					926	930		10.1056/NEJM199209243271305	http://dx.doi.org/10.1056/NEJM199209243271305			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JP014	1513349				2022-12-28	WOS:A1992JP01400005
J	SMOLLER, J				SMOLLER, J			THE INTERNS VEIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1992	268	11					1379	1379						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JM849	1512896				2022-12-28	WOS:A1992JM84900001
J	SHEA, S; MISRA, D; EHRLICH, MH; FIELD, L; FRANCIS, CK				SHEA, S; MISRA, D; EHRLICH, MH; FIELD, L; FRANCIS, CK			PREDISPOSING FACTORS FOR SEVERE, UNCONTROLLED HYPERTENSION IN AN INNER-CITY MINORITY POPULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUBLIC HOSPITAL EMERGENCY; ORAL CLONIDINE; HEART-DISEASE; STROKE; CARE; CONSEQUENCES; EXPERIENCE; URGENCIES; COST	Background. Hypertensive emergency and urgent hypertension are the most severe forms of uncontrolled hypertension and are now seen predominantly in poor, minority populations. We studied the characteristics of the medical care received by patients with these conditions in order to identify risk factors for severe, uncontrolled hypertension. Methods. Using a case-control study design, we interviewed 93 patients with severe, uncontrolled hypertension who presented in the hospital emergency room and 114 control patients with hypertension; both groups were seen at two New York City hospitals from 1989 through 1991. All the patients were black or Hispanic. Multiple logistic-regression models were used to adjust for age, sex, race or ethnic background, education, smoking status, alcohol-related problems, and use of illicit drugs during the previous year. Results. After additional adjustment for lack of health insurance, severe, uncontrolled hypertension was found to be more common among patients who had no primary care physician (adjusted odds ratio, 3.5; 95 percent confidence interval, 1.6 to 7.7) and among those who did not comply with treatment for their hypertension (adjusted odds ratio, 1.9; 95 percent confidence interval, 1.4 to 2.5). Lack of health insurance was marginally associated with severe, uncontrolled hypertension (adjusted odds ratio, 1.9; 95 percent confidence interval, 0.8 to 4.6) after adjustment for lack of a primary care physician and noncompliance with antihypertensive treatment. Patients without a primary care physician and without health insurance were more likely to have their blood pressure checked and receive prescriptions for blood-pressure medications in emergency rooms than in physicians' offices or clinics. Conclusions. Characteristics of both the health care system and patients' behavior are associated with severe, uncontrolled hypertension. Improving access to primary care physicians, through health insurance or other means, may be an effective strategy for improving control of hypertension in disadvantaged minority populations.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, DIV GEN MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, NEW YORK, NY 10027 USA; HARLEM HOSP MED CTR, DEPT MED, NEW YORK, NY 10037 USA	Columbia University; Columbia University					NHLBI NIH HHS [R01-HL38260] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038260] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085; BENNETT NM, 1988, AM J PUBLIC HEALTH, V78, P636, DOI 10.2105/AJPH.78.6.636; BERKSON DM, 1980, AM J PUBLIC HEALTH, V70, P389, DOI 10.2105/AJPH.70.4.389; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; BRAND FN, 1977, PUBLIC HEALTH REP, V92, P72; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; EISEN SA, 1990, ARCH INTERN MED, V150, P1881, DOI 10.1001/archinte.150.9.1881; FERGUSON RK, 1986, JAMA-J AM MED ASSOC, V255, P1607, DOI 10.1001/jama.255.12.1607; FOLSOM AR, 1983, JAMA-J AM MED ASSOC, V250, P916, DOI 10.1001/jama.250.7.916; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GRANT BF, 1991, ALCOHOL HLTH RES WOR, V0015; HAYNES RB, 1980, NIH812102 PUBL; HOUSTON MC, 1986, ARCH INTERN MED, V146, P586, DOI 10.1001/archinte.146.3.586; JAKER M, 1989, ARCH INTERN MED, V149, P260, DOI 10.1001/archinte.149.2.260; KAPLAN NM, 1990, CLIN HYPERTENSION, P268; KEELER EB, 1985, JAMA-J AM MED ASSOC, V254, P1926; KELSEY JL, 1986, MONOGRAPHS EPIDEMIOL, V10, P109; KITTNER SJ, 1990, JAMA-J AM MED ASSOC, V264, P1267, DOI 10.1001/jama.264.10.1267; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; NORUSIS MJ, 1990, SPSS PCPLUS V40 IBM; OSTFELD AM, 1990, EPIDEMIOL REV, V12, P253, DOI 10.1093/oxfordjournals.epirev.a036059; Roccella E J, 1988, Health Psychol, V7 Suppl, P297, DOI 10.1037/0278-6133.7.Suppl.297; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SHEA S, 1991, AM J EPIDEMIOL, V134, P567, DOI 10.1093/oxfordjournals.aje.a116130; SHULMAN NB, 1986, AM J PUBLIC HEALTH, V76, P1105, DOI 10.2105/AJPH.76.9.1105; STERN RS, 1991, JAMA-J AM MED ASSOC, V266, P2238, DOI 10.1001/jama.266.16.2238; THOM TJ, 1988, TRENDS CORONARY HEAR, P11; WILLIAMS GH, 1987, HARRISONS PRINCIPLES, V1, P1028; ZELLER KR, 1989, ARCH INTERN MED, V149, P2186, DOI 10.1001/archinte.149.10.2186; 1991, DHHS PHS9150213 DEP, P112; 1990, MMWR MORB MORTAL WKL, V39, P704; 1986, VITAL HLTH STATIS 11, V234; 1991, SAS SYSTEM REGRESSIO; 1987, MMWR MORB MORTAL WKL, V36, P144; 1984, ANN INTERN MED, V101, P393; 1980, DHHS PHS801260 DEP H	39	285	288	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					776	781		10.1056/NEJM199209103271107	http://dx.doi.org/10.1056/NEJM199209103271107			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501654				2022-12-28	WOS:A1992JL66100007
J	SULLIVAN, LW				SULLIVAN, LW			THE BUSH ADMINISTRATIONS HEALTH-CARE PLAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											SULLIVAN, LW (corresponding author), US DEPT HHS,WASHINGTON,DC 20201, USA.							ZEDLEWSKI SR, 1992, HLTH BENEFITS WORKFO; 1990, HLTH PEOPLE 2000 NAT; 1992, B CLINTONS AM HLTH C; 1992, ECONOMIST       0718	4	18	18	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					801	804		10.1056/NEJM199209103271111	http://dx.doi.org/10.1056/NEJM199209103271111			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JL661	1501656				2022-12-28	WOS:A1992JL66100011
J	BUCCI, C; PARTON, RG; MATHER, IH; STUNNENBERG, H; SIMONS, K; HOFLACK, B; ZERIAL, M				BUCCI, C; PARTON, RG; MATHER, IH; STUNNENBERG, H; SIMONS, K; HOFLACK, B; ZERIAL, M			THE SMALL GTPASE RAB5 FUNCTIONS AS A REGULATORY FACTOR IN THE EARLY ENDOCYTIC PATHWAY	CELL			English	Article							CELL-FREE SYSTEM; RECEPTOR-MEDIATED ENDOCYTOSIS; RECOMBINANT VACCINIA VIRUS; BINDING YPT1 PROTEIN; COATED VESICLES; ENDOPLASMIC-RETICULUM; TRANSFERRIN RECEPTORS; VESICULAR TRANSPORT; GOLGI TRANSPORT; FUSION INVITRO	We have investigated the in vivo functional role of rab5, a small GTPase associated with the plasma membrane and early endosomes. Wild-type rab5 or rab5ile133, a mutant protein defective in GTP binding, was overexpressed in baby hamster kidney cells. In cells expressing the rab5ile133 protein, the rate of endocytosis was decreased by 50% compared with normal, while the rate of recycling was not significantly affected. The morphology of early endosomes was also drastically changed by the mutant protein, which induced accumulation of small tubules and vesicles at the periphery of the cell. Surprisingly, overexpression of wild-type rab5 accelerated the uptake of endocytic markers and led to the appearance of atypically large early endosomes. We conclude that rab5 is a rate-limiting component of the machinery regulating the kinetics of membrane traffic in the early endocytic pathway.	UNIV MARYLAND,DEPT ANIM SCI,COLL PK,MD 20742	University System of Maryland; University of Maryland College Park	BUCCI, C (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Bucci, Cecilia/F-6699-2012; Parton, Robert G/C-5673-2009; Stunnenberg, Hendrik G./D-6875-2012; HOFLACK, Bernard/AAZ-6668-2020	Bucci, Cecilia/0000-0002-6232-6183; Parton, Robert G/0000-0002-7494-5248; Stunnenberg, Hendrik G./0000-0002-0066-1576; Simons, Kai/0000-0002-9231-9996				BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; CROWTHER RA, 1976, J MOL BIOL, V103, P785, DOI 10.1016/0022-2836(76)90209-6; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DAVEY J, 1985, CELL, V43, P643, DOI 10.1016/0092-8674(85)90236-3; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; MACKETT M, 1985, DNA CLONING PRACTICA, P191; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; RODRIGUEZ JF, 1985, J VIROL, V56, P482, DOI 10.1128/JVI.56.2.482-488.1985; SAHAGIAN GG, 1985, J BIOL CHEM, V260, P9838; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VOS JC, 1988, EMBO J, V7, P3487, DOI 10.1002/j.1460-2075.1988.tb03224.x; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x	70	1152	1177	1	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 4	1992	70	5					715	728		10.1016/0092-8674(92)90306-W	http://dx.doi.org/10.1016/0092-8674(92)90306-W			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516130	hybrid			2022-12-28	WOS:A1992JL66300004
J	CUMMINGS, M				CUMMINGS, M			CHALLENGE TO OSTEOPATHIC EDUCATION - RETURNING TO ITS PRIMARY CARE ROOTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-SCHOOL				CUMMINGS, M (corresponding author), CHICAGO COLL OSTEOPATH MED,OFF ASSOCIATE DEAN ACADEM AFFAIRS,555 31ST ST,DOWNERS GROVE,IL 60515, USA.							LIEU TA, 1989, ACAD MED, V64, P622, DOI 10.1097/00001888-198910000-00015; MOBRAY RM, 1989, AUST NZ J MED, V19, P389; RABINOWITZ HK, 1988, NEW ENGL J MED, V319, P480, DOI 10.1056/NEJM198808253190805; REZLER AG, 1989, J FAM PRACTICE, V29, P652	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1139	1140						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK681	1501339				2022-12-28	WOS:A1992JK68100014
J	ERICKSON, MA; ROBINSON, P; LISMAN, J				ERICKSON, MA; ROBINSON, P; LISMAN, J			DEACTIVATION OF VISUAL TRANSDUCTION WITHOUT GUANOSINE TRIPHOSPHATE HYDROLYSIS BY G-PROTEIN	SCIENCE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; GTP-BINDING PROTEIN; ROD OUTER SEGMENTS; LIGHT-ACTIVATED PHOSPHODIESTERASE; FROG PHOTORECEPTOR-MEMBRANES; RETINAL RODS; CGMP PHOSPHODIESTERASE; MECHANISM; SUBUNIT; GDP	G proteins couple receptors to their target enzymes in many signal transduction cascades. It has generally been thought that deactivation of such cascades cannot occur without the hydrolysis of guanosine triphosphate (GTP) by G protein. This requirement has now been reexamined in both vertebrate and invertebrate phototransduction. Results indicate that GTP hydrolysis is not required for deactivation. Evidence is presented for an alternative model in which the target enzyme is deactivated by an inhibitory factor that is available even when GTP hydrolysis is blocked.	BRANDEIS UNIV,DEPT BIOCHEM,BIOPHYS PROGRAM,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Brandeis University; Brandeis University					NATIONAL EYE INSTITUTE [R01EY001496, R37EY001496] Funding Source: NIH RePORTER; NEI NIH HHS [EY 01496] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADOLPH AR, 1964, J GEN PHYSIOL, V48, P297, DOI 10.1085/jgp.48.2.297; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BARKDOLL AE, 1989, J GEN PHYSIOL, V93, P1091, DOI 10.1085/jgp.93.6.1091; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BIERNBAUM MS, 1985, J GEN PHYSIOL, V85, P83, DOI 10.1085/jgp.85.1.83; BOLSOVER SR, 1982, J PHYSIOL-LONDON, V332, P325, DOI 10.1113/jphysiol.1982.sp014416; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CLACK JW, 1983, NATURE, V305, P50, DOI 10.1038/305050a0; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FATHI M, 1991, J CHROMATOGR-BIOMED, V563, P356, DOI 10.1016/0378-4347(91)80042-B; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HOFFMANN KP, 1983, BIOCHIM BIOPHYS ACTA, V725, P60; HURLEY JB, 1982, J BIOL CHEM, V257, P8188; HURLEY JM, UNPUB; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1981, J GEN PHYSIOL, V77, P571, DOI 10.1085/jgp.77.5.571; KIRKWOOD A, 1989, P NATL ACAD SCI USA, V86, P3872, DOI 10.1073/pnas.86.10.3872; KONDO H, 1988, P NATL ACAD SCI USA, V85, P1322, DOI 10.1073/pnas.85.4.1322; KROLL S, 1989, J BIOL CHEM, V264, P4490; LAMB TD, 1988, J PHYSIOL-LONDON, V407, P463, DOI 10.1113/jphysiol.1988.sp017426; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; LISMAN J, 1985, J GEN PHYSIOL, V85, P171, DOI 10.1085/jgp.85.2.171; MIKI N, 1975, J BIOL CHEM, V250, P6320; ROBINSON PH, UNPUB; ROBINSON PR, 1980, J GEN PHYSIOL, V76, P631, DOI 10.1085/jgp.76.5.631; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P651, DOI 10.1021/bi00351a021; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P1205; STRYER L, 1981, TRENDS BIOCHEM SCI, V6, P245, DOI 10.1016/0968-0004(81)90089-X; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WHEELER GL, 1977, P NATL ACAD SCI USA, V74, P4238, DOI 10.1073/pnas.74.10.4238; YAMANAKA G, 1986, BIOCHEMISTRY-US, V25, P6149, DOI 10.1021/bi00368a048; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YEE R, 1978, J BIOL CHEM, V253, P8902	37	37	37	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 28	1992	257	5074					1255	1258		10.1126/science.1519062	http://dx.doi.org/10.1126/science.1519062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL050	1519062				2022-12-28	WOS:A1992JL05000026
J	WYNN, K				WYNN, K			ADDITION AND SUBTRACTION BY HUMAN INFANTS	NATURE			English	Article							PERCEPTION; NUMEROSITY; OBJECT	HUMAN infants can discriminate between different small numbers of items1-4, and can determine numerical equivalence across perceptual modalities5,6. This may indicate the possession of true numerical concepts1,4-7. Alternatively, purely perceptual discriminations may underlie these abilities8,9. This debate addresses the nature of subitization, the ability to quantify small numbers of items without conscious counting10,11. Subitization may involve the holistic recognition of canonical perceptual patterns that do not reveal ordinal relationships between the numbers12, or may instead be an iterative or 'counting' process that specifies these numerical relationships4,13. Here I show that 5-month-old infants can calculate the results of simple arithmetical operations on small numbers of items. This indicates that infants possess true numerical concepts, and suggests that humans are innately endowed with arithmetical abilities. It also suggests that subitization is a process that encodes ordinal information, not a pattern-recognition process yielding non-numerical percepts.			WYNN, K (corresponding author), UNIV ARIZONA, DEPT PSYCHOL, TUCSON, AZ 85721 USA.		Wynn, Karen/C-8067-2013	Wynn, Karen/0000-0001-8908-6258				ANTELL SE, 1983, CHILD DEV, V54, P695, DOI 10.2307/1130057; BAILLARGEON R, 1991, COGNITION, V38, P13, DOI 10.1016/0010-0277(91)90021-U; BAILLARGEON R, 1991, CHILD DEV, V62, P1227, DOI 10.2307/1130803; CHI MTH, 1975, J EXP CHILD PSYCHOL, V19, P434, DOI 10.1016/0022-0965(75)90072-7; COPPER RG, 1984, ORIGINS COGNITIVE SK, P157; GALLISTEL CR, 1990, ORG LEARNING, P343; MANDLER G, 1982, J EXP PSYCHOL GEN, V111, P1, DOI 10.1037/0096-3445.111.1.1; SILVERMAN IW, 1980, DEV PSYCHOL, V16, P539, DOI 10.1037/0012-1649.16.5.539; SPELKE ES, 1990, COGNITIVE SCI, V14, P29, DOI 10.1207/s15516709cog1401_3; SPELKE ES, 1988, MINNESOTA S CHILD PS, V20, P197; STARKEY P, 1985, SCIENCE, V228, P1222, DOI 10.1126/science.228.4704.1222-a; STARKEY P, 1990, COGNITION, V36, P97, DOI 10.1016/0010-0277(90)90001-Z; STARKEY P, 1983, SCIENCE, V222, P179, DOI 10.1126/science.6623069; STARKEY P, 1980, SCIENCE, V210, P1033, DOI 10.1126/science.7434014; STRAUSS MS, 1981, CHILD DEV, V52, P1146, DOI 10.2307/1129500; VANLOOSBROEK E, 1990, DEV PSYCHOL, V26, P916, DOI 10.1037/0012-1649.26.6.911.b; WYNN K, 1992, COGNITIVE PSYCHOL, V24, P220, DOI 10.1016/0010-0285(92)90008-P; WYNN K, IN PRESS MIND LANG	18	864	889	2	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 27	1992	358	6389					749	750		10.1038/358749a0	http://dx.doi.org/10.1038/358749a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1508269				2022-12-28	WOS:A1992JK69900050
J	GOODENOUGH, UW				GOODENOUGH, UW			GREEN YEAST	CELL			English	Review							CHLAMYDOMONAS-REINHARDTII; TRANSFORMATION				GOODENOUGH, UW (corresponding author), WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130, USA.							BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HUANG B, 1982, CELL, V28, P115, DOI 10.1016/0092-8674(82)90381-6; KAMIYA R, 1984, J CELL BIOL, V98, P97, DOI 10.1083/jcb.98.1.97; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; KREIMER G, 1990, EUR J CELL BIOL, V53, P101; LEFEBVRE PA, 1986, ANNU REV CELL BIOL, V2, P517, DOI 10.1146/annurev.cb.02.110186.002505; LEVINE RP, 1968, SCIENCE, V162, P768, DOI 10.1126/science.162.3855.768; LEWIN RA, 1954, J GEN MICROBIOL, V11, P358, DOI 10.1099/00221287-11-3-358; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; LUCK DJL, 1984, J CELL BIOL, V98, P789, DOI 10.1083/jcb.98.3.789; PASQUALE SM, 1987, J CELL BIOL, V105, P2279, DOI 10.1083/jcb.105.5.2279; SAGER R, 1954, P NATL ACAD SCI USA, V40, P345; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3	14	61	63	2	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					533	538		10.1016/0092-8674(92)90424-B	http://dx.doi.org/10.1016/0092-8674(92)90424-B			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505022				2022-12-28	WOS:A1992JJ88600004
J	MEZARD, C; POMPON, D; NICOLAS, A				MEZARD, C; POMPON, D; NICOLAS, A			RECOMBINATION BETWEEN SIMILAR BUT NOT IDENTICAL DNA-SEQUENCES DURING YEAST TRANSFORMATION OCCURS WITHIN SHORT STRETCHES OF IDENTITY	CELL			English	Article							DOUBLE-STRAND BREAKS; HUMAN ARGININOSUCCINATE LYASE; AMINO-ACID-SEQUENCES; MISMATCH REPAIR GENE; MOUSE L-CELLS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; STREPTOCOCCUS-PNEUMONIAE; HOMOLOGOUS RECOMBINATION	Interactions between similar but not identical (homeologous) DNA sequences play an important biological role in the evolution of genes and genomes. To gain insight into the underlying molecular mechanism(s) of genetic recombination, we have studied inter- and intramolecular homeologous recombination in S. cerevisiae during transformation. We found that homeologous DNAs recombine efficiently. Hybrid sequences were obtained between two mammalian cytochrome P450 cDNAs, sharing 73% identity, and between the yeast ARG4 gene and its human homeologous cDNA, sharing 52% identity. Sequencing data showed that the preferred recombination events are those corresponding to the overall alignment of the DNA sequences and that the junctions are within stretches of identity of variable length (2-21 nt). We suggest that these events occur by a conventional homologous recombination mechanism.	UNIV PIERRE & MARIE CURIE,PROPRE ASSOCIE LAB,CNRS,CTR GENET MOLEC,F-91190 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	MEZARD, C (corresponding author), UNIV PARIS 11,INST GENET & MICROBIOL,F-91405 ORSAY,FRANCE.							AHN BY, 1988, MOL CELL BIOL, V8, P2442, DOI 10.1128/MCB.8.6.2442; AUASUBEL FM, 1987, CURRENT PROTOCOLS MO; BAILIS AM, 1990, GENETICS, V126, P535; BAUER GA, 1988, J BIOL CHEM, V263, P917; BEACHAM IR, 1984, GENE, V29, P271, DOI 10.1016/0378-1119(84)90056-8; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BURGERS PMJ, 1988, J BIOL CHEM, V263, P8099; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CHEVALLIER MR, 1979, FEBS LETT, V108, P179, DOI 10.1016/0014-5793(79)81204-1; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; DOUTRIAUX MP, 1986, P NATL ACAD SCI USA, V83, P2576, DOI 10.1073/pnas.83.8.2576; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; ERNST JF, 1981, P NATL ACAD SCI-BIOL, V78, P6334, DOI 10.1073/pnas.78.10.6334; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; GLICKMAN BW, 1980, P NATL ACAD SCI-BIOL, V77, P1063, DOI 10.1073/pnas.77.2.1063; GOGUEL V, 1992, MOL CELL BIOL, V12, P696, DOI 10.1128/MCB.12.2.696; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HSIAO CL, 1979, P NATL ACAD SCI USA, V76, P3829, DOI 10.1073/pnas.76.8.3829; IOANNIDES C, 1990, DRUG METAB REV, V22, P1, DOI 10.3109/03602539008991444; JACOBSEN H, 1974, EUR J BIOCHEM, V45, P623, DOI 10.1111/j.1432-1033.1974.tb03588.x; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; KARIMOVA GA, 1985, MOL GENET MIKROBIOL, V10, P29; KIMURA S, 1984, J BIOL CHEM, V259, P705; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; KUCHERLAPATI R, 1988, GENETIC RECOMBINATIO; KUNES S, 1984, COLD SPRING HARB SYM, V49, P617, DOI 10.1101/SQB.1984.049.01.070; LAU PP, 1979, NUCLEIC ACIDS RES, V6, P331, DOI 10.1093/nar/6.1.331; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; LISKAY RM, 1987, GENETICS, V115, P161; MANKOVICH JA, 1989, J BACTERIOL, V171, P5325, DOI 10.1128/jb.171.10.5325-5331.1989; MARYON E, 1991, MOL CELL BIOL, V11, P3278, DOI 10.1128/MCB.11.6.3278; MATUO S, 1988, FEBS LETT, V234, P395, DOI 10.1016/0014-5793(88)80124-8; MAUTNER V, 1984, VIROLOGY, V139, P43, DOI 10.1016/0042-6822(84)90328-3; Miller J.H., 1972, EXPT MOL GENETICS; MUNZ P, 1981, A BENZON S, V16, P264; NICKOLOFF JA, 1989, J MOL BIOL, V207, P527, DOI 10.1016/0022-2836(89)90462-2; OBRIEN WE, 1986, P NATL ACAD SCI USA, V83, P7211, DOI 10.1073/pnas.83.19.7211; ORRWEAVER TL, 1985, MICROBIOL REV, V49, P33, DOI 10.1128/MMBR.49.1.33-58.1985; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; OZENBERGER BA, 1991, MOL CELL BIOL, V11, P1222, DOI 10.1128/MCB.11.3.1222; POMPON D, 1989, GENE, V83, P15, DOI 10.1016/0378-1119(89)90399-5; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; PRUDHOMME M, 1989, J BACTERIOL, V171, P5332, DOI 10.1128/jb.171.10.5332-5338.1989; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RAYSSIGUIER C, 1990, BIOCHIMIE, V73, P371; RESNICK MA, 1989, P NATL ACAD SCI USA, V86, P2276, DOI 10.1073/pnas.86.7.2276; RUBNITZ J, 1984, MOL CELL BIOL, V5, P529; RUDIN N, 1989, GENETICS, V122, P519; RUDOLPH H, 1985, GENE, V36, P87, DOI 10.1016/0378-1119(85)90072-1; Sambrook J, 1989, MOL CLONING LABORATO; SCHIESTL RH, 1991, P NATL ACAD SCI USA, V88, P7585, DOI 10.1073/pnas.88.17.7585; SHEN P, 1986, GENETICS, V112, P441; SHEN P, 1989, MOL GEN GENET, V218, P358, DOI 10.1007/BF00331291; Sherman F., 1986, METHODS YEAST GENETI; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALDMAN AS, 1987, P NATL ACAD SCI USA, V84, P5340, DOI 10.1073/pnas.84.15.5340; WALDMAN AS, 1988, MOL CELL BIOL, V8, P5350, DOI 10.1128/MCB.8.12.5350; WATT VM, 1985, P NATL ACAD SCI USA, V82, P4766; WHEELER CJ, 1990, NATURE, V347, P192, DOI 10.1038/347192a0; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	72	110	124	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					659	670		10.1016/0092-8674(92)90434-E	http://dx.doi.org/10.1016/0092-8674(92)90434-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505030				2022-12-28	WOS:A1992JJ88600014
J	YUSTE, R; PEINADO, A; KATZ, LC				YUSTE, R; PEINADO, A; KATZ, LC			NEURONAL DOMAINS IN DEVELOPING NEOCORTEX	SCIENCE			English	Article							CEREBRAL-CORTEX; VISUAL-CORTEX; STRIATE CORTEX; CALCIUM; CELLS; CAT; ORGANIZATION; ASTROCYTES; SYNAPSES; SYSTEM	The mammalian neocortex consists of a mosaic of columnar units whose development is poorly understood. Optical recordings of brain slices labeled with the fluorescent calcium indicator fura-2 revealed that the neonatal rat cortex was partitioned into distinct domains of spontaneously coactive neurons. In tangential slices, these domains were 50 to 120 micrometers in diameter; in coronal slices they spanned several cortical layers and resembled columns found in the adult cortex. In developing somatosensory cortex, domains were smaller than, and distinct from, the barrels, which represent sensory input from a single vibrissa. The neurons within each domain were coupled by gap junctions. Thus, nonsynaptic communication during cortical development defines discrete multicellular patterns that could presage adult functional architecture.			YUSTE, R (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,BOX 3209,DURHAM,NC 27710, USA.				NATIONAL EYE INSTITUTE [R01EY007960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH015177] Funding Source: NIH RePORTER; NEI NIH HHS [EY07960] Funding Source: Medline; NIMH NIH HHS [MH15177] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARMSTRONGJAMES M, 1975, J PHYSIOL-LONDON, V246, P501, DOI 10.1113/jphysiol.1975.sp010902; ARMSTRONGJAMES M, 1970, Z ZELLFORSCH MIK ANA, V110, P559, DOI 10.1007/BF00330104; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CONNORS BW, 1983, J NEUROSCI, V3, P773; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CRAGG BG, 1975, J COMP NEUROL, V160, P147, DOI 10.1002/cne.901600202; DELANEY KR, 1989, J NEUROSCI, V9, P3558; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; GUTNICK MJ, 1981, SCIENCE, V211, P67, DOI 10.1126/science.7444449; Hebb DO, 1949, ORG BEHAVIOR, P62; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; JENSEN AM, 1990, J NEUROSCI, V10, P1165; KATZ LC, 1989, J NEUROSCI, V9, P1389; KATZ LC, 1987, J NEUROSCI, V7, P1223; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; KAUR C, 1989, ACTA ANAT, V136, P204; LEVRAM V, 1987, BIOPHYS J, V52, P571, DOI 10.1016/S0006-3495(87)83246-0; Lorente de No R., 1949, PHYSL NERVOUS SYSTEM, P274; LOTURCO JJ, 1991, SCIENCE, V252, P563, DOI 10.1126/science.1850552; LOWEL S, 1992, SCIENCE, V255, P209, DOI 10.1126/science.1372754; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MISSON JP, 1991, GLIA, V4, P138, DOI 10.1002/glia.440040205; Mountcastle V.B., 1978, MINDFUL BRAIN CORTIC, P7; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; VANEY DI, 1991, NEUROSCI LETT, V125, P187, DOI 10.1016/0304-3940(91)90024-N; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; YUESTE R, 1991, NEURON, V6, P333	35	365	370	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 31	1992	257	5070					666	669		10.1126/science.1496379	http://dx.doi.org/10.1126/science.1496379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF852	1496379				2022-12-28	WOS:A1992JF85200035
J	KEE, F; WILSON, RH; GILLILAND, R; SLOAN, JM; ROWLANDS, BJ; MOOREHEAD, RJ				KEE, F; WILSON, RH; GILLILAND, R; SLOAN, JM; ROWLANDS, BJ; MOOREHEAD, RJ			CHANGING SITE DISTRIBUTION OF COLORECTAL-CANCER	BRITISH MEDICAL JOURNAL			English	Article									NO HLTH & SOCIAL SERV BOARD,DEPT PUBL HLTH MED,BALLYMENA BT42 1QB,NORTH IRELAND; QUEENS UNIV BELFAST,DEPT SURG,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND; QUEENS UNIV BELFAST,DEPT SMALL ANIM MED & SURG,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	Queens University Belfast; Queens University Belfast								ARMITAGE P, 1987, STATISTICAL METHODS; BEART RW, 1983, DIS COLON RECTUM, V26, P393, DOI 10.1007/BF02553382; JASS JR, 1991, DIS COLON RECTUM, V34, P56, DOI 10.1007/BF02050208; KEE F, 1990, ULSTER MED J, V59, P155; MUIR C, 1987, CANCER INCIDENCE 5 C, V5	5	65	67	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					158	158		10.1136/bmj.305.6846.158	http://dx.doi.org/10.1136/bmj.305.6846.158			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515832	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JF06300024
J	STRANG, JR; PUGH, EJ				STRANG, JR; PUGH, EJ			MENINGOCOCCAL INFECTIONS - REDUCING THE CASE FATALITY RATE BY GIVING PENICILLIN BEFORE ADMISSION TO HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Objective-To determine whether parenteral penicillin given before admission to hospital reduces the case fatality rate in patients with meningococcal disease. Design-Retrospective analysis of 46 consecutive patients admitted to hospital with meningococcal disease from january 1986 to March 1991. Setting-District general hospital. Main outcome measure-Hospital case fatality rate. Results-None of the 13 patients given parenteral penicillin by the referring doctor before admission died, compared with eight deaths (24%) in 33 patients admitted without such treatment. Conclusion-Parenteral penicillin given before admission probably contributed to a reduction in the case fatality rate from meningococcal disease, and primary care physicians should be encouraged to give such treatment immediately on suspicion of the diagnosis before transferring the patient to hospital. Public health physicians are well placed to inform and alert general practitioners of the potential benefit of this action.	MEM HOSP DARLINGTON,PUBL HLTH MED,DARLINGTON DL3 6HX,ENGLAND									BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; CARTWRIGHT KAV, 1986, LANCET, V2, P558; GEDDE-DAHL T W, 1990, NIPH (National Institute of Public Health) Annals (Oslo), V13, P45; HAVENS PL, 1989, PEDIATR INFECT DIS J, V8, P8, DOI 10.1097/00006454-198901000-00003; HOPKIN D A B, 1978, Lancet, V2, P1193; Jones D M, 1991, CDR (Lond Engl Rev), V1, pR76; SURTEES SJ, 1991, BRIT MED J, V302, P1051, DOI 10.1136/bmj.302.6784.1051; WELSBY PD, 1990, BRIT MED J, V300, P1150, DOI 10.1136/bmj.300.6733.1150; 1980, INFECTIONS DISEASES; 1989, COMMUNICABLE DISEASE, V8, P3; 1960, IMMUNISATION INFECTI, P166; 1988, MENINGOCOCCAL INFECT	12	117	119	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					141	143		10.1136/bmj.305.6846.141	http://dx.doi.org/10.1136/bmj.305.6846.141			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515826	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1992JF06300018
J	CHRYSANTHOPOULOS, C; KOUNIS, N				CHRYSANTHOPOULOS, C; KOUNIS, N			RHABDOMYOLYSIS DUE TO COMBINED TREATMENT WITH LOVASTATIN AND CHOLESTYRAMINE	BRITISH MEDICAL JOURNAL			English	Letter							ACUTE-RENAL-FAILURE; RECEIVING LOVASTATIN; MYOPATHY; THERAPY		PATRAS TECHNOL EDUC INST,GR-26221 PATRAS,GREECE	Western Greece University of Applied Sciences (TEI of Western Greece)	CHRYSANTHOPOULOS, C (corresponding author), PATRAS MED SCH,PATRAS,GREECE.							CORPIER CL, 1988, JAMA-J AM MED ASSOC, V260, P239, DOI 10.1001/jama.260.2.239; EAST C, 1988, NEW ENGL J MED, V318, P47; KOGAN AD, 1990, POSTGRAD MED J, V66, P294, DOI 10.1136/pgmj.66.774.294; MAHER VMG, 1989, LANCET, V2, P1098; MARAIS GE, 1990, ANN INTERN MED, V112, P228, DOI 10.7326/0003-4819-112-3-228; NORMAN DJ, 1988, NEW ENGL J MED, V318, P46; PIERCE LR, 1990, JAMA-J AM MED ASSOC, V264, P71, DOI 10.1001/jama.264.1.71; WALRAVENS PA, 1989, LANCET, V2, P1097	8	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1225	1225		10.1136/bmj.304.6836.1225	http://dx.doi.org/10.1136/bmj.304.6836.1225			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515796	Green Published, Bronze			2022-12-28	WOS:A1992HT96400025
J	HAWKINS, RE; LLEWELYN, MB; RUSSELL, SJ				HAWKINS, RE; LLEWELYN, MB; RUSSELL, SJ			MONOCLONAL-ANTIBODIES IN MEDICINE .2. ADAPTING ANTIBODIES FOR CLINICAL USE	BRITISH MEDICAL JOURNAL			English	Article							EXPRESSION; LIBRARIES; PHAGE	Techniques for antibody engineering are now overcoming the problems that have prevented monoclonal antibodies being used routinely in clinical practice. With chemical and genetic manipulation antibodies can be linked to bacterial toxins, enzymes, radionuclides, or cytotoxic drugs, atlowing targeting of treatment. Antigen binding sites from antibodies raised in mice can be joined with human IgG to reduce immunogenicity. In vitro gene amplification and genetic engineering of bacteriophage have produced large antibody gene libraries and facilitated large scale production of human monoclonal antibodies with high specificity. The trickle of monoclonal antibodies into clinical practice may soon become a flood.	ADDENBROOKES HOSP,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	HAWKINS, RE (corresponding author), MRC,CAMBRIDGE CB2 2QH,ENGLAND.		Llewelyn, Martin/A-7194-2011	Llewelyn, Martin/0000-0002-6811-1124				BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; EMBLETON MJ, 1992, NUCLEIC ACIDS RES, V20, P3831, DOI 10.1093/nar/20.15.3831; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; HALE G, 1988, LANCET, V2, P1394; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HAWKINS RE, 1992, EUR J IMMUNOL, V22, P867, DOI 10.1002/eji.1830220336; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KOSTELNY SA, 1992, J IMMUNOL, V148, P1547; LLEWELYN MB, 1992, BMJ-BRIT MED J, V305, P1269, DOI 10.1136/bmj.305.6864.1269; MacCafferty J, 1990, NATURE, V348, P552; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; MEREDITH RF, 1992, J NUCL MED, V33, P23; MILSTEIN C, 1983, NATURE, V305, P537, DOI 10.1038/305537a0; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; NITTA T, 1990, LANCET, V335, P368, DOI 10.1016/0140-6736(90)90205-J; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; ROSENBERG SA, 1992, J CLIN ONCOL, V10, P180, DOI 10.1200/JCO.1992.10.2.180; RUSSELL S J, 1992, British Medical Journal, V304, P585; SCHLOM J, 1992, CANCER RES, V52, P1067; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	25	17	20	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1348	1352		10.1136/bmj.305.6865.1348	http://dx.doi.org/10.1136/bmj.305.6865.1348			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483085	Bronze, Green Submitted, Green Published			2022-12-28	WOS:A1992KA77300032
J	PAYKEL, ES; PRIEST, RG				PAYKEL, ES; PRIEST, RG			RECOGNITION AND MANAGEMENT OF DEPRESSION IN GENERAL-PRACTICE - CONSENSUS STATEMENT	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-ILLNESS; CONTROLLED TRIAL; PRIMARY CARE; EMOTIONAL DISORDERS; COGNITIVE THERAPY; FAMILY DOCTORS; AMITRIPTYLINE; PRACTITIONER; INTERVENTION; PSYCHOTHERAPY		ST MARYS HOSP,SCH MED,LONDON,ENGLAND	Imperial College London	PAYKEL, ES (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,CAMBRIDGE CB2 2QQ,ENGLAND.							ANDREWS G, 1991, CURRENT OPINION PSYC, V4, P379; [Anonymous], 1992, ICD 10 CLASSIFICATIO; BEBBINGTON P, 1981, PSYCHOL MED, V11, P561, DOI 10.1017/S0033291700052879; BLACKBURN IM, 1981, BRIT J PSYCHIAT, V139, P181, DOI 10.1192/bjp.139.3.181; BLACKBURN IM, 1990, COGNITIVE THERAPY DE; BLACKER CVR, 1988, PSYCHOPHARMACOLOGY, V95, pS14; BLACKER CVR, 1987, BRIT J PSYCHIAT, V150, P737, DOI 10.1192/bjp.150.6.737; BLASHKI TG, 1971, BMJ-BRIT MED J, V1, P133, DOI 10.1136/bmj.1.5741.133; BRIDGES K, 1987, PRESENTATION DEPRESS, P9; BRODATY H, 1983, BRIT J PSYCHIAT, V143, P11, DOI 10.1192/bjp.143.1.11; CATALAN J, 1991, PSYCHOL MED, V21, P1013, DOI 10.1017/S0033291700030002; CORNEY R, 1984, PSYCHOL MED S6, V14, P47; CORNEY RH, 1987, BRIT J PSYCHIAT, V151, P652, DOI 10.1192/bjp.151.5.652; CREED F, 1990, BRIT J GEN PRACT, V40, P450; EDWARDS JG, 1992, BRIT MED J, V304, P1644, DOI 10.1136/bmj.304.6843.1644; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; FREELING P, 1985, BMJ-BRIT MED J, V290, P1880, DOI 10.1136/bmj.290.6485.1880; FREELING P, 1992, HDB AFFECTIVE DISORD, P651; FRIEDMAN AS, 1975, ARCH GEN PSYCHIAT, V32, P619; GASK L, 1989, J PSYCHOSOM RES, V33, P697, DOI 10.1016/0022-3999(89)90085-8; GASK L, 1989, MED EDUC, V22, P132; Goldberg D., 1983, INT J REHABIL RES, V6, P127, DOI [10.1097/00004356-198303000-00021, DOI 10.1097/00004356-198303000-00021]; GOLDBERG DP, 1980, ACTA PSYCHIAT SCAND, V62, P41, DOI 10.1111/j.1600-0447.1980.tb07671.x; GOLDBERG DP, 1980, LANCET, V2, P521; Goldberg DP., 1992, COMMON MENTAL DISORD; HARRIS CM, 1987, PRESENTATION DEPRESS, P1; HAWTON K, 1989, COGNITIVE BEHAVIOUR; HOEPER EW, 1984, LANCET, V1, P33; HOLDEN JM, 1989, BRIT MED J, V298, P223, DOI 10.1136/bmj.298.6668.223; JABLENSKY A, 1987, PSYCHOL MED, V17, P1, DOI 10.1017/S0033291700012915; JOHNSON DAW, 1981, ACTA PSYCHIAT SCAND, V63, P447, DOI 10.1111/j.1600-0447.1981.tb00751.x; JOHNSTONE A, 1976, LANCET, V1, P605, DOI 10.1016/S0140-6736(76)90415-3; KAESER AC, 1971, PSYCHOL MED, V1, P312, DOI 10.1017/S0033291700042288; KESSEL N, 1963, LANCET, V1, P1092; MACDONALD AJD, 1986, BRIT MED J, V292, P1365, DOI 10.1136/bmj.292.6532.1365; MARKS JN, 1979, PSYCHOL MED, V9, P337, DOI 10.1017/S0033291700030853; MILLAR T, 1991, BRIT J GEN PRACT, V41, P357; Montgomery S A, 1989, J Psychopharmacol, V3, P47, DOI 10.1177/026988118900300201; ORMEL J, 1990, PUBLIC HEALTH IMPACT OF MENTAL DISORDER, P154; Parker I., 1995, HDB AFFECTIVE DISORD; PAYKEL ES, 1988, J AFFECT DISORDERS, V14, P83, DOI 10.1016/0165-0327(88)90075-4; PAYKEL ES, 1989, BRIT J PSYCHIAT, V155, P754, DOI 10.1192/bjp.155.6.754; PAYKEL ES, 1976, PHARMAKOPSYCH NEURO, V9, P127, DOI 10.1055/s-0028-1094487; PAYKEL ES, 1989, DEPRESSION INTEGRATI, P3; PRIEN RF, 1992, HDB AFFECTIVE DISORD, P419; PRUSOFF BA, 1980, ARCH GEN PSYCHIAT, V37, P796; RAND EH, 1988, GEN HOSP PSYCHIAT, V10, P189, DOI 10.1016/0163-8343(88)90018-7; Rodin G., 1991, DEPRESSION MED ILL I; RORSMAN B, 1990, BRIT J PSYCHIAT, V156, P336, DOI 10.1192/bjp.156.3.336; ROSS M, 1985, J ROY COLL GEN PRACT, V35, P239; SCOTT AIF, 1992, BRIT MED J, V304, P883, DOI 10.1136/bmj.304.6831.883; SHAPIRO S, 1987, MED CARE, V25, P327, DOI 10.1097/00005650-198704000-00006; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P113, DOI 10.1192/bjp.147.2.113; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P119, DOI 10.1192/bjp.147.2.119; TEASDALE JD, 1984, BRIT J PSYCHIAT, V144, P400, DOI 10.1192/bjp.144.4.400; THOMPSON C, 1989, Human Psychopharmacology, V4, P191, DOI 10.1002/hup.470040305; THOMSON J, 1982, PSYCHOL MED, V12, P741, DOI 10.1017/S0033291700049047; TYLEE A, 1989, DEPRESSION INTEGRATI, P216; WEISSMAN MM, 1988, PSYCHOL MED, V18, P141, DOI 10.1017/S0033291700001975; WHEWELL PJ, 1988, J ROY COLL GEN PRACT, V38, P259; WILLIAMS P, 1988, PSYCHOL MED, V18, P469, DOI 10.1017/S003329170000800X; WRIGHT AF, 1987, J ROY COLL GEN PRACT, V37, P164; ZUNG WWK, 1983, J CLIN PSYCHIAT, V44, P3; 1987, DIAGNOSTIC STATISTIC; 1992, BMJ, V304, P337	65	409	411	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1992	305	6863					1198	1202		10.1136/bmj.305.6863.1198	http://dx.doi.org/10.1136/bmj.305.6863.1198			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JY777	1467723	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JY77700023
J	CHAMPSI, JH; DERESINSKI, S				CHAMPSI, JH; DERESINSKI, S			CUTANEOUS TUBERCULOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AIDS COMMUNITY RES CONSORTIUM, REDWOOD CITY, CA USA; SANTA CLARA VALLEY MED CTR, DEPT MED, DIV INFECT DIS, SAN JOSE, CA 95128 USA	Santa Clara Valley Medical Center	CHAMPSI, JH (corresponding author), STANFORD UNIV, MED CTR, DEPT MED, DIV INFECT DIS, STANFORD, CA 94305 USA.							BEYT BE, 1981, MEDICINE, V60, P95, DOI 10.1097/00005792-198103000-00003; KAKAKHEL KU, 1989, INT J DERMATOL, V28, P355, DOI 10.1111/j.1365-4362.1989.tb02478.x; SEHGAL VN, 1990, INT J DERMATOL, V29, P237	3	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1992	268	10					1339	1339		10.1001/jama.268.10.1339	http://dx.doi.org/10.1001/jama.268.10.1339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL608	1507383				2022-12-28	WOS:A1992JL60800039
J	SKLAR, DP				SKLAR, DP			THE INTUBATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1072	1072						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK681	1501327				2022-12-28	WOS:A1992JK68100001
J	HAGLUND, MM; OJEMANN, GA; HOCHMAN, DW				HAGLUND, MM; OJEMANN, GA; HOCHMAN, DW			OPTICAL IMAGING OF EPILEPTIFORM AND FUNCTIONAL-ACTIVITY IN HUMAN CEREBRAL-CORTEX	NATURE			English	Article							SALAMANDER OLFACTORY-BULB; INTRINSIC-SIGNALS; NEURONAL-ACTIVITY; VISUAL-CORTEX; ORGANIZATION; ARCHITECTURE; BRAIN; STIMULATION; VOLUNTARY; MOVEMENTS	OPTICAL imaging of animal somatosensory, olfactory and visual cortices has revealed maps of functional activity1-12. In non-human primates, high-resolution maps of the visual cortex have been obtained using only an intrinsic reflection signal3,4,6,13,14. Although the time course of the signal is slower than membrane potential changes, the maximum optical changes correspond to the maximal neuronal activity3,6. The intrinsic optical signal may represent the flow of ionic currents, oxygen delivery, changes in blood volume, potassium accumulation or glial swelling3,4,6,8,15-18. Here we use similar techniques to obtain maps from human cortex during stimulation-evoked epileptiform afterdischarges and cognitively evoked functional activity. Optical changes increased in magnitude as the intensity and duration of the afterdischarges increased. In areas surrounding the afterdischarge activity, optical changes were in the opposite direction and possibly represent an inhibitory surround. Large optical changes were found in the sensory cortex during tongue movement and in Broca's and Wernicke's language areas during naming exercises. The adaptation of high-resolution optical imaging for use on human cortex provides a new technique for investigation of the organization of the sensory and motor cortices, language, and other cognitive processes.	UNIV WASHINGTON,DEPT NEUROL SURG,RI-20,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; COHEN LB, 1973, PHYSIOL REV, V53, P373; COHEN LB, 1972, J PHYSIOL-LONDON, V224, P727, DOI 10.1113/jphysiol.1972.sp009920; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; FRITH CD, 1991, J NEUROPSYCHOLOGIA, V29, P1137; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Gonzalez R. C., 1987, DIGITAL IMAGE PROCES; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; GRINVALD A, 1991, P NATL ACAD SCI USA, V88, P11559, DOI 10.1073/pnas.88.24.11559; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HAGLUND MM, 1991, MONITORING NEURONAL, P85; KAUER JS, 1988, NATURE, V331, P166, DOI 10.1038/331166a0; LEE BI, 1986, ANN NEUROL, V20, P32, DOI 10.1002/ana.410200107; LIEKE EE, 1989, ANNU REV PHYSIOL, V51, P543, DOI 10.1146/annurev.physiol.51.1.543; LIPTON P, 1973, J PHYSIOL-LONDON, V231, P365, DOI 10.1113/jphysiol.1973.sp010238; LONDON JA, 1989, J NEUROSCI, V9, P2182; MACVICAR BA, 1991, J NEUROSCI, V11, P1458; OJEMANN GA, 1983, BEHAV BRAIN SCI, V6, P189, DOI 10.1017/S0140525X00015491; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; ORBACH HS, 1983, J NEUROSCI, V3, P2251; ORBACH HS, 1985, J NEUROSCI, V5, P1886; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; Raichle M. E., 1987, HDB PHYSL NERVOUS SY, V1, P643; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; WOHLBERG G, 1988, DIGITAL IMAGING WARP; [No title captured]	29	254	277	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1992	358	6388					668	671		10.1038/358668a0	http://dx.doi.org/10.1038/358668a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JJ882	1495561				2022-12-28	WOS:A1992JJ88200053
J	KAPUR, S; MIECZKOWSKI, T; MANN, JJ				KAPUR, S; MIECZKOWSKI, T; MANN, JJ			ANTIDEPRESSANT MEDICATIONS AND THE RELATIVE RISK OF SUICIDE ATTEMPT AND SUICIDE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DATA-COLLECTION-SYSTEM; DOUBLE-BLIND; DISORDERS; AMITRIPTYLINE; FLUVOXAMINE; TOXICITY; OVERDOSE; DEPRESSION; FLUOXETINE; MIANSERIN	Objective.-Suicide by drug overdose is a major public health problem, and antidepressant medications are the most common agent involved. European studies suggest differences in the rates of suicide by overdose among antidepressants, but no reports have been published for the United States. We estimated the comparative risks of suicide attempts and suicides, and the relative risk of fatality in the event of an overdose for the major antidepressants currently marketed in the United States. Data Sources.-Information regarding suicide attempts and suicides by antidepressant overdose was obtained from the published reports of the Drug Abuse and Warning Network and the annual report of the American Association of Poison Control Centers, and corrected for differences in total annual prescriptions using data from the National Prescription Audit. Results.-The risk of a suicide attempt did not appear to differ among antidepressants. The tricyclic antidepressants were associated with a higher rate of death in the event of an overdose than the newer nontricyclic antidepressants in both the annual report of the American Association of Poison Control Centers and the Drug Abuse and Warning Network data. The chance of death after an overdose was greater for desipramine hydrochloride than for other tricyclics. Conclusion.-The higher risk of suicide with tricyclics vs nontricyclics may be explained by a higher rate of death from overdose rather than more suicide attempts. Tricyclics carry the risk of greater cardiotoxicity. The basis for the even higher rate of death/overdose of desipramine is not known and requires further research. If these findings are replicated in a case-control study design, they have important implications for the choice of an antidepressant for the depressed patient at risk for suicidal behavior.	UNIV PITTSBURGH,WESTERN PSYCHIAT INST & CLIN,SCH MED,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC	MANN, JJ (corresponding author), UNIV PITTSBURGH,WESTERN PSYCHIAT INST & CLIN,SCH MED,PITTSBURGH,PA 15213, USA.		anand, amit/A-7222-2009	Kapur, Shitij/0000-0002-2231-2924; Santibanez, Tammy A./0000-0002-5784-7427	NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH046745, P50MH046745] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-46745] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Asberg M., 1987, PSYCHOPHARMACOLOGY 3, P655; BALDESSARINI RJ, 1989, J CLIN PSYCHIAT, V50, P117; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; BEAUMONT G, 1989, BRIT J PSYCHIAT, V154, P454, DOI 10.1192/bjp.154.4.454; BRENT DA, 1988, AM PSYCHIATRIC REV P, V7, P353; BROADHEAD WE, 1991, J FAM PRACTICE, V33, P24; BULIK CM, 1990, J AFFECT DISORDERS, V18, P29, DOI 10.1016/0165-0327(90)90114-N; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; COCCARO EF, 1989, ARCH GEN PSYCHIAT, V46, P587; COLE JO, 1990, J CLIN PSYCHIAT, V51, P21; CROME P, 1979, J ROY SOC MED, V72, P649, DOI 10.1177/014107687907200905; DAMLUJI NF, 1988, J CLIN PSYCHOPHARM, V8, P347; DEWILDE J, 1991, ACTA PSYCHIAT SCAND, P89; GALLANT DM, 1987, PSYCHOPATHOLOGY, V20, P75, DOI 10.1159/000284526; GONELLA G, 1990, CURR MED RES OPIN, V12, P177, DOI 10.1185/03007999009111499; GUZE SB, 1970, BRIT J PSYCHIAT, V117, P437, DOI 10.1192/bjp.117.539.437; HALPER JP, 1988, BRIT J PSYCHIAT, V153, P87, DOI 10.1192/S0007125000297341; HANZLICK R, 1989, AM J FOREN MED PATH, V10, P326, DOI 10.1097/00000433-198912000-00009; INMAN WHW, 1988, LANCET, V2, P90; KING LA, 1985, HUM TOXICOL, V4, P273, DOI 10.1177/096032718500400307; KING RA, 1991, J AM ACAD CHILD PSY, V30, P179, DOI 10.1097/00004583-199103000-00003; LEONARD BE, 1986, LANCET, V2, P1105; LITOVITZ TL, 1991, AM J EMERG MED, V9, P461, DOI 10.1016/0735-6757(91)90216-7; LITOVITZ TL, 1990, AM J EMERG MED, V8, P394, DOI 10.1016/0735-6757(90)90234-Q; MANN JJ, 1991, ARCH GEN PSYCHIAT, V48, P1027; MANN JJ, 1989, PSYCHOPHARMACOL BULL, V25, P407; MANN JJ, 1989, BRIT J PSYCHIAT, V155, P7, DOI 10.1192/S000712500029171X; MONTGOMERY SA, 1981, ACTA PSYCHIAT SCAND, V63, P314, DOI 10.1111/j.1600-0447.1981.tb00735.x; MONTGOMERY SA, 1987, PSYCHOPHARMACOLOGY, V92, P265; MONTGOMERY SA, 1989, ACTA PSYCHIAT SCAND, V80, P47, DOI 10.1111/j.1600-0447.1989.tb03046.x; MULLIN JM, 1988, BRIT J CLIN PRACT, V42, P51; NATHAN RS, 1990, J CLIN PSYCHIAT, V51, P367; PEREZ A, 1990, CURR MED RES OPIN, V12, P234, DOI 10.1185/03007999009111652; POLLACK MH, 1987, J CLIN PSYCHIAT, V48, P3; ROTTERSTOL N, 1989, ACTA PSYCHIATR S354, V80, P61; ROULLION F, 1989, ENCEPHALE, V15, P527; SACCHETTI E, 1991, SEROTONIN RELATED PS, P47; SOLOFF PH, 1987, PSYCHOPHARMACOL BULL, V23, P177; SOLOFF PH, 1986, AM J PSYCHIAT, V143, P1603; TEICHER MH, 1990, AM J PSYCHIAT, V147, P207; VUORI E, 1989, ACTA PSYCHIAT SCAND, V80, P55, DOI 10.1111/j.1600-0447.1989.tb03047.x; WAKELIN JS, 1988, ADV BIOL PSYCHIAT, V17, P70; 1989, STAT ABSTR US 1989; 1990, NIDA STATISTICAL SER, V1	44	162	164	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3441	3445		10.1001/jama.268.24.3441	http://dx.doi.org/10.1001/jama.268.24.3441			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KC839	1460734				2022-12-28	WOS:A1992KC83900031
J	MICHAELS, D; LEVINE, C				MICHAELS, D; LEVINE, C			ESTIMATES OF THE NUMBER OF MOTHERLESS YOUTH ORPHANED BY AIDS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; WOMEN; MORTALITY; HISPANICS; EPIDEMIC; IMPACT	Objective.-To estimate the number of youth in the United States who have been or will be left motherless by the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic, in order to project the need for family supports, age-appropriate foster and congregate care, and mental health and social services. Design.-Orphans are defined as youth whose mothers (the usual caregiving parent) die of HIV/AIDS-related causes. A mathematical model was constructed to estimate the number of such motherless youth. Cumulative fertility rates were applied to the number of reported AIDS deaths (1981 through 1990) and projected deaths (1991 through 1995) of adult women less than 50 years old. The results were adjusted for underreporting of HIV/AIDS-related mortality, pediatric AIDS deaths, infant mortality, ethnic and racial variation in fertility, and decreased fertility associated with late-stage HIV disease. Estimates were made for the number who were children (less than 13 years of age), adolescents (1 3 to 17 years of age), or young adults (1 8 years of age or older) at the time of their mothers' death. Results.-By the end of 1995, maternal deaths caused by the HIV/AIDS epidemic will have orphaned an estimated 24 600 children and 21 000 adolescents in the United States; unless the course of the epidemic changes dramatically, by the year 2000, the overall number of motherless children and adolescents will exceed 80000. In 1991, an estimated 13% of US children and 9% of adolescents whose mothers died of all causes were children of women who died of HIV/AIDS-related diseases. These proportions will surpass 17% and 12%, respectively, by 1995. The vast majority of these motherless youth will come from poor communities of color. Conclusions.-A large and rapidly growing number of American youth are being orphaned by the HIV/AIDS epidemic. Unless increased attention and resources are devoted to this vulnerable population, a social catastrophe is unavoidable.	ORPHAN PROJECT,121 AVE AMER,6TH FL,NEW YORK,NY 10013; CUNY,SCH MED,SOPHIE DAVIS SCH BIOMED EDUC,DEPT COMMUNITY HLTH & SOCIAL MED,NEW YORK,NY 10021	City University of New York (CUNY) System; Sophie Davis School of Biomedical Education	LEVINE, C (corresponding author), ORPHAN PROJECT,121 AVE AMER,6TH FL,NEW YORK,NY 10013, USA.			Michaels, David/0000-0001-8558-7733				BENNETT JV, 1991, AM J DIS CHILD, V145, P1242, DOI 10.1001/archpedi.1991.02160110034016; BOYLAN L, 1991, EPIDEMIOL REV, V13, P143, DOI 10.1093/oxfordjournals.epirev.a036067; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BUEHLER JW, 1992, AM J PUBLIC HEALTH, V82, P1500, DOI 10.2105/AJPH.82.11.1500; CALDWELL MB, 1992, PEDIATRICS, V90, P482; CARPENTER CCJ, 1991, MEDICINE, V70, P307, DOI 10.1097/00005792-199109000-00003; Carr J N, 1975, Pediatr Ann, V4, P65, DOI 10.3928/0090-4481-19750701-11; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; DEREN S, 1986, 50 NEW YORK STATE DI; DRUCKER E, 1991, AIDS READER; ELLERBROCK TV, 1991, JAMA-J AM MED ASSOC, V265, P2971, DOI 10.1001/jama.265.22.2971; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; MENENDEZ BS, 1990, J ACQ IMMUN DEF SYND, V3, P644; PIVNICK A, 1991, MED ANTHROPOL Q, V5, P153, DOI 10.1525/maq.1991.5.2.02a00030; PREBLE EA, 1990, SOC SCI MED, V31, P671, DOI 10.1016/0277-9536(90)90249-R; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; RUMLEY RL, 1991, AIDS, V5, P1373, DOI 10.1097/00002030-199111000-00015; SELIK RM, 1989, AM J PUBLIC HEALTH, V79, P836, DOI 10.2105/AJPH.79.7.836; 1991, AIDS MICROFICHE DATA; 1992, AIDS SURVEILLANCE UP; 1991, 1991 M AIDS ORPH AFR, P5; 1989, SUMMARY VITAL STATIS; 1992, HIV AIDS SURVEILANCE, P1; 1991, MONTHLY VITAL STA S1, V40, P1; 1992, MMWR, V41, P28; 1991, LANCET, V337, P253; 1992, MMWR, V41, P121; 1992, MONTHLY VITAL STA S2, V40, P1; 1990, MMWR, V39, P1; 1991, VITAL STATISTICS US, V2	30	111	111	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3456	3461		10.1001/jama.268.24.3456	http://dx.doi.org/10.1001/jama.268.24.3456			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KC839	1460736				2022-12-28	WOS:A1992KC83900034
J	GROVES, T				GROVES, T			COUNTDOWN TO COMMUNITY CARE .2. WHAT THE CHANGES MEAN	BRITISH MEDICAL JOURNAL			English	Article													Groves, Trish/A-9119-2009	Groves, Trish/0000-0001-7915-6419				MURPHY E, 1991, ASYLUMS COMMUNITY CA; 1992, CARING PEOPLE NEWSLE, V11; 1989, CARING PEOPLE COMMUN; 1986, MAKIGN REALITY COMMU; 1990, PEOPLE 1ST COMMUNITY; 1992, PRIORITIES COMMUNITY; 1992, COMMUNITY CARE REVOL	7	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1489	1490		10.1136/bmj.305.6867.1489	http://dx.doi.org/10.1136/bmj.305.6867.1489			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493400	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KC91800032
J	MAYNARD, A; SHELDON, T				MAYNARD, A; SHELDON, T			REFORMING THE DEPARTMENT-OF-HEALTHS RESEARCH-AND-DEVELOPMENT POLICY - FROM THE DEVIL TO THE DEEP BLUE SEA	BRITISH MEDICAL JOURNAL			English	Article								Research into health and social services in Britain is largely funded by the Department of Health. Regional NHS research and development has recently been reformed and a new report now proposes replacement of the 13 research units funded by the department with three or four large multidisciplinary centres. Evidence to support such a step is lacking, and many criticisms of the existing units arise from poor departmental planning rather than deficiencies of the units themselves. Large units may make research less responsive to the department's needs, and it is essential that the proposed new structure is thoroughly evaluated before it is introduced.			MAYNARD, A (corresponding author), UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Sheldon, Trevor/AAK-7088-2021	Sheldon, Trevor/0000-0002-7479-5913				CLARKE M, 1992, BRIT MED J, V304, P1675, DOI 10.1136/bmj.304.6843.1675; DELAMOTHE T, 1992, BRIT MED J, V305, P1117; WILLIAMS PO, 1992, REV ROLE DOH FUNDED; 1991, RES HLTH RES DEV STR; 1988, PRIORITIES MED RES, V1	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1992	305	6863					1209	1210		10.1136/bmj.305.6863.1209	http://dx.doi.org/10.1136/bmj.305.6863.1209			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467725	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992JY77700026
J	JARMAN, B; BOSANQUET, N				JARMAN, B; BOSANQUET, N			PRIMARY HEALTH-CARE IN LONDON - CHANGES SINCE THE ACHESON REPORT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine changes in primary care in London in the 11 years since the Acheson report on primary health care in inner London. Design-Analysis of key data from the family health services authority performance indicators and from the Department of Health; study of trends since the time of the Acheson report; examination of the provision of primary care in 1990-1 and its relation to health and social factors. Setting-Comparisons between the family health services authorities of inner London, outer London, and England as a whole, with a special study of Birmingham, Liverpool, and Manchester. Subjects-The family health services authorities of England. Results-There has been an improvement in the provision of primary care in inner London as judged by the criteria of the Acheson report, but these improvements have occurred only as part of an overall improvement in the provision of primary care in the country as a whole. None of the recommendations of the Acheson report specifically oriented to London have been implemented. There are some worrying trends in inner London, such as the increasing proportion of practices with more than 2500 patients. The problems faced by practitioners in inner London resemble those in other large inner city areas, but the primary care provision to deal with them is relatively poor.			JARMAN, B (corresponding author), ST MARYS HOSP,SCH MED,LISSON GROVE HLTH CTR,DEPT GEN PRACTICE,LONDON NW8 8EG,ENGLAND.							BOSANQUET N, 1988, BRIT MED J, V296, P1576, DOI 10.1136/bmj.296.6636.1576; HUGHES J, 1992, 11 KINGS FUND LOND A; JARMAN BA, 1981, 16 ROYAL COLL GEN PR; 1986, MAKING REALITY COMMU; 1987, CMND249; 1982, LOCAL AUTHORITY VITA; 1992, LONDON HLTH CARE 201, P76; 1989, CMND555; 1981, PRIMARY HLTH CARE IN	9	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1130	1133		10.1136/bmj.305.6862.1130	http://dx.doi.org/10.1136/bmj.305.6862.1130			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463950	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JX84100024
J	MOON, M; HOLAHAN, J				MOON, M; HOLAHAN, J			CAN STATES TAKE THE LEAD IN HEALTH-CARE REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											MOON, M (corresponding author), URBAN INST,2100 M ST NW,WASHINGTON,DC 20037, USA.							BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V67, P1113; DEMKOVICH L, 1990, STATES UNINSURED SLO; GARAMENDI J, 1992, SACRAMENTO BEE, V271, pF1; GOLD SD, 1992, NATL TAX J, V44, P1; LEWIN JC, 1991, 2ND ANN HLTH CAR S L; WEINER JM, BROOKINGS REV, V10, P26; WOOD DW, 1991, HLTH CARE 90S LEARNI; 1989, UNIVERSAL NEW YORK H; 1992, 3 BUR NAT AFF INC ME, V3, P339; 1992, 3 BUR NAT AFF INC ME, V3, P209; 1991, COLORADO CARE STATEW	11	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1588	1594		10.1001/jama.268.12.1588	http://dx.doi.org/10.1001/jama.268.12.1588			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JN256	1518114				2022-12-28	WOS:A1992JN25600031
J	MCLEOD, GX; HAMMER, SM				MCLEOD, GX; HAMMER, SM			ZIDOVUDINE - 5 YEARS LATER	ANNALS OF INTERNAL MEDICINE			English	Review						ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; OPPORTUNISTIC INFECTIONS; DRUG RESISTANCE, MICROBIAL; ZALCITABINE	HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; COLONY-STIMULATING FACTOR; HEPATITIS-B VIRUS; RECOMBINANT-HUMAN-ERYTHROPOIETIN; HIV-1 REVERSE-TRANSCRIPTASE; BONE-MARROW TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; LOW-DOSE ZIDOVUDINE	Zidovudine, a nucleoside analog, was the first agent proved to be effective in the management of human immunodeficiency virus type 1 (HIV-1) infection. After demonstration of zidovudine's in-vitro activity against HIV-1 in 1985, the drug was rapidly evaluated in phase I and phase II clinical trials and was found to be effective in decreasing both mortality and the incidence of opportunistic infections in patients with the acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex; the drug was also found to have a substantial but tolerable toxicity profile. Since the licensure of zidovudine in 1987, an intensive clinical research effort has established the drug's efficacy in the prevention of disease progression in asymptomatic and mildly symptomatic HIV-infected persons and has established the success of lower-dose therapy in patients at all stages of disease. The current recommendation is to use zidovudine at a dose of 500 to 600 mg/d in both symptomatic and asymptomatic persons with CD4 counts of less than 500/mm3. The major toxicities of anemia and neutropenia are less frequent at the lower doses presently used and can be managed by dose reduction or by use of hematopoietic growth factors. The inexorable disease progression seen despite zidovudine therapy and the isolation of clinical strains of HIV-1 resistant to zidovudine in vitro highlight the limitations of prolonged monotherapy with this agent. Although alternative dideoxynucleoside agents (for example, didanosine [dideoxyinosine and zalcitabine dideoxycytidine]) are available for the management of HIV-infected persons, zidovudine remains the cornerstone of antiretroviral therapy. Current research efforts are directed at elucidating the clinical relevance of zidovudine resistance and studying regimens in which zidovudine is used in combination with other agents. This latter approach holds great promise for improving efficacy, limiting toxicity, and perhaps preventing the emergence of viral resistance. For the forseeable future, zidovudine will continue to play a role in the development and in our understanding of antiretroviral therapy.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	MCLEOD, GX (corresponding author), NEW ENGLAND DEACONESS HOSP, DIV INFECT DIS, 185 PILGRIM RD, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027659] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43510] Funding Source: Medline; NIAID NIH HHS [AI27659] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AOKISEI S, 1991, J INFECT DIS, V164, P843, DOI 10.1093/infdis/164.5.843; ARNETT FC, 1991, RHEUM DIS CLIN N AM, V17, P59; AYERS KM, 1988, AM J MED, V85, P186; BALIS FM, 1989, ANN INTERN MED, V110, P279, DOI 10.7326/0003-4819-110-4-279; BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P897, DOI 10.1016/0006-2952(88)90178-5; BENDICK C, 1989, ARCH DERMATOL, V125, P1285, DOI 10.1001/archderm.125.9.1285; BERGLUND O, 1991, J INFECT DIS, V163, P710, DOI 10.1093/infdis/163.4.710; BESSEN LJ, 1988, NEW ENGL J MED, V318, P708; BLANCHE S, 1988, AM J MED, V85, P203; BLUM MR, 1988, AM J MED, V85, P189; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; BOYAR A, 1991, AIDS, V5, P1351, DOI 10.1097/00002030-199111000-00011; BROUWERS P, 1990, J PEDIATR-US, V117, P980, DOI 10.1016/S0022-3476(05)80150-7; BROWN N, 1990, 30TH INT C ANT AG CH, P169; CHAISSON RE, 1988, ARCH INTERN MED, V148, P2151, DOI 10.1001/archinte.148.10.2151; CHAISSON RE, 1986, NEW ENGL J MED, V315, P1610, DOI 10.1056/NEJM198612183152511; CHALMERS AC, 1991, NEUROLOGY, V41, P1181, DOI 10.1212/WNL.41.8.1181; CHILD S, 1991, J ACQ IMMUN DEF SYND, V4, P865; CLOAD PA, 1989, J INFECTION, V18, P15, DOI 10.1016/S0163-4453(89)80076-3; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; CONNOLLY KJ, 1991, AM J MED, V91, P471, DOI 10.1016/0002-9343(91)90182-W; CONWAY B, 1990, REV INFECT DIS, V12, P479; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COOPER DA, 1991, AIDS, V5, P933, DOI 10.1097/00002030-199108000-00003; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; DAAR ES, 1991, AM J MED, V90, pS22, DOI 10.1016/0002-9343(91)90407-O; DAHLBERG JE, 1987, P NATL ACAD SCI USA, V84, P2469, DOI 10.1073/pnas.84.8.2469; DALAKAS MC, 1988, ANN NEUROL, V23, pS92, DOI 10.1002/ana.410230724; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DECLERCQ E, 1980, BIOCHEM PHARMACOL, V29, P1849, DOI 10.1016/0006-2952(80)90149-5; DEMIRANDA P, 1989, CLIN PHARMACOL THER, V46, P494, DOI 10.1038/clpt.1989.176; DERAY G, 1988, NEW ENGL J MED, V319, P1606, DOI 10.1056/NEJM198812153192412; DEWOLF F, 1988, LANCET, V1, P373; DON PC, 1990, ANN INTERN MED, V112, P145, DOI 10.7326/0003-4819-112-2-145; DORNSIFE RE, 1991, ANTIMICROB AGENTS CH, V35, P322, DOI 10.1128/AAC.35.2.322; DOURNON E, 1988, LANCET, V2, P1297; DRUSANO GL, 1991, 31ST INT C ANT AG CH, P226; DUBIN G, 1989, ANN INTERN MED, V110, P85, DOI 10.7326/0003-4819-110-1-85; DURAND E, 1991, NEW ENGL J MED, V324, P1062; DUVIC M, 1987, LANCET, V2, P627; EASTERBROOK PJ, 1991, JAMA-J AM MED ASSOC, V266, P2713, DOI 10.1001/jama.266.19.2713; Ebert S, 1991, Wis Med J, V90, P161; EDLIN BR, 1992, J INFECT DIS, V165, P793, DOI 10.1093/infdis/165.5.793; EDWARDS P, 1990, ANN INTERN MED, V112, P65, DOI 10.7326/0003-4819-112-1-65; ELWELL LP, 1987, ANTIMICROB AGENTS CH, V31, P274, DOI 10.1128/AAC.31.2.274; ERON JJ, 1992, ANTIMICROB AGENTS CH, V36, P1559, DOI 10.1128/AAC.36.7.1559; FAUCI AS, 1992, ANN INTERN MED, V116, P85, DOI 10.7326/0003-4819-116-1-85; FAZELY F, 1991, J ACQ IMMUN DEF SYND, V4, P1093; FIALA M, 1988, REV INFECT DIS, V10, P250; FISCHL M, 1990, NEW ENGL J MED, V322, P1488, DOI 10.1056/NEJM199005243222103; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; FURMAN PA, 1988, AM J MED, V85, P176; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; FURTH PA, 1987, ANN INTERN MED, V107, P350, DOI 10.7326/0003-4819-107-2-350; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; GAZZARD BG, 1992, BRIT MED J, V304, P456, DOI 10.1136/bmj.304.6825.456; GERTNER E, 1989, AM J MED, V86, P814, DOI 10.1016/0002-9343(89)90478-6; GORARD DA, 1988, LANCET, V1, P1050; GOTTLIEB MS, 1987, AIDS RES HUM RETROV, V3, P109, DOI 10.1089/aid.1987.3.109; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GREENBERG RG, 1990, J AM ACAD DERMATOL, V22, P327, DOI 10.1016/0190-9622(90)70039-K; GROARK SP, 1989, AM ACAD DERMATOL, V5, P1032; GROOPMAN JE, 1987, NEW ENGL J MED, V317, P593, DOI 10.1056/NEJM198709033171003; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HAO Z, 1988, MOL PHARMACOL, V34, P431; HARITANI H, 1989, J MED VIROL, V29, P244, DOI 10.1002/jmv.1890290405; HARTSHORN KL, 1987, ANTIMICROB AGENTS CH, V31, P168, DOI 10.1128/AAC.31.2.168; HEAGY W, 1991, J CLIN INVEST, V87, P1916, DOI 10.1172/JCI115217; HELBERT M, 1988, LANCET, V2, P689; HENDERSON DK, 1989, J INFECT DIS, V160, P321, DOI 10.1093/infdis/160.2.321; HENRY DH, 1990, ANN NY ACAD SCI, V616, P526; HERSKOWITZ A, 1992, ANN INTERN MED, V116, P311, DOI 10.7326/0003-4819-116-4-311; HIRSCHEL B, 1988, ANN INTERN MED, V109, P718, DOI 10.7326/0003-4819-109-9-718; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO HT, 1989, ANTIMICROB AGENTS CH, V33, P844, DOI 10.1128/AAC.33.6.844; HOCHSTER H, 1990, ANN INTERN MED, V113, P111, DOI 10.7326/0003-4819-113-2-111; HOFFKEN G, 1991, 7 INT C AIDS FLOR, P218; HOLLAND HK, 1989, ANN INTERN MED, V111, P973, DOI 10.7326/0003-4819-111-12-973; HOLLANDER H, 1989, AM J MED, V87, P628, DOI 10.1016/S0002-9343(89)80394-8; HORWITZ JP, 1964, J ORG CHEM, V29, P2076, DOI 10.1021/jo01030a546; HYMES KB, 1988, NEW ENGL J MED, V318, P516, DOI 10.1056/NEJM198802253180812; ISRAEL RJ, 1991, BLOOD, V77, P2085; JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401; JACKSON GG, 1988, ANN INTERN MED, V108, P175, DOI 10.7326/0003-4819-108-2-175; JACOBSON MA, 1991, J INFECT DIS, V163, P1219, DOI 10.1093/infdis/163.6.1219; JAPOUR AJ, 1991, P NATL ACAD SCI USA, V88, P3092, DOI 10.1073/pnas.88.8.3092; JEFFRIES DJ, 1991, BRIT MED J, V302, P1349, DOI 10.1136/bmj.302.6789.1349; JOHNSON VA, 1990, J INFECT DIS, V161, P1059, DOI 10.1093/infdis/161.6.1059; JOHNSON VA, 1991, J INFECT DIS, V164, P646, DOI 10.1093/infdis/164.4.646; JONES P, 1989, J INFECTION, V18, P53, DOI 10.1016/S0163-4453(89)80080-5; KAPLAN LD, 1991, J CLIN ONCOL, V9, P929, DOI 10.1200/JCO.1991.9.6.929; KAPLAN MH, 1989, J AM ACAD DERMATOL, V20, P76, DOI 10.1016/S0190-9622(89)70011-6; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49; KORNHAUSER DM, 1989, LANCET, V2, P473; KOUP RA, 1991, J INFECT DIS, V163, P966, DOI 10.1093/infdis/163.5.966; KOVACS JA, 1989, ANN INTERN MED, V111, P280, DOI 10.7326/0003-4819-111-4-280; KROWN SE, 1990, ANN INTERN MED, V112, P812, DOI 10.7326/0003-4819-112-11-812; KUSTER H, 1991, J INFECT DIS, V164, P773, DOI 10.1093/infdis/164.4.773; LAGAKOS S, 1991, JAMA-J AM MED ASSOC, V266, P2709, DOI 10.1001/jama.266.19.2709; LALONDE RG, 1991, ANN INTERN MED, V114, P297, DOI 10.7326/0003-4819-114-4-297; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LAND S, 1990, J INFECT DIS, V161, P326, DOI 10.1093/infdis/161.2.326; LANE HC, 1990, ANN INTERN MED, V113, P512, DOI 10.7326/0003-4819-113-7-512; LANE HC, 1989, ANN INTERN MED, V111, P41, DOI 10.7326/0003-4819-111-1-41; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; LANGTRY HD, 1989, DRUGS, V37, P408, DOI 10.2165/00003495-198937040-00003; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LASKIN OL, 1989, J INFECT DIS, V159, P745, DOI 10.1093/infdis/159.4.745; LIN JC, 1989, J INFECT DIS, V159, P248, DOI 10.1093/infdis/159.2.248; LIN JC, 1988, ANTIMICROB AGENTS CH, V32, P265, DOI 10.1128/AAC.32.2.265; LOOKE DFM, 1990, LANCET, V335, P1280, DOI 10.1016/0140-6736(90)91343-9; LUTTON JD, 1990, AM J HEMATOL, V35, P1, DOI 10.1002/ajh.2830350102; MAXWELL S, 1988, JAMA-J AM MED ASSOC, V259, P3406, DOI 10.1001/jama.259.23.3406; MAYERS D, 1991, 7 INT C AIDS, P211; MCCLOSKEY SE, 1988, CLIN RES, V36, pA21; MCKINNEY RE, 1991, PEDIATR CLIN N AM, V38, P133; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; MCLEOD GX, 1992, ANTIMICROB AGENTS CH, V36, P920, DOI 10.1128/AAC.36.5.920; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; MERIGAN TC, 1991, AM J MED, V90, pS8, DOI 10.1016/0002-9343(91)90405-M; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MHIRI C, 1991, ANN NEUROL, V29, P606, DOI 10.1002/ana.410290607; MILDVAN D, 1991, 7 INT C AIDS FLOR, P64; MITSUYA H, 1987, NATURE, V325, P773, DOI 10.1038/325773a0; MITSUYA H, 1988, AIDS RES HUM RETROV, V4, P107, DOI 10.1089/aid.1988.4.107; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOORE RD, 1991, JAMA-J AM MED ASSOC, V265, P2208, DOI 10.1001/jama.265.17.2208; MOORE RD, 1991, ARCH INTERN MED, V151, P981, DOI 10.1001/archinte.151.5.981; MORSE GD, 1989, ANTIVIR RES, V11, P57, DOI 10.1016/0166-3542(89)90008-9; MORSE GD, 1990, ANTIMICROB AGENTS CH, V34, P394, DOI 10.1128/AAC.34.3.394; NUNBERG JH, 1991, 7 INT C AIDS FLOR, P95; ODOWD MA, 1988, JAMA-J AM MED ASSOC, V260, P3587, DOI 10.1001/jama.1988.03410240045015; OGINO MT, 1991, 31ST INT C ANT AG CH, P203; ORHOLM M, 1989, AIDS, V3, P97, DOI 10.1097/00002030-198902000-00008; OSTERTAG W, 1974, P NATL ACAD SCI USA, V71, P4980, DOI 10.1073/pnas.71.12.4980; PANEGYRES PK, 1988, LANCET, V1, P1050; PAOLI I, 1992, NEW ENGL J MED, V326, P839, DOI 10.1056/NEJM199203193261216; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; PIZZO PA, 1990, J PEDIATR-US, V117, P799, DOI 10.1016/S0022-3476(05)83348-7; PIZZO PA, 1990, AM J MED, V88, pS16, DOI 10.1016/0002-9343(90)90416-B; PLUDA JM, 1990, BLOOD, V76, P463; PLUDA JM, 1991, HEMATOL ONCOL CLIN N, V5, P229, DOI 10.1016/S0889-8588(18)30438-6; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; PONS JC, 1991, EUR J OBSTET GYN R B, V40, P229, DOI 10.1016/0028-2243(91)90122-2; POTTAGE JC, 1988, JAMA-J AM MED ASSOC, V260, P3045, DOI 10.1001/jama.260.20.3045; RARICK MU, 1991, AIDS, V5, P1357, DOI 10.1097/00002030-199111000-00012; REISS P, 1988, LANCET, V1, P420; RICHMAN DD, 1991, J INFECT DIS, V164, P1075, DOI 10.1093/infdis/164.6.1075; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; RICHMAN DD, 1988, AM J MED, V85, P208; ROOKE R, 1989, AIDS, V3, P411, DOI 10.1097/00002030-198907000-00001; ROOKE R, 1991, ANTIMICROB AGENTS CH, V35, P988, DOI 10.1128/AAC.35.5.988; ROZENCWEIG M, 1990, REV INFECT DIS, V12, pS570; RUEDY J, 1990, ANN INTERN MED, V112, P721, DOI 10.7326/0003-4819-112-10-721; RUPRECHT RM, 1986, NATURE, V323, P467, DOI 10.1038/323467a0; SAHAI J, 1991, AIDS, V5, P1395, DOI 10.1097/00002030-199111000-00025; SATTLER FR, 1991, ANN INTERN MED, V114, P937, DOI 10.7326/0003-4819-114-11-937; SCHINAZI RF, 1990, 30TH INT C ANT AG CH, V962, P246; SCHMITT FA, 1988, NEW ENGL J MED, V319, P1573, DOI 10.1056/NEJM198812153192404; SHIH CC, 1991, J INFECT DIS, V163, P625, DOI 10.1093/infdis/163.3.625; SIM SM, 1991, BRIT J CLIN PHARMACO, V32, P17, DOI 10.1111/j.1365-2125.1991.tb05607.x; SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1; SINGER J, 1991, 7 INT C AIDS FLOR; SINGLAS E, 1989, CLIN PHARMACOL THER, V46, P190, DOI 10.1038/clpt.1989.125; SINGLAS E, 1989, EUR J CLIN PHARMACOL, V36, P639, DOI 10.1007/BF00637752; SOMMADOSSI JP, 1987, ANTIMICROB AGENTS CH, V31, P452, DOI 10.1128/AAC.31.3.452; SOMMADOSSI JP, 1989, MOL PHARMACOL, V36, P9; SPECTOR SA, 1989, ANTIMICROB AGENTS CH, V33, P920, DOI 10.1128/AAC.33.6.920; SPECTOR SA, 1989, J INFECT DIS, V159, P822, DOI 10.1093/infdis/159.5.822; SPERLING RS, 1992, NEW ENGL J MED, V326, P857, DOI 10.1056/NEJM199203263261303; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; SURBONE A, 1988, ANN INTERN MED, V108, P534, DOI 10.7326/0003-4819-108-4-534; TABURET AM, 1990, CLIN PHARMACOL THER, V47, P731, DOI 10.1038/clpt.1990.101; TAN CK, 1991, BIOCHEMISTRY-US, V30, P4831, DOI 10.1021/bi00234a001; TAVARES L, 1987, CANCER RES, V47, P3190; TILL M, 1990, ANN INTERN MED, V113, P492, DOI 10.7326/0003-4819-113-7-492; TINDALL B, 1991, AIDS, V5, P477, DOI 10.1097/00002030-199105000-00001; TIOLLAIS P, 1991, SCI AM, V264, P116, DOI 10.1038/scientificamerican0491-116; TOSTI A, 1990, DERMATOLOGICA, V180, P217, DOI 10.1159/000248033; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X; VANDERWOUW PA, 1991, BRIT J HAEMATOL, V78, P319, DOI 10.1111/j.1365-2141.1991.tb04443.x; VOGT MW, 1987, SCIENCE, V235, P1376, DOI 10.1126/science.2435003; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WAQAR MA, 1984, J CELL PHYSIOL, V121, P402, DOI 10.1002/jcp.1041210218; WETTERAU LM, 1991, 31ST INT C ANT AG CH, P318; YARCHOAN R, 1991, BLOOD, V78, P859; YARCHOAN R, 1990, ANN NY ACAD SCI, V616, P328; YARCHOAN R, 1988, ANN NEUROL, V23, pS82, DOI 10.1002/ana.410230722; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1988, LANCET, V1, P76; YARCHOAN R, 1987, LANCET, V1, P132, DOI 10.1016/S0140-6736(87)91968-4; ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748; 1990, AM J MED, V89, P335; 1991, MMWR, V40, P591; 1990, AM J MED, V88, pS1; 1990, MMWR, V39, P1; 1991, MMWR, V40, P597	211	125	127	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					487	501		10.7326/0003-4819-117-6-487	http://dx.doi.org/10.7326/0003-4819-117-6-487			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503352				2022-12-28	WOS:A1992JN25700009
J	DERVAN, PB				DERVAN, PB			REAGENTS FOR THE SITE-SPECIFIC CLEAVAGE OF MEGABASE DNA	NATURE			English	Article							TRIPLE-HELIX FORMATION; RECOGNITION; MOTIF				DERVAN, PB (corresponding author), CALTECH, DEPT CHEM & CHEM ENGN, PASADENA, CA 91125 USA.							BEAL PA, 1992, J AM CHEM SOC, V114, P4976, DOI 10.1021/ja00039a004; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; Home D. A., 1990, J AM CHEM SOC, V112, P2435; KOH JS, 1992, J AM CHEM SOC, V114, P1470, DOI 10.1021/ja00030a050; KOOB M, 1988, SCIENCE, V241, P1084, DOI 10.1126/science.2842862; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; POVSIC TJ, 1992, J AM CHEM SOC, V114, P5934, DOI 10.1021/ja00041a005; RADHAKRISHNAN I, 1991, BIOCHEMISTRY-US, V30, P9022, DOI 10.1021/bi00101a016; RADHAKRISHNAN I, 1991, J MOL BIOL, V221, P1403, DOI 10.1016/0022-2836(91)90941-X; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; SINGLETON SF, IN PRESS J AM CHEM S; STOBEL SA, 1991, SCIENCE, V254, P1639; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0	20	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1992	359	6390					87	88		10.1038/359087a0	http://dx.doi.org/10.1038/359087a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JL662	1522894				2022-12-28	WOS:A1992JL66200063
J	JOLIN, LD; JOLLY, P; KRAKOWER, JY; BERAN, R				JOLIN, LD; JOLLY, P; KRAKOWER, JY; BERAN, R			UNITED-STATES MEDICAL-SCHOOL FINANCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									ASSOC AMER MED COLL,DIV MED STUDENT & RESIDENT EDUC,WASHINGTON,DC	Association of American Medical Colleges	JOLIN, LD (corresponding author), ASSOC AMER MED COLL,OPERAT STUDIES SECT,2450 N ST NW,WASHINGTON,DC 20037, USA.							1991, PUBLICATION NSB, V911	1	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1992	268	9					1149	&		10.1001/jama.268.9.1149	http://dx.doi.org/10.1001/jama.268.9.1149			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK681	1501343				2022-12-28	WOS:A1992JK68100018
J	JOHNSON, NA; PEREZ, DE; CABOT, EL; HOLLOCHER, H; WU, CI				JOHNSON, NA; PEREZ, DE; CABOT, EL; HOLLOCHER, H; WU, CI			A TEST OF RECIPROCAL X-Y INTERACTIONS AS A CAUSE OF HYBRID STERILITY IN DROSOPHILA	NATURE			English	Article							HALDANE RULE; CHROMOSOME; PSEUDOOBSCURA; MELANOGASTER; PERSIMILIS	ELUCIDATION of the nature of the gene interactions that underly the sterility of interspecific hybrids is important in evolutionary biology1,2. The interactions between the heterospecific X and Y (or Z and W) chromosomes are often used as an explanation for two reasons. First, the fertility of the hybrids of the heterogametic sex is much more often affected than that of the homogametic sex (Haldane's rule3) and X-Y interactions are specific to the heterogametic sex. Second, sex chromosomes, especially the X chromosome, are often considered to be of special importance in determining the fertility of hybrids1,2,4. X-Y interactions have been addressed in studies of males with a heterospecific Y chromosome in a mixed genetic background5-8. A more stringent test of the X-Y interaction model requires each X chromosome sterility factor to be tested separately for its interaction with the Y chromosome in a homogeneous background of the pure species. Here we report such a test of the X-Y interaction model and conclude that X-Y interactions should not be assumed to be the only or even the most common cause of hybrid sterility.	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	University of Chicago; University of Rochester								CLARK AG, 1987, GENETICS, V115, P143; COYNE JA, 1985, NATURE, V314, P736, DOI 10.1038/314736a0; COYNE JA, 1989, HEREDITY, V62, P97, DOI 10.1038/hdy.1989.13; COYNE JA, 1989, SPECIATION ITS CONSE, P181; Dobzhansky T, 1936, GENETICS, V21, P113; Haldane JBS, 1922, J GENET, V12, P101, DOI 10.1007/BF02983075; HENNIG W, 1977, ADV ENZYME REGUL, V15, P363, DOI 10.1016/0065-2571(77)90025-5; Huxley J, 1940, NEW SYSTEMATICS, P185; JOHNSON NA, 1992, GENETICS, V130, P507; JONES JS, 1985, NATURE, V314, P668, DOI 10.1038/314668a0; LIVAK KJ, 1984, GENETICS, V107, P611; OKA HI, 1974, GENETICS, V77, P521; ORR HA, 1987, GENETICS, V116, P555; PANTAZIDIS AC, 1988, HEREDITY, V60, P299, DOI 10.1038/hdy.1988.46; WU CI, 1983, GENETICS, V105, P71; WU CI, IN PRESS MOL PALEOPO	16	47	47	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1992	358	6389					751	753		10.1038/358751a0	http://dx.doi.org/10.1038/358751a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JK699	1508270				2022-12-28	WOS:A1992JK69900051
J	STURMBAUER, C; MEYER, A				STURMBAUER, C; MEYER, A			GENETIC-DIVERGENCE, SPECIATION AND MORPHOLOGICAL STASIS IN A LINEAGE OF AFRICAN CICHLID FISHES	NATURE			English	Article							MITOCHONDRIAL-DNA SEQUENCES; LAKE TANGANYIKA; EVOLUTION	SINCE their discovery at the turn of the century1, the species assemblages of cichlid fishes in the East African Lakes Victoria, Malawi and Tanganyika have fascinated evolutionary biologists. Many models have attempted to account for the 'explosive' evolution of several hundred species within these lakes2-7. Here we report a case of surprisingly large genetic divergence among populations of the endemic Tropheus lineage of Lake Tanganyika. This lineage of six species contains twice as much genetic variation as the entire morphologically highly diverse cichlid assemblage of Lake Malawi and six times more variation than the Lake Victoria species flock. Although it is highly variable in coloration, this group of species and its closest relatives have not undergone appreciable morphological change. The observed geographic pattern of genetic variation suggests that major lake level fluctuations affected the distribution and speciation of this lineage of cichlid fishes.			STURMBAUER, C (corresponding author), SUNY STONY BROOK,DEPT ECOL & EVOLUT,STONY BROOK,NY 11794, USA.		Meyer, Axel/C-9826-2009	Meyer, Axel/0000-0002-0888-8193				AVISE JC, 1990, NATURE, V347, P512, DOI 10.1038/347512a0; BOULENGER CL, 1898, T ZOOL SOC LONDON, V15, P1; BRICHARD P, 1989, CICHLIDS LAKE TANGAN; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; CHARLESWORTH B, 1982, EVOLUTION, V36, P474, DOI 10.1111/j.1558-5646.1982.tb05068.x; CHARLESWORTH B, 1982, NATURE, V296, P610, DOI 10.1038/296610a0; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; DOMINEY WJ, 1984, EVOLUTION FISH SPECI, P231; Fryer G, 1972, CICHLID FISHES GREAT; GASSE F, 1989, NATURE, V342, P57, DOI 10.1038/342057a0; GREENWOOD PH, 1984, EVOLUTION FISH SPECI; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; Kornfield I., 1991, P103; KOSSWIG C, 1947, NATURE, V159, P604, DOI 10.1038/159604b0; Larson A., 1989, P579; Marlier G., 1959, Revue de Zoologie et de Botanique Africaines, V59, P164; Mayr E, 1984, EVOLUTION FISH SPECI, P3; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; NELISSEN M, 1976, Revue de Zoologie Africaine, V90, P17; NISHIDA M, 1991, EXPERIENTIA, V47, P974, DOI 10.1007/BF01929896; OWEN RB, 1990, PROC R SOC SER B-BIO, V240, P519, DOI 10.1098/rspb.1990.0052; POLL M, 1986, Academie Royale de Belgique Memoires de la Classe des Sciences Collection in Octavo, V45, P1; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHOLZ CA, 1990, AAPG MEMOIR, V50, P151; SELANDER RK, 1970, EVOLUTION, V24, P402, DOI 10.1111/j.1558-5646.1970.tb01771.x; STURMBAUER C, 1990, THESIS U INNSBRUCK A; Tiercelin J.J., 1991, LAKE TANGANYIKA ITS, P7; Turner J., 1986, PATTERNS PROCESSES H, P183; WESTEBERHARD MJ, 1983, Q REV BIOL, V58, P155, DOI 10.1086/413215; [No title captured]	30	261	266	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					578	581		10.1038/358578a0	http://dx.doi.org/10.1038/358578a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1501712	Green Submitted			2022-12-28	WOS:A1992JH82900058
J	DENT, MT; GANAPATHY, S; HOLDSWORTH, CD; CHANNER, KC				DENT, MT; GANAPATHY, S; HOLDSWORTH, CD; CHANNER, KC			MESALAZINE INDUCED LUPUS-LIKE SYNDROME	BRITISH MEDICAL JOURNAL			English	Letter							ULCERATIVE-COLITIS; PATIENT				DENT, MT (corresponding author), ROYAL HALLAMSHIRE HOSP,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							DEBOEVER G, 1989, AM J GASTROENTEROL, V84, P85; GRIFFITHS ID, 1977, BMJ-BRIT MED J, V2, P1188, DOI 10.1136/bmj.2.6096.1188; JENSS H, 1990, AM J GASTROENTEROL, V85, P332	3	48	49	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					159	159		10.1136/bmj.305.6846.159-b	http://dx.doi.org/10.1136/bmj.305.6846.159-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515833	Bronze, Green Published, Green Submitted			2022-12-28	WOS:A1992JF06300027
J	CLARK, L; DOYLE, P; DURAN, E; KISHORE, P				CLARK, L; DOYLE, P; DURAN, E; KISHORE, P			EFFECTIVE AUDIT - REPORTING TO THE NATIONAL-CONFIDENTIAL-INQUIRY-INTO-PERIOPERATIVE-DEATHS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To investigate the effectiveness of computer based and manual district and unit information systems for identifying hospital deaths eligible for reporting to the National Confidential Enquiry into Perioperative Deaths (NCEPOD). Design - Prospective six to 10 week study of hospital (death register, immediate coding of medical records) and district information systems followed by six month assessment after modification to entry of data. Setting - Acute units within Lewisham and North Southwark Health District. Patients - All 290 patients dying in hospital during the six weeks, for whom the medical records were obtainable in 231. Main outcome measures - Sensitivity and specificity of the information systems in ascertaining eligible surgical deaths (patients dying in hospital who had during 30 days previously had a surgical procedure while under the care of a consultant in a surgical specialty) tested against validated list of screened medical records. Results - Of 231 medical records, 30 (12 from Lewisham, 18 from North Southwark) met the national inquiry's criteria. The computer based systems of both units detected less than 60% of eligible deaths (sensitivity 53%, specificity 83%); the death register detected about 60% (sensitivity 61%, specificity 89%); manual systems detected all eligible deaths. Subsequent modification to ensure immediate coding of records into the computerised systems during follow up failed to show any improvement. Implications - Routine hospital information systems may miss up to half the deaths eligible for NCEPOD.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine								Buck N, 1987, REPORT CONFIDENTIAL; 1988, PROTOCOL NATIONAL CO	2	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1472	1474		10.1136/bmj.304.6840.1472	http://dx.doi.org/10.1136/bmj.304.6840.1472			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1489397	Green Published, Bronze			2022-12-28	WOS:A1992HY55300021
J	HALSEY, NA; COBERLY, JS; HOLT, E; COREIL, J; KISSINGER, P; MOULTON, LH; BRUTUS, JR; BOULOS, R				HALSEY, NA; COBERLY, JS; HOLT, E; COREIL, J; KISSINGER, P; MOULTON, LH; BRUTUS, JR; BOULOS, R			SEXUAL-BEHAVIOR, SMOKING, AND HIV-1 INFECTION IN HAITIAN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SIMPLEX VIRUS TYPE-2; KILLER-CELL-ACTIVITY; CIGARETTE-SMOKING; CERVICAL-CANCER; UTERINE CERVIX; RISK-FACTORS; INTRAEPITHELIAL NEOPLASIA; CARCINOMA INSITU; SMOKERS; DYSPLASIA	Objective. - To determine whether a previously observed association between human immunodeficiency virus type 1 (HIV-1) infection and smoking in Haitian women could be explained by confounding high-risk behaviors. Design and Setting. - A nested case-control study at a primary care health clinic in Cite Soleil, Haiti. Participants. - Women who reported having smoked (n = 89) and randomly selected nonsmokers (n = 329) who had participated in a survey 1 to 12 months earlier evaluating risk factors for HIV-1 infection. Main Outcome Measures. - Lifetime sexual practices, smoking, health beliefs and practices, and other factors potentially confounding the relationship between smoking and HIV-1 infection. Results. - Compared with nonsmokers, smokers reported higher rates of high-risk behaviors, including more lifetime sex partners (P < .001), being less likely to be married (P < .01), and being more likely to have visited folk healers (P < .01). No intravenous drug use was reported, and no significant differences were noted between smokers and nonsmokers in numbers of past surgical or dental procedures or injections. Adjustment for all factors associated with HIV-1 infection and smoking in regression analyses revealed an independent association between smoking and HIV-1 infection (odds ratio [OR], 3.4; 95% confidence interval [Cl], 1.6 to 7.5). Other factors associated with HIV-1 infection included having more than two lifetime sex partners (OR, 3.4; 95% Cl, 1.7 to 6.8) and lower socioeconomic status as reflected by a dirt floor in the home (OR, 8.6; 95% Cl, 3.3 to 22.0). Conclusions. - Smoking is a marker for high-risk sexual behavior and is associated with an increased risk of HIV-1 infection in this population. The persistent association between smoking and HIV-1 infection after adjustment for all known risk factors suggests the possibility of a biologic effect of smoking that warrants further evaluation in other populations.	CTR DEV & HLTH,PORT AU PRINCE,HAITI; UNIV S FLORIDA,COLL PUBL HLTH,DEPT COMMUNITY & FAMILY MED,TAMPA,FL 33620	State University System of Florida; University of South Florida	HALSEY, NA (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,615 N WOLFE ST,BALTIMORE,MD 21205, USA.				NIAID NIH HHS [1RO1AI26521] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026521] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGELL M, 1990, NEW ENGL J MED, V323, P823, DOI 10.1056/NEJM199009203231209; AUSTIN DF, 1983, JAMA-J AM MED ASSOC, V250, P516; BARON JA, 1987, SMOKING REPRODUCTIVE, P149; BLAKE GH, 1988, ANN INTERN MED, V109, P198, DOI 10.7326/0003-4819-109-3-198; BOULOS R, 1990, J ACQ IMMUN DEF SYND, V3, P721; BRESCIA RJ, 1986, HUM PATHOL, V17, P552, DOI 10.1016/S0046-8177(86)80126-5; BRINTON LA, 1990, AM J EPIDEMIOL, V131, P958, DOI 10.1093/oxfordjournals.aje.a115615; BRISSON J, 1988, AM J EPIDEMIOL, V128, P337, DOI 10.1093/oxfordjournals.aje.a114973; BUCKLEY JD, 1981, LANCET, V2, P1010; BURNS DN, 1991, J ACQ IMMUN DEF SYND, V4, P76; CLARKE EA, 1982, AM J EPIDEMIOL, V115, P59, DOI 10.1093/oxfordjournals.aje.a113279; CORRE F, 1971, LANCET, V2, P632; DALING JR, 1986, SEX TRANSM DIS, V13, P16, DOI 10.1097/00007435-198601000-00004; FERSON M, 1979, INT J CANCER, V23, P603, DOI 10.1002/ijc.2910230504; GINNS LC, 1985, AM REV RESPIR DIS, V131, P831; Hardell L, 1987, Cancer Detect Prev Suppl, V1, P567; HELLBERG D, 1988, AM J OBSTET GYNECOL, V158, P910, DOI 10.1016/0002-9378(88)90093-2; HOLLY EA, 1986, J NATL CANCER I, V76, P983; HUGHES DA, 1985, CLIN EXP IMMUNOL, V61, P459; ISTVAN J, 1984, PSYCHOL BULL, V95, P301, DOI 10.1037/0033-2909.95.2.301; KARK JD, 1982, NEW ENGL J MED, V307, P1042, DOI 10.1056/NEJM198210213071702; KHAW KT, 1988, NEW ENGL J MED, V318, P1705, DOI 10.1056/NEJM198806303182601; LAYDE PM, 1989, JAMA-J AM MED ASSOC, V261, P1631, DOI 10.1001/jama.261.11.1631; LEE DJ, 1991, AM J PUBLIC HEALTH, V81, P859, DOI 10.2105/AJPH.81.7.859; LYON JL, 1983, AM J PUBLIC HEALTH, V73, P558, DOI 10.2105/AJPH.73.5.558; MARSHALL JR, 1983, JNCI-J NATL CANCER I, V70, P847; MAYBERRY RM, 1985, AM J PUBLIC HEALTH, V75, P676, DOI 10.2105/AJPH.75.6.676; MCCULLAGH P, 1989, GENERALIZED LINEAR M, P456; MONTO AS, 1978, AM J EPIDEMIOL, V107, P57, DOI 10.1093/oxfordjournals.aje.a112508; MONTO AS, 1975, AM REV RESPIR DIS, V111, P27; MONTO AS, 1978, AM REV RESPIR DIS, V119, P1101; NEWELL GR, 1985, PREV MED, V14, P81, DOI 10.1016/0091-7435(85)90023-4; PAPE JW, 1986, AM J MED SCI, V291, P4, DOI 10.1097/00000441-198601000-00002; PETERS RK, 1986, JNCI-J NATL CANCER I, V77, P1063; PETITTI DB, 1986, AM J EPIDEMIOL, V123, P89, DOI 10.1093/oxfordjournals.aje.a114227; PRAKASH SS, 1985, INT J CANCER, V35, P51, DOI 10.1002/ijc.2910350109; ROSE RM, 1986, J INFECT DIS, V154, P611, DOI 10.1093/infdis/154.4.611; ROYCE RA, 1990, AIDS, V4, P327, DOI 10.1097/00002030-199004000-00007; ROYCE RA, 1990, 6TH INT C AIDS SAN F; SARACCI R, 1987, EPIDEMIOL REV, V9, P175, DOI 10.1093/oxfordjournals.epirev.a036301; SASSON IM, 1985, NEW ENGL J MED, V312, P315; SCHIFFMAN MH, 1987, CANCER RES, V47, P3886; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P259; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; STUART JM, 1989, LANCET, V2, P723, DOI 10.1016/S0140-6736(89)90781-2; TOLLERUD DJ, 1989, AM REV RESPIR DIS, V139, P194, DOI 10.1164/ajrccm/139.1.194; TOLLERUD DJ, 1989, AM REV RESPIR DIS, V139, P1446, DOI 10.1164/ajrccm/139.6.1446; TREVATHAN E, 1983, JAMA-J AM MED ASSOC, V250, P499, DOI 10.1001/jama.250.4.499; VONKA V, 1984, INT J CANCER, V33, P49, DOI 10.1002/ijc.2910330110; WALD N, 1990, SMOKIN GHORMONE DISO, P269; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; WINKELSTEIN W, 1984, AM J EPIDEMIOL, V119, P1; 1986, INT AGENCY RES CANCE, V38, P282; 1989, 898411 US DEP HLTH H; 1990, LANCET, V335, P1561; 1979, US DHEW PHS7950066 P; 1986, SUGI SUPPLEMENTAL LI, P269	57	41	41	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1992	267	15					2062	2066		10.1001/jama.267.15.2062	http://dx.doi.org/10.1001/jama.267.15.2062			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HM650	1485894				2022-12-28	WOS:A1992HM65000032
J	WANG, ZQ; OVITT, C; GRIGORIADIS, AE; MOHLESTEINLEIN, U; RUTHER, U; WAGNER, EF				WANG, ZQ; OVITT, C; GRIGORIADIS, AE; MOHLESTEINLEIN, U; RUTHER, U; WAGNER, EF			BONE AND HEMATOPOIETIC DEFECTS IN MICE LACKING C-FOS	NATURE			English	Article							TRANSGENIC MICE; PROTO-ONCOGENE; EXPRESSION; TUMORS; MOUSE; CELLS; RAT	THE proto-oncogene c-fos is the cellular homologue of v-fos originally isolated from murine osteosarcoma1. Fos protein is a major component of the AP-1 transcription factor complex, which includes members of the jun family2. Stable expression of c-fos in mice has been demonstrated in developing bones and teeth, haematopoietic cells, germ cells and in the central nervous system3-11. It has been proposed that c-fos has an important role in signal transduction, cell proliferation and differentiation12-15. We have previously demonstrated that overexpression of c-fos in transgenic and chimaeric mice specifically affects bone, cartilage and haematopoietic cell development16-20. To understand better the function of c-fos in vivo, we used gene targeting in embryonic stem cells to generate cells and mice lacking c-fos. Here we report that heterozygous fos +/- mice appear normal, although females exhibit a distorted transmission frequency. All homozygous fos -/- mice are growth-retarded, develop osteopetrosis with deficiencies in bone remodelling and tooth eruption, and have altered haematopoiesis. These data define the c-Fos protein as an essential molecule for the development of specific cellular compartments.	EMBL, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)	WANG, ZQ (corresponding author), IMP, MOLEC PATHOL RES INST, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA.			Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CAUBET JF, 1988, BIOL CELL, V64, P101, DOI 10.1016/0248-4900(88)90100-1; COHEN DR, IN PRESS ONCOGENE; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; Green MC., 1989, GENETIC VARIANTS STR, P12; HILBERG F, 1992, ONCOGENE, V7, P2371; JONES KL, 1988, SMITHS RECOGNIZABLE, P353; MARKS SC, 1989, AM J ANAT, V186, P325, DOI 10.1002/aja.1001860402; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; PELTOHUIKKO M, 1991, ACTA PHYSIOL SCAND, V141, P283, DOI 10.1111/j.1748-1716.1991.tb09080.x; Revell P. A., 1986, PATHOLOGY BONE; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKAO S, 1991, INT IMMUNOL, V3, P369, DOI 10.1093/intimm/3.4.369; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x	30	802	824	1	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 24	1992	360	6406					741	745		10.1038/360741a0	http://dx.doi.org/10.1038/360741a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465144				2022-12-28	WOS:A1992KE47200034
J	WOLFE, JH; SANDS, MS; BARKER, JE; GWYNN, B; ROWE, LB; VOGLER, CA; BIRKENMEIER, EH				WOLFE, JH; SANDS, MS; BARKER, JE; GWYNN, B; ROWE, LB; VOGLER, CA; BIRKENMEIER, EH			REVERSAL OF PATHOLOGY IN MURINE MUCOPOLYSACCHARIDOSIS TYPE-VII BY SOMATIC-CELL GENE-TRANSFER	NATURE			English	Article							BETA-GLUCURONIDASE DEFICIENCY; HEMATOPOIETIC STEM-CELLS; INVITRO; MOUSE; THERAPY; CDNA	AN inherited deficiency of beta-glucuronidase in humans1, mice2 and dogs3 causes mucopolysaccharidosis VII (Sly syndrome), a progressive degenerative disease that reduces lifespan (to an average of 5 months in mice2) and results from lysosomal storage of undegraded glycosaminoglycans in the spleen, liver, kidney, cornea, brain and skeletal system1-4. Bone marrow transplantation in mutant mice provides a source of normal enzyme ('cross-correction'5), which substantially improves the clinical condition and extends the average lifespan to 18 months6. Gene therapy by transfer of a beta-glucuronidase gene into mutant haematopoietic stem cells is an alternative approach7,8, but it is not known whether the low expression of vector-transferred genes in vivo9,10 would be sufficiently effective. Here we show that retroviral vector-mediated transfer of the gene to mutant stem cells results in long-term expression of low levels of beta-glucuronidase which partially corrects the disease by reducing lysosomal storage in liver and spleen.	UNIV PENN,SCH VET MED,PHILADELPHIA,PA 19104; ST LOUIS UNIV,SCH MED,ST LOUIS,MO 63104	University of Pennsylvania; Saint Louis University	WOLFE, JH (corresponding author), JACKSON LAB,BAR HARBOR,ME 04609, USA.			Sands, Mark/0000-0002-5559-0832				BARKER JE, 1983, BLOOD, V62, P827; BARKER JE, IN PRESS EXPL HEMAT; BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; BIRKENMEIER EH, 1991, BLOOD, V78, P3081; BODINE DM, 1989, P NATL ACAD SCI USA, V86, P8897, DOI 10.1073/pnas.86.22.8897; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; FRASER CC, 1990, BLOOD, V76, P1071; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; HASKINS ME, 1984, PEDIATR RES, V18, P980, DOI 10.1203/00006450-198418100-00014; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; NEUFELD EF, 1970, SCIENCE, V169, P141, DOI 10.1126/science.169.3941.141; Neufeld EF, 1989, METABOLIC BASIS INHE, P1565; NISHIMURA Y, 1986, P NATL ACAD SCI USA, V83, P7292, DOI 10.1073/pnas.83.19.7292; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; SMITH BF, 1990, MOL CELL BIOL, V10, P3268, DOI 10.1128/MCB.10.6.3268; STRAMM LE, 1990, EXP EYE RES, V50, P521, DOI 10.1016/0014-4835(90)90041-R; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952; VOGLER CA, 1991, AM J PATHOL, V136, P207; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877; WOLFE JH, 1992, NAT GENET, V1, P379, DOI 10.1038/ng0892-379	22	211	214	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					749	753		10.1038/360749a0	http://dx.doi.org/10.1038/360749a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465145				2022-12-28	WOS:A1992KE47200036
J	MOUNKES, LC; JONES, RS; LIANG, BC; GELBART, W; FULLER, MT				MOUNKES, LC; JONES, RS; LIANG, BC; GELBART, W; FULLER, MT			A DROSOPHILA MODEL FOR XERODERMA-PIGMENTOSUM AND COCKAYNES-SYNDROME - HAYWIRE ENCODES THE FLY HOMOLOG OF ERCC3, A HUMAN EXCISION REPAIR GENE	CELL			English	Article							AFFECT MICROTUBULE FUNCTION; IRRADIATED MAMMALIAN-CELLS; BETA-TUBULIN SUBUNIT; DNA-REPAIR; ULTRAVIOLET-LIGHT; MOLECULAR CHARACTERIZATION; INTERACTING GENES; HUMAN-FIBROBLASTS; UV IRRADIATION; RNA-SYNTHESIS	The haywire gene of Drosophila encodes a protein with 66% identity to the product of the human ERCC3 gene, associated with xeroderma pigmentosum B (XP-B) and Cockayne's syndrome (CS). XP is a human autosomal recessive disease characterized by extreme sensitivity to ultraviolet irradiation and marked susceptibility to skin cancer. In addition, XP and CS patients often exhibit a variety of defects, ranging f rom central nervous system disorders to hypogonadism. Phenotypes of haywire mutants mimic some of the effects of XP. Many haywire alleles are recessive lethal, viable alleles cause ultraviolet sensitivity, and flies expressing marginal levels of haywire display motor defects and reduced life span. Progeny of females carrying a maternal effect allele show central nervous system defects.	STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; SO METHODIST UNIV, DEPT BIOL SCI, DALLAS, TX 75275 USA; HARVARD UNIV, DEPT CELLULAR & DEV BIOL, CAMBRIDGE, MA 02138 USA	Stanford University; Stanford University; Southern Methodist University; Harvard University	MOUNKES, LC (corresponding author), UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA.			Fuller, Margaret T/0000-0002-3804-4987	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007135] Funding Source: NIH RePORTER; NICHD NIH HHS [HD18127] Funding Source: Medline; NIGMS NIH HHS [5T32GM07135-15] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED FE, 1978, BIOCHIM BIOPHYS ACTA, V521, P805, DOI 10.1016/0005-2787(78)90319-2; ARLETT CF, 1978, DNA REPAIR MECHANISM, P633; BENHUR E, 1980, FEBS LETT, V120, P21, DOI 10.1016/0014-5793(80)81036-2; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; BONNER JJ, 1984, CELL, V37, P979; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUTLAG DL, 1990, COMPUT APPL BIOSCI, V6, P237; BUSCH DB, 1980, SOMAT CELL GENET, V6, P407, DOI 10.1007/BF01542792; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; COLE J, 1992, MUTAT RES, V273, P171, DOI 10.1016/0921-8777(92)90078-H; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DUPUY JM, 1982, J INVEST DERMATOL, V78, P356; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLETJER WL, 1992, P NATL ACAD SCI USA, V89, P261; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GIORNO R, 1976, CELL, V9, P775, DOI 10.1016/0092-8674(76)90140-9; GLOVER TW, 1979, P NATL ACAD SCI USA, V76, P3982, DOI 10.1073/pnas.76.8.3982; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HACKETT PB, 1975, J MOL BIOL, V91, P235, DOI 10.1016/0022-2836(75)90378-2; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JONES RS, 1990, GENETICS, V126, P185; KANTOR GJ, 1979, BIOPHYS J, V27, P359, DOI 10.1016/S0006-3495(79)85223-6; KAUFMANN WK, 1980, BIOCHIM BIOPHYS ACTA, V608, P191, DOI 10.1016/0005-2787(80)90147-1; KEMPHUES KJ, 1982, CELL, V31, P655, DOI 10.1016/0092-8674(82)90321-X; KEMPHUES KJ, 1983, GENETICS, V105, P345; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LEHMANN AR, 1979, CANCER RES, V39, P4237; LEHMANN AR, 1982, CANCER SURV, V1, P93; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MACINNES MA, 1990, PROG CLIN BIOL RES, V340, P265; MAHER VM, 1975, J NATL CANCER I, V54, P1287, DOI 10.1093/jnci/54.6.1287; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; MAYNE LV, 1982, CANCER RES, V42, P1473; MAYNE LV, 1982, MUTAT RES, V106, P179, DOI 10.1016/0027-5107(82)90200-7; MCCORMICK JJ, 1986, CANCER RES, V46, P489; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MICHALKE H, 1969, J MOL BIOL, V41, P1, DOI 10.1016/0022-2836(69)90122-3; MISMER D, 1987, GENETICS, V116, P565; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NOCENTINI S, 1976, BIOCHIM BIOPHYS ACTA, V454, P114, DOI 10.1016/0005-2787(76)90359-2; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; REGAN CL, 1990, GENETICS, V125, P77; REGAN CL, 1988, GENE DEV, V2, P82, DOI 10.1101/gad.2.1.82; ROBBINS JH, 1991, HUM GENET, V88, P242; ROBBINS JH, 1974, ANN INTERN MED, V80, P221, DOI 10.7326/0003-4819-80-2-221; ROBERTSON HM, 1988, GENETICS, V118, P461; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEFANINI M, 1982, SOMAT CELL GENET, V8, P635, DOI 10.1007/BF01542856; STICH HF, 1973, MUTAT RES, V17, P127, DOI 10.1016/0027-5107(73)90261-3; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TATES AD, 1989, MUTAT RES, V213, P73, DOI 10.1016/0027-5107(89)90033-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOOD RD, 1991, NATURE, V350, P190, DOI 10.1038/350190a0; WOOD RD, 1982, MUTAT RES, V95, P505, DOI 10.1016/0027-5107(82)90281-0	70	120	122	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					925	937		10.1016/0092-8674(92)90389-T	http://dx.doi.org/10.1016/0092-8674(92)90389-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458540				2022-12-28	WOS:A1992KB99000006
J	RUSHFORTH, JA; WILSON, N				RUSHFORTH, JA; WILSON, N			SHOULD GENERAL-PRACTITIONERS HAVE ACCESS TO PEDIATRIC CARDIOLOGISTS	BRITISH MEDICAL JOURNAL			English	Article									KILLINGBECK HOSP,LEEDS LS14 6UH,ENGLAND		RUSHFORTH, JA (corresponding author), GEN INFIRM,DEPT PAEDIATR,LEEDS LS2 9NS,ENGLAND.							NEWBURGER JW, 1983, NEW ENGL J MED, V308, P61, DOI 10.1056/NEJM198301133080201; WILSON N, 1986, RECENT ADV PAEDIATRI, V8, P87	2	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1264	1265		10.1136/bmj.305.6864.1264	http://dx.doi.org/10.1136/bmj.305.6864.1264			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477570	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992JZ52100025
J	POTTER, JD				POTTER, JD			RECONCILING THE EPIDEMIOLOGY, PHYSIOLOGY, AND MOLECULAR-BIOLOGY OF COLON CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LARGE-BOWEL-CANCER; COLORECTAL-CANCER; ENVIRONMENTAL FACTORS; PHYSICAL-ACTIVITY; HORMONAL FACTORS; DIETARY FIBER; RISK; GENE; IDENTIFICATION; WOMEN				POTTER, JD (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, MINNEAPOLIS, MN 55454 USA.			Potter, John/0000-0001-5439-1500	NATIONAL CANCER INSTITUTE [P01CA050305, S15CA048898, R01CA051932] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51932, CA 50305, CA 48898] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZANO MA, 1989, CANCER RES, V49, P2898; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; BJELKE E, 1973, EPIDEMIOLOGICAL STUD, V3; BURKITT DP, 1969, LANCET, V2, P1229, DOI 10.1016/S0140-6736(69)90757-0; BYERS T, 1982, J NATL CANCER I, V69, P1059; CORPET DE, 1990, CANCER RES, V50, P6955; CUMMINGS JH, 1983, LANCET, V1, P1206; DRASAR BS, 1973, BRIT J CANCER, V27, P167, DOI 10.1038/bjc.1973.20; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GARABRANT DH, 1984, AM J EPIDEMIOL, V119, P1005, DOI 10.1093/oxfordjournals.aje.a113805; GERHARDSSON M, 1986, AM J EPIDEMIOL, V123, P775, DOI 10.1093/oxfordjournals.aje.a114306; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUILLEM JG, 1990, FAMILIAL ADENOMATOUS, P325; HAENSZEL W, 1973, J NATL CANCER I, V51, P1765, DOI 10.1093/jnci/51.6.1765; HAENSZEL W, 1973, EPIDEMIOLOGICAL STUD, V4; HEATON KW, 1982, COLON NUTRITION, V32, P117; HILL MJ, 1978, LANCET, V1, P245, DOI 10.1016/S0140-6736(78)90487-7; HILL MJ, 1971, J PATHOL, V104, P129, DOI 10.1002/path.1711040207; HIRAYAMA T, 1981, BANBURY REPORT, V7, P409; HOFFMAN RM, 1983, BIOCHIM BIOPHYS ACTA, V738, P49, DOI 10.1016/0304-419X(84)90019-2; HOWE GR, 1985, J NATL CANCER I, V74, P1155; JAIN M, 1980, INT J CANCER, V26, P757, DOI 10.1002/ijc.2910260609; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KADLUBAR FF, IN PRESS ENV HLTH PE; KAPLAN LM, 1988, P NATL ACAD SCI USA, V85, P1065, DOI 10.1073/pnas.85.4.1065; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAMPE JW, IN PRESS GUT; LIPKIN M, 1988, CANCER RES, V48, P235; MANOUSOS O, 1983, INT J CANCER, V32, P1, DOI 10.1002/ijc.2910320102; McMichael A J, 1985, Natl Cancer Inst Monogr, V69, P223; MCMICHAEL AJ, 1980, J NATL CANCER I, V65, P1201; MCMICHAEL AJ, 1983, AM J EPIDEMIOL, V118, P620, DOI 10.1093/oxfordjournals.aje.a113672; MCMICHAEL AJ, 1986, DIET NUTRITION CANCE, P275; MOROTOMI M, 1990, CANCER RES, V50, P3595; MUKAIDA H, 1991, INT J CANCER, V48, P423, DOI 10.1002/ijc.2910480320; NEWMARK HL, 1984, J NATL CANCER I, V72, P1323; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PAPADIMITRIOU C, 1984, INT J EPIDEMIOL, V13, P155, DOI 10.1093/ije/13.2.155; PHILLIPS RL, 1985, JNCI-J NATL CANCER I, V74, P307; POTTER JD, 1986, JNCI-J NATL CANCER I, V76, P557, DOI 10.1093/jnci/76.4.557; POTTER JD, 1983, J NATL CANCER I, V71, P703; POTTER JD, 1989, VERH BD, V24, P137; SLATTERY ML, 1988, AM J EPIDEMIOL, V128, P989; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P427, DOI 10.1007/BF00054304; STEMMERMANN GN, 1984, CANCER RES, V44, P4633; STEPHEN AM, 1980, NATURE, V284, P283, DOI 10.1038/284283a0; STEPHEN AM, 1986, BRIT J NUTR, V56, P349, DOI 10.1079/BJN19860116; STUBS P, 1980, MED ASPECTS DIETARY, P3; SUGIMURA T, 1983, CANCER RES, V43, P2415; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TURESKY RJ, 1991, CARCINOGENESIS, V12, P1417; VENA JE, 1985, AM J EPIDEMIOL, V122, P357, DOI 10.1093/oxfordjournals.aje.a114116; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WATTENBERG LW, 1978, JNCI-J NATL CANCER I, V60, P11, DOI 10.1093/jnci/60.1.11; WATTENBERG LW, 1977, J NATL CANCER I, V58, P395, DOI 10.1093/jnci/58.2.395; WEISS NS, 1981, J NATL CANCER I, V67, P57; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WU AH, 1987, BRIT J CANCER, V55, P687, DOI 10.1038/bjc.1987.140; WYNDER EL, 1969, CANCER, V23, P1210, DOI 10.1002/1097-0142(196905)23:5<1210::AID-CNCR2820230530>3.0.CO;2-M; WYNDER EL, 1967, CANCER, V20, P1529	67	99	100	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1992	268	12					1573	1577						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN256	1518112				2022-12-28	WOS:A1992JN25600028
J	EDLIN, BR; STCLAIR, MH; PITHA, PM; WHALING, SM; KING, DM; BITRAN, JD; WEINSTEIN, RA				EDLIN, BR; STCLAIR, MH; PITHA, PM; WHALING, SM; KING, DM; BITRAN, JD; WEINSTEIN, RA			INVITRO RESISTANCE TO ZIDOVUDINE AND ALPHA-INTERFERON IN HIV-1 ISOLATES FROM PATIENTS - CORRELATIONS WITH TREATMENT DURATION AND RESPONSE	ANNALS OF INTERNAL MEDICINE			English	Article						INTERFERON-ALPHA; HUMAN IMMUNODEFICIENCY VIRUS; ZIDOVUDINE; DRUG RESISTANCE; ACQUIRED IMMUNODEFICIENCY SYNDROME	HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS-SARCOMA; AIDS; SENSITIVITY; INFECTION; TYPE-1; THERAPY	Objective: To measure in-vitro antiviral drug susceptibilities of human immunodeficiency virus type 1 (HIV-1) isolates recovered from patients treated with alpha-interferon or zidovudine and patients not treated with these drugs and to examine the relation of these susceptibility measurements to duration of therapy, disease stage, and response to alpha-interferon therapy. Design: Cross-sectional study. Setting: Outpatient HIV clinic. Patients: Twenty-six ambulatory HIV-1-infected patients: Fifteen of these patients were receiving alpha-interferon therapy, and 11 had never received such therapy. Nine patients were participating in a clinical trial of combination therapy with zidovudine and alpha-interferon. Measurements: The 50% inhibitory concentration (IC50) of zidovudine and alpha-interferon was determined for HIV-1 isolates recovered from each patient. Plasma concentrations of HIV-1 p24 antigen in the nine patients in the clinical trial were measured monthly after alpha-interferon was added to zidovudine monotherapy. Results: Zidovudine IC50 (range, 0.01 to 4.87-mu-M) increased steadily with duration of zidovudine therapy (r = 0.57, P = 0.003). In contrast, alpha-interferon IC50 (range, 0.8 to 415 units/mL) was not related to duration of alpha-interferon treatment; in fact, high IC50s were found in isolates from patients who had never received exogenous alpha-interferon therapy. Resistance to alpha-interferon was greater in isolates from the 15 patients with the acquired immunodeficiency syndrome (AIDS) (median, 104 units/mL) than in those from the 10 patients without AIDS (median, 50 units/mL). Interferon activity was detected in plasma samples from 23 of 24 patients and was also at higher levels in patients with AIDS than in HIV-infected patients without AIDS. Reductions in plasma concentrations of HIV-1 p24 antigen in nine patients after beginning alpha-interferon therapy were greater in those with more susceptible isolates (r = -0.72, P = 0.03). Conclusions: Interferon resistance, possibly due to endogenous interferon, is not related to duration of interferon therapy but may limit the effectiveness of interferon therapy. Determinations of interferon susceptibility may identify patients most likely to benefit from this agent.			EDLIN, BR (corresponding author), CTR DIS CONTROL, DIV HIV AIDS, 1600 CLIFTON RD, E-45, ATLANTA, GA 30333 USA.		Edlin, Brian R/F-2966-2018	Edlin, Brian R/0000-0001-8172-8797				BERGLUND O, 1991, J INFECT DIS, V163, P710, DOI 10.1093/infdis/163.4.710; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; DESTEFANO E, 1982, J INFECT DIS, V146, P451, DOI 10.1093/infdis/146.4.451; DEWIT R, 1988, LANCET, V2, P1214; DEWIT R, 1991, J INTERN MED, V229, P35; EDLIN BR, 1989, LANCET, V1, P156; EDLIN BR, 1992, J INFECT DIS, V165, P793, DOI 10.1093/infdis/165.5.793; EVANS LA, 1987, J IMMUNOL, V138, P3415; FISCHL MA, 1991, J ACQ IMMUN DEF SYND, V4, P1; FRANCIS ML, 1992, AIDS RES HUM RETROV, V8, P199, DOI 10.1089/aid.1992.8.199; HARPER HD, 1973, BIOCHEM BIOPH RES CO, V53, P1220, DOI 10.1016/0006-291X(73)90595-0; HO DD, 1985, LANCET, V1, P602; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; JOKLIK WK, 1985, VIROLOGY, P283; KROWN SE, 1990, ANN INTERN MED, V112, P812, DOI 10.7326/0003-4819-112-11-812; LAND S, 1990, J INFECT DIS, V161, P326, DOI 10.1093/infdis/161.2.326; LANE HC, 1990, ANN INTERN MED, V112, P805, DOI 10.7326/0003-4819-112-11-805; LANE HC, 1988, LANCET, V2, P1218; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; PITHA PM, 1991, J INTERFERON RES, V11, P313, DOI 10.1089/jir.1991.11.313; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X	25	36	36	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					457	460		10.7326/0003-4819-117-6-457	http://dx.doi.org/10.7326/0003-4819-117-6-457			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503348				2022-12-28	WOS:A1992JN25700002
J	MATCHAR, DB; DIVINE, GW; HEYMAN, A; FEUSSNER, JR				MATCHAR, DB; DIVINE, GW; HEYMAN, A; FEUSSNER, JR			THE INFLUENCE OF HYPERGLYCEMIA ON OUTCOME OF CEREBRAL INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERGLYCEMIA; CEREBRAL INFARCTION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); BLOOD GLUCOSE; CEREBROVASCULAR DISORDERS	ACUTE STROKE; DIABETES-MELLITUS; BLOOD-GLUCOSE; PROGNOSTIC VALUE; CEREBROVASCULAR ACCIDENT; GLYCOSYLATED HEMOGLOBIN; NATURAL-HISTORY; BARTHEL INDEX; RECOVERY; ISCHEMIA	Objective: To determine whether hyperglycemia in the acute stroke period is associated with worse survival and functional outcome after accounting for acute stress response and chronic hyperglycemia. Design: Prospective, county-wide, multicenter cohort study. Setting: A community hospital, a university hospital, and a Veterans Affairs hospital. Patients: A cohort of 146 patients hospitalized with new atherothrombotic stroke. Measurements: Admission blood glucose concentration, demographic characteristics of patients, 24-hour urinary catecholamine, serum cortisol, and glycosylated hemoglobin levels; outcomes included mortality and functional outcome (Barthel index and Fugl-Meyer score) at 5, 30, 90, and 180 days after stroke. Results: Of the 996 patients with possible acute stroke who were screened, 146 (15%) were eligible for and consented to participate in the study; in most cases, exclusion from study was based on the absence of acute, atherothrombotic stroke. Overall, no evidence was found of a significant univariate association between admission blood glucose level and survival (relative risk, 1.02; 95% CI, 0.94 to 1.09) or functional outcome (univariate regression coefficient for adjusted Fugl-Meyer score at day 30, - 0.36; CI, - 1.08 to 0.27). This absence of an association persisted after adjustment for significant predictors of outcome in a multivariate model. Conclusions: These data do not support an association between level of glycemia and outcome from acute stroke.	DUKE UNIV, MED CTR, DEPT MED, DIV NEUROL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DIV GEN INTERNAL MED, DURHAM, NC 27710 USA; VET AFFAIRS MED CTR, DURHAM, NC USA	Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	MATCHAR, DB (corresponding author), DUKE UNIV, CTR HLTH POLICY RES & EDUC, SUITE 125, OLD CHEM BLDG, DURHAM, NC 27706 USA.		Matchar, David/M-3951-2019	Matchar, David/0000-0003-3020-2108	NINDS NIH HHS [NS 06233] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS006233] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUZEID HAH, 1978, ARCH NEUROL-CHICAGO, V35, P213, DOI 10.1001/archneur.1978.00500280031005; ACHESON J, 1971, Q J MED, V40, P25; ARONSON SM, 1973, J NEUROPATH EXP NEUR, V32, P183, DOI 10.1097/00005072-197304000-00001; ASPLUND K, 1980, ACTA MED SCAND, V207, P417; BARNES AJ, 1977, LANCET, V2, P789; BENTSEN N, 1975, STROKE, V6, P497, DOI 10.1161/01.STR.6.5.497; BERGER L, 1986, STROKE, V17, P865, DOI 10.1161/01.STR.17.5.865; BUTTERFIELD WJH, 1955, LANCET, V1, P489; CANDELISE L, 1985, ARCH NEUROL-CHICAGO, V42, P661, DOI 10.1001/archneur.1985.04060070051014; COX NH, 1986, POSTGRAD MED J, V62, P7, DOI 10.1136/pgmj.62.723.7; CRUICKSHANK JM, 1974, BRIT HEART J, V36, P697; DUNCAN PW, 1983, PHYS THER, V63, P1606, DOI 10.1093/ptj/63.10.1606; ENTMACHER PS, 1964, DIABETES, V13, P373, DOI 10.2337/diab.13.4.373; FEIBEL JH, 1977, JAMA-J AM MED ASSOC, V238, P1374, DOI 10.1001/jama.238.13.1374; FRITHZ G, 1976, ACTA MED SCAND, V199, P133; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; FULLERTON KJ, 1988, Q J MED, V66, P147; GINSBERG MD, 1987, STROKE, V18, P570, DOI 10.1161/01.STR.18.3.570; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GIROUD M, 1987, PRESSE MED, V16, P1079; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P14; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P145; GRAY CS, 1987, DIABETIC MED, V4, P237, DOI 10.1111/j.1464-5491.1987.tb00870.x; GRAY CS, 1989, POSTGRAD MED J, V65, P720, DOI 10.1136/pgmj.65.768.720; GRUNNET ML, 1963, NEUROLOGY, V13, P486, DOI 10.1212/WNL.13.6.486; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HELGASON CM, 1988, STROKE, V19, P1049, DOI 10.1161/01.STR.19.8.1049; Huff TA, 1972, STROKE, V3, P543, DOI 10.1161/01.STR.3.5.543; JACHUCK SJ, 1975, BRIT MED J, V1, P242, DOI 10.1136/bmj.1.5952.242; Kannel WB, 1971, STROKE, V2, P295, DOI 10.1161/01.STR.2.4.295; KESSLER II, 1971, AM J MED, V51, P715, DOI 10.1016/0002-9343(71)90299-3; KUSHNER M, 1990, ANN NEUROL, V28, P129, DOI 10.1002/ana.410280204; LAVY S, 1968, J NEUROL SCI, V7, P409, DOI 10.1016/0022-510X(68)90049-X; LAVY S, 1974, STROKE, V5, P775, DOI 10.1161/01.STR.5.6.775; LEBOVITZ HE, 1969, CIRCULATION, V39, P171, DOI 10.1161/01.CIR.39.2.171; MAHONEY F I, 1965, Md State Med J, V14, P61; MARSH WR, 1986, J NEUROSURG, V65, P693, DOI 10.3171/jns.1986.65.5.0693; MATCHAR DB, 1989, CLIN RES, V37, pA84; MCDONALD L, 1969, LANCET, V2, P1021; MCMILLAN DE, 1978, DIABETES, V27, P895, DOI 10.2337/diab.27.9.895; MELAMED E, 1976, J NEUROL SCI, V29, P267, DOI 10.1016/0022-510X(76)90176-3; MEYER JS, 1973, BRAIN, V96, P277, DOI 10.1093/brain/96.2.277; MIAH K, 1983, J CHRON DIS, V36, P279, DOI 10.1016/0021-9681(83)90063-2; MYERS MG, 1981, STROKE, V12, P200, DOI 10.1161/01.STR.12.2.200; MYERS RE, 1976, NEUROLOGY, V26, P345; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; ONEILL PA, 1991, STROKE, V22, P842, DOI 10.1161/01.STR.22.7.842; OPPENHEIMER SM, 1985, BRIT MED J, V291, P1014, DOI 10.1136/bmj.291.6501.1014-a; OXBURY JM, 1975, BRIT MED J, V3, P125, DOI 10.1136/bmj.3.5976.125; POWER MJ, 1988, AGE AGEING, V17, P164, DOI 10.1093/ageing/17.3.164; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; RIDDLE MC, 1982, STROKE, V13, P356, DOI 10.1161/01.STR.13.3.356; SCHOENBERG BS, 1980, ANN NEUROL, V8, P101; SELYE H, 1946, J CLIN ENDOCR METAB, V6, P117, DOI 10.1210/jcem-6-2-117; SIEMKOWICZ E, 1981, ACTA NEUROL SCAND, V64, P207; SIEMKOWICZ E, 1978, ACTA NEUROL SCAND, V58, P1; SILBERBAUER K, 1979, NEW ENGL J MED, V300, P366; TOMOMATSU T, 1964, JPN CIRC J, V28, P884; TOPIC E, 1989, DIABETIC MED, V6, P12, DOI 10.1111/j.1464-5491.1989.tb01131.x; WAUTIER JL, 1981, NEW ENGL J MED, V305, P237, DOI 10.1056/NEJM198107303050501; WEIDLER DJ, 1974, STROKE, V5, P759, DOI 10.1161/01.STR.5.6.759; WOO E, 1988, STROKE, V19, P185, DOI 10.1161/01.STR.19.2.185; [No title captured]	64	60	61	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1992	117	6					449	456		10.7326/0003-4819-117-6-449	http://dx.doi.org/10.7326/0003-4819-117-6-449			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JN257	1503347				2022-12-28	WOS:A1992JN25700001
J	SCHANTZ, PM; MOORE, AC; MUNOZ, JL; HARTMAN, BJ; SCHAEFER, JA; ARON, AM; PERSAUD, D; SARTI, E; WILSON, M; FLISSER, A				SCHANTZ, PM; MOORE, AC; MUNOZ, JL; HARTMAN, BJ; SCHAEFER, JA; ARON, AM; PERSAUD, D; SARTI, E; WILSON, M; FLISSER, A			NEUROCYSTICERCOSIS IN AN ORTHODOX JEWISH-COMMUNITY IN NEW-YORK-CITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED IMMUNOELECTROTRANSFER BLOT; CEREBRAL CYSTICERCOSIS; UNITED-STATES; DIAGNOSIS	Background and Methods. From June 1990 through July 1991, intracerebral infection with the larval stage of the pork tapeworm Taenia solium was diagnosed in four unrelated persons in an Orthodox Jewish community in New York City. None of the patients had eaten pork, and only one had traveled to a country in which T solium infection was endemic. We investigated this outbreak, screened serum samples from family members and household contacts for antibodies to cysticercosis, and examined stool specimens from household employees for eggs of taenia species. Results. The four patients had recurrent seizures and brain lesions that were radiologically consistent with the presence of cysticerci. The diagnosis was confirmed in two patients by a brain biopsy, and in two by immunoblot assays for cysticercus antibodies. Of 17 immediate family members screened serologically, 7 from two families had cysticercus antibodies. Magnetic resonance imaging of the brain showed cystic lesions in two of the seropositive family members, one of whom had had a seizure. Examinations of six domestic employees from all four households revealed an active infection with taenia species in one and a positive serologic test in another. Since these women had recently emigrated from Latin American countries where T. solium infection is endemic, they were the most likely sources of infection in the members of these households. Conclusions. A diagnosis of neurocysticercosis should be considered in patients with seizures and radiologic evidence of cystic brain lesions, even in those who do not eat pork and who have not traveled to a country in which T. solium infection is endemic. Recent emigrants from countries in which T. solium infection is endemic should be screened for tapeworm infection in their stools before they are employed as housekeepers or food handlers.	NYU MED CTR,DEPT PEDIAT,NEW YORK,NY 10016; CORNELL UNIV,SCH MED,DIV INFECT DIS,ITHACA,NY 14853; CORNELL UNIV,SCH MED,DEPT NEUROL,ITHACA,NY 14853; MT SINAI MED CTR,DIV PEDIAT NEUROL,NEW YORK,NY 10029; SECRETARIAT HLTH,GEN DIRECTORATE EPIDEMIOL,MEXICO CITY,MEXICO; BIOMED RES INST,MEXICO CITY,MEXICO	New York University; Cornell University; Cornell University; Icahn School of Medicine at Mount Sinai	SCHANTZ, PM (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV PARASIT DIS F13,ATLANTA,GA 30333, USA.		Sarti, Elsa/ABB-8450-2021	Flisser, Ana/0000-0002-1744-8480				[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; Campagna M., 1954, Journal of Parasitology, V40, P46; COHEN B, 1962, SOUTHERN MED J, V55, P48, DOI 10.1097/00007611-196201000-00013; DEKAMINSKY RG, 1991, T ROY SOC TROP MED H, V85, P531, DOI 10.1016/0035-9203(91)90245-T; DIAZ JF, 1992, AM J TROP MED HYG, V46, P610, DOI 10.4269/ajtmh.1992.46.610; EARNEST MP, 1987, REV INFECT DIS, V9, P961; FLISSER A, 1988, PARASITOL TODAY, V4, P131, DOI 10.1016/0169-4758(88)90187-1; Garbutt G D, 1967, Bull Los Angeles Neurol Soc, V32, P6; GEMMELL M, 1983, WHO VPH8349 DOC; KEANE JR, 1980, ANN NEUROL, V8, P643, DOI 10.1002/ana.410080624; LOO L, 1982, MEDICINE, V61, P341, DOI 10.1097/00005792-198211000-00001; Mahajan R.C., 1982, P39; Mazzotti L., 1944, REV INST SALUBRIDAD Y ENFERM TROP, V5, P207; McCormick G F, 1985, Bull Clin Neurosci, V50, P76; MELVIN DM, 1982, DHHS CDC828282 CTR D; MITCHELL WG, 1988, PEDIATRICS, V82, P76; NASH TE, 1984, NEW ENGL J MED, V311, P1492, DOI 10.1056/NEJM198412063112307; PILCHER J B, 1991, American Journal of Tropical Medicine and Hygiene, V45, P131; Prevention and control of intestinal parasitic infections, 1987, WHO TECH REP SER, V749, P1; RICHARDS FO, 1985, JAMA-J AM MED ASSOC, V254, P3444, DOI 10.1001/jama.254.24.3444; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; Schantz P M, 1991, Southeast Asian J Trop Med Public Health, V22 Suppl, P65; SCHANTZ P M, 1989, Acta Leidensia, V57, P153; SCHARF D, 1988, ARCH NEUROL-CHICAGO, V45, P777, DOI 10.1001/archneur.1988.00520310087022; Schenone H., 1982, P25; SCHULTZ TS, 1978, NEUROSURGERY, V3, P164, DOI 10.1227/00006123-197809000-00006; SHANLEY JD, 1980, ARCH INTERN MED, V140, P1309, DOI 10.1001/archinte.140.10.1309; SORVILLO FJ, 1992, AM J TROP MED HYG, V47, P365, DOI 10.4269/ajtmh.1992.47.365; TASKER WG, 1979, PEDIATRICS, V63, P761; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; WILSON M, 1991, J INFECT DIS, V164, P1007, DOI 10.1093/infdis/164.5.1007; 1990, CALIFORNIA MORBIDITY; 1991, 1990 CENSUS PROFILE, P1; 1986, MED LETT DRUGS THER, V28, P9	34	309	321	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					692	695		10.1056/NEJM199209033271004	http://dx.doi.org/10.1056/NEJM199209033271004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1495521				2022-12-28	WOS:A1992JL23500004
J	VAZQUEZ, V; SOTELO, J				VAZQUEZ, V; SOTELO, J			THE COURSE OF SEIZURES AFTER TREATMENT FOR CEREBRAL CYSTICERCOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARENCHYMAL BRAIN CYSTICERCOSIS; LATE-ONSET EPILEPSY; NEUROCYSTICERCOSIS; PROGNOSIS; THERAPY; PRAZIQUANTEL; ALBENDAZOLE; CHILDHOOD; CT	Background. Worldwide, cerebral cysticercosis is one of the most common causes of seizure disorders. Modern cysticidal drugs can usually eliminate the parasite from the brain, but there have been doubts as to whether such treatment improves the seizure disorder. Methods. We studied 240 patients with seizures and cysticercosis of the brain parenchyma. Of these patients, 118 received cysticidal therapy (albendazole, praziquantel, or both) for lesions without inflammation on imaging studies (group 1); 49 patients with similar lesions either were not offered or refused cysticidal medication (group 2). Another 58 patients with inflammation around cysts (making spontaneous resolution more likely) also did not receive cysticidal medication (group 3), whereas cysticerci were removed surgically in 15 patients (group 4). The 240 patients were followed for a mean (+/-SE) of 92+/-7 months. Results. In the patients treated with cysticidal medications, there was an 82 percent reduction in the mean number of brain cysts (from 5.0 to 0.9) and a 95 percent reduction in the mean frequency of seizures (from 11.3 to 0.6 per year; P<0.001). After three years of follow-up, 64 patients in group 1 (54 percent) were seizure-free. By contrast, the untreated patients (group 2) averaged 10.9 seizures per year; none were seizure-free. Among those with inflamed cysts (group 3), there was a 74 percent reduction in the frequency of seizures (from 7.5 to 2.7 per year), and 18 patients (31 percent) became seizure-free. After surgical treatment (group 4), there was an 87 percent reduction in the frequency of seizures (from 12.8 to 1.7 per year), and six patients (40 percent) became seizure-free. Conclusions. After medical treatment of neurocysticercosis, there is usually remission or marked improvement in the associated seizure disorder.	INST NACL NEUROL & NEUROCIRUG MANUEL VELASCO SUARE, DIV RES, INSURGENTES 3877, MEXICO CITY 14269, MEXICO									AEBI C, 1991, EUR J PEDIATR, V150, P282, DOI 10.1007/BF01955533; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1991, Lancet, V337, P1175; ARTS WFM, 1988, EPILEPSIA, V29, P244, DOI 10.1111/j.1528-1157.1988.tb03713.x; BHATTACHARYYA GK, 1977, STATISTICAL CONCEPTS; BRORSON LO, 1987, EPILEPSIA, V28, P324, DOI 10.1111/j.1528-1157.1987.tb03651.x; CALLAGHAN N, 1988, NEW ENGL J MED, V318, P942, DOI 10.1056/NEJM198804143181502; Del Brutto O. H., 1991, Journal of Tropical and Geographical Neurology, V1, P31; DELBRUTTO OH, 1992, NEUROLOGY, V42, P389, DOI 10.1212/WNL.42.2.389; DELBRUTTO OH, 1988, REV INFECT DIS, V10, P1075; Draper N.R., 1981, APPL REGRESSION ANAL, Vsecond, DOI DOI 10.1002/9781118625590; EARNEST MP, 1987, REV INFECT DIS, V9, P961; Escobar A., 1983, CYSTICERCOSIS CENTRA, P27; ESCOBAR A, 1972, PATHOLOGY NERVOUS SY, V3, P2503; FISH DR, 1989, ACTA NEUROL SCAND, V80, P524, DOI 10.1111/j.1600-0404.1989.tb03921.x; HORNIG CR, 1990, EUR ARCH PSY CLIN N, V239, P379, DOI 10.1007/BF01734546; JUNG H, 1990, J NEUROL, V237, P279, DOI 10.1007/BF00314741; KATAOKA K, 1988, EUR NEUROL, V28, P279, DOI 10.1159/000116284; KERANEN T, 1988, ACTA NEUROL SCAND, V78, P7, DOI 10.1111/j.1600-0404.1988.tb07997.x; KLEINBAUM DG, 1978, APPLIED REGRESSION A; LOPEZ JLP, 1985, ACTA NEUROL SCAND, V72, P380; MEDINA MT, 1990, ARCH INTERN MED, V150, P325, DOI 10.1001/archinte.150.2.325; MILLER B, 1983, NEUROLOGY, V33, P1377, DOI 10.1212/WNL.33.10.1377; MOODLEY M, 1989, LANCET, V1, P262, DOI 10.1016/S0140-6736(89)91268-3; REYNOLDS EH, 1990, BRIT MED J, V301, P1112, DOI 10.1136/bmj.301.6761.1112; ROBITAILLE Y, 1987, CURRENT PROBLEMS EPI, V3, P95; ROBLES C, 1987, J NEUROSURG, V66, P359, DOI 10.3171/jns.1987.66.3.0359; RODRIGUEZCARBAJAL J, 1987, CHILD NERV SYST, V3, P199, DOI 10.1007/BF00274044; RODRIQUEZCARBAJAL J, 1983, AM J NEURORADIOL, V4, P51; SANTOYO H, 1991, NEW ENGL J MED, V324, P1137; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SHINTON RA, 1988, J NEUROL NEUROSUR PS, V51, P273, DOI 10.1136/jnnp.51.2.273; SOTELO J, 1990, J NEUROL, V237, P69, DOI 10.1007/BF00314663; SOTELO J, 1985, ARCH INTERN MED, V145, P442, DOI 10.1001/archinte.145.3.442; SOTELO J, 1988, ARCH NEUROL-CHICAGO, V45, P1130, DOI 10.1001/archneur.1988.00520340084017; SOTELO J, 1984, NEW ENGL J MED, V310, P1001, DOI 10.1056/NEJM198404193101601; SOTELO J, 1987, CURRENT THERAPY NEUR, P114; Sotelo-Morales J, 1989, Gac Med Mex, V125, P31; 1991, LANCET, V337, P1193	39	161	162	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1992	327	10					696	701		10.1056/NEJM199209033271005	http://dx.doi.org/10.1056/NEJM199209033271005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL235	1495522	Bronze			2022-12-28	WOS:A1992JL23500005
J	SAFER, DJ; KRAGER, JM				SAFER, DJ; KRAGER, JM			EFFECT OF A MEDIA BLITZ AND A THREATENED LAWSUIT ON STIMULANT TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RITALIN	Objective.-To enumerate and evaluate changes in the rate of medication treatment for hyperactive/inattentive students subsequent to negative media publicity about methylphenidate (Ritalin) and related lawsuits threatened or initiated from late 1987 to early 1989. Design.-Biennial 1971 to 1991 school nurse surveys of medication treatment for hyperactive/inattentive students; a 1989 school nurse questionnaire on parent attitudes about medication; annual 1984 through 1991 hyperkinetic clinic treatment data; annual 1986 through 1990 Drug Enforcement Administration estimates of retail sales of methylphenidate, nationally and locally. Primary Setting.-All public and private elementary and secondary schools in Baltimore County, Maryland. Patients.-Students receiving medication for hyperactivity/inattentiveness. Results.-Whereas the medication rate for the treatment of hyperactive/inattentive students in Baltimore County doubled every 4 to 7 years from 1971 through 1987, it declined 39% in the 1989 and 1991 surveys from its 1987 peak. This drop occurred after the 1987 through 1989 media blitz against methylphenidate and after a well-publicized threatened lawsuit locally. Parents became fearful of media-reported medication "side effects" and school staff hesitated to refer restless, impulsive, and inattentive students to physicians. Most inhibited from the prospect of medication treatment were less affluent parents and parents of hyperactive/inattentive elementary schoolchildren who had never received medication. Drug Enforcement Administration data revealed that the Baltimore metropolitan area had a far greater decline in methylphenidate use than that which occurred nationally. Conclusion.-Strong circumstantial evidence suggests that the prominent 1989 and 1991 declines in the initiation of stimulant medication for hyperactive/inattentive students were related to the apprehension of parents and involved professionals. generated by the methylphenidate media blitz and the threatened lawsuit.	JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	Johns Hopkins University	SAFER, DJ (corresponding author), BALTIMORE CTY DEPT HLTH,9100 FRANKLIN SQ DR,BALTIMORE,MD 21237, USA.							BORNEMANN A, 1989, NE TIMES REP    0111, P8; Burton Thomas M., 1991, WALL STREET J; BURTON TM, 1991, WALL ST J       0419, pA2; CALLAHAM M, 1985, ANN EMERG MED, V14, P1, DOI 10.1016/S0196-0644(85)80725-3; COLINO S, 1988, BALTIMORE MAG, V81, P66; COLINO S, 1988, BALTIMORE MAG, V81, P96; COWART VS, 1988, JAMA-J AM MED ASSOC, V259, P2521; DIVOKY D, 1989, PHI DELTA KAPPAN, V70, P599; DUNN SG, 1988, TOWSON TIMES    0525, P19; KOHN A, 1989, ATLANTIC MONTHLY, V264, P90; KRAGER JM, 1979, J SCHOOL HEALTH, V49, P317, DOI 10.1111/j.1746-1561.1979.tb07722.x; MORGAN M, 1980, J BROADCASTING, V24, P117, DOI 10.1080/08838158009363973; MOSS DC, 1988, ABA J, V74, P19; NORTON M, 1989, BALTIMORE EVENI 0104, pD3; NORTON M, 1989, BALTIMORE EVENI 0104, pD1; PRESKORN SH, 1991, J CLIN PSYCHIAT, V52, P23; SAFER DJ, 1988, JAMA-J AM MED ASSOC, V260, P2256, DOI 10.1001/jama.260.15.2256; SAPPEL J, 1990, BALTIMORE SUN   0807, P8; SHERMAN SL, 1988, BALTIMORE DAILY 0518, P1; SHERMAN SL, 1988, BALTIMORE DAILY 0518, P11; SPRAGUE RL, 1991, OCT WORLD C PSYCH AT, V6, P569; THOMPSON K, 1987, BALTIMORE SUN   1211, P1; TREADWELL D, 1987, BALTIMORE SUN   1230, pC8; TREADWELL D, 1987, BALTIMORE SUN   1230, pC1; WELKE R, 1990, DET CL REV, P125; Wright JC, 1990, TELEVISION AM FAMILY, P227; 1989, BALTIMORE SUN   0104, pD1; 1970, NEWSWEEK        0209, P52; 1991, ARCOS DATA BASE 1986	29	42	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1992	268	8					1004	1007		10.1001/jama.268.8.1004	http://dx.doi.org/10.1001/jama.268.8.1004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK129	1501304				2022-12-28	WOS:A1992JK12900025
J	VOLKMUTH, WD; AUSTIN, RH				VOLKMUTH, WD; AUSTIN, RH			DNA ELECTROPHORESIS IN MICROLITHOGRAPHIC ARRAYS	NATURE			English	Article							GEL-ELECTROPHORESIS; ELECTRIC-FIELD; AGAROSE GELS; MOLECULES; MICROSCOPY; MOBILITY; DYNAMICS	WE have used optical microlithography to fabricate capped quasi-two-dimensional obstacle courses in SiO2. We report here observations using epifluorescence microscopy of the electrophoresis and length fractionation of large DNA molecules confined in arrays. Simple reptation theory, based on the work of deGennes1, predicts that at low electric fields the electrophoretic mobility of a polymer of length L much greater than the persistence length p scales inversely with L (ref. 2). But elongation of the coil in the matrix at sufficiently strong electric fields3 results in a length-independent electrophoretic mobility4,5. The application of suitably timed pulsed electric fields restores the fractionating power of gels for long molecules6 but the protocols of pulsed-field electrophoresis are semi-empirical because the complex and ill-understood gel matrix plays a critical role in fractionation. Microlithographically constructed obstacle arrays, with their low dimensionality, small volume and extremely reproducible topography, will make it possible to understand the motion and fractionation of large polymer molecules in complex but well characterized topologies.			VOLKMUTH, WD (corresponding author), PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544, USA.							BUSTAMANTE C, 1991, ANNU REV BIOPHYS BIO, V20, P415, DOI 10.1146/annurev.bb.20.060191.002215; DEGENNES P, 1991, SCALING CONCEPTS POL, P223; DEUTSCH JM, 1989, J CHEM PHYS, V90, P2476, DOI 10.1063/1.455990; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HERVET H, 1987, BIOPOLYMERS, V26, P727, DOI 10.1002/bip.360260512; HOLMES DL, 1990, ELECTROPHORESIS, V11, P5, DOI 10.1002/elps.1150110103; KOZAK MW, 1990, LANGMUIR, V6, P1585, DOI 10.1021/la00100a010; LALANDE M, 1988, NUCLEIC ACIDS RES, V16, P5427, DOI 10.1093/nar/16.12.5427; LERMAN LS, 1982, BIOPOLYMERS, V21, P995, DOI 10.1002/bip.360210511; LUMKIN OJ, 1985, BIOPOLYMERS, V24, P1573; MANNING GS, 1969, J CHEM PHYS, V51, P924, DOI 10.1063/1.1672157; MORIKAWA K, 1981, J BIOCHEM-TOKYO, V89, P693, DOI 10.1093/oxfordjournals.jbchem.a133247; SCHURR JM, 1990, BIOPOLYMERS, V29, P1161, DOI 10.1002/bip.360290806; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; SERWER P, 1989, ELECTROPHORESIS, V10, P327, DOI 10.1002/elps.1150100510; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; SONG L, 1991, J BIOMOL STRUCT DYN, V9, P87, DOI 10.1080/07391102.1991.10507895; WALLIS G, 1969, J APPL PHYS, V40, P3946, DOI 10.1063/1.1657121	19	398	488	0	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1992	358	6387					600	602		10.1038/358600a0	http://dx.doi.org/10.1038/358600a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JH829	1501715				2022-12-28	WOS:A1992JH82900065
J	MORIARTY, KJ; IRVING, MH				MORIARTY, KJ; IRVING, MH			ABC OF COLORECTAL DISEASES - CONSTIPATION	BRITISH MEDICAL JOURNAL			English	Article									HOPE HOSP,DEPT SURG,SALFORD M6 8HD,LANCS,ENGLAND		MORIARTY, KJ (corresponding author), BOLTON GEN HOSP,BOLTON,ENGLAND.							BURKITT, 1972, LANCET, V2, P1408	1	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1237	1240		10.1136/bmj.304.6836.1237	http://dx.doi.org/10.1136/bmj.304.6836.1237			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515801	Green Published, Bronze			2022-12-28	WOS:A1992HT96400032
J	ABBOTT, A				ABBOTT, A			GERMAN STATE UNEXPECTEDLY APPROVES 1ST GENE TRIALS	NATURE			English	Editorial Material																		1992, NATURE, V360, P399	1	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					702	702		10.1038/360702a0	http://dx.doi.org/10.1038/360702a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465137	Bronze			2022-12-28	WOS:A1992KE47200007
J	OPPENHEIM, RW; YIN, QW; PREVETTE, D; YAN, Q				OPPENHEIM, RW; YIN, QW; PREVETTE, D; YAN, Q			BRAIN-DERIVED NEUROTROPHIC FACTOR RESCUES DEVELOPING AVIAN MOTONEURONS FROM CELL-DEATH	NATURE			English	Article							EMBRYO SPINAL-CORD; NERVE GROWTH-FACTOR; CHICK-EMBRYO; RETROGRADE TRANSPORT; MOTOR NEURONS; MESSENGER-RNA; SURVIVAL; NGF; MUSCLE; DEGENERATION	DURING normal vertebrate development, about half of spinal motoneurons are lost by a process of naturally occurring or programmed cell death1,2. Additional developing motoneurons degenerate after the removal of targets3,4 or afferents5. Naturally occurring motoneuron death as well as motoneuron death after loss of targets or after axotomy can. be prevented by in vivo treatment with putative target (muscle) derived or other neurotrophic agents6-8. Motoneurons can also be prevented from dying in vitro9-12 and in vivo (Y.Q.-W., R.W., D.P., J. Johnson and L. Van Eldik, unpublished data and refs 7, 13, 14) by treatment with central nervous system extracts (brain or spinal cord) and purified central nervous system and glia-derived proteins. Here we report that in vivo treatment of chick embryos with brain-derived neurotrophic factor rescues motoneurons from naturally occurring cell death. Furthermore, in vivo treatment with brain-derived neurotrophic factor (and nerve growth factor) also prevents the induced death of motoneurons that occurs following the removal of descending afferent input(deafferentation)5. These data indicate that members of the neurotrophin family can promote the survival of developing avian motoneurons.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,NEUROSCI PROGRAM,WINSTON SALEM,NC 27103; AMGEN INC,AMGEN CTR,NEUROBIOL PROGRAM,THOUSAND OAKS,CA 91320	Wake Forest University; Wake Forest Baptist Medical Center; Amgen	OPPENHEIM, RW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROBIOL & ANAT,WINSTON SALEM,NC 27103, USA.							ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BHATTACHARYYA A, IN PRESS J NEUROBIOL; BLOCHGALLEGO E, 1991, DEVELOPMENT, V111, P221; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; DOHRMANN U, 1987, DEV BIOL, V124, P145, DOI 10.1016/0012-1606(87)90467-2; DOHRMANN U, 1986, DEV BIOL, V188, P20; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; HAMBURGER V, 1958, AM J ANAT, V102, P465; HOFER MM, 1988, NATURE, V331, P361; HULST JR, 1986, DEV BRAIN RES, V25, P153, DOI 10.1016/0165-3806(86)90164-1; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARCHETTI D, 1991, DEV BIOL, V148, P306, DOI 10.1016/0012-1606(91)90339-5; OKADO N, 1984, J NEUROSCI, V4, P1639; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1982, J COMP NEUROL, V210, P174, DOI 10.1002/cne.902100208; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OPPENHEIM RW, 1978, J COMP NEUROL, V177, P87, DOI 10.1002/cne.901770107; OPPENHEIM RW, 1988, SCIENCE, V240, P919, DOI 10.1126/science.3363373; OPPENHEIM RW, 1989, DEV BIOL, V133, P468, DOI 10.1016/0012-1606(89)90050-X; OPPENHEIM RW, IN PRESS J NEUROSCI; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; WAYNE DB, 1988, DEV BIOL, V127, P220, DOI 10.1016/0012-1606(88)90203-5; WAYNE DB, 1990, DEV BIOL, V138, P473, DOI 10.1016/0012-1606(90)90213-3; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1988, NEURON, V1, P335	28	445	462	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					755	759		10.1038/360755a0	http://dx.doi.org/10.1038/360755a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465146				2022-12-28	WOS:A1992KE47200038
J	ROZAKISADCOCK, M; MCGLADE, J; MBAMALU, G; PELICCI, G; DALY, R; LI, W; BATZER, A; THOMAS, S; BRUGGE, J; PELICCI, PG; SCHLESSINGER, J; PAWSON, T				ROZAKISADCOCK, M; MCGLADE, J; MBAMALU, G; PELICCI, G; DALY, R; LI, W; BATZER, A; THOMAS, S; BRUGGE, J; PELICCI, PG; SCHLESSINGER, J; PAWSON, T			ASSOCIATION OF THE SHC AND GRB2/SEM5 SH2-CONTAINING PROTEINS IS IMPLICATED IN ACTIVATION OF THE RAS PATHWAY BY TYROSINE KINASES	NATURE			English	Article							NERVE GROWTH-FACTOR; TRK PROTOONCOGENE; PC12 CELLS; RECEPTOR; DIFFERENTIATION; INHIBITION; AFFINITY; MUTATION; VECTORS	THE mammalian shc gene encodes two overlapping, widely expressed proteins of 46 and 52K, with a carboxy-terminal SH2 domain that binds activated growth factor receptors, and a more amino-terminal glycine/proline-rich region1. These shc gene products (Shc) are transforming when overexpressed in fibroblasts1. Shc proteins become phosphorylated on tyrosine in cells stimulated with a variety of growth factors1, and in cells transformed by v-src (ref. 2), suggesting that they are tyrosine kinase targets that control a mitogenic signalling pathway. Here we report that tyrosine-phosphorylated Shc proteins form a specific complex with a non-phosphorylated 23K polypeptide encoded by the grb2/sem-5 gene3,4. The grb2/sem-5 gene product itself contains an SH2 domain, which mediates binding to Shc, and is implicated in activation of the Ras guanine nucleotide-binding protein by tyrosine kinases in both Caenorhabditis elegans and mammalian cells3,4. Consistent with a role in signalling through Ras, shc overexpression induced Ras-dependent neurite outgrowth in PC12 cells. These results suggest that Shc tyrosine phosphorylation can couple tyrosine kinases to Grb2/Sem-5, through formation of a Shc-Grb2/Sem-5 complex, and thereby regulate the mammalian Ras signalling pathway.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Takeda Pharmaceutical Company Ltd; Takeda Oncology; University of Toronto; University of Perugia; New York University			Franzeck, Fabian C/B-5055-2011; Daly, Roger J/C-8179-2009; Pelicci, Giuliana/AAA-8921-2022; Pawson, Tony J/E-4578-2013; Pelicci, Pier Giuseppe/AAL-6572-2020	Pelicci, Giuliana/0000-0003-0986-8255; Daly, Roger/0000-0002-5739-8027				BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUO K, 1990, ONCOGENE, V5, P921; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	23	941	978	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					689	692		10.1038/360689a0	http://dx.doi.org/10.1038/360689a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465135				2022-12-28	WOS:A1992KD08200062
J	LOWRY, S				LOWRY, S			MEDICAL-EDUCATION .4. STRATEGIES FOR IMPLEMENTING CURRICULUM CHANGE	BRITISH MEDICAL JOURNAL			English	Article							STUDENTS											Branda L A, 1990, J Dent Educ, V54, P548; COLES CR, 1985, MED EDUC, V19, P308, DOI 10.1111/j.1365-2923.1985.tb01327.x; Harden R M, 1984, Med Educ, V18, P284; LOWRY S, 1992, BRIT MED J, V305, P1409, DOI 10.1136/bmj.305.6866.1409; LOWRY S, 1992, BRIT MED J, V305, P1277, DOI 10.1136/bmj.305.6864.1277; Mitchell D L, 1975, Br J Med Educ, V9, P133; NEUFELD VR, 1981, MED EDUC, V15, P315, DOI 10.1111/j.1365-2923.1981.tb02495.x; OSWALD N, 1989, LANCET, V2, P148; OSWALD N, 1991, BRIT MED J, V303, P71, DOI 10.1136/bmj.303.6794.71; STILLMAN PL, 1986, ANN INTERN MED, V105, P762, DOI 10.7326/0003-4819-105-5-762; TOWLE A, 1991, CRITICAL THINKING FU; WALTON HJ, 1989, MED EDUC, V23, P542, DOI 10.1111/j.1365-2923.1989.tb01581.x; WALTON JN, 1977, BRIT MED J, V1, P1262, DOI 10.1136/bmj.1.6071.1262; 1992, TEACHING HOSPITAL DO; 1992, IMPROVING STUDENT LE; 1991, UNDERGRADUATE MED ED	16	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1482	1485		10.1136/bmj.305.6867.1482	http://dx.doi.org/10.1136/bmj.305.6867.1482			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493398	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KC91800029
J	BLACK, FL				BLACK, FL			WHY DID THEY DIE	SCIENCE			English	Editorial Material							HLA				BLACK, FL (corresponding author), YALE UNIV,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510, USA.							BAUR MP, 1982, HISTOCOMPATIBILITY T; BELICH MP, 1992, NATURE, V357, P326, DOI 10.1038/357326a0; BHATIA K, 1989, HUM BIOL, V61, P45; BLACK FL, 1971, J INFECT DIS, V124, P306, DOI 10.1093/infdis/124.3.306; BORST P, 1991, PARASITOL TODAY, V8, pA29; CATTANEO R, 1986, VIROLOGY, V154, P97, DOI 10.1016/0042-6822(86)90433-2; DEHAY C, 1987, TISSUE ANTIGENS, V30, P49; Denevan W, 1992, NATIVE POPULATION AM; DUTOIT ED, 1990, TISSUE ANTIGENS, V36, P122, DOI 10.1111/j.1399-0039.1990.tb01812.x; FLEMINGMORAN M, 1991, HUM BIOL, V63, P835; FRIKEL P, 1963, REV MUS PAUL, V14, P11145; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; HEDRICK PW, 1983, GENETICS, V104, P449; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KILLIAMS RC, 1981, AM J PHYS ANTHROPOL, V56, P291; LEE TD, 1988, TISSUE ANTIGENS, V32, P188, DOI 10.1111/j.1399-0039.1988.tb01656.x; MCCRUMB FR, 1963, AM J DIS CHILD, V101, P689; Salzano FM, 1988, S AM INDIANS CASE ST; SULLIVAN PJ, 1992, SCIENCE, V256, P1743, DOI 10.1126/science.1520396; WATKINS DI, 1992, NATURE, V357, P329, DOI 10.1038/357329a0; [No title captured]	21	119	121	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1739	1741		10.1126/science.1465610	http://dx.doi.org/10.1126/science.1465610			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465610				2022-12-28	WOS:A1992KB96400023
J	FRIEDBERG, EC				FRIEDBERG, EC			XERODERMA-PIGMENTOSUM, COCKAYNES-SYNDROME, HELICASES, AND DNA-REPAIR - WHATS THE RELATIONSHIP	CELL			English	Review											FRIEDBERG, EC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PATHOL,MOLEC PATHOL LAB,DALLAS,TX 75235, USA.							BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; DECOCK JGR, 1992, MUTAT RES, V293, P11, DOI 10.1016/0921-8777(92)90003-L; FLETJER WL, 1992, P NATL ACAD SCI USA, V89, P261; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; JOHNSON RE, 1992, MOL CELL BIOL, V1, P3807; MOUNKES LC, 1992, CELL, V71; MURRAY JM, 1992, NUCLEIC ACIDS RES, V20, P2673, DOI 10.1093/nar/20.11.2673; NAEGELI H, 1992, J BIOL CHEM, V267, P392; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; REYNOLDS PR, 1992, NUCLEIC ACIDS RES, V20, P2327, DOI 10.1093/nar/20.9.2327; RONG L, 1992, IN PRESS J BIOL CHEM; SCHILD D, 1992, YEAST, V8, P385, DOI 10.1002/yea.320080506; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X	17	74	77	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					887	889		10.1016/0092-8674(92)90384-O	http://dx.doi.org/10.1016/0092-8674(92)90384-O			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458537				2022-12-28	WOS:A1992KB99000001
J	JOWELL, T				JOWELL, T			LONDON AFTER TOMLINSON - COMMUNITY CARE IN LONDON - THE PROSPECTS	BRITISH MEDICAL JOURNAL			English	Article								Elderly and disabled people have been led to expect great improvements in the quality of community care after April 1993. The choice to live safely at home is to be offered as an alternative to residential care. The financial and organisational relationships are all intended to support this in practice. The Tomlinson recommendations will create instability for providers, and much new and overdue investment in primary and community services is needed if the community care reforms are to work. There are, however, other obstacles looming which pose an even greater threat to the smooth transition after April 1993. The formula by which government money for implementation will be distributed discriminates against London. The sheer complexity of the organisational transformation has also been underestimated; the machinery of government both locally and centrally is ill equipped to maintain the precedence of the consumer. There are examples of good practice in London boroughs, but the dangers of Londoners ending up with the worst of all worlds are great.										JARMAN B, 1992, BRIT MED J, V305, P1130, DOI 10.1136/bmj.305.6862.1130; 1992, INQUIRY LONDONS HLTH; 1991, I KNOW I AM COPING W; 1992, LONDON HLTH CARE 201; 1992, COMMUNITY CARE MANAG	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1418	1420		10.1136/bmj.305.6866.1418	http://dx.doi.org/10.1136/bmj.305.6866.1418			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486310	Green Published, Green Submitted, Bronze			2022-12-28	WOS:A1992KB85600029
J	VONMUTIUS, E; FRITZSCH, C; WEILAND, SK; ROLL, G; MAGNUSSEN, H				VONMUTIUS, E; FRITZSCH, C; WEILAND, SK; ROLL, G; MAGNUSSEN, H			PREVALENCE OF ASTHMA AND ALLERGIC DISORDERS AMONG CHILDREN IN UNITED GERMANY - A DESCRIPTIVE COMPARISON	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SULFUR-OXIDES; HOSPITAL ADMISSIONS; RESPIRATORY HEALTH; NEW-ZEALAND; HAY-FEVER; RESPONSIVENESS; ADOLESCENTS; POLLINOSIS; MORTALITY; MORBIDITY	Objectives-To compare the prevalence of asthma and allergic disorders among children in Munich, western Germany, and Letpzig, eastern Germany, where environmental exposure, particularly air concentrations of sulphur dioxide and particulate matter, and living conditions have differed over the past 45 years. Design-Prevalence surveys among school-children aged 9-11 years in Leipzig and Munich. Self completion of written questionnaire by the children's parents and lung function measurements. Subjects-1051 children in Leipzig and 5030 in Munich. Setting-Primary schools. Main outcome measures-Reported lifetime prevalence of asthma and allergic disorders, and bronchial hyperresponsiveness assessed by cold air inhalation challenge. Results-The lifetime prevalence of asthma diagnosed by a doctor was 7.3% (72) in Leipzig and 9.3% (435) in Munich; prevalences of wheezing were 20% (191) and 17% (786) respectively. The prevalence of diagnosed bronchitis was higher in Leipzig than Munich (30.9% (303) v 15.9% (739); p<0.01). A significant drop in forced expiratory volume (>9%) after cold air challenge was measured in 6.4% (57) of children in Leipzig and in 7.7% (345) of those in Munich. Hay fever (2.4% (24) v 8.6% (410); p<0.01) and typical symptoms of rhinitis (16.6% (171) v 19.7% (961); p<0.05) were reported less often in Leipzig than in Munich. Conclusions-No significant differences were seen in the lifetime prevalence of asthma, wheezing, and bronchial hyperresponsiveness between children in Leipzig and Munich. The lifetime prevalence of bronchitis was higher in Leipzig than in Munich. The lower prevalence rates of allergic disorders in Leipzig could point toward aetiological factors that are associated with Western lifestyle and living conditions.	CHILDRENS HOSP LEIPZIG, O-7050 LEIPZIG, GERMANY; RUHR UNIV BOCHUM, DEPT SOCIAL MED & EPIDEMIOL, W-4630 BOCHUM, GERMANY; GSF MEDIS INST, ENVIRONM & HUMAN HLTH RES CTR, W-8000 MUNICH, GERMANY; KRANKENHAUS GROSSHANSDORF HAMBURG, ZENTRUM PNEUMOL & THORAXCHIRURG, HAMBURG, GERMANY	Ruhr University Bochum	VONMUTIUS, E (corresponding author), UNIV MUNICH, CHILDRENS HOSP, DR VON HAUNERSCHE KINDERKLIN, W-8000 MUNICH 2, GERMANY.							ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42, DOI 10.1164/ajrccm/145.1.42; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; DODGE R, 1985, AM J EPIDEMIOL, V121, P720, DOI 10.1093/aje/121.5.720; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FLEISS JL, 1980, STATISTICAL METHODS; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; FRIDAY GA, 1988, PEDIATR CLIN N AM, V35, P1149; GORE AT, 1968, BR J PREV SOC MED, V12, P104; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; JORRES R, 1990, EUR RESPIR J, V3, P132; KOENIG JQ, 1985, J ALLERGY CLIN IMMUN, V76, P813, DOI 10.1016/0091-6749(85)90754-7; LOGAN WPD, 1953, LANCET, V264, P336; LUNN JE, 1970, BRIT J PREV SOC MED, V24, P223; LUNN JE, 1967, BRIT J PREV SOC MED, V21, P7; MITCHELL EA, 1989, J ASTHMA, V26, P349, DOI 10.3109/02770908909073277; MITCHELL EA, 1989, EUR RESPIR J, V2, P470; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; NICOLAI T, IN PRESS AM REV RESP; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEINBRUCK P, 1969, MONATSSCHR LUNGENKR, V12, P289; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; VARONIER HS, 1984, HELV PAEDIATR ACTA, V39, P129; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; WUTHRICH B, 1986, SCHWEIZ MED WSCHR, V116, P909; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; 1990, STATISTICAL ANAL VER	36	363	369	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1992	305	6866					1395	1399		10.1136/bmj.305.6866.1395	http://dx.doi.org/10.1136/bmj.305.6866.1395			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486303	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1992KB85600021
J	BRANGER, PJ; VANDERWOUDEN, JC; SCHUDEL, BR; VERBOOG, E; DUISTERHOUT, JS; VANDERLEI, J; VANBEMMEL, JH				BRANGER, PJ; VANDERWOUDEN, JC; SCHUDEL, BR; VERBOOG, E; DUISTERHOUT, JS; VANDERLEI, J; VANBEMMEL, JH			ELECTRONIC COMMUNICATION BETWEEN PROVIDERS OF PRIMARY AND SECONDARY CARE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; SPECIALISTS	Objective-To study the effects of the introduction of electronic data interchange between primary and secondary care providers on speed of communication, efficiency of data handling, and satisfaction of general practitioners with communication. Design-Comparison of traditional paper based communication for laboratory reports and admission-discharge reports between hospital and general practitioners and electronic data interchange. Setting-Twenty-seven general practitioners whose offices were equipped with a practice information system and two general hospitals. Outcome measures-Paper based communication was evaluated by questionnaire responses from and interviews with care providers; electronic communication was evaluated by measuring time intervals between generation and delivery of messages and by assessing doctors' satisfaction with electronic data interchange by questionnaire. Results-Via paper mail admission-discharge reports took a median of 2-4 days, and laboratory reports 2 days, to reach general practitioners. With electronic data interchange almost all admission-discharge reports were available to general practitioners within one hour of generation. When samples were analysed on the day of collection (as was the case for 174/542 samples in one hospital and 443/854 in the other) the laboratory reports were also available to the general practitioner the same day via electronic data interchange. Fifteen general practitioners (of the 24 who returned the questionnaire) reported that the use of electronic admission-discharge reports provided more accurate and complete information about the care delivered to their patients. Ten general practitioners reported that electronic laboratory reports lessened the work of processing the data. Conclusion-Electronic communication between primary and secondary care providers is a feasible option for improving communication.	ERASMUS UNIV,DEPT GEN PRACTICE,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC	BRANGER, PJ (corresponding author), ERASMUS UNIV,DEPT MED INFORMAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		van der Wouden, Johannes C/O-5109-2019; van der Wouden, Johannes C/C-2597-2009; Greiver, Michelle/N-8764-2015	van der Wouden, Johannes C/0000-0001-6639-6050; Greiver, Michelle/0000-0001-8957-0285				AMENT A, 1990, LECTURE NOTES MED IN, V40, P130; DOELEMAN F, 1987, FAM PRACT, V4, P176, DOI 10.1093/fampra/4.3.176; DUISTERHOUT JS, 1991, TELEMATICS IN MEDICINE, P151; HULL FM, 1986, BRIT MED J, V293, P311, DOI 10.1136/bmj.293.6542.311; JACOBS LGH, 1990, BRIT MED J, V301, P470, DOI 10.1136/bmj.301.6750.470; KINKHORST OM, 1991, TELEMATICS IN MEDICINE, P313; MAGEEAN RJ, 1986, BRIT MED J, V293, P1283, DOI 10.1136/bmj.293.6557.1283; SANDLER DA, 1987, BRIT MED J, V295, P1523, DOI 10.1136/bmj.295.6612.1523; TULLOCH AJ, 1975, BRIT MED J, V4, P443, DOI 10.1136/bmj.4.5994.443; WALKER RJ, 1989, 1ST STEPS EDI; WESTERHOF HP, 1987, LECTURE NOTES MED IN, P1; WESTERMAN RF, 1990, BRIT J GEN PRACT, V40, P445; WILLIAMS EI, 1990, BRIT MED J, V300, P159, DOI 10.1136/bmj.300.6718.159; 1988, ISO9735 UN EC COMM E	14	76	77	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1068	1070		10.1136/bmj.305.6861.1068	http://dx.doi.org/10.1136/bmj.305.6861.1068			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467688	Bronze, Green Published			2022-12-28	WOS:A1992JW70100021
J	NIEMANN, JT				NIEMANN, JT			CURRENT CONCEPTS - CARDIOPULMONARY-RESUSCITATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HOSPITAL VENTRICULAR-FIBRILLATION; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; ESOPHAGEAL OBTURATOR AIRWAY; CORONARY PERFUSION-PRESSURE; CARDIAC-ARREST; BLOOD-FLOW; SODIUM-BICARBONATE; VALVE MOTION; MYOCARDIAL PERFUSION; ELECTRICAL MODEL		UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	NIEMANN, JT (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT EMERGENCY MED,1000 W CARSON ST,TORRANCE,CA 90509, USA.			Niemann, James/0000-0002-2626-7681				BABBS CF, 1984, AM J EMERG MED, V2, P299, DOI 10.1016/0735-6757(84)90124-4; BARTON CW, 1988, ANN EMERG MED, V17, P393; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BIRCHER N, 1984, ANN EMERG MED, V13, P770, DOI 10.1016/S0196-0644(84)80432-1; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; BROWN CG, 1990, RESUSCITATION, V19, P1, DOI 10.1016/0300-9572(90)90094-U; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CRILEY JM, 1976, JAMA-J AM MED ASSOC, V236, P1246, DOI 10.1001/jama.236.11.1246; CUMMINS RO, 1988, ANN EMERG MED, V17, P813, DOI 10.1016/S0196-0644(88)80561-4; CUMMINS RO, 1989, CLIN CRITICAL CARE M, V16, P87; DELGUERCIO LR, 1965, CIRCULATION, V31, P171; DESHMUKH HG, 1989, CHEST, V95, P1092, DOI 10.1378/chest.95.5.1092; EISENBERG M, 1981, JAMA-J AM MED ASSOC, V246, P50, DOI 10.1001/jama.246.1.50; EWY GA, 1981, CRIT CARE MED, V9, P841, DOI 10.1097/00003246-198112000-00008; FALK JL, 1988, NEW ENGL J MED, V318, P607, DOI 10.1056/NEJM198803103181005; FENELEY MP, 1987, CIRCULATION, V76, P363, DOI 10.1161/01.CIR.76.2.363; FISER DH, 1990, NEW ENGL J MED, V322, P1579; FISHER J, 1982, CIRCULATION, V65, P188, DOI 10.1161/01.CIR.65.1.188; FOX M, 1983, NEW ENGL J MED, V309, P607, DOI 10.1056/NEJM198309083091010; FRASS M, 1987, CRIT CARE MED, V15, P609, DOI 10.1097/00003246-198706000-00015; GANDO S, 1990, ANN EMERG MED, V19, P850, DOI 10.1016/S0196-0644(05)81556-2; GARNETT AR, 1987, JAMA-J AM MED ASSOC, V257, P512, DOI 10.1001/jama.257.4.512; GEEHR EC, 1986, NEW ENGL J MED, V314, P1189; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GUERCI AD, 1986, CIRCULATION, V74, P75; HARGARTEN KM, 1990, ANN EMERG MED, V19, P157, DOI 10.1016/S0196-0644(05)81801-3; HAYNES RE, 1981, AM J CARDIOL, V48, P353, DOI 10.1016/0002-9149(81)90619-6; HEDGES JR, 1987, CIRCULATION, V76, P1337, DOI 10.1161/01.CIR.76.6.1337; HEDGES JR, 1984, ANN EMERG MED, V13, P822, DOI 10.1016/S0196-0644(84)80450-3; HERSHEY CO, 1982, LANCET, V1, P31, DOI 10.1016/S0140-6736(82)92567-3; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KETTE F, 1991, JAMA-J AM MED ASSOC, V266, P2121, DOI 10.1001/jama.266.15.2121; KETTE F, 1990, CIRCULATION, V81, P1660, DOI 10.1161/01.CIR.81.5.1660; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; Kremers M S, 1989, Dis Mon, V35, P381; KRISCHER JP, 1987, CHEST, V92, P287, DOI 10.1378/chest.92.2.287; MAIER GW, 1984, CIRCULATION, V70, P86, DOI 10.1161/01.CIR.70.1.86; MARTIN GB, 1990, ANN EMERG MED, V19, P396, DOI 10.1016/S0196-0644(05)82345-5; MEADOR SA, 1986, RESUSCITATION, V13, P145, DOI 10.1016/0300-9572(86)90096-1; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; MICHAEL TAD, 1985, CHEST, V87, P814, DOI 10.1378/chest.87.6.814; MINUCK M, 1977, ANESTH ANALG, V56, P38; NIEMANN JT, 1981, CIRCULATION, V64, P985, DOI 10.1161/01.CIR.64.5.985; NIEMANN JT, 1980, CRIT CARE MED, V8, P141, DOI 10.1097/00003246-198003000-00011; NIEMANN JT, 1985, ANN EMERG MED, V14, P521, DOI 10.1016/S0196-0644(85)80774-5; NIEMANN JT, 1984, ANN EMERG MED, V13, P849, DOI 10.1016/S0196-0644(84)80458-8; NIEMANN JT, 1984, ANN EMERG MED, V13, P781, DOI 10.1016/S0196-0644(84)80435-7; PARADIS NA, 1990, ANN EMERG MED, V19, P1288, DOI 10.1016/S0196-0644(05)82289-9; PARADIS NA, 1989, CIRCULATION, V80, P361, DOI 10.1161/01.CIR.80.2.361; PEATFIELD RC, 1977, LANCET, V1, P1223; REDDING JS, 1968, J AMER MED ASSOC, V203, P255; RICH S, 1981, AM HEART J, V102, P368, DOI 10.1016/0002-8703(81)90311-2; RUDIKOFF MT, 1980, CIRCULATION, V61, P345, DOI 10.1161/01.CIR.61.2.345; SANDERS AB, 1985, J AM COLL CARDIOL, V6, P113, DOI 10.1016/S0735-1097(85)80261-8; SANDERS AB, 1984, CRIT CARE MED, V12, P871, DOI 10.1097/00003246-198410000-00007; SANDERS AB, 1984, ANN EMERG MED, V13, P672, DOI 10.1016/S0196-0644(84)80723-4; SANDERS AB, 1984, ANN EMERG MED, V13, P676, DOI 10.1016/S0196-0644(84)80724-6; SHERMAN BW, 1991, ANN EMERG MED, V20, P949; SMITH JP, 1983, JAMA-J AM MED ASSOC, V250, P1081, DOI 10.1001/jama.250.8.1081; STERNER S, 1991, ANN EMERG MED, V20, P949; SUTTONTYRRELL K, 1988, ANN EMERG MED, V17, P572, DOI 10.1016/S0196-0644(88)80394-9; SWENSON RD, 1988, CIRCULATION, V78, P630, DOI 10.1161/01.CIR.78.3.630; THOMPSON BM, 1986, CIRCULATION, V74, P90; URBAN P, 1988, ANN INTERN MED, V109, P110, DOI 10.7326/0003-4819-109-2-110; VINCENT JL, 1981, CIRCULATION, V64, P18, DOI 10.1161/01.CIR.64.1.18; WARNER LL, 1985, CHEST, V87, P22, DOI 10.1378/chest.87.1.22; WEAVER WD, 1985, ANN INTERN MED, V102, P53, DOI 10.7326/0003-4819-102-1-53; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; WEIL MH, 1986, NEW ENGL J MED, V315, P153, DOI 10.1056/NEJM198607173150303; WERNER JA, 1981, CIRCULATION, V63, P1417, DOI 10.1161/01.CIR.63.6.1417; 1988, LANCET, V1, P743; 1986, JAMA-J AM MED ASSOC, V255, P2920; 1986, JAMA-J AM MED ASSOC, V256, P1727	74	57	63	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1992	327	15					1075	1080						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR321	1522844				2022-12-28	WOS:A1992JR32100007
J	BERGSTEIN, JM; RILEY, M; BANG, NU				BERGSTEIN, JM; RILEY, M; BANG, NU			ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN THE PATHOGENESIS AND OUTCOME OF THE HEMOLYTIC UREMIC SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL-CELLS; PLASMA INHIBITOR; PLATELETS	Background. Deposition of fibrin in glomeruli and renal failure are characteristic features of the hemolytic uremic syndrome. An inhibitor of glomerular fibrinolysis has been detected in plasma from children with this disorder. In this study, we define the inhibitor and show that its plasma level is correlated with the outcome of the disease. Methods and Results. Plasminogen-activator inhibitor type 1 (PAI-1) in plasma was measured with an assay employing a specific monoclonal antibody in 40 consecutive children hospitalized with the hemolytic uremic syndrome: 12 who recovered adequate renal function (serum creatinine, less-than-or-equal-to 2.0 mg per deciliter [177-mu-mol per liter]) without dialysis, 23 who recovered adequate renal function after peritoneal dialysis, and 5 who did not recover adequate renal function after undergoing dialysis. At presentation, plasma PAI-1 levels were higher in the patients with the hemolytic uremic syndrome than in nine children with other forms of acute renal failure. That the inhibitor was PAI-1 was indicated by the fact that it was a potent inhibitor of tissue plasminogen activator, was acid-resistant, and was not inhibited by denaturation (all unique traits of PAI-1) and that it was neutralized by an antibody specific for PAI-1. Multivariate discriminant-function analysis revealed that the duration of elevated PAI-1 activity was strongly correlated with the outcome of the disease (P<0.001). Peritoneal dialysis reduced plasma PAI-1 levels dramatically. Conclusions. Our studies suggest that PAI-1 is the circulating inhibitor of fibrinolysis in the hemolytic uremic syndrome. Normalization of plasma PAI-1 levels (e.g., by peritoneal dialysis) is correlated with improvement in renal function. However, the possibility that increased plasma levels of PAI-1 are either causes or effects of the hemolytic uremic syndrome is not unequivocally established by these studies.	INDIANA UNIV, SCH MED, LILLY RES LABS, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT PEDIAT, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Eli Lilly; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis								[Anonymous], 1987, PEDIATRICS, V79, P1; BANCROFT H, 1962, INTRO BIOSTATISTICS; BERGSTEIN JM, 1988, KIDNEY INT, V33, P868, DOI 10.1038/ki.1988.78; BERGSTEIN JM, 1982, AM J MED, V73, P322, DOI 10.1016/0002-9343(82)90717-3; BOOTH NA, 1988, BRIT J HAEMATOL, V70, P327, DOI 10.1111/j.1365-2141.1988.tb02490.x; DECLERCK PJ, 1988, BLOOD, V71, P220; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; ERICKSON LA, 1986, BLOOD, V68, P1298; HEKMAN CM, 1987, SEMIN THROMB HEMOST, V13, P514, DOI 10.1055/s-2007-1003527; KREDIET RT, 1986, NEPHRON, V42, P133, DOI 10.1159/000183652; KRUITHOF EKO, 1986, THROMB HAEMOSTASIS, V55, P65; LOSKUTOFF DJ, 1977, P NATL ACAD SCI USA, V74, P3903, DOI 10.1073/pnas.74.9.3903; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; SPRENGERS ED, 1987, BLOOD, V69, P381; 1990, AM J KIDNEY DIS S2, V16, P65	15	84	85	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1992	327	11					755	759		10.1056/NEJM199209103271102	http://dx.doi.org/10.1056/NEJM199209103271102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JL661	1501651				2022-12-28	WOS:A1992JL66100002
J	SMITH, JL; WILSON, JE; MACDONALD, PM				SMITH, JL; WILSON, JE; MACDONALD, PM			OVEREXPRESSION OF OSKAR DIRECTS ECTOPIC ACTIVATION OF NANOS AND PRESUMPTIVE POLE CELL-FORMATION IN DROSOPHILA EMBRYOS	CELL			English	Article							POSTERIOR DETERMINANT NANOS; MATERNAL-EFFECT MUTATIONS; DOUBLE-ABDOMEN EMBRYOS; GAP GENE GIANT; GERM PLASM; MESSENGER-RNA; ANTEROPOSTERIOR POLARITY; CAENORHABDITIS-ELEGANS; SEQUENCE SIMILARITY; BODY PATTERN	In Drosophila, a small group of maternal effect genes, including oskar, defines a shared pathway leading to the provision of two determinants at the posterior pole of the embryo. One determinant is the posterior body patterning morphogen nanos, and the other directs germ cell formation. Overexpression of oskar causes the shared pathway to be hyperactivated, with excess nanos activity present throughout the embryo and a superabundance of posterior pole cells. In addition, presumptive pole cells appear at a novel anterior position. Strikingly, formation of these ectopic pole cells is enhanced in nanos mutants. This observation may reflect competition between nanos and the germ cell determinant for a shared and limiting precursor.			SMITH, JL (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042612] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42612] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; Davidson E. H., 1986, GENE ACTIVITY EARLY; EDDY EM, 1975, INT REV CYTOL, V43, P229; ELDON ED, 1991, DEVELOPMENT, V111, P367; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GOLUMBESKI GS, 1991, GENE DEV, V5, P2060, DOI 10.1101/gad.5.11.2060; HAY B, 1990, DEVELOPMENT, V109, P425; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; ILLMENSEE K, 1976, EXP CELL RES, V97, P127, DOI 10.1016/0014-4827(76)90662-5; KERR JB, 1974, J EMBRYOL EXP MORPH, V32, P573; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MAHOWALD AP, 1977, AM ZOOL, V17, P551; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P803; NIKI Y, 1986, DEV BIOL, V113, P255, DOI 10.1016/0012-1606(86)90127-2; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Wieschaus E., 1986, P199	50	174	175	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1992	70	5					849	859		10.1016/0092-8674(92)90318-7	http://dx.doi.org/10.1016/0092-8674(92)90318-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JL663	1516136				2022-12-28	WOS:A1992JL66300016
J	HENRY, MF; CRONAN, JE				HENRY, MF; CRONAN, JE			A NEW MECHANISM OF TRANSCRIPTIONAL REGULATION - RELEASE OF AN ACTIVATOR TRIGGERED BY SMALL MOLECULE-BINDING	CELL			English	Article							FATTY-ACID DEGRADATION; ESCHERICHIA-COLI K-12; POSITIVE CONTROL; PRIMARY SEQUENCE; OPERON FUSION; DNA FRAGMENTS; GENE; CLONING; PROTEIN; SYSTEM	The FadR protein of E. coli activates transcription of the fabA gene, a key enzyme of fatty acid synthesis. We report that FadR binds to a DNA sequence positioned at -40 relative to the start site of the FadR-regulated fabA transcript (the location favored by positive activators). This binding was found to be specifically antagonized by long chain acyl-CoAs. The chain length specificity of the disassociation of the FadR-DNA complex by acyl-CoAs observed in vitro reflects that seen in the repression of fabA transcription observed upon addition of fatty acids to bacterial cultures. Acyl-CoA antagonism of FadR-DNA interactions is readily reversible. These data indicate that repression of fabA transcription by fatty acids is the first reported example of a repression system mediated by positive control.	UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADHYA S, 1990, J BIOL CHEM, V265, P10797; ARPS PJ, 1987, J BACTERIOL, V169, P1061, DOI 10.1128/jb.169.3.1061-1070.1987; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; CASADABAN MJ, 1975, P NATL ACAD SCI USA, V72, P809, DOI 10.1073/pnas.72.3.809; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG YY, 1988, J BACTERIOL, V170, P3937, DOI 10.1128/jb.170.9.3937-3945.1988; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CLARK D, 1981, J BACTERIOL, V148, P521, DOI 10.1128/JB.148.2.521-526.1981; CLARK DP, 1983, BIOCHEMISTRY-US, V22, P5897, DOI 10.1021/bi00294a032; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CRONAN JE, 1984, J BACTERIOL, V159, P773, DOI 10.1128/JB.159.2.773-775.1984; CRONAN JE, 1988, J BIOL CHEM, V263, P4641; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; CRONAN JE, 1973, J BIOL CHEM, V248, P1188; CRONAN JE, 1984, J BACTERIOL, V158, P357, DOI 10.1128/JB.158.1.357-361.1984; CRONAN JE, 1987, CELLULAR MOL BIOL, V1, P474; Davis R., 1980, ADV BACTERIAL GENETI; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; HENRY MF, 1989, J BACTERIOL, V171, P5254, DOI 10.1128/jb.171.10.5254-5261.1989; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; HILL FF, 1972, MOL GEN GENET, V117, P143, DOI 10.1007/BF00267611; HUGHES KT, 1988, J BACTERIOL, V170, P1666, DOI 10.1128/jb.170.4.1666-1671.1988; JASIN M, 1984, J BACTERIOL, V159, P783, DOI 10.1128/JB.159.2.783-786.1984; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEWIN B, 1990, GENES, V4, P257; Maniatis T., 1982, MOL CLONING; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; NAKAHIGASHI K, 1990, NUCLEIC ACIDS RES, V18, P4937, DOI 10.1093/nar/18.16.4937; NUNN WD, 1983, J BACTERIOL, V154, P554, DOI 10.1128/JB.154.2.554-560.1983; NUNN WD, 1987, CELLULAR MOL BIOL, V1, P31; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; POWELL GL, 1981, J BIOL CHEM, V256, P2740; RAIBAUD O, 1984, ANNU REV GENET, V18, P173, DOI 10.1146/annurev.ge.18.120184.001133; SALLUS L, 1983, J BACTERIOL, V155, P1450, DOI 10.1128/JB.155.3.1450-1454.1983; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGEAU MA, 1989, THEORETICAL BIOLOGY, P42; SAVAGEAU MA, 1979, BIOL REGUL DEV, V1, P57; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; Silhavy T. J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1980, J BACTERIOL, V142, P621, DOI 10.1128/JB.142.2.621-632.1980; SMITH RH, 1986, ARCH BIOCHEM BIOPHYS, V244, P357, DOI 10.1016/0003-9861(86)90124-4; STRUHL K, 1989, CURRENT PROTOCOLS MO, V2; TABOR S, 1987, CURRENT PROTOCOLS MO, V1; TAKETA K, 1966, J BIOL CHEM, V241, P720; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	52	134	136	2	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1992	70	4					671	679		10.1016/0092-8674(92)90435-F	http://dx.doi.org/10.1016/0092-8674(92)90435-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505031				2022-12-28	WOS:A1992JJ88600015
J	LAI, ZC; RUBIN, GM				LAI, ZC; RUBIN, GM			NEGATIVE CONTROL OF PHOTORECEPTOR DEVELOPMENT IN DROSOPHILA BY THE PRODUCT OF THE YAN GENE, AN ETS DOMAIN PROTEIN	CELL			English	Article							CELL-CELL-INTERACTION; TYROSINE-KINASE; DNA-BINDING; SEVENLESS PROTEIN; FATE; EYE; EXPRESSION; RECEPTOR; MELANOGASTER; ONCOGENE	Loss-of-function mutations in the yan gene result in the differentiation of supernumerary photoreceptors in the Drosophila eye. The yan gene encodes a protein with an ETS DNA-binding domain that accumulates in the nuclei of undifferentiated cells during the early stages of eye development. Our data suggest that yan functions as a cell-autonomous negative regulator of photoreceptor development; in the presumptive R7 and cone cells, yan appears to act antagonistically to the proneural signal mediated by sevenless and Ras1.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	LAI, ZC (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; FISCHERVIZE JA, 1992, DEVELOPMENT, V115, P89; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; FREEMAN M, 1992, IN PRESS DEVELOPMENT; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBERTSON HM, 1988, GENETICS, V118, P461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	50	235	238	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 21	1992	70	4					609	620		10.1016/0092-8674(92)90430-K	http://dx.doi.org/10.1016/0092-8674(92)90430-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JJ886	1505027				2022-12-28	WOS:A1992JJ88600010
J	TALLSTEDT, L; LUNDELL, G; TORRING, O; WALLIN, G; LJUNGGREN, JG; BLOMGREN, H; TAUBE, A				TALLSTEDT, L; LUNDELL, G; TORRING, O; WALLIN, G; LJUNGGREN, JG; BLOMGREN, H; TAUBE, A			OCCURRENCE OF OPHTHALMOPATHY AFTER TREATMENT FOR GRAVES HYPERTHYROIDISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TEMPORAL RELATIONSHIP; EYE CHANGES; DISEASE; THERAPY; CLASSIFICATION; MANAGEMENT; ONSET; DRUGS	Background. Ophthalmopathy caused by Graves' disease may first appear or worsen during or after treatment for hyperthyroidism. It is not known, however, whether choosing to treat hyperthyroidism with antithyroid drugs, iodine-131, or surgery affects the development or aggravation of Graves' ophthalmopathy. Methods. We studied 168 patients with hyperthyroidism caused by Graves' disease, stratified into two age groups - 20 to 34 years (54 patients, group 1) and 35 to 55 years (114 patients, group 2). The patients in group 1 were randomly assigned to treatment with methimazole for 18 months or subtotal thyroidectomy, and those in group 2 to either of these two treatments or to iodine-131 therapy. All the patients received thyroxine to avert hypothyroidism, except those treated with iodine-131, who received thyroxine only if hypothyroidism developed. The duration of follow-up was at least 24 months. Results. Twenty-two patients (13 percent) had infiltrative Graves' ophthalmopathy at randomization. During follow-up, ophthalmopathy developed for the first time in 22 patients (13 percent) and worsened in 8 patients (5 percent). The frequency of the development or worsening of ophthalmopathy was similar among the patients in group 1 (medical therapy, 4 of 27 patients [15 percent]; and surgery, 3 of 27 patients [11 percent]). In group 2, ophthalmopathy developed or worsened in 4 of the 38 patients (10 percent) treated medically, 6 of the 37 patients (16 percent) treated surgically, and 13 of the 39 patients (33 percent) given iodine-131 (P = 0.02 for the comparison between the iodine-131 subgroup and the others combined). The risk of the development or worsening of ophthalmopathy increased as pretreatment serum triiodothyronine concentrations increased. Conclusions. As compared with other forms of antithyroid therapy, iodine-131 is more likely to be followed by the development or exacerbation of Graves' ophthalmopathy.	ST ERIKS EYE HOSP,STOCKHOLM,SWEDEN; RADIUMHEMMET,DEPT GEN ONCOL,STOCKHOLM,SWEDEN; RADIUMHEMMET,DEPT ENDOCRINOL,STOCKHOLM,SWEDEN; RADIUMNEMMET,DEPT SURG,STOCKHOLM,SWEDEN; KAROLINSKA HOSP,S-10401 STOCKHOLM 60,SWEDEN; ST GORANS UNIV HOSP,DEPT MED,S-11281 STOCKHOLM,SWEDEN; UNIV UPPSALA,DEPT STAT,S-75105 UPPSALA,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Saint Goran's Hospital; Uppsala University			Torring, Ove/AAF-7141-2020					ALMQVIST S, 1972, ACTA OPHTHALMOL, V50, P761; ARANOW H, 1965, J CLIN ENDOCR METAB, V25, P1; BARBOSA J, 1972, ARCH INTERN MED, V130, P111, DOI 10.1001/archinte.130.1.111; BARTALENA L, 1989, ACTA ENDOCRINOL-COP, V121, P190; BARTALENA L, 1989, NEW ENGL J MED, V321, P1349, DOI 10.1056/NEJM198911163212001; CALISSENDORFF BM, 1986, ACTA OPHTHALMOL, V64, P698; DONALDSON SS, 1973, J CLIN ENDOCR METAB, V37, P276, DOI 10.1210/jcem-37-2-276; Glinoer D, 1987, Acta Endocrinol Suppl (Copenh), V285, P3; GORMAN CA, 1983, MAYO CLIN PROC, V58, P515; GWINUP G, 1982, JAMA-J AM MED ASSOC, V247, P2135, DOI 10.1001/jama.247.15.2135; HAMILTON RD, 1967, MAYO CLIN PROC, V42, P812; LARSSON L G, 1955, Acta Radiol Suppl, V126, P1; MOURITS MP, 1989, BRIT J OPHTHALMOL, V73, P639, DOI 10.1136/bjo.73.8.639; ROMALDINI JH, 1983, J CLIN ENDOCR METAB, V57, P563, DOI 10.1210/jcem-57-3-563; SERGOTT RC, 1981, INVEST OPHTH VIS SCI, V20, P173; SMITH TJ, 1989, J CLIN ENDOCR METAB, V69, P1019, DOI 10.1210/jcem-69-5-1019; SOLEM JH, 1979, ACTA MED SCAND, V205, P111; SOLOMON B, 1990, J CLIN ENDOCR METAB, V70, P1518, DOI 10.1210/jcem-70-6-1518; SRIDAMA V, 1989, AM J MED, V87, P70, DOI 10.1016/S0002-9343(89)80485-1; ULLER RP, 1978, J CLIN ENDOCR METAB, V46, P747, DOI 10.1210/jcem-46-5-747; VANDYK HJL, 1981, OPHTHALMOLOGY, V88, P479; WERNER SC, 1977, AM J OPHTHALMOL, V83, P725, DOI 10.1016/0002-9394(77)90140-4; WERNER SC, 1969, J CLIN ENDOCR METAB, V29, P982, DOI 10.1210/jcem-29-7-982; WIERSINGA WM, 1988, J ENDOCRINOL INVEST, V11, P615, DOI 10.1007/BF03350193; YOUNG ET, 1988, Q J MED, V66, P175	25	388	412	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1992	326	26					1733	1738		10.1056/NEJM199206253262603	http://dx.doi.org/10.1056/NEJM199206253262603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ894	1489388				2022-12-28	WOS:A1992HZ89400003
J	HUSSAIN, SF; WATURA, R; CASHMAN, B; CAMPBELL, IA; EVANS, MR				HUSSAIN, SF; WATURA, R; CASHMAN, B; CAMPBELL, IA; EVANS, MR			AUDIT OF A TUBERCULOSIS CONTACT TRACING CLINIC	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the efficiency of tuberculosis contact tracing in South Glamorgan 1987-9. Design - Review of records of contact tracing clinic and of data from the Mycobacterium Reference Unit. The clinic's practice was compared with 1983 British Thoracic Society's recommendations. Setting - Health authority tuberculosis control programme. Main outcome measures - Proportion of contacts screened, follow up attendance rates, number of secondary cases detected, and quality of record keeping. Results - 101 index patients and 611 contacts were identified. 596 (97.5%) contacts were screened, of whom 139 should not have been. Of 356 contacts requiring a Heaf test, 237 were tested, seven refused the test, and 112 had chest radiography without a Heaf test. 95 contacts were unnecessarily tested. 87 contacts had chest radiography unnecessarily and seven should have had radiography but did not. 34 contacts were given follow up appointments inappropriately and seven were overlooked for follow up. Tuberculosis was diagnosed in five asymptomatic contacts, all at initial screening and all close contacts of index patients with pulmonary disease. Conclusion - Inadequacy of data, non-adherence to contact tracing guidelines, and failure to define the term highly infectious index case resulted in many contacts being unnecessarily screened or followed up. Implications - The efficiency of tracing contacts would be improved by specifying smear results and ethnic origin of the index case on the notification form, clearly classifying contacts as close or casual, and clearly defining the term highly infectious.	LLANDOUGH HOSP,DEPT CHEST MED,CARDIFF CF6 1XX,WALES; TEMPLE PEACE & HLTH,CTR APPL PUBL HLTH,CARDIFF CF1 3NW,WALES; TEMPLE PEACE & HLTH,DEPT PUBL HLTH MED,CARDIFF CF1 3NW,WALES				Evans, Meirion/C-2990-2008	Evans, Meirion/0000-0003-3578-1866				[Anonymous], 1978, Tubercle, V59, P245; ESMONDE TFG, 1991, RESP MED, V85, P421, DOI 10.1016/S0954-6111(06)80188-5; JONES JS, 1983, LANCET, V1, P232; SELBY CD, 1988, THORAX, V43, pP834; 1990, BMJ, V300, P995; 1983, BMJ, V287, P1118	6	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1213	1215		10.1136/bmj.304.6836.1213	http://dx.doi.org/10.1136/bmj.304.6836.1213			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515789	Green Published, Bronze			2022-12-28	WOS:A1992HT96400019
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW ANTIARRHYTHMIC APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3418	3418		10.1001/jama.268.24.3418	http://dx.doi.org/10.1001/jama.268.24.3418			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460725				2022-12-28	WOS:A1992KC83900008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CONTRACEPTIVE INJECTION APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3418	3418		10.1001/jama.268.24.3418	http://dx.doi.org/10.1001/jama.268.24.3418			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460725				2022-12-28	WOS:A1992KC83900007
J	COHEN, J				COHEN, J			GALLO PROBE - DINGELL RIPS HEALY FOR OBSTRUCTIONISM	SCIENCE			English	Editorial Material																		DINGELL, SCI GOVT REPORT 1201; PALCA J, 1992, SCIENCE, V256, P735, DOI 10.1126/science.1589751	2	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1992	258	5089					1729	1729						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465608				2022-12-28	WOS:A1992KB96400018
J	COHEN, J				COHEN, J			AIDS VACCINES - TRIALS SET IN HIGH-RISK POPULATIONS	SCIENCE			English	Editorial Material																			0	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1992	258	5089					1729	1729						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465608				2022-12-28	WOS:A1992KB96400019
C	FAITHFULL, NS		Erdmann, W; Bruley, DF		FAITHFULL, NS			ARTIFICIAL OXYGEN CARRYING BLOOD SUBSTITUTES	OXYGEN TRANSPORT TO TISSUE XIV	ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY		English	Proceedings Paper	19TH ANNUAL MEETING OF THE INTERNATIONAL SOC OXYGEN TRANSPORT TO TISSUE	AUG 24-30, 1991	WILLEMSTAD, NETH ANTILLES	INT SOC OXYGEN TRANSPORT TISSUE, BOEHRINGER INGELHEIM, HEWLETT PACKARD, KLM, LILLY NEDERLAND, MED SYSTEM, ORTOMED, ABM, CURACAOSCHE ZUURSTOFFABRIK, REFINERIA ISLA CURACAO															0	147	149	0	5	PLENUM PRESS DIV PLENUM PUBLISHING CORP	NEW YORK	NEW YORK	0065-2598		0-306-44232-9	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		1992	317						55	72						18	Medicine, General & Internal; Medicine, Research & Experimental; Physiology	Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Research & Experimental Medicine; Physiology	BX33D	1288172				2022-12-28	WOS:A1992BX33D00006
